Accession	Source Database	Name	Experiment Type	Resolution	Chains	Proteins	Protein Length	Structure Location	matches
1a06	pdb	CALMODULIN-DEPENDENT PROTEIN KINASE FROM RAT	x-ray	2.5	A	q63450	374		12..292
1a9u	pdb	THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580	x-ray	2.5	A	q16539	360		9..349
1ad5	pdb	SRC FAMILY KINASE HCK-AMP-PNP COMPLEX	x-ray	2.6	A;B	p08631;p08631	526;526	;	249..518;249..518
1agw	pdb	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR	x-ray	2.4	A;B	p11362;p11362	822;822	;	468..754;468..754
1apm	pdb	2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT	x-ray	2	E	p05132	351		28..339
1aq1	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE	x-ray	2	A	p24941	298		1..292
1atp	pdb	2.2 angstrom refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MNATP and a peptide inhibitor	x-ray	2.2	E	p05132	351		28..339
1b38	pdb	HUMAN CYCLIN-DEPENDENT KINASE 2	x-ray	2	A	p24941	298		1..292
1b39	pdb	HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160	x-ray	2.1	A	p24941	298		1..292
1b6c	pdb	CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12	x-ray	2.6	B;D;F;H	p36897;p36897;p36897;p36897	503;503;503;503	;;;	180..492;180..492;180..492;180..492
1bi7	pdb	MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX	x-ray	3.4	A	q00534	326		9..303
1bi8	pdb	MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX	x-ray	2.8	A;C	q00534;q00534	326;326	;	9..303;9..303
1bkx	pdb	A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY	x-ray	2.6	A	p05132	351		28..339
1bl6	pdb	THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995	x-ray	2.5	A	q16539	360		9..349
1bl7	pdb	THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025	x-ray	2.5	A	q16539	360		9..349
1blx	pdb	P19INK4D/CDK6 COMPLEX	x-ray	1.9	A	q00534	326		9..303
1bmk	pdb	THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655	x-ray	2.4	A	q16539	360		9..349
1buh	pdb	CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1	x-ray	2.6	A	p24941	298		1..292
1bx6	pdb	CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE	x-ray	2.1	A	p05132	351		28..339
1byg	pdb	KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE	x-ray	2.4	A	p41240	450		182..446
1cdk	pdb	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C	x-ray	2	A;B	p36887;p36887	351;351	;	32..339;32..339
1cja	pdb	ACTIN-FRAGMIN KINASE, CATALYTIC DOMAIN FROM PHYSARUM POLYCEPHALUM	x-ray	2.9	A;B	p80197;p80197	737;737	;	3..342;3..342
1cki	pdb	RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317	x-ray	2.3	A;B	q06486;q06486	415;415	;	5..290;5..290
1ckj	pdb	CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE	x-ray	2.46	A;B	q06486;q06486	415;415	;	5..290;5..290
1ckp	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B	x-ray	2.05	A	p24941	298		1..292
1cm8	pdb	PHOSPHORYLATED MAP KINASE P38-GAMMA	x-ray	2.4	A;B	p53778;p53778	367;367	;	18..351;18..351
1cmk	pdb	CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS	x-ray	2.9	E	p36887	351		32..339
1csn	pdb	BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP	x-ray	2	A	p40233	446		8..296
1ctp	pdb	STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION	x-ray	2.9	E	p36887	351		32..339
1daw	pdb	CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP	x-ray	2.2	A	p28523	332		11..323
1day	pdb	CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP	x-ray	2.2	A	p28523	332		11..323
1di8	pdb	THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE	x-ray	2.2	A	p24941	298		1..292
1di9	pdb	THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-6,7-DIMETHOXYQUINAZOLINE	x-ray	2.6	A	q16539	360		9..349
1dm2	pdb	HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE	x-ray	2.1	A	p24941	298		1..292
1ds5	pdb	DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.	x-ray	3.16	A;B;C;D	p28523;p28523;p28523;p28523	332;332;332;332	;;;	11..323;11..323;11..323;11..323
1e1v	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058	x-ray	1.95	A	p24941	298		1..292
1e1x	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027	x-ray	1.85	A	p24941	298		1..292
1e7u	pdb	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine	x-ray	2	A	o02697	1102		728..1089
1e7v	pdb	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine	x-ray	2.4	A	o02697	1102		728..1089
1e8w	pdb	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine	x-ray	2.5	A	o02697	1102		728..1089
1e8x	pdb	STRUCTURAL INSIGHTS INTO PHOSHOINOSITIDE 3-KINASE ENZYMATIC MECHANISM AND SIGNALLING	x-ray	2.2	A	o02697	1102		728..1089
1e8y	pdb	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine	x-ray	2	A	p48736	1102		728..1089
1e8z	pdb	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine	x-ray	2.4	A	p48736	1102		728..1089
1e90	pdb	Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine	x-ray	2.7	A	o02697	1102		728..1089
1e9h	pdb	Thr 160 phosphorylated CDK2 - Human cyclin A3 complex with the inhibitor indirubin-5-sulphonate bound	x-ray	2.5	A;C	p24941;p24941	298;298	;	1..292;1..292
1eh4	pdb	BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR, IC261	x-ray	2.8	A;B	p40233;p40233	446;446	;	8..296;8..296
1f0q	pdb	CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN	x-ray	2.63	A	p28523	332		11..323
1f3m	pdb	CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1	x-ray	2.3	C;D	q13153;q13153	545;545	;	261..522;261..522
1f5q	pdb	CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2	x-ray	2.5	A;C	p24941;p24941	298;298	;	1..292;1..292
1fgi	pdb	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR	x-ray	2.5	A;B	p11362;p11362	822;822	;	468..754;468..754
1fgk	pdb	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1	x-ray	2	A;B	p11362;p11362	822;822	;	468..754;468..754
1fin	pdb	CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX	x-ray	2.3	A;C	p24941;p24941	298;298	;	1..292;1..292
1fmk	pdb	CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC	x-ray	1.5	A	p12931	536		259..529
1fmo	pdb	CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE	x-ray	2.2	E	p05132	351		28..339
1fot	pdb	STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE	x-ray	2.8	A	p06244	397		60..366
1fpu	pdb	CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR	x-ray	2.4	A;B	p00520;p00520	1123;1123	;	231..498;231..498
1fq1	pdb	CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2	x-ray	3	B	p24941	298		1..292
1fvr	pdb	TIE2 KINASE DOMAIN	x-ray	2.2	A;B	q02763;q02763	1124;1124	;	819..1107;819..1107
1fvt	pdb	THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR	x-ray	2.2	A	p24941	298		1..292
1fvv	pdb	THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR	x-ray	2.8	A;C	p24941;p24941	298;298	;	1..292;1..292
1g3n	pdb	STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX	x-ray	2.9	A;E	q00534;q00534	326;326	;	9..303;9..303
1g5s	pdb	CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717	x-ray	2.61	A	p24941	298		1..292
1gag	pdb	CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR	x-ray	2.7	A				
1gih	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR	x-ray	2.8	A	p24941	298		1..292
1gii	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR	x-ray	2	A	p24941	298		1..292
1gij	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR	x-ray	2.2	A	p24941	298		1..292
1gjo	pdb	The FGFr2 tyrosine kinase domain	x-ray	2.4	A	p21802	821		471..757
1gng	pdb	Glycogen synthase kinase-3 beta (GSK3) complex with FRATtide peptide	x-ray	2.6	A;B	p49841;p49841	420;420	;	55..377;55..377
1gol	pdb	COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52	x-ray	2.8	A	p63086	358		17..320
1gy3	pdb	pCDK2/cyclin A in complex with MgADP, nitrate and peptide substrate	x-ray	2.7	A;C	;	;	;	;
1gz8	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-Amino-6-(3'-methyl-2'-oxo)butoxypurine	x-ray	1.3	A	p24941	298		1..292
1gzk	pdb	Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation	x-ray	2.3	A	p31751	481		147..460
1gzn	pdb	Structure of PKB kinase domain	x-ray	2.5	A	p31751	481		147..460
1gzo	pdb	Structure of protein kinase B unphosphorylated	x-ray	2.75	A	p31751	481		147..460
1h00	pdb	CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitor	x-ray	1.6	A	p24941	298		1..292
1h01	pdb	CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitor	x-ray	1.79	A	p24941	298		1..292
1h07	pdb	CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitor	x-ray	1.85	A	p24941	298		1..292
1h08	pdb	CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitor	x-ray	1.8	A	p24941	298		1..292
1h0v	pdb	Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[(R)-pyrrolidino-5'-yl]methoxypurine	x-ray	1.9	A	p24941	298		1..292
1h0w	pdb	Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[cyclohex-3-enyl]methoxypurine	x-ray	2.1	A	p24941	298		1..292
1h1p	pdb	Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU2058	x-ray	2.1	A;C	p24941;p24941	298;298	;	1..292;1..292
1h1q	pdb	Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6094	x-ray	2.5	A;C	p24941;p24941	298;298	;	1..292;1..292
1h1r	pdb	Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6086	x-ray	2	A;C	p24941;p24941	298;298	;	1..292;1..292
1h1s	pdb	Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6102	x-ray	2	A;C	p24941;p24941	298;298	;	1..292;1..292
1h1w	pdb	High resolution crystal structure of the human PDK1 catalytic domain	x-ray	2	A	o15530	556		79..400
1h24	pdb	CDK2/CyclinA in complex with a 9 residue recruitment peptide from E2F	x-ray	2.5	A;C	p24941;p24941	298;298	;	1..292;1..292
1h25	pdb	CDK2/Cyclin A in complex with an 11-residue recruitment peptide from retinoblastoma-associated protein	x-ray	2.5	A;C	p24941;p24941	298;298	;	1..292;1..292
1h26	pdb	CDK2/CyclinA in complex with an 11-residue recruitment peptide from p53	x-ray	2.24	A;C	p24941;p24941	298;298	;	1..292;1..292
1h27	pdb	CDK2/CyclinA in complex with an 11-residue recruitment peptide from p27	x-ray	2.2	A;C	p24941;p24941	298;298	;	1..292;1..292
1h28	pdb	CDK2/CyclinA in complex with an 11-residue recruitment peptide from p107	x-ray	2.8	A;C	p24941;p24941	298;298	;	1..292;1..292
1h4l	pdb	Structure and regulation of the CDK5-p25(nck5a) complex	x-ray	2.65	A;B	q00535;q00535	292;292	;	1..290;1..290
1h8f	pdb	Glycogen Synthase Kinase 3 beta.	x-ray	2.8	A;B	p49841;p49841	420;420	;	55..377;55..377
1hck	pdb	HUMAN CYCLIN-DEPENDENT KINASE 2	x-ray	1.9	A	p24941	298		1..292
1hcl	pdb	HUMAN CYCLIN-DEPENDENT KINASE 2	x-ray	1.8	A	p24941	298		1..292
1he8	pdb	Ras G12V - PI 3-kinase gamma complex	x-ray	3	A	p48736	1102		728..1089
1how	pdb	THE X-RAY CRYSTAL STRUCTURE OF SKY1P, AN SR PROTEIN KINASE IN YEAST	x-ray	2.1	A	q03656	742		154..720
1i09	pdb	STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)	x-ray	2.7	A;B	p49841;p49841	420;420	;	55..377;55..377
1i44	pdb	CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE	x-ray	2.4	A	p06213	1382		996..1290
1ia8	pdb	THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1	x-ray	1.7	A	o14757	476		6..317
1ia9	pdb	CRYSTAL STRUCTURE OF THE ATYPICAL PROTEIN KINASE DOMAIN OF A TRP CA-CHANNEL, CHAK (AMPPNP COMPLEX)	x-ray	2	A;B	q923j1;q923j1	1863;1863	;	1552..1827;1552..1827
1iah	pdb	CRYSTAL STRUCTURE OF THE ATYPICAL PROTEIN KINASE DOMAIN OF A TRP CA-CHANNEL, CHAK (ADP-MG COMPLEX)	x-ray	2.4	A;B	q923j1;q923j1	1863;1863	;	1552..1827;1552..1827
1iaj	pdb	CRYSTAL STRUCTURE OF THE ATYPICAL PROTEIN KINASE DOMAIN OF A TRP CA-CHANNEL, CHAK (APO)	x-ray	2.8	A;B	q923j1;q923j1	1863;1863	;	1552..1827;1552..1827
1ian	pdb	HUMAN P38 MAP KINASE INHIBITOR COMPLEX	x-ray	2	A	q16539	360		9..349
1ias	pdb	CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12	x-ray	2.9	A;B;C;D;E	p36897;p36897;p36897;p36897;p36897	503;503;503;503;503	;;;;	180..492;180..492;180..492;180..492;180..492
1iep	pdb	CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.	x-ray	2.1	A;B	p00520;p00520	1123;1123	;	231..498;231..498
1ig1	pdb	1.8A X-Ray structure of ternary complex of a catalytic domain of death-associated protein kinase with ATP analogue and Mn.	x-ray	1.8	A	p53355	1430		6..291
1ir3	pdb	PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG	x-ray	1.9	A				
1irk	pdb	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR	x-ray	2.1	A	p06213	1382		996..1290
1j1b	pdb	Binary complex structure of human tau protein kinase I with AMPPNP	x-ray	1.8	A;B	p49841;p49841	420;420	;	55..377;55..377
1j1c	pdb	Binary complex structure of human tau protein kinase I with ADP	x-ray	2.1	A;B	p49841;p49841	420;420	;	55..377;55..377
1j3h	pdb	Crystal structure of apoenzyme cAMP-dependent protein kinase catalytic subunit	x-ray	2.9	A;B	p05132;p05132	351;351	;	28..339;28..339
1j7i	pdb	"Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa Apoenzyme"	x-ray	3.2	A	p0a3y5	264		3..264
1j7l	pdb	"Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa ADP Complex"	x-ray	2.2	A;B	p0a3y5;p0a3y5	264;264	;	3..264;3..264
1j7u	pdb	"Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa AMPPNP Complex"	x-ray	2.4	A;B	p0a3y5;p0a3y5	264;264	;	3..264;3..264
1j91	pdb	Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the ATP-competitive inhibitor 4,5,6,7-tetrabromobenzotriazole	x-ray	2.22	A;B	p28523;p28523	332;332	;	11..323;11..323
1jam	pdb	Crystal structure of apo-form of Z. Mays CK2 protein kinase alpha subunit	x-ray	2.18	A	p28523	332		11..323
1jbp	pdb	Crystal Structure of the Catalytic Subunit of cAMP-dependent Protein Kinase Complexed with a Substrate Peptide, ADP and Detergent	x-ray	2.2	E	p05132	351		28..339
1jkk	pdb	2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.	x-ray	2.4	A	p53355	1430		6..291
1jkl	pdb	1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE	x-ray	1.62	A	p53355	1430		6..291
1jks	pdb	1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE	x-ray	1.5	A	p53355	1430		6..291
1jkt	pdb	TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE	x-ray	3.5	A;B	p53355;p53355	1430;1430	;	6..291;6..291
1jlu	pdb	Crystal Structure of the Catalytic Subunit of cAMP-dependent Protein Kinase Complexed with a Phosphorylated Substrate Peptide and Detergent	x-ray	2.25	E	p05132	351		28..339
1jnk	pdb	THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP	x-ray	2.3	A	p53779	464		52..396
1jow	pdb	Crystal structure of a complex of human CDK6 and a viral cyclin	x-ray	3.1	B	q00534	326		9..303
1jpa	pdb	Crystal Structure of unphosphorylated EphB2 receptor tyrosine kinase and juxtamembrane region	x-ray	1.91	A;B	p54763;p54763	986;986	;	613..914;613..914
1jqh	pdb	IGF-1 receptor kinase domain	x-ray	2.1	A;B;C	p08069;p08069;p08069	1367;1367;1367	;;	970..1264;970..1264;970..1264
1jst	pdb	PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A	x-ray	2.6	A;C	p24941;p24941	298;298	;	1..292;1..292
1jsu	pdb	P27(KIP1)/CYCLIN A/CDK2 COMPLEX	x-ray	2.3	A	p24941	298		1..292
1jsv	pdb	The structure of cyclin-dependent kinase 2 (CDK2) in complex with 4-[(6-amino-4-pyrimidinyl)amino]benzenesulfonamide	x-ray	1.96	A	p24941	298		1..292
1jvp	pdb	Crystal structure of human CDK2 (unphosphorylated) in complex with PKF049-365	x-ray	1.53	P	p24941	298		1..292
1jwh	pdb	Crystal Structure of Human Protein Kinase CK2 Holoenzyme	x-ray	3.1	A;B	p68400;p68400	391;391	;	5..328;5..328
1k2p	pdb	Crystal structure of Bruton's tyrosine kinase domain	x-ray	2.1	A;B	q06187;q06187	659;659	;	382..648;382..648
1k3a	pdb	Structure of the Insulin-like Growth Factor 1 Receptor Kinase	x-ray	2.1	A	p08069	1367		970..1264
1k9a	pdb	Crystal structure analysis of full-length carboxyl-terminal Src kinase at 2.5 A resolution	x-ray	2.5	A;B;C;D;E;F	p32577;p32577;p32577;p32577;p32577;p32577	450;450;450;450;450;450	;;;;;	182..446;182..446;182..446;182..446;182..446;182..446
1ke5	pdb	CDK2 complexed with N-methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide	x-ray	2.2	A	p24941	298		1..292
1ke6	pdb	CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE	x-ray	2	A	p24941	298		1..292
1ke7	pdb	CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE	x-ray	2	A	p24941	298		1..292
1ke8	pdb	CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE	x-ray	2	A	p24941	298		1..292
1ke9	pdb	CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE	x-ray	2	A	p24941	298		1..292
1koa	pdb	TWITCHIN KINASE FRAGMENT (C.ELEGANS), AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS	x-ray	3.3	A	q23551	7158		6236..6575
1kob	pdb	TWITCHIN KINASE FRAGMENT (APLYSIA), AUTOREGULATED PROTEIN KINASE DOMAIN	x-ray	2.3	A;B	q16980;q16980	451;451	;	19..364;19..364
1ksw	pdb	Structure of Human c-Src Tyrosine Kinase (Thr338Gly Mutant) in Complex with N6-benzyl ADP	x-ray	2.8	A	p12931	536		259..529
1kv1	pdb	p38 MAP Kinase in Complex with Inhibitor 1	x-ray	2.5	A	q16539	360		9..349
1kv2	pdb	Human p38 MAP Kinase in Complex with BIRB 796	x-ray	2.8	A	q16539	360		9..349
1kwp	pdb	Crystal Structure of MAPKAP2	x-ray	2.8	A;B	p49137;p49137	400;400	;	59..369;59..369
1l3r	pdb	Crystal Structure of a Transition State Mimic of the Catalytic Subunit of cAMP-dependent Protein Kinase	x-ray	2	E	p05132	351		28..339
1l8t	pdb	"Crystal Structure Of 3',5""-Aminoglycoside Phosphotransferase Type IIIa ADP Kanamycin A Complex"	x-ray	2.4	A	p0a3y5	264		3..264
1lew	pdb	CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A	x-ray	2.3	A	p47811	360		9..349
1lez	pdb	CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B	x-ray	2.3	A	p47811	360		9..349
1lp4	pdb	Crystal structure of a binary complex of the catalytic subunit of protein kinase CK2 with Mg-AMPPNP	x-ray	1.86	A	p28523	332		11..323
1lpu	pdb	Low Temperature Crystal Structure of the Apo-form of the catalytic subunit of protein kinase CK2 from Zea mays	x-ray	1.86	A	p28523	332		11..323
1lr4	pdb	Room Temperature Crystal Structure of the Apo-form of the catalytic subunit of protein kinase CK2 from Zea mays	x-ray	2	A	p28523	332		11..323
1luf	pdb	Crystal Structure of the MuSK Tyrosine Kinase: Insights into Receptor Autoregulation	x-ray	2.05	A	q62838	868		565..855
1m14	pdb	Tyrosine Kinase Domain from Epidermal Growth Factor Receptor	x-ray	2.6	A	p00533	1210		708..1003
1m17	pdb	Epidermal Growth Factor Receptor tyrosine kinase domain with 4-anilinoquinazoline inhibitor erlotinib	x-ray	2.6	A	p00533	1210		708..1003
1m2p	pdb	Crystal structure of 1,8-di-hydroxy-4-nitro-anthraquinone/CK2 kinase complex	x-ray	2	A	p28523	332		11..323
1m2q	pdb	Crystal structure of 1,8-di-hydroxy-4-nitro-xanten-9-one/CK2 kinase complex	x-ray	1.79	A	p28523	332		11..323
1m2r	pdb	Crystal structure of 5,8-di-amino-1,4-di-hydroxy-anthraquinone/CK2 kinase complex	x-ray	1.7	A	p28523	332		11..323
1m52	pdb	Crystal Structure of the c-Abl Kinase domain in complex with PD173955	x-ray	2.6	A;B	p00520;p00520	1123;1123	;	231..498;231..498
1m7n	pdb	Crystal Structure of Unactivated APO Insulin-like Growth Factor-1 Receptor Kinase Domain	x-ray	2.7	A;B	p08069;p08069	1367;1367	;	970..1264;970..1264
1m7q	pdb	Crystal structure of p38 MAP kinase in complex with a dihydroquinazolinone inhibitor	x-ray	2.4	A	q16539	360		9..349
1mp8	pdb	Crystal structure of Focal Adhesion Kinase (FAK)	x-ray	1.6	A	q05397	1052		409..693
1mq4	pdb	Crystal Structure of Aurora-A Protein Kinase	x-ray	1.9	A	o14965	403		120..386
1mqb	pdb	Crystal Structure of Ephrin A2 (ephA2) Receptor Protein Kinase	x-ray	2.3	A;B	p29317;p29317	976;976	;	605..909;605..909
1mru	pdb	Intracellular Ser/Thr protein kinase domain of Mycobacterium tuberculosis PknB.	x-ray	3	A;B	p9wi81;p9wi81	626;626	;	8..275;8..275
1mrv	pdb	crystal structure of an inactive Akt2 kinase domain	x-ray	2.8	A	p31751	481		147..460
1mry	pdb	crystal structure of an inactive akt2 kinase domain	x-ray	2.8	A	p31751	481		147..460
1muo	pdb	CRYSTAL STRUCTURE OF AURORA-2, AN ONCOGENIC SERINE-THREONINE KINASE	x-ray	2.9	A	o14965	403		120..386
1na7	pdb	Crystal structure of the catalytic subunit of human protein kinase CK2	x-ray	2.4	A	p68400	391		5..328
1nd4	pdb	Crystal structure of aminoglycoside-3'-phosphotransferase-IIa	x-ray	2.1	A;B	p00552;p00552	264;264	;	12..264;12..264
1nvq	pdb	The Complex Structure Of Checkpoint Kinase Chk1/UCN-01	x-ray	2	A				
1nvr	pdb	The Complex Structure Of Checkpoint Kinase Chk1/Staurosporine	x-ray	1.8	A				
1nvs	pdb	The Complex Structure Of Checkpoint Kinase Chk1/SB218078	x-ray	1.8	A				
1nw1	pdb	Crystal Structure of Choline Kinase	x-ray	2.02	A;B	q22942;q22942	429;429	;	33..424;33..424
1nxk	pdb	Crystal structure of staurosporine bound to MAP KAP kinase 2	x-ray	2.7	A;B;C;D	p49137;p49137;p49137;p49137	400;400;400;400	;;;	59..369;59..369;59..369;59..369
1ny3	pdb	Crystal structure of ADP bound to MAP KAP kinase 2	x-ray	3	A	p49137	400		59..369
1o6k	pdb	Structure of activated form of PKB kinase domain S474D with GSK3 peptide and AMP-PNP	x-ray	1.7	A	p31751	481		147..460
1o6l	pdb	Crystal structure of an activated Akt/protein kinase B (PKB-PIF chimera) ternary complex with AMP-PNP and GSK3 peptide	x-ray	1.6	A	p31751	481		147..460
1o6y	pdb	Catalytic domain of PknB kinase from Mycobacterium tuberculosis	x-ray	2.2	A	p9wi81	626		8..275
1o9u	pdb	GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE	x-ray	2.4	A	p49841	420		55..377
1ob3	pdb	Structure of P. falciparum PfPK5	x-ray	1.9	A;B	q07785;q07785	288;288	;	1..286;1..286
1oec	pdb	FGFr2 kinase domain	x-ray	2.4	A	p21802	821		471..757
1ogu	pdb	STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR	x-ray	2.6	A;C	p24941;p24941	298;298	;	1..292;1..292
1oi9	pdb	Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor	x-ray	2.1	A;C	p24941;p24941	298;298	;	1..292;1..292
1oiq	pdb	Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified through Structure-based hybridisation	x-ray	2.31	A	p24941	298		1..292
1oir	pdb	Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified through Structure-based hybridisation	x-ray	1.91	A	p24941	298		1..292
1oit	pdb	Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified through Structure-based hybridisation	x-ray	1.6	A	p24941	298		1..292
1oiu	pdb	Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor	x-ray	2	A;C	p24941;p24941	298;298	;	1..292;1..292
1oiy	pdb	Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor	x-ray	2.4	A;C	p24941;p24941	298;298	;	1..292;1..292
1okv	pdb	Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Ile-Phe-NH2	x-ray	2.4	A;C	;	;	;	;
1okw	pdb	Cyclin A binding groove inhibitor Ac-Arg-Arg-Leu-Asn-(m-Cl-Phe)-NH2	x-ray	2.5	A;C	;	;	;	;
1oky	pdb	Structure of human PDK1 kinase domain in complex with staurosporine	x-ray	2.3	A	o15530	556		79..400
1okz	pdb	Structure of human PDK1 kinase domain in complex with UCN-01	x-ray	2.51	A	o15530	556		79..400
1ol1	pdb	Cyclin A binding groove inhibitor H-Cit-Cit-Leu-Ile-(p-F-Phe)-NH2	x-ray	2.9	A;C	;	;	;	;
1ol2	pdb	Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Asn-(p-F-Phe)-NH2	x-ray	2.6	A;C	;	;	;	;
1ol5	pdb	Structure of Aurora-A 122-403, phosphorylated on Thr287, Thr288 and bound to TPX2 1-43	x-ray	2.5	A	o14965	403		120..386
1ol6	pdb	Structure of unphosphorylated D274N mutant of Aurora-A	x-ray	3	A	o14965	403		120..386
1ol7	pdb	Structure of Human Aurora-A 122-403 phosphorylated on Thr287, Thr288	x-ray	2.75	A	o14965	403		120..386
1om1	pdb	Crystal structure of maize CK2 alpha in complex with IQA	x-ray	1.68	A	p28523	332		11..323
1omw	pdb	Crystal Structure of the complex between G Protein-Coupled Receptor Kinase 2 and Heterotrimeric G Protein beta 1 and gamma 2 subunits	x-ray	2.5	A	p21146	689		187..532
1opj	pdb	Structural basis for the auto-inhibition of c-Abl tyrosine kinase	x-ray	1.75	A;B	p00520;p00520	1123;1123	;	231..498;231..498
1opk	pdb	Structural basis for the auto-inhibition of c-Abl tyrosine kinase	x-ray	1.8	A	p00520	1123		231..498
1opl	pdb	Structural basis for the auto-inhibition of c-Abl tyrosine kinase	x-ray	3.42	A;B	p00519;p00519	1130;1130	;	231..498;231..498
1ouk	pdb	The structure of p38 alpha in complex with a pyridinylimidazole inhibitor	x-ray	2.5	A	q16539	360		9..349
1ouy	pdb	The structure of p38 alpha in complex with a dihydropyrido-pyrimidine inhibitor	x-ray	2.5	A	q16539	360		9..349
1ove	pdb	The structure of p38 alpha in complex with a dihydroquinolinone	x-ray	2.1	A	q16539	360		9..349
1oz1	pdb	P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR	x-ray	2.1	A	q16539	360		9..349
1p14	pdb	Crystal structure of a catalytic-loop mutant of the insulin receptor tyrosine kinase	x-ray	1.9	A	p06213	1382		996..1290
1p2a	pdb	The structure of cyclin dependent kinase 2 (CKD2) with a trisubstituted naphthostyril inhibitor	x-ray	2.5	A	p24941	298		1..292
1p4f	pdb	DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT	x-ray	1.9	A	p53355	1430		6..291
1p4o	pdb	Structure of Apo unactivated IGF-1R KInase domain at 1.5A resolution.	x-ray	1.5	A;B	p08069;p08069	1367;1367	;	970..1264;970..1264
1p5e	pdb	The structure of phospho-CDK2/cyclin A in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazole (TBS)	x-ray	2.22	A;C	p24941;p24941	298;298	;	1..292;1..292
1pf8	pdb	Crystal Structure of Human Cyclin-Dependent Kinase 2 Complexed with a Nucleoside Inhibitor	x-ray	2.51	A	p24941	298		1..292
1phk	pdb	TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE, KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE, SUBSTRATE-ANALOGUE AND PRODUCT	x-ray	2.2	A	p00518	387		14..324
1pjk	pdb	Crystal Structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit	x-ray	2.5	A	p68400	391		5..328
1pkd	pdb	THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A	x-ray	2.3	A;C	p24941;p24941	298;298	;	1..292;1..292
1pkg	pdb	Structure of a c-Kit Kinase Product Complex	x-ray	2.9	A;B	p10721;p10721	976;976	;	564..923;564..923
1pme	pdb	STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE	x-ray	2	A	p28482	360		19..322
1pmn	pdb	Crystal structure of JNK3 in complex with an imidazole-pyrimidine inhibitor	x-ray	2.2	A	p53779	464		52..396
1pmu	pdb	The crystal structure of JNK3 in complex with a phenantroline inhibitor	x-ray	2.7	A	p53779	464		52..396
1pmv	pdb	The structure of JNK3 in complex with a dihydroanthrapyrazole inhibitor	x-ray	2.5	A	p53779	464		52..396
1pw2	pdb	APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2	x-ray	1.95	A	p24941	298		1..292
1pxi	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,5-Dichloro-thiophen-3-yl)-pyrimidin-2-ylamine	x-ray	1.95	A	p24941	298		1..292
1pxj	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine	x-ray	2.3	A	p24941	298		1..292
1pxk	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)pyrimidin-2-yl]-N'-hydroxyiminoformamide	x-ray	2.8	A	p24941	298		1..292
1pxl	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-amine	x-ray	2.5	A	p24941	298		1..292
1pxm	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol	x-ray	2.53	A	p24941	298		1..292
1pxn	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol	x-ray	2.5	A	p24941	298		1..292
1pxo	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine	x-ray	1.96	A	p24941	298		1..292
1pxp	pdb	HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-N',N'-dimethyl-benzene-1,4-diamine	x-ray	2.3	A	p24941	298		1..292
1py5	pdb	Crystal Structure of TGF-beta receptor I kinase with inhibitor	x-ray	2.3	A	p36897	503		180..492
1pye	pdb	Crystal structure of CDK2 with inhibitor	x-ray	2	A	p24941	298		1..292
1pyx	pdb	GSK-3 Beta complexed with AMP-PNP	x-ray	2.4	A;B	p49841;p49841	420;420	;	55..377;55..377
1q24	pdb	PKA double mutant model of PKB in complex with MgATP	x-ray	2.6	A	p00517	351		32..339
1q3d	pdb	GSK-3 Beta complexed with Staurosporine	x-ray	2.2	A;B	p49841;p49841	420;420	;	55..377;55..377
1q3w	pdb	GSK-3 Beta complexed with Alsterpaullone	x-ray	2.3	A;B	p49841;p49841	420;420	;	55..377;55..377
1q41	pdb	GSK-3 Beta complexed with Indirubin-3'-monoxime	x-ray	2.1	A;B	p49841;p49841	420;420	;	55..377;55..377
1q4l	pdb	GSK-3 Beta complexed with Inhibitor I-5	x-ray	2.77	A;B	p49841;p49841	420;420	;	55..377;55..377
1q5k	pdb	crystal structure of Glycogen synthase kinase 3 in complexed with inhibitor	x-ray	1.94	A;B	p49841;p49841	420;420	;	55..377;55..377
1q61	pdb	PKA triple mutant model of PKB	x-ray	2.1	A	p00517	351		32..339
1q62	pdb	PKA double mutant model of PKB	x-ray	2.3	A	p00517	351		32..339
1q8t	pdb	The Catalytic Subunit of cAMP-dependent Protein Kinase (PKA) in Complex with Rho-kinase Inhibitor Y-27632	x-ray	2	A	p00517	351		32..339
1q8u	pdb	The Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Rho-kinase Inhibitor H-1152P	x-ray	1.9	A	p00517	351		32..339
1q8w	pdb	The Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Rho-kinase Inhibitor Fasudil (HA-1077)	x-ray	2.2	A	p00517	351		32..339
1q8y	pdb	The structure of the yeast SR protein kinase, Sky1p, with bound ADP	x-ray	2.05	A;B	q03656;q03656	742;742	;	154..720;154..720
1q8z	pdb	The apoenzyme structure of the yeast SR protein kinase, Sky1p	x-ray	2.35	A;B	q03656;q03656	742;742	;	154..720;154..720
1q97	pdb	The structure of the Saccharomyces cerevisiae SR protein kinase, Sky1p, with bound ATP	x-ray	2.3	A;B	q03656;q03656	742;742	;	154..720;154..720
1q99	pdb	Crystal structure of the Saccharomyces cerevisiae SR protein kinsae, Sky1p, complexed with the non-hydrolyzable ATP analogue, AMP-PNP	x-ray	2.11	A;B	q03656;q03656	742;742	;	154..720;154..720
1qcf	pdb	CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY-SELECTIVE TYROSINE KINASE INHIBITOR	x-ray	2	A	p08631	526		249..518
1ql6	pdb	THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES	x-ray	2.4	A	p00518	387		14..324
1qmz	pdb	PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX	x-ray	2.2	A;C	;	;	;	;
1qpc	pdb	STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS	x-ray	1.6	A	p06239	509		231..500
1qpd	pdb	STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS	x-ray	2	A	p06239	509		231..500
1qpe	pdb	STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS	x-ray	2	A	p06239	509		231..500
1qpj	pdb	CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.	x-ray	2.2	A	p06239	509		231..500
1r0e	pdb	Glycogen synthase kinase-3 beta in complex with 3-indolyl-4-arylmaleimide inhibitor	x-ray	2.25	A;B	p49841;p49841	420;420	;	55..377;55..377
1r0p	pdb	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met in complex with the microbial alkaloid K-252a	x-ray	1.8	A	p08581	1390		1079..1341
1r1w	pdb	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET	x-ray	1.8	A	p08581	1390		1079..1341
1r39	pdb	THE STRUCTURE OF P38ALPHA	x-ray	2.3	A	q16539	360		9..349
1r3c	pdb	THE STRUCTURE OF P38ALPHA C162S MUTANT	x-ray	2	A	q16539	360		9..349
1r78	pdb	CDK2 complex with a 4-alkynyl oxindole inhibitor	x-ray	2	A	p24941	298		1..292
1rdq	pdb	Hydrolysis of ATP in the crystal of Y204A mutant of cAMP-dependent protein kinase	x-ray	1.26	E				
1re8	pdb	Crystal structure of cAMP-dependent protein kinase complexed with balanol analog 2	x-ray	2.1	A	p05132	351		28..339
1rej	pdb	Crystal structure of cAMP-dependent protein kinase complexed with balanol analog 1	x-ray	2.2	A	p05132	351		28..339
1rek	pdb	Crystal structure of cAMP-dependent protein kinase complexed with balanol analog 8	x-ray	2.3	A	p05132	351		28..339
1rjb	pdb	Crystal Structure of FLT3	x-ray	2.1	A	p36888	993		576..941
1rqq	pdb	Crystal Structure of the Insulin Receptor Kinase in Complex with the SH2 Domain of APS	x-ray	2.6	A;B	;	;	;	;
1rw8	pdb	Crystal Structure of TGF-beta receptor I kinase with ATP site inhibitor	x-ray	2.4	A	p36897	503		180..492
1s9i	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 2 (MEK2)in a complex with ligand and MgATP	x-ray	3.2	A;B	p36507;p36507	400;400	;	64..374;64..374
1s9j	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP	x-ray	2.4	A	q02750	393		63..365
1sm2	pdb	Crystal structure of the phosphorylated Interleukin-2 tyrosine kinase catalytic domain	x-ray	2.3	A;B	q08881;q08881	620;620	;	352..613;352..613
1smh	pdb	Protein kinase A variant complex with completely ordered N-terminal helix	x-ray	2.044	A	p00517	351		32..339
1snu	pdb	CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN	x-ray	2.5	A;B	q08881;q08881	620;620	;	352..613;352..613
1snx	pdb	CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN	x-ray	3.2	A;B	q08881;q08881	620;620	;	352..613;352..613
1stc	pdb	CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE	x-ray	2.3	E	p00517	351		32..339
1sve	pdb	Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 1	x-ray	2.49	A	p00517	351		32..339
1svg	pdb	Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 4	x-ray	2.02	A	p00517	351		32..339
1svh	pdb	Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 8	x-ray	2.3	A	p00517	351		32..339
1syk	pdb	Crystal structure of E230Q mutant of cAMP-dependent protein kinase reveals unexpected apoenzyme conformation	x-ray	2.8	A;B	p05132;p05132	351;351	;	28..339;28..339
1szm	pdb	DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)	x-ray	2.5	A;B	p00517;p00517	351;351	;	32..339;32..339
1t45	pdb	STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE	x-ray	1.9	A	p10721	976		564..923
1t46	pdb	STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE	x-ray	1.6	A	p10721	976		564..923
1tki	pdb	AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN	x-ray	2	A;B	q8wz42;q8wz42	34350;34350	;	32174..32462;32174..32462
1tqi	pdb	Crystal Structure of A. Fulgidus Rio2 Serine Protein Kinase	x-ray	2	A	o30245	282		94..277
1tqm	pdb	Crystal Structure of A. fulgidus Rio2 Serine Protein Kinase Bound to AMPPNP	x-ray	1.99	A	o30245	282		94..277
1tqp	pdb	Crystal Structure of A. fulgidus Rio2 Serine Protein Kinase Bound to ATP	x-ray	2.1	A	o30245	282		94..277
1tvo	pdb	The structure of ERK2 in complex with a small molecule inhibitor	x-ray	2.5	A	p28482	360		19..322
1u46	pdb	Crystal Structure of the Unphosphorylated Kinase Domain of the Tyrosine Kinase ACK1	x-ray	2	A;B	q07912;q07912	1038;1038	;	120..398;120..398
1u4d	pdb	Structure of the ACK1 Kinase Domain bound to Debromohymenialdisine	x-ray	2.1	A;B	q07912;q07912	1038;1038	;	120..398;120..398
1u54	pdb	Crystal Structures of the Phosphorylated and Unphosphorylated Kinase Domains of the CDC42-associated Tyrosine Kinase ACK1 bound to AMP-PCP	x-ray	2.8	A;B	q07912;q07912	1038;1038	;	120..398;120..398
1u59	pdb	Crystal Structure of the ZAP-70 Kinase Domain in Complex with Staurosporine	x-ray	2.3	A	p43403	619		343..599
1u5q	pdb	Crystal Structure of the TAO2 Kinase Domain: Activation and Specifity of a Ste20p MAP3K	x-ray	2.1	A;B	q9jls3;q9jls3	1235;1235	;	28..282;28..282
1u5r	pdb	Crystal Structure of the TAO2 Kinase Domain: Activation and Specifity of a Ste20p MAP3K	x-ray	2.1	A;B	q9jls3;q9jls3	1235;1235	;	28..282;28..282
1ua2	pdb	Crystal Structure of Human CDK7	x-ray	3.02	A;B;C;D	p50613;p50613;p50613;p50613	346;346;346;346	;;;	8..299;8..299;8..299;8..299
1ukh	pdb	Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125	x-ray	2.35	A	p45983	427		12..357
1uki	pdb	Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125	x-ray	2.7	A	p45983	427		12..357
1ung	pdb	Structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine and indirubin.	x-ray	2.3	A;B	q00535;q00535	292;292	;	1..290;1..290
1unh	pdb	Structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine and indirubin.	x-ray	2.35	A;B	q00535;q00535	292;292	;	1..290;1..290
1unl	pdb	Structural mechanism for the inhibition of CD5-p25 from the roscovitine, aloisine and indirubin.	x-ray	2.2	A;B	q00535;q00535	292;292	;	1..290;1..290
1urc	pdb	Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly	x-ray	2.6	A;C	;	;	;	;
1urw	pdb	CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-b]PYRIDAZINE	x-ray	1.6	A	p24941	298		1..292
1uu3	pdb	Structure of human PDK1 kinase domain in complex with LY333531	x-ray	1.7	A	o15530	556		79..400
1uu7	pdb	Structure of human PDK1 kinase domain in complex with BIM-2	x-ray	1.9	A	o15530	556		79..400
1uu8	pdb	Structure of human PDK1 kinase domain in complex with BIM-1	x-ray	2.5	A	o15530	556		79..400
1uu9	pdb	Structure of human PDK1 kinase domain in complex with BIM-3	x-ray	1.95	A	o15530	556		79..400
1uv5	pdb	GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3'-OXIME	x-ray	2.8	A	p49841	420		55..377
1uvr	pdb	Structure of human PDK1 kinase domain in complex with BIM-8	x-ray	2.81	A	o15530	556		79..400
1uwh	pdb	The complex of wild type B-RAF and BAY439006.	x-ray	2.95	A;B	p15056;p15056	766;766	;	449..717;449..717
1uwj	pdb	The complex of mutant V599E B-RAF and BAY439006.	x-ray	3.5	A;B	p15056;p15056	766;766	;	449..717;449..717
1v0b	pdb	Crystal structure of the t198a mutant of pfpk5	x-ray	2.2	A;B	q07785;q07785	288;288	;	1..286;1..286
1v0o	pdb	Structure of P. falciparum PfPK5-Indirubin-5-sulphonate ligand complex	x-ray	1.9	A;B	q07785;q07785	288;288	;	1..286;1..286
1v0p	pdb	Structure of P. falciparum PfPK5-Purvalanol B ligand complex	x-ray	2	A;B	q07785;q07785	288;288	;	1..286;1..286
1v1k	pdb	CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR	x-ray	2.31	A	p24941	298		1..292
1veb	pdb	Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 5	x-ray	2.89	A	p00517	351		32..339
1vjy	pdb	Crystal Structure of a Naphthyridine Inhibitor of Human TGF-beta Type I Receptor	x-ray	2	A	p36897	503		180..492
1vr2	pdb	HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN	x-ray	2.4	A	p35968	1356		815..1160
1vyw	pdb	Structure of CDK2/Cyclin A with PNU-292137	x-ray	2.3	A;C	p24941;p24941	298;298	;	1..292;1..292
1vyz	pdb	Structure of CDK2 complexed with PNU-181227	x-ray	2.21	A	p24941	298		1..292
1vzo	pdb	The structure of the N-terminal kinase domain of MSK1 reveals a novel autoinhibitory conformation for a dual kinase protein	x-ray	1.8	A	o75582	802		46..397,429..703
1w0x	pdb	Crystal structure of human CDK2 in complex with the inhibitor olomoucine.	x-ray	2.2	C	p24941	298		1..292
1w7h	pdb	p38 Kinase crystal structure in complex with small molecule inhibitor	x-ray	2.214	A	q16539	360		9..349
1w82	pdb	p38 Kinase crystal structure in complex with small molecule inhibitor	x-ray	2.2	A	q16539	360		9..349
1w83	pdb	p38 Kinase crystal structure in complex with small molecule inhibitor	x-ray	2.5	A	q16539	360		9..349
1w84	pdb	p38 Kinase crystal structure in complex with small molecule inhibitor	x-ray	2.2	A	q16539	360		9..349
1w8c	pdb	CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H-PURIN-2- YLAMINE AND MONOMERIC CDK2	x-ray	2.05	A	p24941	298		1..292
1w98	pdb	The structural basis of CDK2 activation by cyclin E	x-ray	2.15	A	p24941	298		1..292
1wak	pdb	X-ray structure of SRPK1	x-ray	1.73	A	q96sb4	655		67..654
1wbn	pdb	fragment based p38 inhibitors	x-ray	2.4	A	q16539	360		9..349
1wbo	pdb	fragment based p38 inhibitors	x-ray	2.16	A	q16539	360		9..349
1wbp	pdb	SRPK1 bound to 9mer docking motif peptide	x-ray	2.4	A	q96sb4	655		67..654
1wbs	pdb	Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation.	x-ray	1.8	A	q16539	360		9..349
1wbt	pdb	Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation.	x-ray	2	A	q16539	360		9..349
1wbv	pdb	Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation.	x-ray	2	A	q16539	360		9..349
1wbw	pdb	Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation.	x-ray	2.41	A	q16539	360		9..349
1wcc	pdb	Screening for fragment binding by X-ray crystallography	x-ray	2.2	A	p24941	298		1..292
1wfc	pdb	STRUCTURE OF APO, UNPHOSPHORYLATED, P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN	x-ray	2.3	A	q16539	360		9..349
1wmk	pdb	Human death-associated kinase DRP-1, mutant S308D d40	x-ray	3.6	A;B;C;D;E;F;G;H	q9uik4;q9uik4;q9uik4;q9uik4;q9uik4;q9uik4;q9uik4;q9uik4	370;370;370;370;370;370;370;370	;;;;;;;	13..302;13..302;13..302;13..302;13..302;13..302;13..302;13..302
1wvw	pdb	Crystal structures of kinase domain of DAP kinase in complex with small molecular inhibitors	x-ray	2.4	A	p53355	1430		6..291
1wvx	pdb	Crystal structures of kinase domain of DAP kinase in complex with small molecular inhibitors	x-ray	2.6	A	p53355	1430		6..291
1wvy	pdb	Crystal structures of kinase domain of DAP kinase in complex with small molecular inhibitors	x-ray	2.8	A	p53355	1430		6..291
1wzy	pdb	Crystal structure of human ERK2 complexed with a pyrazolopyridazine derivative	x-ray	2.5	A	p28482	360		19..322
1x8b	pdb	Structure of human Wee1A kinase: kinase domain complexed with inhibitor PD0407824	x-ray	1.81	A	p30291	646		279..580
1xba	pdb	Crystal structure of apo syk tyrosine kinase domain	x-ray	2	A	p43405	635		375..627
1xbb	pdb	Crystal structure of the syk tyrosine kinase domain with Gleevec	x-ray	1.57	A	p43405	635		375..627
1xbc	pdb	Crystal structure of the syk tyrosine kinase domain with Staurosporin	x-ray	2	A	p43405	635		375..627
1xh4	pdb	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants	x-ray	2.45	A	p00517	351		32..339
1xh5	pdb	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants	x-ray	2.05	A	p00517	351		32..339
1xh6	pdb	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants	x-ray	1.9	A	p00517	351		32..339
1xh7	pdb	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants	x-ray	2.47	A	p00517	351		32..339
1xh8	pdb	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants	x-ray	1.6	A	p00517	351		32..339
1xh9	pdb	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants	x-ray	1.64	A	p00517	351		32..339
1xha	pdb	Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants	x-ray	2.46	A	p00517	351		32..339
1xjd	pdb	Crystal Structure of PKC-theta complexed with Staurosporine at 2A resolution	x-ray	2	A	q04759	706		377..683
1xkk	pdb	EGFR kinase domain complexed with a quinazoline inhibitor- GW572016	x-ray	2.4	A	p00533	1210		708..1003
1xo2	pdb	Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin	x-ray	2.9	B	q00534	326		9..303
1xqz	pdb	Crystal Structure of hPim-1 kinase at 2.1 A resolution	x-ray	2.1	A	p11309	313		36..296
1xr1	pdb	Crystal structure of hPim-1 kinase in complex with AMP-PNP at 2.1 A Resolution	x-ray	2.1	A	p11309	313		36..296
1xws	pdb	Crystal Structure of the human PIM1 kinase domain	x-ray	1.8	A	p11309	313		36..296
1y57	pdb	Structure of unphosphorylated c-Src in complex with an inhibitor	x-ray	1.91	A	p12931	536		259..529
1y6a	pdb	Crystal structure of VEGFR2 in complex with a 2-anilino-5-aryl-oxazole inhibitor	x-ray	2.1	A	p35968	1356		815..1160
1y6b	pdb	Crystal structure of VEGFR2 in complex with a 2-anilino-5-aryl-oxazole inhibitor	x-ray	2.1	A	p35968	1356		815..1160
1y8g	pdb	Catalytic and ubiqutin-associated domains of MARK2/PAR-1: Inactive double mutant with selenomethionine	x-ray	2.501	A;B	o08679;o08679	722;722	;	50..305;50..305
1y8y	pdb	Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor	x-ray	1.996	A	p24941	298		1..292
1y91	pdb	Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor	x-ray	2.15	A	p24941	298		1..292
1ydr	pdb	STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE	x-ray	2.2	E	p00517	351		32..339
1yds	pdb	Structure of CAMP-dependent protein kinase, alpha-catalytic subunit in complex with H8 protein kinase inhibitor [N-(2-methylamino)ethyl]-5-isoquinolinesulfonamide	x-ray	2.2	E	p00517	351		32..339
1ydt	pdb	STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE	x-ray	2.3	E	p00517	351		32..339
1yhs	pdb	Crystal structure of Pim-1 bound to staurosporine	x-ray	2.15	A	p11309	313		36..296
1yhv	pdb	Crystal Structure of PAK1 kinase domain with two point mutations (K299R, T423E)	x-ray	1.8	A	q13153	545		261..522
1yhw	pdb	Crystal Structure of PAK1 kinase domain with one point mutations (K299R)	x-ray	1.8	A	q13153	545		261..522
1yi3	pdb	Crystal Structure of Pim-1 bound to LY294002	x-ray	2.5	A	p11309	313		36..296
1yi4	pdb	Structure of Pim-1 bound to adenosine	x-ray	2.4	A	p11309	313		36..296
1yi6	pdb	C-term tail segment of human tyrosine kinase (258-533)	x-ray	2	A;B	p12931;p12931	536;536	;	259..529;259..529
1ykr	pdb	Crystal structure of cdk2 with an aminoimidazo pyridine inhibitor	x-ray	1.8	A	p24941	298		1..292
1ym7	pdb	G Protein-Coupled Receptor Kinase 2 (GRK2)	x-ray	4.5	A;B;C;D	p21146;p21146;p21146;p21146	689;689;689;689	;;;	187..532;187..532;187..532;187..532
1yoj	pdb	Crystal structure of Src kinase domain	x-ray	1.95	A;B	p12931;p12931	536;536	;	259..529;259..529
1yol	pdb	Crystal structure of Src kinase domain in complex with CGP77675	x-ray	2.3	A;B	p12931;p12931	536;536	;	259..529;259..529
1yom	pdb	Crystal structure of Src kinase domain in complex with Purvalanol A	x-ray	2.9	A;B	p12931;p12931	536;536	;	259..529;259..529
1yqj	pdb	Crystal Structure of p38 Alpha in Complex with a Selective Pyridazine Inhibitor	x-ray	2	A	q16539	360		9..349
1yrp	pdb	Catalytic domain of human ZIP kinase phosphorylated at Thr265	x-ray	3.1	A;B	o43293;o43293	454;454	;	6..313;6..313
1yvj	pdb	Crystal structure of the Jak3 kinase domain in complex with a staurosporine analogue	x-ray	2.55	A	p52333	1124		508..788,820..1097
1yw2	pdb	Mutated Mus Musculus P38 Kinase (mP38)	x-ray	2.01	A	p47811	360		9..349
1ywn	pdb	Vegfr2 in complex with a novel 4-amino-furo[2,3-d]pyrimidine	x-ray	1.71	A	p35968	1356		815..1160
1ywr	pdb	Crystal Structure Analysis of inactive P38 kinase domain in complex with a Monocyclic Pyrazolone Inhibitor	x-ray	1.95	A	p47811	360		9..349
1ywv	pdb	Crystal Structures of Proto-Oncogene Kinase Pim1: a Target of Aberrant Somatic Hypermutations in Diffuse Large Cell Lymphoma	x-ray	2	A	p11309	313		36..296
1yxs	pdb	Crystal Structure of Kinase Pim1 with P123M mutation	x-ray	2.2	A	p11309	313		36..296
1yxt	pdb	Crystal Structure of Kinase Pim1 in complex with AMPPNP	x-ray	2	A	p11309	313		36..296
1yxu	pdb	Crystal Structure of Kinase Pim1 in Complex with AMP	x-ray	2.24	A;B;C;D	p11309;p11309;p11309;p11309	313;313;313;313	;;;	36..296;36..296;36..296;36..296
1yxv	pdb	Crystal Structure of Kinase Pim1 in complex with 3,4-Dihydroxy-1-methylquinolin-2(1H)-one	x-ray	2	A	p11309	313		36..296
1yxx	pdb	Crystal Structure of Kinase Pim1 in complex with (3E)-3-[(4-HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE	x-ray	2	A	p11309	313		36..296
1z57	pdb	Crystal structure of human CLK1 in complex with 10Z-Hymenialdisine	x-ray	1.7	A	p49759	484		150..478
1z5m	pdb	Crystal Structure Of N1-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethylpropanediamide Complexed with Human PDK1	x-ray	2.17	A	o15530	556		79..400
1z9x	pdb	Human DRP-1 kinase, W305S S308A D40 mutant, crystal form with 3 monomers in the asymmetric unit	x-ray	3.93	A;B;C	q9uik4;q9uik4;q9uik4	370;370;370	;;	13..302;13..302;13..302
1zao	pdb	Crystal Structure of A.fulgidus Rio2 Kinase Complexed With ATP and Manganese Ions	x-ray	1.84	A	o30245	282		94..277
1zar	pdb	Crystal Structure of A.fulgidus Rio2 Kinase Complexed With ADP and Manganese Ions	x-ray	1.75	A	o30245	282		94..277
1zlt	pdb	Crystal Structure of Chk1 Complexed with a Hymenaldisine Analog	x-ray	1.74	A	o14757	476		6..317
1zmu	pdb	Catalytic and ubiqutin-associated domains of MARK2/PAR-1: Wild type	x-ray	2.9	A;B	o08679;o08679	722;722	;	50..305;50..305
1zmv	pdb	Catalytic and ubiqutin-associated domains of MARK2/PAR-1: K82R mutant	x-ray	3.105	A;B	o08679;o08679	722;722	;	50..305;50..305
1zmw	pdb	Catalytic and ubiqutin-associated domains of MARK2/PAR-1: T208A/S212A inactive double mutant	x-ray	2.802	A;B	o08679;o08679	722;722	;	50..305;50..305
1zoe	pdb	Crystal structure of protein kinase CK2 in complex with TBB-derivatives inhibitors	x-ray	1.77	A	p28523	332		11..323
1zog	pdb	Crystal structure of protein kinase CK2 in complex with TBB-derivatives	x-ray	2.3	A	p28523	332		11..323
1zoh	pdb	Crystal structure of protein kinase CK2 in complex with TBB-derivatives inhibitors	x-ray	1.81	A	p28523	332		11..323
1zp9	pdb	Crystal Structure of full-legnth A.fulgidus Rio1 Serine Kinase bound to ATP and Mn2+ ions.	x-ray	2	A;B;C;D	o28471;o28471;o28471;o28471	258;258;258;258	;;;	52..240;52..240;52..240;52..240
1zrz	pdb	Crystal Structure of the Catalytic Domain of Atypical Protein Kinase C-iota	x-ray	3	A	p41743	596		252..578
1ztf	pdb	Crystal Structure of A.fulgidus Rio1 serine protein kinase	x-ray	1.99	A	o28471	258		52..240
1zth	pdb	Crystal Structure of A.fulgidus Rio1 serine protein kinase bound to ADP and Manganese ion	x-ray	1.89	A;B;C;D	o28471;o28471;o28471;o28471	258;258;258;258	;;;	52..240;52..240;52..240;52..240
1zws	pdb	Crystal structure of the catalytic domain of human DRP-1 kinase	x-ray	2.9	A;B;C;D;E;F;G;H	q9uik4;q9uik4;q9uik4;q9uik4;q9uik4;q9uik4;q9uik4;q9uik4	370;370;370;370;370;370;370;370	;;;;;;;	13..302;13..302;13..302;13..302;13..302;13..302;13..302;13..302
1zxe	pdb	Crystal Structure of eIF2alpha Protein Kinase GCN2: D835N Inactivating Mutant in Apo Form	x-ray	2.6	A;B;C;D;E;F	p15442;p15442;p15442;p15442;p15442;p15442	1659;1659;1659;1659;1659;1659	;;;;;	299..529,588..1019;299..529,588..1019;299..529,588..1019;299..529,588..1019;299..529,588..1019;299..529,588..1019
1zy4	pdb	Crystal Structure of eIF2alpha Protein Kinase GCN2: R794G Hyperactivating Mutant in Apo Form.	x-ray	1.95	A;B	p15442;p15442	1659;1659	;	299..529,588..1019;299..529,588..1019
1zy5	pdb	Crystal Structure of eIF2alpha Protein Kinase GCN2: R794G Hyperactivating Mutant Complexed with AMPPNP.	x-ray	2	A;B	p15442;p15442	1659;1659	;	299..529,588..1019;299..529,588..1019
1zyc	pdb	Crystal Structure of eIF2alpha Protein Kinase GCN2: Wild-Type in Apo Form.	x-ray	3	A;B;C;D	p15442;p15442;p15442;p15442	1659;1659;1659;1659	;;;	299..529,588..1019;299..529,588..1019;299..529,588..1019;299..529,588..1019
1zyd	pdb	Crystal Structure of eIF2alpha Protein Kinase GCN2: Wild-Type Complexed with ATP.	x-ray	2.75	A;B	p15442;p15442	1659;1659	;	299..529,588..1019;299..529,588..1019
1zyj	pdb	Human P38 MAP Kinase in Complex with Inhibitor 1a	x-ray	2	A	q16539	360		9..349
1zyl	pdb	Crystal Structure of Hypothetical Protein YihE from Escherichia coli	x-ray	2.8	A	p0c0k3	328		6..327
1zys	pdb	Co-crystal structure of Checkpoint Kinase Chk1 with a pyrrolo-pyridine inhibitor	x-ray	1.7	A				
1zz2	pdb	Two Classes of p38alpha MAP Kinase Inhibitors Having a Common Diphenylether Core but Exhibiting Divergent Binding Modes	x-ray	2	A	q16539	360		9..349
1zzl	pdb	Crystal structure of P38 with triazolopyridine	x-ray	2	A	q16539	360		9..349
2a0c	pdb	Human CDK2 in complex with olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor	x-ray	1.95	X	p24941	298		1..292
2a19	pdb	PKR kinase domain- eIF2alpha- AMP-PNP complex.	x-ray	2.5	B;C	p19525;p19525	551;551	;	259..536;259..536
2a1a	pdb	PKR kinase domain-eIF2alpha Complex	x-ray	2.8	B	p19525	551		259..536
2a27	pdb	Human DRP-1 kinase, W305S S308A D40 mutant, crystal form with 8 monomers in the asymmetric unit	x-ray	3	A;B;C;D;E;F;G;H	q9uik4;q9uik4;q9uik4;q9uik4;q9uik4;q9uik4;q9uik4;q9uik4	370;370;370;370;370;370;370;370	;;;;;;;	13..302;13..302;13..302;13..302;13..302;13..302;13..302;13..302
2a2a	pdb	High-resolution crystallographic analysis of the autoinhibited conformation of a human death-associated protein kinase	x-ray	1.47	A;B;C;D	q9uik4;q9uik4;q9uik4;q9uik4	370;370;370;370	;;;	13..302;13..302;13..302;13..302
2a4l	pdb	Human cyclin-dependent kinase 2 in complex with roscovitine	x-ray	2.4	A	p24941	298		1..292
2a4z	pdb	Crystal Structure of human PI3Kgamma complexed with AS604850	x-ray	2.9	A	p48736	1102		728..1089
2a5u	pdb	Crystal Structure of human PI3Kgamma complexed with AS605240	x-ray	2.7	A	p48736	1102		728..1089
2ac3	pdb	Structure of human Mnk2 Kinase Domain	x-ray	2.1	A	q9hbh9	465		87..395
2ac5	pdb	Structure of human Mnk2 Kinase Domain mutant D228G	x-ray	3.2	A	q9hbh9	465		87..395
2acx	pdb	Crystal Structure of G protein coupled receptor kinase 6 bound to AMPPNP	x-ray	2.6	A;B	p43250;p43250	576;576	;	184..526;184..526
2auh	pdb	Crystal structure of the Grb14 BPS region in complex with the insulin receptor tyrosine kinase	x-ray	3.2	A	p06213	1382		996..1290
2ayp	pdb	Crystal Structure of CHK1 with an Indol Inhibitor	x-ray	2.9	A	o14757	476		6..317
2b0q	pdb	"Crystal Structure Of 3',5""-Aminoglycoside Phosphotransferase Type IIIa ADP Neomycin B Complex"	x-ray	2.7	A	p0a3y5	264		3..264
2b1p	pdb	inhibitor complex of JNK3	x-ray	1.9	A	p53779	464		52..396
2b4s	pdb	Crystal structure of a complex between PTP1B and the insulin receptor tyrosine kinase	x-ray	2.3	B;D	p06213;p06213	1382;1382	;	996..1290;996..1290
2b52	pdb	Human cyclin dependent kinase 2 (CDK2) complexed with DPH-042562	x-ray	1.88	A	p24941	298		1..292
2b53	pdb	Human cyclin dependent kinase 2 (CDK2) complexed with DIN-234325	x-ray	2	A	p24941	298		1..292
2b54	pdb	Human cyclin dependent kinase 2 (CKD2)complexed with DIN-232305	x-ray	1.85	A	p24941	298		1..292
2b55	pdb	Human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole DIN-101312	x-ray	1.85	A	p24941	298		1..292
2b7a	pdb	The structural basis of Janus Kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor	x-ray	2	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
2b9f	pdb	Crystal structure of non-phosphorylated Fus3	x-ray	1.8	A	p16892	353		6..318
2b9h	pdb	Crystal structure of Fus3 with a docking motif from Ste7	x-ray	1.55	A				
2b9i	pdb	Crystal structure of Fus3 with a docking motif from Msg5	x-ray	2.5	A				
2b9j	pdb	Crystal structure of Fus3 with a docking motif from Far1	x-ray	2.3	A				
2baj	pdb	p38alpha bound to pyrazolourea	x-ray	2.25	A	q16539	360		9..349
2bak	pdb	p38alpha MAP kinase bound to MPAQ	x-ray	2.2	A	q16539	360		9..349
2bal	pdb	p38alpha MAP kinase bound to pyrazoloamine	x-ray	2.1	A	q16539	360		9..349
2baq	pdb	p38alpha bound to Ro3201195	x-ray	2.8	A	q16539	360		9..349
2bcj	pdb	Crystal Structure of G Protein-Coupled Receptor Kinase 2 in Complex with Galpha-q and Gbetagamma Subunits	x-ray	3.061	A	p21146	689		187..532
2bdf	pdb	Src kinase in complex with inhibitor AP23451	x-ray	2.1	A;B	p12931;p12931	536;536	;	259..529;259..529
2bdj	pdb	Src kinase in complex with inhibitor AP23464	x-ray	2.5	A	p12931	536		259..529
2bdw	pdb	Crystal Structure of the Auto-Inhibited Kinase Domain of Calcium/Calmodulin Activated Kinase II	x-ray	1.8	A;B	o62305;o62305	720;720	;	9..270;9..270
2bfx	pdb	Mechanism of Aurora-B activation by INCENP and inhibition by Hesperadin.	x-ray	1.8	A;B	q6de08;q6de08	361;361	;	71..354;71..354
2bfy	pdb	Complex of Aurora-B with INCENP and Hesperadin.	x-ray	1.8	A;B	q6de08;q6de08	361;361	;	71..354;71..354
2bhe	pdb	HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE	x-ray	1.9	A	p24941	298		1..292
2bhh	pdb	HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE	x-ray	2.6	A	p24941	298		1..292
2bik	pdb	Human Pim1 phosphorylated on Ser261	x-ray	1.8	B	p11309	313		36..296
2bil	pdb	The human protein kinase Pim1 in complex with its consensus peptide Pimtide	x-ray	2.55	B				
2biy	pdb	Structure of PDK1-S241A mutant kinase domain	x-ray	1.95	A	o15530	556		79..400
2bkk	pdb	Crystal structure of Aminoglycoside Phosphotransferase APH(3')-IIIa in complex with the inhibitor AR_3a	x-ray	2.15	A;C	;	;	;	;
2bkz	pdb	STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611	x-ray	2.6	A;C	p24941;p24941	298;298	;	1..292;1..292
2bmc	pdb	Aurora-2 T287D T288D complexed with PHA-680632	x-ray	2.6	A;B;C;D;E;F	o14965;o14965;o14965;o14965;o14965;o14965	403;403;403;403;403;403	;;;;;	120..386;120..386;120..386;120..386;120..386;120..386
2bpm	pdb	STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529	x-ray	2.4	A;C	p24941;p24941	298;298	;	1..292;1..292
2br1	pdb	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity	x-ray	2	A	o14757	476		6..317
2brb	pdb	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity	x-ray	2.1	A	o14757	476		6..317
2brg	pdb	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity	x-ray	2.1	A	o14757	476		6..317
2brh	pdb	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity	x-ray	2.1	A	o14757	476		6..317
2brm	pdb	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity	x-ray	2.2	A	o14757	476		6..317
2brn	pdb	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity	x-ray	2.8	A	o14757	476		6..317
2bro	pdb	Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity	x-ray	2.2	A	o14757	476		6..317
2btr	pdb	STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873	x-ray	1.85	A	p24941	298		1..292
2bts	pdb	STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032	x-ray	1.99	A	p24941	298		1..292
2buj	pdb	Crystal structure of the human Serine-threonine Kinase 16 in complex with staurosporine	x-ray	2.6	A;B	o75716;o75716	305;305	;	12..288;12..288
2bva	pdb	Crystal structure of the human P21-activated kinase 4	x-ray	2.3	A;B	o96013;o96013	591;591	;	323..578;323..578
2bzh	pdb	CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1	x-ray	1.9	B	p11309	313		36..296
2bzi	pdb	CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2	x-ray	1.9	B	p11309	313		36..296
2bzj	pdb	CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3	x-ray	2.05	A	p11309	313		36..296
2bzk	pdb	CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AMPPNP AND PIMTIDE	x-ray	2.45	B				
2c0i	pdb	Src family kinase Hck with bound inhibitor A-420983	x-ray	2.3	A;B	p08631;p08631	526;526	;	249..518;249..518
2c0o	pdb	Src family kinase Hck with bound inhibitor A-770041	x-ray	2.85	A;B	p08631;p08631	526;526	;	249..518;249..518
2c0t	pdb	Src family kinase Hck with bound inhibitor A-641359	x-ray	2.15	A;B	p08631;p08631	526;526	;	249..518;249..518
2c1a	pdb	Structure of cAMP-dependent protein kinase complexed with Isoquinoline-5-sulfonic acid (2-(2-(4-chlorobenzyloxy)ethylamino) ethyl)amide	x-ray	1.95	A	p00517	351		32..339
2c1b	pdb	Structure of cAMP-dependent protein kinase complexed with (4R,2S)-5'-(4-(4-Chlorobenzyloxy)pyrrolidin-2-ylmethanesulfonyl)isoquinoline	x-ray	2	A	p00517	351		32..339
2c30	pdb	Crystal Structure Of The Human P21-Activated Kinase 6	x-ray	1.6	A	q9nqu5	681		412..667
2c3i	pdb	CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH IMIDAZOPYRIDAZIN I	x-ray	1.9	B				
2c3j	pdb	Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification	x-ray	2.1	A	o14757	476		6..317
2c3k	pdb	Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification	x-ray	2.6	A	o14757	476		6..317
2c3l	pdb	Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification	x-ray	2.35	A	o14757	476		6..317
2c47	pdb	Structure of casein kinase 1 gamma 2	x-ray	2.4	A;B;C;D	p78368;p78368;p78368;p78368	415;415;415;415	;;;	42..329;42..329;42..329;42..329
2c4g	pdb	STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514	x-ray	2.7	A;C	p24941;p24941	298;298	;	1..292;1..292
2c5n	pdb	Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design	x-ray	2.1	A;C	p24941;p24941	298;298	;	1..292;1..292
2c5o	pdb	Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design	x-ray	2.1	A;C	p24941;p24941	298;298	;	1..292;1..292
2c5v	pdb	Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design	x-ray	2.9	A;C	;	;	;	;
2c5x	pdb	Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design	x-ray	2.9	A;C	p24941;p24941	298;298	;	1..292;1..292
2c5y	pdb	DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN	x-ray	2.25	A	p24941	298		1..292
2c68	pdb	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor	x-ray	1.95	A	p24941	298		1..292
2c69	pdb	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor	x-ray	2.1	A	p24941	298		1..292
2c6d	pdb	Aurora A kinase activated mutant (T287D) in complex with ADPNP	x-ray	2.2	A	o14965	403		120..386
2c6e	pdb	Aurora A kinase activated mutant (T287D) in complex with a 5- aminopyrimidinyl quinazoline inhibitor	x-ray	2.1	A;B	o14965;o14965	403;403	;	120..386;120..386
2c6i	pdb	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor	x-ray	1.8	A	p24941	298		1..292
2c6k	pdb	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor	x-ray	1.9	A	p24941	298		1..292
2c6l	pdb	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor	x-ray	2.3	A	p24941	298		1..292
2c6m	pdb	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor	x-ray	1.9	A	p24941	298		1..292
2c6o	pdb	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor	x-ray	2.1	A	p24941	298		1..292
2c6t	pdb	Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor	x-ray	2.61	A;C	p24941;p24941	298;298	;	1..292;1..292
2cch	pdb	The crystal structure of CDK2 cyclin A in complex with a substrate peptide derived from CDC modified with a gamma-linked ATP analogue	x-ray	1.7	A;C	p24941;p24941	298;298	;	1..292;1..292
2cci	pdb	Crystal structure of phospho-CDK2 Cyclin A in complex with a peptide containing both the substrate and recruitment sites of CDC6	x-ray	2.7	A;C	p24941;p24941	298;298	;	1..292;1..292
2cdz	pdb	CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A	x-ray	2.3	A	o96013	591		323..578
2cgu	pdb	Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening	x-ray	2.5	A	o14757	476		6..317
2cgv	pdb	Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening	x-ray	2.6	A	o14757	476		6..317
2cgw	pdb	Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening	x-ray	2.2	A	o14757	476		6..317
2cgx	pdb	Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening	x-ray	2.2	A	o14757	476		6..317
2chl	pdb	Structure of casein kinase 1 gamma 3	x-ray	1.95	A	q9y6m4	447		39..325
2chw	pdb	A pharmacological map of the PI3-K family defines a role for p110 alpha in signaling: The structure of complex of phosphoinositide 3- kinase gamma with inhibitor PIK-39	x-ray	2.6	A	p48736	1102		728..1089
2chx	pdb	A pharmacological map of the PI3-K family defines a role for p110alpha in signaling: The structure of complex of phosphoinositide 3-kinase gamma with inhibitor PIK-90	x-ray	2.5	A	p48736	1102		728..1089
2chz	pdb	A pharmacological map of the PI3-K family defines a role for p110alpha in signaling: The structure of complex of phosphoinositide 3-kinase gamma with inhibitor PIK-93	x-ray	2.6	A	p48736	1102		728..1089
2cjm	pdb	Mechanism of CDK inhibition by active site phosphorylation: CDK2 Y15p T160p in complex with cyclin A structure	x-ray	2.3	A;C	p24941;p24941	298;298	;	1..292;1..292
2cke	pdb	Human death-associated DRP-1 kinase in complex with inhibitor	x-ray	2.8	A;B;C;D	q9uik4;q9uik4;q9uik4;q9uik4	370;370;370;370	;;;	13..302;13..302;13..302;13..302
2cko	pdb	Crystal structure of Human Choline Kinase alpha 2	x-ray	2.15	A;B	p35790;p35790	457;457	;	82..455;82..455
2ckp	pdb	Crystal structure of Human Choline Kinase alpha-2 in complex with ADP	x-ray	3.1	A;B	p35790;p35790	457;457	;	82..455;82..455
2ckq	pdb	Crystal structure of Human Choline Kinase alpha 2 in complex with Phosphocholine	x-ray	2.4	A;B	p35790;p35790	457;457	;	82..455;82..455
2clq	pdb	Structure of mitogen-activated protein kinase kinase kinase 5	x-ray	2.3	A;B	q99683;q99683	1374;1374	;	685..939;685..939
2clx	pdb	4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects	x-ray	1.8	A	p24941	298		1..292
2cmw	pdb	Structure of Human Casein kinase 1 gamma-1 in complex with 2-(2- Hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine	x-ray	1.75	A	q9hcp0	422		40..328
2cn5	pdb	Crystal structure of human Chk2 in complex with ADP	x-ray	2.25	A	o96017	543		213..500
2cn8	pdb	Crystal structure of human Chk2 in complex with debromohymenialdisine	x-ray	2.7	A	o96017	543		213..500
2cpk	pdb	CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE	x-ray	2.7	E	p05132	351		28..339
2csn	pdb	BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7	x-ray	2.5	A	p40233	446		8..296
2dq7	pdb	Crystal Structure of Fyn kinase domain complexed with staurosporine	x-ray	2.8	X	p06241	537		258..529
2ds1	pdb	Human cyclin dependent kinase 2 complexed with the CDK4 inhibitor	x-ray	2	A	p24941	298		1..292
2duv	pdb	Structure of CDK2 with a 3-hydroxychromones	x-ray	2.2	A	p24941	298		1..292
2dwb	pdb	Aurora-A kinase complexed with AMPPNP	x-ray	2.5	A	o14965	403		120..386
2dyl	pdb	Crystal structure of human mitogen-activated protein kinase kinase 7 activated mutant (S287D, T291D)	x-ray	2.45	A	o14733	419		113..384
2e2b	pdb	Crystal structure of the c-Abl kinase domain in complex with INNO-406	x-ray	2.2	A;B	p00519;p00519	1130;1130	;	231..498;231..498
2e9n	pdb	Structure of h-CHK1 complexed with A767085	x-ray	2.5	A	o14757	476		6..317
2e9o	pdb	Structure of h-CHK1 complexed with AA582939	x-ray	2.1	A	o14757	476		6..317
2e9p	pdb	Structure of h-CHK1 complexed with A771129	x-ray	2.6	A	o14757	476		6..317
2e9u	pdb	Structure of h-CHK1 complexed with A780125	x-ray	2	A	o14757	476		6..317
2e9v	pdb	Structure of h-CHK1 complexed with A859017	x-ray	2	A;B	o14757;o14757	476;476	;	6..317;6..317
2eb2	pdb	Crystal structure of mutated EGFR kinase domain (G719S)	x-ray	2.5	A	p00533	1210		708..1003
2eb3	pdb	Crystal structure of mutated EGFR kinase domain (L858R) in complex with AMPPNP	x-ray	2.84	A	p00533	1210		708..1003
2erk	pdb	PHOSPHORYLATED MAP KINASE ERK2	x-ray	2.4	A	p63086	358		17..320
2erz	pdb	Crystal Structure of c-AMP Dependent Kinase (PKA) bound to hydroxyfasudil	x-ray	2.2	E	p05132	351		28..339
2esm	pdb	Crystal Structure of ROCK 1 bound to fasudil	x-ray	3.2	A;B	q13464;q13464	1354;1354	;	73..413;73..413
2etk	pdb	Crystal Structure of ROCK 1 bound to hydroxyfasudil	x-ray	2.96	A;B	q13464;q13464	1354;1354	;	73..413;73..413
2etm	pdb	Crystal Structure of Focal Adhesion Kinase Domain Complexed with 7H-Pyrrolo [2,3-d] pyrimidine Derivative	x-ray	2.3	A;B	q05397;q05397	1052;1052	;	409..693;409..693
2etr	pdb	Crystal Structure of ROCK I bound to Y-27632	x-ray	2.6	A;B	q13464;q13464	1354;1354	;	73..413;73..413
2eu9	pdb	Crystal Structure of CLK3	x-ray	1.53	A	p49761	490		145..479
2euf	pdb	X-ray structure of human CDK6-Vcyclin in complex with the inhibitor PD0332991	x-ray	3	B	q00534	326		9..303
2eva	pdb	Structural Basis for the Interaction of TAK1 Kinase with its Activating Protein TAB1	x-ray	2	A	o43318	606		14..292
2ewa	pdb	Dual binding mode of pyridinylimidazole to MAP kinase p38	x-ray	2.1	A	p47811	360		9..349
2exc	pdb	Inhibitor complex of JNK3	x-ray	2.75	X	p53779	464		52..396
2exe	pdb	Crystal structure of the phosphorylated CLK3	x-ray	2.35	A	p49761	490		145..479
2exm	pdb	Human CDK2 in complex with isopentenyladenine	x-ray	1.8	A	p24941	298		1..292
2f2c	pdb	X-ray structure of human CDK6-Vcyclinwith the inhibitor aminopurvalanol	x-ray	2.8	B	q00534	326		9..303
2f2u	pdb	crystal structure of the Rho-kinase kinase domain	x-ray	2.4	A;B	q28021;q28021	1388;1388	;	89..412;89..412
2f49	pdb	Crystal structure of Fus3 in complex with a Ste5 peptide	x-ray	1.9	A;B	;	;	;	;
2f4j	pdb	Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680	x-ray	1.91	A	p00519	1130		231..498
2f57	pdb	Crystal Structure Of The Human P21-Activated Kinase 5	x-ray	1.8	A;B	q9p286;q9p286	719;719	;	453..702;453..702
2f7e	pdb	PKA complexed with (S)-2-(1H-Indol-3-yl)-1-(5-isoquinolin-6-yl-pyridin-3-yloxymethyl-etylamine	x-ray	2	E	p00517	351		32..339
2f7x	pdb	Protein Kinase A bound to (S)-2-(1H-Indol-3-yl)-1-[5-((E)-2-pyridin-4-yl-vinyl)-pyridin-3-yloxymethyl]-ethylamine	x-ray	1.9	E	p00517	351		32..339
2f7z	pdb	Protein Kinase A bound to (R)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphtyridin-5-yloxy)-ehylamine	x-ray	3	E	p00517	351		32..339
2f9g	pdb	Crystal structure of Fus3 phosphorylated on Tyr182	x-ray	2.1	A	p16892	353		6..318
2fa2	pdb	Crystal structure of Fus3 without a peptide from Ste5	x-ray	2.85	A;B	p16892;p16892	353;353	;	6..318;6..318
2fb8	pdb	Structure of the B-Raf kinase domain bound to SB-590885	x-ray	2.9	A;B	p15056;p15056	766;766	;	449..717;449..717
2fgi	pdb	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074	x-ray	2.5	A;B	p11362;p11362	822;822	;	468..754;468..754
2fh9	pdb	Structure and dimerization of the kinase domain from yeast Snf1	x-ray	2.8	A	p06782	633		52..307
2fo0	pdb	Organization of the SH3-SH2 Unit in Active and Inactive Forms of the c-Abl Tyrosine Kinase	x-ray	2.27	A	p00519	1130		231..498
2fsl	pdb	mitogen activated protein kinase p38alpha (D176A+F327S) activating mutant form-A	x-ray	1.7	X	q16539	360		9..349
2fsm	pdb	mitogen activated protein kinase p38alpha (D176A+F327S) activating mutant form-B	x-ray	1.86	X	q16539	360		9..349
2fso	pdb	mitogen activated protein kinase p38alpha (D176A) activating mutant	x-ray	1.83	X	q16539	360		9..349
2fst	pdb	mitogen activated protein kinase p38alpha (D176A+F327L) activating mutant	x-ray	1.45	X	q16539	360		9..349
2fum	pdb	Catalytic domain of protein kinase PknB from Mycobacterium tuberculosis in complex with mitoxantrone	x-ray	2.89	A;B;C;D	p9wi81;p9wi81;p9wi81;p9wi81	626;626;626;626	;;;	8..275;8..275;8..275;8..275
2fvd	pdb	Cyclin Dependent Kinase 2 (CDK2) with diaminopyrimidine inhibitor	x-ray	1.85	A	p24941	298		1..292
2fys	pdb	Crystal structure of Erk2 complex with KIM peptide derived from MKP3	x-ray	2.5	A;B	p63086;p63086	358;358	;	17..320;17..320
2g01	pdb	Pyrazoloquinolones as Novel, Selective JNK1 inhibitors	x-ray	3.5	A;B	p45983;p45983	427;427	;	12..357;12..357
2g15	pdb	Structural Characterization of autoinhibited c-Met kinase	x-ray	2.15	A	p08581	1390		1079..1341
2g1t	pdb	A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain	x-ray	1.8	A;B;C;D	;;;	;;;	;;;	;;;
2g2f	pdb	A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain	x-ray	2.7	A;B	;	;	;	;
2g2h	pdb	A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain	x-ray	2	A;B	p00519;p00519	1130;1130	;	231..498;231..498
2g2i	pdb	A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain	x-ray	3.12	A;B	;	;	;	;
2g9x	pdb	Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor NU6271	x-ray	2.5	A;C	p24941;p24941	298;298	;	1..292;1..292
2gcd	pdb	TAO2 kinase domain-staurosporine structure	x-ray	2.55	A;B	q9jls3;q9jls3	1235;1235	;	28..282;28..282
2gdo	pdb	4-(Aminoalkylamino)-3-Benzimidazole-Quinolinones As Potent CHK1 Inhibitors	x-ray	3	A	o14757	476		6..317
2gfc	pdb	cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24	x-ray	1.87	A	p00517	351		32..339
2gfs	pdb	P38 Kinase Crystal Structure in complex with RO3201195	x-ray	1.752	A	q16539	360		9..349
2ghg	pdb	h-CHK1 complexed with A431994	x-ray	3.5	A	o14757	476		6..317
2ghl	pdb	Mutant Mus Musculus P38 Kinase Domain in Complex with Inhibitor PG-874743	x-ray	2.099	A	p47811	360		9..349
2ghm	pdb	Mutated MAP kinase P38 (Mus Musculus) in complex with Inhbitor PG-895449	x-ray	2.35	A	p47811	360		9..349
2gmx	pdb	Selective Aminopyridine-Based C-Jun N-terminal Kinase inhibitors with cellular activity	x-ray	3.5	A;B	p45983;p45983	427;427	;	12..357;12..357
2gnf	pdb	Protein kinase A fivefold mutant model of Rho-kinase with Y-27632	x-ray	2.28	A	p00517	351		32..339
2gng	pdb	Protein kinase A fivefold mutant model of Rho-kinase	x-ray	1.87	A	p00517	351		32..339
2gnh	pdb	PKA five fold mutant model of Rho-kinase with H1152P	x-ray	2.05	A	p00517	351		32..339
2gni	pdb	PKA fivefold mutant model of Rho-kinase with inhibitor Fasudil (HA1077)	x-ray	2.27	A	p00517	351		32..339
2gnj	pdb	PKA three fold mutant model of Rho-kinase with Y-27632	x-ray	2.28	A	p00517	351		32..339
2gnl	pdb	PKA threefold mutant model of Rho-kinase with inhibitor H-1152P	x-ray	2.6	A	p00517	351		32..339
2gph	pdb	Docking motif interactions in the MAP kinase ERK2	x-ray	1.9	A	p63086	358		17..320
2gqg	pdb	X-ray Crystal Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain	x-ray	2.4	A;B	p00519;p00519	1130;1130	;	231..498;231..498
2gs2	pdb	Crystal Structure of the active EGFR kinase domain	x-ray	2.8	A	p00533	1210		708..1003
2gs6	pdb	Crystal Structure of the active EGFR kinase domain in complex with an ATP analog-peptide conjugate	x-ray	2.6	A				
2gs7	pdb	Crystal Structure of the inactive EGFR kinase domain in complex with AMP-PNP	x-ray	2.6	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
2gsf	pdb	The Human Epha3 Receptor Tyrosine Kinase and Juxtamembrane Region	x-ray	1.77	A	p29320	983		614..915
2gtm	pdb	Mutated Mouse P38 MAP Kinase Domain in complex with Inhibitor PG-892579	x-ray	1.9	A	p47811	360		9..349
2gtn	pdb	Mutated MAP kinase P38 (Mus Musculus) in complex with Inhbitor PG-951717	x-ray	1.8	A	p47811	360		9..349
2gu8	pdb	Discovery of 2-Pyrimidyl-5-Amidothiophenes as Novel and Potent Inhibitors for AKT: Synthesis and SAR Studies	x-ray	2.2	A				
2h34	pdb	Apoenzyme crystal structure of the tuberculosis serine/threonine kinase, PknE	x-ray	2.8	A;B	p9wi77;p9wi77	566;566	;	13..326;13..326
2h6d	pdb	Protein Kinase Domain of the Human 5'-AMP-activated protein kinase catalytic subunit alpha-2 (AMPK alpha-2 chain)	x-ray	1.85	A	p54646	552		13..269
2h8h	pdb	Src kinase in complex with a quinazoline inhibitor	x-ray	2.2	A	p12931	536		259..529
2h96	pdb	Discovery of Potent, Highly Selective, and Orally Bioavailable Pyridine Carboxamide C-jun NH2-terminal Kinase Inhibitors	x-ray	3	A;B	p45983;p45983	427;427	;	12..357;12..357
2h9v	pdb	Structural basis for induced-fit binding of Rho-kinase to the inhibitor Y27632	x-ray	3.1	A	q28021	1388		89..412
2hak	pdb	Catalytic and ubiqutin-associated domains of MARK1/PAR-1	x-ray	2.6	A;B;C;D;E;F;G;H	q9p0l2;q9p0l2;q9p0l2;q9p0l2;q9p0l2;q9p0l2;q9p0l2;q9p0l2	795;795;795;795;795;795;795;795	;;;;;;;	57..312;57..312;57..312;57..312;57..312;57..312;57..312;57..312
2hck	pdb	SRC FAMILY KINASE HCK-QUERCETIN COMPLEX	x-ray	3	A;B	p08631;p08631	526;526	;	249..518;249..518
2hel	pdb	Crystal structure of a mutant EphA4 kinase domain (Y742A)	x-ray	2.35	A	q03137	986		613..907
2hen	pdb	Crystal Structure of the EphB2 Receptor Kinase domain in complex with ADP	x-ray	2.6	A;B;C;D	p54763;p54763;p54763;p54763	986;986;986;986	;;;	613..914;613..914;613..914;613..914
2hiw	pdb	Crystal Structure of Inactive Conformation Abl Kinase Catalytic Domain Complexed with Type II Inhibitor	x-ray	2.2	A;B	p00519;p00519	1130;1130	;	231..498;231..498
2hk5	pdb	Hck Kinase in Complex with Lck targetted Inhibitor PG-1009247	x-ray	2	A	p08631	526		249..518
2hog	pdb	crystal structure of Chek1 in complex with inhibitor 20	x-ray	1.9	A	o14757	476		6..317
2hw6	pdb	Crystal structure of Mnk1 catalytic domain	x-ray	2.5	A;B	q9bub5;q9bub5	465;465	;	53..393;53..393
2hw7	pdb	Crystal Structure of Mnk2-D228G in complex with Staurosporine	x-ray	2.71	A	q9hbh9	465		87..395
2hwo	pdb	Crystal structure of Src kinase domain in complex with covalent inhibitor	x-ray	2.5	A;B	p00523;p00523	533;533	;	256..526;256..526
2hwp	pdb	Crystal structure of Src kinase domain in complex with covalent inhibitor PD168393	x-ray	2.48	A;B	p00523;p00523	533;533	;	256..526;256..526
2hxl	pdb	crystal structure of Chek1 in complex with inhibitor 1	x-ray	1.8	A	o14757	476		6..317
2hxq	pdb	crystal structure of Chek1 in complex with inhibitor 2	x-ray	2	A	o14757	476		6..317
2hy0	pdb	crystal structure of chek1 in complex with inhibitor 22	x-ray	1.7	A	o14757	476		6..317
2hy8	pdb	PAK1 complex with ST2001	x-ray	2	1	q13153	545		261..522
2hyy	pdb	Human Abl kinase domain in complex with imatinib (STI571, Glivec)	x-ray	2.4	A;B;C;D	p00519;p00519;p00519;p00519	1130;1130;1130;1130	;;;	231..498;231..498;231..498;231..498
2hz0	pdb	Abl kinase domain in complex with NVP-AEG082	x-ray	2.1	A;B	p00519;p00519	1130;1130	;	231..498;231..498
2hz4	pdb	Abl kinase domain unligated and in complex with tetrahydrostaurosporine	x-ray	2.8	A;B;C	p00519;p00519;p00519	1130;1130;1130	;;	231..498;231..498;231..498
2hzi	pdb	Abl kinase domain in complex with PD180970	x-ray	1.7	A;B	p00519;p00519	1130;1130	;	231..498;231..498
2hzn	pdb	Abl kinase domain in complex with NVP-AFG210	x-ray	2.7	A	p00520	1123		231..498
2i0e	pdb	Structure of catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor	x-ray	2.6	A;B	p05771;p05771	671;671	;	338..665;338..665
2i0h	pdb	The structure of p38alpha in complex with an arylpyridazinone	x-ray	2	A	q16539	360		9..349
2i0v	pdb	c-FMS tyrosine kinase in complex with a quinolone inhibitor	x-ray	2.8	A	p07333	972		551..909
2i0y	pdb	cFMS tyrosine kinase (FGF KID) in complex with an arylamide inhibitor	x-ray	1.9	A	p07333	972		551..909
2i1m	pdb	cFMS tyrosine kinase (tie2 KID) in complex with an arylamide inhibitor	x-ray	1.8	A	p07333	972		551..909
2i40	pdb	Cdk2/Cyclin A complexed with a thiophene carboxamide inhibitor	x-ray	2.8	A;C	p24941;p24941	298;298	;	1..292;1..292
2i7q	pdb	Crystal structure of Human Choline Kinase A	x-ray	1.9	A	p35790	457		82..455
2ig7	pdb	Crystal structure of Human Choline Kinase B	x-ray	1.8	A;B	q9y259;q9y259	395;395	;	47..388;47..388
2ijm	pdb	Crystal Structure of Focal Adhesion Kinase Domain with 2 molecules in the Asymmetric Unit Complexed with ADP and ATP	x-ray	2.187	A;B	q05397;q05397	1052;1052	;	409..693;409..693
2in6	pdb	Wee1 kinase complex with inhibitor PD311839	x-ray	1.9	A	p30291	646		279..580
2io6	pdb	Wee1 kinase complexed with inhibitor PD330961	x-ray	2.2	A	p30291	646		279..580
2itn	pdb	Crystal structure of EGFR kinase domain G719S mutation in complex with AMP-PNP	x-ray	2.47	A	p00533	1210		708..1003
2ito	pdb	Crystal structure of EGFR kinase domain G719S mutation in complex with Iressa	x-ray	3.25	A	p00533	1210		708..1003
2itp	pdb	Crystal structure of EGFR kinase domain G719S mutation in complex with AEE788	x-ray	2.74	A	p00533	1210		708..1003
2itq	pdb	Crystal structure of EGFR kinase domain G719S mutation in complex with AFN941	x-ray	2.68	A	p00533	1210		708..1003
2itt	pdb	Crystal structure of EGFR kinase domain L858R mutation in complex with AEE788	x-ray	2.73	A	p00533	1210		708..1003
2itu	pdb	Crystal structure of EGFR kinase domain L858R mutation in complex with AFN941	x-ray	2.8	A	p00533	1210		708..1003
2itv	pdb	Crystal structure of EGFR kinase domain L858R mutation in complex with AMP-PNP	x-ray	2.47	A	p00533	1210		708..1003
2itw	pdb	Crystal structure of EGFR kinase domain in complex with AFN941	x-ray	2.88	A	p00533	1210		708..1003
2itx	pdb	Crystal structure of EGFR kinase domain in complex with AMP-PNP	x-ray	2.98	A	p00533	1210		708..1003
2ity	pdb	Crystal structure of EGFR kinase domain in complex with Iressa	x-ray	3.42	A	p00533	1210		708..1003
2itz	pdb	Crystal structure of EGFR kinase domain L858R mutation in complex with Iressa	x-ray	2.8	A	p00533	1210		708..1003
2ivs	pdb	Crystal structure of non-phosphorylated RET tyrosine kinase domain	x-ray	2	A;B	p07949;p07949	1114;1114	;	699..1005;699..1005
2ivt	pdb	Crystal structure of phosphorylated RET tyrosine kinase domain	x-ray	2.6	A	p07949	1114		699..1005
2ivu	pdb	Crystal structure of phosphorylated RET tyrosine kinase domain complexed with the inhibitor ZD6474	x-ray	2.5	A	p07949	1114		699..1005
2ivv	pdb	Crystal structure of phosphorylated RET tyrosine kinase domain complexed with the inhibitor PP1	x-ray	2.25	A	p07949	1114		699..1005
2iw6	pdb	STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR	x-ray	2.3	A;C	p24941;p24941	298;298	;	1..292;1..292
2iw8	pdb	STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR	x-ray	2.3	A;C	p24941;p24941	298;298	;	1..292;1..292
2iw9	pdb	STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR	x-ray	2	A;C	p24941;p24941	298;298	;	1..292;1..292
2iwi	pdb	CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1	x-ray	2.8	A;B	q9p1w9;q9p1w9	311;311	;	31..290;31..290
2izr	pdb	Structure of casein kinase gamma 3 in complex with inhibitor	x-ray	1.3	A	q9y6m4	447		39..325
2izs	pdb	Structure of casein kinase gamma 3 in complex with inhibitor	x-ray	1.95	A	q9y6m4	447		39..325
2izt	pdb	Structure of casein kinase gamma 3 in complex with inhibitor	x-ray	2	A	q9y6m4	447		39..325
2izu	pdb	Structure of casein kinase gamma 3 in complex with inhibitor	x-ray	1.85	A	q9y6m4	447		39..325
2j0i	pdb	CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4	x-ray	1.6	A	o96013	591		323..578
2j0j	pdb	Crystal structure of a fragment of focal adhesion kinase containing the FERM and kinase domains.	x-ray	2.8	A	q00944	1053		409..698
2j0k	pdb	Crystal structure of a fragment of focal adhesion kinase containing the FERM and kinase domains.	x-ray	3	A;B	q00944;q00944	1053;1053	;	409..698;409..698
2j0l	pdb	Crystal structure of a the active conformation of the kinase domain of focal adhesion kinase with a phosphorylated activation loop.	x-ray	2.3	A	q00944	1053		409..698
2j0m	pdb	Crystal structure a two-chain complex between the FERM and kinase domains of focal adhesion kinase.	x-ray	2.8	B	q00944	1053		409..698
2j2i	pdb	Crystal Structure of the humab PIM1 in complex with LY333531	x-ray	1.9	B	p11309	313		36..296
2j4z	pdb	Structure of Aurora-2 in complex with PHA-680626	x-ray	2	A;B	o14965;o14965	403;403	;	120..386;120..386
2j50	pdb	Structure of Aurora-2 in complex with PHA-739358	x-ray	3	A;B	o14965;o14965	403;403	;	120..386;120..386
2j51	pdb	Crystal structure of Human STE20-like kinase bound to 5-Amino-3-((4-(aminosulfonyl)phenyl)amino) -N-(2,6-difluorophenyl)-1H-1,2,4-triazole- 1-carbothioamide	x-ray	2.1	A	q9h2g2	1235		29..293
2j5e	pdb	Crystal structure of EGFR kinase domain in complex with an irreversible inhibitor 13-jab	x-ray	3.1	A	p00533	1210		708..1003
2j5f	pdb	Crystal structure of EGFR kinase domain in complex with an irreversible inhibitor 34-jab	x-ray	3	A	p00533	1210		708..1003
2j6m	pdb	Crystal structure of EGFR kinase domain in complex with AEE788	x-ray	3.1	A	p00533	1210		708..1003
2j7t	pdb	Crystal structure of human serine threonine kinase-10 bound to SU11274	x-ray	2	A	o94804	968		31..302
2j90	pdb	Crystal structure of human ZIP kinase in complex with a tetracyclic pyridone inhibitor (Pyridone 6)	x-ray	2	A;B	o43293;o43293	454;454	;	6..313;6..313
2j9m	pdb	Crystal Structure of CDK2 in complex with Macrocyclic Aminopyrimidine	x-ray	2.5	A	p24941	298		1..292
2jam	pdb	Crystal structure of human calmodulin-dependent protein kinase I G	x-ray	1.7	A;B	;	;	;	;
2jav	pdb	Human Kinase with pyrrole-indolinone ligand	x-ray	2.2	A	p51955	445		5..280
2jbo	pdb	Protein kinase MK2 in complex with an inhibitor (crystal form-1, soaking)	x-ray	3.1	A	p49137	400		59..369
2jbp	pdb	Protein kinase MK2 in complex with an inhibitor (crystal form-2, co- crystallization)	x-ray	3.31	A;B;C;D;E;F;G;H;I;J;K;L	p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137	400;400;400;400;400;400;400;400;400;400;400;400	;;;;;;;;;;;	59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369
2jc6	pdb	Crystal structure of human calmodulin-dependent protein kinase 1D	x-ray	2.3	A;C	q8iu85;q8iu85	385;385	;	16..307;16..307
2jd5	pdb	Sky1p bound to Npl3p-derived substrate peptide	x-ray	2.5	A;B	q03656;q03656	742;742	;	154..720;154..720
2jdo	pdb	STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE	x-ray	1.8	A	p31751	481		147..460
2jdr	pdb	STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A-443654	x-ray	2.3	A	p31751	481		147..460
2jds	pdb	Structure of cAMP-dependent protein kinase complexed with A-443654	x-ray	2	A	p00517	351		32..339
2jdt	pdb	Structure of PKA-PKB chimera complexed with ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE	x-ray	2.15	A	p00517	351		32..339
2jdv	pdb	Structure of PKA-PKB chimera complexed with A-443654	x-ray	2.08	A	p00517	351		32..339
2jed	pdb	The crystal structure of the kinase domain of the protein kinase C theta in complex with NVP-XAA228 at 2.32A resolution.	x-ray	2.32	A;B	q04759;q04759	706;706	;	377..683;377..683
2jfl	pdb	CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(2,6- DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE	x-ray	2.2	A	q9h2g2	1235		29..293
2jfm	pdb	CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)	x-ray	2.85	A	q9h2g2	1235		29..293
2jgz	pdb	Crystal structure of phospho-CDK2 in complex with Cyclin B	x-ray	2.9	A	p24941	298		1..292
2jii	pdb	Structure of vaccinia related kinase 3	x-ray	2	A;B	q8iv63;q8iv63	474;474	;	197..466;197..466
2jit	pdb	Crystal structure of EGFR kinase domain T790M mutation	x-ray	3.1	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
2jiu	pdb	Crystal structure of EGFR kinase domain T790M mutation in complex with AEE788	x-ray	3.05	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
2jiv	pdb	Crystal structure of EGFR kinase domain T790M mutation in compex with HKI-272	x-ray	3.5	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
2jkk	pdb	Focal Adhesion Kinase catalytic domain in complex with bis-anilino pyrimidine inhibitor	x-ray	2	A	q00944	1053		409..698
2jkm	pdb	Focal Adhesion Kinase catalytic domain in complex with bis-anilino pyrimidine inhibitor	x-ray	2.31	A	q00944	1053		409..698
2jko	pdb	Focal Adhesion Kinase catalytic domain in complex with bis-anilino pyrimidine inhibitor	x-ray	1.65	A	q00944	1053		409..698
2jkq	pdb	Focal Adhesion Kinase catalytic domain in complex with bis-anilino pyrimidine inhibitor	x-ray	2.6	A	q00944	1053		409..698
2jld	pdb	Extremely Tight Binding of Ruthenium Complex to Glycogen Synthase Kinase 3	x-ray	2.35	A;B	;	;	;	;
2kty	pdb	Solution Structure of human Vaccinia Related Kinase-1	nmr		A	q99986	396		31..340
2kul	pdb	Solution structure of human vaccinia related kinase 1(VRK1)	nmr		A	q99986	396		31..340
2lav	pdb	NMR solution structure of human Vaccinia-Related Kinase 1	nmr		A	q99986	396		31..340
2lgc	pdb	Joint NMR and X-ray refinement reveals the structure of a novel dibenzo[a,d]cycloheptenone inhibitor/p38 MAP kinase complex in solution	nmr		A	q16539	360		9..349
2no3	pdb	Novel 4-anilinopyrimidines as potent JNK1 Inhibitors	x-ray	3.2	A;B	;	;	;	;
2np8	pdb	Structural Basis for the Inhibition of Aurora A Kinase by a Novel Class of High Affinity Disubstituted Pyrimidine Inhibitors	x-ray	2.25	A	o14965	403		120..386
2npq	pdb	A Novel Lipid Binding Site in the p38 alpha MAP Kinase	x-ray	1.8	A	q16539	360		9..349
2nru	pdb	Crystal structure of IRAK-4	x-ray	2	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
2nry	pdb	Crystal structure of IRAK-4	x-ray	2.15	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
2o0u	pdb	Crystal structure of human JNK3 complexed with N-{3-cyano-6-[3-(1-piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl}-1-naphthalenecarboxamide	x-ray	2.1	A	p53779	464		52..396
2o2u	pdb	Crystal structure of human JNK3 complexed with N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide	x-ray	2.45	A	p53779	464		52..396
2o3p	pdb	Crystal structure of Pim1 with Quercetin	x-ray	2.24	A	p11309	313		36..296
2o5k	pdb	Crystal Structure of GSK3beta in complex with a benzoimidazol inhibitor	x-ray	3.2	A	p49841	420		55..377
2o63	pdb	Crystal structure of Pim1 with Myricetin	x-ray	2	A	p11309	313		36..296
2o64	pdb	Crystal structure of Pim1 with Quercetagetin	x-ray	2.44	A	p11309	313		36..296
2o65	pdb	Crystal structure of Pim1 with Pentahydroxyflavone	x-ray	2.85	A	p11309	313		36..296
2o8y	pdb	Apo IRAK4 Kinase Domain	x-ray	2.4	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
2obj	pdb	Crystal structure of human PIM-1 Kinase in complex with inhibitor	x-ray	2.5	A	p11309	313		36..296
2of2	pdb	crystal structure of furanopyrimidine 8 bound to lck	x-ray	2	A	p06239	509		231..500
2of4	pdb	crystal structure of furanopyrimidine 1 bound to lck	x-ray	2.7	A	p06239	509		231..500
2ofu	pdb	x-ray crystal structure of 2-aminopyrimidine carbamate 43 bound to Lck	x-ray	2	A	p06239	509		231..500
2ofv	pdb	crystal structure of aminoquinazoline 1 bound to Lck	x-ray	2	A;B	p06239;p06239	509;509	;	231..500;231..500
2og8	pdb	crystal structure of aminoquinazoline 36 bound to Lck	x-ray	2.3	A;B	p06239;p06239	509;509	;	231..500;231..500
2ogv	pdb	Crystal Structure of the Autoinhibited Human c-Fms Kinase Domain	x-ray	2.7	A	p07333	972		551..909
2oh0	pdb	Crystal structure of Protein Kinase A in complex with Pyridine-Pyrazolopyridine Based Inhibitors	x-ray	2.2	E				
2oh4	pdb	Crystal structure of Vegfr2 with a benzimidazole-urea inhibitor	x-ray	2.05	A	p35968	1356		815..1160
2oi4	pdb	Crystal structure of human PIM1 in complex with fluorinated ruthenium pyridocarbazole	x-ray	2.2	X	p11309	313		36..296
2oib	pdb	Crystal structure of IRAK4 kinase domain apo form	x-ray	2	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
2oic	pdb	Crystal structure of IRAK4 kinase domain complexed with staurosporine	x-ray	2.4	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
2oid	pdb	Crystal structure of IRAK4 kinase domain complexed with AMPPNP	x-ray	2.3	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
2oiq	pdb	Crystal Structure of chicken c-Src kinase domain in complex with the cancer drug imatinib.	x-ray	2.07	A;B	p00523;p00523	533;533	;	256..526;256..526
2oj9	pdb	Structure of IGF-1R kinase domain complexed with a benzimidazole inhibitor	x-ray	2	A	p08069	1367		970..1264
2ojf	pdb	Crystal structure of Protein Kinase A in complex with Pyridine-Pyrazolopyridine based inhibitors	x-ray	2.1	E				
2ojg	pdb	Crystal structure of ERK2 in complex with N,N-dimethyl-4-(4-phenyl-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide	x-ray	2	A	p28482	360		19..322
2oji	pdb	Crystal structure of ERK2 in complex with N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide	x-ray	2.6	A	p28482	360		19..322
2ojj	pdb	Crystal structure of ERK2 in complex with (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide	x-ray	2.4	A	p28482	360		19..322
2ok1	pdb	Crystal structure of JNK3 bound to N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide	x-ray	2.4	A	p53779	464		52..396
2okr	pdb	Crystal Structure of the P38a-MAPKAP kinase 2 Heterodimer	x-ray	2	A;D	q16539;q16539	360;360	;	9..349;9..349
2olc	pdb	Crystal structure of 5-methylthioribose kinase in complex with ADP-2Ho	x-ray	2	A;B	o31663;o31663	397;397	;	9..392;9..392
2onl	pdb	Crystal Structure of the p38a-MAPKAP kinase 2 Heterodimer	x-ray	4	A;B;C;D	q16539;q16539;p49137;p49137	360;360;400;400	;;;	9..349;9..349;59..369;59..369
2oo8	pdb	Synthesis, Structural Analysis, and SAR Studies of Triazine Derivatives as Potent, Selective Tie-2 Inhibitors	x-ray	2.2	X	q02763	1124		819..1107
2osc	pdb	Synthesis, Structural Analysis, and SAR Studies of Triazine Derivatives as Potent, Selective Tie-2 Inhibitors	x-ray	2.8	A	q02763	1124		819..1107
2ou7	pdb	Structure of the Catalytic Domain of Human Polo-like Kinase 1	x-ray	2.4	A	p53350	603		51..338
2ow3	pdb	Glycogen synthase kinase-3 beta in complex with bis-(indole)maleimide pyridinophane inhibitor	x-ray	2.8	A;B	p49841;p49841	420;420	;	55..377;55..377
2owb	pdb	Structure of the Catalytic Domain of Human Polo-like Kinase 1	x-ray	2.1	A	p53350	603		51..338
2oxd	pdb	Protein kinase CK2 in complex with tetrabromobenzoimidazole K17, K22 and K32 inhibitors	x-ray	2.3	A	p28523	332		11..323
2oxx	pdb	Protein kinase CK2 in complex with tetrabromobenzoimidazole derivatives K17, K22 and K32	x-ray	2.3	A	p28523	332		11..323
2oxy	pdb	Protein kinase CK2 in complex with tetrabromobenzoimidazole derivatives K17, K22 and K32	x-ray	1.812	A;B	p28523;p28523	332;332	;	11..323;11..323
2oza	pdb	Structure of p38alpha complex	x-ray	2.7	A;B	p49137;p47811	400;360	;	59..369;9..349
2ozo	pdb	Autoinhibited intact human ZAP-70	x-ray	2.6	A	p43403	619		343..599
2p0c	pdb	Catalytic Domain of the Proto-oncogene Tyrosine-protein Kinase MER	x-ray	2.4	A;B	q12866;q12866	999;999	;	578..872;578..872
2p2h	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a pyridinyl-triazine inhibitor	x-ray	1.95	A	p35968	1356		815..1160
2p2i	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a nicotinamide inhibitor	x-ray	2.4	A;B	p35968;p35968	1356;1356	;	815..1160;815..1160
2p33	pdb	Synthesis and SAR of Aminopyrimidines as Novel c-Jun N-Terminal Kinase (JNK) Inhibitors	x-ray	2.4	A	p53779	464		52..396
2p3g	pdb	Crystal structure of a pyrrolopyridine inhibitor bound to MAPKAP Kinase-2	x-ray	3.8	X	p49137	400		59..369
2p4i	pdb	Evolution of a highly Selective and Potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 Kinase Inhibitor	x-ray	2.5	A;B	q02763;q02763	1124;1124	;	819..1107;819..1107
2p55	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP	x-ray	2.8	A	q02750	393		63..365
2pe0	pdb	CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-Hydroxy-3-[1-(1H-pyrrol-2-yl)-eth-(Z)-ylidene]-1,3-dihydro-indol-2-one COMPLEX	x-ray	2.35	A	o15530	556		79..400
2pe1	pdb	CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-Oxo-3-[1-(1H-pyrrol-2-yl)-eth-(Z)-ylidene]-2,3-dihydro-1H-indol-5-yl}-urea {BX-517} COMPLEX	x-ray	2.14	A	o15530	556		79..400
2pe2	pdb	CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-Oxo-5-ureido-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrol-3-yl}-N-(2-piperidin-1-yl-ethyl)-benzamide COMPLEX	x-ray	2.13	A	o15530	556		79..400
2phk	pdb	THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION	x-ray	2.6	A				
2pk9	pdb	Structure of the Pho85-Pho80 CDK-cyclin Complex of the Phosphate-responsive Signal Transduction Pathway	x-ray	2.906	A;C	p17157;p17157	305;305	;	4..302;4..302
2pl0	pdb	LCK bound to imatinib	x-ray	2.8	A	p06239	509		231..500
2pmi	pdb	Structure of the Pho85-Pho80 CDK-cyclin Complex of the Phosphate-responsive Signal Transduction Pathway with Bound ATP-gamma-S	x-ray	2.9	A;C	p17157;p17157	305;305	;	4..302;4..302
2pml	pdb	Crystal structure of PfPK7 in complex with an ATP analogue	x-ray	2.6	X	o96214	320		18..317
2pmn	pdb	Crystal structure of PfPK7 in complex with an ATP-site inhibitor	x-ray	2.8	X	q7ytf7	343		18..330
2pmo	pdb	Crystal structure of PfPK7 in complex with hymenialdisine	x-ray	2.9	X	q7ytf7	343		18..330
2ppq	pdb	Crystal structure of the homoserine kinase from Agrobacterium tumefaciens	x-ray	2	A	q8uha8	322		5..311
2psq	pdb	Crystal Structure of Unphosphorylated Unactivated Wild Type FGF Receptor 2 (FGFR2) Kinase Domain	x-ray	2.4	A;B	p21802;p21802	821;821	;	471..757;471..757
2ptk	pdb	CHICKEN SRC TYROSINE KINASE	x-ray	2.35	A	p00523	533		256..526
2pu8	pdb	Structures of 5-methylthioribose kinase reveal substrate specificity and unusual mode of nucleotide binding	x-ray	2.1	A;B	o31663;o31663	397;397	;	9..392;9..392
2pui	pdb	Structures of 5-methylthioribose kinase reveal substrate specificity and unusual mode of nucleotide binding	x-ray	2.2	A;B	o31663;o31663	397;397	;	9..392;9..392
2pul	pdb	Structures of 5-methylthioribose kinase reveal substrate specificity and unusual mode of nucleotide binding	x-ray	2	A;B	o31663;o31663	397;397	;	9..392;9..392
2pun	pdb	Structures of 5-methylthioribose kinase reveal substrate specificity and unusual mode of nucleotide binding	x-ray	2.3	A;B	o31663;o31663	397;397	;	9..392;9..392
2pup	pdb	Structures of 5-methylthioribose kinase reveal substrate specificity and unusual mode of nucleotide binding	x-ray	2.6	A;B	o31663;o31663	397;397	;	9..392;9..392
2puu	pdb	Crystal structure of p38 complex with 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea	x-ray	2.5	A	p47811	360		9..349
2pvf	pdb	Crystal Structure of Tyrosine Phosphorylated Activated FGF Receptor 2 (FGFR2) Kinase Domain in Complex with ATP Analog and Substrate Peptide	x-ray	1.8	A	p21802	821		471..757
2pvh	pdb	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2	x-ray	2.2	A	p28523	332		11..323
2pvj	pdb	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2	x-ray	1.7	A	p28523	332		11..323
2pvk	pdb	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2	x-ray	1.9	A	p28523	332		11..323
2pvl	pdb	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2	x-ray	1.9	A	p28523	332		11..323
2pvm	pdb	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2	x-ray	2	A	p28523	332		11..323
2pvn	pdb	Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2	x-ray	2	A	p28523	332		11..323
2pvr	pdb	Crystal structure of the catalytic subunit of protein kinase CK2 (C-terminal deletion mutant 1-335) in complex with two sulfate ions	x-ray	1.605	A	p68400	391		5..328
2pvy	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome.	x-ray	2.2	A;B;C;D	p21802;p21802;p21802;p21802	821;821;821;821	;;;	471..757;471..757;471..757;471..757
2pwl	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic N549H Mutation Responsible for Crouzon Syndrome.	x-ray	2.4	A;B	p21802;p21802	821;821	;	471..757;471..757
2py3	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic E565G Mutation Responsible for Pfeiffer Syndrome	x-ray	2.3	A;B	p21802;p21802	821;821	;	471..757;471..757
2pyw	pdb	Structure of A. thaliana 5-methylthioribose kinase in complex with ADP and MTR	x-ray	1.9	A;B	q9c6d2;q9c6d2	420;420	;	5..418;5..418
2pz5	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic N549T Mutation Responsible for Pfeiffer Syndrome	x-ray	2.4	A;B	p21802;p21802	821;821	;	471..757;471..757
2pzi	pdb	Crystal Structure of Protein kinase PknG from Mycobacterium tuberculosis in Complex with Tetrahydrobenzothiophene AX20017	x-ray	2.4	A;B	p9wi73;p9wi73	750;750	;	131..402;131..402
2pzp	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K526E Mutation Responsible for Crouzon Syndrome	x-ray	2.4	A;B	p21802;p21802	821;821	;	471..757;471..757
2pzr	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K641R Mutation Responsible for Pfeiffer Syndrome	x-ray	3	A;B	p21802;p21802	821;821	;	471..757;471..757
2pzy	pdb	Structure of MK2 Complexed with Compound 76	x-ray	2.9	A;B;C;D	p49137;p49137;p49137;p49137	400;400;400;400	;;;	59..369;59..369;59..369;59..369
2q0b	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic E565A Mutation Responsible for Pfeiffer Syndrome	x-ray	2.9	A;B	p21802;p21802	821;821	;	471..757;471..757
2q0n	pdb	Structure of human p21 activating kinase 4 (PAK4) in complex with a consensus peptide	x-ray	1.75	A				
2q83	pdb	Crystal structure of ytaA (2635576) from Bacillus subtilis at 2.50 A resolution	x-ray	2.5	A;B	o34656;o34656	357;357	;	32..344;32..344
2qc6	pdb	Protein kinase CK2 in complex with DBC	x-ray	1.85	A	p28523	332		11..323
2qcs	pdb	A complex structure between the Catalytic and Regulatory subunit of Protein Kinase A that represents the inhibited state	x-ray	2.2	A	p05132	351		28..339
2qd9	pdb	P38 Alpha Map Kinase inhibitor based on heterobicyclic scaffolds	x-ray	1.7	A	q16539	360		9..349
2qg5	pdb	Cryptosporidium parvum calcium dependent protein kinase cgd7_1840	x-ray	2.3	A;B;D	q5cyl9;q5cyl9;q5cyl9	676;676;676	;;	190..472;190..472;190..472
2qg7	pdb	Plasmodium vivax ethanolamine kinase Pv091845	x-ray	2.407	A;B;D;E	a5k4q6;a5k4q6;a5k4q6;a5k4q6	473;473;473;473	;;;	70..447;70..447;70..447;70..447
2qhm	pdb	crystal structure of Chek1 in complex with inhibitor 2a	x-ray	2	A	o14757	476		6..317
2qhn	pdb	Crystal Structure of Chek1 in Complex with Inhibitor 1a	x-ray	1.7	A	o14757	476		6..317
2qi8	pdb	Crystal structure of drug resistant SRC kinase domain	x-ray	2.32	A;B	p00523;p00523	533;533	;	256..526;256..526
2qkr	pdb	Cryptosporidium parvum cyclin-dependent kinase cgd5_2510 with indirubin 3'-monoxime bound	x-ray	2.6	A	q5crj8	295		2..290
2qkw	pdb	Structural basis for activation of plant immunity by bacterial effector protein AvrPto	x-ray	3.2	B	q40234	321		15..310
2qlq	pdb	Crystal structure of SRC kinase domain with covalent inhibitor RL3	x-ray	2.33	A;B	p00523;p00523	533;533	;	256..526;256..526
2qlu	pdb	Crystal structure of Activin receptor type II kinase domain from human	x-ray	2	A	q13705	512		179..476
2qnj	pdb	Kinase and Ubiquitin-associated domains of MARK3/Par-1	x-ray	2.7	A;B	p27448;p27448	753;753	;	53..308;53..308
2qo2	pdb	Human EphA3 kinase and juxtamembrane region, dephosphorylated, apo structure	x-ray	1.6	A	p29320	983		614..915
2qo7	pdb	Human EphA3 kinase and juxtamembrane region, dephosphorylated, AMP-PNP bound	x-ray	1.605	A	p29320	983		614..915
2qo9	pdb	Human EphA3 kinase and juxtamembrane region, phosphorylated, AMP-PNP bound	x-ray	1.55	A	p29320	983		614..915
2qob	pdb	Human EphA3 kinase domain, base structure	x-ray	1.65	A	p29320	983		614..915
2qoc	pdb	Human EphA3 kinase domain, phosphorylated, AMP-PNP bound structure	x-ray	1.25	A	p29320	983		614..915
2qod	pdb	Human EphA3 kinase and juxtamembrane region, Y602F mutant	x-ray	1.15	A	p29320	983		614..915
2qof	pdb	Human EphA3 kinase and juxtamembrane region, Y596F mutant	x-ray	1.2	A	p29320	983		614..915
2qoh	pdb	Crystal Structure of Abl kinase bound with PPY-A	x-ray	1.95	A;B	p00520;p00520	1123;1123	;	231..498;231..498
2qoi	pdb	Human EphA3 kinase and juxtamembrane region, Y596F:Y602F double mutant	x-ray	1.25	A	p29320	983		614..915
2qok	pdb	Human EphA3 kinase and juxtamembrane region, Y596F:Y602F:S768A triple mutant	x-ray	1.2	A	p29320	983		614..915
2qol	pdb	Human EphA3 kinase and juxtamembrane region, Y596:Y602:S768G triple mutant	x-ray	1.07	A	p29320	983		614..915
2qon	pdb	Human EphA3 kinase and juxtamembrane region, Y596F:Y602F:Y742A triple mutant	x-ray	1.79	A	p29320	983		614..915
2qoo	pdb	Human EphA3 kinase and juxtamembrane region, Y596F:Y602F:Y742F triple mutant	x-ray	1.25	A	p29320	983		614..915
2qoq	pdb	Human EphA3 kinase and juxtamembrane region, base, AMP-PNP bound structure	x-ray	1.6	A	p29320	983		614..915
2qq7	pdb	Crystal structure of drug resistant SRC kinase domain with irreversible inhibitor	x-ray	2.38	A;B	p00523;p00523	533;533	;	256..526;256..526
2qr7	pdb	2.0A X-ray structure of C-terminal kinase domain of p90 ribosomal S6 kinase 2: Se-Met derivative	x-ray	2	A	p18654	740		66..390,402..717
2qr8	pdb	2.0A X-ray structure of C-terminal kinase domain of p90 ribosomal S6 kinase 2 (RSK2)	x-ray	2	A	p18654	740		66..390,402..717
2qu5	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a benzimidazole inhibitor	x-ray	2.95	A	p35968	1356		815..1160
2qu6	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a benzoxazole inhibitor	x-ray	2.1	A;B	p35968;p35968	1356;1356	;	815..1160;815..1160
2qur	pdb	Crystal Structure of F327A/K285P Mutant of cAMP-dependent Protein Kinase	x-ray	2.5	A	p05132	351		28..339
2qvs	pdb	Crystal Structure of Type IIa Holoenzyme of cAMP-dependent Protein Kinase	x-ray	2.5	E	p05132	351		28..339
2r0i	pdb	Crystal structure of a kinase MARK2/Par-1 mutant	x-ray	2.202	A;B	o08679;o08679	722;722	;	50..305;50..305
2r0u	pdb	Crystal Structure of Chek1 in Complex with Inhibitor 54	x-ray	1.9	A	o14757	476		6..317
2r2p	pdb	Kinase domain of human ephrin type-A receptor 5 (EphA5)	x-ray	2.4	A	p54756	1037		669..949
2r3f	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.5	A	p24941	298		1..292
2r3g	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.55	A	p24941	298		1..292
2r3h	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.5	A	p24941	298		1..292
2r3i	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.28	A	p24941	298		1..292
2r3j	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.65	A	p24941	298		1..292
2r3k	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.7	A	p24941	298		1..292
2r3l	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.65	A	p24941	298		1..292
2r3m	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.7	A	p24941	298		1..292
2r3n	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.63	A	p24941	298		1..292
2r3o	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.8	A	p24941	298		1..292
2r3p	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.66	A	p24941	298		1..292
2r3q	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.35	A	p24941	298		1..292
2r3r	pdb	Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor	x-ray	1.47	A	p24941	298		1..292
2r4b	pdb	ErbB4 kinase domain complexed with a thienopyrimidine inhibitor	x-ray	2.4	A;B	q15303;q15303	1308;1308	;	715..1007;715..1007
2r5t	pdb	Crystal Structure of Inactive Serum and Glucocorticoid- Regulated Kinase 1 in Complex with AMP-PNP	x-ray	1.9	A	o00141	431		74..401
2r64	pdb	Crystal structure of a 3-aminoindazole compound with CDK2	x-ray	2.3	A	p24941	298		1..292
2r7b	pdb	Crystal Structure of the Phosphoinositide-dependent Kinase-1 (PDK-1)Catalytic Domain bound to a dibenzonaphthyridine inhibitor	x-ray	2.7	A	o15530	556		79..400
2r7i	pdb	Crystal structure of catalytic subunit of protein kinase CK2	x-ray	3.003	A;B;C;D	p19139;p19139;p19139;p19139	391;391;391;391	;;;	5..328;5..328;5..328;5..328
2r9s	pdb	c-Jun N-terminal Kinase 3 with 3,5-Disubstituted Quinoline inhibitor	x-ray	2.4	A;B	p53779;p53779	464;464	;	52..396;52..396
2rd0	pdb	Structure of a human p110alpha/p85alpha complex	x-ray	3.05	A	p42336	1068		699..1060
2rei	pdb	Kinase domain of human ephrin type-A receptor 7 (Epha7)	x-ray	1.6	A	q15375	998		626..925
2rf9	pdb	Crystal structure of the complex between the EGFR kinase domain and a Mig6 peptide	x-ray	3.5	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
2rfd	pdb	Crystal structure of the complex between the EGFR kinase domain and a Mig6 peptide	x-ray	3.6	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
2rfe	pdb	Crystal structure of the complex between the EGFR kinase domain and a Mig6 peptide	x-ray	2.9	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
2rfn	pdb	x-ray structure of c-Met with inhibitor.	x-ray	2.5	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
2rfs	pdb	X-ray structure of SU11274 bound to c-Met	x-ray	2.2	A	p08581	1390		1079..1341
2rg5	pdb	Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11B	x-ray	2.4	A	q16539	360		9..349
2rg6	pdb	Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11J	x-ray	1.72	A	q16539	360		9..349
2rgp	pdb	Structure of EGFR in complex with hydrazone, a potent dual inhibitor	x-ray	2	A	p00533	1210		708..1003
2rio	pdb	Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation of non-conventional splicing	x-ray	2.4	A;B	p32361;p32361	1115;1115	;	677..992;677..992
2rku	pdb	Structure of PLK1 in complex with BI2536	x-ray	1.95	A	p53350	603		51..338
2rl5	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a 2,3-dihydro-1,4-benzoxazine inhibitor	x-ray	2.65	A	p35968	1356		815..1160
2rsv	pdb	Solution structure of human full-length vaccinia related kinase 1 (VRK1)	nmr		A	q99986	396		31..340
2src	pdb	CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC, IN COMPLEX WITH AMP-PNP	x-ray	1.5	A	p12931	536		259..529
2uue	pdb	REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors	x-ray	2.06	A;C	;	;	;	;
2uv2	pdb	Crystal Structure Of Human Ste20-Like Kinase Bound To 4-(4-(5- Cyclopropyl-1H-pyrazol-3-ylamino)-quinazolin-2-ylamino)-phenyl)- acetonitrile	x-ray	2.3	A	q9h2g2	1235		29..293
2uvx	pdb	Structure of PKA-PKB chimera complexed with 7-azaindole	x-ray	2	A	p00517	351		32..339
2uvy	pdb	Structure of PKA-PKB chimera complexed with methyl-(4-(9H-purin-6-yl)- benzyl)-amine	x-ray	1.95	A	p00517	351		32..339
2uvz	pdb	Structure of PKA-PKB chimera complexed with C-Phenyl-C-(4-(9H-purin-6- yl)-phenyl)-methylamine	x-ray	1.94	A	p00517	351		32..339
2uw0	pdb	Structure of PKA-PKB chimera complexed with 6-(4-(4-(4-Chloro-phenyl) -piperidin-4-yl)-phenyl)-9H-purine	x-ray	2	A	p00517	351		32..339
2uw3	pdb	Structure of PKA-PKB chimera complexed with 5-methyl-4-phenyl-1H- pyrazole	x-ray	2.19	A	p00517	351		32..339
2uw4	pdb	Structure of PKA-PKB chimera complexed with 2-(4-(5-methyl-1H-pyrazol- 4-yl)-phenyl)-ethylamine	x-ray	2	A	p00517	351		32..339
2uw5	pdb	Structure of PKA-PKB chimera complexed with (R)-2-(4-chloro-phenyl)- 2-(4-1H-pyrazol-4-yl)-phenyl)-ethylamine	x-ray	2.14	A	p00517	351		32..339
2uw6	pdb	Structure of PKA-PKB chimera complexed with (S)-2-(4-chloro-phenyl)- 2-(4-1H-pyrazol-4-yl)-phenyl)-ethylamine	x-ray	2.23	A	p00517	351		32..339
2uw7	pdb	Structure of PKA-PKB chimera complexed with 4-(4-chloro-phenyl)-4-(4- (1H-pyrazol-4-yl)-phenyl)-piperidine	x-ray	2.1	A	p00517	351		32..339
2uw8	pdb	Structure of PKA-PKB chimera complexed with 2-(4-chloro-phenyl)-2- phenyl-ethylamine	x-ray	2	A	p00517	351		32..339
2uw9	pdb	STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-chloro-phenyl)-4-(4-(1H-pyrazol-4-yl)-phenyl)-piperidine	x-ray	2.1	A	p31751	481		147..460
2uzb	pdb	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor	x-ray	2.7	A;C	p24941;p24941	298;298	;	1..292;1..292
2uzd	pdb	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor	x-ray	2.72	A;C	p24941;p24941	298;298	;	1..292;1..292
2uze	pdb	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor	x-ray	2.4	A;C	p24941;p24941	298;298	;	1..292;1..292
2uzl	pdb	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor	x-ray	2.4	A;C	p24941;p24941	298;298	;	1..292;1..292
2uzn	pdb	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor	x-ray	2.3	A	p24941	298		1..292
2uzo	pdb	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor	x-ray	2.3	A	p24941	298		1..292
2uzt	pdb	PKA structures of AKT, indazole-pyridine inhibitors	x-ray	2.1	A	p00517	351		32..339
2uzu	pdb	PKA structures of indazole-pyridine series of AKT inhibitors	x-ray	2.4	E	p00517	351		32..339
2uzv	pdb	PKA structures of indazole-pyridine series of AKT inhibitors	x-ray	2.5	A	p00517	351		32..339
2uzw	pdb	PKA structures of indazole-pyridine series of AKT inhibitors	x-ray	2.2	E	p00517	351		32..339
2v0d	pdb	Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor	x-ray	2.2	A	p24941	298		1..292
2v22	pdb	REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors	x-ray	2.6	A;C	p24941;p24941	298;298	;	1..292;1..292
2v4l	pdb	complex of human phosphoinositide 3-kinase catalytic subunit gamma (p110 gamma) with PIK-284	x-ray	2.5	A	p48736	1102		728..1089
2v55	pdb	Mechanism of multi-site phosphorylation from a ROCK-I:RhoE complex structure	x-ray	3.705	A;C	q13464;q13464	1354;1354	;	73..413;73..413
2v5q	pdb	CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN	x-ray	2.3	A;B	;	;	;	;
2v62	pdb	Structure of vaccinia-related kinase 2	x-ray	1.7	A;B	q86y07;q86y07	508;508	;	23..317;23..317
2v7a	pdb	Crystal structure of the T315I Abl mutant in complex with the inhibitor PHA-739358	x-ray	2.5	A;B	p00519;p00519	1130;1130	;	231..498;231..498
2v7o	pdb	Crystal structure of human calcium-calmodulin-dependent protein kinase II gamma	x-ray	2.25	A	q13555	558		10..273
2vag	pdb	Crystal structure of di-phosphorylated human CLK1 in complex with a novel substituted indole inhibitor	x-ray	1.8	A	p49759	484		150..478
2vd5	pdb	Structure of Human Myotonic Dystrophy Protein Kinase in Complex with the Bisindoylmaleide inhibitor BIM VIII	x-ray	2.8	A;B	q09013;q09013	629;629	;	49..377;49..377
2vgo	pdb	Crystal structure of Aurora B kinase in complex with Reversine inhibitor	x-ray	1.7	A;B	q6de08;q6de08	361;361	;	71..354;71..354
2vgp	pdb	Crystal structure of Aurora B kinase in complex with a aminothiazole inhibitor	x-ray	1.7	A;B	q6de08;q6de08	361;361	;	71..354;71..354
2vn9	pdb	Crystal Structure of Human Calcium Calmodulin dependent Protein Kinase II delta isoform 1, CAMKD	x-ray	2.3	A;B	q13557;q13557	499;499	;	10..273;10..273
2vnw	pdb	Structure of PKA-PKB chimera complexed with (1-(9H-Purin-6-yl) piperidin-4-yl)methanamine	x-ray	2.09	A	p00517	351		32..339
2vny	pdb	Structure of PKA-PKB chimera complexed with (1-(9H-Purin-6-yl) piperidin-4-yl)amine	x-ray	1.96	A	p00517	351		32..339
2vo0	pdb	Structure of PKA-PKB chimera complexed with C-(4-(4-Chlorophenyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-yl)methylamine	x-ray	1.94	A	p00517	351		32..339
2vo3	pdb	Structure of PKA-PKB chimera complexed with C-(4-(4-Chlorophenyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-yl)methylamine	x-ray	1.98	A	p00517	351		32..339
2vo6	pdb	Structure of PKA-PKB chimera complexed with 4-(4-Chlorobenzyl)-1-(7H- pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-ylamine	x-ray	1.97	A	p00517	351		32..339
2vo7	pdb	Structure of PKA complexed with 4-(4-Chlorobenzyl)-1-(7H-pyrrolo(2,3- d)pyrimidin-4-yl)piperidin-4-ylamine	x-ray	1.98	A	p00517	351		32..339
2vrx	pdb	Structure of Aurora B kinase in complex with ZM447439	x-ray	1.86	A;B	q6de08;q6de08	361;361	;	71..354;71..354
2vta	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.	x-ray	2	A	p24941	298		1..292
2vth	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design	x-ray	1.9	A	p24941	298		1..292
2vti	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.	x-ray	2	A	p24941	298		1..292
2vtj	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design	x-ray	2.2	A	p24941	298		1..292
2vtl	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design	x-ray	2	A	p24941	298		1..292
2vtm	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.	x-ray	2.25	A	p24941	298		1..292
2vtn	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.	x-ray	2.2	A	p24941	298		1..292
2vto	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.	x-ray	2.19	A	p24941	298		1..292
2vtp	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.	x-ray	2.15	A	p24941	298		1..292
2vtq	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.	x-ray	1.9	A	p24941	298		1..292
2vtr	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design	x-ray	1.89	A	p24941	298		1..292
2vts	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.	x-ray	1.9	A	p24941	298		1..292
2vtt	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.	x-ray	1.68	A	p24941	298		1..292
2vu3	pdb	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.	x-ray	1.85	A	p24941	298		1..292
2vuw	pdb	Structure of human haspin kinase domain	x-ray	1.8	A	q8tf76	798		474..698
2vv9	pdb	CDK2 in complex with an imidazole piperazine	x-ray	1.9	A	p24941	298		1..292
2vwb	pdb	Structure of the archaeal Kae1-Bud32 fusion protein MJ1130: a model for the eukaryotic EKC-KEOPS subcomplex involved in transcription and telomere homeostasis.	x-ray	3.05	A;B	q58530;q58530	535;535	;	337..484;337..484
2vwi	pdb	Structure of the OSR1 kinase, a hypertension drug target	x-ray	2.15	A;B;C;D	o95747;o95747;o95747;o95747	527;527;527;527	;;;	8..310;8..310;8..310;8..310
2vwu	pdb	ephB4 kinase domain inhibitor complex	x-ray	2	A	p54760	987		609..886
2vwv	pdb	ephB4 kinase domain inhibitor complex	x-ray	1.9	A	p54760	987		609..886
2vww	pdb	ephB4 kinase domain inhibitor complex	x-ray	1.9	A	p54760	987		609..886
2vwx	pdb	ephB4 kinase domain inhibitor complex	x-ray	1.65	A	p54760	987		609..886
2vwy	pdb	ephB4 kinase domain inhibitor complex	x-ray	1.65	A	p54760	987		609..886
2vwz	pdb	ephB4 kinase domain inhibitor complex	x-ray	1.65	A	p54760	987		609..886
2vx0	pdb	ephB4 kinase domain inhibitor complex	x-ray	2.1	A	p54760	987		609..886
2vx1	pdb	ephB4 kinase domain inhibitor complex	x-ray	1.65	A	p54760	987		609..886
2vx3	pdb	Crystal structure of the human dual specificity tyrosine- phosphorylation-regulated kinase 1A	x-ray	2.4	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
2vz6	pdb	Structure of human calcium calmodulin dependent protein kinase type II alpha (CAMK2A) in complex with Indirubin E804	x-ray	2.3	A;B	q9uqm7;q9uqm7	478;478	;	9..272;9..272
2w05	pdb	Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5b	x-ray	1.9	A	p24941	298		1..292
2w06	pdb	Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5c	x-ray	2.04	A	p24941	298		1..292
2w0j	pdb	Crystal structure of Chk2 in complex with NSC 109555, a specific inhibitor	x-ray	2.05	A	o96017	543		213..500
2w17	pdb	CDK2 in complex with the imidazole pyrimidine amide, compound (S)-8b	x-ray	2.15	A	p24941	298		1..292
2w1c	pdb	Structure determination of Aurora Kinase in complex with inhibitor	x-ray	3.24	A	o14965	403		120..386
2w1d	pdb	Structure determination of Aurora Kinase in complex with inhibitor	x-ray	2.97	A	o14965	403		120..386
2w1e	pdb	Structure determination of Aurora Kinase in complex with inhibitor	x-ray	2.93	A	o14965	403		120..386
2w1f	pdb	Structure determination of Aurora Kinase in complex with inhibitor	x-ray	2.85	A	o14965	403		120..386
2w1g	pdb	Structure determination of Aurora Kinase in complex with inhibitor	x-ray	2.71	A	o14965	403		120..386
2w1h	pdb	Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283), a Multi- targeted Kinase Inhibitor with Potent Aurora Kinase Activity	x-ray	2.15	A	p24941	298		1..292
2w1i	pdb	Structure determination of Aurora Kinase in complex with inhibitor	x-ray	2.6	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
2w1z	pdb	ROP2 from Toxoplasma gondii: A virulence factor with a protein- kinase fold and no enzymatic activity.	x-ray	1.97	A;B	q27007;q27007	561;561	;	296..529;296..529
2w4j	pdb	X-ray structure of a DAP-Kinase 2-277	x-ray	1.3	A	p53355	1430		6..291
2w4k	pdb	X-ray structure of a DAP-Kinase 2-302	x-ray	1.9	A	p53355	1430		6..291
2w4o	pdb	Crystal structure of Human CAMK4 in complex with 4-Amino(sulfamoyl- phenylamino)-triazole-carbothioic acid (2,6-difluoro-phenyl)-amide)	x-ray	2.17	A	q16566	473		40..321
2w5a	pdb	Human Nek2 kinase ADP-bound	x-ray	1.55	A	p51955	445		5..280
2w5b	pdb	Human Nek2 kinase ATPgammaS-bound	x-ray	2.4	A	p51955	445		5..280
2w5h	pdb	Human Nek2 kinase Apo	x-ray	2.33	A	p51955	445		5..280
2w7x	pdb	Cellular inhibition of checkpoint kinase 2 and potentiation of cytotoxic drugs by novel Chk2 inhibitor PV1019	x-ray	2.07	A	o96017	543		213..500
2w96	pdb	Crystal Structure of CDK4 in complex with a D-type cyclin	x-ray	2.3	B	p11802	303		3..297
2w99	pdb	Crystal Structure of CDK4 in complex with a D-type cyclin	x-ray	2.8	B	p11802	303		3..297
2w9f	pdb	Crystal Structure of CDK4 in complex with a D-type cyclin	x-ray	2.85	B	p11802	303		3..297
2w9z	pdb	Crystal Structure of CDK4 in complex with a D-type cyclin	x-ray	2.45	B	p11802	303		3..297
2waj	pdb	Crystal structure of human Jnk3 complexed with a 1-aryl-3,4- dihydroisoquinoline inhibitor	x-ray	2.4	A	p53779	464		52..396
2wb8	pdb	Crystal structure of Haspin kinase	x-ray	2.15	A	q8tf76	798		474..698
2wd1	pdb	Human c-Met Kinase in complex with azaindole inhibitor	x-ray	2	A	p08581	1390		1079..1341
2wei	pdb	Crystal structure of the kinase domain of Cryptosporidium parvum calcium dependent protein kinase in complex with 3-MB-PP1	x-ray	1.65	A	a3fq16	538		69..348
2wel	pdb	Crystal structure of SU6656-bound calcium/calmodulin-dependent protein kinase II delta in complex with calmodulin	x-ray	1.9	A	q13557	499		10..273
2wev	pdb	Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design	x-ray	2.3	A;C	;	;	;	;
2wfy	pdb	Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design	x-ray	2.53	A;C	;	;	;	;
2wgj	pdb	X-ray Structure of PF-02341066 bound to the kinase domain of c-Met	x-ray	2	A	p08581	1390		1079..1341
2whb	pdb	Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design	x-ray	2.9	A;C	;	;	;	;
2wih	pdb	STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125	x-ray	2.5	A;C	p24941;p24941	298;298	;	1..292;1..292
2wip	pdb	STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO- 1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID	x-ray	2.8	A;C	p24941;p24941	298;298	;	1..292;1..292
2wkm	pdb	X-ray Structure of PHA-00665752 bound to the kinase domain of c-Met	x-ray	2.2	A	p08581	1390		1079..1341
2wma	pdb	Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin A	x-ray	2.8	A;C	;	;	;	;
2wmb	pdb	Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin A	x-ray	2.6	A;C	;	;	;	;
2wmq	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.48	A	o14757	476		6..317
2wmr	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.43	A	o14757	476		6..317
2wms	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.7	A	o14757	476		6..317
2wmt	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.55	A	o14757	476		6..317
2wmu	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.6	A	o14757	476		6..317
2wmv	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.009	A	o14757	476		6..317
2wmw	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.43	A	o14757	476		6..317
2wmx	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.45	A	o14757	476		6..317
2wnt	pdb	Crystal Structure of the Human Ribosomal protein S6 kinase	x-ray	2.4	A;B	q15418;q15418	735;735	;	60..381,400..719;60..381,400..719
2wo6	pdb	Human Dual-Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A in complex with a consensus substrate peptide	x-ray	2.5	A;B	q13627;q13627	763;763	;	147..489;147..489
2wot	pdb	ALK5 IN COMPLEX WITH 4-((5,6-dimethyl-2-(2-pyridyl)-3-pyridyl)oxy)-N-(3,4,5-trimethoxyphenyl)pyridin-2-amine	x-ray	1.85	A	p36897	503		180..492
2wou	pdb	ALK5 IN COMPLEX WITH 4-((4-((2,6-dimethyl-3-pyridyl)oxy)-2-pyridyl) amino)benzenesulfonamide	x-ray	2.3	A	p36897	503		180..492
2wpa	pdb	Optimisation of 6,6-Dimethyl Pyrrolo 3,4-c pyrazoles: Identification of PHA-793887, a Potent CDK Inhibitor Suitable for Intravenous Dosing	x-ray	2.51	A;C	p24941;p24941	298;298	;	1..292;1..292
2wqb	pdb	Structure of the Tie2 kinase domain in complex with a thiazolopyrimidine inhibitor	x-ray	2.95	A	q02763	1124		819..1107
2wqe	pdb	Structure of S155R Aurora-A somatic mutant	x-ray	2.5	A	o14965	403		120..386
2wqm	pdb	Structure of apo human Nek7	x-ray	2.1	A	q8tdx7	302		18..290
2wqn	pdb	Structure of ADP-bound human Nek7	x-ray	2.3	A	q8tdx7	302		18..290
2wqo	pdb	STRUCTURE OF NEK2 BOUND TO THE AMINOPYRIDINE CCT241950	x-ray	2.167	A	p51955	445		5..280
2wtc	pdb	CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR	x-ray	3	A	o96017	543		213..500
2wtd	pdb	Crystal structure of Chk2 in complex with an inhibitor	x-ray	2.75	A	o96017	543		213..500
2wti	pdb	CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR	x-ray	2.5	A	o96017	543		213..500
2wtj	pdb	CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR	x-ray	2.1	A	o96017	543		213..500
2wtk	pdb	Structure of the heterotrimeric LKB1-STRADalpha-MO25alpha complex	x-ray	2.65	B;C;E;F	q7rtn6;q15831;q7rtn6;q15831	431;433;431;433	;;;	57..401;41..336;57..401;41..336
2wtv	pdb	Aurora-A Inhibitor Structure	x-ray	2.4	A;B;C;D	o14965;o14965;o14965;o14965	403;403;403;403	;;;	120..386;120..386;120..386;120..386
2wtw	pdb	Aurora-A Inhibitor Structure (2nd crystal form)	x-ray	3.302	A	o14965	403		120..386
2wu6	pdb	Crystal Structure of the Human CLK3 in complex with DKI	x-ray	1.92	A	p49761	490		145..479
2wu7	pdb	Crystal Structure of the Human CLK3 in complex with V25	x-ray	2.25	A	p49761	490		145..479
2wxf	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with PIK-39.	x-ray	1.9	A	o35904	1043		677..1032
2wxg	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with SW13.	x-ray	2	A	o35904	1043		677..1032
2wxh	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with SW14.	x-ray	1.9	A	o35904	1043		677..1032
2wxi	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with SW30.	x-ray	2.8	A	o35904	1043		677..1032
2wxj	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with INK654.	x-ray	2.6	A	o35904	1043		677..1032
2wxk	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with INK666.	x-ray	2.9	A	o35904	1043		677..1032
2wxl	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with ZSTK474.	x-ray	1.99	A	o35904	1043		677..1032
2wxm	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with DL06.	x-ray	2.8	A	o35904	1043		677..1032
2wxn	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with DL07.	x-ray	2.6	A	o35904	1043		677..1032
2wxo	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with AS5.	x-ray	2.49	A	o35904	1043		677..1032
2wxp	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with GDC-0941.	x-ray	2.3	A	o35904	1043		677..1032
2wxq	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with AS15.	x-ray	2.7	A	o35904	1043		677..1032
2wxr	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta.	x-ray	2.5	A	o35904	1043		677..1032
2wxv	pdb	Structure of CDK2-CYCLIN A with a Pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor	x-ray	2.6	A;C	p24941;p24941	298;298	;	1..292;1..292
2wzj	pdb	Catalytic and UBA domain of kinase MARK2/(Par-1) K82R, T208E double mutant	x-ray	2.786	A;B;C;D;E;F	o08679;o08679;o08679;o08679;o08679;o08679	722;722;722;722;722;722	;;;;;	50..305;50..305;50..305;50..305;50..305;50..305
2x0g	pdb	X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX	x-ray	2.2	A	p53355	1430		6..291
2x1n	pdb	Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design	x-ray	2.75	A;C	;	;	;	;
2x2k	pdb	Crystal Structure of phosphorylated RET tyrosine kinase domain with inhibitor	x-ray	2.6	A	p07949	1114		699..1005
2x2l	pdb	Crystal Structure of phosphorylated RET tyrosine kinase domain with inhibitor	x-ray	2	A	p07949	1114		699..1005
2x2m	pdb	Crystal Structure of phosphorylated RET tyrosine kinase domain with inhibitor	x-ray	2.5	A;B	p07949;p07949	1114;1114	;	699..1005;699..1005
2x38	pdb	The crystal structure of the murine class IA PI 3-kinase p110delta in complex with IC87114.	x-ray	2.2	A	o35904	1043		677..1032
2x39	pdb	Structure of 4-Amino-N-(4-chlorobenzyl)-1-(7H-pyrrolo(2,3-d)pyrimidin- 4-yl)piperidine-4-carboxamide bound to PKB	x-ray	1.93	A	p31751	481		147..460
2x4f	pdb	The Crystal Structure of the human myosin light chain kinase LOC340156.	x-ray	2.67	A;B	q86yv6;q86yv6	388;388	;	107..367;107..367
2x4z	pdb	Crystal Structure of the Human p21-Activated Kinase 4 in Complex with PF-03758309	x-ray	2.1	A	o96013	591		323..578
2x6d	pdb	Aurora-A bound to an inhibitor	x-ray	2.796	A	o14965	403		120..386
2x6e	pdb	Aurora-A bound to an inhibitor	x-ray	3.35	A	o14965	403		120..386
2x6f	pdb	THE CRYSTAL STRUCTURE OF THE DROSOPHILA CLASS III PI3-KINASE VPS34 IN COMPLEX WITH 3-METHYLADENINE	x-ray	3.3	A;B	q9w1m7;q9w1m7	949;949	;	601..945;601..945
2x6h	pdb	THE CRYSTAL STRUCTURE OF THE DROSOPHILA CLASS III PI3-KINASE VPS34	x-ray	2.9	A;B	q9w1m7;q9w1m7	949;949	;	601..945;601..945
2x6i	pdb	THE CRYSTAL STRUCTURE OF THE DROSOPHILA CLASS III PI3-KINASE VPS34 IN COMPLEX WITH PIK-90	x-ray	3.4	A;B	q9w1m7;q9w1m7	949;949	;	601..945;601..945
2x6j	pdb	THE CRYSTAL STRUCTURE OF THE DROSOPHILA CLASS III PI3-KINASE VPS34 IN COMPLEX WITH PIK-93	x-ray	3.5	A;B	q9w1m7;q9w1m7	949;949	;	601..945;601..945
2x6k	pdb	THE CRYSTAL STRUCTURE OF THE DROSOPHILA CLASS III PI3-KINASE VPS34 IN COMPLEX WITH PI-103	x-ray	3.5	A;B	q9w1m7;q9w1m7	949;949	;	601..945;601..945
2x7f	pdb	Crystal structure of the kinase domain of human Traf2- and Nck- interacting Kinase with Wee1Chk1 inhibitor	x-ray	2.8	A;B;C;D;E	q9uke5;q9uke5;q9uke5;q9uke5;q9uke5	1360;1360;1360;1360;1360	;;;;	24..290;24..290;24..290;24..290;24..290
2x7g	pdb	Structure of human serine-arginine-rich protein-specific kinase 2 (SRPK2) bound to purvalanol B	x-ray	2.5	A	p78362	688		68..687
2x7o	pdb	Crystal structure of TGFbRI complexed with an indolinone inhibitor	x-ray	3.7	A;B;C;D;E	p36897;p36897;p36897;p36897;p36897	503;503;503;503;503	;;;;	180..492;180..492;180..492;180..492;180..492
2x81	pdb	STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054	x-ray	2.91	A	o14965	403		120..386
2x8d	pdb	Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration	x-ray	1.9	A	o14757	476		6..317
2x8e	pdb	Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration	x-ray	2.5	A	o14757	476		6..317
2x8i	pdb	Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration	x-ray	1.92	A	o14757	476		6..317
2x9e	pdb	HUMAN MPS1 IN COMPLEX WITH NMS-P715	x-ray	3.1	A	p33981	857		516..792
2x9f	pdb	ephB4 kinase domain inhibitor complex	x-ray	1.75	A	p54760	987		609..886
2xa4	pdb	Inhibitors of Jak2 Kinase domain	x-ray	2.04	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
2xb7	pdb	Structure of Human Anaplastic Lymphoma Kinase in complex with NVP- TAE684	x-ray	2.5	A	q9um73	1620		1089..1381
2xba	pdb	Structure of Human Anaplastic Lymphoma Kinase in complex with PHA- E429	x-ray	1.95	A	q9um73	1620		1089..1381
2xbj	pdb	Crystal Structure of Chk2 in complex with an inhibitor	x-ray	2.3	A	o96017	543		213..500
2xch	pdb	Crystal structure of PDK1 in complex with a pyrazoloquinazoline inhibitor	x-ray	2	A	o15530	556		79..400
2xck	pdb	Crystal structure of PDK1 in complex with a pyrazoloquinazoline inhibitor	x-ray	2.3	A	o15530	556		79..400
2xey	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.7	A	o14757	476		6..317
2xez	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.25	A	o14757	476		6..317
2xf0	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.4	A	o14757	476		6..317
2xh5	pdb	Structure of 4-(4-tert-Butylbenzyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4- yl)piperidin-4-amine bound to PKB	x-ray	2.72	A	p31751	481		147..460
2xik	pdb	Structure of Human YSK1 (Yeast Sps1-Ste20-related Kinase 1)	x-ray	1.97	A	o00506	426		20..329
2xir	pdb	Crystal structure of the VEGFR2 kinase domain in complex with PF- 00337210 (N,2-dimethyl-6-(7-(2-morpholinoethoxy)quinolin-4-yloxy) benzofuran-3-carboxamide)	x-ray	1.5	A	p35968	1356		815..1160
2xix	pdb	Protein kinase Pim-1 in complex with fragment-1 from crystallographic fragment screen	x-ray	2.4	A	p11309	313		36..296
2xiy	pdb	Protein kinase Pim-1 in complex with fragment-2 from crystallographic fragment screen	x-ray	2.2	A	p11309	313		36..296
2xiz	pdb	Protein kinase Pim-1 in complex with fragment-3 from crystallographic fragment screen	x-ray	2.21	A	p11309	313		36..296
2xj0	pdb	Protein kinase Pim-1 in complex with fragment-4 from crystallographic fragment screen	x-ray	3.1	A	p11309	313		36..296
2xj1	pdb	Protein kinase Pim-1 in complex with small molecule inibitor	x-ray	2.13	A	p11309	313		36..296
2xj2	pdb	Protein kinase Pim-1 in complex with small molecule inhibitor	x-ray	2.2	A	p11309	313		36..296
2xk3	pdb	Structure of Nek2 bound to Aminopyrazine compound 35	x-ray	2.2	A	p51955	445		5..280
2xk4	pdb	Structure of Nek2 bound to aminopyrazine compound 17	x-ray	2.1	A	p51955	445		5..280
2xk6	pdb	Structure of Nek2 bound to aminopyrazine compound 36	x-ray	2.2	A	p51955	445		5..280
2xk7	pdb	Structure of Nek2 bound to aminopyrazine compound 23	x-ray	1.992	A	p51955	445		5..280
2xk8	pdb	Structure of Nek2 bound to aminopyrazine compound 15	x-ray	2.001	A	p51955	445		5..280
2xk9	pdb	Structural analysis of checkpoint kinase 2 (Chk2) in complex with inhibitor PV1533	x-ray	2.35	A	o96017	543		213..500
2xkc	pdb	Structure of Nek2 bound to aminopyrazine compound 14	x-ray	2.5	A	p51955	445		5..280
2xkd	pdb	Structure of Nek2 bound to aminopyrazine compound 12	x-ray	1.96	A	p51955	445		5..280
2xke	pdb	Structure of Nek2 bound to Aminipyrazine Compound 5	x-ray	2.203	A	p51955	445		5..280
2xkf	pdb	Structure of Nek2 bound to aminopyrazine compound 2	x-ray	2.35	A	p51955	445		5..280
2xm8	pdb	Co-crystal structure of a small molecule inhibitor bound to the kinase domain of Chk2	x-ray	3.4	A	o96017	543		213..500
2xm9	pdb	Structure of a small molecule inhibitor with the kinase domain of Chk2	x-ray	2.5	A	o96017	543		213..500
2xmy	pdb	Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents	x-ray	1.9	A	p24941	298		1..292
2xnb	pdb	Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents	x-ray	1.85	A	p24941	298		1..292
2xne	pdb	Structure of Aurora-A bound to an imidazopyrazine inhibitor	x-ray	2.8	A	o14965	403		120..386
2xng	pdb	Structure of Aurora-A bound to a selective imidazopyrazine inhibitor	x-ray	2.605	A	o14965	403		120..386
2xnm	pdb	Structure of NEK2 bound to CCT	x-ray	1.85	A	p51955	445		5..280
2xnn	pdb	Structure of Nek2 bound to CCT242430	x-ray	2.5	A	p51955	445		5..280
2xno	pdb	Structure of Nek2 bound to CCT243779	x-ray	1.98	A	p51955	445		5..280
2xnp	pdb	Structure of Nek2 bound to CCT244858	x-ray	1.98	A	p51955	445		5..280
2xp2	pdb	Structure of the Human Anaplastic Lymphoma Kinase in Complex with Crizotinib (PF-02341066)	x-ray	1.9	A	q9um73	1620		1089..1381
2xru	pdb	AURORA-A T288E COMPLEXED WITH PHA-828300	x-ray	2.9	A	o14965	403		120..386
2xrw	pdb	Linear binding motifs for JNK and for calcineurin antagonistically control the nuclear shuttling of NFAT4	x-ray	1.33	A	p45983	427		12..357
2xs0	pdb	Linear binding motifs for JNK and for calcineurin antagonistically control the nuclear shuttling of NFAT4	x-ray	2.6	A	p45983	427		12..357
2xuu	pdb	Crystal structure of a DAP-kinase 1 mutant	x-ray	1.8	A	p53355	1430		6..291
2xvd	pdb	ephB4 kinase domain inhibitor complex	x-ray	1.7	A	p54760	987		609..886
2xyn	pdb	HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680	x-ray	2.81	A;B;C	p42684;p42684;p42684	1182;1182;1182	;;	279..551;279..551;279..551
2xyu	pdb	Crystal structure of EphA4 kinase domain in complex with VUF 12058	x-ray	2.117	A	q03137	986		613..907
2xzs	pdb	Death associated protein kinase 1 residues 1-312	x-ray	2	A;B	p53355;p53355	1430;1430	;	6..291;6..291
2y0a	pdb	Structure of DAPK1 construct residues 1-304	x-ray	2.6	A	p53355	1430		6..291
2y3a	pdb	Crystal structure of p110beta in complex with icSH2 of p85beta and the drug GDC-0941	x-ray	3.3	A	q8bti9	1064		700..1054
2y4i	pdb	KSR2-MEK1 heterodimer	x-ray	3.46	B;C	q6vab6;p29678	950;393	;	642..928;63..365
2y4p	pdb	Dimeric structure of DAPK-1 catalytic domain	x-ray	2.65	A;B;C;D	p53355;p53355;p53355;p53355	1430;1430;1430;1430	;;;	6..291;6..291;6..291;6..291
2y6m	pdb	Crystal structure of EphA4 kinase domain	x-ray	1.7	A	q03137	986		613..907
2y6o	pdb	Crystal structure of EphA4 kinase domain in complex with Dasatinib.	x-ray	1.543	A	q03137	986		613..907
2y7j	pdb	Structure of human phosphorylase kinase, gamma 2	x-ray	2.5	A;B;C;D	p15735;p15735;p15735;p15735	406;406;406;406	;;;	17..317;17..317;17..317;17..317
2y8o	pdb	Crystal structure of human p38alpha complexed with a MAPK docking peptide	x-ray	1.95	A	q16539	360		9..349
2y9q	pdb	Crystal structure of human ERK2 complexed with a MAPK docking peptide	x-ray	1.55	A	p28482	360		19..322
2ya9	pdb	Crystal structure of the autoinhibited form of mouse DAPK2	x-ray	2.3	A;B	q8vdf3;q8vdf3	370;370	;	13..301;13..301
2yaa	pdb	Crystal structure of the autoinhibited form of mouse DAPK2 in complex with ATP	x-ray	2.3	A;B	q8vdf3;q8vdf3	370;370	;	13..301;13..301
2yab	pdb	Crystal structure of the autoinhibited form of mouse DAPK2 in complex with AMP	x-ray	1.9	A;B	q8vdf3;q8vdf3	370;370	;	13..301;13..301
2yac	pdb	Crystal structure of Polo-like kinase 1 in complex with NMS-P937	x-ray	2.2	A	p53350	603		51..338
2yak	pdb	Structure of death-associated protein Kinase 1 (dapk1) in complex with a ruthenium octasporine ligand (OSV)	x-ray	2.2	A	p53355	1430		6..291
2ycf	pdb	Crystal Structure of Checkpoint Kinase 2 in complex with Inhibitor PV1531	x-ray	1.77	A	o96017	543		213..500
2ycq	pdb	Crystal structure of checkpoint kinase 2 in complex with inhibitor PV1115	x-ray	2.05	A	o96017	543		213..500
2ycr	pdb	Crystal structure of checkpoint kinase 2 in complex with inhibitor PV976	x-ray	2.2	A	o96017	543		213..500
2ycs	pdb	Crystal structure of checkpoint kinase 2 in complex with PV788	x-ray	2.35	A	o96017	543		213..500
2ydi	pdb	Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thiophene Carboxamide Ureas	x-ray	1.6	A	o14757	476		6..317
2ydj	pdb	Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thiophene Carboxamide Ureas	x-ray	1.85	A;B	o14757;o14757	476;476	;	6..317;6..317
2ydk	pdb	Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thiophene Carboxamide Ureas	x-ray	1.9	A	o14757	476		6..317
2yer	pdb	Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors	x-ray	1.83	A	o14757	476		6..317
2yex	pdb	Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors	x-ray	1.3	A	o14757	476		6..317
2yfx	pdb	Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib	x-ray	1.7	A	q9um73	1620		1089..1381
2yhv	pdb	Structure of L1196M Mutant Anaplastic Lymphoma Kinase	x-ray	1.9	A	q9um73	1620		1089..1381
2yiq	pdb	Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1322	x-ray	1.89	A	o96017	543		213..500
2yir	pdb	Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1352	x-ray	2.1	A	o96017	543		213..500
2yis	pdb	triazolopyridine inhibitors of p38 kinase.	x-ray	2	A	q16539	360		9..349
2yit	pdb	Structural analysis of checkpoint kinase 2 in complex with PV1162, a novel inhibitor	x-ray	2.2	A	o96017	543		213..500
2yiw	pdb	triazolopyridine inhibitors of p38 kinase	x-ray	2	A	q16539	360		9..349
2yix	pdb	Triazolopyridine Inhibitors of p38	x-ray	2.3	A	q16539	360		9..349
2yiy	pdb	Crystal structure of compound 8 bound to TAK1-TAB	x-ray	2.49	A	q15750	504		
2yjr	pdb	Structure of F1174L Mutant Anaplastic Lymphoma Kinase	x-ray	1.9	A	q9um73	1620		1089..1381
2yjs	pdb	Structure of C1156Y Mutant Anaplastic Lymphoma Kinase	x-ray	1.9	A	q9um73	1620		1089..1381
2ym3	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.007	A	o14757	476		6..317
2ym4	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.35	A	o14757	476		6..317
2ym5	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.03	A	o14757	476		6..317
2ym6	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.01	A	o14757	476		6..317
2ym7	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	1.81	A	o14757	476		6..317
2ym8	pdb	Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors	x-ray	2.07	A	o14757	476		6..317
2yn8	pdb	ephB4 kinase domain inhibitor complex	x-ray	2.11	A;B	p54760;p54760	987;987	;	609..886;609..886
2ywp	pdb	Crystal Structure of CHK1 with a Urea Inhibitor	x-ray	2.9	A	o14757	476		6..317
2yza	pdb	Crystal structure of kinase domain of Human 5'-AMP-activated protein kinase alpha-2 subunit mutant (T172D)	x-ray	3.02	A	p54646	552		13..269
2z2w	pdb	Human Wee1 kinase complexed with inhibitor PF0335770	x-ray	2.22	A	p30291	646		279..580
2z60	pdb	Crystal Structure of the T315I Mutant of Abl kinase bound with PPY-A	x-ray	1.95	A	p00520	1123		231..498
2z7l	pdb	Unphosphorylated Mitogen Activated Protein Kinase ERK2 in Complex with (4-{[5-Carbamoyl-4-(3-Methylanilino)Pyrimidin 2-Yl]Amino}Phenyl)Acetic Acid	x-ray	2.41	A	p63086	358		17..320
2z7q	pdb	Crystal structure of the N-terminal kinase domain of human RSK-1 bound to AMP-PCP	x-ray	2	A	q15418	735		60..381,400..719
2z7r	pdb	Crystal Structure of the N-terminal Kinase Domain of Human RSK1 bound to Staurosporine	x-ray	2	A	q15418	735		60..381,400..719
2z7s	pdb	Crystal Structure of the N-terminal Kinase Domain of Human RSK1 bound to Purvalnol A	x-ray	2.1	A	q15418	735		60..381,400..719
2z8c	pdb	Phosphorylated insulin receptor tyrosine kinase in complex with (4-{[5-carbamoyl-4-(3-methylanilino)pyrimidin-2-yl]amino}phenyl)acetic acid	x-ray	3.25	A	p06213	1382		996..1290
2zaz	pdb	Crystal structure of P38 in complex with 4-anilino quinoline inhibitor	x-ray	1.8	A	q16539	360		9..349
2zb0	pdb	Crystal structure of P38 in complex with biphenyl amide inhibitor	x-ray	2.1	A	q16539	360		9..349
2zb1	pdb	Crystal structure of P38 in complex with biphenyl amide inhibitor	x-ray	2.5	A	q16539	360		9..349
2zdt	pdb	Crystal Structure of human JNK3 complexed with an isoquinolone inhibitor	x-ray	2	A	p53779	464		52..396
2zdu	pdb	Crystal Structure of human JNK3 complexed with an isoquinolone inhibitor	x-ray	2.5	A	p53779	464		52..396
2zjw	pdb	Crystal structure of human CK2 alpha complexed with Ellagic acid	x-ray	2.4	A	p68400	391		5..328
2zm1	pdb	Crystal structure of imidazo pyrazin 1 bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)	x-ray	2.1	A	p06239	509		231..500
2zm3	pdb	Complex Structure of Insulin-like Growth Factor Receptor and Isoquinolinedione Inhibitor	x-ray	2.5	A;B;C;D	p08069;p08069;p08069;p08069	1367;1367;1367;1367	;;;	970..1264;970..1264;970..1264;970..1264
2zm4	pdb	Crystal structure of imidazo quinoxaline 1 bound to the kinase domain of human LCK, activated form (auto-phosphorylated on TYR394)	x-ray	2.7	A	p06239	509		231..500
2zmc	pdb	Crystal structure of human mitotic checkpoint kinase Mps1 catalytic domain apo form	x-ray	3.14	A	p33981	857		516..792
2zmd	pdb	Crystal structure of human Mps1 catalytic domain T686A mutant in complex with SP600125 inhibitor	x-ray	2.88	A	p33981	857		516..792
2zoq	pdb	Structural dissection of human mitogen-activated kinase ERK1	x-ray	2.39	A;B	p27361;p27361	379;379	;	36..339;36..339
2zv2	pdb	Crystal structure of human calcium/calmodulin-dependent protein kinase kinase 2, beta, CaMKK2 kinase domain in complex with STO-609	x-ray	2.4	A	q96rr4	588		153..484
2zv7	pdb	Lyn Tyrosine Kinase Domain, apo form	x-ray	2.5	A	p25911	512		234..500
2zv8	pdb	Lyn Tyrosine Kinase Domain-AMP-PNP complex	x-ray	2.7	A	p25911	512		234..500
2zv9	pdb	Lyn Tyrosine Kinase Domain-PP2 complex	x-ray	2.76	A	p25911	512		234..500
2zva	pdb	Lyn Tyrosine Kinase Domain-Dasatinib complex	x-ray	2.6	A	p25911	512		234..500
2zyb	pdb	Crystal structure of phenylimidazo pyrazin 2 bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)	x-ray	2.55	A	p06239	509		231..500
3a2c	pdb	Crystal structure of a pyrazolopyrimidine inhibitor complex bound to MAPKAP Kinase-2 (MK2)	x-ray	2.9	A;B;C;D;E;F;G;H;I;J;K;L	p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137	400;400;400;400;400;400;400;400;400;400;400;400	;;;;;;;;;;;	59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369
3a4o	pdb	Lyn kinase domain	x-ray	3	X	p07948	512		234..500
3a4p	pdb	human c-MET kinase domain complexed with 6-benzyloxyquinoline inhibitor	x-ray	2.54	A	p08581	1390		1079..1341
3a60	pdb	Crystal structure of unphosphorylated p70S6K1 (Form I)	x-ray	2.8	A;B	p23443;p23443	525;525	;	86..409;86..409
3a61	pdb	Crystal structure of unphosphorylated p70S6K1 (Form II)	x-ray	3.43	A	p23443	525		86..409
3a62	pdb	Crystal structure of phosphorylated p70S6K1	x-ray	2.35	A	p23443	525		86..409
3a7f	pdb	Human MST3 kinase	x-ray	1.55	A	q9y6e0	443		36..320
3a7g	pdb	Human MST3 kinase	x-ray	2	A;B	q9y6e0;q9y6e0	443;443	;	36..320;36..320
3a7h	pdb	Human MST3 kinase in complex with ATP	x-ray	1.96	A;B	q9y6e0;q9y6e0	443;443	;	36..320;36..320
3a7i	pdb	Human MST3 kinase in complex with adenine	x-ray	1.45	A	q9y6e0	443		36..320
3a7j	pdb	Human MST3 kinase in complex with MnADP	x-ray	1.5	A	q9y6e0	443		36..320
3a8w	pdb	Crystal Structure of PKCiota kinase domain	x-ray	2.1	A;B	p41743;p41743	596;596	;	252..578;252..578
3a8x	pdb	Crystal Structure of PKCiota kinase domain	x-ray	2	A;B	p41743;p41743	596;596	;	252..578;252..578
3a99	pdb	Structure of PIM-1 kinase crystallized in the presence of P27KIP1 Carboxy-terminal peptide	x-ray	1.6	A	p11309	313		36..296
3ac1	pdb	Crystal structure of pyrazin derivative bound to the kinase domain of Human LCK, (Auto-phosphorylated on TYR394)	x-ray	1.99	A	p06239	509		231..500
3ac2	pdb	Crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)	x-ray	2.1	A	p06239	509		231..500
3ac3	pdb	Crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)	x-ray	2.55	A	p06239	509		231..500
3ac4	pdb	Crystal structure of triazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)	x-ray	2.7	A	p06239	509		231..500
3ac5	pdb	Crystal structure of triazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)	x-ray	2.5	A	p06239	509		231..500
3ac8	pdb	Crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)	x-ray	2.3	A	p06239	509		231..500
3acj	pdb	Crystal structure of imidazo pyrimidine derivative bound to the kinase domain of human LCK, (Auto-phosphorylated on TYR394)	x-ray	2.2	A	p06239	509		231..500
3ack	pdb	Crystal structure of Pyrrolo pyrazine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)	x-ray	2.6	A	p06239	509		231..500
3ad4	pdb	Crystal Structure of Methoxy Benzofuran Derivative bound to the Kinase domain of human LCK, (auto-phosphorylated on TYR394)	x-ray	2.2	A	p06239	509		231..500
3ad5	pdb	Crystal structure of Triazolone derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)	x-ray	2	A	p06239	509		231..500
3ad6	pdb	Crystal structure of Pyrazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394)	x-ray	2.15	A	p06239	509		231..500
3ag9	pdb	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1012	x-ray	2	A;B	p00517;p00517	351;351	;	32..339;32..339
3agl	pdb	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1039	x-ray	2.1	A;B	p17612;p17612	351;351	;	30..339;30..339
3agm	pdb	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-670	x-ray	2	A				
3aln	pdb	Crystal Structure of human non-phosphorylated MKK4 kinase domain complexed with AMP-PNP	x-ray	2.3	A;B;C	p45985;p45985;p45985	399;399;399	;;	93..384;93..384;93..384
3alo	pdb	Crystal structure of human non-phosphorylated MKK4 kinase domain ternary complex with AMP-PNP and p38 peptide	x-ray	2.6	A				
3ama	pdb	Protein kinase A sixfold mutant model of Aurora B with inhibitor JNJ-7706621	x-ray	1.75	A	p17612	351		30..339
3amb	pdb	Protein kinase A sixfold mutant model of Aurora B with inhibitor VX-680	x-ray	2.25	A	p17612	351		30..339
3amy	pdb	Crystal structure of human CK2 alpha complexed with apigenin	x-ray	2.3	A	p68400	391		5..328
3anq	pdb	human DYRK1A/inhibitor complex	x-ray	2.6	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
3anr	pdb	human DYRK1A/harmine complex	x-ray	2.6	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
3aox	pdb	X-ray crystal structure of human anaplastic lymphoma kinase in complex with CH5424802	x-ray	1.75	A	q9um73	1620		1089..1381
3apc	pdb	Crystal structure of human PI3K-gamma in complex with CH5132799	x-ray	2.544	A	p48736	1102		728..1089
3apd	pdb	Crystal structure of human PI3K-gamma in complex with CH5108134	x-ray	2.55	A	p48736	1102		728..1089
3apf	pdb	Crystal structure of human PI3K-gamma in complex with CH5039699	x-ray	2.82	A	p48736	1102		728..1089
3aqv	pdb	Human AMP-activated protein kinase alpha 2 subunit kinase domain (T172D) complexed with compound C	x-ray	2.08	A	p54646	552		13..269
3at2	pdb	Crystal structure of CK2alpha	x-ray	1.6	A	p68400	391		5..328
3at3	pdb	Crystal structure of CK2alpha with pyradine derivative	x-ray	2.6	A	p68400	391		5..328
3at4	pdb	Crystal structure of CK2alpha with pyradine derivertive	x-ray	2.2	A	p68400	391		5..328
3ats	pdb	Crystal structure of Rv3168	x-ray	1.67	A	p9wi99	378		30..333
3att	pdb	Crystal structure of Rv3168 with ATP	x-ray	2	A	p9wi99	378		30..333
3axw	pdb	Crystal structure of human CK2alpha complexed with a potent inhibitor	x-ray	2.5	A	p68400	391		5..328
3b2t	pdb	Structure of phosphotransferase	x-ray	1.8	A;B	p21802;p21802	821;821	;	471..757;471..757
3b2w	pdb	Crystal structure of pyrimidine amide 11 bound to Lck	x-ray	2.3	A	p06239	509		231..500
3b8q	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a naphthamide inhibitor	x-ray	2.75	A;B	p35968;p35968	1356;1356	;	815..1160;815..1160
3b8r	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a naphthamide inhibitor	x-ray	2.7	A;B	p35968;p35968	1356;1356	;	815..1160;815..1160
3bbt	pdb	crystal structure of the ErbB4 kinase in complex with lapatinib	x-ray	2.8	B;D	q15303;q15303	1308;1308	;	715..1007;715..1007
3bbw	pdb	crystal structure of the ErbB4 kinase in its inactive conformation	x-ray	4	A;B	q15303;q15303	1308;1308	;	715..1007;715..1007
3bce	pdb	Crystal structure of the ErbB4 kinase	x-ray	2.5	A;B;C	q15303;q15303;q15303	1308;1308;1308	;;	715..1007;715..1007;715..1007
3be2	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a benzamide inhibitor	x-ray	1.75	A	p35968	1356		815..1160
3be9	pdb	Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities	x-ray	2	A	p28523	332		11..323
3bea	pdb	cFMS tyrosine kinase (tie2 KID) in complex with a pyrimidinopyridone inhibitor	x-ray	2.02	A	p07333	972		551..909
3beg	pdb	Crystal structure of SR protein kinase 1 complexed to its substrate ASF/SF2	x-ray	2.9	A	q96sb4	655		67..654
3bel	pdb	X-ray structure of EGFR in complex with oxime inhibitor	x-ray	2.3	A	p00533	1210		708..1003
3bgp	pdb	Human Pim-1 complexed with a benzoisoxazole inhibitor VX1	x-ray	2.8	A	p11309	313		36..296
3bgq	pdb	Human Pim-1 kinase in complex with an triazolo pyridazine inhibitor VX2	x-ray	2	A	p11309	313		36..296
3bgz	pdb	Human Pim-1 kinase in complex with diphenyl indole inhibitor VX3	x-ray	2.4	A	p11309	313		36..296
3bhh	pdb	Crystal structure of human calcium/calmodulin-dependent protein kinase IIB isoform 1 (CAMK2B)	x-ray	2.4	A;B;C;D	q13554;q13554;q13554;q13554	666;666;666;666	;;;	10..273;10..273;10..273;10..273
3bht	pdb	Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 3	x-ray	2	A;C	p24941;p24941	298;298	;	1..292;1..292
3bhu	pdb	Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 5	x-ray	2.3	A;C	p24941;p24941	298;298	;	1..292;1..292
3bhv	pdb	Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor variolin B	x-ray	2.1	A;C	p24941;p24941	298;298	;	1..292;1..292
3bhy	pdb	Crystal structure of human death associated protein kinase 3 (DAPK3) in complex with a beta-carboline ligand	x-ray	1.24	A	o43293	454		6..313
3bi6	pdb	Wee1 kinase complex with inhibitor PD352396	x-ray	2.2	A	p30291	646		279..580
3biz	pdb	Wee1 kinase complex with inhibitor PD331618	x-ray	2.2	A	p30291	646		279..580
3bkb	pdb	Crystal structure of human Feline Sarcoma Viral Oncogene Homologue (v-FES)	x-ray	1.78	A	p07332	822		549..818
3blh	pdb	Crystal Structure of Human CDK9/cyclinT1	x-ray	2.48	A	p50750	372		12..321
3blq	pdb	Crystal Structure of Human CDK9/cyclinT1 in Complex with ATP	x-ray	2.9	A	p50750	372		12..321
3blr	pdb	Crystal Structure of Human CDK9/cyclinT1 in complex with Flavopiridol	x-ray	2.8	A	p50750	372		12..321
3bpr	pdb	Crystal structure of catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor C52	x-ray	2.8	A;B;C;D	q12866;q12866;q12866;q12866	999;999;999;999	;;;	578..872;578..872;578..872;578..872
3bqc	pdb	High pH-value crystal structure of emodin in complex with the catalytic subunit of protein kinase CK2	x-ray	1.5	A	p68400	391		5..328
3bqr	pdb	Crystal structure of human death associated protein kinase 3 (DAPK3) in complex with an imidazo-pyridazine ligand	x-ray	1.75	A	o43293	454		6..313
3brb	pdb	Crystal structure of catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with ADP	x-ray	1.9	A;B	q12866;q12866	999;999	;	578..872;578..872
3bu3	pdb	Crystal structure of the insulin receptor kinase in complex with IRS2 KRLB peptide	x-ray	1.65	A	p06213	1382		996..1290
3bu5	pdb	Crystal structure of the insulin receptor kinase in complex with IRS2 KRLB peptide and ATP	x-ray	2.1	A	p06213	1382		996..1290
3bu6	pdb	Crystal structure of the insulin receptor kinase in complex with IRS2 KRLB phosphopeptide	x-ray	1.95	A	p06213	1382		996..1290
3bv2	pdb	Morpholino pyrrolotriazine P38 Alpha map kinase inhibitor compound 30	x-ray	2.4	A	q16539	360		9..349
3bv3	pdb	Morpholino pyrrolotriazine P38 Alpha Map Kinase inhibitor compound 2	x-ray	2.59	A	q16539	360		9..349
3bwf	pdb	Crystal structure of the human Pim1 in complex with an osmium compound	x-ray	2.35	A	p11309	313		36..296
3bwj	pdb	Complex of PKA with the bisubstrate protein kinase inhibitor lead compound Arc-1034	x-ray	2.3	A	p00517	351		32..339
3bx5	pdb	P38 alpha map kinase complexed with BMS-640994	x-ray	2.4	A	q16539	360		9..349
3bym	pdb	X-ray co-crystal structure aminobenzimidazole triazine 1 bound to Lck	x-ray	2	A	p06239	509		231..500
3byo	pdb	X-Ray co-crystal structure of 2-amino-6-phenylpyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-one 25 bound to Lck	x-ray	2	A	p06239	509		231..500
3bys	pdb	co-crystal structure of Lck and aminopyrimidine amide 10b	x-ray	2.2	A	p06239	509		231..500
3byu	pdb	co-crystal structure of Lck and aminopyrimidine reverse amide 23	x-ray	2.3	A	p06239	509		231..500
3byv	pdb	Crystal structure of Toxoplasma gondii specific rhoptry antigen kinase domain	x-ray	1.8	A	o15693	575		270..557
3bz3	pdb	Crystal Structure Analysis of Focal Adhesion Kinase with a Methanesulfonamide Diaminopyrimidine Inhibitor	x-ray	2.2	A	q05397	1052		409..693
3c0g	pdb	CASK CaM-Kinase Domain- 3'-AMP complex, P1 form	x-ray	2.19	A;B	o14936;o14936	926;926	;	7..292;7..292
3c0h	pdb	CASK CaM-Kinase Domain- AMPPNP complex, P1 form	x-ray	2.3	A;B	o14936;o14936	926;926	;	7..292;7..292
3c0i	pdb	CASK CaM-Kinase Domain- 3'-AMP complex, P212121 form	x-ray	1.85	A	o14936	926		7..292
3c13	pdb	Low pH-value crystal structure of emodin in complex with the catalytic subunit of protein kinase CK2	x-ray	1.95	A	p68400	391		5..328
3c1x	pdb	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET in complex with a Pyrrolotriazine based inhibitor	x-ray	2.17	A	p08581	1390		1079..1341
3c4c	pdb	B-Raf Kinase in Complex with PLX4720	x-ray	2.57	A;B	p15056;p15056	766;766	;	449..717;449..717
3c4e	pdb	Pim-1 Kinase Domain in Complex with 3-aminophenyl-7-azaindole	x-ray	1.98	A;B;C;D	p11309;p11309;p11309;p11309	313;313;313;313	;;;	36..296;36..296;36..296;36..296
3c4f	pdb	FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3-methoxybenzyl)-7-azaindole	x-ray	2.07	A;B	p11362;p11362	822;822	;	468..754;468..754
3c4w	pdb	Crystal Structure of G protein coupled receptor kinase 1 bound to ATP and magnesium chloride at 2.7A	x-ray	2.7	A;B	p28327;p28327	561;561	;	187..529;187..529
3c4x	pdb	Crystal Structure of G protein coupled receptor kinase 1 bound to ATP and magnesium chloride at 2.9A	x-ray	2.9	A;B	p28327;p28327	561;561	;	187..529;187..529
3c4y	pdb	Crystal Structure of Apo form of G protein coupled receptor kinase 1 at 7.51A	x-ray	7.509	A;B	p28327;p28327	561;561	;	187..529;187..529
3c4z	pdb	Crystal structure of G protein coupled receptor kinase 1 bound to ADP and magnesium chloride at 1.84A	x-ray	1.84	A	p28327	561		187..529
3c50	pdb	Crystal Structure of G protein coupled receptor kinase 1 bound to ADP and magnesium chloride at 2.6A	x-ray	2.6	A;B	p28327;p28327	561;561	;	187..529;187..529
3c51	pdb	Crystal structure of G protein coupled receptor kinase 1 bound to ADP and magnesium chloride at 3.55A	x-ray	3.55	A;B	p28327;p28327	561;561	;	187..529;187..529
3c5i	pdb	Crystal structure of Plasmodium knowlesi choline kinase, PKH_134520	x-ray	2.2	A;B;C;D	;;;	;;;	;;;	;;;
3c5u	pdb	P38 ALPHA map kinase complexed with a benzothiazole based inhibitor	x-ray	2.8	A	q16539	360		9..349
3c7q	pdb	Structure of VEGFR2 kinase domain in complex with BIBF1120	x-ray	2.1	A	p35968	1356		815..1160
3c9w	pdb	Crystal Structure of ERK-2 with hypothemycin covalently bound	x-ray	2.5	A;B	p63086;p63086	358;358	;	17..320;17..320
3cbl	pdb	Crystal structure of human feline sarcoma viral oncogene homologue (v-FES) in complex with staurosporine and a consensus peptide	x-ray	1.75	A				
3cc6	pdb	Crystal structure of kinase domain of protein tyrosine kinase 2 beta (PTK2B)	x-ray	1.6	A	q14289	1009		417..694
3ccn	pdb	X-ray structure of c-Met with triazolopyridazine inhibitor.	x-ray	1.9	A	p08581	1390		1079..1341
3cd3	pdb	Crystal structure of phosphorylated human feline sarcoma viral oncogene homologue (v-FES) in complex with staurosporine and a consensus peptide	x-ray	1.98	A				
3cd8	pdb	X-ray Structure of c-Met with triazolopyridazine Inhibitor.	x-ray	2	A	p08581	1390		1079..1341
3ce3	pdb	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with a Pyrrolopyridinepyridone based inhibitor	x-ray	2.4	A	p08581	1390		1079..1341
3cek	pdb	Crystal structure of human dual specificity protein kinase (TTK)	x-ray	2.3	A	p33981	857		516..792
3cgf	pdb	IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine binding	x-ray	3	A	p53779	464		52..396
3cgo	pdb	IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine binding	x-ray	3	A	p53779	464		52..396
3cik	pdb	Human GRK2 in Complex with Gbetagamma subunits	x-ray	2.75	A	p25098	689		187..532
3cjf	pdb	Crystal structure of VEGFR2 in complex with a 3,4,5-trimethoxy aniline containing pyrimidine	x-ray	2.15	A	p35968	1356		815..1160
3cjg	pdb	Crystal structure of VEGFR2 in complex with a 3,4,5-trimethoxy aniline containing pyrimidine	x-ray	2.25	A	p35968	1356		815..1160
3ckw	pdb	Crystal structure of sterile 20-like kinase 3 (MST3, STK24)	x-ray	1.96	A	q9y6e0	443		36..320
3ckx	pdb	Crystal structure of sterile 20-like kinase 3 (MST3, STK24) in complex with staurosporine	x-ray	2.7	A	q9y6e0	443		36..320
3cly	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domains Trapped in Trans-Phosphorylation Reaction	x-ray	2	A	p21802	821		471..757
3coh	pdb	Crystal structure of Aurora-A in complex with a pentacyclic inhibitor	x-ray	2.7	A;B	o14965;o14965	403;403	;	120..386;120..386
3coi	pdb	Crystal structure of p38delta kinase	x-ray	2.09	A	o15264	365		19..314
3cok	pdb	Crystal structure of PLK4 kinase	x-ray	2.25	A;B	o00444;o00444	970;970	;	9..266;9..266
3com	pdb	Crystal structure of Mst1 kinase	x-ray	2.2	A;B	q13043;q13043	487;487	;	27..285;27..285
3cp9	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a pyridone inhibitor	x-ray	2.5	A;B	p35968;p35968	1356;1356	;	815..1160;815..1160
3cpb	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a bisamide inhibitor	x-ray	2.7	A;B	p35968;p35968	1356;1356	;	815..1160;815..1160
3cpc	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a pyridone inhibitor	x-ray	2.4	A;B	p35968;p35968	1356;1356	;	815..1160;815..1160
3cqe	pdb	Wee1 kinase complex with inhibitor PD074291	x-ray	2.5	A	p30291	646		279..580
3cqu	pdb	Crystal Structure of Akt-1 complexed with substrate peptide and inhibitor	x-ray	2.2	A	p31749	480		145..459
3cqw	pdb	Crystal Structure of Akt-1 complexed with substrate peptide and inhibitor	x-ray	2	A	p31749	480		145..459
3cr0	pdb	Wee1 kinase complex with inhibitor PD259_809	x-ray	2.3	A	p30291	646		279..580
3cs9	pdb	Human ABL kinase in complex with nilotinib	x-ray	2.21	A;B;C;D	p00519;p00519;p00519;p00519	1130;1130;1130;1130	;;;	231..498;231..498;231..498;231..498
3csf	pdb	Crystal structure of PI3K p110gamma catalytical domain in complex with organoruthenium inhibitor DW2	x-ray	2.8	A	p48736	1102		728..1089
3cst	pdb	Crystal structure of PI3K p110gamma catalytical domain in complex with organoruthenium inhibitor E5E2	x-ray	3.2	A	p48736	1102		728..1089
3csv	pdb	Crystal structure of a putative aminoglycoside phosphotransferase (YP_614837.1) from Silicibacter sp. TM1040 at 2.15 A resolution	x-ray	2.15	A	q1gcp1	332		5..310
3cth	pdb	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with a aminopyridine based inhibitor	x-ray	2.3	A	p08581	1390		1079..1341
3ctj	pdb	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with a aminopyridine based inhibitor	x-ray	2.5	A	p08581	1390		1079..1341
3ctq	pdb	Structure of MAP kinase p38 in complex with a 1-o-tolyl-1,2,3-triazole-4-carboxamide	x-ray	1.95	A	q16539	360		9..349
3cxw	pdb	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a beta carboline ligand I	x-ray	2.1	A				
3cy2	pdb	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a beta carboline ligand II	x-ray	2.01	A				
3cy3	pdb	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and the JNK inhibitor V	x-ray	2.15	A				
3d0e	pdb	Crystal structure of human Akt2 in complex with GSK690693	x-ray	2	A;B	p31751;p31751	481;481	;	147..460;147..460
3d14	pdb	Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)-ethyl]- thiazol-2-yl}-3-(3-trifluoromethyl-phenyl)-urea	x-ray	1.9	A	p97477	395		110..378
3d15	pdb	Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with 1-(3-chloro-phenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)- ethyl]-thiazol-2-yl}-urea [SNS-314]	x-ray	2.3	A	p97477	395		110..378
3d2i	pdb	Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with 1-{5-[2-(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamino)-ethyl]-thiazol-2-yl}-3-(3-trifluoromethyl-phenyl)-urea	x-ray	2.9	A	p97477	395		110..378
3d2k	pdb	Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with [7-(2-{2-[3-(3-chloro-phenyl)-ureido]-thiazol-5-yl}-ethylamino)-pyrazolo[4,3-d]pyrimidin-1-yl]-acetic acid	x-ray	2.5	A	p97477	395		110..378
3d4q	pdb	Pyrazole-based inhibitors of B-Raf kinase	x-ray	2.8	A;B	p15056;p15056	766;766	;	449..717;449..717
3d5u	pdb	Crystal structure of a wildtype Polo-like kinase 1 (Plk1) catalytic domain.	x-ray	2.8	A	q6drk7	595		35..322
3d5v	pdb	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain.	x-ray	2.4	A	q6drk7	595		35..322
3d5w	pdb	Crystal structure of a phosphorylated Polo-like kinase 1 (Plk1) catalytic domain in complex with ADP.	x-ray	2.6	A	q4kmi8	595		35..322
3d5x	pdb	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with wortmannin.	x-ray	2.8	A	q4kmi8	595		35..322
3d7t	pdb	Structural basis for the recognition of c-Src by its inactivator Csk	x-ray	2.899	A;B	p41240;p00523	450;533	;	182..446;256..526
3d7u	pdb	Structural basis for the recognition of c-Src by its inactivator Csk	x-ray	4.111	A;B;C;D	p41240;p00523;p41240;p00523	450;533;450;533	;;;	182..446;256..526;182..446;256..526
3d7z	pdb	Crystal Structure of P38 Kinase in Complex with a biphenyl amide inhibitor	x-ray	2.1	A	q16539	360		9..349
3d83	pdb	Crystal structure of P38 kinase in complex with a biphenyl amide inhibitor	x-ray	1.9	A	q16539	360		9..349
3d94	pdb	Crystal structure of the insulin-like growth factor-1 receptor kinase in complex with PQIP	x-ray	2.3	A	p08069	1367		970..1264
3d9v	pdb	CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI-METHYLATED VARIANT OF FASUDIL	x-ray	3.3	A;B	q13464;q13464	1354;1354	;	73..413;73..413
3da6	pdb	Crystal Structure of human JNK3 complexed with N-(3-methyl-4-(3-(2-(methylamino)pyrimidin-4-yl)pyridin-2-yloxy)naphthalen-1-yl)-1H-benzo[d]imidazol-2-amine	x-ray	2	A	p53779	464		52..396
3dae	pdb	Crystal structure of phosphorylated SNF1 kinase domain	x-ray	2.899	A;B	p06782;p06782	633;633	;	52..307;52..307
3daj	pdb	Crystal structure of Aurora A complexed with an inhibitor discovered through site-directed dynamic tethering	x-ray	2	A	p97477	395		110..378
3dak	pdb	Crystal Structure of Domain-Swapped OSR1 kinase domain	x-ray	2.25	A;B;C;D	o95747;o95747;o95747;o95747	527;527;527;527	;;;	8..310;8..310;8..310;8..310
3db6	pdb	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 902	x-ray	2.85	A	q4kmi8	595		35..322
3db8	pdb	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 041	x-ray	3.15	A	q4kmi8	595		35..322
3dbc	pdb	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 257	x-ray	3.35	A	q4kmi8	595		35..322
3dbd	pdb	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 094	x-ray	3.05	A	q4kmi8	595		35..322
3dbe	pdb	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 557	x-ray	3.32	A	q4kmi8	595		35..322
3dbf	pdb	Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 562	x-ray	3.2	A	q4kmi8	595		35..322
3dbq	pdb	Crystal structure of TTK kinase domain	x-ray	2.7	A	p33981	857		516..792
3dbs	pdb	Structure of PI3K gamma in complex with GDC0941	x-ray	2.8	A	p48736	1102		728..1089
3dcv	pdb	Crystal structure of human Pim1 kinase complexed with 4-(4-hydroxy-3-methyl-phenyl)-6-phenylpyrimidin-2(1H)-one	x-ray	2.7	A	p11309	313		36..296
3ddp	pdb	Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8	x-ray	2.7	A;C	p24941;p24941	298;298	;	1..292;1..292
3ddq	pdb	Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor roscovitine	x-ray	1.8	A;C	p24941;p24941	298;298	;	1..292;1..292
3dfa	pdb	Crystal structure of kinase domain of calcium-dependent protein kinase cgd3_920 from Cryptosporidium parvum	x-ray	2.45	A	a3fq16	538		69..348
3dfc	pdb	Crystal structure of a glycine-rich loop mutant of the death associated protein kinase catalytic domain with AMPPNP	x-ray	1.9	B	p53355	1430		6..291
3dgk	pdb	Crystal structure of a glycine-rich loop mutant of the death associated protein kinase catalytic domain	x-ray	1.7	A	p53355	1430		6..291
3dj5	pdb	Crystal structure of the mouse Aurora-A catalytic domain (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with Compound 290.	x-ray	1.8	A	p97477	395		110..378
3dj6	pdb	Crystal structure of the mouse Aurora-A catalytic domain (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with Compound 823.	x-ray	1.7	A	p97477	395		110..378
3dj7	pdb	Crystal structure of the mouse Aurora-A catalytic domain (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with Compound 130.	x-ray	2.8	A	p97477	395		110..378
3dk3	pdb	Crystal structure of mutant ABL kinase domain in complex with small molecule fragment	x-ray	2.02	A;B	p00520;p00520	1123;1123	;	231..498;231..498
3dk6	pdb	Crystal structure of mutant ABL kinase domain in complex with small molecule fragment	x-ray	2.02	A;B	p00520;p00520	1123;1123	;	231..498;231..498
3dk7	pdb	Crystal structure of mutant ABL kinase domain in complex with small molecule fragment	x-ray	2.01	A;B	p00520;p00520	1123;1123	;	231..498;231..498
3dkc	pdb	Structure of MET receptor tyrosine kinase in complex with ATP	x-ray	1.52	A	p08581	1390		1079..1341
3dkf	pdb	Structure of MET receptor tyrosine kinase in complex with inhibitor SGX-523	x-ray	1.8	A	p08581	1390		1079..1341
3dkg	pdb	Structure of Mutant(Y1248L) MET receptor tyrosine kinase in complex with inhibitor SGX-523	x-ray	1.91	A	p08581	1390		1079..1341
3dko	pdb	Complex between the kinase domain of human ephrin type-a receptor 7 (epha7) and inhibitor alw-ii-49-7	x-ray	2	A	q15375	998		626..925
3dls	pdb	Crystal structure of human PAS kinase bound to ADP	x-ray	2.3	A;B;C;D;E;F	q96rg2;q96rg2;q96rg2;q96rg2;q96rg2;q96rg2	1323;1323;1323;1323;1323;1323	;;;;;	997..1275;997..1275;997..1275;997..1275;997..1275;997..1275
3dlz	pdb	Crystal structure of human haspin in complex with AMP	x-ray	1.85	A	q8tf76	798		474..698
3dnd	pdb	cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24	x-ray	2.26	A	p00517	351		32..339
3dne	pdb	cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24	x-ray	2	A	p00517	351		32..339
3dog	pdb	Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor N-&-N1	x-ray	2.7	A;C	p24941;p24941	298;298	;	1..292;1..292
3dpd	pdb	Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-Dihydro-2H-benzo[1,4]oxazines	x-ray	2.85	A	p48736	1102		728..1089
3dpk	pdb	cFMS tyrosine kinase in complex with a pyridopyrimidinone inhibitor	x-ray	1.95	A	p07333	972		551..909
3dqw	pdb	c-Src kinase domain Thr338Ile mutant in complex with ATPgS	x-ray	2.017	A;B;C;D	p00523;p00523;p00523;p00523	533;533;533;533	;;;	256..526;256..526;256..526;256..526
3dqx	pdb	chicken c-Src kinase domain in complex with ATPgS	x-ray	2.3	A;B	p00523;p00523	533;533	;	256..526;256..526
3ds6	pdb	P38 complex with a phthalazine inhibitor	x-ray	2.9	A;B;C;D	q16539;q16539;q16539;q16539	360;360;360;360	;;;	9..349;9..349;9..349;9..349
3dt1	pdb	P38 Complexed with a quinazoline inhibitor	x-ray	2.8	A	q16539	360		9..349
3dtc	pdb	Crystal structure of mixed-lineage kinase MLK1 complexed with compound 16	x-ray	2.6	A	p80192	1104		120..403
3dtw	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a benzisoxazole inhibitor	x-ray	2.9	A;B	p35968;p35968	1356;1356	;	815..1160;815..1160
3du8	pdb	Crystal structure of GSK-3 beta in complex with NMS-869553A	x-ray	2.2	A;B	p49841;p49841	420;420	;	55..377;55..377
3dv3	pdb	MEK1 with PF-04622664 Bound	x-ray	2.3	A	q02750	393		63..365
3dxn	pdb	Crystal structure of the calcium-dependent kinase from toxoplasma gondii, 541.m00134, kinase domain.	x-ray	2.17	A	q3hnm6	537		55..338
3dxp	pdb	Crystal structure of a putative aminoglycoside phosphotransferase (reut_a1007) from ralstonia eutropha jmp134 at 2.32 A resolution	x-ray	2.32	A	q473p7	358		20..354
3dxq	pdb	Crystal structure of choline/ethanolamine kinase family protein (NP_106042.1) from MESORHIZOBIUM LOTI at 2.55 A resolution	x-ray	2.55	A;B	q98bz3;q98bz3	300;300	;	27..282;27..282
3dy7	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP	x-ray	2.7	A	q02750	393		63..365
3dzo	pdb	Crystal structure of a rhoptry kinase from toxoplasma gondii	x-ray	1.8	A	q06ak3	257		73..239
3dzq	pdb	Human EphA3 kinase domain in complex with inhibitor AWL-II-38.3	x-ray	1.75	A	p29320	983		614..915
3e3b	pdb	Crystal structure of catalytic subunit of human protein kinase CK2alpha prime with a potent indazole-derivative inhibitor	x-ray	3.2	X	p19784	350		13..330
3e3p	pdb	Glycogen synthase kinase from Leishmania major	x-ray	2	A;B	q4qe15;q4qe15	355;355	;	16..319;16..319
3e5a	pdb	Crystal structure of Aurora A in complex with VX-680 and TPX2	x-ray	2.3	A	o14965	403		120..386
3e62	pdb	Fragment based discovery of JAK-2 inhibitors	x-ray	1.922	A	o60674	1132		522..814,842..1119
3e63	pdb	Fragment based discovery of JAK-2 inhibitors	x-ray	1.9	A	o60674	1132		522..814,842..1119
3e64	pdb	Fragment based discovery of JAK-2 inhibitors	x-ray	1.8	A	o60674	1132		522..814,842..1119
3e7o	pdb	Crystal Structure of JNK2	x-ray	2.14	A;B	p45984;p45984	424;424	;	13..356;13..356
3e7v	pdb	Crystal Structure of Human Haspin with a pyrazolo-pyrimidine ligand	x-ray	2	A	q8tf76	798		474..698
3e87	pdb	Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors	x-ray	2.3	A;B	p31751;p31751	481;481	;	147..460;147..460
3e88	pdb	Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors	x-ray	2.5	A;B	p31751;p31751	481;481	;	147..460;147..460
3e8c	pdb	Crystal structures of the kinase domain of PKA in complex with ATP-competitive inhibitors	x-ray	2.2	A;B;C;D;E;F	p00517;p00517;p00517;p00517;p00517;p00517	351;351;351;351;351;351	;;;;;	32..339;32..339;32..339;32..339;32..339;32..339
3e8d	pdb	Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors	x-ray	2.7	A;B	p31751;p31751	481;481	;	147..460;147..460
3e8e	pdb	Crystal structures of the kinase domain of PKA in complex with ATP-competitive inhibitors	x-ray	2	A;B;E;I;L;P	p00517;p00517;p00517;p00517;p00517;p00517	351;351;351;351;351;351	;;;;;	32..339;32..339;32..339;32..339;32..339;32..339
3e8n	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) complexed with a potent inhibitor RDEA119 and MgATP	x-ray	2.5	A	q02750	393		63..365
3e92	pdb	Crystal Structure of P38 Kinase in Complex with A Biaryl Amide Inhibitor	x-ray	2	A	q16539	360		9..349
3e93	pdb	Crystal Structure of P38 Kinase in Complex with A Biaryl Amide Inhibitor	x-ray	2	A	q16539	360		9..349
3eb0	pdb	Crystal Structure of cgd4_240 from cryptosporidium Parvum in complex with indirubin E804	x-ray	2.65	A;C	a3fqn0;a3fqn0	433;433	;	48..384;48..384
3efj	pdb	Structure of c-Met with pyrimidone inhibitor 7	x-ray	2.6	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
3efk	pdb	Structure of c-Met with pyrimidone inhibitor 50	x-ray	2.2	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
3efl	pdb	Crystal structure of the VEGFR2 kinase domain in complex with motesanib	x-ray	2.2	A;B	p35968;p35968	1356;1356	;	815..1160;815..1160
3efw	pdb	Structure of AuroraA with pyridyl-pyrimidine urea inhibitor	x-ray	2.29	A;B	o14965;o14965	403;403	;	120..386;120..386
3eh9	pdb	Crystal structure of death associated protein kinase complexed with ADP	x-ray	1.7	A	p53355	1430		6..291
3eha	pdb	Crystal structure of death associated protein kinase complexed with AMPPNP	x-ray	1.6	A	p53355	1430		6..291
3eid	pdb	CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor	x-ray	3.15	A;C	p24941;p24941	298;298	;	1..292;1..292
3ej1	pdb	CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor	x-ray	3.22	A;C	p24941;p24941	298;298	;	1..292;1..292
3ekk	pdb	Insulin receptor kinase complexed with an inhibitor	x-ray	2.1	A	p06213	1382		996..1290
3ekn	pdb	Insulin receptor kinase complexed with an inhibitor	x-ray	2.2	A	p06213	1382		996..1290
3el7	pdb	Crystal structure of c-Src in complex with pyrazolopyrimidine 3	x-ray	2.8	A	p00523	533		256..526
3el8	pdb	Crystal structure of c-Src in complex with pyrazolopyrimidine 5	x-ray	2.3	A;B	p00523;p00523	533;533	;	256..526;256..526
3elj	pdb	Jnk1 complexed with a bis-anilino-pyrrolopyrimidine inhibitor.	x-ray	1.8	A	p45983	427		12..357
3emg	pdb	Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK)	x-ray	2.6	A	p43405	635		375..627
3en4	pdb	Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with PP121, a multitargeted kinase inhibitor	x-ray	2.55	A;B	p00523;p00523	533;533	;	256..526;256..526
3en5	pdb	Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with PP494, a multitargeted kinase inhibitor	x-ray	2.66	A;B	p00523;p00523	533;533	;	256..526;256..526
3en6	pdb	Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with PP102, a multitargeted kinase inhibitor	x-ray	2.39	A;B	p00523;p00523	533;533	;	256..526;256..526
3en7	pdb	Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with S1, a multitargeted kinase inhibitor	x-ray	2.81	A;B	p00523;p00523	533;533	;	256..526;256..526
3en9	pdb	Structure of the Methanococcus jannaschii KAE1-BUD32 fusion protein	x-ray	2.67	A;B	q58530;q58530	535;535	;	337..484;337..484
3ene	pdb	Complex of PI3K gamma with an inhibitor	x-ray	2.4	A	p48736	1102		728..1089
3enh	pdb	Crystal structure of Cgi121/Bud32/Kae1 complex	x-ray	3.6	A;B	q58530;q58530	535;535	;	337..484;337..484
3enm	pdb	The structure of the MAP2K MEK6 reveals an autoinhibitory dimer	x-ray	2.35	A;B;C;D	p52564;p52564;p52564;p52564	334;334;334;334	;;;	41..315;41..315;41..315;41..315
3eoc	pdb	Cdk2/CyclinA complexed with a imidazo triazin-2-amine	x-ray	3.2	A;C	p24941;p24941	298;298	;	1..292;1..292
3eqb	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP	x-ray	2.62	A	q02750	393		63..365
3eqc	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a ternary complex with compound 1, ATP-GS AND MG2P	x-ray	1.8	A	q02750	393		63..365
3eqd	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a binary complex with ATP-GS and MG2P	x-ray	2.1	A	q02750	393		63..365
3eqf	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a binary complex with K252A and MG2P	x-ray	2.7	A	q02750	393		63..365
3eqg	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a ternary complex with PD, ADP AND MG2P	x-ray	2.5	A	q02750	393		63..365
3eqh	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a ternary complex with U0126, ADP and MG2P	x-ray	2	A	q02750	393		63..365
3eqi	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a binary complex with ADP and MG2P	x-ray	1.9	A	q02750	393		63..365
3eqp	pdb	Crystal Structure of Ack1 with compound T95	x-ray	2.3	A;B	q07912;q07912	1038;1038	;	120..398;120..398
3eqr	pdb	Crystal Structure of Ack1 with compound T74	x-ray	2	A;B	q07912;q07912	1038;1038	;	120..398;120..398
3erk	pdb	THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025	x-ray	2.1	A	p63086	358		17..320
3et7	pdb	Crystal structure of PYK2 complexed with PF-2318841	x-ray	2.7	A	q14289	1009		417..694
3eta	pdb	Kinase domain of insulin receptor complexed with a pyrrolo pyridine inhibitor	x-ray	2.6	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
3ewh	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a pyridyl-pyrimidine benzimidazole inhibitor	x-ray	1.6	A	p35968	1356		815..1160
3eyg	pdb	Crystal structures of JAK1 and JAK2 inhibitor complexes	x-ray	1.9	A	p23458	1154		565..850,873..1146
3eyh	pdb	Crystal structures of JAK1 and JAK2 inhibitor complexes	x-ray	2	A	p23458	1154		565..850,873..1146
3ezr	pdb	CDK-2 with indazole inhibitor 17 bound at its active site	x-ray	1.9	A	p24941	298		1..292
3ezv	pdb	CDK-2 with indazole inhibitor 9 bound at its active site	x-ray	1.99	A	p24941	298		1..292
3f2a	pdb	Crystal structure of human Pim-1 in complex with DAPPA	x-ray	1.9	A	p11309	313		36..296
3f2n	pdb	Crystal Structure of Human Haspin with an Imidazo-pyridazine ligand	x-ray	1.8	A	q8tf76	798		474..698
3f2r	pdb	Crystal structure of human choline kinase alpha in complex with hemicholinium-3	x-ray	2.35	A;B	p35790;p35790	457;457	;	82..455;82..455
3f3t	pdb	Kinase domain of cSrc in complex with inhibitor RL38 (Type III)	x-ray	2.5	A;B	p00523;p00523	533;533	;	256..526;256..526
3f3u	pdb	Kinase domain of cSrc in complex with inhibitor RL37 (Type III)	x-ray	2.5	A;B	p00523;p00523	533;533	;	256..526;256..526
3f3v	pdb	Kinase domain of cSrc in complex with inhibitor RL45 (Type II)	x-ray	2.6	A;B	p00523;p00523	533;533	;	256..526;256..526
3f3w	pdb	Drug resistant cSrc kinase domain in complex with inhibitor RL45 (Type II)	x-ray	2.6	A;B	p00523;p00523	533;533	;	256..526;256..526
3f3z	pdb	Crystal structure of Cryptosporidium parvum calcium dependent protein kinase cgd7_1840 in presence of indirubin E804	x-ray	1.84	A	q5cyl9	676		190..472
3f5g	pdb	Crystal structure of death associated protein kinase in complex with ADP and Mg2+	x-ray	1.85	A	p53355	1430		6..291
3f5p	pdb	Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor	x-ray	2.9	A;B;C;D;E;F;G;H;I;J;K;L;M;R;S;T	p08069;p08069;p08069;p08069;p08069;p08069;p08069;p08069;p08069;p08069;p08069;p08069;p08069;p08069;p08069;p08069	1367;1367;1367;1367;1367;1367;1367;1367;1367;1367;1367;1367;1367;1367;1367;1367	;;;;;;;;;;;;;;;	970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264
3f5u	pdb	Crystal structure of the death associated protein kinase in complex with AMPPNP and Mg2+	x-ray	2	A	p53355	1430		6..291
3f5x	pdb	CDK-2-Cyclin complex with indazole inhibitor 9 bound at its active site	x-ray	2.4	A;C	p24941;p24941	298;298	;	1..292;1..292
3f61	pdb	Crystal Structure of M. tuberculosis PknB Leu33Asp/Val222Asp double mutant in complex with ADP	x-ray	1.8	A	p9wi81	626		8..275
3f66	pdb	Human c-Met Kinase in complex with quinoxaline inhibitor	x-ray	1.4	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
3f69	pdb	Crystal structure of the Mycobacterium tuberculosis PknB mutant kinase domain in complex with KT5720	x-ray	2.8	A;B	p9wi81;p9wi81	626;626	;	8..275;8..275
3f6x	pdb	c-Src kinase domain in complex with small molecule inhibitor	x-ray	2.35	A;B;C;D	p00523;p00523;p00523;p00523	533;533;533;533	;;;	256..526;256..526;256..526;256..526
3f7w	pdb	Crystal structure of putative fructosamine-3-kinase (YP_290396.1) from THERMOBIFIDA FUSCA YX-ER1 at 1.85 A resolution	x-ray	1.85	A	q47me9	287		29..282
3f7z	pdb	X-ray Co-Crystal Structure of Glycogen Synthase Kinase 3beta in Complex with an Inhibitor	x-ray	2.4	A;B	p49841;p49841	420;420	;	55..377;55..377
3f82	pdb	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide	x-ray	2.5	A	p08581	1390		1079..1341
3f88	pdb	glycogen synthase Kinase 3beta inhibitor complex	x-ray	2.6	A;B	p49841;p49841	420;420	;	55..377;55..377
3f9n	pdb	Crystal structure of chk1 kinase in complex with inhibitor 38	x-ray	1.9	A	o14757	476		6..317
3faa	pdb	Crystal structure of TGFbRI complexed with a 2-aminoimidazole inhibitor	x-ray	3.35	A;B;C;D;E	p36897;p36897;p36897;p36897;p36897	503;503;503;503;503	;;;;	180..492;180..492;180..492;180..492;180..492
3fbv	pdb	Crystal structure of the oligomer formed by the kinase-ribonuclease domain of Ire1	x-ray	3.2	A;B;C;D;E;F;G;H;I;J;K;L;M;N	p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361	1115;1115;1115;1115;1115;1115;1115;1115;1115;1115;1115;1115;1115;1115	;;;;;;;;;;;;;	677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992
3fc1	pdb	Crystal structure of p38 kinase bound to pyrimido-pyridazinone inhibitor	x-ray	2.4	X	q16539	360		9..349
3fc2	pdb	PLK1 in complex with BI6727	x-ray	2.45	A	p53350	603		51..338
3fdn	pdb	Structure-based drug design of novel Aurora kinase A inhibitors: Structure basis for potency and specificity	x-ray	1.9	A	o14965	403		120..386
3fe3	pdb	Crystal structure of the kinase MARK3/Par-1: T211A-S215A double mutant	x-ray	1.9	A;B	p27448;p27448	753;753	;	53..308;53..308
3feg	pdb	Crystal structure of human choline kinase beta in complex with phosphorylated hemicholinium-3 and adenosine nucleotide	x-ray	1.302	A	q9y259	395		47..388
3fhi	pdb	Crystal structure of a complex between the catalytic and regulatory (RI{alpha}) subunits of PKA	x-ray	2	A	p05132	351		28..339
3fhr	pdb	High resolution crystal structure of mitogen-activated protein kinase-activated protein kinase 3 (MK3)-inhibitor complex	x-ray	1.9	A	q16644	382		36..343
3fi2	pdb	Crystal structure of JNK3 with amino-pyrazole inhibitor, SR-3451	x-ray	2.28	A	p53779	464		52..396
3fi3	pdb	Crystal structure of JNK3 with indazole inhibitor, SR-3737	x-ray	2.2	A	p53779	464		52..396
3fi4	pdb	P38 kinase crystal structure in complex with RO4499	x-ray	2.2	A	q16539	360		9..349
3fi8	pdb	Crystal structure of choline kinase from Plasmodium Falciparum, PF14_0020	x-ray	2.3	A	q8im71	440		64..429
3fjq	pdb	Crystal structure of cAMP-dependent protein kinase catalytic subunit alpha in complex with peptide inhibitor PKI alpha (6-25)	x-ray	1.6	E	p05132	351		28..339
3fkl	pdb	P38 kinase crystal structure in complex with RO9552	x-ray	2	A	q16539	360		9..349
3fkn	pdb	P38 kinase crystal structure in complex with RO7125	x-ray	2	A	q16539	360		9..349
3fko	pdb	P38 kinase crystal structure in complex with RO3668	x-ray	2	A	q16539	360		9..349
3fl4	pdb	P38 kinase crystal structure in complex with RO5634	x-ray	1.8	A	q16539	360		9..349
3fl5	pdb	Protein kinase CK2 in complex with the inhibitor Quinalizarin	x-ray	2.3	A	p28523	332		11..323
3fln	pdb	P38 kinase crystal structure in complex with R1487	x-ray	1.9	C	q16539	360		9..349
3flq	pdb	P38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)-2-((s)-2-methanesulfonyl-1-methyl-ethylamino)-8-methyl-8h-pyrido[2,3-d]pyrimidin	x-ray	1.9	A	q16539	360		9..349
3fls	pdb	P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-2-((R)-2-methanesulfonyl-1-methyl-ethylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one	x-ray	2.3	A	q16539	360		9..349
3flw	pdb	P38 kinase crystal structure in complex with pamapimod	x-ray	2.1	A	q16539	360		9..349
3fly	pdb	P38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)-2-isopropylamino-8-methyl-8h-pyrido[2,3-d]pyrimidin-7-one	x-ray	1.8	A	q16539	360		9..349
3flz	pdb	P38 kinase crystal structure in complex WITH 8-Methyl-6-phenoxy-2-(tetrahydro-pyran-4-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one	x-ray	2.23	A	q16539	360		9..349
3fmd	pdb	Crystal Structure of Human Haspin with an Isoquinoline ligand	x-ray	2	A	q8tf76	798		474..698
3fme	pdb	Crystal Structure of Human Mitogen-Activated Protein Kinase Kinase 6 (MEK6) Activated Mutant (S207D, T211D)	x-ray	2.26	A	p52564	334		41..315
3fmh	pdb	P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-8-methyl-2-((R)-1-methyl-2-tetrazol-2-yl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one	x-ray	1.9	A	q16539	360		9..349
3fmj	pdb	P38 kinase crystal structure in complex with 4-(5-Methyl-3-phenyl-isoxazol-4-yl)-pyrimidin-2-ylamine	x-ray	2	A	q16539	360		9..349
3fmk	pdb	P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-8-methyl-2-((S)-1-methyl-2-tetrazol-2-yl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one	x-ray	1.7	A	q16539	360		9..349
3fml	pdb	P38 kinase crystal structure in complex with RO6224	x-ray	2.1	A	q16539	360		9..349
3fmm	pdb	P38 kinase crystal structure in complex with RO6226	x-ray	2	A	q16539	360		9..349
3fmn	pdb	P38 kinase crystal structure in complex with RO2530	x-ray	1.9	A	q16539	360		9..349
3fpm	pdb	Crystal Structure of a Squarate Inhibitor bound to MAPKAP Kinase-2	x-ray	3.3	A	p49137	400		59..369
3fqe	pdb	Crystal structure of spleen tyrosine kinase complexed with YM193306	x-ray	2.5	A	p43405	635		375..627
3fqh	pdb	Crystal structure of spleen tyrosine kinase complexed with a 2-substituted 7-azaindole	x-ray	2.26	A;B	p43405;p43405	635;635	;	375..627;375..627
3fqs	pdb	Crystal structure of spleen tyrosine kinase complexed with R406	x-ray	2.1	A	p43405	635		375..627
3fsf	pdb	P38 kinase crystal structure in complex with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1-methyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one	x-ray	2.1	A	q16539	360		9..349
3fsk	pdb	P38 kinase crystal structure in complex with RO6257	x-ray	2	A	q16539	360		9..349
3fup	pdb	Crystal structures of JAK1 and JAK2 inhibitor complexes	x-ray	2.4	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
3fv8	pdb	JNK3 bound to piperazine amide inhibitor, SR2774.	x-ray	2.28	A	p53779	464		52..396
3fwq	pdb	Inactive conformation of human protein kinase CK2 catalytic subunit	x-ray	2.3	A;B	p68400;p68400	391;391	;	5..328;5..328
3fxw	pdb	High resolution crystal structure of mitogen-activated protein kinase-activated protein kinase 3/inhibitor 2 complex	x-ray	2	A	q16644	382		36..343
3fxx	pdb	Human EphA3 Kinase and Juxtamembrane Region Bound to Substrate KQWDNYE[pTyr]IW	x-ray	1.7	A				
3fxz	pdb	Crystal structure of PAK1 kinase domain with ruthenium complex lambda-FL172	x-ray	1.64	A	q13153	545		261..522
3fy0	pdb	Crystal structure of PAK1 kinase domain with ruthenium complex DW1	x-ray	2.35	A	q13153	545		261..522
3fy2	pdb	Human EphA3 Kinase and Juxtamembrane Region Bound to Substrate KQWDNYEFIW	x-ray	1.8	A				
3fyj	pdb	Crystal structure of an optimzied benzothiophene inhibitor bound to MAPKAP Kinase-2 (MK-2)	x-ray	3.8	X	p49137	400		59..369
3fyk	pdb	Crystal structure of a benzthiophene lead bound to MAPKAP Kinase-2 (MK-2)	x-ray	3.5	X	p49137	400		59..369
3fz1	pdb	Crystal structure of a benzthiophene inhibitor bound to human Cyclin-dependent Kinase-2 (CDK-2)	x-ray	1.9	A	p24941	298		1..292
3fzo	pdb	Crystal Structure of PYK2-Apo, Proline-rich Tyrosine Kinase	x-ray	2.2	A	q14289	1009		417..694
3fzp	pdb	Crystal structure of PYK2 complexed with ATPgS	x-ray	2.1	A	q14289	1009		417..694
3fzr	pdb	Crystal structure of PYK2 complexed with PF-431396	x-ray	2.7	A	q14289	1009		417..694
3fzs	pdb	Crystal Structure of PYK2 complexed with BIRB796	x-ray	1.75	A	q14289	1009		417..694
3fzt	pdb	Crystal structure of PYK2 complexed with PF-4618433	x-ray	1.95	A	q14289	1009		417..694
3g0e	pdb	KIT kinase domain in complex with sunitinib	x-ray	1.6	A	p10721	976		564..923
3g0f	pdb	KIT kinase domain mutant D816H in complex with sunitinib	x-ray	2.6	A;B	p10721;p10721	976;976	;	564..923;564..923
3g15	pdb	Crystal structure of human choline kinase alpha in complex with hemicholinium-3 and ADP	x-ray	1.7	A;B	p35790;p35790	457;457	;	82..455;82..455
3g2f	pdb	Crystal structure of the kinase domain of bone morphogenetic protein receptor type II (BMPR2) at 2.35 A resolution	x-ray	2.35	A;B	q13873;q13873	1038;1038	;	186..499;186..499
3g33	pdb	Crystal structure of CDK4/cyclin D3	x-ray	3	A;C	p11802;p11802	303;303	;	3..297;3..297
3g51	pdb	Structural diversity of the active conformation of the N-terminal kinase domain of p90 ribosomal S6 kinase 2	x-ray	1.8	A	p18654	740		66..390,402..717
3g5d	pdb	Kinase domain of cSrc in complex with Dasatinib	x-ray	2.2	A;B	p00523;p00523	533;533	;	256..526;256..526
3g6g	pdb	Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations	x-ray	2.31	A;B	p00523;p00523	533;533	;	256..526;256..526
3g6h	pdb	Src Thr338Ile inhibited in the DFG-Asp-Out conformation	x-ray	2.35	A;B	p00523;p00523	533;533	;	256..526;256..526
3g90	pdb	JNK-3 bound to (Z)-5-fluoro-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)indolin-2-one	x-ray	2.4	X	p53779	464		52..396
3g9l	pdb	JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-styrylindolin-2-one	x-ray	2.2	X	p53779	464		52..396
3g9n	pdb	JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-phenylindolin-2-one	x-ray	2.8	A	p53779	464		52..396
3gb2	pdb	GSK3beta inhibitor complex	x-ray	2.4	A	p49841	420		55..377
3gbz	pdb	Structure of the CMGC CDK Kinase from Giardia lamblia	x-ray	1.85	A	a8bz95	308		10..303
3gc0	pdb	Structure of the CMGC CDK Kinase from Giardia lamblia in complex with AMP	x-ray	2	A	a8bz95	308		10..303
3gc7	pdb	The structure of p38alpha in complex with a dihydroquinazolinone	x-ray	1.8	A	q16539	360		9..349
3gc8	pdb	The structure of p38beta C162S in complex with a dihydroquinazolinone	x-ray	2.4	A;B	q15759;q15759	364;364	;	10..348;10..348
3gc9	pdb	The structure of p38beta C119S, C162S in complex with a dihydroquinazolinone inhibitor	x-ray	2.05	A;B	q15759;q15759	364;364	;	10..348;10..348
3gcp	pdb	Human P38 MAP Kinase in Complex with SB203580	x-ray	2.25	A	q16539	360		9..349
3gcq	pdb	Human P38 MAP kinase in complex with RL45	x-ray	2	A	q16539	360		9..349
3gcs	pdb	Human P38 MAP kinase in complex with Sorafenib	x-ray	2.1	A	q16539	360		9..349
3gcu	pdb	Human P38 MAP kinase in complex with RL48	x-ray	2.1	A;B	q16539;q16539	360;360	;	9..349;9..349
3gcv	pdb	Human P38 MAP Kinase in Complex with RL62	x-ray	2.3	A	q16539	360		9..349
3gen	pdb	The 1.6 A crystal structure of human bruton's tyrosine kinase bound to a pyrrolopyrimidine-containing compound	x-ray	1.6	A	q06187	659		382..648
3geq	pdb	Structural basis for the chemical rescue of Src kinase activity	x-ray	2.2	A;B	p00523;p00523	533;533	;	256..526;256..526
3gfe	pdb	Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Pyrazolopyridinone Inhibitor	x-ray	2.1	A	q16539	360		9..349
3gfw	pdb	Crystal Structure of Human Dual Specificity Protein Kinase (TTK) in complex with a pyrolo-pyridin ligand	x-ray	2.74	A	p33981	857		516..792
3ggf	pdb	Crystal structure of human Serine/threonine-protein kinase MST4 in complex with an quinazolin	x-ray	2.35	A;B	q9p289;q9p289	416;416	;	24..320;24..320
3gi3	pdb	Crystal structure of a N-Phenyl-N'-Naphthylurea analog in complex with p38 MAP kinase	x-ray	2.4	A	q16539	360		9..349
3gni	pdb	Structure of STRAD and MO25	x-ray	2.35	B	q7rtn6	431		57..401
3gok	pdb	Binding site mapping of protein ligands	x-ray	3.2	A;B;C;D;E;F;G;H;I;J;K;L	p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137	400;400;400;400;400;400;400;400;400;400;400;400	;;;;;;;;;;;	59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369
3gop	pdb	Crystal structure of the EGF receptor juxtamembrane and kinase domains	x-ray	2.8	A	p00533	1210		708..1003
3gp0	pdb	Crystal Structure of Human Mitogen Activated Protein Kinase 11 (p38 beta) in complex with Nilotinib	x-ray	1.9	A	q15759	364		10..348
3gqi	pdb	Crystal Structure of activated receptor tyrosine kinase in complex with substrates	x-ray	2.5	A	p11362	822		468..754
3gql	pdb	Crystal Structure of activated receptor tyrosine kinase in complex with substrates	x-ray	2.8	A;B;C	p11362;p11362;p11362	822;822;822	;;	468..754;468..754;468..754
3gt8	pdb	Crystal structure of the inactive EGFR kinase domain in complex with AMP-PNP	x-ray	2.955	A;B;C;D	;;;	;;;	;;;	;;;
3gu4	pdb	Crystal structure of DAPKQ23V-AMPPNP	x-ray	1.35	A	p53355	1430		6..291
3gu5	pdb	Crystal structure of DAPKQ23V-AMPPNP-Mg2+	x-ray	1.65	A	p53355	1430		6..291
3gu6	pdb	Crystal structure of DAPKQ23V-ADP	x-ray	1.49	A	p53355	1430		6..291
3gu7	pdb	Crystal structure of DAPKQ23V-ADP-Mg2+	x-ray	1.9	A	p53355	1430		6..291
3gu8	pdb	Crystal structure of DAPKL93G with N6-cyclopentyladenosine	x-ray	1.6	A	p53355	1430		6..291
3gub	pdb	Crystal structure of DAPKL93G complexed with N6-(2-Phenylethyl)adenosine	x-ray	1.71	A	p53355	1430		6..291
3gvu	pdb	The crystal structure of human ABL2 in complex with GLEEVEC	x-ray	2.05	A	p42684	1182		279..551
3gxl	pdb	ALK-5 kinase complex with GW857175	x-ray	1.8	A	p36897	503		180..492
3h0y	pdb	Aurora A in complex with a bisanilinopyrimidine	x-ray	2.5	A	o14965	403		120..386
3h0z	pdb	Aurora A in complex with a bisanilinopyrimidine	x-ray	2.92	A;B;C	o14965;o14965;o14965	403;403;403	;;	120..386;120..386;120..386
3h10	pdb	Aurora A inhibitor complex	x-ray	2.2	A;B;D	o14965;o14965;o14965	403;403;403	;;	120..386;120..386;120..386
3h30	pdb	Crystal structure of the catalytic subunit of human protein kinase CK2 with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole	x-ray	1.56	A;B	p68400;p68400	391;391	;	5..328;5..328
3h3c	pdb	Crystal structure of PYK2 in complex with Sulfoximine-substituted trifluoromethylpyrimidine analog	x-ray	2	A	q14289	1009		417..694
3h4j	pdb	crystal structure of pombe AMPK KDAID fragment	x-ray	2.8	A;B	o74536;o74536	576;576	;	31..286;31..286
3h9f	pdb	Crystal Structure of Human Dual Specificity Protein Kinase (TTK) in complex with a pyrimido-diazepin ligand	x-ray	2.6	A	p33981	857		516..792
3h9o	pdb	Phosphoinositide-dependent protein kinase 1 (PDK-1) in complex with compound 9	x-ray	2.3	A	o15530	556		79..400
3h9r	pdb	Crystal structure of the kinase domain of type I activin receptor (ACVR1) in complex with FKBP12 and dorsomorphin	x-ray	2.35	A	q04771	509		186..496
3ha6	pdb	Crystal structure of aurora A in complex with TPX2 and compound 10	x-ray	2.36	A	o14965	403		120..386
3ha8	pdb	THE COMPLEX STRUCTURE OF THE MAP KINASE P38/Compound 14b	x-ray	2.48	A	q16539	360		9..349
3ham	pdb	"Structure of the gentamicin-APH(2"")-IIa complex"	x-ray	2.5	A;B	q9evd7;q9evd7	299;299	;	5..251;5..251
3hav	pdb	"Structure of the streptomycin-ATP-APH(2"")-IIa ternary complex"	x-ray	2.45	A;B;C	q9evd7;q9evd7;q9evd7	299;299;299	;;	5..251;5..251;5..251
3hdm	pdb	Crystal structure of serum and glucocorticoid-regulated kinase 1 in complex with compound 1	x-ray	2.6	A	o00141	431		74..401
3hdn	pdb	Crystal structure of serum and glucocorticoid-regulated kinase 1 in complex with compound 2	x-ray	3.1	A	o00141	431		74..401
3hec	pdb	P38 in complex with Imatinib	x-ray	2.5	A	q16539	360		9..349
3heg	pdb	P38 in complex with Sorafenib	x-ray	2.2	A	q16539	360		9..349
3hgk	pdb	crystal structure of effect protein AvrptoB complexed with kinase Pto	x-ray	3.3	A;B;C;D	q40234;q40234;q40234;q40234	321;321;321;321	;;;	15..310;15..310;15..310;15..310
3hhm	pdb	Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha and the drug wortmannin	x-ray	2.8	A	p42336	1068		699..1060
3hiz	pdb	Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha	x-ray	3.3	A	p42336	1068		699..1060
3hko	pdb	Crystal structure of a cdpk kinase domain from cryptosporidium Parvum, cgd7_40	x-ray	1.8	A	q5cz29	824		123..452
3hl7	pdb	Crystal Structure of Human p38alpha complexed with SD-0006	x-ray	1.88	A	q16539	360		9..349
3hll	pdb	Crystal Structure of Human p38alpha complexed with PH-797804	x-ray	1.95	A	q16539	360		9..349
3hmi	pdb	The crystal structure of human ABL2 in complex with 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE	x-ray	1.65	A	p42684	1182		279..551
3hmm	pdb	Structure of Alk5 + GW855857	x-ray	1.7	A	p36897	503		180..492
3hmn	pdb	Crystal structure of human Mps1 catalytic domain in complex with ATP	x-ray	2.7	A	p33981	857		516..792
3hmo	pdb	Crystal structure of human Mps1 catalytic domain in complex with the inhibitor staurosporine	x-ray	2.4	A	p33981	857		516..792
3hmp	pdb	Crystal structure of human Mps1 catalytic domain in complex with a quinazolin ligand Compound 4	x-ray	2.3	A	p33981	857		516..792
3hng	pdb	Crystal structure of VEGFR1 in complex with N-(4-Chlorophenyl)-2-((pyridin-4-ylmethyl)amino)benzamide	x-ray	2.7	A	p17948	1338		807..1153
3hp2	pdb	Crystal Structure of Human p38alpha complexed with a pyridinone compound	x-ray	2.15	A	q16539	360		9..349
3hp5	pdb	Crystal Structure of Human p38alpha complexed with a pyrimidopyridazinone compound	x-ray	2.3	A	q16539	360		9..349
3hrb	pdb	p38 kinase Crystal structure in complex with small molecule inhibitor	x-ray	2.2	A	q16539	360		9..349
3hrc	pdb	Crystal structure of a mutant of human PDK1 Kinase domain in complex with ATP	x-ray	1.91	A	o15530	556		79..400
3hrf	pdb	Crystal structure of Human PDK1 kinase domain in complex with an allosteric activator bound to the PIF-pocket	x-ray	1.9	A	o15530	556		79..400
3hub	pdb	Human p38 MAP Kinase in Complex with Scios-469	x-ray	2.25	A	q16539	360		9..349
3huc	pdb	Human p38 MAP Kinase in Complex with RL40	x-ray	1.8	A	q16539	360		9..349
3hv3	pdb	Human p38 MAP Kinase in Complex with RL49	x-ray	2	A	q16539	360		9..349
3hv4	pdb	Human p38 MAP Kinase in Complex with RL51	x-ray	2.6	A;B	q16539;q16539	360;360	;	9..349;9..349
3hv5	pdb	Human p38 MAP Kinase in Complex with RL24	x-ray	2.25	A;B	q16539;q16539	360;360	;	9..349;9..349
3hv6	pdb	Human p38 MAP Kinase in Complex with RL39	x-ray	1.95	A	q16539	360		9..349
3hv7	pdb	Human p38 MAP Kinase in Complex with RL38	x-ray	2.4	A	q16539	360		9..349
3hvc	pdb	Crystal structure of human p38alpha MAP kinase	x-ray	2.1	A	q16539	360		9..349
3hx4	pdb	Crystal structure of CDPK1 of Toxoplasma gondii, TGME49_101440, in presence of calcium	x-ray	1.95	A	q9bjf5	507		35..330
3hyh	pdb	Crystal structure of the protein kinase domain of yeast AMP-activated protein kinase Snf1	x-ray	2.2	A;B	p06782;p06782	633;633	;	52..307;52..307
3hzt	pdb	Crystal structure of Toxoplasma gondii CDPK3, TGME49_105860	x-ray	2	A	q3hnm6	537		55..338
3i0o	pdb	Crystal Structure of Spectinomycin Phosphotransferase, APH(9)-Ia, in complex with ADP and Spectinomcyin	x-ray	2.4	A	o06916	331		5..293
3i0q	pdb	Crystal Structure of the AMP-bound complex of Spectinomycin Phosphotransferase, APH(9)-Ia	x-ray	2.8	A	o06916	331		5..293
3i1a	pdb	Crystal Structure of apo Spectinomycin Phosphotransferase, APH(9)-Ia	x-ray	1.7	A;B	o06916;o06916	331;331	;	5..293;5..293
3i4b	pdb	Crystal structure of GSK3b in complex with a pyrimidylpyrrole inhibitor	x-ray	2.3	A;B	p49841;p49841	420;420	;	55..377;55..377
3i5n	pdb	Crystal structure of c-Met with triazolopyridazine inhibitor 13	x-ray	2	A	p08581	1390		1079..1341
3i5z	pdb	Crystal structure of ERK2 bound to (S)-N-(2-hydroxy-1-phenylethyl)-4-(5-methyl-2-(phenylamino)pyrimidin-4-yl)-1H-pyrrole-2-carboxamide	x-ray	2.2	A	p28482	360		19..322
3i60	pdb	Crystal structure of ERK2 bound to (S)-4-(2-(2-chlorophenylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-2-carboxamide	x-ray	2.5	A	p28482	360		19..322
3i6u	pdb	Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase	x-ray	3	A;B	o96017;o96017	543;543	;	213..500;213..500
3i6w	pdb	Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase	x-ray	3.25	A;B;C;D;E;F;G;H	o96017;o96017;o96017;o96017;o96017;o96017;o96017;o96017	543;543;543;543;543;543;543;543	;;;;;;;	213..500;213..500;213..500;213..500;213..500;213..500;213..500;213..500
3i79	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1)	x-ray	2.04	A	q9bjf5	507		35..330
3i7b	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor NM-PP1	x-ray	1.988	A	q9bjf5	507		35..330
3i7c	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor NA-PP2	x-ray	1.98	A	q9bjf5	507		35..330
3i81	pdb	Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with BMS-754807 [1-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N-(6-fluoro-3-pyridinyl)-2-methyl-L-prolinamide]	x-ray	2.08	A	p08069	1367		970..1264
3ibe	pdb	Crystal Structure of a Pyrazolopyrimidine Inhibitor Bound to PI3 Kinase Gamma	x-ray	2.798	A	p48736	1102		728..1089
3idb	pdb	Crystal structure of (108-268)RIIb:C holoenzyme of cAMP-dependent protein kinase	x-ray	1.62	A	p05132	351		28..339
3idc	pdb	Crystal structure of (102-265)RIIb:C holoenzyme of cAMP-dependent protein kinase	x-ray	2.7	A	p05132	351		28..339
3idp	pdb	B-Raf V600E kinase domain in complex with an aminoisoquinoline inhibitor	x-ray	2.7	A;B	p15056;p15056	766;766	;	449..717;449..717
3iec	pdb	Helicobacter pylori CagA Inhibits PAR1/MARK Family Kinases by Mimicking Host Substrates	x-ray	2.2	A;B;C;D	q7kzi7;q7kzi7;q7kzi7;q7kzi7	788;788;788;788	;;;	50..305;50..305;50..305;50..305
3ig7	pdb	Novel CDK-5 inhibitors - crystal structure of inhibitor EFP with CDK-2	x-ray	1.8	A	p24941	298		1..292
3igg	pdb	Novel CDK-5 inhibitors - crystal structure of inhibitor EFQ with CDK-2	x-ray	1.8	A	p24941	298		1..292
3igo	pdb	Crystal structure of Cryptosporidium parvum CDPK1, cgd3_920	x-ray	2.25	A	a3fq16	538		69..348
3ihy	pdb	Human PIK3C3 crystal structure	x-ray	2.8	A;B;C;D;E	q8neb9;q8neb9;q8neb9;q8neb9;q8neb9	887;887;887;887;887	;;;;	538..883;538..883;538..883;538..883;538..883
3ii5	pdb	The Complex of wild-type B-RAF with Pyrazolo pyrimidine inhibitor	x-ray	2.79	A;B	p15056;p15056	766;766	;	449..717;449..717
3ik3	pdb	AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance	x-ray	1.9	A;B	p00520;p00520	1123;1123	;	231..498;231..498
3ika	pdb	Crystal Structure of EGFR 696-1022 T790M Mutant Covalently Binding to WZ4002	x-ray	2.9	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
3io7	pdb	2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2	x-ray	2.6	A	o60674	1132		522..814,842..1119
3iok	pdb	2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2	x-ray	2.1	A	o60674	1132		522..814,842..1119
3ion	pdb	PDK1 in complex with Compound 8h	x-ray	2.4	A	o15530	556		79..400
3iop	pdb	PDK-1 in complex with the inhibitor Compound-8i	x-ray	2.2	A	o15530	556		79..400
3iph	pdb	Crystal structure of p38 in complex with a biphenylamide inhibitor	x-ray	2.1	A	q16539	360		9..349
3iq7	pdb	Crystal Structure of human Haspin in complex with 5-Iodotubercidin	x-ray	2	A	q8tf76	798		474..698
3is5	pdb	Crystal structure of CDPK kinase domain from toxoplasma Gondii, TGME49_018720	x-ray	2.55	A;B;C;D;E;F	;;;;;	;;;;;	;;;;;	;;;;;
3itz	pdb	Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Pyrazolopyridazine Inhibitor	x-ray	2.25	A	q16539	360		9..349
3iw4	pdb	Crystal structure of PKC alpha in complex with NVP-AEB071	x-ray	2.8	A;B;C	p17252;p17252;p17252	672;672;672	;;	335..631;335..631;335..631
3iw5	pdb	Human p38 MAP Kinase in Complex with an Indole Derivative	x-ray	2.5	A	q16539	360		9..349
3iw6	pdb	Human p38 MAP Kinase in Complex with a Benzylpiperazin-Pyrrol	x-ray	2.1	A	q16539	360		9..349
3iw7	pdb	Human p38 MAP Kinase in Complex with an Imidazo-pyridine	x-ray	2.4	A	q16539	360		9..349
3iw8	pdb	Structure of Inactive Human p38 MAP Kinase in Complex with a Thiazole-Urea	x-ray	2	A	q16539	360		9..349
3j4q	pdb	Pseudo-atomic model of the AKAP18-PKA complex in a bent conformation derived from electron microscopy	em	35	D;E	p05132;p05132	351;351	;	28..339;28..339
3j4r	pdb	Pseudo-atomic model of the AKAP18-PKA Complex in a linear conformation derived from electron microscopy	em	35	D;E	p05132;p05132	351;351	;	28..339;28..339
3jbz	pdb	Crystal structure of mTOR docked into EM map of dimeric ATM kinase	em	28	A	p42345	2549		2095..2451
3jpv	pdb	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a pyrrolo[2,3-a]carbazole ligand	x-ray	2.35	A				
3jr1	pdb	Crystal structure of Putative fructosamine-3-kinase (YP_719053.1) from HAEMOPHILUS SOMNUS 129PT at 2.32 A resolution	x-ray	2.32	A;B	q0i3m3;q0i3m3	334;334	;	48..307;48..307
3js2	pdb	Crystal structure of minimal kinase domain of fibroblast growth factor receptor 1 in complex with 5-(2-thienyl)nicotinic acid	x-ray	2.2	A;B	p11362;p11362	822;822	;	468..754;468..754
3juh	pdb	Crystal structure of a mutant of human protein kinase CK2alpha with altered cosubstrate specificity	x-ray	1.66	A;B	p68400;p68400	391;391	;	5..328;5..328
3jvr	pdb	Characterization of the Chk1 allosteric inhibitor binding site	x-ray	1.76	A	o14757	476		6..317
3jvs	pdb	Characterization of the Chk1 allosteric inhibitor binding site	x-ray	1.9	A	o14757	476		6..317
3jxw	pdb	Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as Potent, Highly Selective and Orally Bioavailable Pim Kinases Inhibitors	x-ray	2.8	A	p11309	313		36..296
3jy0	pdb	Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as Potent, Highly Selective and Orally Bioavailable Pim Kinases Inhibitors	x-ray	2.4	A	p11309	313		36..296
3jy9	pdb	Janus Kinase 2 Inhibitors	x-ray	2.1	A	o60674	1132		522..814,842..1119
3jya	pdb	Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as Potent, Highly Selective and Orally Bioavailable Pim Kinases Inhibitors	x-ray	2.1	A	p11309	313		36..296
3k2l	pdb	Crystal Structure of dual-specificity tyrosine phosphorylation regulated kinase 2 (DYRK2)	x-ray	2.36	A	q92630	601		212..543
3k3i	pdb	p38alpha bound to novel DGF-out compound PF-00215955	x-ray	1.7	A	q16539	360		9..349
3k3j	pdb	P38alpha bound to novel DFG-out compound PF-00416121	x-ray	1.995	A	q16539	360		9..349
3k54	pdb	Structures of human Bruton's tyrosine kinase in active and inactive conformations suggests a mechanism of activation for TEC family kinases.	x-ray	1.94	A	q06187	659		382..648
3k5u	pdb	Identification, SAR Studies and X-ray Cocrystal Analysis of a Novel Furano-pyrimidine Aurora Kinase A Inhibitor	x-ray	2.35	A	o14965	403		120..386
3k5v	pdb	Structure of Abl kinase in complex with imatinib and GNF-2	x-ray	1.74	A;B	p00520;p00520	1123;1123	;	231..498;231..498
3ka0	pdb	MK2 complex with inhibitor 6-(5-(2-aminopyrimidin-4-ylamino)-2-hydroxyphenyl)-N-methylbenzo[b]thiophene-2-carboxamide	x-ray	2.9	A	p49137	400		59..369
3kb7	pdb	Crystal structure of Polo-like kinase 1 in complex with a pyrazoloquinazoline inhibitor	x-ray	2.5	A	p53350	603		51..338
3kc3	pdb	MK2 complexed to inhibitor N4-(7-(benzofuran-2-yl)-1H-indazol-5-yl)pyrimidine-2,4-diamine	x-ray	2.9	A;B;C;D;E;F;G;H;I;J;K;L	p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137	400;400;400;400;400;400;400;400;400;400;400;400	;;;;;;;;;;;	59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369
3kcf	pdb	Crystal structure of TGFbRI complexed with a pyrazolone inhibitor	x-ray	2.8	A;B;C;D;E	p36897;p36897;p36897;p36897;p36897	503;503;503;503;503	;;;;	180..492;180..492;180..492;180..492;180..492
3kck	pdb	A Novel Chemotype of Kinase Inhibitors	x-ray	2.2	A	o60674	1132		522..814,842..1119
3kex	pdb	Crystal structure of the catalytically inactive kinase domain of the human epidermal growth factor receptor 3 (HER3)	x-ray	2.797	A;B	p21860;p21860	1342;1342	;	706..977;706..977
3kf4	pdb	Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template	x-ray	1.9	A;B	p00520;p00520	1123;1123	;	231..498;231..498
3kf7	pdb	Crystal Structure of Human p38alpha Complexed With a Triazolopyrimidine compound	x-ray	2	A	q16539	360		9..349
3kfa	pdb	Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template	x-ray	1.22	A;B	p00520;p00520	1123;1123	;	231..498;231..498
3kga	pdb	Crystal structure of MAPKAP kinase 2 (MK2) complexed with a potent 3-aminopyrazole ATP site inhibitor	x-ray	2.55	A	p49137	400		59..369
3kk8	pdb	CaMKII Substrate Complex A	x-ray	1.72	A	o62305	720		9..270
3kk9	pdb	CaMKII Substrate Complex B	x-ray	3.206	A	o62305	720		9..270
3kkv	pdb	Structure of PKA with a protein Kinase B-selective inhibitor.	x-ray	1.8	A				
3kl8	pdb	CaMKIINtide Inhibitor Complex	x-ray	3.372	A;C;E;G;I	o62305;o62305;o62305;o62305;o62305	720;720;720;720;720	;;;;	9..270;9..270;9..270;9..270;9..270
3kmm	pdb	Structure of human LCK kinase with a small molecule inhibitor	x-ray	2.8	A	p06239	509		231..500
3kmu	pdb	Crystal structure of the ILK/alpha-parvin core complex (apo)	x-ray	1.8	A	q13418	452		177..444
3kmw	pdb	Crystal structure of the ILK/alpha-parvin core complex (MgATP)	x-ray	2	A	q13418	452		177..444
3kn5	pdb	Crystal structure of the C-terminal kinase domain of msk1 in complex with AMP-PNP	x-ray	2.4	A;B	o75582;o75582	802;802	;	46..397,429..703;46..397,429..703
3kn6	pdb	Crystal structure of the C-terminal kinase domain of MSK1	x-ray	2	A;B	o75582;o75582	802;802	;	46..397,429..703;46..397,429..703
3kq7	pdb	Structure of human p38alpha with N-[4-methyl-3-(6-{[2-(1-methylpyrrolidin-2-yl)ethyl]amino}pyridine-3-amido)phenyl]-2-(morpholin-4-yl)pyridine-4-carboxamide	x-ray	1.8	A	q16539	360		9..349
3krj	pdb	cFMS tyrosine kinase in complex with 4-Cyano-1H-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide	x-ray	2.1	A	p11362	822		468..754
3krl	pdb	cFMS Tyrosine kinase in complex with 5-Cyano-furan-2-carboxylic acid [4-(4-methyl-piperazin-1-yl)-2-piperidin-1-yl-phenyl]-amide	x-ray	2.4	A	p11362	822		468..754
3krr	pdb	Crystal Structure of JAK2 complexed with a potent quinoxaline ATP site inhibitor	x-ray	1.8	A	o60674	1132		522..814,842..1119
3krw	pdb	Human GRK2 in complex with Gbetgamma subunits and balanol (soak)	x-ray	2.9	A	p25098	689		187..532
3krx	pdb	Human GRK2 in complex with Gbetgamma subunits and balanol (co-crystal)	x-ray	3.1	A	p25098	689		187..532
3ku2	pdb	Crystal Structure of inactivated form of CDPK1 from toxoplasma gondii, TGME49.101440	x-ray	2.3	A	q9bjf5	507		35..330
3kul	pdb	Kinase domain of human ephrin type-A receptor 8 (EPHA8)	x-ray	2.15	A;B	p29322;p29322	1005;1005	;	628..914;628..914
3kvw	pdb	Crystal Structure of dual-specificity tyrosine phosphorylation regulated kinase 2 (DYRK2) in complex with an indirubin ligand	x-ray	2.28	A	q92630	601		212..543
3kvx	pdb	JNK3 bound to aminopyrimidine inhibitor, SR-3562	x-ray	2.4	A	p53779	464		52..396
3kxg	pdb	Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor 3,4,5,6,7-pentabromo-1H-indazole (K64)	x-ray	1.7	A	p28523	332		11..323
3kxh	pdb	Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor (2-dymethylammino-4,5,6,7-tetrabromobenzoimidazol-1yl-acetic acid (K66)	x-ray	1.7	A	p28523	332		11..323
3kxm	pdb	Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor K74	x-ray	1.75	A	p28523	332		11..323
3kxn	pdb	Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor tetraiodobenzimidazole (K88)	x-ray	2	A	p28523	332		11..323
3kxx	pdb	Structure of the mutant Fibroblast Growth Factor receptor 1	x-ray	3.2	A;B;C;D	p11362;p11362;p11362;p11362	822;822;822;822	;;;	468..754;468..754;468..754;468..754
3kxz	pdb	The complex crystal structure of LCK with a probe molecule w259	x-ray	2.37	A	p06239	509		231..500
3ky2	pdb	Crystal structure of Fibroblast Growth Factor Receptor 1 kinase domain	x-ray	2.7	A;B	p11362;p11362	822;822	;	468..754;468..754
3l08	pdb	Structure of Pi3K gamma with a potent inhibitor: GSK2126458	x-ray	2.7	A	p48736	1102		728..1089
3l13	pdb	Crystal Structures of Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors	x-ray	3	A	p48736	1102		728..1089
3l16	pdb	Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer	x-ray	2.9	A	p48736	1102		728..1089
3l17	pdb	Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer	x-ray	3	A	p48736	1102		728..1089
3l1s	pdb	3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3	x-ray	2.9	A;B	p49841;p49841	420;420	;	55..377;55..377
3l54	pdb	Structure of Pi3K gamma with inhibitor	x-ray	2.3	A	p48736	1102		728..1089
3l8p	pdb	Crystal structure of cytoplasmic kinase domain of Tie2 complexed with inhibitor CEP11207	x-ray	2.4	A	q02763	1124		819..1107
3l8s	pdb	Human p38 MAP Kinase in Complex with CP-547632	x-ray	2.35	A	q16539	360		9..349
3l8v	pdb	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with a biarylamine based inhibitor	x-ray	2.4	A	p08581	1390		1079..1341
3l8x	pdb	P38 alpha kinase complexed with a pyrazolo-pyrimidine based inhibitor	x-ray	2.4	A	q16539	360		9..349
3l9l	pdb	Crystal structure of pka with compound 36	x-ray	2	A;B	p17612;p17612	351;351	;	30..339;30..339
3l9m	pdb	Crystal structure of PKAB3 (pka triple mutant V123A, L173M, Q181K) with compound 18	x-ray	1.9	A;B	p17612;p17612	351;351	;	30..339;30..339
3l9n	pdb	crystal structure of PKAB3 (pka triple mutant V123A, L173M, Q181K) with compound 27	x-ray	2	A	p17612	351		30..339
3l9p	pdb	Crystal Structure of the Anaplastic Lymphoma Kinase Catalytic Domain	x-ray	1.8	A	q9um73	1620		1089..1381
3lau	pdb	Crystal Structure of Aurora2 kinase in complex with a GSK3beta inhibitor	x-ray	2.1	A	o14965	403		120..386
3lcd	pdb	Inhibitor Bound to A DFG-In structure of the Kinase Domain of CSF-1R	x-ray	2.5	A	p07333	972		551..909
3lck	pdb	THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK), ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)	x-ray	1.7	A	p06239	509		231..500
3lco	pdb	Inhibitor Bound to A DFG-Out structure of the Kinase Domain of CSF-1R	x-ray	3.4	A	p07333	972		551..909
3lcs	pdb	Crystal Structure of the Anaplastic Lymphoma Kinase Catalytic Domain	x-ray	1.95	A	q9um73	1620		1089..1381
3lct	pdb	Crystal Structure of the Anaplastic Lymphoma Kinase Catalytic Domain	x-ray	2.1	A	q9um73	1620		1089..1381
3le6	pdb	The structure of cyclin dependent kinase 2 (CKD2) with a pyrazolobenzodiazepine inhibitor	x-ray	2	A	p24941	298		1..292
3lfa	pdb	Human p38 MAP Kinase in Complex with Dasatinib	x-ray	2.1	A	q16539	360		9..349
3lfb	pdb	Human p38 MAP Kinase in Complex with RL98	x-ray	2.6	A	q16539	360		9..349
3lfc	pdb	Human p38 MAP Kinase in Complex with RL99	x-ray	2.8	A	q16539	360		9..349
3lfd	pdb	Human p38 MAP Kinase in Complex with RL113	x-ray	3.4	A	q16539	360		9..349
3lfe	pdb	Human p38 MAP Kinase in Complex with RL116	x-ray	2.3	A	q16539	360		9..349
3lff	pdb	Human p38 MAP Kinase in Complex with RL166	x-ray	1.5	A	q16539	360		9..349
3lfn	pdb	Crystal structure of CDK2 with SAR57, an aminoindazole type inhibitor	x-ray	2.28	A	p24941	298		1..292
3lfq	pdb	Crystal structure of CDK2 with SAR60, an aminoindazole type inhibitor	x-ray	2.03	A	p24941	298		1..292
3lfs	pdb	Crystal structure of CDK2 with SAR37, an aminoindazole type inhibitor	x-ray	2.4	A	p24941	298		1..292
3lhj	pdb	Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Pyrazolopyridinone Inhibitor.	x-ray	3.31	A	q16539	360		9..349
3lij	pdb	Crystal structure of full length CpCDPK3 (cgd5_820) in complex with Ca2+ and AMPPNP	x-ray	1.9	A	q5cs01	523		47..334
3lj0	pdb	IRE1 complexed with ADP and Quercetin	x-ray	3.2	A;B	p32361;p32361	1115;1115	;	677..992;677..992
3lj1	pdb	IRE1 complexed with Cdk1/2 Inhibitor III	x-ray	3.33	A;B	p32361;p32361	1115;1115	;	677..992;677..992
3lj2	pdb	IRE1 complexed with JAK Inhibitor I	x-ray	3.33	A;B	p32361;p32361	1115;1115	;	677..992;677..992
3lj3	pdb	PI3-kinase-gamma with a pyrrolopyridine-benzofuran inhibitor	x-ray	2.43	A	p48736	1102		728..1089
3lkm	pdb	1.6 Angstrom Crystal Structure of the Alpha-kinase Domain of Myosin Heavy Chain Kinase A Complex with AMP	x-ray	1.6	A	p42527	1146		551..805
3lla	pdb	Crystal Structure of the Alpha-kinase Domain of Myosin Heavy Chain Kinase A Complex with AMPPCP	x-ray	2.11	A;B	p42527;p42527	1146;1146	;	551..805;551..805
3llt	pdb	Crystal structure of PF14_0431, kinase domain.	x-ray	2.5	A	q8il19	881		540..878
3lm0	pdb	Crystal Structure of human Serine/Threonine Kinase 17B (STK17B)	x-ray	2.35	A	o94768	372		28..321
3lm5	pdb	Crystal Structure of human Serine/Threonine Kinase 17B (STK17B) in complex with Quercetin	x-ray	2.29	A	o94768	372		28..321
3lmg	pdb	Crystal structure of the ERBB3 kinase domain in complex with AMP-PNP	x-ray	2.8	A;B	p21860;p21860	1342;1342	;	706..977;706..977
3lmh	pdb	Crystal Structure of the Alpha-kinase Domain of Myosin Heavy Chain Kinase A Complex with ADP	x-ray	2	A;B	p42527;p42527	1146;1146	;	551..805;551..805
3lmi	pdb	Crystal Structure of the Inactive Alpha-kinase Domain of Myosin Heavy Chain Kinase A (D766A) complex with ATP	x-ray	2.2	A;B;C;D	p42527;p42527;p42527;p42527	1146;1146;1146;1146	;;;	551..805;551..805;551..805;551..805
3lok	pdb	Drug resistant cSrc kinase domain in complex with covalent inhibitor PD168393	x-ray	2.48	A;B	p00523;p00523	533;533	;	256..526;256..526
3lpb	pdb	Crystal structure of Jak2 complexed with a potent 2,8-diaryl-quinoxaline inhibitor	x-ray	2	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
3lq3	pdb	Crystal structure of human choline kinase beta in complex with phosphorylated hemicholinium-3 and adenosine nucleotide	x-ray	1.42	A	q9y259	395		47..388
3lq5	pdb	Structure of CDK9/CyclinT in complex with S-CR8	x-ray	3	A	p50750	372		12..321
3lq8	pdb	Structure of the kinase domain of c-Met bound to XL880 (GSK1363089)	x-ray	2.02	A	p08581	1390		1079..1341
3ls8	pdb	Crystal structure of human PIK3C3 in complex with 3-[4-(4-Morpholinyl)thieno[3,2-d]pyrimidin-2-yl]-phenol	x-ray	2.25	A;B	q8neb9;q8neb9	887;887	;	538..883;538..883
3lvp	pdb	Crystal structure of bisphosphorylated IGF1-R Kinase domain (2P) in complex with a bis-azaindole inhibitor	x-ray	3	A;B;C;D	p08069;p08069;p08069;p08069	1367;1367;1367;1367	;;;	970..1264;970..1264;970..1264;970..1264
3lw0	pdb	IGF-1RK in complex with ligand MSC1609119A-1	x-ray	1.79	A;B;C;D	p08069;p08069;p08069;p08069	1367;1367;1367;1367	;;;	970..1264;970..1264;970..1264;970..1264
3lxk	pdb	Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6	x-ray	2	A	p52333	1124		508..788,820..1097
3lxl	pdb	Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6	x-ray	1.74	A	p52333	1124		508..788,820..1097
3lxn	pdb	Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6	x-ray	2.5	A	p29597	1187		576..879,887..1166
3lxp	pdb	Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6	x-ray	1.65	A	p29597	1187		576..879,887..1166
3lzb	pdb	EGFR kinase domain complexed with an imidazo[2,1-b]thiazole inhibitor	x-ray	2.7	A;B;C;D;E;F;G;H	p00533;p00533;p00533;p00533;p00533;p00533;p00533;p00533	1210;1210;1210;1210;1210;1210;1210;1210	;;;;;;;	708..1003;708..1003;708..1003;708..1003;708..1003;708..1003;708..1003;708..1003
3m11	pdb	Crystal Structure of Aurora A Kinase complexed with inhibitor	x-ray	2.75	A	o14965	403		120..386
3m1s	pdb	Structure of Ruthenium Half-Sandwich Complex Bound to Glycogen Synthase Kinase 3	x-ray	3.134	A;B	p49841;p49841	420;420	;	55..377;55..377
3m2w	pdb	Crystal structure of MAPKAK kinase 2 (MK2) complexed with a spiroazetidine-tetracyclic ATP site inhibitor	x-ray	2.41	A	p49137	400		59..369
3m42	pdb	Crystal structure of MAPKAP kinase 2 (MK2) complexed with a tetracyclic ATP site inhibitor	x-ray	2.68	A	p49137	400		59..369
3ma3	pdb	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a naphtho-difuran ligand	x-ray	2.3	A				
3ma6	pdb	Crystal structure of kinase domain of TgCDPK1 in presence of 3BrB-PP1	x-ray	2.5	A;B	q9bjf5;q9bjf5	507;507	;	35..330;35..330
3mb6	pdb	Human CK2 catalytic domain in complex with a difurane derivative inhibitor (CPA)	x-ray	1.75	A	p68400	391		5..328
3mb7	pdb	Human CK2 catalytic domain in complex with a difurane derivative inhibitor (AMR)	x-ray	1.65	A	p68400	391		5..328
3mbl	pdb	Crystal Structure of the human mitogen-activated protein kinase kinase 1 (MEK 1) in complex with ligand and MgADP	x-ray	2.6	A	q02750	393		63..365
3mdy	pdb	Crystal structure of the cytoplasmic domain of the bone morphogenetic protein receptor type-1B (BMPR1B) in complex with FKBP12 and LDN-193189	x-ray	2.05	A;C	o00238;o00238	502;502	;	180..491;180..491
3mes	pdb	Crystal structure of choline kinase from Cryptosporidium parvum Iowa II, cgd3_2030	x-ray	2.35	A;B	q5cup2;q5cup2	405;405	;	29..391;29..391
3mfr	pdb	CASK-4M CaM Kinase Domain, native	x-ray	2	A	o14936	926		7..292
3mfs	pdb	CASK-4M CaM Kinase Domain, AMPPNP	x-ray	2.1	A	o14936	926		7..292
3mft	pdb	CASK-4M CaM Kinase Domain, Mn2+	x-ray	2.2	A	o14936	926		7..292
3mfu	pdb	CASK-4M CaM Kinase Domain, AMPPNP-Mn2+	x-ray	2.3	A	o14936	926		7..292
3mgy	pdb	Mutagenesis of p38 MAP Kinase eshtablishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state	x-ray	2.1	A	q16539	360		9..349
3mh0	pdb	Mutagenesis of p38 MAP Kinase eshtablishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state	x-ray	2	A	q16539	360		9..349
3mh1	pdb	Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state	x-ray	2.2	A	q16539	360		9..349
3mh2	pdb	Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state	x-ray	2.3	A	q16539	360		9..349
3mh3	pdb	Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state	x-ray	2.2	A	q16539	360		9..349
3mi9	pdb	Crystal structure of HIV-1 Tat complexed with human P-TEFb	x-ray	2.1	A	p50750	372		12..321
3mia	pdb	Crystal structure of HIV-1 Tat complexed with ATP-bound human P-TEFb	x-ray	3	A	p50750	372		12..321
3miy	pdb	X-ray crystal structure of ITK complexed with sunitinib	x-ray	1.67	A;B	q08881;q08881	620;620	;	352..613;352..613
3mj1	pdb	X-ray crystal structure of ITK complexed with inhibitor RO5191614	x-ray	1.72	A	q08881	620		352..613
3mj2	pdb	X-ray crystal structure of ITK complexed with inhibitor BMS-509744	x-ray	1.9	A	q08881	620		352..613
3mjw	pdb	PI3 Kinase gamma with a benzofuranone inhibitor	x-ray	2.87	A	p48736	1102		728..1089
3ml8	pdb	Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04691502 through Structure Based Drug Design	x-ray	2.7	A	p48736	1102		728..1089
3ml9	pdb	Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04691502 through Structure Based Drug Design	x-ray	2.55	A	p48736	1102		728..1089
3mn3	pdb	An inhibited conformation for the protein kinase domain of the Saccharomyces cerevisiae AMPK homolog Snf1	x-ray	2.38	A	p06782	633		52..307
3mpa	pdb	Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding	x-ray	2.1	A	q16539	360		9..349
3mpm	pdb	LCK complexed with a pyrazolopyrimidine	x-ray	1.95	A	p06239	509		231..500
3mpt	pdb	Crystal structure of P38 kinase in complex with a pyrrole-2-carboxamide inhibitor	x-ray	1.89	A	q16539	360		9..349
3ms9	pdb	ABL kinase in complex with imatinib and a fragment (FRAG1) in the myristate pocket	x-ray	1.8	A;B	p00520;p00520	1123;1123	;	231..498;231..498
3mss	pdb	Abl kinase in complex with imatinib and fragment (FRAG2) in the myristate site	x-ray	1.95	A;B;C;D	p00520;p00520;p00520;p00520	1123;1123;1123;1123	;;;	231..498;231..498;231..498;231..498
3mtf	pdb	Crystal structure of the ACVR1 kinase in complex with a 2-aminopyridine inhibitor	x-ray	2.15	A;B	q04771;q04771	509;509	;	186..496;186..496
3mtl	pdb	Crystal structure of the PCTAIRE1 kinase in complex with Indirubin E804	x-ray	2.4	A	q00536	496		159..448
3mv5	pdb	Crystal structure of Akt-1-inhibitor complexes	x-ray	2.47	A	p31749	480		145..459
3mvh	pdb	Crystal structure of Akt-1-inhibitor complexes	x-ray	2.01	A				
3mvj	pdb	Human cyclic AMP-dependent protein kinase PKA inhibitor complex	x-ray	2.49	A;B;E	p17612;p17612;p17612	351;351;351	;;	30..339;30..339;30..339
3mvl	pdb	P38 Alpha Map Kinase complexed with pyrrolotriazine inhibitor 7K	x-ray	2.8	A;B	q16539;q16539	360;360	;	9..349;9..349
3mvm	pdb	P38 Alpha Map Kinase complexed with pyrrolotriazine inhibitor 7V	x-ray	2	A;B	q16539;q16539	360;360	;	9..349;9..349
3mw1	pdb	p38 kinase Crystal structure in complex with small molecule inhibitor	x-ray	2.8	A	q16539	360		9..349
3mwu	pdb	Activated Calcium-Dependent Protein Kinase 1 from Cryptosporidium parvum (CpCDPK1) in complex with bumped kinase inhibitor RM-1-95	x-ray	1.98	A	a3fq16	538		69..348
3my0	pdb	Crystal structure of the ACVRL1 (ALK1) kinase domain bound to LDN-193189	x-ray	2.65	A;B;C;D;E;F;G;H;I;J;K;L;M;N;O;P;Q;R;S;T	p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023;p37023	503;503;503;503;503;503;503;503;503;503;503;503;503;503;503;503;503;503;503;503	;;;;;;;;;;;;;;;;;;;	187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490;187..490
3my1	pdb	Structure of CDK9/cyclinT1 in complex with DRB	x-ray	2.8	A	p50750	372		12..321
3my5	pdb	CDk2/cyclinA in complex with DRB	x-ray	2.1	A;C	p24941;p24941	298;298	;	1..292;1..292
3myg	pdb	Aurora A Kinase complexed with SCH 1473759	x-ray	2.4	A	o14965	403		120..386
3n4t	pdb	"apo APH(2"")-IVa form I"	x-ray	2.2	A	o68183	301		3..264
3n4u	pdb	"app APH(2"")-IVa form II"	x-ray	2.2	A	o68183	301		3..264
3n4v	pdb	"apo APH(2"")-IVa form III"	x-ray	2.4	A;B	o68183;o68183	301;301	;	3..264;3..264
3n51	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor RM-1-95	x-ray	2.1	A	q9bjf5	507		35..330
3n9x	pdb	Crystal structure of Map Kinase from plasmodium berghei, PB000659.00.0	x-ray	2.05	A;B	;	;	;	;
3nax	pdb	PDK1 in complex with inhibitor MP7	x-ray	1.75	A	o15530	556		79..400
3nay	pdb	PDK1 in complex with inhibitor MP6	x-ray	2.6	A;B	o15530;o15530	556;556	;	79..400;79..400
3ncg	pdb	Activated Calcium-Dependent Protein Kinase 1 from Cryptosporidium parvum (CpCDPK1) in complex with bumped kinase inhibitor NM-PP1	x-ray	2.49	A	a3fq16	538		69..348
3ncz	pdb	X-Ray Co-structure of Rho-Associated Protein Kinase (ROCK1) with a potent 2H-isoquinolin-1-one inhibitor	x-ray	3	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
3ndm	pdb	Crystal structure of Rho-Associated Protein Kinase (ROCK1) with a potent isoquinolone derivative	x-ray	3.3	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
3new	pdb	p38-alpha complexed with Compound 10	x-ray	2.51	A	q16539	360		9..349
3nga	pdb	Human CK2 catalytic domain in complex with CX-4945	x-ray	2.71	A;B	p68400;p68400	391;391	;	5..328;5..328
3nie	pdb	Crystal Structure of PF11_0147	x-ray	2.3	A;B	q7kqk7;q7kqk7	508;508	;	99..452;99..452
3niz	pdb	Cryptosporidium parvum cyclin-dependent kinase cgd5_2510 with ADP bound.	x-ray	2.4	A	q5crj8	295		2..290
3nlb	pdb	Novel kinase profile highlights the temporal basis of context dependent checkpoint pathways to cell death	x-ray	1.9	A	o14757	476		6..317
3nnu	pdb	Crystal structure of P38 alpha in complex with DP1376	x-ray	2.4	A	q16539	360		9..349
3nnv	pdb	Crystal structure of P38 alpha in complex with DP437	x-ray	2.1	A	q16539	360		9..349
3nnw	pdb	Crystal structure of P38 alpha in complex with DP802	x-ray	1.89	A	q16539	360		9..349
3nnx	pdb	Crystal structure of phosphorylated P38 alpha in complex with DP802	x-ray	2.28	A	q16539	360		9..349
3npc	pdb	Crystal structure of JNK2 complexed with BIRB796	x-ray	2.35	A;B	p45984;p45984	424;424	;	13..356;13..356
3nr9	pdb	Structure of human CDC2-like kinase 2 (CLK2)	x-ray	2.89	A;B;C	p49760;p49760;p49760	499;499;499	;;	150..488;150..488;150..488
3nrm	pdb	Imidazo[1,2-a]pyrazine-based Aurora Kinase Inhibitors	x-ray	3.05	A	o14965	403		120..386
3ns9	pdb	Crystal structure of CDK2 in complex with inhibitor BS-194	x-ray	1.78	A	p24941	298		1..292
3nsz	pdb	Human CK2 catalytic domain in complex with AMPPN	x-ray	1.3	A	p68400	391		5..328
3nun	pdb	phosphoinositide-dependent kinase-1 (PDK1) with lead compound	x-ray	2.2	A	o15530	556		79..400
3nup	pdb	CDK6 (monomeric) in complex with inhibitor	x-ray	2.6	A	q00534	326		9..303
3nus	pdb	phosphoinositide-dependent kinase-1 (PDK1) with fragment8	x-ray	2.75	A	o15530	556		79..400
3nuu	pdb	phosphoinositide-dependent kinase-1 (PDK1) with fragment11	x-ray	1.9803	A	o15530	556		79..400
3nux	pdb	CDK6 (monomeric) in complex with inhibitor	x-ray	2.7	A	q00534	326		9..303
3nuy	pdb	phosphoinositide-dependent kinase-1 (PDK1) with fragment17	x-ray	2.1	A	o15530	556		79..400
3nw5	pdb	Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with a carbon-linked proline isostere inhibitor (11B)	x-ray	2.14	A	p08069	1367		970..1264
3nw6	pdb	Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with a carbon-linked proline isostere inhibitor (11A)	x-ray	2.2	A	p08069	1367		970..1264
3nw7	pdb	Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with a carbon-linked proline isostere inhibitor (34)	x-ray	2.11	A	p08069	1367		970..1264
3nww	pdb	P38 Alpha kinase complexed with a 2-aminothiazol-5-yl-pyrimidine based inhibitor	x-ray	2.09	A	q16539	360		9..349
3nx8	pdb	human cAMP dependent protein kinase in complex with phenol	x-ray	2	A	p17612	351		30..339
3nyn	pdb	Crystal Structure of G Protein-Coupled Receptor Kinase 6 in Complex with Sangivamycin	x-ray	2.72	A;B	p43250;p43250	576;576	;	184..526;184..526
3nyo	pdb	Crystal Structure of G Protein-Coupled Receptor Kinase 6 in Complex with AMP	x-ray	2.92	A;B	p43250;p43250	576;576	;	184..526;184..526
3nyv	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with non-specific inhibitor WHI-P180	x-ray	1.88	A	q9bjf5	507		35..330
3nyx	pdb	Non-phosphorylated TYK2 JH1 domain with Quinoline-Thiadiazole-Thiophene Inhibitor	x-ray	2.5	A	p29597	1187		576..879,887..1166
3nz0	pdb	Non-phosphorylated TYK2 kinase with CMP6	x-ray	2	A	p29597	1187		576..879,887..1166
3nzs	pdb	Structure-based Optimization of Pyrazolo -Pyrimidine and -Pyridine Inhibitors of PI3-Kinase	x-ray	2.75	A	p48736	1102		728..1089
3nzu	pdb	Structure-based Optimization of Pyrazolo -Pyrimidine and -Pyridine Inhibitors of PI3-Kinase	x-ray	2.6	A	p48736	1102		728..1089
3o0g	pdb	Crystal Structure of Cdk5:p25 in complex with an ATP analogue	x-ray	1.95	A;B	q00535;q00535	292;292	;	1..290;1..290
3o17	pdb	Crystal Structure of JNK1-alpha1 isoform	x-ray	3	A;B	p45983;p45983	427;427	;	12..357;12..357
3o23	pdb	Human unphosphorylated IGF1-R Kinase domain in complex with an hydantoin inhibitor	x-ray	2.1	A	p08069	1367		970..1264
3o2m	pdb	Crystal Structure of JNK1-alpha1 isoform complex with a biaryl tetrazol (A-82118)	x-ray	2.7	A;B	p45983;p45983	427;427	;	12..357;12..357
3o50	pdb	Crystal structure of benzamide 9 bound to AuroraA	x-ray	2	A;B	o14965;o14965	403;403	;	120..386;120..386
3o51	pdb	Crystal structure of anthranilamide 10 bound to AuroraA	x-ray	3.2	A	o14965	403		120..386
3o71	pdb	Crystal structure of ERK2/DCC peptide complex	x-ray	1.95	A	p63086	358		17..320
3o7l	pdb	Crystal Structure of phospholamban (1-19):PKA C-subunit:AMP-PNP:Mg2+ complex	x-ray	2.8	B;D	p05132;p05132	351;351	;	28..339;28..339
3o8p	pdb	Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding	x-ray	2.1	A	q16539	360		9..349
3o8t	pdb	Conformational plasticity of p38 MAP kinase DFG-motif mutants in response to inhibitor binding	x-ray	2	A	q16539	360		9..349
3o8u	pdb	Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding	x-ray	2.1	A	q16539	360		9..349
3o96	pdb	Crystal Structure of Human AKT1 with an Allosteric Inhibitor	x-ray	2.7	A	p31749	480		145..459
3oaw	pdb	4-Methylpteridineones as Orally Active and Selective PI3K/mTOR Dual Inhibitors	x-ray	2.75	A	p48736	1102		728..1089
3obg	pdb	Conformational plasticity of p38 MAP kinase DFG mutants in response to inhibitor binding	x-ray	2.8	A	q16539	360		9..349
3obj	pdb	Conformational plasticity of p38 MAP kinase DFG mutants in response to inhibitor binding	x-ray	2.4	A	q16539	360		9..349
3oc1	pdb	Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding	x-ray	2.59	A	q16539	360		9..349
3ocb	pdb	Akt1 kinase domain with pyrrolopyrimidine inhibitor	x-ray	2.7	A;B	;	;	;	;
3ocg	pdb	P38 Alpha kinase complexed with a 5-amino-pyrazole based inhibitor	x-ray	2.21	A	q16539	360		9..349
3ocs	pdb	Crystal structure of bruton's tyrosine kinase in complex with inhibitor CGI1746	x-ray	1.8	A	q06187	659		382..648
3oct	pdb	Crystal structure of bruton's tyrosine kinase mutant V555R in complex with dasatinib	x-ray	1.95	A	q06187	659		382..648
3od6	pdb	Crystal structure of p38alpha Y323T active mutant	x-ray	2.682	X	q16539	360		9..349
3ody	pdb	Crystal structure of p38alpha Y323Q active mutant	x-ray	2.2	X	q16539	360		9..349
3odz	pdb	Crystal structure of P38alpha Y323R active mutant	x-ray	2.3	X	q16539	360		9..349
3oef	pdb	Crystal structure of Y323F inactive mutant of p38alpha MAP kinase	x-ray	1.6	X	q16539	360		9..349
3oez	pdb	crystal structure of the L317I mutant of the chicken c-Src tyrosine kinase domain complexed with imatinib	x-ray	2.4	A;B	p00523;p00523	533;533	;	256..526;256..526
3of0	pdb	crystal structure of the L317I mutant of the chicken c-Src tyrosine kinase domain	x-ray	2.7	A;B	p00523;p00523	533;533	;	256..526;256..526
3ofm	pdb	Structure of a human CK2alpha prime, the paralog isoform of the catalytic subunit of protein kinase CK2 from Homo sapiens	x-ray	2	A	p19784	350		13..330
3og7	pdb	B-Raf Kinase V600E oncogenic mutant in complex with PLX4032	x-ray	2.45	A;B	p15056;p15056	766;766	;	449..717;449..717
3oht	pdb	Crystal Structure of Salmo Salar p38alpha	x-ray	2.7	A;B	a9ujz9;a9ujz9	361;361	;	10..347;10..347
3omv	pdb	Crystal structure of c-raf (raf-1)	x-ray	4	A;B	p04049;p04049	648;648	;	344..611;344..611
3oog	pdb	human cAMP-dependent protein kinase in complex with a small fragment	x-ray	2	A	p17612	351		30..339
3oom	pdb	Crystal structure of the ACVR1 kinase domain in complex with the imidazo[1,2-b]pyridazine inhibitor K00507	x-ray	2	A	q04771	509		186..496
3op5	pdb	Human vaccinia-related kinase 1	x-ray	2.4	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
3ori	pdb	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 1)	x-ray	2	A;B;C;D	p9wi81;p9wi81;p9wi81;p9wi81	626;626;626;626	;;;	8..275;8..275;8..275;8..275
3ork	pdb	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 2)	x-ray	1.6	A	p9wi81	626		8..275
3orl	pdb	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 3)	x-ray	2.9	A	p9wi81	626		8..275
3orm	pdb	Mycobacterium tuberculosis PknB kinase domain D76A mutant	x-ray	2.5	A	p9wi81	626		8..275
3orn	pdb	Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4987655 and MgAMP-PNP	x-ray	2.8	A	q02750	393		63..365
3oro	pdb	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 4)	x-ray	1.9	A	p9wi81	626		8..275
3orp	pdb	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 5)	x-ray	2.1	A	p9wi81	626		8..275
3ort	pdb	Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 6)	x-ray	1.9	A	p9wi81	626		8..275
3orx	pdb	PDK1 mutant bound to allosteric disulfide fragment inhibitor 1F8	x-ray	2.2044	A;B;C;D;E;F;G;H	o15530;o15530;o15530;o15530;o15530;o15530;o15530;o15530	556;556;556;556;556;556;556;556	;;;;;;;	79..400;79..400;79..400;79..400;79..400;79..400;79..400;79..400
3orz	pdb	PDK1 mutant bound to allosteric disulfide fragment activator 2A2	x-ray	1.9995	A;B;C;D	o15530;o15530;o15530;o15530	556;556;556;556	;;;	79..400;79..400;79..400;79..400
3os3	pdb	Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4858061 and MgATP	x-ray	2.8	A	q02750	393		63..365
3ot3	pdb	X-ray crystal structure of compound 22k bound to human Chk1 kinase domain	x-ray	1.44	A	o14757	476		6..317
3ot8	pdb	X-ray crystal structure of compound 17r bound to human Chk1 kinase domain	x-ray	1.6455	A	o14757	476		6..317
3otu	pdb	PDK1 mutant bound to allosteric disulfide fragment activator JS30	x-ray	2.1013	A	o15530	556		79..400
3otv	pdb	Crystal structure of the intracellular domain of Rv3910 from Mycobacterium tuberculosis	x-ray	3.094	A;B;C;D	p9wjk3;p9wjk3;p9wjk3;p9wjk3	1184;1184;1184;1184	;;;	723..879;723..879;723..879;723..879
3ouk	pdb	Crystal structure of Rv3910 from Mycobacterium Tuberculosis	x-ray	3.402	A	p9wjk3	1184		723..879
3oun	pdb	Crystal structure of the FhaA FHA domain complexed with the intracellular domain of Rv3910	x-ray	2.705	B	p9wjk3	1184		723..879
3ovv	pdb	Human cAMP-dependent protein kinase in complex with an inhibitor	x-ray	1.58	A	p17612	351		30..339
3ow3	pdb	Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors	x-ray	1.9	A	p05132	351		28..339
3ow4	pdb	Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors	x-ray	2.6	A;B	p31749;p31749	480;480	;	145..459;145..459
3owj	pdb	Human CK2 catalytic domain in complex with a pyridocarbazole derivative inhibitor	x-ray	1.85	A	p68400	391		5..328
3owk	pdb	Human CK2 catalytic domain in complex with a benzopyridoindole derivative inhibitor	x-ray	1.8	A	p68400	391		5..328
3owl	pdb	Human CK2 catalytic domain in complex with a benzopyridoindole derivative inhibitor	x-ray	2.1	A	p68400	391		5..328
3owp	pdb	Human cAMP-dependent protein kinase in complex with an inhibitor	x-ray	1.88	A	p17612	351		30..339
3oxi	pdb	Design and Synthesis of Disubstituted Thiophene and Thiazole Based Inhibitors of JNK for the Treatment of Neurodegenerative Diseases	x-ray	2.2	A	p53779	464		52..396
3oxt	pdb	Human cAMP-dependent protein kinase in complex with an inhibitor	x-ray	2.2	A	p17612	351		30..339
3oxz	pdb	Crystal structure of ABL kinase domain bound with a DFG-out inhibitor AP24534	x-ray	2.2	A	p00520	1123		231..498
3oy1	pdb	Highly Selective c-Jun N-Terminal Kinase (JNK) 2 and 3 Inhibitors with In Vitro CNS-like Pharmacokinetic Properties	x-ray	1.7	A	p53779	464		52..396
3oy3	pdb	Crystal structure of ABL T315I mutant kinase domain bound with a DFG-out inhibitor AP24589	x-ray	1.95	A;B	p00520;p00520	1123;1123	;	231..498;231..498
3oz6	pdb	Crystal structure of MapK from Cryptosporidium Parvum, cgd2_1960	x-ray	2.37	A;B	a3fq79;a3fq79	710;710	;	7..341;7..341
3p08	pdb	Crystal structure of the human BTK kinase domain	x-ray	2.3	A;B	q06187;q06187	659;659	;	382..648;382..648
3p0m	pdb	Human cAMP-dependent protein kinase in complex with an inhibitor	x-ray	2.03	A	p17612	351		30..339
3p1a	pdb	Structure of human Membrane-associated Tyrosine- and Threonine-specific cdc2-inhibitory kinase MYT1 (PKMYT1)	x-ray	1.7	A	q99640	499		108..419
3p23	pdb	Crystal structure of the Human kinase and RNase domains in complex with ADP	x-ray	2.7	A;B;C;D	o75460;o75460;o75460;o75460	977;977;977;977	;;;	571..851;571..851;571..851;571..851
3p2b	pdb	Crystal Structure of PI3K gamma with 3-(2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenol	x-ray	3.2	A	p48736	1102		728..1089
3p4k	pdb	The third conformation of p38a MAP kinase observed in phosphorylated p38a and in solution	x-ray	2.304	A				
3p5k	pdb	P38 inhibitor-bound	x-ray	2.09	A	p47811	360		9..349
3p78	pdb	P38 inhibitor-bound	x-ray	2.3	A	p47811	360		9..349
3p79	pdb	P38 inhibitor-bound	x-ray	2.1	A	p47811	360		9..349
3p7a	pdb	p38 inhibitor-bound	x-ray	2.31	A	p47811	360		9..349
3p7b	pdb	p38 inhibitor-bound	x-ray	1.9	A	p47811	360		9..349
3p7c	pdb	p38 inhibitor-bound	x-ray	2.3	A	p47811	360		9..349
3p86	pdb	Crystal structure of CTR1 kinase domain mutant D676N in complex with staurosporine	x-ray	2.496	A;B	q05609;q05609	821;821	;	541..805;541..805
3p9j	pdb	Aurora A kinase domain with phthalazinone pyrazole inhibitor	x-ray	2.8	A	o14965	403		120..386
3pa3	pdb	X-ray crystal structure of compound 70 bound to human CHK1 kinase domain	x-ray	1.4	A	o14757	476		6..317
3pa4	pdb	X-ray crystal structure of compound 2a bound to human CHK1 kinase domain	x-ray	1.59	A	o14757	476		6..317
3pa5	pdb	X-ray crystal structure of compound 1 bound to human CHK1 kinase domain	x-ray	1.7	A	o14757	476		6..317
3pdt	pdb	Crystal Structure of the C-terminal Truncated Alpha-Kinase Domain of Myosin Heavy chain Kinase	x-ray	1.8	A	p42527	1146		551..805
3pe1	pdb	Crystal structure of human protein kinase CK2 alpha subunit in complex with the inhibitor CX-4945	x-ray	1.6	A	p68400	391		5..328
3pe2	pdb	Crystal structure of human protein kinase CK2 in complex with the inhibitor CX-5011	x-ray	1.9	A	p68400	391		5..328
3pfq	pdb	Crystal Structure and Allosteric Activation of Protein Kinase C beta II	x-ray	4	A	p68403	671		338..665
3pg1	pdb	MAP kinase LmaMPK10 from Leishmania major (1.95 angs resolution)	x-ray	1.95	A	q4qhj8	407		19..325
3pg3	pdb	Human p38 MAP Kinase in Complex with RL182	x-ray	2	A	q16539	360		9..349
3pix	pdb	Crystal structure of BTK kinase domain complexed with 2-Isopropyl-7-(4-methyl-piperazin-1-yl)-4-(5-methyl-2H-pyrazol-3-ylamino)-2H-phthalazin-1-one	x-ray	1.85	A	q06187	659		382..648
3piy	pdb	Crystal structure of BTK kinase domain complexed with R406	x-ray	2.55	A	q06187	659		382..648
3piz	pdb	Crystal structure of BTK kinase domain complexed with (5-Amino-1-o-tolyl-1H-pyrazol-4-yl)-[3-(1-methanesulfonyl-piperidin-4-yl)-phenyl]-methanone	x-ray	2.21	A	q06187	659		382..648
3pj1	pdb	Crystal structure of BTK kinase domain complexed with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1-methyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one	x-ray	2	A	q06187	659		382..648
3pj2	pdb	Crystal structure of BTK kinase domain complexed with 2-[4-(2-Diethylamino-ethoxy)-phenylamino]-6-(4-fluoro-phenoxy)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one	x-ray	1.75	A	q06187	659		382..648
3pj3	pdb	Crystal structure of BTK kinase domain complexed with 2-Methyl-5-[(E)-(3-phenyl-acryloyl)amino]-N-(2-phenyl-3H-imidazo[4,5-b]pyridin-6-yl)-benzamide	x-ray	1.85	A	q06187	659		382..648
3pj8	pdb	Structure of CDK2 in complex with a Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine.	x-ray	1.96	A	p24941	298		1..292
3pjc	pdb	Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family	x-ray	2.2	A	p52333	1124		508..788,820..1097
3pls	pdb	RON in complex with ligand AMP-PNP	x-ray	2.24	A	q04912	1400		1085..1344
3poo	pdb	human cAMP-dependent protein kinase in complex with an inhibitor	x-ray	1.6	A	p17612	351		30..339
3poz	pdb	EGFR Kinase domain complexed with tak-285	x-ray	1.5	A	p00533	1210		708..1003
3pp0	pdb	Crystal Structure of the Kinase domain of Human HER2 (erbB2).	x-ray	2.25	A;B	p04626;p04626	1255;1255	;	716..992;716..992
3pp1	pdb	Crystal Structure of the Human Mitogen-activated protein kinase kinase 1 (MEK 1) in complex with ligand and MgATP	x-ray	2.7	A	q02750	393		63..365
3ppj	pdb	Human B-Raf Kinase in Complex with a Furopyridine Inhibitor	x-ray	3.7	A;B	p15056;p15056	766;766	;	449..717;449..717
3ppk	pdb	Human B-Raf Kinase in Complex with a Non-Oxime Furopyridine Inhibitor	x-ray	3	A;B	p15056;p15056	766;766	;	449..717;449..717
3ppz	pdb	Crystal structure of CTR1 kinase domain in complex with staurosporine	x-ray	2.99	A;B	q05609;q05609	821;821	;	541..805;541..805
3pre	pdb	Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.	x-ray	2.91	A	p48736	1102		728..1089
3prf	pdb	Crystal Structure of Human B-Raf Kinase Domain in Complex with a Non-Oxime Furopyridine Inhibitor	x-ray	2.9	A;B	p15056;p15056	766;766	;	449..717;449..717
3pri	pdb	Crystal Structure of Human B-Raf Kinase in Complex with a Non-Oxime Furopyridine Inhibitor	x-ray	3.5	A;B	p15056;p15056	766;766	;	449..717;449..717
3prz	pdb	Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.	x-ray	2.6	A	p48736	1102		728..1089
3ps6	pdb	Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.	x-ray	2.6	A	p48736	1102		728..1089
3psb	pdb	Furo[2,3-c]pyridine-based Indanone Oximes as Potent and Selective B-Raf Inhibitors	x-ray	3.4	A;B	p15056;p15056	766;766	;	449..717;449..717
3psc	pdb	Bovine GRK2 in complex with Gbetagamma subunits	x-ray	2.67	A	p21146	689		187..532
3psd	pdb	Non-oxime pyrazole based inhibitors of B-Raf kinase	x-ray	3.6	A;B	p15056;p15056	766;766	;	449..717;449..717
3ptg	pdb	Design and Synthesis of a Novel, Orally Efficacious Tri-substituted Thiophene Based JNK Inhibitor	x-ray	2.43	A	p53779	464		52..396
3pup	pdb	Structure of Glycogen Synthase Kinase 3 beta (GSK3B) in complex with a ruthenium octasporine ligand (OS1)	x-ray	2.99	A;B	p49841;p49841	420;420	;	55..377;55..377
3pvb	pdb	Crystal structure of (73-244)RIa:C holoenzyme of cAMP-dependent Protein kinase	x-ray	3.3	A	p05132	351		28..339
3pvg	pdb	Crystal structure of Z. mays CK2 alpha subunit in complex with the inhibitor 4,5,6,7-tetrabromo-1-carboxymethylbenzimidazole (K68)	x-ray	1.5	A	p28523	332		11..323
3pvu	pdb	Bovine GRK2 in complex with Gbetagamma subunits and a selective kinase inhibitor (CMPD101)	x-ray	2.48	A	p21146	689		187..532
3pvw	pdb	Bovine GRK2 in complex with Gbetagamma subunits and a selective kinase inhibitor (CMPD103A)	x-ray	2.49	A	p21146	689		187..532
3pwd	pdb	Crystal structure of maize CK2 in complex with NBC (Z1)	x-ray	2.2	A	p28523	332		11..323
3pwy	pdb	Crystal structure of an extender (SPD28345)-modified human PDK1 complex 2	x-ray	3.5	A	o15530	556		79..400
3pxf	pdb	CDK2 in complex with two molecules of 8-anilino-1-naphthalene sulfonate	x-ray	1.8	A	p24941	298		1..292
3pxk	pdb	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH Pyrrolo[2,3-d]thiazole	x-ray	1.79	A;B	q05397;q05397	1052;1052	;	409..693;409..693
3pxq	pdb	CDK2 in complex with 3 molecules of 8-anilino-1-naphthalene sulfonate	x-ray	1.9	A	p24941	298		1..292
3pxr	pdb	Apo CDK2 crystallized from Jeffamine	x-ray	2	A	p24941	298		1..292
3pxy	pdb	CDK2 in complex with inhibitor JWS648	x-ray	1.8	A	p24941	298		1..292
3pxz	pdb	CDK2 ternary complex with JWS648 and ANS	x-ray	1.7	A	p24941	298		1..292
3py0	pdb	CDK2 in complex with inhibitor SU9516	x-ray	1.75	A	p24941	298		1..292
3py1	pdb	CDK2 ternary complex with SU9516 and ANS	x-ray	2.05	A	p24941	298		1..292
3py3	pdb	Crystal structure of phosphorylated p38alpha MAP kinase	x-ray	2.1	A	p47811	360		9..349
3pyy	pdb	Discovery and Characterization of a Cell-Permeable, Small-molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site	x-ray	1.85	A;B	p00519;p00519	1130;1130	;	231..498;231..498
3pze	pdb	JNK1 in complex with inhibitor	x-ray	2	A	p45983	427		12..357
3pzh	pdb	Crystal structure of maize CK2 alpha in complex with emodin at 1.92 A resolution	x-ray	1.919	A	p28523	332		11..323
3q04	pdb	Crystal structure of the apo-form of human CK2 alpha at pH 8.5	x-ray	1.8	A	p68400	391		5..328
3q2j	pdb	"Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa Protein Kinase Inhibitor CKI-7 Complex"	x-ray	2.1501	A;B	p0a3y5;p0a3y5	264;264	;	3..264;3..264
3q2m	pdb	Crystal Structure of Spectinomycin Phosphotransferase, APH(9)-Ia, Protein Kinase Inhibitor CKI-7 Complex	x-ray	2.9	A	o06916	331		5..293
3q32	pdb	Structure of Janus kinase 2 with a pyrrolotriazine inhibitor	x-ray	2.5	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
3q3b	pdb	6-Amino-4-(pyrimidin-4-yl)pyridones: Novel Glycogen Synthase Kinase-3 Inhibitors	x-ray	2.7	A;B	p49841;p49841	420;420	;	55..377;55..377
3q4c	pdb	Crystal Structure of Wild Type BRAF kinase domain in complex with organometallic inhibitor CNS292	x-ray	3.2	A;B	p15056;p15056	766;766	;	449..717;449..717
3q4t	pdb	Crystal structure of Activin receptor type-IIA (ACVR2A) kinase domain in complex with dorsomorphin	x-ray	1.96	A;B	p27037;p27037	513;513	;	180..476;180..476
3q4u	pdb	Crystal structure of the ACVR1 kinase domain in complex with LDN-193189	x-ray	1.82	A;B;C;D	q04771;q04771;q04771;q04771	509;509;509;509	;;;	186..496;186..496;186..496;186..496
3q4z	pdb	Structure of unphosphorylated PAK1 kinase domain	x-ray	1.887	A;B	q13153;q13153	545;545	;	261..522;261..522
3q52	pdb	Structure of phosphorylated PAK1 kinase domain	x-ray	1.801	A	q13153	545		261..522
3q53	pdb	Structure of phosphorylated PAK1 kinase domain in complex with ATP	x-ray	2.09	A	q13153	545		261..522
3q5i	pdb	Crystal Structure of PBANKA_031420	x-ray	2.1	A	a0a509ahb6	523		38..335
3q5z	pdb	Crystal structure of virulent allele ROP5B pseudokinase domain	x-ray	1.9	A	f2ygr7	549		234..534
3q60	pdb	Crystal structure of virulent allele ROP5B pseudokinase domain bound to ATP	x-ray	1.72	A	f2ygr7	549		234..534
3q6u	pdb	Structure of the apo MET receptor kinase in the dually-phosphorylated, activated state	x-ray	1.6	A	p08581	1390		1079..1341
3q6w	pdb	Structure of dually-phosphorylated MET receptor kinase in complex with an MK-2461 analog with specificity for the activated receptor	x-ray	1.75	A	p08581	1390		1079..1341
3q96	pdb	B-Raf kinase domain in complex with a tetrahydronaphthalene inhibitor	x-ray	3.1	A;B	p15056;p15056	766;766	;	449..717;449..717
3q9w	pdb	Crystal structure of human CK2 alpha in complex with emodin at pH 8.5	x-ray	1.7	A	p68400	391		5..328
3q9x	pdb	Crystal structure of human CK2 alpha in complex with emodin at pH 6.5	x-ray	2.2	A;B	p68400;p68400	391;391	;	5..328;5..328
3q9y	pdb	Crystal structure of human CK2 alpha in complex with Quinalizarin at pH 8.5	x-ray	1.8	A	p68400	391		5..328
3q9z	pdb	Crystal structure of human CK2 alpha in complex with Quinalizarin at pH 6.5	x-ray	2.2	A;B	p68400;p68400	391;391	;	5..328;5..328
3qa0	pdb	Crystal structure of the apo-form of human CK2 alpha at pH 6.5	x-ray	2.5	A;B	p68400;p68400	391;391	;	5..328;5..328
3qa8	pdb	Crystal Structure of inhibitor of kappa B kinase beta	x-ray	3.6	A;B;C;D;E;F;G;H	q6int1;q6int1;q6int1;q6int1;q6int1;q6int1;q6int1;q6int1	742;742;742;742;742;742;742;742	;;;;;;;	3..274;3..274;3..274;3..274;3..274;3..274;3..274;3..274
3qal	pdb	Crystal Structure of Arg280Ala mutant of Catalytic subunit of cAMP-dependent Protein Kinase	x-ray	1.7	E	p05132	351		28..339
3qam	pdb	Crystal Structure of Glu208Ala mutant of catalytic subunit of cAMP-dependent protein kinase	x-ray	1.92	E	p05132	351		28..339
3qaq	pdb	Crystal structure of PI3K-gamma in complex with triazine-benzimidazole 1	x-ray	2.9	A	p48736	1102		728..1089
3qar	pdb	Crystal structure of PI3K-gamma in complex with triazine-benzimidazole 32	x-ray	2.65	A	p48736	1102		728..1089
3qbn	pdb	Structure of Human Aurora A in Complex with a diaminopyrimidine	x-ray	3.5	A	o14965	403		120..386
3qc4	pdb	PDK1 in complex with DFG-OUT inhibitor xxx	x-ray	1.8	A;B	o15530;o15530	556;556	;	79..400;79..400
3qc9	pdb	Crystal structure of cross-linked bovine GRK1 T8C/N480C double mutant complexed with ADP and Mg	x-ray	2.7	A;B;C;D	p28327;p28327;p28327;p28327	561;561;561;561	;;;	187..529;187..529;187..529;187..529
3qcq	pdb	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-(3-Amino-1H-indazol-6-yl)-N4-ethyl-2,4-pyrimidinediamine	x-ray	2.501	A	o15530	556		79..400
3qcs	pdb	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-[2-Amino-6-(4-morpholinyl)-4-pyrimidinyl]-1H-indazol-3-amine	x-ray	2.487	A	o15530	556		79..400
3qcx	pdb	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-{2-Amino-6-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl}-1H-indazol-3-amine	x-ray	2.3	A	o15530	556		79..400
3qcy	pdb	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 4-[2-Amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-N-phenyl-2-morpholinecarboxamide	x-ray	2.2	A	o15530	556		79..400
3qd0	pdb	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with (2R,5S)-1-[2-Amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-6-methyl-N-phenyl-3-piperidinecarboxamide	x-ray	1.99	A	o15530	556		79..400
3qd2	pdb	Crystal structure of mouse PERK kinase domain	x-ray	2.81	B	q9z2b5	1114		584..1087
3qd3	pdb	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 1,1-Dimethylethyl {(3R,6S)-1-[2-amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-6-methyl-3-piperidinyl}carbamate	x-ray	2	A	o15530	556		79..400
3qd4	pdb	Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 1,1-Dimethylethyl{(3R,5R)-1-[2-amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-5-methyl-3-piperidinyl}carbamate	x-ray	2.3	A	o15530	556		79..400
3qf9	pdb	Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a furan-thiazolidinedione ligand	x-ray	2.2	A				
3qfv	pdb	MRCK beta in complex with TPCA-1	x-ray	2.65	A;B	q9y5s2;q9y5s2	1711;1711	;	56..396;56..396
3qgw	pdb	Crystal Structure of ITK kinase bound to an inhibitor	x-ray	2.1	A;B	q08881;q08881	620;620	;	352..613;352..613
3qgy	pdb	Crystal structure of ITK inhibitor complex	x-ray	2.1	A;B	q08881;q08881	620;620	;	352..613;352..613
3qhr	pdb	Structure of a pCDK2/CyclinA transition-state mimic	x-ray	2.17	A;C	;	;	;	;
3qhw	pdb	Structure of a pCDK2/CyclinA transition-state mimic	x-ray	1.91	A;C	;	;	;	;
3qjz	pdb	Crystal structure of PI3K-gamma in complex with benzothiazole 1	x-ray	2.9	A	p48736	1102		728..1089
3qk0	pdb	Crystal structure of PI3K-gamma in complex with benzothiazole 82	x-ray	2.85	A	p48736	1102		728..1089
3qkk	pdb	Spirochromane Akt Inhibitors	x-ray	2.3	A	p31749	480		145..459
3qkl	pdb	Spirochromane Akt Inhibitors	x-ray	1.9	A	p31749	480		145..459
3qkm	pdb	Spirocyclic sulfonamides as AKT inhibitors	x-ray	2.2	A	p31749	480		145..459
3ql8	pdb	CDK2 in complex with inhibitor JWS-6-260	x-ray	1.9	A	p24941	298		1..292
3qlf	pdb	Crystal structure of the L317I mutant of the C-src tyrosine kinase domain complexed with pyrazolopyrimidine 5	x-ray	2.75	A;B	p00523;p00523	533;533	;	256..526;256..526
3qlg	pdb	Crystal structure of the L317I mutant of the C-src tyrosine kinase domain complexed with dasatinib	x-ray	2.75	A;B	p00523;p00523	533;533	;	256..526;256..526
3qqf	pdb	CDK2 in complex with inhibitor L1	x-ray	1.75	A	p24941	298		1..292
3qqg	pdb	CDK2 in complex with inhibitor L2-5	x-ray	1.9	A	p24941	298		1..292
3qqh	pdb	CDK2 in complex with inhibitor L2-2	x-ray	1.87	A	p24941	298		1..292
3qqj	pdb	CDK2 in complex with inhibitor L2	x-ray	1.7	A	p24941	298		1..292
3qqk	pdb	CDK2 in complex with inhibitor L4	x-ray	1.86	A	p24941	298		1..292
3qql	pdb	CDK2 in complex with inhibitor L3	x-ray	1.85	A	p24941	298		1..292
3qqu	pdb	Cocrystal structure of unphosphorylated igf with pyrimidine 8	x-ray	2.9	A;B;C;D	p08069;p08069;p08069;p08069	1367;1367;1367;1367	;;;	970..1264;970..1264;970..1264;970..1264
3qri	pdb	The crystal structure of human abl1 kinase domain in complex with DCC-2036	x-ray	2.1	A;B	p00519;p00519	1130;1130	;	231..498;231..498
3qrj	pdb	The crystal structure of human abl1 kinase domain T315I mutant in complex with DCC-2036	x-ray	1.82	A;B	p00519;p00519	1130;1130	;	231..498;231..498
3qrk	pdb	The crystal structure of human abl1 kinase domain in complex with DP-987	x-ray	2.3	A	p00519	1130		231..498
3qrt	pdb	CDK2 in complex with inhibitor NSK-MC2-55	x-ray	1.75	A	p24941	298		1..292
3qru	pdb	CDK2 in complex with inhibitor NSK-MC1-12	x-ray	1.95	A	p24941	298		1..292
3qti	pdb	c-Met Kinase in Complex with NVP-BVU972	x-ray	2	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
3qtq	pdb	CDK2 in complex with inhibitor RC-1-137	x-ray	1.8	A	p24941	298		1..292
3qtr	pdb	CDK2 in complex with inhibitor RC-1-148	x-ray	1.85	A	p24941	298		1..292
3qts	pdb	CDK2 in complex with inhibitor RC-2-12	x-ray	1.9	A	p24941	298		1..292
3qtu	pdb	CDK2 in complex with inhibitor RC-2-132	x-ray	1.82	A	p24941	298		1..292
3qtw	pdb	CDK2 in complex with inhibitor RC-2-13	x-ray	1.85	A	p24941	298		1..292
3qtx	pdb	CDK2 in complex with inhibitor RC-2-35	x-ray	1.95	A	p24941	298		1..292
3qtz	pdb	CDK2 in complex with inhibitor RC-2-36	x-ray	2	A	p24941	298		1..292
3qu0	pdb	CDK2 in complex with inhibitor RC-2-38	x-ray	1.95	A	p24941	298		1..292
3qud	pdb	Human p38 MAP Kinase in Complex with 2-amino-phenylamino-benzophenone	x-ray	2	A	q16539	360		9..349
3que	pdb	Human p38 MAP Kinase in Complex with Skepinone-L	x-ray	2.7	A	q16539	360		9..349
3qup	pdb	Inhibitor bound structure of the kinase domain of the murine receptor tyrosine kinase TYRO3 (Sky)	x-ray	1.9	A	p55144	880		499..796
3qwj	pdb	CDK2 in complex with inhibitor KVR-1-142	x-ray	1.75	A	p24941	298		1..292
3qwk	pdb	CDK2 in complex with inhibitor KVR-1-150	x-ray	1.85	A	p24941	298		1..292
3qx2	pdb	CDK2 in complex with inhibitor KVR-1-190	x-ray	1.75	A	p24941	298		1..292
3qx4	pdb	CDK2 in complex with inhibitor KVR-1-78	x-ray	1.92	A	p24941	298		1..292
3qxo	pdb	CDK2 in complex with inhibitor KVR-1-84	x-ray	1.75	A	p24941	298		1..292
3qxp	pdb	CDK2 in complex with inhibitor RC-3-89	x-ray	1.75	A	p24941	298		1..292
3qyw	pdb	Crystal structure of ERK2 in complex with an inhibitor	x-ray	1.5	A	p63086	358		17..320
3qyz	pdb	Crystal structure of ERK2 in complex with an inhibitor	x-ray	1.46	A	p63086	358		17..320
3qzf	pdb	CDK2 in complex with inhibitor JWS-6-52	x-ray	2	A	p24941	298		1..292
3qzg	pdb	CDK2 in complex with inhibitor JWS-6-76	x-ray	1.75	A	p24941	298		1..292
3qzh	pdb	CDK2 in complex with inhibitor KVR-1-124	x-ray	1.95	A	p24941	298		1..292
3qzi	pdb	CDK2 in complex with inhibitor KVR-1-126	x-ray	1.75	A	p24941	298		1..292
3r00	pdb	The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors	x-ray	2.1	A	p11309	313		36..296
3r01	pdb	The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors	x-ray	2.6	A	p11309	313		36..296
3r02	pdb	The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors	x-ray	1.95	A	p11309	313		36..296
3r04	pdb	The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors	x-ray	1.7	A	p11309	313		36..296
3r0t	pdb	Crystal structure of human protein kinase CK2 alpha subunit in complex with the inhibitor CX-5279	x-ray	1.75	A	p68400	391		5..328
3r1n	pdb	MK3 kinase bound to Compound 5b	x-ray	2.09	A	q16644	382		36..343
3r1q	pdb	CDK2 in complex with inhibitor KVR-1-102	x-ray	1.85	A	p24941	298		1..292
3r1s	pdb	CDK2 in complex with inhibitor KVR-1-127	x-ray	1.8	A	p24941	298		1..292
3r1y	pdb	CDK2 in complex with inhibitor KVR-1-134	x-ray	1.8	A	p24941	298		1..292
3r21	pdb	Design, synthesis, and biological evaluation of pyrazolopyridine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (Part I)	x-ray	2.9	A	o14965	403		120..386
3r22	pdb	Design, synthesis, and biological evaluation of pyrazolopyridine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (Part I)	x-ray	2.9	A	o14965	403		120..386
3r28	pdb	CDK2 in complex with inhibitor KVR-1-140	x-ray	1.75	A	p24941	298		1..292
3r2b	pdb	MK2 kinase bound to Compound 5b	x-ray	2.9	A;B;C;D;E;F;G;H;I;J;K;L	p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137	400;400;400;400;400;400;400;400;400;400;400;400	;;;;;;;;;;;	59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369
3r2y	pdb	MK2 kinase bound to Compound 1	x-ray	3	A	p49137	400		59..369
3r30	pdb	MK2 kinase bound to Compound 2	x-ray	3.2	A	p49137	400		59..369
3r63	pdb	Structure of ERK2 (SPE) mutant (S246E)	x-ray	1.7	A	p63086	358		17..320
3r6x	pdb	CDK2 in complex with inhibitor KVR-1-158	x-ray	1.75	A	p24941	298		1..292
3r71	pdb	CDK2 in complex with inhibitor KVR-1-162	x-ray	1.75	A	p24941	298		1..292
3r73	pdb	CDK2 in complex with inhibitor KVR-1-164	x-ray	1.7	A	p24941	298		1..292
3r7e	pdb	CDK2 in complex with inhibitor KVR-1-67	x-ray	1.9	A	p24941	298		1..292
3r7i	pdb	CDK2 in complex with inhibitor KVR-1-74	x-ray	1.85	A	p24941	298		1..292
3r7o	pdb	Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-2461 analog	x-ray	2.3	A	p08581	1390		1079..1341
3r7q	pdb	Structure-based design of thienobenzoxepin inhibitors of PI3- kinase	x-ray	2.5	A	p48736	1102		728..1089
3r7r	pdb	Structure-based design of thienobenzoxepin inhibitors of PI3-Kinase	x-ray	2.9	A	p48736	1102		728..1089
3r7u	pdb	CDK2 in complex with inhibitor KVR-1-75	x-ray	1.75	A	p24941	298		1..292
3r7v	pdb	CDK2 in complex with inhibitor KVR-1-9	x-ray	1.95	A	p24941	298		1..292
3r7y	pdb	CDK2 in complex with inhibitor KVR-2-88	x-ray	1.9	A	p24941	298		1..292
3r83	pdb	CDK2 in complex with inhibitor KVR-2-92	x-ray	1.75	A	p24941	298		1..292
3r8l	pdb	CDK2 in complex with inhibitor L3-4	x-ray	1.9	A	p24941	298		1..292
3r8m	pdb	CDK2 in complex with inhibitor L3-3	x-ray	1.8	A	p24941	298		1..292
3r8p	pdb	CDK2 in complex with inhibitor NSK-MC1-6	x-ray	1.8	A	p24941	298		1..292
3r8u	pdb	CDK2 in complex with inhibitor RC-1-132	x-ray	2	A	p24941	298		1..292
3r8v	pdb	CDK2 in complex with inhibitor RC-1-135	x-ray	1.9	A	p24941	298		1..292
3r8z	pdb	CDK2 in complex with inhibitor RC-1-136	x-ray	1.85	A	p24941	298		1..292
3r9d	pdb	CDK2 in complex with inhibitor RC-2-135	x-ray	1.95	A	p24941	298		1..292
3r9h	pdb	CDK2 in complex with inhibitor RC-2-142	x-ray	2.1	A	p24941	298		1..292
3r9n	pdb	CDK2 in complex with inhibitor RC-2-21	x-ray	1.75	A	p24941	298		1..292
3r9o	pdb	CDK2 in complex with inhibitor RC-2-143	x-ray	1.9	A	p24941	298		1..292
3rah	pdb	CDK2 in complex with inhibitor RC-2-22	x-ray	1.75	A	p24941	298		1..292
3rai	pdb	CDK2 in complex with inhibitor KVR-1-160	x-ray	1.7	A	p24941	298		1..292
3rak	pdb	CDK2 in complex with inhibitor RC-2-32	x-ray	1.75	A	p24941	298		1..292
3ral	pdb	CDK2 in complex with inhibitor RC-2-34	x-ray	1.75	A	p24941	298		1..292
3raw	pdb	Crystal Structure of human CDC-like kinase 3 isoform in complex with leucettine L41	x-ray	2.09	A;B	p49761;p49761	490;490	;	145..479;145..479
3rcd	pdb	HER2 Kinase Domain Complexed with TAK-285	x-ray	3.21	A;B;C;D	p04626;p04626;p04626;p04626	1255;1255;1255;1255	;;;	716..992;716..992;716..992;716..992
3rcj	pdb	Rapid preparation of triazolyl substituted NH-heterocyclic kinase inhibitors via one-pot Sonogashira coupling TMS-deprotection CuAAC sequence	x-ray	1.7	A	o15530	556		79..400
3re4	pdb	Crystal Structure of Archaeoglobus Fulgidus Rio1 Kinase bound to Toyocamycin.	x-ray	1.997	A;B	o28471;o28471	258;258	;	52..240;52..240
3rep	pdb	Crystal structure of the ILK/alpha-parvin core complex (MnATP)	x-ray	1.8	A	q13418	452		177..444
3rgf	pdb	Crystal Structure of human CDK8/CycC	x-ray	2.2	A	p49336	464		25..341
3rhk	pdb	Crystal structure of the catalytic domain of c-Met kinase in complex with ARQ 197	x-ray	1.94	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
3rhx	pdb	Crystal structure of the catalytic domain of FGFR1 kinase in complex with ARQ 069	x-ray	2.01	A;B	p11362;p11362	822;822	;	468..754;468..754
3ri1	pdb	Crystal structure of the catalytic domain of FGFR2 kinase in complex with ARQ 069	x-ray	2.1	A;B	p21802;p21802	821;821	;	471..757;471..757
3rin	pdb	p38 kinase crystal structure in complex with small molecule inhibitor	x-ray	2.2	A	q16539	360		9..349
3rjc	pdb	CDK2 in complex with inhibitor L4-12	x-ray	1.85	A	p24941	298		1..292
3rk5	pdb	CDK2 in complex with inhibitor RC-2-72	x-ray	2	A	p24941	298		1..292
3rk7	pdb	CDK2 in complex with inhibitor RC-2-71	x-ray	1.8	A	p24941	298		1..292
3rk9	pdb	CDK2 in complex with inhibitor RC-2-74	x-ray	1.85	A	p24941	298		1..292
3rkb	pdb	CDK2 in complex with inhibitor RC-2-73	x-ray	2	A	p24941	298		1..292
3rm6	pdb	CDK2 in complex with inhibitor KVR-2-80	x-ray	1.6	A	p24941	298		1..292
3rm7	pdb	CDK2 in complex with inhibitor KVR-1-91	x-ray	1.85	A	p24941	298		1..292
3rmf	pdb	CDK2 in complex with inhibitor RC-2-33	x-ray	1.75	A	p24941	298		1..292
3rni	pdb	CDK2 in complex with inhibitor RC-3-86	x-ray	1.95	A	p24941	298		1..292
3rny	pdb	Crystal structure of human RSK1 C-terminal kinase domain	x-ray	2.7	A;B	q15418;q15418	735;735	;	60..381,400..719;60..381,400..719
3roc	pdb	Crystal structure of human p38 alpha complexed with a pyrimidinone compound	x-ray	1.7	A	q16539	360		9..349
3roy	pdb	CDK2 in complex with inhibitor KVR-1-154	x-ray	1.75	A	p24941	298		1..292
3rp9	pdb	Crystal Structure of the apo MapK from Toxoplasma Gondii, 25.m01780 or TGME49_007820	x-ray	2.4	A	b6kp12	548		138..495
3rpo	pdb	CDK2 in complex with inhibitor KVR-1-156	x-ray	1.75	A	p24941	298		1..292
3rpr	pdb	CDK2 in complex with inhibitor RC-2-49	x-ray	1.75	A	p24941	298		1..292
3rps	pdb	Structure of human CK2alpha in complex with the ATP-competitive inhibitor 3-(4,5,6,7-tetrabromo-1H-benzotriazol-1-yl)propan-1-ol	x-ray	2.3	A;B	p68400;p68400	391;391	;	5..328;5..328
3rpv	pdb	CDK2 in complex with inhibitor RC-2-88	x-ray	1.8	A	p24941	298		1..292
3rpy	pdb	CDK2 in complex with inhibitor RC-2-40	x-ray	1.9	A	p24941	298		1..292
3rtp	pdb	Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration	x-ray	2.4	A	p53779	464		52..396
3rvg	pdb	Crystals structure of Jak2 with a 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitor	x-ray	2.498	A	o60674	1132		522..814,842..1119
3rwp	pdb	Discovery of a Novel, Potent and Selective Inhibitor of 3-Phosphoinositide Dependent Kinase (PDK1)	x-ray	1.92	A	o15530	556		79..400
3rwq	pdb	Discovery of a Novel, Potent and Selective Inhibitor of 3-Phosphoinositide Dependent Kinase (PDK1)	x-ray	2.55	A	o15530	556		79..400
3rzb	pdb	CDK2 in complex with inhibitor RC-2-23	x-ray	1.9	A	p24941	298		1..292
3rzf	pdb	Crystal Structure of Inhibitor of kappaB kinase beta (I4122)	x-ray	4	A	q6int1	742		3..274
3s00	pdb	CDK2 in complex with inhibitor L4-14	x-ray	1.8	A	p24941	298		1..292
3s0o	pdb	CDK2 in complex with inhibitor RC-1-138	x-ray	2	A	p24941	298		1..292
3s1h	pdb	CDK2 in complex with inhibitor RC-2-39	x-ray	1.75	A	p24941	298		1..292
3s2a	pdb	Crystal structure of PI3K-gamma in complex with a quinoline inhibitor	x-ray	2.55	A	p48736	1102		728..1089
3s2p	pdb	Crystal structure of CDK2 with a 2-aminopyrimidine compound	x-ray	2.3	A	p24941	298		1..292
3s3i	pdb	p38 kinase crystal structure in complex with small molecule inhibitor	x-ray	1.8	A	q16539	360		9..349
3s4q	pdb	P38 alpha kinase complexed with a pyrazolo-triazine based inhibitor	x-ray	2.27	A	q16539	360		9..349
3s95	pdb	Crystal structure of the human LIMK1 kinase domain in complex with staurosporine	x-ray	1.65	A;B	p53667;p53667	647;647	;	329..616;329..616
3sa0	pdb	Complex of ERK2 with norathyriol	x-ray	1.5947	A	p28482	360		19..322
3say	pdb	Crystal structure of human glycogen synthase kinase 3 beta (GSK3b) in complex with inhibitor 142	x-ray	2.231	A;B	p49841;p49841	420;420	;	55..377;55..377
3sc1	pdb	Novel Isoquinolone PDK1 Inhibitors Discovered through Fragment-Based Lead Discovery	x-ray	2.7	A	o15530	556		79..400
3sd0	pdb	Identification of a Glycogen Synthase Kinase-3b Inhibitor that Attenuates Hyperactivity in CLOCK Mutant Mice	x-ray	2.7	A;B	p49841;p49841	420;420	;	55..377;55..377
3sd5	pdb	Crystal Structure of PI3K gamma with 5-(2,4-dimorpholinopyrimidin-6-yl)-4-(trifluoromethyl)pyridin-2-amine	x-ray	3.2	A	p48736	1102		728..1089
3sdj	pdb	Structure of RNase-inactive point mutant of oligomeric kinase/RNase Ire1	x-ray	3.65	A;B;C;D;E;F;G;H;I;J;K;L;M;N	p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361;p32361	1115;1115;1115;1115;1115;1115;1115;1115;1115;1115;1115;1115;1115;1115	;;;;;;;;;;;;;	677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992;677..992
3sdm	pdb	Structure of oligomeric kinase/RNase Ire1 in complex with an oligonucleotide	x-ray	6.6	A;B;C;D;E;F;G	p32361;p32361;p32361;p32361;p32361;p32361;p32361	1115;1115;1115;1115;1115;1115;1115	;;;;;;	677..992;677..992;677..992;677..992;677..992;677..992;677..992
3sg8	pdb	Crystal Structure of Aminoglycoside-2''-Phosphotransferase Type IVa Tobramycin Complex	x-ray	1.8	A;B	o68183;o68183	301;301	;	3..264;3..264
3sg9	pdb	Crystal Structure of Aminoglycoside-2''-Phosphotransferase Type IVa Kanamycin A Complex	x-ray	2.15	A;B	o68183;o68183	301;301	;	3..264;3..264
3sgc	pdb	Crystal Structure of Apo Aminoglycoside-2''-Phosphotransferase Type IVa	x-ray	2.05	A	o68183	301		3..264
3she	pdb	Novel ATP-competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series	x-ray	2.25	A	q16644	382		36..343
3skc	pdb	Human B-Raf Kinase in Complex with an Amide Linked Pyrazolopyridine Inhibitor	x-ray	3.2	A;B	p15056;p15056	766;766	;	449..717;449..717
3sls	pdb	Crystal Structure of human MEK-1 kinase in complex with UCB1353770 and AMPPNP	x-ray	2.3	A;B	q02750;q02750	393;393	;	63..365;63..365
3soa	pdb	Full-length human CaMKII	x-ray	3.5501	A	q9uqm7	478		9..272
3soc	pdb	Crystal structure of Activin receptor type-IIA (ACVR2A) kinase domain in complex with a quinazolin	x-ray	1.95	A;B	p27037;p27037	513;513	;	180..476;180..476
3sqq	pdb	CDK2 in complex with inhibitor RC-3-96	x-ray	1.85	A	p24941	298		1..292
3srv	pdb	Crystal structure of spleen tyrosine kinase (SYK) in complex with a diaminopyrimidine carboxamide inhibitor	x-ray	1.95	A;B	p43405;p43405	635;635	;	375..627;375..627
3sv0	pdb	Crystal structure of casein kinase-1 like protein in plant	x-ray	2	A	q8lr51	472		5..290
3svv	pdb	Crystal Structure of T338C c-Src covalently bound to vinylsulfonamide-pyrazolopyrimidine 9	x-ray	2.204	A;B	p00523;p00523	533;533	;	256..526;256..526
3sw4	pdb	Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitor	x-ray	1.7	A	p24941	298		1..292
3sw7	pdb	Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitor	x-ray	1.8	A	p24941	298		1..292
3sx9	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-132	x-ray	2.65	A	q9bjf5	507		35..330
3sxf	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-89	x-ray	2.04	A	q9bjf5	507		35..330
3sxr	pdb	Crystal structure of BMX non-receptor tyrosine kinase complex with dasatinib	x-ray	2.4	A;B	p51813;p51813	675;675	;	396..664;396..664
3sxs	pdb	Crystal structure of BMX non-receptor tyrosine kinase complexed with PP2	x-ray	1.89	A	p51813	675		396..664
3t3u	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-130	x-ray	2.1	A	q9bjf5	507		35..330
3t3v	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-87	x-ray	2.04	A	q9bjf5	507		35..330
3t8m	pdb	Rational Design of PI3K-alpha Inhibitors that Exhibit Selectivity Over the PI3K-beta Isoform	x-ray	2.5	A	p48736	1102		728..1089
3t8o	pdb	Rhodopsin kinase (GRK1) L166K mutant at 2.5A resolution	x-ray	2.5	A	p28327	561		187..529
3t9i	pdb	Pim1 complexed with a novel 3,6-disubstituted indole at 2.6 Ang Resolution	x-ray	2.6	A	p11309	313		36..296
3t9t	pdb	Crystal structure of BTK mutant (F435T,K596R) complexed with Imidazo[1,5-a]quinoxaline	x-ray	1.65	A	q08881	620		352..613
3tac	pdb	Crystal Structure of the Liprin-alpha/CASK complex	x-ray	2.2	A	o14936	926		7..292
3tcp	pdb	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC569	x-ray	2.69	A;B	q12866;q12866	999;999	;	578..872;578..872
3tdv	pdb	Structure of the GDP complex of wild-type aminoglycoside 2'-phosphotransferase-IIIa	x-ray	2.2	A;B	p96762;p96762	306;306	;	13..254;13..254
3tdw	pdb	The GDP complex of the aminoglycoside 2'-phosphotransfere-IIIa F108L mutant	x-ray	1.7	A	p96762	306		13..254
3tei	pdb	Crystal structure of human ERK2 complexed with a MAPK docking peptide	x-ray	2.404	A	p28482	360		19..322
3tg1	pdb	Crystal structure of p38alpha in complex with a MAPK docking partner	x-ray	2.71	A	p47811	360		9..349
3thb	pdb	Structure of PLK1 kinase domain in complex with a benzolactam-derived inhibitor	x-ray	2.5	A	p53350	603		51..338
3ti1	pdb	CDK2 in complex with SUNITINIB	x-ray	1.99	A	p24941	298		1..292
3tiy	pdb	CDK2 in complex with NSC 35676	x-ray	1.84	A	p24941	298		1..292
3tiz	pdb	CDK2 in complex with NSC 111848	x-ray	2.02	A	p24941	298		1..292
3tjc	pdb	Co-crystal structure of jak2 with thienopyridine 8	x-ray	2.4	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
3tjd	pdb	co-crystal structure of Jak2 with thienopyridine 19	x-ray	2.9	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
3tjp	pdb	Crystal Structure of PI3K gamma with N6-(3,4-dimethoxyphenyl)-2-morpholino-[4,5'-bipyrimidine]-2',6-diamine	x-ray	2.7	A	p48736	1102		728..1089
3tkh	pdb	Crystal structure of Chk1 in complex with inhibitor S01	x-ray	1.79	A	o14757	476		6..317
3tki	pdb	Crystal structure of Chk1 in complex with inhibitor S25	x-ray	1.6	A	o14757	476		6..317
3tku	pdb	MRCK beta in complex with fasudil	x-ray	2.15	A;B	q9y5s2;q9y5s2	1711;1711	;	56..396;56..396
3tl5	pdb	Discovery of GDC-0980: a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor for the Treatment of Cancer	x-ray	2.788	A	p48736	1102		728..1089
3tl8	pdb	The AvrPtoB-BAK1 complex reveals two structurally similar kinaseinteracting domains in a single type III effector	x-ray	2.5	A;D;G;H	q94f62;q94f62;q94f62;q94f62	615;615;615;615	;;;	268..564;268..564;268..564;268..564
3tm0	pdb	"Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa AMPPNP Butirosin A Complex"	x-ray	2.1	A	p0a3y5	264		3..264
3tn8	pdb	CDK9/cyclin T in complex with CAN508	x-ray	2.95	A	p50750	372		12..321
3tnh	pdb	CDK9/cyclin T in complex with CAN508	x-ray	3.202	A	p50750	372		12..321
3tni	pdb	structure of CDK9/cyclin T F241L	x-ray	3.234	A	p50750	372		12..321
3tnp	pdb	Structure and Allostery of the PKA RIIb Tetrameric Holoenzyme	x-ray	2.3	C;F	p05132;p05132	351;351	;	28..339;28..339
3tnq	pdb	Structure and Allostery of the PKA RIIb Tetrameric Holoenzyme	x-ray	3.097	B	p27791	351		31..339
3tnw	pdb	Structure of CDK2/cyclin A in complex with CAN508	x-ray	2	A;C	p24941;p24941	298;298	;	1..292;1..292
3tt0	pdb	Co-structure of Fibroblast Growth Factor Receptor 1 kinase domain with 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (BGJ398)	x-ray	2.8	A;B	p11362;p11362	822;822	;	468..754;468..754
3tti	pdb	Crystal Structure of JNK3 complexed with CC-930, an orally active anti-fibrotic JNK inhibitor	x-ray	2.2	A	p53779	464		52..396
3ttj	pdb	Crystal Structure of JNK3 complexed with CC-359, a JNK inhibitor for the prevention of ischemia-reperfusion injury	x-ray	2.1	A	p53779	464		52..396
3tub	pdb	Crystal structure of SYK kinase domain with 1-(5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-yl)-3-((1R,2S)-2-phenylcyclopropyl)urea	x-ray	2.23	A	p43405	635		375..627
3tuc	pdb	Crystal structure of SYK kinase domain with 1-benzyl-N-(5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide	x-ray	2.1	A	p43405	635		375..627
3tud	pdb	Crystal structure of SYK kinase domain with N-(4-methyl-3-(8-methyl-7-oxo-2-(phenylamino)-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamide	x-ray	2.33	A	p43405	635		375..627
3tv4	pdb	Human B-Raf Kinase Domain in Complex with an Bromopyridine Benzamide Inhibitor	x-ray	3.4	A;B	p15056;p15056	766;766	;	449..717;449..717
3tv6	pdb	Human B-Raf Kinase Domain in Complex with a Methoxypyrazolopyridinyl Benzamide Inhibitor	x-ray	3.3	A;B	p15056;p15056	766;766	;	449..717;449..717
3tv7	pdb	Human Rho-associated protein kinase 1 (ROCK 1) in COMPLEX WITH RKI1342	x-ray	2.75	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
3twj	pdb	Rho-associated protein kinase 1 (ROCK 1) IN COMPLEX WITH RKI1447	x-ray	2.9	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
3txo	pdb	PKC eta kinase in complex with a naphthyridine	x-ray	2.05	A	p24723	683		352..677
3tyk	pdb	Crystal structure of aminoglycoside phosphotransferase APH(4)-Ia	x-ray	1.95	A	p00557	341		12..270
3tz7	pdb	Kinase domain of cSrc in complex with RL103	x-ray	3.3	A;B	p00523;p00523	533;533	;	256..526;256..526
3tz8	pdb	Kinase domain of cSrc in complex with RL104	x-ray	2.7	A;B	p00523;p00523	533;533	;	256..526;256..526
3tz9	pdb	Kinase domain of cSrc in complex with RL130	x-ray	3.1	A;B	p00523;p00523	533;533	;	256..526;256..526
3tzm	pdb	TGF-beta Receptor type 1 in complex with SB431542	x-ray	1.7	A	p36897	503		180..492
3u4u	pdb	Casein kinase 2 in complex with AZ-Inhibitor	x-ray	2.2	A	p68400	391		5..328
3u4w	pdb	Src in complex with DNA-templated macrocyclic inhibitor MC4b	x-ray	1.9	A				
3u51	pdb	Src in complex with DNA-templated macrocyclic inhibitor MC1	x-ray	2.241	A;B	;	;	;	;
3u6h	pdb	Crystal structure of c-Met in complex with pyrazolone inhibitor 26	x-ray	2	A	p08581	1390		1079..1341
3u6i	pdb	Crystal structure of c-Met in complex with pyrazolone inhibitor 58a	x-ray	2.1	A	p08581	1390		1079..1341
3u6j	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a pyrazolone inhibitor	x-ray	2.15	A	p35968	1356		815..1160
3u87	pdb	Structure of a chimeric construct of human CK2alpha and human CK2alpha' in complex with a non-hydrolysable ATP-analogue	x-ray	2.9	A;B	p19784;p68400	350;391	;	13..330;5..328
3u8w	pdb	Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Triazolopyridazinone inhibitor	x-ray	2.15	A	q16539	360		9..349
3u9c	pdb	Structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit with the ATP-competitive inhibitor resorufin	x-ray	3.2	A;B	p68400;p68400	391;391	;	5..328;5..328
3u9n	pdb	X-ray crystal structure of compound 1 bound to human CHK1 kinase domain	x-ray	1.85	A	o14757	476		6..317
3ubd	pdb	Structure of N-terminal domain of RSK2 kinase in complex with flavonoid glycoside SL0101	x-ray	1.53	A	p18654	740		66..390,402..717
3uc3	pdb	The crystal structure of Snf1-related kinase 2.3	x-ray	1.9	A	q39193	361		14..313
3uc4	pdb	The crystal structure of Snf1-related kinase 2.6	x-ray	2.3	A;B	q940h6;q940h6	362;362	;	13..304;13..304
3udb	pdb	Crystal structure of SnRK2.6	x-ray	2.567	A;B;C;D;E;F	q940h6;q940h6;q940h6;q940h6;q940h6;q940h6	362;362;362;362;362;362	;;;;;	13..304;13..304;13..304;13..304;13..304;13..304
3ue4	pdb	Structural and spectroscopic analysis of the kinase inhibitor bosutinib binding to the Abl tyrosine kinase domain	x-ray	2.424	A;B	p00519;p00519	1130;1130	;	231..498;231..498
3ug1	pdb	Crystal structure of the mutated EGFR kinase domain (G719S/T790M) in the apo form	x-ray	2.75	A	p00533	1210		708..1003
3ug2	pdb	Crystal structure of the mutated EGFR kinase domain (G719S/T790M) in complex with gefitinib	x-ray	2.5	A	p00533	1210		708..1003
3ugc	pdb	Structural basis of Jak2 inhibition by the type II inhibtor NVP-BBT594	x-ray	1.34	A	o60674	1132		522..814,842..1119
3uib	pdb	Map kinase LMAMPK10 from leishmania major in complex with SB203580	x-ray	2.65	A	q4qhj8	407		19..325
3uim	pdb	Structural basis for the impact of phosphorylation on plant receptor-like kinase BAK1 activation	x-ray	2.2	A	q94f62	615		268..564
3uiu	pdb	Crystal structure of Apo-PKR kinase domain	x-ray	2.903	A;B	p19525;p19525	551;551	;	259..536;259..536
3uix	pdb	Crystal structure of Pim1 kinase in complex with small molecule inhibitor	x-ray	2.2	A	p11309	313		36..296
3ujg	pdb	Crystal structure of SnRK2.6 in complex with HAB1	x-ray	2.6	A	q940h6	362		13..304
3uli	pdb	Human Cyclin Dependent Kinase 2 (CDK2) bound to azabenzimidazole derivative	x-ray	2	A	p24941	298		1..292
3ulz	pdb	Crystal structure of apo BAK1	x-ray	2.6	A	q94f62	615		268..564
3umw	pdb	Crystal structure of Pim1 kinase in complex with inhibitor (Z)-2-[(1H-indazol-3-yl)methylene]-6-methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one	x-ray	2.08	A	p11309	313		36..296
3umx	pdb	Crystal structure of Pim1 kinase in complex with inhibitor (Z)-2-[(1H-indol-3-yl)methylene]-7-(azepan-1-ylmethyl)-6-hydroxybenzofuran-3(2H)-one	x-ray	2.55	A	p11309	313		36..296
3unj	pdb	CDK2 in complex with inhibitor YL1-038-31	x-ray	1.9001	A	p24941	298		1..292
3unk	pdb	CDK2 in complex with inhibitor YL5-083	x-ray	2.1	A	p24941	298		1..292
3unz	pdb	Aurora A in Complex with RPM1679	x-ray	2.8	A;B	o14965;o14965	403;403	;	120..386;120..386
3uo4	pdb	Aurora A in complex with RPM1680	x-ray	2.45	A	o14965	403		120..386
3uo5	pdb	Aurora A in complex with YL1-038-31	x-ray	2.7012	A	o14965	403		120..386
3uo6	pdb	Aurora A in complex with YL5-083	x-ray	2.8002	A;B	o14965;o14965	403;403	;	120..386;120..386
3uod	pdb	Aurora A in complex with RPM1693	x-ray	2.5002	A	o14965	403		120..386
3uoh	pdb	Aurora A in complex with RPM1722	x-ray	2.8002	A;B	o14965;o14965	403;403	;	120..386;120..386
3uoj	pdb	Aurora A in complex with RPM1715	x-ray	2.9003	A;B	o14965;o14965	403;403	;	120..386;120..386
3uok	pdb	Aurora A in complex with YL5-81-1	x-ray	2.9506	A;B	o14965;o14965	403;403	;	120..386;120..386
3uol	pdb	Aurora A in complex with SO2-162	x-ray	2.4	A;B	o14965;o14965	403;403	;	120..386;120..386
3up2	pdb	Aurora A in complex with RPM1686	x-ray	2.3001	A	o14965	403		120..386
3up7	pdb	Aurora A in complex with YL1-038-09	x-ray	3.05	A	o14965	403		120..386
3upx	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1300	x-ray	2.27	A	q9bjf5	507		35..330
3upz	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumpless BKI analog UW1243	x-ray	2.2	A	q9bjf5	507		35..330
3uqc	pdb	Structure of the Intracellular Kinase Homology Domain of Rv3910 at 2.2 A resolution	x-ray	2.256	A;B;C;D	p9wjk3;p9wjk3;p9wjk3;p9wjk3	1184;1184;1184;1184	;;;	723..879;723..879;723..879;723..879
3uqf	pdb	c-SRC kinase domain in complex with BKI RM-1-89	x-ray	2.27	A;B	p00523;p00523	533;533	;	256..526;256..526
3uqg	pdb	c-SRC kinase domain in complex with bumpless BKI analog UW1243	x-ray	2.2	A;B	p00523;p00523	533;533	;	256..526;256..526
3uto	pdb	Twitchin kinase region from C.elegans (Fn31-NL-kin-CRD-Ig26)	x-ray	2.4	A;B	q23551;q23551	7158;7158	;	6236..6575;6236..6575
3uvp	pdb	Human p38 MAP Kinase in Complex with a Benzamide Substituted Benzosuberone	x-ray	2.4	A	q16539	360		9..349
3uvq	pdb	Human p38 MAP Kinase in Complex with a Dibenzosuberone Derivative	x-ray	2.2	A	q16539	360		9..349
3uvr	pdb	Human p38 MAP Kinase in Complex with KM064	x-ray	2.1	A	q16539	360		9..349
3uys	pdb	Crystal structure of apo human ck1d	x-ray	2.3	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
3uyt	pdb	crystal structure of ck1d with PF670462 from P1 crystal form	x-ray	2	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
3uzp	pdb	crystal structure of ck1d with PF670462 from P21 crystal form	x-ray	1.94	A;B	p48730;p48730	415;415	;	5..290;5..290
3uzr	pdb	Crystal structure of aminoglycoside phosphotransferase APH(2'')-Ib, apo form	x-ray	1.95	A	q93et9	299		5..251
3uzs	pdb	Structure of the C13.28 RNA Aptamer Bound to the G Protein-Coupled Receptor Kinase 2-Heterotrimeric G Protein Beta 1 and Gamma 2 Subunit Complex	x-ray	4.52	A	p21146	689		187..532
3uzt	pdb	Structure of the C13.18 RNA Aptamer in Complex with G Protein-Coupled Receptor Kinase 2	x-ray	3.51	A	p21146	689		187..532
3v01	pdb	Discovery of Novel Allosteric MEK Inhibitors Possessing Classical and Non-classical Bidentate Ser212 Interactions.	x-ray	2.705	A	q02750	393		63..365
3v04	pdb	Discovery of Novel Allosteric MEK Inhibitors Possessing Classical and Non-classical Bidentate Ser212 Interactions.	x-ray	2.7	A	q02750	393		63..365
3v3v	pdb	Structural and functional analysis of quercetagetin, a natural JNK1 inhibitor	x-ray	2.7	A	p45983	427		12..357
3v51	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor RM-1-176	x-ray	1.95	A	q9bjf5	507		35..330
3v5j	pdb	Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 090	x-ray	2.59	A;B	q08881;q08881	620;620	;	352..613;352..613
3v5l	pdb	Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 542	x-ray	1.86	A;B;C;D	q08881;q08881;q08881;q08881	620;620;620;620	;;;	352..613;352..613;352..613;352..613
3v5p	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1288	x-ray	2.1	A	q9bjf5	507		35..330
3v5q	pdb	Discovery of a selective TRK Inhibitor with efficacy in rodent cancer tumor models	x-ray	2.2001	A;B	q16288;q16288	839;839	;	514..824;514..824
3v5t	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1299	x-ray	2.13	A	q9bjf5	507		35..330
3v5w	pdb	Human G Protein-Coupled Receptor Kinase 2 in Complex with Soluble Gbetagamma Subunits and Paroxetine	x-ray	2.07	A	p25098	689		187..532
3v6r	pdb	Discovery of potent and selective covalent inhibitors of JNK	x-ray	2.6	A;B	p53779;p53779	464;464	;	52..396;52..396
3v6s	pdb	Discovery of potent and selective covalent inhibitors of JNK	x-ray	2.97	A;B	p53779;p53779	464;464	;	52..396;52..396
3v8s	pdb	Human RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)	x-ray	2.286	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
3v8t	pdb	Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 477	x-ray	2	A;B	q08881;q08881	620;620	;	352..613;352..613
3v8w	pdb	Crystal Structure of Interleukin-2 Inducible T-cell Kinase Itk Catalytic Domain with Thienopyrazolylindole Inhibitor 469	x-ray	2.27	A;B	q08881;q08881	620;620	;	352..613;352..613
3vap	pdb	Synthesis and SAR Studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off target kinase selectivity	x-ray	2.66	A	o14965	403		120..386
3vbq	pdb	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design	x-ray	1.85	A	p11309	313		36..296
3vbt	pdb	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design	x-ray	2.23	A	p11309	313		36..296
3vbv	pdb	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design	x-ray	2.08	A	p11309	313		36..296
3vbw	pdb	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design	x-ray	2.48	A	p11309	313		36..296
3vbx	pdb	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design	x-ray	2.03	A	p11309	313		36..296
3vby	pdb	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design	x-ray	2.27	A	p11309	313		36..296
3vc4	pdb	Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design	x-ray	2.23	A	p11309	313		36..296
3vf8	pdb	Crystal Structure of Spleen Tyrosine Kinase Syk Catalytic Domain with Pyrazolylbenzimidazole Inhibitor 416	x-ray	2.08	A	p43405	635		375..627
3vf9	pdb	Crystal Structure of Spleen Tyrosine Kinase Syk Catalytic Domain with Thienopyrazolylindole Inhibitor 027	x-ray	2.3	A	p43405	635		375..627
3vhe	pdb	Crystal structure of human VEGFR2 kinase domain with a novel pyrrolopyrimidine inhibitor.	x-ray	1.55	A	p35968	1356		815..1160
3vhk	pdb	Crystal structure of the VEGFR2 kinase domain in complex with a back pocket binder	x-ray	2.49	A	p35968	1356		815..1160
3vid	pdb	Crystal structure of human VEGFR2 kinase domain with Compound A.	x-ray	2.3	A	p35968	1356		815..1160
3vjn	pdb	Crystal structure of the mutated EGFR kinase domain (G719S/T790M) in complex with AMPPNP.	x-ray	2.34	A	p00533	1210		708..1003
3vjo	pdb	Crystal structure of the wild-type EGFR kinase domain in complex with AMPPNP.	x-ray	2.64	A	p00533	1210		708..1003
3vn9	pdb	Rifined Crystal structure of non-phosphorylated MAP2K6 in a putative auto-inhibition state	x-ray	2.6	A	p52564	334		41..315
3vnt	pdb	Crystal Structure of the Kinase domain of Human VEGFR2 with a [1,3]thiazolo[5,4-b]pyridine derivative	x-ray	1.64	A	p35968	1356		815..1160
3vo3	pdb	Crystal Structure of the Kinase domain of Human VEGFR2 with imidazo[1,2-b]pyridazine derivative	x-ray	1.52	A	p35968	1356		815..1160
3vqh	pdb	Bromine SAD partially resolves multiple binding modes for PKA inhibitor H-89	x-ray	1.95	A	p17612	351		30..339
3vqu	pdb	CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-[(4-amino-5-cyano-6-ethoxypyridin-2- yl)amino]benzamide	x-ray	2.4	A	p33981	857		516..792
3vry	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-cyclopentane	x-ray	2.481	A;B	p08631;p08631	526;526	;	249..518;249..518
3vrz	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 1-[4-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-benzylurea	x-ray	2.218	A;B	p08631;p08631	526;526	;	249..518;249..518
3vs0	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor N-[4-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]benzamide	x-ray	2.934	A;B	p08631;p08631	526;526	;	249..518;249..518
3vs1	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 1-[4-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-phenylurea	x-ray	2.464	A;B	p08631;p08631	526;526	;	249..518;249..518
3vs2	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 7-[cis-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	x-ray	2.609	A;B	p08631;p08631	526;526	;	249..518;249..518
3vs3	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 7-[trans-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	x-ray	2.17	A;B	p08631;p08631	526;526	;	249..518;249..518
3vs4	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 5-(4-phenoxyphenyl)-7-(tetrahydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	x-ray	2.747	A;B	p08631;p08631	526;526	;	249..518;249..518
3vs5	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor 7-(1-methylpiperidin-4-yl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	x-ray	2.851	A;B	p08631;p08631	526;526	;	249..518;249..518
3vs6	pdb	Crystal structure of HCK complexed with a pyrazolo-pyrimidine inhibitor tert-butyl {4-[4-amino-1-(propan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl}carbamate	x-ray	2.373	A;B	p08631;p08631	526;526	;	249..518;249..518
3vs7	pdb	Crystal structure of HCK complexed with a pyrazolo-pyrimidine inhibitor 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine	x-ray	3.001	A;B	p08631;p08631	526;526	;	249..518;249..518
3vud	pdb	Crystal structure of a cysteine-deficient mutant M1 in MAP kinase JNK1	x-ray	3.5	A	p45983	427		12..357
3vug	pdb	Crystal structure of a cysteine-deficient mutant M2 in MAP kinase JNK1	x-ray	3.24	A	p45983	427		12..357
3vuh	pdb	Crystal structure of a cysteine-deficient mutant M3 in MAP kinase JNK1	x-ray	2.7	A	p45983	427		12..357
3vui	pdb	Crystal structure of a cysteine-deficient mutant M2 in MAP kinase JNK1	x-ray	2.8	A	p45983	427		12..357
3vuk	pdb	Crystal structure of a cysteine-deficient mutant M5 in MAP kinase JNK1	x-ray	2.95	A	p45983	427		12..357
3vul	pdb	Crystal structure of a cysteine-deficient mutant M1 in MAP kinase JNK1	x-ray	2.81	A	p45983	427		12..357
3vum	pdb	Crystal structure of a cysteine-deficient mutant M7 in MAP kinase JNK1	x-ray	2.69	A	p45983	427		12..357
3vut	pdb	Crystal structures of non-phosphorylated MAP2K4	x-ray	3.5	A;B	p45985;p45985	399;399	;	93..384;93..384
3vvh	pdb	X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in complex with an inhibitor and MgATP	x-ray	2	A;B;C	q02750;q02750;q02750	393;393;393	;;	63..365;63..365;63..365
3vw6	pdb	Crystal structure of human apoptosis signal-regulating kinase 1 (ASK1) with imidazopyridine inhibitor	x-ray	2.4	A;B	q99683;q99683	1374;1374	;	685..939;685..939
3vw8	pdb	Crystal structure of human c-Met kinase domain with its inhibitor	x-ray	2.1	A	p08581	1390		1079..1341
3w0m	pdb	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia, apo form	x-ray	1.9	A	p00557	341		12..270
3w0n	pdb	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia, ternary complex with AMP-PNP and hygromycin B	x-ray	1.9	A	p00557	341		12..270
3w0o	pdb	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia, ternary complex with ADP and hygromycin B	x-ray	1.5	A	p00557	341		12..270
3w0p	pdb	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia (D198A), ternary complex with ADP and hygromycin B	x-ray	2	A	p00557	341		12..270
3w0q	pdb	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia (N203A), ternary complex with AMP-PNP and hygromycin B	x-ray	1.8	A	p00557	341		12..270
3w0r	pdb	Crystal structure of a thermostable mutant of aminoglycoside phosphotransferase APH(4)-Ia (N202A), ternary complex with AMP-PNP and hygromycin B	x-ray	2.3	A	p00557	341		12..270
3w0s	pdb	Crystal structure of aminoglycoside phosphotransferase APH(4)-Ia, ternary complex with AMP-PNP and hygromycin B	x-ray	1.77	A	p00557	341		12..270
3w10	pdb	Aurora kinase A complexed to pyrazole aminoquinoline I	x-ray	2.7	A	o14965	403		120..386
3w16	pdb	Structure of Aurora kinase A complexed to pyrazole-aminoquinoline inhibitor III	x-ray	2.8	A	o14965	403		120..386
3w18	pdb	Structure of Aurora kinase A complexed to benzoimidazole-indazole inhibitor XIII	x-ray	2.5	A;B	o14965;o14965	403;403	;	120..386;120..386
3w1f	pdb	Crystal structure of Human MPS1 catalytic domain in complex with 5-(5-ethoxy-6-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-2-methylbenzenesulfonamide	x-ray	2.7	A	p33981	857		516..792
3w2c	pdb	Structure of Aurora kinase A complexed to benzoimidazole-indazole inhibitor XV	x-ray	2.45	A;C;E;G	o14965;o14965;o14965;o14965	403;403;403;403	;;;	120..386;120..386;120..386;120..386
3w2o	pdb	EGFR Kinase domain T790M/L858R Mutant with TAK-285	x-ray	2.35	A	p00533	1210		708..1003
3w2p	pdb	EGFR Kinase domain T790M/L858R mutant with compound 2	x-ray	2.05	A	p00533	1210		708..1003
3w2q	pdb	EGFR kinase domain T790M/L858R mutant with HKI-272	x-ray	2.2	A	p00533	1210		708..1003
3w2r	pdb	EGFR Kinase domain T790M/L858R mutant with compound 4	x-ray	2.05	A	p00533	1210		708..1003
3w2s	pdb	EGFR kinase domain with compound4	x-ray	1.9	A	p00533	1210		708..1003
3w32	pdb	EGFR kinase domain complexed with compound 20a	x-ray	1.8	A	p00533	1210		708..1003
3w33	pdb	EGFR kinase domain complexed with compound 19b	x-ray	1.7	A	p00533	1210		708..1003
3w55	pdb	The structure of ERK2 in complex with FR148083	x-ray	3	A	p28482	360		19..322
3w8l	pdb	Crystal structure of human CK2 in complex with inositol hexakisphosphate	x-ray	2.4	A;B	p68400;p68400	391;391	;	5..328;5..328
3w8q	pdb	Structure of the Human Mitogen-Activated Protein Kinase Kinase 1 (MEK1)	x-ray	2.2	A	q02750	393		63..365
3war	pdb	Crystal structure of human CK2a	x-ray	1.04	A	p68400	391		5..328
3wbl	pdb	Crystal structure of CDK2 in complex with pyrazolopyrimidine inhibitor	x-ray	2	A	p24941	298		1..292
3we4	pdb	Crystal structure of S6K1 kinase domain in complex with a pyrimidine derivative PF-4708671 2-{[4-(5-ethylpyrimidin-4-yl)piperazin-1-yl]methyl}-5-(trifluoromethyl)-1H-benzimidazole	x-ray	1.995	A	p23443	525		86..409
3we8	pdb	Pim-1 kinase in complex with Ruthenium-based inhibitor	x-ray	1.954	A	p11309	313		36..296
3wf5	pdb	Crystal structure of S6K1 kinase domain in complex with a pyrazolopyrimidine derivative 4-[4-(1H-benzimidazol-2-yl)piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	x-ray	2.099	A	p23443	525		86..409
3wf6	pdb	Crystal structure of S6K1 kinase domain in complex with a pyrazolopyrimidine derivative 4-[4-(1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-1H-pyrazolo[3,4-d]pyrimidine	x-ray	2.031	A	p23443	525		86..409
3wf7	pdb	Crystal structure of S6K1 kinase domain in complex with a purine derivative 1-(9H-purin-6-yl)-N-[3-(trifluoromethyl)phenyl]piperidine-4-carboxamide	x-ray	1.85	A	p23443	525		86..409
3wf8	pdb	Crystal structure of S6K1 kinase domain in complex with a quinoline derivative 2-oxo-2-[(4-sulfamoylphenyl)amino]ethyl 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinoline-11-carboxylate	x-ray	1.975	A	p23443	525		86..409
3wf9	pdb	Crystal structure of S6K1 kinase domain in complex with a quinoline derivative 1-oxo-1-[(4-sulfamoylphenyl)amino]propan-2-yl-2-methyl-1,2,3,4-tetrahydroacridine-9-carboxylate	x-ray	2.035	A	p23443	525		86..409
3wi6	pdb	Crystal structure of MAPKAP Kinase-2 (MK2) in complex with non-selective inhibitor	x-ray	2.99	A;B;C;D;E;F	p49137;p49137;p49137;p49137;p49137;p49137	400;400;400;400;400;400	;;;;;	59..369;59..369;59..369;59..369;59..369;59..369
3wig	pdb	Human MEK1 kinase in complex with CH5126766 and MgAMP-PNP	x-ray	2.7	A	q02750	393		63..365
3wik	pdb	Crystal structure of the CK2alpha/compound10 complex	x-ray	1.995	A	p68400	391		5..328
3wil	pdb	Crystal structure of the CK2alpha/compound3 complex	x-ray	2.9	A	p68400	391		5..328
3wow	pdb	Crystal structure of human CK2a with AMPPNP	x-ray	2.5	A	p68400	391		5..328
3wyx	pdb	CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6-((3-(cyanomethoxy)-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-2-(cyclohexylamino)nicotinonitrile	x-ray	2.9	A	p33981	857		516..792
3wyy	pdb	CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)-3-(4-((6-(((3s,5s,7s)-adamantan-1-yl)amino)-4-amino-5-cyanopyridin-2-yl)amino)-2-(cyanomethoxy)phenyl)-N-(2-methoxyethyl)acrylamide	x-ray	3.05	A	p33981	857		516..792
3wzd	pdb	KDR in complex with ligand lenvatinib	x-ray	1.57	A	p35968	1356		815..1160
3wze	pdb	KDR in complex with ligand sorafenib	x-ray	1.9	A	p35968	1356		815..1160
3wzj	pdb	CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6-(cyclohexylamino)-8-(((tetrahydro-2H-pyran-4-yl)methyl)amino)imidazo[1,2-b]pyridazin-3-yl)-N-cyclopropylbenzamide	x-ray	2.75	A	p33981	857		516..792
3wzk	pdb	CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N-cyclopropyl-4-(8-((thiophen-2-ylmethyl)amino)imidazo[1,2-a]pyrazin-3-yl)benzamide	x-ray	2.3	A	p33981	857		516..792
3wzu	pdb	THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-oxozeaenol	x-ray	3.01	A	o14733	419		113..384
3x2u	pdb	Michaelis-like initial complex of cAMP-dependent Protein Kinase Catalytic Subunit.	x-ray	2.4	A	p05132	351		28..339
3x2v	pdb	Michaelis-like complex of cAMP-dependent Protein Kinase Catalytic Subunit	x-ray	1.77	A	p05132	351		28..339
3x2w	pdb	Michaelis complex of cAMP-dependent Protein Kinase Catalytic Subunit	x-ray	1.7	A	p05132	351		28..339
3zbf	pdb	Structure of Human ROS1 Kinase Domain in Complex with Crizotinib	x-ray	2.2	A	p08922	2347		1935..2215
3zbx	pdb	X-ray Structure of c-Met kinase in complex with inhibitor 6-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,3-b)(1,2,4)triazin-3-yl)methyl) quinoline.	x-ray	2.2	A	p08581	1390		1079..1341
3zc5	pdb	X-ray Structure of c-Met kinase in complex with inhibitor (S)-6-(1-(6- (1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)ethyl) quinoline.	x-ray	2.2	A	p08581	1390		1079..1341
3zc6	pdb	Crystal structure of JAK3 kinase domain in complex with an indazole substituted pyrrolopyrazine inhibitor	x-ray	2.42	A;B;C;D	p52333;p52333;p52333;p52333	1124;1124;1124;1124	;;;	508..788,820..1097;508..788,820..1097;508..788,820..1097;508..788,820..1097
3zcl	pdb	X-ray Structure of c-Met kinase in complex with inhibitor (S)-3-(1-(1H-pyrrolo(2,3-b)pyridin-3-yl)ethyl)-N-isopropyl-(1,2,4)triazolo(4,3- b)pyridazin-6-amine	x-ray	1.4	A	p08581	1390		1079..1341
3zdi	pdb	Glycogen Synthase Kinase 3 Beta complexed with Axin Peptide and Inhibitor 7d	x-ray	2.645	A	p49841	420		55..377
3zdu	pdb	Crystal structure of the human CDKL3 kinase domain	x-ray	2.2	A	q8ivw4	592		2..288
3zep	pdb	Crystal Structure of JAK3 Kinase Domain in Complex with a Pyrrolopyrazine-2-phenyl Ether Inhibitor	x-ray	2.35	A;B;C;D	p52333;p52333;p52333;p52333	1124;1124;1124;1124	;;;	508..788,820..1097;508..788,820..1097;508..788,820..1097;508..788,820..1097
3zew	pdb	Crystal structure of EphB4 in complex with staurosporine	x-ray	2.5	A;B	p54760;p54760	987;987	;	609..886;609..886
3zfm	pdb	Crystal structure of EphB2	x-ray	2.27	A	p29323	1055		613..914
3zfx	pdb	Crystal structure of EphB1	x-ray	2.5	A;B;C;D;E;F;G;H;I	p54762;p54762;p54762;p54762;p54762;p54762;p54762;p54762;p54762	984;984;984;984;984;984;984;984;984	;;;;;;;;	614..915;614..915;614..915;614..915;614..915;614..915;614..915;614..915;614..915
3zfy	pdb	Crystal structure of EphB3	x-ray	2.2	A;B	p54753;p54753	998;998	;	626..925;626..925
3zh8	pdb	A novel small molecule aPKC inhibitor	x-ray	2.739	A;B;C	p41743;p41743;p41743	596;596;596	;;	252..578;252..578;252..578
3zhp	pdb	Human MST3 (STK24) in complex with MO25beta	x-ray	2.9	C;D	q9y6e0;q9y6e0	443;443	;	36..320;36..320
3zim	pdb	Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kalpha	x-ray	2.85	A	p42336	1068		699..1060
3zls	pdb	Crystal structure of MEK1 in complex with fragment 6	x-ray	2.5	A	q02750	393		63..365
3zlw	pdb	Crystal structure of MEK1 in complex with fragment 3	x-ray	2.12	A	q02750	393		63..365
3zlx	pdb	Crystal structure of MEK1 in complex with fragment 18	x-ray	2.2	A	q02750	393		63..365
3zly	pdb	Crystal structure of MEK1 in complex with fragment 8	x-ray	2.11	A	q02750	393		63..365
3zm4	pdb	Crystal structure of MEK1 in complex with fragment 1	x-ray	2.37	A	q02750	393		63..365
3zm9	pdb	The mechanism of allosteric coupling in choline kinase a1 revealed by a rationally designed inhibitor	x-ray	1.9	A;B	p35790;p35790	457;457	;	82..455;82..455
3zmm	pdb	Inhibitors of Jak2 Kinase domain	x-ray	2.51	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
3zo1	pdb	The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors	x-ray	2	A	p00517	351		32..339
3zo2	pdb	The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors	x-ray	1.98	A	p00517	351		32..339
3zo3	pdb	The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors	x-ray	2.1	A	p00517	351		32..339
3zo4	pdb	The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors	x-ray	1.65	A	p00517	351		32..339
3zon	pdb	Human TYK2 pseudokinase domain bound to a kinase inhibitor	x-ray	2.15	A	p29597	1187		576..879,887..1166
3zos	pdb	Structure of the DDR1 kinase domain in complex with ponatinib	x-ray	1.92	A;B	q08345;q08345	913;913	;	603..904;603..904
3zrk	pdb	Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors	x-ray	2.37	A;B	p49841;p49841	420;420	;	55..377;55..377
3zrl	pdb	Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors	x-ray	2.48	A;B	p49841;p49841	420;420	;	55..377;55..377
3zrm	pdb	Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors	x-ray	2.49	A;B	p49841;p49841	420;420	;	55..377;55..377
3zs5	pdb	Structural basis for kinase selectivity of three clinical p38alpha inhibitors	x-ray	1.6	A	q16539	360		9..349
3zsg	pdb	X-ray structure of p38alpha bound to TAK-715	x-ray	1.89	A	q16539	360		9..349
3zsh	pdb	X-ray structure of p38alpha bound to SCIO-469	x-ray	2.05	A	q16539	360		9..349
3zsi	pdb	X-ray structure of p38alpha bound to VX-745	x-ray	2.4	A	q16539	360		9..349
3ztx	pdb	Aurora kinase selective inhibitors identified using a Taxol-induced checkpoint sensitivity screen.	x-ray	1.95	A;B	q6de08;q6de08	361;361	;	71..354;71..354
3zu7	pdb	Crystal structure of a designed selected Ankyrin Repeat protein in complex with the MAP kinase ERK2	x-ray	1.97	A				
3zut	pdb	The structure of OST1 (D160A) kinase	x-ray	2.5	A;B	q940h6;q940h6	362;362	;	13..304;13..304
3zuu	pdb	The structure of OST1 (D160A, S175D) kinase in complex with gold	x-ray	2.7	A;B	q940h6;q940h6	362;362	;	13..304;13..304
3zuv	pdb	Crystal structure of a designed selected Ankyrin Repeat protein in complex with the phosphorylated MAP kinase ERK2	x-ray	2.72	A;C	;	;	;	;
3zvv	pdb	Fragment Bound to PI3Kinase gamma	x-ray	2.5	A	p48736	1102		728..1089
3zw3	pdb	Fragment based discovery of a novel and selective PI3 Kinase inhibitor	x-ray	2.8	A	p48736	1102		728..1089
3zxt	pdb	Dimeric structure of DAPK-1 catalytic domain in complex with AMPPCP- Mg	x-ray	2.65	A;B;C;D	p53355;p53355;p53355;p53355	1430;1430;1430;1430	;;;	6..291;6..291;6..291;6..291
3zxz	pdb	X-ray Structure of PF-04217903 bound to the kinase domain of c-Met	x-ray	1.8	A	p08581	1390		1079..1341
3zya	pdb	Human p38 MAP Kinase in Complex with 2-amino-phenylamino- dibenzosuberone	x-ray	1.9	A	q16539	360		9..349
3zze	pdb	Crystal structure of C-MET kinase domain in complex with N'-((3Z)-4- chloro-7-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2-(4- hydroxyphenyl)propanohydrazide	x-ray	1.87	A	p08581	1390		1079..1341
3zzw	pdb	Crystal structure of the kinase domain of ROR2	x-ray	2.9	A;B	q01974;q01974	943;943	;	443..745;443..745
4a06	pdb	Human PDK1 Kinase Domain in Complex with Allosteric Activator PS114 Bound to the PIF-Pocket	x-ray	2	A	o15530	556		79..400
4a07	pdb	Human PDK1 Kinase Domain in Complex with Allosteric Activator PS171 Bound to the PIF-Pocket	x-ray	1.85	A	o15530	556		79..400
4a4l	pdb	CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO- PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR	x-ray	2.35	A	p53350	603		51..338
4a4o	pdb	CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2-(2-AMINO- PYRIMIDIN-4-YL)-1,5,6,7-TETRAHYDRO-PYRROLOPYRIDIN-4-ONE INHIBITOR	x-ray	2.7	A	p53350	603		51..338
4a4x	pdb	NEK2-EDE bound to CCT248662	x-ray	2.4	A	p51955	445		5..280
4a55	pdb	Crystal structure of p110alpha in complex with iSH2 of p85alpha and the inhibitor PIK-108	x-ray	3.5	A	p42337	1068		699..1060
4a7c	pdb	Crystal structure of PIM1 kinase with ETP46546	x-ray	2.3	A	p11309	313		36..296
4a9r	pdb	CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR	x-ray	2.85	A	o96017	543		213..500
4a9s	pdb	CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR	x-ray	2.66	A	o96017	543		213..500
4a9t	pdb	CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR	x-ray	2.7	A	o96017	543		213..500
4a9u	pdb	CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR	x-ray	2.48	A	o96017	543		213..500
4a9y	pdb	P38ALPHA MAP KINASE BOUND TO CMPD 8	x-ray	2.2	A	q16539	360		9..349
4aa0	pdb	P38ALPHA MAP KINASE BOUND TO CMPD 2	x-ray	1.8	A	q16539	360		9..349
4aa4	pdb	P38ALPHA MAP KINASE BOUND TO CMPD 22	x-ray	2.3	A	q16539	360		9..349
4aa5	pdb	P38ALPHA MAP KINASE BOUND TO CMPD 33	x-ray	2.38	A	q16539	360		9..349
4aaa	pdb	Crystal structure of the human CDKL2 kinase domain	x-ray	1.53	A	q92772	493		1..288
4aac	pdb	P38ALPHA MAP KINASE BOUND TO CMPD 29	x-ray	2.5	A	q16539	360		9..349
4acc	pdb	GSK3b in complex with inhibitor	x-ray	2.21	A;B	p49841;p49841	420;420	;	55..377;55..377
4acd	pdb	GSK3b in complex with inhibitor	x-ray	2.6	A;B	p49841;p49841	420;420	;	55..377;55..377
4acg	pdb	GSK3b in complex with inhibitor	x-ray	2.6	A;B	p49841;p49841	420;420	;	55..377;55..377
4ach	pdb	GSK3b in complex with inhibitor	x-ray	2.6	A;B	p49841;p49841	420;420	;	55..377;55..377
4acm	pdb	CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE	x-ray	1.63	A	p24941	298		1..292
4ae6	pdb	Structure and Function of the Human Sperm-Specific Isoform of Protein Kinase A (PKA) Catalytic Subunit Calpha 2	x-ray	2.1	A;B	p17612;p17612	351;351	;	30..339;30..339
4ae9	pdb	Structure and function of the Human Sperm-Specific Isoform of Protein Kinase A (PKA) Catalytic Subunit C alpha 2	x-ray	2.3	A;B	p17612;p17612	351;351	;	30..339;30..339
4af3	pdb	Human Aurora B Kinase in complex with INCENP and VX-680	x-ray	2.75	A	q96gd4	344		57..337
4afe	pdb	Nek2 bound to hybrid compound 21	x-ray	2.597	A	p51955	445		5..280
4afj	pdb	5-aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors	x-ray	1.98	A;B	p49841;p49841	420;420	;	55..377;55..377
4ag8	pdb	CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-Methyl-2-(3-((E)-2-pyridin-2-yl-vinyl)-1H- indazol-6-ylsulfanyl)-benzamide)	x-ray	1.95	A	p35968	1356		815..1160
4agc	pdb	CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-Methyl-2-(3-((E)-2-pyridin-2-yl- vinyl)-1H-indazol-6-ylsulfanyl)-benzamide)	x-ray	2	A	p35968	1356		815..1160
4agd	pdb	CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2-diethylaminoethyl)-5-((Z)-(5- fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3- carboxamide)	x-ray	2.81	A	p35968	1356		815..1160
4agu	pdb	CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN	x-ray	2.4	A;B;C	q00532;q00532;q00532	357;357;357	;;	1..291;1..291;1..291
4agw	pdb	Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases	x-ray	2.6	A;B	p00523;p00523	533;533	;	256..526;256..526
4ajw	pdb	Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3KBeta Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers	x-ray	2.8	A;B	o35904;o35904	1043;1043	;	677..1032;677..1032
4alu	pdb	Benzofuropyrimidinone Inhibitors of Pim-1	x-ray	2.6	A	p11309	313		36..296
4alv	pdb	Benzofuropyrimidinone Inhibitors of Pim-1	x-ray	2.59	A	p11309	313		36..296
4alw	pdb	Benzofuropyrimidinone Inhibitors of Pim-1	x-ray	1.92	A	p11309	313		36..296
4an2	pdb	Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs.	x-ray	2.5	A	q02750	393		63..365
4an3	pdb	Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs.	x-ray	2.1	A	q02750	393		63..365
4an9	pdb	Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs.	x-ray	2.8	A	q02750	393		63..365
4anb	pdb	Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs.	x-ray	2.2	A	q02750	393		63..365
4anl	pdb	Structure of G1269A Mutant Anaplastic Lymphoma Kinase	x-ray	1.7	A	q9um73	1620		1089..1381
4anm	pdb	Complex of CK2 with a CDC7 inhibitor	x-ray	1.7	A	p28523	332		11..323
4anq	pdb	Structure of G1269A Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib	x-ray	1.76	A	q9um73	1620		1089..1381
4ans	pdb	Structure of L1196M,G1269A Double Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib	x-ray	1.85	A	q9um73	1620		1089..1381
4anu	pdb	Complexes of PI3Kgamma with isoform selective inhibitors.	x-ray	2.81	A	p48736	1102		728..1089
4anv	pdb	Complexes of PI3Kgamma with isoform selective inhibitors.	x-ray	2.13	A	p48736	1102		728..1089
4anw	pdb	Complexes of PI3Kgamma with isoform selective inhibitors.	x-ray	2.31	A	p48736	1102		728..1089
4anx	pdb	Complexes of PI3Kgamma with isoform selective inhibitors.	x-ray	2.73	A	p48736	1102		728..1089
4aof	pdb	Selective small molecule inhibitor discovered by chemoproteomic assay platform reveals regulation of Th17 cell differentiation by PI3Kgamma	x-ray	3.3	A	p48736	1102		728..1089
4aoi	pdb	Crystal structure of C-MET kinase domain in complex with 4-(3-((1H- pyrrolo(2,3-b)pyridin-3-yl)methyl)-(1,2,4)triazolo(4,3-b)(1,2,4) triazin-6-yl)benzonitrile	x-ray	1.9	A	p08581	1390		1079..1341
4aoj	pdb	Human TrkA in complex with the inhibitor AZ-23	x-ray	2.75	A;B;C	p04629;p04629;p04629	796;796;796	;;	494..779;494..779;494..779
4aot	pdb	Crystal Structure of Human Serine Threonine Kinase-10 (LOK) Bound to GW830263A	x-ray	2.33	A;B	o94804;o94804	968;968	;	31..302;31..302
4ap7	pdb	Crystal structure of C-MET kinase domain in complex with 4-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,3-b)(1,2,4)triazin-3-yl)methyl)phenol	x-ray	1.8	A	p08581	1390		1079..1341
4apc	pdb	Crystal Structure of Human NIMA-related Kinase 1 (NEK1)	x-ray	2.1	A;B	q96py6;q96py6	1258;1258	;	1..286;1..286
4app	pdb	Crystal Structure of the Human p21-Activated Kinase 4 in Complex with (S)-N-(5-(3-benzyl-1-methylpiperazine-4-carbonyl)-6,6-dimethyl-1,4,5, 6-tetrahydropyrrolo(3,4-c)pyrazol-3-yl)-3-phenoxybenzamide	x-ray	2.2	A	o96013	591		323..578
4aqc	pdb	Triazolopyridine-based Inhibitor of Janus Kinase 2	x-ray	1.9	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
4ark	pdb	CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH A SMALL MOLECULE INHIBITOR AND ADP	x-ray	2.6	A	q02750	393		63..365
4as0	pdb	Cyclometalated Phthalimides as Protein Kinase Inhibitors	x-ray	2.3	A	p11309	313		36..296
4asd	pdb	Crystal Structure of VEGFR2 (Juxtamembrane and Kinase Domains) in Complex with SORAFENIB (BAY 43-9006)	x-ray	2.03	A	p35968	1356		815..1160
4ase	pdb	CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)	x-ray	1.83	A	p35968	1356		815..1160
4asx	pdb	Crystal structure of Activin receptor type-IIA (ACVR2A) kinase domain in complex with dihydro-Bauerine C	x-ray	2.05	A;B	p27037;p27037	513;513	;	180..476;180..476
4asz	pdb	Crystal structure of apo TrkB kinase domain	x-ray	1.7	A	q16620	822		517..805
4at3	pdb	CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N	x-ray	1.77	A	q16620	822		517..805
4at4	pdb	CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429	x-ray	2.36	A	q16620	822		517..805
4at5	pdb	CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580	x-ray	1.71	A	q16620	822		517..805
4au8	pdb	Crystal structure of compound 4a in complex with cdk5, showing an unusual binding mode to the hinge region via a water molecule	x-ray	1.9	A;B	q00535;q00535	292;292	;	1..290;1..290
4aua	pdb	Liganded X-ray crystal structure of cyclin dependent kinase 6 (CDK6)	x-ray	2.31	A	q00534	326		9..303
4aw0	pdb	Human PDK1 Kinase Domain in Complex with Allosteric Compound PS182 Bound to the PIF-Pocket	x-ray	1.43	A	o15530	556		79..400
4aw1	pdb	Human PDK1 Kinase Domain in Complex with Allosteric Compound PS210 Bound to the PIF-Pocket	x-ray	1.68	A	o15530	556		79..400
4aw2	pdb	Crystal structure of CDC42 binding protein kinase alpha (MRCK alpha)	x-ray	1.7	A	o54874	1732		74..407
4aw5	pdb	Complex of the EphB4 kinase domain with an oxindole inhibitor	x-ray	2.33	A	p54760	987		609..886
4awi	pdb	Human Jnk1alpha kinase with 4-phenyl-7-azaindole IKK2 inhibitor.	x-ray	1.91	A	p45983	427		12..357
4ax8	pdb	Medium resolution structure of the bifunctional kinase- methyltransferase WbdD	x-ray	3	A	j7i4b7	708		232..428
4axa	pdb	Structure of PKA-PKB chimera complexed with (1S)-2-amino-1-(4- chlorophenyl)-1-(4-(1H-pyrazol-4-yl)phenyl)ethan-1-ol	x-ray	1.9	A	p00517	351		32..339
4aze	pdb	Human DYRK1A in complex with Leucettine L41	x-ray	3.15	A;B;C	;;	;;	;;	;;
4azf	pdb	Human DYRK2 in complex with Leucettine L41	x-ray	2.55	A	q92630	601		212..543
4azs	pdb	High resolution (2.2 A) crystal structure of WbdD.	x-ray	2.15	A	q47592	708		232..428
4azt	pdb	Co-crystal structure of WbdD and kinase inhibitor LY294002.	x-ray	2.34	A	q47592	708		232..428
4azv	pdb	Co-crystal structure of WbdD and kinase inhibitor GW435821x.	x-ray	3.291	A	q47592	708		232..428
4azw	pdb	Crystal structure of monomeric WbdD.	x-ray	2.47	A	q47592	708		232..428
4b0g	pdb	Complex of Aurora-A bound to an Imidazopyridine-based inhibitor	x-ray	2.5	A	o14965	403		120..386
4b4l	pdb	CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT	x-ray	1.75	A	p53355	1430		6..291
4b6l	pdb	Discovery of Oral Polo-Like Kinase (PLK) Inhibitors with Enhanced Selectivity Profile using Residue Targeted Drug Design	x-ray	1.9	A	q9h4b4	646		61..354
4b7t	pdb	Glycogen Synthase Kinase 3 Beta complexed with Axin Peptide and Leucettine L4	x-ray	2.772	A	p49841	420		55..377
4b8l	pdb	Aurora B kinase P353G mutant	x-ray	3	A	q6de08	361		71..354
4b8m	pdb	Aurora B kinase in complex with VX-680	x-ray	1.85	A;B	q6de08;q6de08	361;361	;	71..354;71..354
4b99	pdb	Crystal Structure of MAPK7 (ERK5) with inhibitor	x-ray	2.8	A	q13164	816		48..356
4b9d	pdb	Crystal Structure of Human NIMA-related Kinase 1 (NEK1) with inhibitor.	x-ray	1.9	A;B	q96py6;q96py6	1258;1258	;	1..286;1..286
4bb4	pdb	ephB4 kinase domain inhibitor complex	x-ray	1.65	A	p54760	987		609..886
4bbe	pdb	Aminoalkylpyrimidine Inhibitor Complexes with JAK2	x-ray	1.9	A;B;C;D	o60674;o60674;o60674;o60674	1132;1132;1132;1132	;;;	522..814,842..1119;522..814,842..1119;522..814,842..1119;522..814,842..1119
4bbf	pdb	Aminoalkylpyrimidine Inhibitor Complexes with JAK2	x-ray	2	A;B;C;D	o60674;o60674;o60674;o60674	1132;1132;1132;1132	;;;	522..814,842..1119;522..814,842..1119;522..814,842..1119;522..814,842..1119
4bbm	pdb	CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312	x-ray	2	A;B	q92772;q92772	493;493	;	1..288;1..288
4bc6	pdb	Crystal structure of human serine threonine kinase-10 bound to novel Bosutinib Isoform 1, previously thought to be Bosutinib	x-ray	2.2	A	o94804	968		31..302
4bcf	pdb	Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor	x-ray	3.011	A	p50750	372		12..321
4bcg	pdb	Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor	x-ray	3.085	A	p50750	372		12..321
4bch	pdb	Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor	x-ray	2.958	A	p50750	372		12..321
4bci	pdb	Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor	x-ray	3.1	A	p50750	372		12..321
4bcj	pdb	Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor	x-ray	3.162	A	p50750	372		12..321
4bck	pdb	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor	x-ray	2.052	A;C	p24941;p24941	298;298	;	1..292;1..292
4bcm	pdb	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor	x-ray	2.45	A;C	p24941;p24941	298;298	;	1..292;1..292
4bcn	pdb	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor	x-ray	2.1	A;C	p24941;p24941	298;298	;	1..292;1..292
4bco	pdb	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor	x-ray	2.05	A;C	p24941;p24941	298;298	;	1..292;1..292
4bcp	pdb	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor	x-ray	2.26	A;C	p24941;p24941	298;298	;	1..292;1..292
4bcq	pdb	Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor	x-ray	2.4	A;C	p24941;p24941	298;298	;	1..292;1..292
4bda	pdb	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)	x-ray	2.6	A	o96017	543		213..500
4bdb	pdb	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)	x-ray	2.5	A	o96017	543		213..500
4bdc	pdb	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)	x-ray	3	A	o96017	543		213..500
4bdd	pdb	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)	x-ray	2.67	A	o96017	543		213..500
4bde	pdb	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)	x-ray	2.55	A	o96017	543		213..500
4bdf	pdb	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)	x-ray	2.7	A	o96017	543		213..500
4bdg	pdb	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)	x-ray	2.84	A	o96017	543		213..500
4bdh	pdb	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)	x-ray	2.7	A	o96017	543		213..500
4bdi	pdb	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)	x-ray	2.32	A	o96017	543		213..500
4bdj	pdb	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)	x-ray	3.01	A	o96017	543		213..500
4bdk	pdb	Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)	x-ray	3.3	A	o96017	543		213..500
4bf2	pdb	Crystal Structures of Ask1-inhibitor Complexes	x-ray	2.11	A;B	q99683;q99683	1374;1374	;	685..939;685..939
4bfm	pdb	The crystal structure of mouse PK38	x-ray	2.35	A	q61846	643		8..311
4bfr	pdb	Discovery and Optimization of Pyrimidone Indoline Amide PI3Kbeta Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers	x-ray	2.8	A;B	q8bti9;q8bti9	1064;1064	;	700..1054;700..1054
4bgg	pdb	Crystal structure of the ACVR1 kinase in complex with LDN-213844	x-ray	2.56	A;B;C;D	q04771;q04771;q04771;q04771	509;509;509;509	;;;	186..496;186..496;186..496;186..496
4bgh	pdb	Crystal Structure of CDK2 in complex with pan-CDK Inhibitor	x-ray	1.95	A	p24941	298		1..292
4bgq	pdb	Crystal structure of the human CDKL5 kinase domain	x-ray	2	A	o76039	960		8..301
4bhn	pdb	Crystal Structures of Ask1-inhibitor Complexes	x-ray	2.3	A;B	q99683;q99683	1374;1374	;	685..939;685..939
4bhz	pdb	Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor	x-ray	2.85	A	p33981	857		516..792
4bi0	pdb	Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor	x-ray	2.84	A	p33981	857		516..792
4bi1	pdb	Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor	x-ray	2.7	A	p33981	857		516..792
4bi2	pdb	Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor	x-ray	3.11	A	p33981	857		516..792
4bib	pdb	Crystal Structures of Ask1-inhibitor Complexes	x-ray	2.43	A;B	q99683;q99683	1374;1374	;	685..939;685..939
4bic	pdb	Crystal Structures of Ask1-inhibitor Complexes	x-ray	2.62	A;B	q99683;q99683	1374;1374	;	685..939;685..939
4bid	pdb	Crystal Structures of Ask1-inhibitor Complexes	x-ray	2.8	A;B	q99683;q99683	1374;1374	;	685..939;685..939
4bie	pdb	Crystal Structures of Ask1-inhibitor Complexes	x-ray	2.36	A;B	q99683;q99683	1374;1374	;	685..939;685..939
4bkj	pdb	Crystal structure of the human DDR1 kinase domain in complex with imatinib	x-ray	1.7	A;B	q08345;q08345	913;913	;	603..904;603..904
4bky	pdb	Crystal structure of unphosphorylated Maternal Embryonic Leucine zipper Kinase (MELK) in complex with pyrrolopyrazole inhibitor	x-ray	1.83	A	q14680	651		8..308
4bkz	pdb	Crystal structure of unphosphorylated Maternal Embryonic Leucine zipper Kinase (MELK) in complex with a benzodipyrazole inhibitor	x-ray	2.2	A	q14680	651		8..308
4bl1	pdb	Crystal structure of unphosphorylated Maternal Embryonic Leucine zipper Kinase (MELK) in complex with AMP-PNP	x-ray	2.6	A	q14680	651		8..308
4bn1	pdb	Crystal structure of V174M mutant of Aurora-A kinase	x-ray	2.499	A	o14965	403		120..386
4br3	pdb	Determination of potential scaffolds for human choline kinase alpha 1 by chemical deconvolution studies	x-ray	2.2	A;B	p35790;p35790	457;457	;	82..455;82..455
4brx	pdb	Focal Adhesion Kinase catalytic domain in complex with a diarylamino- 1,3,5-triazine inhibitor	x-ray	2.05	A	q00944	1053		409..698
4btf	pdb	Structure of MLKL	x-ray	2.604	A	q9d2y4	472		197..447
4btj	pdb	TTBK1 in complex with ATP	x-ray	2.16	A;B	q5tcy1;q5tcy1	1321;1321	;	30..311;30..311
4btk	pdb	TTBK1 in complex with inhibitor	x-ray	2	A	q5tcy1	1321		30..311
4btm	pdb	TTBK1 in complex with inhibitor	x-ray	2.54	A;B	q5tcy1;q5tcy1	1321;1321	;	30..311;30..311
4bvu	pdb	Structure of Shigella effector OspG in complex with host UbcH5c- Ubiquitin conjugate	x-ray	2.7	A	q99pz6	196		29..161
4bwk	pdb	Structure of Neurospora crassa PAN3 pseudokinase	x-ray	3.3	A;B	q7sdp4;q7sdp4	656;656	;	283..466;283..466
4bwp	pdb	Structure of Drosophila Melanogaster PAN3 pseudokinase	x-ray	3.6	A;B	q95rr8;q95rr8	790;790	;	407..642;407..642
4bwx	pdb	Structure of Neurospora crassa PAN3 pseudokinase mutant	x-ray	2.85	A;B	q7sdp4;q7sdp4	656;656	;	283..466;283..466
4byi	pdb	Aurora A kinase bound to a highly selective imidazopyridine inhibitor	x-ray	2.6	A	o14965	403		120..386
4byj	pdb	Aurora A kinase bound to a highly selective imidazopyridine inhibitor	x-ray	2.75	A	o14965	403		120..386
4bzd	pdb	Structure of CDK2 in complex with a benzimidazopyrimidine	x-ray	1.83	A	p24941	298		1..292
4bzn	pdb	Crystal structure of PIM1 in complex with a Pyrrolo(1,2-a)Pyrazinone inhibitor	x-ray	1.9	A	p11309	313		36..296
4bzo	pdb	Crystal structure of PIM1 in complex with a Pyrrolo-Pyrazinone inhibitor	x-ray	2.1	A	p11309	313		36..296
4c02	pdb	Crystal structure of human ACVR1 (ALK2) in complex with FKBP12.6 and dorsomorphin	x-ray	2.17	A	q04771	509		186..496
4c0t	pdb	Candida albicans PKh Kinase Domain	x-ray	3.16	A	q5a3p6	947		238..581
4c2v	pdb	Aurora B kinase in complex with the specific inhibitor Barasertib	x-ray	1.49	A;B	q6de08;q6de08	361;361	;	71..354;71..354
4c2w	pdb	Crystal structure of Aurora B in complex with AMP-PNP	x-ray	1.7	A;B	q6de08;q6de08	361;361	;	71..354;71..354
4c33	pdb	PKA-S6K1 Chimera Apo	x-ray	1.7	A	p00517	351		32..339
4c34	pdb	PKA-S6K1 Chimera with Staurosporine bound	x-ray	1.78	A	p00517	351		32..339
4c35	pdb	PKA-S6K1 Chimera with compound 1 (NU1085) bound	x-ray	2.19	A	p00517	351		32..339
4c36	pdb	PKA-S6K1 Chimera with compound 15e (CCT147581) bound	x-ray	1.98	A	p00517	351		32..339
4c37	pdb	PKA-S6K1 Chimera with compound 21a (CCT196539) bound	x-ray	1.7	A	p00517	351		32..339
4c38	pdb	PKA-S6K1 Chimera with compound 21e (CCT239066) bound	x-ray	1.58	A	p00517	351		32..339
4c3f	pdb	Structure of Lck in complex with a compound discovered by Virtual Fragment Linking	x-ray	1.72	A	p06239	509		231..500
4c3p	pdb	Structure of dephosphorylated Aurora A (122-403) bound to TPX2 and AMPPCP	x-ray	2.69	A;D	o14965;o14965	403;403	;	120..386;120..386
4c3r	pdb	Structure of dephosphorylated Aurora A (122-403) bound to AMPPCP	x-ray	2.79	A	o14965	403		120..386
4c4e	pdb	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1	x-ray	2.6	A	p33981	857		516..792
4c4f	pdb	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1	x-ray	2.36	A	p33981	857		516..792
4c4g	pdb	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1	x-ray	2.65	A	p33981	857		516..792
4c4h	pdb	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1	x-ray	2.8	A	p33981	857		516..792
4c4i	pdb	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1	x-ray	2.65	A	p33981	857		516..792
4c4j	pdb	Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1	x-ray	2.5	A	p33981	857		516..792
4c57	pdb	Structure of GAK kinase in complex with a nanobody	x-ray	2.55	A;B	;	;	;	;
4c58	pdb	Structure of GAK kinase in complex with nanobody (NbGAK_4)	x-ray	2.16	A				
4c59	pdb	Structure of GAK kinase in complex with nanobody (NbGAK_4)	x-ray	2.8	A				
4c61	pdb	Inhibitors of Jak2 Kinase domain	x-ray	2.45	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
4c62	pdb	Inhibitors of Jak2 Kinase domain	x-ray	2.75	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
4c7t	pdb	Focal Adhesion Kinase catalytic domain in complex with a diarylamino- 1,3,5-triazine inhibitor	x-ray	2.05	A	q00944	1053		409..698
4c8b	pdb	Structure of the kinase domain of human RIPK2 in complex with ponatinib	x-ray	2.75	A;B	o43353;o43353	540;540	;	11..297;11..297
4ccb	pdb	Structure of the Human Anaplastic Lymphoma Kinase in Complex with 3-((R)-1-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)ethoxy)-5-(5-methyl-1H- pyrazol-4-yl)pyridin-2-amine	x-ray	2.03	A	q9um73	1620		1089..1381
4ccu	pdb	Structure of the Human Anaplastic Lymphoma Kinase in Complex with 2-(5-(6-amino-5-((R)-1-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)ethoxy) pyridin-3-yl)-4-methylthiazol-2-yl)propan-2-ol	x-ray	2	A	q9um73	1620		1089..1381
4cd0	pdb	Structure of L1196M Mutant Human Anaplastic Lymphoma Kinase in Complex with 2-(5-(6-amino-5-((R)-1-(5-fluoro-2-(2H-1,2,3-triazol-2- yl)phenyl)ethoxy)pyridin-3-yl)-4-methylthiazol-2-yl)propane-1,2-diol	x-ray	2.23	A	q9um73	1620		1089..1381
4ceg	pdb	Crystal structure of Aurora A 122-403 C290A, C393A bound to ADP	x-ray	2.1	A	o14965	403		120..386
4cfe	pdb	Structure of full length human AMPK in complex with a small molecule activator, a benzimidazole derivative (991)	x-ray	3.023	A;C	p54646;p54646	552;552	;	13..269;13..269
4cff	pdb	Structure of full length human AMPK in complex with a small molecule activator, a thienopyridone derivative (A-769662)	x-ray	3.924	A;C	p54646;p54646	552;552	;	13..269;13..269
4cfh	pdb	Structure of an active form of mammalian AMPK	x-ray	3.24	A	p54645	559		24..308
4cfm	pdb	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.	x-ray	2.85	A;C	p24941;p24941	298;298	;	1..292;1..292
4cfn	pdb	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.	x-ray	2.2	A;C	p24941;p24941	298;298	;	1..292;1..292
4cfu	pdb	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.	x-ray	2.2	A;C	p24941;p24941	298;298	;	1..292;1..292
4cfv	pdb	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.	x-ray	2	A;C	p24941;p24941	298;298	;	1..292;1..292
4cfw	pdb	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.	x-ray	2.45	A;C	p24941;p24941	298;298	;	1..292;1..292
4cfx	pdb	Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.	x-ray	3.5	A;C	p24941;p24941	298;298	;	1..292;1..292
4cg8	pdb	Human choline kinase a1 in complex with compound 14	x-ray	1.75	A	p35790	457		82..455
4cg9	pdb	Human choline kinase a1 in complex with compound 12	x-ray	1.83	A	p35790	457		82..455
4cga	pdb	Human choline kinase a1 in complex with compound 5	x-ray	1.74	A	p35790	457		82..455
4ci6	pdb	Mechanisms of crippling actin-dependent phagocytosis by YopO	x-ray	2.651	B	q93kq6	729		151..407
4cki	pdb	Crystal Structure of oncogenic RET tyrosine kinase M918T bound to adenosine	x-ray	2.116	A	p07949	1114		699..1005
4ckj	pdb	Crystal structure of RET tyrosine kinase domain bound to adenosine	x-ray	1.65	A	p07949	1114		699..1005
4ckr	pdb	Crystal structure of the human DDR1 kinase domain in complex with DDR1-IN-1	x-ray	2.2	A	q08345	913		603..904
4cli	pdb	Structure of the Human Anaplastic Lymphoma Kinase in Complex with PF- 06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16, 17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).	x-ray	2.05	A	q9um73	1620		1089..1381
4clj	pdb	Structure of L1196M Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).	x-ray	1.66	A	q9um73	1620		1089..1381
4cmo	pdb	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor 2-((1R)-1-((3-amino-6-(2-methoxypyridin-3-yl)pyrazin-2-yl) oxy)ethyl)-4-fluoro-N-methylbenzamide	x-ray	2.05	A	q9um73	1620		1089..1381
4cmt	pdb	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor 3-((1R)-1-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)ethoxy)- 5-(3-(methylsulfonyl)phenyl)pyridin-2-amine	x-ray	1.73	A	q9um73	1620		1089..1381
4cmu	pdb	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor (10R)-7-amino-12-fluoro-1,3,10,16-tetramethyl-16,17-dihydro- 1H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecin-15(10H)-one	x-ray	1.8	A	q9um73	1620		1089..1381
4cnh	pdb	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor 3-((1R)-1-(5-fluoro-2-methoxyphenyl)ethoxy)-5-(1-methyl-1H- 1,2,3-triazol-5-yl)pyridin-2-amine	x-ray	1.9	A;B	q9um73;q9um73	1620;1620	;	1089..1381;1089..1381
4cqe	pdb	B-Raf Kinase V600E mutant in complex with a diarylthiazole B-Raf Inhibitor	x-ray	2.3	A;B	p15056;p15056	766;766	;	449..717;449..717
4cqg	pdb	The crystal structure of MPK38 in complex with OTSSP167, an orally- administrative MELK selective inhibitor	x-ray	2.57	A	q61846	643		8..311
4crl	pdb	Crystal structure of human CDK8-Cyclin C in complex with cortistatin A	x-ray	2.4	A	p49336	464		25..341
4crs	pdb	Human Protein Kinase N2 (PKN2, PRKCL2) in complex with ATPgammaS	x-ray	2.75	A	q16513	984		653..965
4csv	pdb	Tyrosine kinase AS - a common ancestor of Src and Abl bound to Gleevec	x-ray	2.05	A				
4ct1	pdb	Human PDK1-PKCzeta Kinase Chimera in Complex with Allosteric Compound PS315 Bound to the PIF-Pocket	x-ray	1.85	A	o15530	556		79..400
4ct2	pdb	Human PDK1-PKCzeta Kinase Chimera	x-ray	1.25	A	o15530	556		79..400
4ctb	pdb	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor (5R)-8-amino-3-fluoro-5,19-dimethyl-20-oxo-5,18,19,20- tetrahydro-7,11-(azeno)pyrido(2',1':2,3)imidazo(4,5-h)(2,5,11) benzoxadiazacyclotetradecine-14-carbonitrile	x-ray	1.79	A	q9um73	1620		1089..1381
4ctc	pdb	Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor 7-amino-3-cyclopropyl-12-fluoro-1,10,16-trimethyl-16,17- dihydro-1H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecin-15(10H)-one	x-ray	2.03	A	q9um73	1620		1089..1381
4cv8	pdb	MPS1 kinase with 3-aminopyridin-2-one inhibitors	x-ray	3	A	p33981	857		516..792
4cv9	pdb	MPS1 kinase with 3-aminopyridin-2-one inhibitors	x-ray	2.5	A	p33981	857		516..792
4cva	pdb	MPS1 kinase with 3-aminopyridin-2-one inhibitors	x-ray	2.5	A	p33981	857		516..792
4cxa	pdb	Crystal structure of the human CDK12-cyclin K complex bound to AMPPNP	x-ray	3.15	A;C	q9nyv4;q9nyv4	1490;1490	;	721..1024;721..1024
4cyi	pdb	Chaetomium thermophilum Pan3	x-ray	2.42	A;B;C;D;E;F;G;H	g0s0y3;g0s0y3;g0s0y3;g0s0y3;g0s0y3;g0s0y3;g0s0y3;g0s0y3	640;640;640;640;640;640;640;640	;;;;;;;	268..486;268..486;268..486;268..486;268..486;268..486;268..486;268..486
4cyj	pdb	Chaetomium thermophilum Pan2:Pan3 complex	x-ray	2.59	A;B;C;D	g0s0y3;g0s0y3;g0s0y3;g0s0y3	640;640;640;640	;;;	268..486;268..486;268..486;268..486
4czt	pdb	Crystal structure of the kinase domain of CIPK23	x-ray	2.3	A;B;C;D	q93vd3;q93vd3;q93vd3;q93vd3	482;482;482;482	;;;	28..292;28..292;28..292;28..292
4czu	pdb	Crystal structure of the kinase domain of CIPK23 T190D mutant	x-ray	1.9	A;B;C;D	q93vd3;q93vd3;q93vd3;q93vd3	482;482;482;482	;;;	28..292;28..292;28..292;28..292
4czy	pdb	Complex of Neurospora crassa PAN2 (WD40-CS1) with PAN3 (pseudokinase and C-term)	x-ray	3.4	B;D	q7sdp4;q7sdp4	656;656	;	283..466;283..466
4d0l	pdb	Phosphatidylinositol 4-kinase III beta-PIK93 in a complex with Rab11a- GTP gammaS	x-ray	2.94	A;C;E	q9ubf8;q9ubf8;q9ubf8	816;816;816	;;	325..810;325..810;325..810
4d0m	pdb	Phosphatidylinositol 4-kinase III beta in a complex with Rab11a-GTP- gamma-S and the Rab-binding domain of FIP3	x-ray	6	A;C;G;I;M;O;Q;S;W;Y;c;g	q9ubf8;q9ubf8;q9ubf8;q9ubf8;q9ubf8;q9ubf8;q9ubf8;q9ubf8;q9ubf8;q9ubf8;q9ubf8;q9ubf8	816;816;816;816;816;816;816;816;816;816;816;816	;;;;;;;;;;;	325..810;325..810;325..810;325..810;325..810;325..810;325..810;325..810;325..810;325..810;325..810;325..810
4d0w	pdb	Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors	x-ray	1.77	A	o60674	1132		522..814,842..1119
4d0x	pdb	Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors	x-ray	1.82	A	o60674	1132		522..814,842..1119
4d1s	pdb	Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors	x-ray	1.66	A	o60674	1132		522..814,842..1119
4d1x	pdb	CDK2 in complex with Luciferin	x-ray	2.1	A	p24941	298		1..292
4d1z	pdb	CDK2 in complex with a Luciferin derivate	x-ray	1.851	A	p24941	298		1..292
4d28	pdb	Crystal structure of the kinase domain of CIPK24/SOS2	x-ray	3.3	A;B;C;D	q9ldi3;q9ldi3;q9ldi3;q9ldi3	446;446;446;446	;;;	7..265;7..265;7..265;7..265
4d2p	pdb	Structure of MELK in complex with inhibitors	x-ray	2.55	A;B;C;D	q14680;q14680;q14680;q14680	651;651;651;651	;;;	8..308;8..308;8..308;8..308
4d2r	pdb	Human IGF in complex with a Dyrk1B inhibitor	x-ray	2.1	A	p08069	1367		970..1264
4d2s	pdb	Human TTK in complex with a Dyrk1B inhibitor	x-ray	2.5	A	p33981	857		516..792
4d2t	pdb	Structure of MELK in complex with inhibitors	x-ray	2.7	A;B;C;D	q14680;q14680;q14680;q14680	651;651;651;651	;;;	8..308;8..308;8..308;8..308
4d2v	pdb	Structure of MELK in complex with inhibitors	x-ray	2.45	A;B;C;D	q14680;q14680;q14680;q14680	651;651;651;651	;;;	8..308;8..308;8..308;8..308
4d2w	pdb	Structure of MELK in complex with inhibitors	x-ray	1.92	A;B;C;D	q14680;q14680;q14680;q14680	651;651;651;651	;;;	8..308;8..308;8..308;8..308
4d4r	pdb	Focal Adhesion Kinase catalytic domain	x-ray	1.55	A;B	q00944;q00944	1053;1053	;	409..698;409..698
4d4s	pdb	Focal Adhesion Kinase catalytic domain	x-ray	2	A;B	q00944;q00944	1053;1053	;	409..698;409..698
4d4v	pdb	Focal Adhesion Kinase catalytic domain	x-ray	2.1	A;B	q00944;q00944	1053;1053	;	409..698;409..698
4d4y	pdb	Focal Adhesion Kinase catalytic domain	x-ray	1.8	A;B	q00944;q00944	1053;1053	;	409..698;409..698
4d55	pdb	Focal Adhesion Kinase catalytic domain	x-ray	2.3	A	q00944	1053		409..698
4d58	pdb	Focal Adhesion Kinase catalytic domain in complex with bis-anilino pyrimidine inhibitor	x-ray	1.95	A;B	q00944;q00944	1053;1053	;	409..698;409..698
4d5h	pdb	Focal Adhesion Kinase catalytic domain	x-ray	1.75	A;B	q00944;q00944	1053;1053	;	409..698;409..698
4d5k	pdb	Focal Adhesion Kinase catalytic domain	x-ray	1.75	A;B	q00944;q00944	1053;1053	;	409..698;409..698
4d9t	pdb	Rsk2 C-terminal Kinase Domain with inhibitor (E)-methyl 3-(4-amino-7-(3-hydroxypropyl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-cyanoacrylate	x-ray	2.4	A	p51812	740		66..390,402..717
4d9u	pdb	Rsk2 C-terminal Kinase Domain, (E)-tert-butyl 3-(4-amino-7-(3-hydroxypropyl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-cyanoacrylate	x-ray	2.4	A	p51812	740		66..390,402..717
4da5	pdb	Choline Kinase alpha acts through a double-displacement kinetic mechanism involving enzyme isomerisation, as determined through enzyme and inhibitor kinetics and structural biology	x-ray	2.4	A;B	p35790;p35790	457;457	;	82..455;82..455
4daw	pdb	Crystal structure of PAK1 kinase domain with the ruthenium phthalimide complex	x-ray	2	A	q13153	545		261..522
4dbn	pdb	Crystal Structure of the Kinase domain of Human B-raf with a [1,3]thiazolo[5,4-b]pyridine derivative	x-ray	3.15	A;B	p15056;p15056	766;766	;	449..717;449..717
4dbx	pdb	"Crystal structure of aminoglycoside phosphotransferase APH(2"")-ID/APH(2"")-IVA"	x-ray	2.004	A	o68183	301		3..264
4dc2	pdb	Structure of PKC in Complex with a Substrate Peptide from Par-3	x-ray	2.4	A	q62074	595		251..577
4dca	pdb	Crystal structure of aminoglycoside phosphotransferase APH(2'')-Ib, ADP-bound	x-ray	1.8	A	q93et9	299		5..251
4dce	pdb	Crystal structure of human anaplastic lymphoma kinase in complex with a piperidine-carboxamide inhibitor	x-ray	2.03	A;B	q9um73;q9um73	1620;1620	;	1089..1381;1089..1381
4de4	pdb	"Crystal structure of aminoglycoside phosphotransferase APH(2"")-Id/APH(2"")-IVa in complex with HEPES"	x-ray	2	A;B	o68183;o68183	301;301	;	3..264;3..264
4dea	pdb	Aurora A in complex with YL1-038-18	x-ray	2.45	A	o14965	403		120..386
4deb	pdb	Aurora A in complex with RK2-17-01	x-ray	3.05	A	o14965	403		120..386
4ded	pdb	Aurora A in complex with YL1-038-21	x-ray	3.05	A	o14965	403		120..386
4dee	pdb	Aurora A in complex with ADP	x-ray	2.3	A	o14965	403		120..386
4deg	pdb	Crystal structure of c-Met in complex with triazolopyridazine inhibitor 2	x-ray	2	A	p08581	1390		1079..1341
4deh	pdb	Crystal structure of c-Met in complex with triazolopyridinone inhibitor 3	x-ray	2	A	p08581	1390		1079..1341
4dei	pdb	Crystal structure of c-Met in complex with triazolopyridinone inhibitor 24	x-ray	2.05	A	p08581	1390		1079..1341
4dfb	pdb	"Crystal structure of aminoglycoside phosphotransferase aph(2"")-id/aph(2"")-iva in complex with kanamycin"	x-ray	1.95	A;B	o68183;o68183	301;301	;	3..264;3..264
4dfl	pdb	Crystal structure of spleen tyrosine kinase complexed with a sulfonamidopyrazine piperidine inhibitor	x-ray	1.98	A	p43405	635		375..627
4dfn	pdb	Crystal structure of spleen tyrosine kinase complexed with an adamantylpyrazine inhibitor	x-ray	2.48	A	p43405	635		375..627
4dfu	pdb	"Inhibition of an antibiotic resistance enzyme: crystal structure of aminoglycoside phosphotransferase APH(2"")-ID/APH(2"")-IVA in complex with kanamycin inhibited with quercetin"	x-ray	1.98	A;B	o68183;o68183	301;301	;	3..264;3..264
4dfx	pdb	Crystal structure of myristoylated K7C catalytic subunit of cAMP-dependent protein kinase in complex with SP20 and AMP-PNP	x-ray	1.35	E	p05132	351		28..339
4dfy	pdb	Crystal structure of R194A mutant of cAMP-dependent protein kinase with unphosphorylated activation loop	x-ray	2.997	A;E	p05132;p05132	351;351	;	28..339;28..339
4dfz	pdb	Crystal structure of myristoylated K7C catalytic subunit of cAMP-dependent protein kinase in complex with SP20	x-ray	2	E	p05132	351		28..339
4dg0	pdb	Crystal structure of myristoylated WT catalytic subunit of cAMP-dependent protein kinase in complex with SP20 and AMP-PNP	x-ray	2	E	p05132	351		28..339
4dg2	pdb	Crystal structure of myristoylated WT catalytic subunit of cAMP-dependent protein kinase in complex with SP20	x-ray	2	E	p05132	351		28..339
4dg3	pdb	Crystal structure of R336A mutant of cAMP-dependent protein kinase with unphosphorylated turn motif.	x-ray	1.8	E	p05132	351		28..339
4dgg	pdb	c-SRC kinase domain in complex with RM-1-176	x-ray	2.65	A;B	p00523;p00523	533;533	;	256..526;256..526
4dgl	pdb	Crystal Structure of the CK2 Tetrameric Holoenzyme	x-ray	3	C;D	p68400;p68400	391;391	;	5..328;5..328
4dgm	pdb	Crystal Structure of maize CK2 in complex with the inhibitor apigenin	x-ray	1.65	A	p28523	332		11..323
4dgn	pdb	Crystal Structure of maize CK2 in complex with the inhibitor luteolin	x-ray	1.75	A	p28523	332		11..323
4dh1	pdb	Low temperature X-ray structure of cAMP dependent Protein Kinase A catalytic subunit with low Mg2+, ATP and IP20	x-ray	2	A	p05132	351		28..339
4dh3	pdb	Low temperature X-ray structure of cAMP dependent Protein Kinase A catalytic subunit with high Mg2+, ATP and IP20	x-ray	2.2	A	p05132	351		28..339
4dh5	pdb	Room temperature X-ray structure of cAMP dependent Protein Kinase A catalytic subunit with high Mg2+, ADP, Phosphate, and IP20	x-ray	2.2	A	p05132	351		28..339
4dh7	pdb	Low temperature X-ray structure of cAMP dependent Protein Kinase A catalytic subunit with high Mg2+, AMP-PNP and IP20'	x-ray	1.8	A	p05132	351		28..339
4dh8	pdb	Room temperature X-ray structure of cAMP dependent Protein Kinase A catalytic subunit with high Mg2+, AMP-PNP and IP20	x-ray	2.3	A	p05132	351		28..339
4dhf	pdb	Structure of Aurora A mutant bound to Biogenidec cpd 15	x-ray	2.8	A;B	o14965;o14965	403;403	;	120..386;120..386
4din	pdb	Novel Localization and Quaternary Structure of the PKA RI beta Holoenzyme	x-ray	3.7	A	p05132	351		28..339
4dit	pdb	Crystal Structure of GSK3beta in complex with a Imidazopyridine inhibitor	x-ray	2.6	A	p49841	420		55..377
4dk5	pdb	Crystal structure of human PI3K-gamma in complex with a pyridyl-triazine inhibitor	x-ray	2.95	A	p48736	1102		728..1089
4dli	pdb	Human p38 MAP kinase in complex with RL87	x-ray	1.91	A	q16539	360		9..349
4dlj	pdb	Human p38 MAP kinase in complex with RL163	x-ray	2.6	A	q16539	360		9..349
4dn5	pdb	Crystal Structure of NF-kB-inducing Kinase (NIK)	x-ray	2.5	A;B	q99558;q99558	947;947	;	405..654;405..654
4dt8	pdb	Crystal Structure of Aminoglycoside-2''-Phosphotransferase Type IVa in Complex with Adenosine	x-ray	2.15	A;B	o68183;o68183	301;301	;	3..264;3..264
4dt9	pdb	Crystal Structure of Aminoglycoside-2''-Phosphotransferase Type IVa in Complex with Guanosine	x-ray	2.1	A;B	o68183;o68183	301;301	;	3..264;3..264
4dta	pdb	Crystal Structure of F95M Aminoglycoside-2''-Phosphotransferase Type IVa in Complex with Adenosine	x-ray	2.35	A;B	o68183;o68183	301;301	;	3..264;3..264
4dtb	pdb	Crystal Structure of F95Y Aminoglycoside-2''-Phosphotransferase Type IVa in Complex with Guanosine	x-ray	2.1	A;B	o68183;o68183	301;301	;	3..264;3..264
4dtk	pdb	Novel and selective pan-PIM kinase inhibitor	x-ray	1.86	A	p11309	313		36..296
4dym	pdb	Crystal structure of the ACVR1 kinase domain in complex with the imidazo[1,2-b]pyridazine inhibitor K00135	x-ray	2.42	A	q04771	509		186..496
4e1z	pdb	Structure of mouse Tyk-2 complexed to a 3-aminoindazole inhibitor	x-ray	2.5	A	q9r117	1184		575..869,887..1170
4e20	pdb	Structure of mouse Tyk-2 complexed to a 3-aminoindazole inhibitor	x-ray	2.6	A	q9r117	1184		575..869,887..1170
4e26	pdb	BRAF in complex with an organic inhibitor 7898734	x-ray	2.55	A;B	p15056;p15056	766;766	;	449..717;449..717
4e3c	pdb	X-ray crystal structure of human IKK2 in an active conformation	x-ray	3.98	A;B;C;D;E;F	o14920;o14920;o14920;o14920;o14920;o14920	756;756;756;756;756;756	;;;;;	11..290;11..290;11..290;11..290;11..290;11..290
4e4l	pdb	JAK1 kinase (JH1 domain) in complex with compound 30	x-ray	2	A;B;D;E	p23458;p23458;p23458;p23458	1154;1154;1154;1154	;;;	565..850,873..1146;565..850,873..1146;565..850,873..1146;565..850,873..1146
4e4m	pdb	JAK2 kinase (JH1 domain) in complex with compound 30	x-ray	2.25	A;B;D;E	o60674;o60674;o60674;o60674	1132;1132;1132;1132	;;;	522..814,842..1119;522..814,842..1119;522..814,842..1119;522..814,842..1119
4e4n	pdb	JAK1 kinase (JH1 domain) in complex with compound 49	x-ray	1.9	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
4e4x	pdb	Crystal Structure of B-Raf Kinase Domain in Complex with a Dihydropyrido[2,3-d]pyrimidinone-based Inhibitor	x-ray	3.6	A;B	p15056;p15056	766;766	;	449..717;449..717
4e5a	pdb	The W197A mutant of p38a MAP kinase	x-ray	1.87	X	q16539	360		9..349
4e5b	pdb	Structure of p38a MAP kinase without BOG	x-ray	2	A	q16539	360		9..349
4e5w	pdb	JAK1 kinase (JH1 domain) in complex with compound 26	x-ray	1.86	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
4e6a	pdb	p38a-PIA23 complex	x-ray	2.09	A	q16539	360		9..349
4e6c	pdb	p38a-perifosine Complex	x-ray	2.39	A	q16539	360		9..349
4e6d	pdb	JAK2 kinase (JH1 domain) triple mutant in complex with compound 7	x-ray	2.22	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
4e6q	pdb	JAK2 kinase (JH1 domain) triple mutant in complex with compound 12	x-ray	1.948	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
4e73	pdb	Crystal structure of JNK1beta-JIP in complex with an azaquinolone inhbitor	x-ray	2.27	A	p45983	427		12..357
4e7w	pdb	Structure of GSK3 from Ustilago maydis	x-ray	3.3	A				
4e8a	pdb	The crystal structure of p38a MAP kinase in complex with PIA24	x-ray	2.7	A	q16539	360		9..349
4e93	pdb	Crystal structure of human Feline Sarcoma Viral Oncogene Homologue (v-FES)in complex with TAE684	x-ray	1.84	A	p07332	822		549..818
4ebv	pdb	Structure of Focal Adhesion Kinase catalytic domain in complex with novel allosteric inhibitor	x-ray	1.67	A	q05397	1052		409..693
4ebw	pdb	Structure of Focal Adhesion Kinase catalytic domain in complex with novel allosteric inhibitor	x-ray	2.65	A	q05397	1052		409..693
4ec8	pdb	Structure of full length CDK9 in complex with cyclinT and DRB	x-ray	3.6	A	p50750	372		12..321
4ec9	pdb	Crystal structure of full-length cdk9 in complex with cyclin t	x-ray	3.21	A	p50750	372		12..321
4eev	pdb	Crystal structure of c-Met in complex with LY2801653	x-ray	1.8	A	p08581	1390		1079..1341
4eh2	pdb	Human p38 MAP kinase in complex with NP-F1 and RL87	x-ray	2	A	q16539	360		9..349
4eh3	pdb	Human p38 MAP kinase in complex with NP-F2 and RL87	x-ray	2.4	A	q16539	360		9..349
4eh4	pdb	Human p38 MAP kinase in complex with NP-F3 and RL87	x-ray	2.5	A	q16539	360		9..349
4eh5	pdb	Human p38 MAP kinase in complex with NP-F4 and RL87	x-ray	2	A	q16539	360		9..349
4eh6	pdb	Human p38 MAP kinase in complex with NP-F5 and RL87	x-ray	2.1	A	q16539	360		9..349
4eh7	pdb	Human p38 MAP kinase in complex with NP-F6 and RL87	x-ray	2.1	A	q16539	360		9..349
4eh8	pdb	Human p38 MAP kinase in complex with NP-F7 and RL87	x-ray	2.2	A	q16539	360		9..349
4eh9	pdb	Human p38 MAP kinase in complex with NP-F11 and RL87	x-ray	2.1	A	q16539	360		9..349
4ehe	pdb	B-Raf Kinase Domain in Complex with an Aminothienopyrimidine-based Inhibitor	x-ray	3.3	A;B	p15056;p15056	766;766	;	449..717;449..717
4ehg	pdb	B-Raf Kinase Domain in Complex with an Aminopyridimine-based Inhibitor	x-ray	3.5	A;B	p15056;p15056	766;766	;	449..717;449..717
4ehv	pdb	Human p38 MAP kinase in complex with NP-F10 and RL87	x-ray	1.6	A	q16539	360		9..349
4ehz	pdb	The Jak1 kinase domain in complex with inhibitor	x-ray	2.174	A;B;C;D	p23458;p23458;p23458;p23458	1154;1154;1154;1154	;;;	565..850,873..1146;565..850,873..1146;565..850,873..1146;565..850,873..1146
4ei4	pdb	JAK1 kinase (JH1 domain) in complex with compound 20	x-ray	2.22	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
4ej7	pdb	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, ATP-bound	x-ray	2.29	A;B;C	;;	;;	;;	;;
4ejn	pdb	Crystal structure of autoinhibited form of AKT1 in complex with N-(4-(5-(3-acetamidophenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)-3-fluorobenzamide	x-ray	2.19	A	p31749	480		145..459
4ek3	pdb	Crystal structure of apo CDK2	x-ray	1.34	A	p24941	298		1..292
4ek4	pdb	Crystal structure of the cdk2 in complex with aminopyrazole inhibitor	x-ray	1.26	A	p24941	298		1..292
4ek5	pdb	Crystal structure of the cdk2 in complex with aminopyrazole inhibitor	x-ray	1.6	A	p24941	298		1..292
4ek6	pdb	Crystal structure of the cdk2 in complex with aminopyrazole inhibitor	x-ray	1.52	A	p24941	298		1..292
4ek8	pdb	Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor	x-ray	1.7	A	p24941	298		1..292
4ekk	pdb	Akt1 with AMP-PNP	x-ray	2.8	A;B	p31749;p31749	480;480	;	145..459;145..459
4ekl	pdb	Akt1 with GDC0068	x-ray	2	A	p31749	480		145..459
4el9	pdb	Structure of N-terminal kinase domain of RSK2 with afzelin	x-ray	1.55	A	p18654	740		66..390,402..717
4enx	pdb	Crystal Structure of Pim-1 Kinase in complex with inhibitor (2E,5Z)-2-(2-chlorophenylimino)-5-(4-hydroxy-3-nitrobenzylidene)thiazolidin-4-one	x-ray	2.8	A	p11309	313		36..296
4eny	pdb	Crystal Structure of Pim-1 kinase in complex with (2E,5Z)-2-(2-chlorophenylimino)-5-(4-hydroxy-3-methoxybenzylidene)thiazolidin-4-one	x-ray	2.801	A	p11309	313		36..296
4eoi	pdb	Thr 160 phosphorylated CDK2 K89D, Q131E - human cyclin A3 complex with the inhibitor RO3306	x-ray	2	A;C	p24941;p24941	298;298	;	1..292;1..292
4eoj	pdb	Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with ATP	x-ray	1.65	A;C	p24941;p24941	298;298	;	1..292;1..292
4eok	pdb	Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor NU6102	x-ray	2.57	A;C	p24941;p24941	298;298	;	1..292;1..292
4eol	pdb	Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor RO3306	x-ray	2.4	A;C	p24941;p24941	298;298	;	1..292;1..292
4eom	pdb	Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with ATP	x-ray	2.1	A;C	p24941;p24941	298;298	;	1..292;1..292
4eon	pdb	Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with the inhibitor RO3306	x-ray	2.4	A;C	p24941;p24941	298;298	;	1..292;1..292
4eoo	pdb	Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with ATP	x-ray	2.1	A;C	p24941;p24941	298;298	;	1..292;1..292
4eop	pdb	Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with the inhibitor RO3306	x-ray	1.99	A;C	p24941;p24941	298;298	;	1..292;1..292
4eoq	pdb	Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with ATP	x-ray	2.15	A;C	p24941;p24941	298;298	;	1..292;1..292
4eor	pdb	Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor NU6102	x-ray	2.2	A;C	p24941;p24941	298;298	;	1..292;1..292
4eos	pdb	Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor RO3306	x-ray	2.57	A;C	p24941;p24941	298;298	;	1..292;1..292
4eqc	pdb	Crystal structure of PAK1 kinase domain in complex with FRAX597 inhibitor	x-ray	2.01	A	q13153	545		261..522
4eqm	pdb	Structural analysis of Staphylococcus aureus serine/threonine kinase PknB	x-ray	3	A;B;C;D;E;F	a0a0h3jme9;a0a0h3jme9;a0a0h3jme9;a0a0h3jme9;a0a0h3jme9;a0a0h3jme9	664;664;664;664;664;664	;;;;;	6..304;6..304;6..304;6..304;6..304;6..304
4equ	pdb	Human STK-10 (LOK) kinase domain in DFG-out conformation with inhibitor DSA-7	x-ray	2	A;B	o94804;o94804	968;968	;	31..302;31..302
4erk	pdb	THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE	x-ray	2.2	A	p63086	358		17..320
4erw	pdb	CDK2 in complex with staurosporine	x-ray	2	A	p24941	298		1..292
4eut	pdb	Structure of BX-795 Complexed with Unphosphorylated Human TBK1 Kinase-ULD Domain	x-ray	2.6	A;B	q9uhd2;q9uhd2	729;729	;	9..297;9..297
4euu	pdb	Structure of BX-795 Complexed with Human TBK1 Kinase Domain Phosphorylated on Ser172	x-ray	1.8	A;B	q9uhd2;q9uhd2	729;729	;	9..297;9..297
4ewh	pdb	Co-crystal structure of ACK1 with inhibitor	x-ray	2.5	A;B	q07912;q07912	1038;1038	;	120..398;120..398
4ewq	pdb	Human p38 alpha MAPK in complex with a pyridazine based inhibitor	x-ray	2.1	A	q16539	360		9..349
4eyj	pdb	MAPK13 Complex with inhibitor	x-ray	2.102	A	o15264	365		19..314
4eym	pdb	MAPK13 complex with inhibitor	x-ray	2.353	A	o15264	365		19..314
4ez3	pdb	CDK2 in complex with NSC 134199	x-ray	2	A	p24941	298		1..292
4ez5	pdb	CDK6 (monomeric) in complex with inhibitor	x-ray	2.7	A	q00534	326		9..303
4ez7	pdb	CDK2 in complex with staurosporine and 2 molecules of 8-anilino-1-naphthalene sulfonic acid	x-ray	2.49	A	p24941	298		1..292
4ezj	pdb	Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf	x-ray	2.67	A	p48736	1102		728..1089
4ezk	pdb	Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf	x-ray	2.803	A	p48736	1102		728..1089
4ezl	pdb	Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf	x-ray	2.94	A	p48736	1102		728..1089
4f08	pdb	Discovery and Optimization of C-2 Methyl Imidazo-pyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2	x-ray	2.82	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
4f09	pdb	Discovery and Optimization of C-2 Methyl Imidazo-pyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2	x-ray	2.4	A	o60674	1132		522..814,842..1119
4f0f	pdb	Crystal Structure of the Roco4 Kinase Domain bound to AppCp from D. discoideum	x-ray	1.8	A	q6xhb2	1726		1019..1315
4f0g	pdb	Crystal Structure of the Roco4 Kinase Domain from D. discoideum	x-ray	2	A	q6xhb2	1726		1019..1315
4f0i	pdb	Crystal structure of apo TrkA	x-ray	2.302	A;B	p04629;p04629	796;796	;	494..779;494..779
4f1m	pdb	Crystal Structure of the G1179S Roco4 Kinase Domain bound to AppCp from D. discoideum.	x-ray	2.04	A	q6xhb2	1726		1019..1315
4f1o	pdb	Crystal Structure of the L1180T mutant Roco4 Kinase Domain from D. discoideum bound to AppCp	x-ray	2.3	A	q6xhb2	1726		1019..1315
4f1s	pdb	Crystal structure of human PI3K-gamma in complex with a pyridyl-triazine-sulfonamide inhibitor	x-ray	3	A	p48736	1102		728..1089
4f1t	pdb	Crystal Structure of the Roco4 Kinase Domain from D. discoideum bound to the ROCK Inhibitor H1152	x-ray	2.3	A	q6xhb2	1726		1019..1315
4f4p	pdb	SYK in COMPLEX WITH LIGAND LASW836	x-ray	2.37	A	p43405	635		375..627
4f63	pdb	Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compound 1	x-ray	2.55	A;B	p11362;p11362	822;822	;	468..754;468..754
4f64	pdb	Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compound 6	x-ray	2.05	A;B	p11362;p11362	822;822	;	468..754;468..754
4f65	pdb	Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compound 8	x-ray	2.26	A;B	p11362;p11362	822;822	;	468..754;468..754
4f6s	pdb	Crystal structure of human CDK8/CYCC in complex with compound 7 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]urea)	x-ray	2.6	A	p49336	464		25..341
4f6u	pdb	Crystal structure of human CDK8/CYCC in complex with compound 5 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-[3-(morpholin-4-yl)propyl]urea)	x-ray	2.1	A	p49336	464		25..341
4f6w	pdb	Crystal structure of human CDK8/CYCC in complex with compound 1 (N-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-4-[2-({[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]carbamoyl}amino)ethyl]piperazine-1-carboxamide)	x-ray	2.39	A	p49336	464		25..341
4f70	pdb	Crystal structure of human CDK8/CYCC in complex with compound 4 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-[2-(morpholin-4-yl)ethyl]urea)	x-ray	3	A	p49336	464		25..341
4f7j	pdb	Crystal structure of human CDK8/CYCC in complex with compound 3 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-(2-hydroxyethyl)urea)	x-ray	2.6	A	p49336	464		25..341
4f7l	pdb	Crystal structure of human CDK8/CYCC in complex with compound 2 (tert-butyl [3-({[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]carbamoyl}amino)propyl]carbamate)	x-ray	2.9	A	p49336	464		25..341
4f7n	pdb	Crystal structure of human CDK8/CYCC in complex with compound 11 (1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-(5-hydroxypentyl)urea)	x-ray	2.65	A	p49336	464		25..341
4f7s	pdb	Crystal structure of human CDK8/CYCC in the DMG-in conformation	x-ray	2.2	A	p49336	464		25..341
4f99	pdb	Human CDC7 kinase in complex with DBF4 and nucleotide	x-ray	2.33	A	o00311	574		46..572
4f9a	pdb	Human CDC7 kinase in complex with DBF4 and nucleotide	x-ray	2.17	A;C	o00311;o00311	574;574	;	46..572;46..572
4f9b	pdb	Human CDC7 kinase in complex with DBF4 and PHA767491	x-ray	2.5	A;C	o00311;o00311	574;574	;	46..572;46..572
4f9c	pdb	Human CDC7 kinase in complex with DBF4 and XL413	x-ray	2.08	A	o00311	574		46..572
4f9w	pdb	Human P38alpha MAPK in Complex with a Novel and Selective Small Molecule Inhibitor	x-ray	2	A	q16539	360		9..349
4f9y	pdb	Human P38 alpha MAPK In Complex With a Novel and Selective Small Molecule Inhibitor	x-ray	1.85	A	q16539	360		9..349
4fa2	pdb	Human P38 alpha Mitogen-Activated Kinase In Complex With SB239063	x-ray	2	A	q16539	360		9..349
4fa6	pdb	Design and Synthesis of a Novel Pyrrolidinyl Pyrido Pyrimidinone Derivative as a Potent Inhibitor of PI3Ka and mTOR	x-ray	2.7	A	p48736	1102		728..1089
4fad	pdb	Design and Synthesis of a Novel Pyrrolidinyl Pyrido Pyrimidinone Derivative as a Potent Inhibitor of PI3Ka and mTOR	x-ray	2.7	A	p48736	1102		728..1089
4fbx	pdb	Complex structure of human protein kinase CK2 catalytic subunit crystallized in the presence of a bisubstrate inhibitor	x-ray	2.33	A				
4fc0	pdb	Crystal Structure of Human Kinase Domain of B-raf with a DFG-out Inhibitor	x-ray	2.95	A;B	p15056;p15056	766;766	;	449..717;449..717
4feq	pdb	Inhibitor bound structure of the kinase domain of the murine receptor tyrosine kinase TYRO3 (Sky)	x-ray	2.2	A	p55144	880		499..796
4feu	pdb	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor anthrapyrazolone SP600125	x-ray	2.37	A;B;C;D;E;F	;;;;;	;;;;;	;;;;;	;;;;;
4fev	pdb	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor pyrazolopyrimidine PP1	x-ray	1.89	A;B;C;D;E;F	;;;;;	;;;;;	;;;;;	;;;;;
4few	pdb	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor pyrazolopyrimidine PP2	x-ray	1.98	A;B;C;D;E;F	;;;;;	;;;;;	;;;;;	;;;;;
4fex	pdb	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor tyrphostin AG1478	x-ray	2.71	A;B;C;D;E	;;;;	;;;;	;;;;	;;;;
4ff8	pdb	Inhibitor bound structure of the kinase domain of the murine receptor tyrosine kinase TYRO3 (Sky)	x-ray	2.4	A	p55144	880		499..796
4fg7	pdb	Crystal structure of human calcium/calmodulin-dependent protein kinase I 1-293 in complex with ATP	x-ray	2.7	A	q14012	370		12..291
4fg8	pdb	Crystal structure of human calcium/calmodulin-dependent protein kinase I 1-315 in complex with ATP	x-ray	2.2	A;B	q14012;q14012	370;370	;	12..291;12..291
4fg9	pdb	Crystal structure of human calcium/calmodulin-dependent protein kinase I 1-320 in complex with ATP	x-ray	2.4	A;B	q14012;q14012	370;370	;	12..291;12..291
4fgb	pdb	Crystal structure of human calcium/calmodulin-dependent protein kinase I apo form	x-ray	2.6	A	q14012	370		12..291
4fhj	pdb	Crystal Structure of PI3K-gamma in Complex with Imidazopyridine 2	x-ray	2.6	A	p48736	1102		728..1089
4fhk	pdb	Crystal Structure of PI3K-gamma in Complex with Imidazopyridazine 19e	x-ray	3	A	p48736	1102		728..1089
4fi1	pdb	Crystal structure of scCK2 alpha in complex with ATP	x-ray	2.09	A	p15790	372		16..367
4fic	pdb	Kinase domain of cSrc in complex with a hinge region-binding fragment	x-ray	2.5	A;B	p00523;p00523	533;533	;	256..526;256..526
4fie	pdb	Full-length human PAK4	x-ray	3.11	A;B	o96013;o96013	591;591	;	323..578;323..578
4fif	pdb	Catalytic domain of human PAK4 with RPKPLVDP peptide	x-ray	2.6	A;B	o96013;o96013	591;591	;	323..578;323..578
4fig	pdb	Catalytic domain of human PAK4	x-ray	3.01	A;B	o96013;o96013	591;591	;	323..578;323..578
4fih	pdb	Catalytic domain of human PAK4 with QKFTGLPRQW peptide	x-ray	1.97	A	o96013	591		323..578
4fii	pdb	Catalytic domain of human PAK4 with RPKPLVDP peptide	x-ray	2	A	o96013	591		323..578
4fij	pdb	Catalytic domain of human PAK4	x-ray	2.3	A	o96013	591		323..578
4fjy	pdb	Crystal structure of PI3K-gamma in complex with quinoline-indoline inhibitor 24f	x-ray	2.9	A	p48736	1102		728..1089
4fjz	pdb	Crystal structure of PI3K-gamma in complex with pyrrolo-pyridine inhibitor 63	x-ray	3	A	p48736	1102		728..1089
4fk3	pdb	B-Raf Kinase V600E Oncogenic Mutant in Complex with PLX3203	x-ray	2.65	A;B	p15056;p15056	766;766	;	449..717;449..717
4fk6	pdb	JAK1 kinase (JH1 domain) in complex with compound 72	x-ray	2.2	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
4fkg	pdb	Crystal structure of the cdk2 in complex with aminopyrazole inhibitor	x-ray	1.51	A	p24941	298		1..292
4fki	pdb	Crystal Structure of the Cdk2 in Complex with Aminopyrazole Inhibitor	x-ray	1.6	A	p24941	298		1..292
4fkj	pdb	Crystal structure of the cdk2 in complex with aminopyrazole inhibitor	x-ray	1.63	A	p24941	298		1..292
4fkl	pdb	Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor	x-ray	1.26	A	p24941	298		1..292
4fko	pdb	Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor	x-ray	1.55	A	p24941	298		1..292
4fkp	pdb	Crystal structure of the cdk2 in complex with oxindole inhibitor	x-ray	1.6	A	p24941	298		1..292
4fkq	pdb	Crystal structure of the cdk2 in complex with oxindole inhibitor	x-ray	1.75	A	p24941	298		1..292
4fkr	pdb	Crystal structure of the cdk2 in complex with oxindole inhibitor	x-ray	1.9	A	p24941	298		1..292
4fks	pdb	Crystal structure of the cdk2 in complex with oxindole inhibitor	x-ray	1.55	A	p24941	298		1..292
4fkt	pdb	Crystal structure of the cdk2 in complex with oxindole inhibitor	x-ray	1.6	A	p24941	298		1..292
4fku	pdb	Crystal structure of the cdk2 in complex with oxindole inhibitor	x-ray	1.47	A	p24941	298		1..292
4fkv	pdb	Crystal structure of the cdk2 in complex with oxindole inhibitor	x-ray	1.7	A	p24941	298		1..292
4fkw	pdb	Crystal structure of the cdk2 in complex with oxindole inhibitor	x-ray	1.8	A	p24941	298		1..292
4fl1	pdb	Structural and Biophysical Characterization of the Syk Activation Switch	x-ray	1.79	A	p43405	635		375..627
4fl2	pdb	Structural and Biophysical Characterization of the Syk Activation Switch	x-ray	2.19	A	p43405	635		375..627
4fl3	pdb	Structural and Biophysical Characterization of the Syk Activation Switch	x-ray	1.9	A	p43405	635		375..627
4flh	pdb	Crystal structure of human PI3K-gamma in complex with AMG511	x-ray	2.6	A	p48736	1102		728..1089
4fmq	pdb	Crystal structure of human ERK2 complexed with a MAPK docking peptide	x-ray	2.098	A				
4fnw	pdb	Crystal structure of the apo F1174L anaplastic lymphoma kinase catalytic domain	x-ray	1.75	A	q9um73	1620		1089..1381
4fnx	pdb	Crystal structure of the apo R1275Q anaplastic lymphoma kinase catalytic domain	x-ray	1.7	A	q9um73	1620		1089..1381
4fny	pdb	Crystal structure of the R1275Q anaplastic lymphoma kinase catalytic domain in complex with a benzoxazole inhibitor	x-ray	2.45	A	q9um73	1620		1089..1381
4fnz	pdb	Crystal structure of human anaplastic lymphoma kinase in complex with piperidine-carboxamide inhibitor 2	x-ray	2.6	A	q9um73	1620		1089..1381
4fob	pdb	Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 1	x-ray	1.9	A	q9um73	1620		1089..1381
4foc	pdb	Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 2	x-ray	1.7	A	q9um73	1620		1089..1381
4fod	pdb	Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 36	x-ray	2	A	q9um73	1620		1089..1381
4fr4	pdb	Crystal structure of human serine/threonine-protein kinase 32A (YANK1)	x-ray	2.29	A;B;C;D;E;F	q8wu08;q8wu08;q8wu08;q8wu08;q8wu08;q8wu08	396;396;396;396;396;396	;;;;;	20..325;20..325;20..325;20..325;20..325;20..325
4fsm	pdb	Crystal Structure of the CHK1	x-ray	2.3	A	o14757	476		6..317
4fsn	pdb	Crystal Structure of the CHK1	x-ray	2.1	A	o14757	476		6..317
4fsq	pdb	Crystal Structure of the CHK1	x-ray	2.4	A	o14757	476		6..317
4fsr	pdb	Crystal Structure of the CHK1	x-ray	2.5	A	o14757	476		6..317
4fst	pdb	Crystal Structure of the CHK1	x-ray	1.9	A	o14757	476		6..317
4fsu	pdb	Crystal Structure of the CHK1	x-ray	2.1	A	o14757	476		6..317
4fsw	pdb	Crystal Structure of the CHK1	x-ray	2.3	A	o14757	476		6..317
4fsy	pdb	Crystal Structure of the CHK1	x-ray	2.3	A	o14757	476		6..317
4fsz	pdb	Crystal Structure of the CHK1	x-ray	2.3	A	o14757	476		6..317
4ft0	pdb	Crystal Structure of the CHK1	x-ray	2.3	A	o14757	476		6..317
4ft3	pdb	Crystal Structure of the CHK1	x-ray	2.5	A	o14757	476		6..317
4ft5	pdb	Crystal Structure of the CHK1	x-ray	2.4	A	o14757	476		6..317
4ft7	pdb	Crystal Structure of the CHK1	x-ray	2.2	A	o14757	476		6..317
4ft9	pdb	Crystal Structure of the CHK1	x-ray	2.2	A	o14757	476		6..317
4fta	pdb	Crystal Structure of the CHK1	x-ray	2.4	A	o14757	476		6..317
4ftc	pdb	Crystal Structure of the CHK1	x-ray	2	A	o14757	476		6..317
4fti	pdb	Crystal Structure of the CHK1	x-ray	2.2	A	o14757	476		6..317
4ftj	pdb	Crystal Structure of the CHK1	x-ray	2.2	A	o14757	476		6..317
4ftk	pdb	Crystal Structure of the CHK1	x-ray	2.3	A	o14757	476		6..317
4ftl	pdb	Crystal Structure of the CHK1	x-ray	2.5	A	o14757	476		6..317
4ftm	pdb	Crystal Structure of the CHK1	x-ray	1.9	A	o14757	476		6..317
4ftn	pdb	Crystal Structure of the CHK1	x-ray	2.02	A	o14757	476		6..317
4fto	pdb	Crystal Structure of the CHK1	x-ray	2.1	A	o14757	476		6..317
4ftq	pdb	Crystal Structure of the CHK1	x-ray	2	A	o14757	476		6..317
4ftr	pdb	Crystal Structure of the CHK1	x-ray	2.25	A	o14757	476		6..317
4ftt	pdb	Crystal Structure of the CHK1	x-ray	2.3	A	o14757	476		6..317
4ftu	pdb	Crystal Structure of the CHK1	x-ray	2.1	A	o14757	476		6..317
4ful	pdb	PI3 Kinase Gamma bound to a pyrmidine inhibitor	x-ray	2.47	A	p48736	1102		728..1089
4fux	pdb	Crystal Structure of the ERK2 complexed with E75	x-ray	2.2	A	p28482	360		19..322
4fuy	pdb	Crystal Structure of the ERK2 complexed with EK2	x-ray	2	A	p28482	360		19..322
4fv0	pdb	Crystal Structure of the ERK2 complexed with EK3	x-ray	2.1	A	p28482	360		19..322
4fv1	pdb	Crystal Structure of the ERK2 complexed with EK4	x-ray	1.99	A	p28482	360		19..322
4fv2	pdb	Crystal Structure of the ERK2 complexed with EK5	x-ray	2	A	p28482	360		19..322
4fv3	pdb	Crystal Structure of the ERK2 complexed with EK6	x-ray	2.2	A	p28482	360		19..322
4fv4	pdb	Crystal Structure of the ERK2 complexed with EK7	x-ray	2.5	A	p28482	360		19..322
4fv5	pdb	Crystal Structure of the ERK2 complexed with EK9	x-ray	2.4	A	p28482	360		19..322
4fv6	pdb	Crystal Structure of the ERK2 complexed with E57	x-ray	2.5	A	p28482	360		19..322
4fv7	pdb	Crystal Structure of the ERK2 complexed with E94	x-ray	1.9	A	p28482	360		19..322
4fv8	pdb	Crystal Structure of the ERK2 complexed with E63	x-ray	2	A	p28482	360		19..322
4fv9	pdb	Crystal Structure of the ERK2 complexed with E71	x-ray	2.11	A	p28482	360		19..322
4fvp	pdb	Crystal structure of the Jak2 pseudokinase domain (apo form)	x-ray	2.01	A	o60674	1132		522..814,842..1119
4fvq	pdb	Crystal structure of the Jak2 pseudokinase domain (Mg-ATP-bound form)	x-ray	1.75	A	o60674	1132		522..814,842..1119
4fvr	pdb	Crystal structure of the Jak2 pseudokinase domain mutant V617F (Mg-ATP-bound form)	x-ray	2	A	o60674	1132		522..814,842..1119
4fx3	pdb	Crystal Structure of the CDK2/Cyclin A complex with oxindole inhibitor	x-ray	2.75	A;C	p24941;p24941	298;298	;	1..292;1..292
4fyn	pdb	Crystal structure of spleen tyrosine kinase complexed with 3-(8-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-phenylamino}-imidazo[1,2-a]pyrazin-5-yl)-phenol	x-ray	2.318	A	p43405	635		375..627
4fyo	pdb	Crystal structure of spleen tyrosine kinase complexed with N-{(S)-1-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-pyrrolidin-3-yl}-terephthalamic acid	x-ray	1.4	A	p43405	635		375..627
4fz6	pdb	Crystal structure of spleen tyrosine kinase complexed with [6-((S)-2-Methyl-pyrrolidin-1-yl)-pyridin-2-yl]-(6-phenyl-imidazo[1,2-b]pyridazin-8-yl)-amine	x-ray	1.85	A	p43405	635		375..627
4fz7	pdb	Crystal structure of spleen tyrosine kinase complexed with 6-((1R,2S)-2-Amino-cyclohexylamino)-4-(6-ethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide	x-ray	1.75	A	p43405	635		375..627
4fza	pdb	Crystal structure of MST4-MO25 complex	x-ray	3.15	B	q9p289	416		24..320
4fzd	pdb	Crystal structure of MST4-MO25 complex with WSF motif	x-ray	3.25	B	q9p289	416		24..320
4fzf	pdb	Crystal structure of MST4-MO25 complex with DKI	x-ray	3.64	B	q9p289	416		24..320
4g11	pdb	X-ray structure of PI3K-gamma bound to a 4-(morpholin-4-yl)- (6-oxo-1,6-dihydropyrimidin-2-yl)amide inhibitor	x-ray	3.4	A	p48736	1102		728..1089
4g16	pdb	Crystal structure of ck1g3 with 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2-YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE	x-ray	2.3	A	q9y6m4	447		39..325
4g17	pdb	Crystal structure of ck1g3 with 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE	x-ray	2.1	A	q9y6m4	447		39..325
4g1w	pdb	Crystal structure of JNK1 in complex with JIP1 peptide and 7-Fluoro-3-[4-(2-hydroxy-ethanesulfonyl)-benzyl]-4-oxo-1-phenyl-1,4-dihydro-quinoline-2-carboxylic acid methyl ester	x-ray	2.45	A	p45983	427		12..357
4g2f	pdb	Human EphA3 kinase domain in complex with compound 7	x-ray	1.699	A	p29320	983		614..915
4g31	pdb	Crystal Structure of GSK6414 Bound to PERK (R587-R1092, delete A660-T867) at 2.28 A Resolution	x-ray	2.28	A	q9nzj5	1116		587..1090
4g34	pdb	Crystal Structure of GSK6924 Bound to PERK (R587-R1092, delete A660-T867) at 2.70 A Resolution	x-ray	2.7	A	q9nzj5	1116		587..1090
4g3c	pdb	Crystal structure of apo murine Nf-kappaB inducing kinase (NIK)	x-ray	2.15	A;B	q9wul6;q9wul6	942;942	;	407..656;407..656
4g3d	pdb	Crystal structure of human NF-kappaB inducing kinase (NIK)	x-ray	2.9	A;B;D;E	q99558;q99558;q99558;q99558	947;947;947;947	;;;	405..654;405..654;405..654;405..654
4g3e	pdb	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to a 6-alkynylindoline (cmp1)	x-ray	2.5	A;B	q9wul6;q9wul6	942;942	;	407..656;407..656
4g3f	pdb	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to a 2-(aminothiazoly)phenol (cmp2)	x-ray	1.642	A	q9wul6	942		407..656
4g3g	pdb	Crystal structure of murine NF-kappaB inducing kinase (NIK) V408L bound to a 2-(aminothiazolyl)phenol (cmp3)	x-ray	2.5	A	q9wul6	942		407..656
4g5j	pdb	Crystal structure of EGFR kinase in complex with BIBW2992	x-ray	2.8	A	p00533	1210		708..1003
4g5p	pdb	Crystal structure of EGFR kinase T790M in complex with BIBW2992	x-ray	3.17	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
4g6l	pdb	Crystal structure of human CDK8/CYCC in the DMG-in conformation	x-ray	2.7	A	p49336	464		25..341
4g6n	pdb	Crystal Structure of the ERK2	x-ray	2	A	p28482	360		19..322
4g6o	pdb	Crystal Structure of the ERK2	x-ray	2.2	A	p28482	360		19..322
4g9c	pdb	Human B-Raf Kinase Domain bound to a Type II Pyrazolopyridine Inhibitor	x-ray	3.5	A;B	p15056;p15056	766;766	;	449..717;449..717
4g9r	pdb	B-Raf V600E Kinase Domain Bound to a Type II Dihydroquinazoline Inhibitor	x-ray	3.2	A;B	p15056;p15056	766;766	;	449..717;449..717
4gb9	pdb	Potent and Highly Selective Benzimidazole Inhibitors of PI3K-delta	x-ray	2.438	A	p48736	1102		728..1089
4gcj	pdb	CDK2 in complex with inhibitor RC-3-89	x-ray	1.42	A	p24941	298		1..292
4geo	pdb	P38a MAP kinase DEF-pocket penta mutant (M194A, L195A, H228A, I229A, Y258A)	x-ray	1.66	A	q16539	360		9..349
4gfg	pdb	Crystal structure of spleen tyrosine kinase complexed with r9021	x-ray	2.35	A	p43405	635		375..627
4gfm	pdb	JAK2 kinase (JH1 domain) with 2,6-DICHLORO-N-(2-OXO-2,5-DIHYDROPYRIDIN-4-YL)BENZAMIDE	x-ray	2.3	A	o60674	1132		522..814,842..1119
4gfo	pdb	TYK2 kinase (JH1 domain) with 2,6-DICHLORO-N-(2-OXO-2,5-DIHYDROPYRIDIN-4-YL)BENZAMIDE	x-ray	2.3	A	p29597	1187		576..879,887..1166
4gg5	pdb	Crystal structure of CMET in complex with novel inhibitor	x-ray	2.423	A	p08581	1390		1079..1341
4gg7	pdb	Crystal structure of cMET in complex with novel inhibitor	x-ray	2.27	A	p08581	1390		1079..1341
4gh2	pdb	Crystal Structure of the CHK1	x-ray	2.03	A	o14757	476		6..317
4gih	pdb	Tyk2 (JH1) in complex with 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE	x-ray	2	A	p29597	1187		576..879,887..1166
4gii	pdb	Tyk2 (JH1) in complex with 2,6-dichloro-4-cyano-N-{2-[(cyclopropylcarbonyl)amino]pyridin-4-yl}benzamide	x-ray	2.31	A	p29597	1187		576..879,887..1166
4gj2	pdb	Tyk2 (JH1) in complex with 2,6-dichloro-N-[2-({[(1R,2R)-2-fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide	x-ray	2.4	A	p29597	1187		576..879,887..1166
4gj3	pdb	Tyk2 (JH1) in complex with 2,6-dichloro-4-cyano-N-[2-({[(1R,2R)-2-fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide	x-ray	2.5	A	p29597	1187		576..879,887..1166
4gk2	pdb	Human EphA3 Kinase domain in complex with ligand 66	x-ray	2.195	A	p29320	983		614..915
4gk3	pdb	Human EphA3 Kinase domain in complex with ligand 87	x-ray	1.898	A	p29320	983		614..915
4gk4	pdb	Human EphA3 Kinase domain in complex with ligand 90	x-ray	2.1	A	p29320	983		614..915
4gkh	pdb	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor 1-NA-PP1	x-ray	1.863	A;B;C;D;E;F;G;H;I;J;K;L	;;;;;;;;;;;	;;;;;;;;;;;	;;;;;;;;;;;	;;;;;;;;;;;
4gki	pdb	Crystal structure of the aminoglycoside phosphotransferase APH(3')-Ia, with substrate kanamycin and small molecule inhibitor 1-NM-PP1	x-ray	1.88	A;B;C;D;E;F;G;H;I;J;K;L	;;;;;;;;;;;	;;;;;;;;;;;	;;;;;;;;;;;	;;;;;;;;;;;
4gl9	pdb	Crystal structure of inhibitory protein SOCS3 in complex with JAK2 kinase domain and fragment of GP130 intracellular domain	x-ray	3.9	A;B;C;D	q62120;q62120;q62120;q62120	1132;1132;1132;1132	;;;	523..814,842..1119;523..814,842..1119;523..814,842..1119;523..814,842..1119
4gmy	pdb	JAK2 kinase (JH1 domain) in complex with 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE	x-ray	2.403	A	o60674	1132		522..814,842..1119
4grb	pdb	Casein kinase 2 (CK2) bound to inhibitor	x-ray	2.15	A	p68400	391		5..328
4gs6	pdb	Irreversible Inhibition of TAK1 Kinase by 5Z-7-Oxozeaenol	x-ray	2.2	A	q15750	504		
4gsb	pdb	Monoclinic crystal form of the apo-ERK2	x-ray	1.8	A	p63086	358		17..320
4gt3	pdb	ATP-bound form of the ERK2 kinase	x-ray	1.68	A	p63086	358		17..320
4gt4	pdb	Structure of unliganded, inactive Ror2 kinase domain	x-ray	2.406	A;B	q01974;q01974	943;943	;	443..745;443..745
4gt5	pdb	Crystal structure of the inactive TrkA kinase domain	x-ray	2.398	A	p04629	796		494..779
4gu6	pdb	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-Cyano-2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-ylamino)- methyl]-pyridin-2-yl}-N-methyl-methanesulfonamide	x-ray	1.95	A;B	q05397;q05397	1052;1052	;	409..693;409..693
4gu9	pdb	Focal adhesion kinase catalytic domain in complex with (2-Fluoro-phenyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine	x-ray	2.4	A;B	q05397;q05397	1052;1052	;	409..693;409..693
4gub	pdb	Casein Kinase II bound to Inhibitor	x-ray	2.2	A	p68400	391		5..328
4gue	pdb	Structure of N-terminal kinase domain of RSK2 with flavonoid glycoside quercitrin	x-ray	1.8	A	p18654	740		66..390,402..717
4gv1	pdb	PKB alpha in complex with AZD5363	x-ray	1.49	A	p31749	480		145..459
4gva	pdb	ADP-bound form of the ERK2 kinase	x-ray	1.83	A	p63086	358		17..320
4gvj	pdb	Tyk2 (JH1) in complex with adenosine di-phosphate	x-ray	2.03	A	p29597	1187		576..879,887..1166
4gw8	pdb	Human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and Leucettine L41	x-ray	2	A				
4gyg	pdb	Crystal structure of the Rio2 kinase from Chaetomium thermophilum	x-ray	2.482	A	g0s5r3	373		73..261
4gyi	pdb	Crystal structure of the Rio2 kinase-ADP/Mg2+-phosphoaspartate complex from Chaetomium thermophilum	x-ray	2.2	A	g0s5r3	373		73..261
4h05	pdb	Crystal structure of aminoglycoside-3'-phosphotransferase of type VIII	x-ray	2.15	A;B	q9f9m5;q9f9m5	267;267	;	5..267;5..267
4h1j	pdb	Crystal structure of PYK2 with the pyrazole 13a	x-ray	2	A	q14289	1009		417..694
4h1m	pdb	Crystal structure of PYK2 with the indole 10c	x-ray	1.99	A	q14289	1009		417..694
4h36	pdb	Crystal Structure of JNK3 in Complex with ATF2 Peptide	x-ray	3	A	p53779	464		52..396
4h39	pdb	Crystal Structure of JNK3 in Complex with JIP1 Peptide	x-ray	1.992	A	p53779	464		52..396
4h3b	pdb	Crystal Structure of JNK3 in Complex with SAB Peptide	x-ray	2.08	A;C	p53779;p53779	464;464	;	52..396;52..396
4h3p	pdb	Crystal structure of human ERK2 complexed with a MAPK docking peptide	x-ray	2.3	A;D	p28482;p28482	360;360	;	19..322;19..322
4h3q	pdb	Crystal structure of human ERK2 complexed with a MAPK docking peptide	x-ray	2.2	A	p28482	360		19..322
4h58	pdb	BRAF in complex with compound 3	x-ray	3.1	A;B;C	p15056;p15056;p15056	766;766;766	;;	449..717;449..717;449..717
4hct	pdb	Crystal structure of ITK in complex with compound 52	x-ray	1.48	A	q08881	620		352..613
4hcu	pdb	Crystal structure of ITK in complext with compound 40	x-ray	1.43	A	q08881	620		352..613
4hcv	pdb	Crystal structure of ITK in complex with compound 53	x-ray	1.48	A	q08881	620		352..613
4hge	pdb	JAK2 kinase (JH1 domain) in complex with compound 8	x-ray	2.3	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
4hgl	pdb	Crystal structure of ck1g3 with compound 1	x-ray	2.4	A	q9y6m4	447		39..325
4hgs	pdb	Crystal structure of ck1gs with compound 13	x-ray	2.4	A	q9y6m4	447		39..325
4hgt	pdb	Crystal structure of ck1d with compound 13	x-ray	1.8	A;B	p48730;p48730	415;415	;	5..290;5..290
4hjo	pdb	Crystal structure of the inactive EGFR tyrosine kinase domain with erlotinib	x-ray	2.75	A	p00533	1210		708..1003
4hle	pdb	Compound 21 (1-alkyl-substituted 1,2,4-triazoles)	x-ray	2.78	A	p48736	1102		728..1089
4hnf	pdb	Crystal structure of ck1d in complex with pf4800567	x-ray	2.07	A;B	p48730;p48730	415;415	;	5..290;5..290
4hni	pdb	crystal structure of ck1e in complex with PF4800567	x-ray	2.74	A;B	p49674;p49674	416;416	;	5..290;5..290
4hok	pdb	crystal structure of apo ck1e	x-ray	2.77	A;C;E;G;I;K;M;O;Q;S;U;W	p49674;p49674;p49674;p49674;p49674;p49674;p49674;p49674;p49674;p49674;p49674;p49674	416;416;416;416;416;416;416;416;416;416;416;416	;;;;;;;;;;;	5..290;5..290;5..290;5..290;5..290;5..290;5..290;5..290;5..290;5..290;5..290;5..290
4hpt	pdb	Crystal structure of the catalytic subunit of cAMP-dependent protein kinase displaying complete phosphoryl transfer of AMP-PNP onto a substrate peptide	x-ray	2.15	E	p05132	351		28..339
4hpu	pdb	Crystal structure of the catalytic subunit of cAMP-dependent protein kinase displaying partial phosphoryl transfer of AMP-PNP onto a substrate peptide	x-ray	1.55	E	p05132	351		28..339
4hvb	pdb	Catalytic unit of PI3Kg in complex with PI3K/mTOR dual inhibitor PF-04979064	x-ray	2.35	A	p48736	1102		728..1089
4hvd	pdb	JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide	x-ray	1.85	A	p52333	1124		508..788,820..1097
4hvg	pdb	JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-hydroxy-1,2-dimethyl-propyl)-amide	x-ray	2.75	A	p52333	1124		508..788,820..1097
4hvh	pdb	JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl	x-ray	2.3	A	p52333	1124		508..788,820..1097
4hvi	pdb	JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-2-oxo-2-piperidin-1-yl-ethyl)-amide	x-ray	2.4	A	p52333	1124		508..788,820..1097
4hvs	pdb	Crystal structure of KIT kinase domain with a small molecule inhibitor, PLX647	x-ray	1.9	A	p10721	976		564..923
4hw7	pdb	Crystal structure of FMS kinase domain with a small molecular inhibitor, PLX647-OME	x-ray	2.9001	A	p07333	972		551..909
4hyh	pdb	X-RAY Crystal structure of compound 39 bound to human chk1 kinase domain	x-ray	1.7	A	o14757	476		6..317
4hyi	pdb	X-RAY Crystal structure of compound 40 bound to human chk1 kinase domain	x-ray	1.399	A	o14757	476		6..317
4hys	pdb	Crystal structure of JNK1 in complex with JIP1 peptide and 4-(4-Indazol-1-yl-pyrimidin-2-ylamino)-cyclohexan	x-ray	2.415	A	p45983	427		12..357
4hyu	pdb	Crystal structure of JNK1 in complex with JIP1 peptide and 4-{4-[4-(3-Methanesulfonyl-propoxy)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexan	x-ray	2.152	A	p45983	427		12..357
4hzr	pdb	Crystal structure of Ack1 kinase domain	x-ray	1.31	A;B	q07912;q07912	1038;1038	;	120..398;120..398
4hzs	pdb	Crystal structure of Ack1 kinase domain with C-terminal SH3 domain	x-ray	3.23	A;B;C;D	q07912;q07912;q07912;q07912	1038;1038;1038;1038	;;;	120..398;120..398;120..398;120..398
4i0r	pdb	Crystal structure of spleen tyrosine kinase complexed with 2-(3,4,5-Trimethoxy-phenyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide	x-ray	2.1	A	p43405	635		375..627
4i0s	pdb	Crystal structure of spleen tyrosine kinase complexed with 2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide	x-ray	1.98	A	p43405	635		375..627
4i0t	pdb	Crystal structure of spleen tyrosine kinase complexed with 2-(5,6,7,8-Tetrahydro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid tert-butylamide	x-ray	1.7	A	p43405	635		375..627
4i1z	pdb	Crystal structure of the monomeric (V948R) form of the gefitinib/erlotinib resistant EGFR kinase domain L858R+T790M	x-ray	3	A	p00533	1210		708..1003
4i20	pdb	Crystal structure of monomeric (V948R) primary oncogenic mutant L858R EGFR kinase domain	x-ray	3.34	A	p00533	1210		708..1003
4i21	pdb	Crystal structure of L858R + T790M EGFR kinase domain in complex with MIG6 peptide	x-ray	3.37	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
4i22	pdb	Structure of the monomeric (V948R)gefitinib/erlotinib resistant double mutant (L858R+T790M) EGFR kinase domain co-crystallized with gefitinib	x-ray	1.71	A	p00533	1210		708..1003
4i23	pdb	Crystal structure of the wild-type EGFR kinase domain in complex with dacomitinib (soaked)	x-ray	2.8	A	p00533	1210		708..1003
4i24	pdb	Structure of T790M EGFR kinase domain co-crystallized with dacomitinib	x-ray	1.8	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
4i3z	pdb	Structure of pCDK2/CyclinA bound to ADP and 2 Magnesium ions	x-ray	2.05	A;C	p24941;p24941	298;298	;	1..292;1..292
4i41	pdb	Crystal Structure of human Ser/Thr kinase Pim1 in complex with mitoxantrone	x-ray	2.7	A	p11309	313		36..296
4i4e	pdb	Structure of Focal Adhesion Kinase catalytic domain in complex with hinge binding pyrazolobenzothiazine compound.	x-ray	1.55	A	q05397	1052		409..693
4i4f	pdb	Structure of Focal Adhesion Kinase catalytic domain in complex with an allosteric binding pyrazolobenzothiazine compound.	x-ray	1.75	A	q05397	1052		409..693
4i5c	pdb	The Jak1 kinase domain in complex with inhibitor	x-ray	2.1	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
4i5h	pdb	Crystal Structure of a Double Mutant Rat Erk2 Complexed With a Type II Quinazoline Inhibitor	x-ray	1.9	A	p63086	358		17..320
4i5m	pdb	Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain	x-ray	1.801	A	q9nyy3	685		80..359
4i5p	pdb	Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain	x-ray	1.738	A	q9nyy3	685		80..359
4i6b	pdb	Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain	x-ray	1.8	A	q9nyy3	685		80..359
4i6f	pdb	Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain	x-ray	2.9	A	q9nyy3	685		80..359
4i6h	pdb	Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce alpha-Synuclein Phosphorylation in Rat Brain	x-ray	1.91	A	q9nyy3	685		80..359
4i6q	pdb	JAK3 kinase domain in complex with 2-Phenoxy-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1-cyclopropyl-ethyl)-amide	x-ray	1.85	A	p52333	1124		508..788,820..1097
4i92	pdb	Structure of the BSK8 kinase domain	x-ray	1.6	A	q9fhd7	487		38..316
4i93	pdb	Structure of the BSK8 kinase domain (SeMet labeled)	x-ray	1.5	A;B	q9fhd7;q9fhd7	487;487	;	38..316;38..316
4i94	pdb	Structure of BSK8 in complex with AMP-PNP	x-ray	1.8	A;B	q9fhd7;q9fhd7	487;487	;	38..316;38..316
4iaa	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with thioridazine	x-ray	2.85	A	p11309	313		36..296
4iac	pdb	X-RAY structure of cAMP dependent protein kinase A in complex with HIGH MG2+ concentration, AMP-PCP AND pseudo-substrate peptide SP20	x-ray	2.15	A	p05132	351		28..339
4iad	pdb	Low temperature X-ray Structure OF cAMP dependent protein kinase A in complex with high Mg2+ concentration, ADP and phosphorylated peptide pSP20	x-ray	1.9	A	p05132	351		28..339
4iaf	pdb	Room temperature X-ray Structure OF cAMP dependent protein kinase A in complex with high Mg2+ concentration, ADP and phosphorylated peptide pSP20	x-ray	2.2	A	p05132	351		28..339
4iai	pdb	X-ray Structure of cAMP dependent protein kinase A in complex with high Ca2+ concentration, ADP and phosphorylated peptide pSP20	x-ray	1.55	A	p05132	351		28..339
4iak	pdb	Low temperature X-ray structure of cAMP dependent protein kinase A in complex with high Sr2+ concentration, ADP and phosphorylated peptide pSP20	x-ray	1.6	A	p05132	351		28..339
4ian	pdb	Crystal Structure of apo Human PRPF4B kinase domain	x-ray	2.44	A;B	q13523;q13523	1007;1007	;	674..1005;674..1005
4iay	pdb	Room temperature X-ray Structure of cAMP dependent protein kinase A in complex with high Sr2+ concentration, ADP and phosphorylated peptide pSP20	x-ray	2	A	p05132	351		28..339
4iaz	pdb	Structure of cAMP dependent protein kinase A in complex with high Ba2+ concentration, ADP and phosphorylated peptide pSP20	x-ray	1.85	A	p05132	351		28..339
4ib0	pdb	X-ray Structure of cAMP dependent protein kinase A in complex with high Na+ concentration, ADP and phosphorylated peptide pSP20	x-ray	1.87	A	p05132	351		28..339
4ib1	pdb	Structure of cAMP dependent protein kinase A in complex with high K+ concentration, ADP and phosphorylated peptide pSP20	x-ray	1.63	A	p05132	351		28..339
4ib3	pdb	Structure of cAMP dependent protein kinase A in complex with ADP, phosphorylated peptide pSP20, and no metal	x-ray	2.2	A	p05132	351		28..339
4ib5	pdb	Structure of human protein kinase CK2 catalytic subunit in complex with a CK2beta-competitive cyclic peptide	x-ray	2.2	A;B;C	;;	;;	;;	;;
4ibm	pdb	Crystal structure of insulin receptor kinase domain in complex with an inhibitor Irfin-1	x-ray	1.8	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
4ic7	pdb	Crystal structure of the ERK5 kinase domain in complex with an MKK5 binding fragment	x-ray	2.6	A;D	q13164;q13164	816;816	;	48..356;48..356
4ic8	pdb	Crystal structure of the apo ERK5 kinase domain	x-ray	2.8	A;B	q13164;q13164	816;816	;	48..356;48..356
4id7	pdb	ACK1 kinase in complex with the inhibitor cis-3-[8-amino-1-(4-phenoxyphenyl)imidazo[1,5-a]pyrazin-3-yl]cyclobutanol	x-ray	3	A	q07912	1038		120..398
4idt	pdb	Crystal Structure of NIK with 11-bromo-5,6,7,8-tetrahydropyrimido[4',5':3,4]cyclohepta[1,2-b]indol-2-amine (T28)	x-ray	2.4	A;B	q99558;q99558	947;947	;	405..654;405..654
4idv	pdb	Crystal Structure of NIK with compound 4-{3-[2-amino-5-(2-methoxyethoxy)pyrimidin-4-yl]-1H-indol-5-yl}-2-methylbut-3-yn-2-ol (13V)	x-ray	2.9	A;B;C;D	q99558;q99558;q99558;q99558	947;947;947;947	;;;	405..654;405..654;405..654;405..654
4ie9	pdb	Bovine PKA C-alpha in complex with 3-pyridylmethyl-5-methyl-1H-pyrazole-3-carboxylate	x-ray	1.92	A	p00517	351		32..339
4ieb	pdb	Crystal Structure of a Gly128Met mutant of the toxoplasma CDPK, TGME49_101440	x-ray	2.05	A	q9bjf5	507		35..330
4ifc	pdb	Crystal Structure of ADP-bound Human PRPF4B kinase domain	x-ray	2.13	A;B	q13523;q13523	1007;1007	;	674..1005;674..1005
4ifg	pdb	Crystal structure of TgCDPK1 with inhibitor bound	x-ray	2.11	A	q9bjf5	507		35..330
4ih8	pdb	Crystal structure of TgCDPK1 with inhibitor bound	x-ray	2.877	A	q9bjf5	507		35..330
4ihp	pdb	Crystal structure of TgCDPK1 with inhibitor bound	x-ray	2.27	A	q9bjf5	507		35..330
4ii5	pdb	Structure of PCDK2/CYCLINA bound to ADP and 1 MAGNESIUM ION	x-ray	2.15	A;C	p24941;p24941	298;298	;	1..292;1..292
4iir	pdb	Crystal Structure of AMPPNP-bound Human PRPF4B kinase domain	x-ray	2	A;B	q13523;q13523	1007;1007	;	674..1005;674..1005
4ij9	pdb	Bovine PKA C-alpha in complex with 2-[[5-(4-pyridyl)-1H-1,2,4-triazol-3-yl]sulfanyl]-1-(2-thiophenyl)ethanone	x-ray	2.55	A	p00517	351		32..339
4ijp	pdb	Crystal Structure of Human PRPF4B kinase domain in complex with 4-{5-[(2-Chloro-pyridin-4-ylmethyl)-carbamoyl]-thiophen-2-yl}-benzo[b]thiophene-2-carboxylic acid amine	x-ray	2.25	A;B	q13523;q13523	1007;1007	;	674..1005;674..1005
4im0	pdb	Structure of Tank-Binding Kinase 1	x-ray	2.4001	A	q9uhd2	729		9..297
4im2	pdb	Structure of Tank-Binding Kinase 1	x-ray	2.5001	A	q9uhd2	729		9..297
4im3	pdb	Structure of Tank-Binding Kinase 1	x-ray	3.342	A	q9uhd2	729		9..297
4imy	pdb	The AFF4 scaffold binds human P-TEFb adjacent to HIV Tat	x-ray	2.94	A;C;E	p50750;p50750;p50750	372;372;372	;;	12..321;12..321;12..321
4iq6	pdb	Gsk-3beta with inhibitor 6-chloro-N-cyclohexyl-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2-amine	x-ray	3.12	A;B	p49841;p49841	420;420	;	55..377;55..377
4ith	pdb	Crystal structure of RIP1 kinase in complex with necrostatin-1 analog	x-ray	2.25	A;B	q13546;q13546	671;671	;	6..286;6..286
4iti	pdb	Crystal structure of RIP1 kinase in complex with necrostatin-3 analog	x-ray	2.86	A;B	q13546;q13546	671;671	;	6..286;6..286
4itj	pdb	Crystal structure of RIP1 kinase in complex with necrostatin-4	x-ray	1.8	A;B	q13546;q13546	671;671	;	6..286;6..286
4iva	pdb	JAK2 kinase (JH1 domain) in complex with the inhibitor TRANS-4-[(8AS)-2-[(1R)-1-HYDROXYETHYL]IMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDIN-1(8AH)-YL]CYCLOHEXANECARBONITRILE	x-ray	1.5	A	o60674	1132		522..814,842..1119
4ivb	pdb	JAK1 kinase (JH1 domain) in complex with the inhibitor TRANS-4-{2-[(1R)-1-HYDROXYETHYL]IMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDIN-1(6H)-YL}CYCLOHEXANECARBONITRILE	x-ray	1.9	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
4ivc	pdb	JAK1 kinase (JH1 domain) in complex with the inhibitor (TRANS-4-{2-[(1R)-1-HYDROXYETHYL]IMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDIN-1(6H)-YL}CYCLOHEXYL)ACETONITRILE	x-ray	2.35	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
4ivd	pdb	JAK1 kinase (JH1 domain) in complex with compound 34	x-ray	1.93	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
4iw0	pdb	Crystal structure and mechanism of activation of TBK1	x-ray	4	A	q9uhd2	729		9..297
4iwd	pdb	Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-8033 analog	x-ray	1.99	A	p08581	1390		1079..1341
4iwo	pdb	Crystal structure and mechanism of activation of TBK1	x-ray	2.61	A	q9uhd2	729		9..297
4iwp	pdb	Crystal structure and mechanism of activation of TBK1	x-ray	3.065	A	q9uhd2	729		9..297
4iwq	pdb	Crystal structure and mechanism of activation of TBK1	x-ray	3	A	q9uhd2	729		9..297
4ix3	pdb	Crystal structure of a Stt7 homolog from Micromonas algae	x-ray	1.35	A;B	c1ebn1;c1ebn1	489;489	;	176..488;176..488
4ix4	pdb	Crystal structure of a Stt7 homolog from Micromonas algae in complex with ADP	x-ray	1.499	A;B	c1ebn1;c1ebn1	489;489	;	176..488;176..488
4ix5	pdb	Crystal structure of a Stt7 homolog from Micromonas algae in complex with AMP-PNP	x-ray	1.7	A;B	c1ebn1;c1ebn1	489;489	;	176..488;176..488
4ix6	pdb	Crystal structure of a Stt7 homolog from Micromonas algae soaked with ATP	x-ray	1.6	A;B	c1ebn1;c1ebn1	489;489	;	176..488;176..488
4ixp	pdb	Crystal structure of Maternal Embryonic Leucine Zipper Kinase (MELK)	x-ray	2.749	A	q14680	651		8..308
4iz5	pdb	Structure of the complex between ERK2 phosphomimetic mutant and PEA-15	x-ray	3.19	A;B;C;D	p28482;p28482;p28482;p28482	360;360;360;360	;;;	19..322;19..322;19..322;19..322
4iz7	pdb	Structure of Non-Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain	x-ray	1.8	A;C	p28482;p28482	360;360	;	19..322;19..322
4iza	pdb	Structure of Dually Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain	x-ray	1.93	A;C	p28482;p28482	360;360	;	19..322;19..322
4izy	pdb	Crystal structure of JNK1 in complex with JIP1 peptide and 4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexan	x-ray	2.3	A	p45983	427		12..357
4j1r	pdb	Crystal Structure of GSK3b in complex with inhibitor 15R	x-ray	2.702	A;B;C;D	p49841;p49841;p49841;p49841	420;420;420;420	;;;	55..377;55..377;55..377;55..377
4j52	pdb	Crystal structure of PLK1 in complex with a pyrimidodiazepinone inhibitor	x-ray	2.3	A	p53350	603		51..338
4j53	pdb	Crystal structure of PLK1 in complex with TAK-960	x-ray	2.5	A	p53350	603		51..338
4j6i	pdb	Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase beta isoform	x-ray	2.9	A	p48736	1102		728..1089
4j71	pdb	Crystal Structure of GSK3b in complex with inhibitor 1R	x-ray	2.31	A;B	p49841;p49841	420;420	;	55..377;55..377
4j7b	pdb	Crystal structure of polo-like kinase 1	x-ray	2.3	A;D	q6drk7;q6drk7	595;595	;	35..322;35..322
4j8m	pdb	Aurora A in complex with CD532	x-ray	1.853	A	o14965	403		120..386
4j8n	pdb	Aurora A Kinase Apo	x-ray	3.135	A;B;C;D	o14965;o14965;o14965;o14965	403;403;403;403	;;;	120..386;120..386;120..386;120..386
4j95	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2.	x-ray	2.3767	A;B;C;D	p21802;p21802;p21802;p21802	821;821;821;821	;;;	471..757;471..757;471..757;471..757
4j96	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer.	x-ray	2.2972	A;B	p21802;p21802	821;821	;	471..757;471..757
4j97	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer.	x-ray	2.5482	A;B;C;D	p21802;p21802;p21802;p21802	821;821;821;821	;;;	471..757;471..757;471..757;471..757
4j98	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659Q Mutation.	x-ray	2.3067	A;B	p21802;p21802	821;821	;	471..757;471..757
4j99	pdb	Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation.	x-ray	1.8474	A;B;C;D	p21802;p21802;p21802;p21802	821;821;821;821	;;;	471..757;471..757;471..757;471..757
4jai	pdb	Crystal Structure of Aurora Kinase A in complex with N-{4-[(6-oxo-5,6-dihydrobenzo[c][1,8]naphthyridin-1-yl)amino]phenyl}benzamide	x-ray	3.2	A	o14965	403		120..386
4jaj	pdb	Crystal Structure of Aurora Kinase A in complex with BENZO[C][1,8]NAPHTHYRIDIN-6(5H)-ONE	x-ray	2.7	A	o14965	403		120..386
4jbo	pdb	Novel Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules	x-ray	2.493	A	o14965	403		120..386
4jbp	pdb	Novel Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules	x-ray	2.45	A	o14965	403		120..386
4jbq	pdb	Novel Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules	x-ray	2.3	A	o14965	403		120..386
4jbv	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1268	x-ray	1.95	A	q9bjf5	507		35..330
4jdh	pdb	Crystal structure of Serine/threonine-protein kinase PAK 4 in complex with Paktide T peptide substrate	x-ray	2	A				
4jdi	pdb	Crystal structure of Serine/threonine-protein kinase PAK 4 in complex with Paktide S peptide substrate	x-ray	1.85	A				
4jdj	pdb	Crystal structure of Serine/threonine-protein kinase PAK 4 F461V mutant in complex with Paktide T peptide substrate	x-ray	2.3	A				
4jdk	pdb	Crystal structure of Serine/threonine-protein kinase PAK 4 F461V mutant in complex with Paktide S peptide substrate	x-ray	2.4	A				
4jg6	pdb	RSK2 CTD bound to 2-cyano-3-(1H-indazol-5-yl)acrylamide	x-ray	2.6	A	p51812	740		66..390,402..717
4jg7	pdb	Structure of RSK2 CTD bound to 3-(3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)phenyl)-2-cyanoacrylamide	x-ray	3.0002	A	p51812	740		66..390,402..717
4jg8	pdb	Structure of RSK2 T493M CTD mutant bound to 2-cyano-N-(1-hydroxy-2-methylpropan-2-yl)-3-(3-(3,4,5-trimethoxyphenyl)-1H-indazol-5-yl)acrylamide	x-ray	3.1002	A	p51812	740		66..390,402..717
4ji9	pdb	JAK2 kinase (JH1 domain) in complex with TG101209	x-ray	2.4	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
4jia	pdb	JAK2 kinase (JH1 domain) in complex with compound 9	x-ray	1.85	A	o60674	1132		522..814,842..1119
4jik	pdb	X-RAY Crystal structure of compound 22a (R)-2-(4-chlorophenyl)-8-(piperidin-3-ylamino)imidazo[1,2-c]pyrimidine-5-carboxamide bound to human chk1 kinase domain	x-ray	1.9	A	o14757	476		6..317
4jin	pdb	X-ray crystal structure of Archaeoglobus fulgidus Rio1 bound to (2E)-N-benzyl-2-cyano-3-(pyridine-4-yl)acrylamide (WP1086)	x-ray	2.095	A	o28471	258		52..240
4jjr	pdb	A P21 crystal form of mammalian casein kinase 1 delta	x-ray	2.4078	A;B	q9dc28;q9dc28	415;415	;	5..290;5..290
4jl9	pdb	Crystal structure of mouse TBK1 bound to BX795	x-ray	3.0999	A	q9wun2	729		9..297
4jlc	pdb	Crystal structure of mouse TBK1 bound to SU6668	x-ray	3	A	q9wun2	729		9..297
4jnw	pdb	Bacterially expressed Titin Kinase	x-ray	2.06	A;B	q8wz42;q8wz42	34350;34350	;	32174..32462;32174..32462
4joa	pdb	Crystal Structure of Human Anaplastic Lymphoma Kinase in complex with 7-azaindole based inhibitor	x-ray	2.7	A	q9um73	1620		1089..1381
4jps	pdb	Co-crystal Structures of the Lipid Kinase PI3K alpha with Pan and Isoform Selective Inhibitors	x-ray	2.2	A	p42336	1068		699..1060
4jq7	pdb	Crystal structure of EGFR kinase domain in complex with compound 2a	x-ray	2.73	A	p00533	1210		708..1003
4jq8	pdb	Crystal structure of EGFR kinase domain in complex with compound 4b	x-ray	2.83	A	p00533	1210		708..1003
4jqe	pdb	Crystal structure of scCK2 alpha in complex with AMPPN	x-ray	1.77	A	p15790	372		16..367
4jr3	pdb	Crystal structure of EGFR kinase domain in complex with compound 3g	x-ray	2.7	A	p00533	1210		708..1003
4jr7	pdb	Crystal structure of scCK2 alpha in complex with GMPPNP	x-ray	1.48	A	p15790	372		16..367
4jrn	pdb	ROP18 kinase domain in complex with AMP-PNP and sucrose	x-ray	2.71	A	q2pay2	554		255..535
4jrv	pdb	Crystal structure of EGFR kinase domain in complex with compound 4c	x-ray	2.8	A	p00533	1210		708..1003
4js8	pdb	Crystal structure of TTK kinase domain with an inhibitor: 401348	x-ray	1.94	A	p33981	857		516..792
4jsn	pdb	structure of mTORdeltaN-mLST8 complex	x-ray	3.2	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
4jsp	pdb	structure of mTORDeltaN-mLST8-ATPgammaS-Mg complex	x-ray	3.3	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
4jsv	pdb	mTOR kinase structure, mechanism and regulation.	x-ray	3.5	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
4jsx	pdb	structure of mTORDeltaN-mLST8-Torin2 complex	x-ray	3.5	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
4jt3	pdb	Crystal Structure of TTK kinase domain with an inhibitor: 400740	x-ray	2.2	A	p33981	857		516..792
4jt5	pdb	mTORdeltaN-mLST8-pp242 complex	x-ray	3.45	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
4jt6	pdb	structure of mTORDeltaN-mLST8-PI-103 complex	x-ray	3.6	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
4jvg	pdb	B-Raf Kinase in Complex with Birb796	x-ray	3.09	A;B;C;D	p15056;p15056;p15056;p15056	766;766;766;766	;;;	449..717;449..717;449..717;449..717
4jx3	pdb	Crystal structure of Pim1 kinase	x-ray	2.5	A	p11309	313		36..296
4jx7	pdb	Crystal structure of Pim1 kinase in complex with inhibitor 2-[(trans-4-aminocyclohexyl)amino]-4-{[3-(trifluoromethyl)phenyl]amino}pyrido[4,3-d]pyrimidin-5(6H)-one	x-ray	2.4	A				
4jxf	pdb	Crystal Structure of PLK4 Kinase with an inhibitor: 400631 ((1R,2S)-2-{3-[(E)-2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}ETHENYL]-2H-INDAZOL-6-YL}-5'-METHOXYSPIRO[CYCLOPROPANE-1,3'-INDOL]-2'(1'H)-ONE)	x-ray	2.4	A	o00444	970		9..266
4k0y	pdb	Structure of PIM-1 kinase bound to N-(4-fluorophenyl)-7-hydroxy-5-(piperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide	x-ray	1.954	A	p11309	313		36..296
4k11	pdb	The structure of 1NA in complex with Src T338G	x-ray	2.3	A	p12931	536		259..529
4k18	pdb	Structure of PIM-1 kinase bound to 5-(4-cyanobenzyl)-N-(4-fluorophenyl)-7-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxamide	x-ray	2.051	A	p11309	313		36..296
4k1b	pdb	Structure of PIM-1 kinase bound to N-(5-(2-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-((((3R,4R)-3-fluoropiperidin-4-yl)methyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide	x-ray	2.082	A	p11309	313		36..296
4k2r	pdb	Structural basis for activation of ZAP-70 by phosphorylation of the SH2-kinase linker	x-ray	3	A	p43403	619		343..599
4k33	pdb	Crystal Structure of FGF Receptor 3 (FGFR3) Kinase Domain Harboring the K650E Mutation, a Gain-of-Function Mutation Responsible for Thanatophoric Dysplasia Type II and Spermatocytic Seminoma	x-ray	2.3405	A	p22607	806		463..748
4k6z	pdb	The Jak1 kinase domain in complex with compound 37	x-ray	2.73	A	p23458	1154		565..850,873..1146
4k77	pdb	JAK1 kinase (JH1 domain) in complex with compound 6	x-ray	2.4	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
4k8a	pdb	Fragment-based discovery of Focal Adhesion Kinase Inhibitors	x-ray	2.91	A;B	q05397;q05397	1052;1052	;	409..693;409..693
4k9y	pdb	FOCAL ADHESION KINASE Catalytic domain in complex with 1-[4-(6-Amino-purin-9-yl)-phenyl]-3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-urea	x-ray	2	A	q05397	1052		409..693
4ka3	pdb	Structure of MAP kinase in complex with a docking peptide	x-ray	2.707	A	p47811	360		9..349
4kab	pdb	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-Methyl-1,4-dihydro-pyrazolo[4,5-c]pyrazole	x-ray	2.71	A;B	q05397;q05397	1052;1052	;	409..693;409..693
4kao	pdb	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(4-pyridin-3- yl-phenyl)-urea	x-ray	2.39	A;B	q05397;q05397	1052;1052	;	409..693;409..693
4kb8	pdb	CK1d in complex with 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE ligand	x-ray	1.95	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
4kba	pdb	CK1d in complex with 9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine inhibitor	x-ray	1.98	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
4kbc	pdb	CK1d in complex with {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2-YL}METHANOL inhibitor	x-ray	1.98	A;B	p48730;p48730	415;415	;	5..290;5..290
4kbk	pdb	CK1d in complex with (3S)-3-{4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridin-2-yl}morpholine inhibitor	x-ray	2.1	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
4kd1	pdb	CDK2 in complex with Dinaciclib	x-ray	1.7	A	p24941	298		1..292
4kik	pdb	Human IkB kinase beta	x-ray	2.83	A;B	o14920;o14920	756;756	;	11..290;11..290
4kin	pdb	Crystal structure of mitogen-activated protein kinase 14 (P38-H5) complex with 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL)-2-THIOPHENECARBOXAMIDE	x-ray	1.97	A;B;C;D	q16539;q16539;q16539;q16539	360;360;360;360	;;;	9..349;9..349;9..349;9..349
4kio	pdb	Kinase domain mutant of human Itk in complex with a covalently-binding inhibitor	x-ray	2.18	A;B;C;D	q08881;q08881;q08881;q08881	620;620;620;620	;;;	352..613;352..613;352..613;352..613
4kip	pdb	Crystal structure of mitogen-activated protein kinase 14 (P38-H5) complex with 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL)-1,3-THIAZOLE-5-CARBOXAMIDE	x-ray	2.27	A;B	q16539;q16539	360;360	;	9..349;9..349
4kiq	pdb	Crystal structure of mitogen-activated protein kinase 14 (P38-H5) complex with ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL)CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE	x-ray	2.5	A;B;C;D	q16539;q16539;q16539;q16539	360;360;360;360	;;;	9..349;9..349;9..349;9..349
4kke	pdb	The crystal structure of AMP-bound JNK3	x-ray	2.2	A	p53779	464		52..396
4kkg	pdb	Crystal structure of apo and AMP-bound JNK3	x-ray	2.4	A	p53779	464		52..396
4kkh	pdb	The crystal structure of inhibitor-bound JNK3	x-ray	2	A	p53779	464		52..396
4knb	pdb	C-Met in complex with OSI ligand	x-ray	2.4	A;B;C;D	p08581;p08581;p08581;p08581	1390;1390;1390;1390	;;;	1079..1341;1079..1341;1079..1341;1079..1341
4krc	pdb	Crystal Structure of Pho85-Pcl10-ATP-gamma-S Complex	x-ray	2.597	A	p17157	305		4..302
4krd	pdb	Crystal Structure of Pho85-Pcl10 Complex	x-ray	1.952	A	p17157	305		4..302
4ks7	pdb	PAK6 kinase domain in complex with PF-3758309	x-ray	1.4	A	q9nqu5	681		412..667
4ks8	pdb	PAK6 kinase domain in complex with sunitinib	x-ray	1.95	A	q9nqu5	681		412..667
4ksp	pdb	Crystal Structure of Human B-raf bound to a DFG-out Inhibitor TAK-632	x-ray	2.93	A;B	p15056;p15056	766;766	;	449..717;449..717
4ksq	pdb	Crystal Structure of Human B-raf bound to a DFG-out Inhibitor 5B	x-ray	3.3	A;B	p15056;p15056	766;766	;	449..717;449..717
4kuj	pdb	Structural and functional characterization of a novel Alpha Kinase from Entamoeba histolytica	x-ray	1.99	A;B	m3tp73;m3tp73	439;439	;	27..268;27..268
4kwp	pdb	Crystal Structure of Human CK2-alpha in complex with a benzimidazole inhibitor (K164) at 1.25 A resolution	x-ray	1.25	A	p68400	391		5..328
4kz0	pdb	Structure of PI3K gamma with Imidazopyridine inhibitors	x-ray	2.87	A	p48736	1102		728..1089
4kzc	pdb	Structure of PI3K gamma with Imidazopyridine inhibitors	x-ray	3.25	A	p48736	1102		728..1089
4l00	pdb	Crystal structure of the apo Jak1 pseudokinase domain	x-ray	1.8	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
4l01	pdb	Crystal structure of the V658F apo Jak1 pseudokinase domain	x-ray	1.9	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
4l1b	pdb	Crystal Structure of p110alpha complexed with niSH2 of p85alpha	x-ray	2.586	A	p42336	1068		699..1060
4l23	pdb	Crystal Structure of p110alpha complexed with niSH2 of p85alpha and PI-103	x-ray	2.501	A	p42336	1068		699..1060
4l2y	pdb	Crystal Structure of p110alpha complexed with niSH2 of p85alpha and compound 9d	x-ray	2.8	A	p42336	1068		699..1060
4l3j	pdb	Crystal structures of human p70S6K1 kinase domain	x-ray	2.1	A	p23443	525		86..409
4l3l	pdb	Crystal structures of human p70S6K1 kinase domain (Zinc anomalous)	x-ray	2.1	A	p23443	525		86..409
4l3p	pdb	Crystal Structure of 2-(1-benzothiophen-7-yl)-4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]furo[2,3-c]pyridin-7-amine bound to TAK1-TAB1	x-ray	2.68	A	o43318	606		14..292
4l42	pdb	Crystal structures of human p70S6K1-PIF	x-ray	2.8	A	p23443	525		86..409
4l43	pdb	Crystal structures of human p70S6K1-T389A (form I)	x-ray	3	A	p23443	525		86..409
4l44	pdb	Crystal structures of human p70S6K1-T389A (form II)	x-ray	2.9	A	p23443	525		86..409
4l45	pdb	Crystal structures of human p70S6K1-T389E	x-ray	2.9	A	p23443	525		86..409
4l46	pdb	Crystal structures of human p70S6K1-WT	x-ray	3.01	A	p23443	525		86..409
4l52	pdb	Crystal Structure of 1-(4-{4-[7-amino-2-(1,2,3-benzothiadiazol-7-yl)furo[2,3-c]pyridin-4-yl]-1H-pyrazol-1-yl}piperidin-1-yl)ethan-1-one bound to TAK1-TAB1	x-ray	2.54	A	o43318	606		14..292
4l53	pdb	Crystal Structure of (1R,4R)-4-{4-[7-amino-2-(1,2,3-benzothiadiazol-7-yl)-3-chlorofuro[2,3-c]pyridin-4-yl]-1H-pyrazol-1-yl}cyclohexan-1-ol bound to TAK1-TAB1	x-ray	2.55	A	o43318	606		14..292
4l67	pdb	Crystal Structure of Catalytic Domain of PAK4	x-ray	2.8	A	o96013	591		323..578
4l68	pdb	Structure of the psedudokinase domain of BIR2, an immune regulator of the RLK/Pelle family	x-ray	2	A;B	q9lsi9;q9lsi9	605;605	;	284..575;284..575
4l6q	pdb	ROCK2 in complex with benzoxaborole	x-ray	2.79	A;B	o75116;o75116	1388;1388	;	89..412;89..412
4l7f	pdb	Co-crystal Structure of JNK1 and AX13587	x-ray	1.95	A	p45983	427		12..357
4l7s	pdb	Kinase domain mutant of human Itk in complex with an aminobenzothiazole inhibitor	x-ray	2.03	A;B	q08881;q08881	620;620	;	352..613;352..613
4l8m	pdb	Human p38 MAP kinase in complex with a Dibenzoxepinone	x-ray	2.1	A	q16539	360		9..349
4l9i	pdb	Bovine G Protein Coupled Receptor Kinase 1 in Complex with Paroxetine	x-ray	2.32	A;B	p28327;p28327	561;561	;	187..529;187..529
4lfi	pdb	Crystal structure of scCK2 alpha in complex with GMPPNP	x-ray	1.85	A;B	p15790;p15790	372;372	;	16..367;16..367
4lg4	pdb	Structural Basis for Autoactivation of Human Mst2 Kinase and Its Regulation by RASSF5	x-ray	2.42	A;B;C;D;E;F	q13188;q13188;q13188;q13188;q13188;q13188	491;491;491;491;491;491	;;;;;	24..287;24..287;24..287;24..287;24..287;24..287
4lgd	pdb	Structural Basis for Autoactivation of Human Mst2 Kinase and Its Regulation by RASSF5	x-ray	3.05	A;B;C;D	q13188;q13188;q13188;q13188	491;491;491;491	;;;	24..287;24..287;24..287;24..287
4lgg	pdb	Structure of 3MB-PP1 bound to analog-sensitive Src kinase	x-ray	2.41	A;B	p00523;p00523	533;533	;	256..526;256..526
4lgh	pdb	Crystal structure of 1NM-PP1 bound to analog-sensitive Src kinase	x-ray	2.84	A;B	p00523;p00523	533;533	;	256..526;256..526
4li5	pdb	EGFR-K IN COMPLEX WITH N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxy-phenyl] Prop-2-enamide	x-ray	2.64	A	p00533	1210		708..1003
4ll0	pdb	EGFR L858R/T790M in complex with PD168393	x-ray	4	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
4ll5	pdb	Crystal Structure of Pim-1 in complex with the fluorescent compound SKF86002	x-ray	2	A	p11309	313		36..296
4lm5	pdb	Crystal structure of Pim1 in complex with 2-{4-[(3-aminopropyl)amino]quinazolin-2-yl}phenol (resulting from displacement of SKF86002)	x-ray	2.25	A	p11309	313		36..296
4lmn	pdb	Crystal Structure of MEK1 kinase bound to GDC0973	x-ray	2.8	A	q02750	393		63..365
4lmu	pdb	Crystal structure of Pim1 in complex with the inhibitor Quercetin (resulting from displacement of SKF86002)	x-ray	2.38	A	p11309	313		36..296
4loo	pdb	Structural basis of autoactivation of p38 alpha induced by TAB1 (Monoclinic crystal form)	x-ray	1.95	A	p47811	360		9..349
4lop	pdb	Structural basis of autoactivation of p38 alpha induced by TAB1 (Tetragonal crystal form)	x-ray	2.049	A;B;C;D	p47811;p47811;p47811;p47811	360;360;360;360	;;;	9..349;9..349;9..349;9..349
4loq	pdb	Structural basis of autoactivation of p38 alpha induced by TAB1 (Tetragonal crystal form with bound sulphate)	x-ray	2.319	A;B;C;D	p47811;p47811;p47811;p47811	360;360;360;360	;;;	9..349;9..349;9..349;9..349
4lqm	pdb	EGFR L858R in complex with PD168393	x-ray	2.5	A	p00533	1210		708..1003
4lqp	pdb	Crystal structure of the Cbk1(T743E)-Mob2 kinase-coactivator complex, in crystal form A	x-ray	4.5	A	p53894	756		334..713
4lqq	pdb	Crystal structure of the Cbk1(T743E)-Mob2 kinase-coactivator complex in crystal form B	x-ray	3.6	A;D	p53894;p53894	756;756	;	334..713;334..713
4lqs	pdb	Crystal structure of the Cbk1-Mob2 kinase-coactivator complex	x-ray	3.3	A	p53894	756		334..713
4lrj	pdb	Bacterial Effector NleH1 Kinase Domain with AMPPNP and Mg2+	x-ray	1.619	A;B	q8x831;q8x831	293;293	;	136..270;136..270
4lrk	pdb	Bacterial Effector NleH2 Kinase Domain	x-ray	2.274	A;B;C;D	q8xal6;q8xal6;q8xal6;q8xal6	303;303;303;303	;;;	;;;
4lrm	pdb	EGFR D770_N771insNPG in complex with PD168393	x-ray	3.526	A;B;C;D;E	p00533;p00533;p00533;p00533;p00533	1210;1210;1210;1210;1210	;;;;	708..1003;708..1003;708..1003;708..1003;708..1003
4lud	pdb	Crystal Structure of HCK in complex with the fluorescent compound SKF86002	x-ray	2.85	A;B	p08631;p08631	526;526	;	249..518;249..518
4lue	pdb	Crystal Structure of HCK in complex with 7-[trans-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (resulting from displacement of SKF86002)	x-ray	3.04	A;B	p08631;p08631	526;526	;	249..518;249..518
4lv5	pdb	Murine IRGa6 bound to Toxoplasma ROP5B, a pseudokinase GDI	x-ray	1.7	A	f2ygr7	549		234..534
4lv8	pdb	Murine IRGa6 bound to Toxoplasma ROP5C, a pseudokinase GDI	x-ray	1.72	A	i6zqr7	549		233..532
4lyn	pdb	Crystal structure of cyclin-dependent kinase 2 (cdk2-wt) complex with (2s)-n-(5-(((5-tert-butyl-1,3-oxazol-2-yl)methyl)sulfanyl)-1,3-thiazol-2-yl)-2-phenylpropanamide	x-ray	2	A	p24941	298		1..292
4m0y	pdb	Crystal structure of ITK in complex with compound 1 [4-(carbamoylamino)-1-(naphthalen-1-yl)-1H-pyrazole-3-carboxamide]	x-ray	1.7	A	q08881	620		352..613
4m0z	pdb	Crystal structure of ITK in complex with compound 5 {4-(carbamoylamino)-1-(7-methoxynaphthalen-1-yl)-1H-pyrazole-3-carboxamide}	x-ray	2	A	q08881	620		352..613
4m12	pdb	Crystal structure of ITK in complex with compound 7 [4-(carbamoylamino)-1-(7-ethoxynaphthalen-1-yl)-1H-pyrazole-3-carboxamide]	x-ray	2.15	A	q08881	620		352..613
4m13	pdb	Crystal structure of ITK in complex with compound 8 [4-(carbamoylamino)-1-(7-propoxynaphthalen-1-yl)-1H-pyrazole-3-carboxamide]	x-ray	1.85	A	q08881	620		352..613
4m14	pdb	Crystal structure of ITK in complex with compound 9 [4-(carbamoylamino)-1-[7-(propan-2-yloxy)naphthalen-1-yl]-1H-pyrazole-3-carboxamide]	x-ray	1.55	A	q08881	620		352..613
4m15	pdb	Crystal structure of ITK in complex with compound 9 [4-(carbamoylamino)-1-[7-(propan-2-yloxy)naphthalen-1-yl]-1H-pyrazole-3-carboxamide] and ADP	x-ray	1.52	A	q08881	620		352..613
4m3q	pdb	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC1917	x-ray	2.718	A;B	q12866;q12866	999;999	;	578..872;578..872
4m66	pdb	Crystal structure of the mouse RIP3 kinase domain	x-ray	2.401	A;B	q9qzl0;q9qzl0	486;486	;	17..285;17..285
4m67	pdb	Crystal structure of the human MLKL kinase-like domain	x-ray	1.9	A	q8nb16	471		213..466
4m68	pdb	Crystal structure of the mouse MLKL kinase-like domain	x-ray	1.696	A	q9d2y4	472		197..447
4m69	pdb	Crystal structure of the mouse RIP3-MLKL complex	x-ray	2.497	A;B	q9qzl0;q9d2y4	486;472	;	17..285;197..447
4m7i	pdb	Crystal Structure of GSK6157 Bound to PERK (R587-R1092, delete A660-T867) at 2.34A Resolution	x-ray	2.34	A	q9nzj5	1116		587..1090
4m84	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1455	x-ray	1.998	A	q9bjf5	507		35..330
4m8t	pdb	RSK2 T493M C-Terminal Kinase Domain in complex with 3-(3-(1H-pyrazol-4-yl)phenyl)-2-cyanoacrylamide	x-ray	3	A	p18654	740		66..390,402..717
4m97	pdb	Calcium-Dependent Protein Kinase 1 from Neospora caninum	x-ray	2.05	A	f0v9w9	506		35..329
4mao	pdb	RSK2 T493M C-Terminal Kinase Domain in Complex with RMM58	x-ray	2.6	A	p18654	740		66..390,402..717
4mbi	pdb	Discovery of Pyrazolo[1,5a]pyrimidine-based Pim1 Inhibitors	x-ray	2.3	A	p11309	313		36..296
4mbj	pdb	Human B-Raf Kinase Domain in Complex with an Imidazopyridine-based Inhibitor	x-ray	3.6	A;B	p15056;p15056	766;766	;	449..717;449..717
4mbl	pdb	Discovery of Pyrazolo[1,5a]pyrimidine-based Pim1 Inhibitors	x-ray	2.6	A	p11309	313		36..296
4mcv	pdb	Star 12 bound to analog-sensitive Src kinase	x-ray	2.73	A;B	p00523;p00523	533;533	;	256..526;256..526
4md7	pdb	Crystal Structure of full-length symmetric CK2 holoenzyme	x-ray	3.1	E;F;G;H	p68400;p68400;p68400;p68400	391;391;391;391	;;;	5..328;5..328;5..328;5..328
4md8	pdb	Crystal Structure of full-length symmetric CK2 holoenzyme with mutated alpha subunit (F121E)	x-ray	3.3	E;F;G;H	p68400;p68400;p68400;p68400	391;391;391;391	;;;	5..328;5..328;5..328;5..328
4md9	pdb	Crystal Structure of symmetric CK2 holoenzyme with mutated alpha subunit (F121E truncated at aa 336)	x-ray	3.5	E;F;G;H;K;L;M;P	p68400;p68400;p68400;p68400;p68400;p68400;p68400;p68400	391;391;391;391;391;391;391;391	;;;;;;;	5..328;5..328;5..328;5..328;5..328;5..328;5..328;5..328
4mf0	pdb	ITK kinase domain in complex with benzothiazole inhibitor compound 12a (1S,2S)-2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(PYRIDIN-3-YL)-1,3-BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE (12a)	x-ray	2.67	A;B	q08881;q08881	620;620	;	352..613;352..613
4mf1	pdb	ITK kinase domain in complex with benzothiazole inhibitor 12b (1S,2S)-2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-1,3-BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE	x-ray	2.113	A;B	q08881;q08881	620;620	;	352..613;352..613
4mh7	pdb	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC1896	x-ray	2.51	A;B	q12866;q12866	999;999	;	578..872;578..872
4mha	pdb	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC1817	x-ray	2.59	A;B	q12866;q12866	999;999	;	578..872;578..872
4mk0	pdb	Crystal structure of G protein-coupled receptor kinase 2 in complex with a a rationally designed paroxetine derivative	x-ray	2.4	A	p25098	689		187..532
4mkc	pdb	Crystal Structure of Anaplastic Lymphoma Kinase Complexed with LDK378	x-ray	2.01	A	q9um73	1620		1089..1381
4mne	pdb	Crystal structure of the BRAF:MEK1 complex	x-ray	2.8483	A;B;C;D;E;F;G;H	q02750;p15056;p15056;q02750;q02750;p15056;p15056;q02750	393;766;766;393;393;766;766;393	;;;;;;;	63..365;449..717;449..717;63..365;63..365;449..717;449..717;63..365
4mnf	pdb	Crystal structure of BRAF-V600E bound to GDC0879	x-ray	2.802	A;B	p15056;p15056	766;766	;	449..717;449..717
4mq1	pdb	The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor	x-ray	2.35	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
4mq2	pdb	The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor	x-ray	2.8	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
4mta	pdb	Crystal structure of Pim-1 kinase domain in complex with 2-methyl-5-phenylfuran-3-carboxylic acid	x-ray	2.2	A	p11309	313		36..296
4mvf	pdb	Crystal Structure of Plasmodium falciparum CDPK2 complexed with inhibitor staurosporine	x-ray	2	A	o15865	513		64..342
4mwh	pdb	Crystal structure of scCK2 alpha in complex with ATP	x-ray	2.09	A	p15790	372		16..367
4mwi	pdb	Crystal structure of the human MLKL pseudokinase domain	x-ray	1.7	A	q8nb16	471		213..466
4mx9	pdb	CDPK1 from Neospora caninum in complex with inhibitor UW1294	x-ray	3.1	A	f0v9w9	506		35..329
4mxa	pdb	CDPK1 from Neospora caninum in complex with inhibitor RM-1-132	x-ray	3	A	f0v9w9	506		35..329
4mxc	pdb	Crystal structure of CMET in complex with novel inhibitor	x-ray	1.632	A	p08581	1390		1079..1341
4mxo	pdb	human Src kinase bound to kinase inhibitor bosutinib	x-ray	2.105	A;B	p12931;p12931	536;536	;	259..529;259..529
4mxx	pdb	Human Src A403T mutant bound to kinase inhibitor bosutinib	x-ray	2.6	A;B	p12931;p12931	536;536	;	259..529;259..529
4mxy	pdb	Src M314L T338M double mutant bound to kinase inhibitor bosutinib	x-ray	2.582	A;B	p12931;p12931	536;536	;	259..529;259..529
4mxz	pdb	Src M314L T338M double mutant bound to kinase inhibitor bosutinib	x-ray	2.582	A;B	p12931;p12931	536;536	;	259..529;259..529
4myg	pdb	MAPK13, active form	x-ray	2.594	A;B	o15264;o15264	365;365	;	19..314;19..314
4n0s	pdb	Complex of ERK2 with caffeic acid	x-ray	1.7992	A	p28482	360		19..322
4n4s	pdb	A Double Mutant Rat Erk2 in Complex With a Pyrazolo[3,4-d]pyrimidine Inhibitor	x-ray	2.2	A;B	p63086;p63086	358;358	;	17..320;17..320
4n57	pdb	Crystal structure of aminoglycoside phosphotransferase APH(2'')-IVa ADP complex	x-ray	2.35	A;B	o68183;o68183	301;301	;	3..264;3..264
4n6y	pdb	Pim1 Complexed with a phenylcarboxamide	x-ray	2.6	A	p11309	313		36..296
4n6z	pdb	Pim1 Complexed with a pyridylcarboxamide	x-ray	2.2	A	p11309	313		36..296
4n70	pdb	Pim1 Complexed with a pyridylcarboxamide	x-ray	2.1	A	p11309	313		36..296
4nct	pdb	Human DYRK1A in complex with PKC412	x-ray	2.597	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
4neu	pdb	X-ray structure of Receptor Interacting Protein 1 (RIP1)kinase domain with a 1-aminoisoquinoline inhibitor	x-ray	2.57	A;B	q13546;q13546	671;671	;	6..286;6..286
4nfm	pdb	Human tau tubulin kinase 1 (TTBK1)	x-ray	2.12	A	q5tcy1	1321		30..311
4nfn	pdb	Human tau tubulin kinase 1 (TTBK1) complexed with 3-({5-[(4-amino-4-methylpiperidin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-5-bromophenol	x-ray	1.42	A	q5tcy1	1321		30..311
4nh1	pdb	Crystal structure of a heterotetrameric CK2 holoenzyme complex carrying the Andante-mutation in CK2beta and consistent with proposed models of autoinhibition and trans-autophosphorylation	x-ray	3.3	A;B	p68400;p68400	391;391	;	5..328;5..328
4nif	pdb	Heterodimeric structure of ERK2 and RSK1	x-ray	2.15	A;B;D;E	q15418;p28482;q15418;p28482	735;360;735;360	;;;	60..381,400..719;19..322;60..381,400..719;19..322
4nj3	pdb	Modulating the interaction between CDK2 and Cyclin A with a Quinoline-based inhibitor	x-ray	1.848	A	p24941	298		1..292
4njd	pdb	Structure of p21-activated kinase 4 with a novel inhibitor KY-04031	x-ray	2.5	A	o96013	591		323..578
4nk9	pdb	Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 1	x-ray	2.57	A;B	p11362;p11362	822;822	;	468..754;468..754
4nka	pdb	Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 2	x-ray	2.19	A;B	p11362;p11362	822;822	;	468..754;468..754
4nks	pdb	Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 3	x-ray	2.5	A;B	p11362;p11362	822;822	;	468..754;468..754
4nl0	pdb	Structural and functional characterization of a novel Alpha Kinase in complex with ADP from Entamoeba histolytica	x-ray	2.41	A;B	m3tp73;m3tp73	439;439	;	27..268;27..268
4nm0	pdb	Crystal structure of peptide inhibitor-free GSK-3/Axin complex	x-ray	2.5	A	p49841	420		55..377
4nm3	pdb	Crystal structure of GSK-3/Axin complex bound to phosphorylated N-terminal auto-inhibitory pS9 peptide	x-ray	2.1	A	p49841	420		55..377
4nm5	pdb	Crystal structure of GSK-3/Axin complex bound to phosphorylated Wnt receptor LRP6 c-motif	x-ray	2.3	A	p49841	420		55..377
4nm7	pdb	Crystal structure of GSK-3/Axin complex bound to phosphorylated Wnt receptor LRP6 e-motif	x-ray	2.3	A	p49841	420		55..377
4nst	pdb	Crystal structure of human Cdk12/Cyclin K in complex with ADP-aluminum fluoride	x-ray	2.2	A;C	q9nyv4;q9nyv4	1490;1490	;	721..1024;721..1024
4nt4	pdb	Crystal structure of the kinase domain of Gilgamesh isoform I from Drosophila melanogaster	x-ray	2.86	A	q86nk8	474		58..351
4nts	pdb	Apo structure of the catalytic subunit of cAMP-dependent protein kinase	x-ray	2.9	A;B	p05132;p05132	351;351	;	28..339;28..339
4ntt	pdb	Structure of the catalytic subunit of cAMP-dependent protein kinase bound to ADP and one magnesium ion	x-ray	3.5	A;B	p05132;p05132	351;351	;	28..339;28..339
4nu1	pdb	Crystal structure of a transition state mimic of the GSK-3/Axin complex bound to phosphorylated N-terminal auto-inhibitory pS9 peptide	x-ray	2.5	A	q9wv60	420		55..377
4nus	pdb	Rsk2 N-terminal kinase in complex with LJH685	x-ray	2.39	A	p51812	740		66..390,402..717
4nw5	pdb	Rsk2 N-terminal kinase in complex with 2-amino-7-substituted benzoxazole compound 8	x-ray	1.94	A	p51812	740		66..390,402..717
4nw6	pdb	Rsk2 N-terminal kinase in complex with 2-amino-7-substituted benzoxazole compound 27	x-ray	1.74	A	p51812	740		66..390,402..717
4nwm	pdb	Crystal structure of Bruton agammaglobulinemia tyrosine kinase complexed with BMS-809959 aka 4-tert-butyl-n-[2-me thyl-3-(6-{[4-(morpholine-4-carbonyl)phenyl]amino}-9h- purin-2-yl)phenyl]benzamide	x-ray	2.03	A;B	q06187;q06187	659;659	;	382..648;382..648
4nzw	pdb	Crystal Structure of STK25-MO25 Complex	x-ray	3.583	B	o00506	426		20..329
4o0r	pdb	Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors	x-ray	2.4	A;B	q13153;q13153	545;545	;	261..522;261..522
4o0s	pdb	Crystal structures of human kinase Aurora A	x-ray	2.5	A	o14965	403		120..386
4o0t	pdb	Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors	x-ray	2.6	A;B	q13153;q13153	545;545	;	261..522;261..522
4o0u	pdb	Crystal structures of human kinase Aurora A	x-ray	2.6	A	o14965	403		120..386
4o0v	pdb	Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors	x-ray	2.8	A	o96013	591		323..578
4o0w	pdb	Crystal structures of human kinase Aurora A	x-ray	2.6	A	o14965	403		120..386
4o0x	pdb	Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors	x-ray	2.483	A	o96013	591		323..578
4o0y	pdb	Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors	x-ray	2.2	A	o96013	591		323..578
4o1o	pdb	Crystal Structure of RNase L in complex with 2-5A	x-ray	3.27	A;B;C;D	a5h025;a5h025;a5h025;a5h025	743;743;743;743	;;;	368..584;368..584;368..584;368..584
4o1p	pdb	Crystal Structure of RNase L in complex with 2-5A and AMP-PNP	x-ray	2.5	A;B;C;D	a5h025;a5h025;a5h025;a5h025	743;743;743;743	;;;	368..584;368..584;368..584;368..584
4o21	pdb	Product complex of metal-free PKAc, ATP-gamma-S and SP20.	x-ray	1.95	A	p05132	351		28..339
4o22	pdb	Binary complex of metal-free PKAc with SP20.	x-ray	1.7	A	p05132	351		28..339
4o27	pdb	Crystal structure of MST3-MO25 complex with WIF motif	x-ray	3.185	B	q9y6e0	443		36..320
4o2p	pdb	Kinase domain of cSrc in complex with a substituted pyrazolopyrimidine	x-ray	2.1	A;B	p00523;p00523	533;533	;	256..526;256..526
4o2z	pdb	Crystal Structure of MPK3 from Leishmania donovani, LdBPK_100540 in the presence of NVP-BBT594	x-ray	2.71	A	a0a3s7wr45	388		27..328
4o38	pdb	Crystal structure of the human cyclin G associated kinase (GAK)	x-ray	2.097	A;B	o14976;o14976	1311;1311	;	39..322;39..322
4o6e	pdb	Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine Inhibitors of Erk2	x-ray	1.95	A	p28482	360		19..322
4o6l	pdb	Crystal Structure of TTK kinase domain with an inhibitor: 401498 (N-[(1R)-1-(2-chlorophenyl)propyl]-3-{4-[(1-methylpiperidin-4-yl)oxy]phenyl}-1H-indazole-5-carboxamide)	x-ray	2.38	A;B	p33981;p33981	857;857	;	516..792;516..792
4o7o	pdb	Crystal structure of Mycobacterium tuberculosis maltose kinase MaK	x-ray	2.4006	A;B	o07177;o07177	455;455	;	141..418;141..418
4o7p	pdb	Crystal structure of Mycobacterium tuberculosis maltose kinase MaK complexed with maltose	x-ray	2.9	A;B	o07177;o07177	455;455	;	141..418;141..418
4o91	pdb	Crystal Structure of type II inhibitor NG25 bound to TAK1-TAB1	x-ray	2.393	A	o43318	606		14..292
4o96	pdb	2.60 Angstrom resolution crystal structure of a protein kinase domain of type III effector NleH2 (ECs1814) from Escherichia coli O157:H7 str. Sakai	x-ray	2.6	A;B;C;D	q8xal6;q8xal6;q8xal6;q8xal6	303;303;303;303	;;;	;;;
4oau	pdb	Complete human RNase L in complex with biological activators.	x-ray	2.6	C	q05823	741		370..590
4oav	pdb	Complete human RNase L in complex with 2-5A (5'-ppp heptamer), AMPPCP and RNA substrate.	x-ray	2.1	B;D	q05823;q05823	741;741	;	370..590;370..590
4obo	pdb	MAP4K4 in complex with inhibitor (compound 22), 6-(3-CHLOROPHENYL)QUINAZOLIN-4-AMINE	x-ray	2.1	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4obp	pdb	MAP4K4 in complex with inhibitor (compound 29), 6-(2-FLUOROPYRIDIN-4-YL)PYRIDO[3,2-D]PYRIMIDIN-4-AMINE	x-ray	2.27	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4obq	pdb	MAP4K4 in complex with inhibitor (compound 31), N-[3-(4-AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE	x-ray	2.19	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4ocj	pdb	N-acetylhexosamine 1-phosphate kinase in complex with GlcNAc	x-ray	1.571	A	e8mf12	359		4..341
4ock	pdb	N-acetylhexosamine 1-phosphate kinase in complex with GlcNAc and AMPPNP	x-ray	1.72	A	e8mf12	359		4..341
4oco	pdb	N-acetylhexosamine 1-phosphate kinase in complex with GlcNAc-1-phosphate	x-ray	2.16	A	e8mf12	359		4..341
4ocp	pdb	N-acetylhexosamine 1-phosphate kinase in complex with GlcNAc-1-phosphate and ADP	x-ray	1.938	A	e8mf12	359		4..341
4ocq	pdb	N-acetylhexosamine 1-phosphate kinase in complex with GalNAc	x-ray	1.878	A	e8mf12	359		4..341
4ocu	pdb	N-acetylhexosamine 1-phosphate kinase_ATCC15697 in complex with GlcNAc	x-ray	1.904	A	b7gn78	359		4..339
4ocv	pdb	N-acetylhexosamine 1-phosphate kinase_ATCC15697 in complex with GlcNAc and AMPPNP	x-ray	1.472	A	b7gn78	359		4..339
4ogr	pdb	crystal structure of P-TEFb complex with AFF4 and Tat	x-ray	3	A;E;I	p50750;p50750;p50750	372;372;372	;;	12..321;12..321;12..321
4oh4	pdb	Crystal structure of BRI1 in complex with BKI1	x-ray	2.25	A;B	o22476;o22476	1196;1196	;	865..1155;865..1155
4oli	pdb	The pseudokinase/kinase protein from JAK-family member TYK2	x-ray	2.8	A	p29597	1187		576..879,887..1166
4ona	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1517	x-ray	2.4	A	q9bjf5	507		35..330
4or5	pdb	Crystal structure of HIV-1 Tat complexed with human P-TEFb and AFF4	x-ray	2.9	A;F	p50750;p50750	372;372	;	12..321;12..321
4ork	pdb	Crystal Structure of the Phosphotransferase Domain of the Bifunctional Aminoglycoside Resistance Enzyme AAC(6')-Ie-APH(2'')-Ia	x-ray	2.3	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
4ot5	pdb	Crystal structure of BTK kinase domain complexed with 4-tert-Butyl-N-(3-{8-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide	x-ray	1.55	A	q06187	659		382..648
4ot6	pdb	Crystal structure of BTK kinase domain complexed with 4-Methanesulfonyl-N-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide	x-ray	2.05	A	q06187	659		382..648
4otd	pdb	Crystal Structure of PRK1 Catalytic Domain	x-ray	2	A	q16512	942		612..923
4otf	pdb	Crystal structure of the kinase domain of Bruton's Tyrosine kinase with GDC0834	x-ray	1.95	A	q06187	659		382..648
4otg	pdb	Crystal Structure of PRK1 Catalytic Domain in Complex with Lestaurtinib	x-ray	2.6	A	q16512	942		612..923
4oth	pdb	Crystal Structure of PRK1 Catalytic Domain in Complex with Ro-31-8220	x-ray	1.8	A	q16512	942		612..923
4oti	pdb	Crystal Structure of PRK1 Catalytic Domain in Complex with Tofacitinib	x-ray	1.93	A	q16512	942		612..923
4otp	pdb	Crystal structure of the catalytic domain of the human RioK1 atypical protein kinase in complex with ADP/Mg2+	x-ray	2.7	A	q9brs2	568		181..368
4otq	pdb	Crystal structure of BTK kinase domain complexed with 1-[5-[3-(7-tert-butyl-4-oxo-quinazolin-3-yl)-2-methyl-phenyl]-1-methyl-2-oxo-3-pyridyl]-3-methyl-urea	x-ray	1.55	A	q06187	659		382..648
4otr	pdb	Crystal structure of BTK kinase domain complexed with 6-cyclopropyl-2-[3-[5-[[5-(4-ethylpiperazin-1-yl)-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-2-(hydroxymethyl)phenyl]-8-fluoro-isoquinolin-1-one	x-ray	1.95	A	q06187	659		382..648
4ouc	pdb	Structure of human haspin in complex with histone H3 substrate	x-ray	1.9	A	q8tf76	798		474..698
4ovu	pdb	Crystal Structure of p110alpha in complex with niSH2 of p85alpha	x-ray	2.96	A	p42336	1068		699..1060
4ovv	pdb	Crystal Structure of PI3Kalpha in complex with diC4-PIP2	x-ray	3.5	A	p42336	1068		699..1060
4ow8	pdb	Crystal structure of kinase domain of PknA from Mtb	x-ray	2.03	A	p9wi83	431		11..274
4oys	pdb	CRYSTAL STRUCTURE OF VPS34 IN COMPLEX WITH SAR405.	x-ray	2.9	A	q8neb9	887		538..883
4p2k	pdb	Structure of Ephrin type-A receptor 2	x-ray	1.499	A	p29317	976		605..909
4p4c	pdb	Human EphA3 Kinase domain in complex with quinoxaline derivatives	x-ray	1.599	A	p29320	983		614..915
4p5q	pdb	Human EphA3 Kinase domain in complex with quinoxaline derivatives	x-ray	1.35	A	p29320	983		614..915
4p5z	pdb	Human EphA3 Kinase domain in complex with quinoxaline derivatives	x-ray	2.002	A	p29320	983		614..915
4p7e	pdb	Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634	x-ray	2.4	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
4p90	pdb	Crystal structure of the kinase domain of human PAK1 in complex with compound 15	x-ray	2.49	A;B	q13153;q13153	545;545	;	261..522;261..522
4pdo	pdb	Structure of Ephrin type-A receptor 2	x-ray	2.104	A;B	p29317;p29317	976;976	;	605..909;605..909
4pdp	pdb	Crystal structure of Rad53 kinase domain and SCD2	x-ray	2.591	A;B	p22216;p22216	821;821	;	190..467;190..467
4pds	pdb	Crystal structure of Rad53 kinase domain and SCD2 in complex with AMPPNP	x-ray	2.9	A;B	p22216;p22216	821;821	;	190..467;190..467
4pdy	pdb	Crystal structure of aminoglycoside phosphotransferase from Alicyclobacillus acidocaldarius subsp. acidocaldarius DSM 446	x-ray	1.35	A	c8ws74	351		41..316
4ped	pdb	Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable coenzyme Q biosynthes	x-ray	1.64	A	q8ni60	647		315..522
4pf4	pdb	1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1, aa 1-277	x-ray	1.13	A	p53355	1430		6..291
4ph4	pdb	The crystal structure of Human VPS34 in complex with PIK-III	x-ray	2.8	B	q8neb9	887		538..883
4pl3	pdb	Crystal structure of murine IRE1 in complex with MKC9989 inhibitor	x-ray	2.9	A;B	q9eqy0;q9eqy0	977;977	;	571..850;571..850
4pl4	pdb	Crystal structure of murine IRE1 in complex with OICR464 inhibitor	x-ray	3	A;B;C;D	q9eqy0;q9eqy0;q9eqy0;q9eqy0	977;977;977;977	;;;	571..850;571..850;571..850;571..850
4pl5	pdb	Crystal structure of murine IRE1 in complex with OICR573 inhibitor	x-ray	3.4	A;B;C;D	q9eqy0;q9eqy0;q9eqy0;q9eqy0	977;977;977;977	;;;	571..850;571..850;571..850;571..850
4pmm	pdb	The structure of TrkA kinase bound to the inhibitor N-(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)-2-{4-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1H-1,2,3-triazol-1-yl}acetamide	x-ray	2	A	p04629	796		494..779
4pmp	pdb	The structure of TrkA kinase bound to the inhibitor 1-cyclopropyl-1-[3-(1,3-thiazol-2-yl)benzyl]-3-[4-(trifluoromethoxy)phenyl]urea	x-ray	1.8	A	p04629	796		494..779
4pms	pdb	The structure of TrkA kinase bound to the inhibitor 4-naphthalen-1-yl-1-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid	x-ray	2.8	A	p04629	796		494..779
4pmt	pdb	The structure of TrkA kinase bound to the inhibitor N~4~-(4-morpholin-4-ylphenyl)-N~6~-(pyridin-3-ylmethyl)pyrido[3,2-d]pyrimidine-4,6-diamine	x-ray	2.1	A	p04629	796		494..779
4pni	pdb	Bovine G protein-coupled receptor kinase 1 in complex with GSK2163632A	x-ray	1.85	A	p28327	561		187..529
4pnk	pdb	G protein-coupled receptor kinase 2 in complex with GSK180736A	x-ray	2.56	A	p25098	689		187..532
4pp7	pdb	Highly Potent and Selective 3-N-methylquinazoline-4(3H)-one Based Inhibitors of B-RafV600E Kinase	x-ray	3.4	A;B	p15056;p15056	766;766	;	449..717;449..717
4pp9	pdb	ITK kinase domain with compound 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4-YL]-2H-INDAZOLE-3-CARBOXAMIDE)	x-ray	2.58	A;B	q08881;q08881	620;620	;	352..613;352..613
4ppa	pdb	ITK kinase domain with compound 11 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)	x-ray	2.67	A;B	q08881;q08881	620;620	;	352..613;352..613
4ppb	pdb	ITK kinase domain with compound 28 (N-{1-[(1S)-3-(DIMETHYLAMINO)-1-PHENYLPROPYL]-1H-PYRAZOL-4-YL}-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)	x-ray	2.82	A;B	q08881;q08881	620;620	;	352..613;352..613
4ppc	pdb	ITK kinase domain with compound 27 (N-{1-[(1R)-3-(DIMETHYLAMINO)-1-PHENYLPROPYL]-1H-PYRAZOL-4-YL}-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)	x-ray	2.95	A;B	q08881;q08881	620;620	;	352..613;352..613
4pqn	pdb	ITK kinase domain with compound GNE-9822	x-ray	1.71	A	q08881	620		352..613
4prj	pdb	Aurora A kinase domain with compound 2 (N-[1-(3-cyanobenzyl)-1H-pyrazol-4-yl]-6-(1H-pyrazol-4-yl)-1H-indazole-3-carboxamide)	x-ray	2.8	A	o14965	403		120..386
4ps3	pdb	Structure of PI3K gamma in complex with 1-[6-(5-methoxypyridin-3-yl)-1,3-benzothiazol-2-yl]-3-[2-(1-propyl-1H-imidazol-4-yl)ethyl]urea	x-ray	2.9	A	p48736	1102		728..1089
4ps7	pdb	Structure of PI3K gamma in complex with N-[6-(pyridin-3-yl)-1,3-benzothiazol-2-yl]acetamide	x-ray	2.69	A	p48736	1102		728..1089
4ps8	pdb	Structure of PI3K gamma in complex with N-[6-(5,6-dimethoxypyridin-3-yl)-1,3-benzothiazol-2-yl]acetamide	x-ray	2.99	A	p48736	1102		728..1089
4ptc	pdb	Structure of a carboxamide compound (3) (2-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~,3-THIAZOLE-5-CARBOXAMIDE) to GSK3b	x-ray	2.711	A;B	p49841;p49841	420;420	;	55..377;55..377
4pte	pdb	Structure of a carvoxamide compound (15) (N-[4-(ISOQUINOLIN-7-YL)PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) to GSK3b	x-ray	2.033	A;B	p49841;p49841	420;420	;	55..377;55..377
4ptg	pdb	Structure of a carboxamine compound (26) (2-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) to GSK3b	x-ray	2.361	A;B	p49841;p49841	420;420	;	55..377;55..377
4puz	pdb	Crystal structure of spleen tyrosine kinase (Syk) in complex with GS-9973	x-ray	2.085	A;B	p43405;p43405	635;635	;	375..627;375..627
4pv0	pdb	Crystal structure of spleen tyrosine kinase (Syk) in complex with an imidazopyrazine inhibitor	x-ray	2	A	p43405	635		375..627
4pwn	pdb	Crystal structure of Active WNK1 kinase	x-ray	1.84	A	q9h4a3	2382		226..769
4px6	pdb	SYK catalytic domain in complex with a potent pyridopyrimidinone inhibitor	x-ray	1.6	A	p43405	635		375..627
4py1	pdb	Crystal structure of Tyk2 in complex with compound 15, 6-((2,5-dimethoxyphenyl)thio)-3-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazine	x-ray	2.16	A	p29597	1187		576..879,887..1166
4q2a	pdb	WNK1: A chloride sensor via autophosphorylation	x-ray	3.5	A	q9jih7	2126		226..480
4q5e	pdb	Shigella Effector Kinase OspG bound to E2-Ub UbcH7-Ub Conjugate	x-ray	1.869	A	q3yth2	196		29..161
4q5h	pdb	Shigella Effector Kinase OspG bound to AMPPNP and E2-Ub UbcH7-Ub Conjugate	x-ray	1.999	A	q3yth2	196		29..161
4q5j	pdb	Crystal structure of SeMet derivative BRI1 in complex with BKI1	x-ray	2.772	A;B	o22476;o22476	1196;1196	;	865..1155;865..1155
4q9s	pdb	Crystal Structure of human Focal Adhesion Kinase (Fak) bound to Compound1 (3,5-DIHYDRO[1,2,4]TRIAZINO[3,4-C][1,4]BENZOXAZIN-2(1H)-ONE)	x-ray	2.07	A	q05397	1052		409..693
4q9z	pdb	Human Protein Kinase C Theta in Complex with Compound35 ((1R)-9-(AZETIDIN-3-YLAMINO)-1,8-DIMETHYL-3,5-DIHYDRO[1,2,4]TRIAZINO[3,4-C][1,4]BENZOXAZIN-2(1H)-ONE)	x-ray	2.6	A;B	q04759;q04759	706;706	;	377..683;377..683
4qd6	pdb	ITK kinase domain in complex with inhibitor compound	x-ray	2.45	A;B	q08881;q08881	620;620	;	352..613;352..613
4qfg	pdb	Structure of AMPK in complex with STAUROSPORINE inhibitor and in the absence of a synthetic activator	x-ray	3.46	A	p54645	559		24..308
4qfr	pdb	Structure of AMPK in complex with Cl-A769662 activator and STAUROSPORINE inhibitor	x-ray	3.34	A	p54645	559		24..308
4qfs	pdb	Structure of AMPK in complex with Br2-A769662core activator and STAUROSPORINE inhibitor	x-ray	3.55	A	p54645	559		24..308
4qml	pdb	MST3 in complex with AMP-PNP	x-ray	1.882	A	q9y6e0	443		36..320
4qmm	pdb	MST3 IN COMPLEX WITH AT-9283, 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM	x-ray	1.852	A	q9y6e0	443		36..320
4qmn	pdb	MST3 in complex with BOSUTINIB	x-ray	2.091	A	q9y6e0	443		36..320
4qmo	pdb	MST3 IN COMPLEX WITH Imidazolo-oxindole PKR inhibitor C16	x-ray	1.898	A	q9y6e0	443		36..320
4qmp	pdb	MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III, 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE	x-ray	2	A	q9y6e0	443		36..320
4qmq	pdb	MST3 in complex with CP-673451	x-ray	1.769	A	q9y6e0	443		36..320
4qms	pdb	MST3 in complex with DASATINIB	x-ray	1.883	A	q9y6e0	443		36..320
4qmt	pdb	MST3 in complex with HESPERADIN	x-ray	1.5	A	q9y6e0	443		36..320
4qmu	pdb	MST3 IN COMPLEX WITH JNJ-7706621, 4-({5-AMINO-1-[(2,6-DIFLUOROPHENYL)CARBONYL]-1H-1,2,4-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE	x-ray	1.546	A	q9y6e0	443		36..320
4qmv	pdb	MST3 IN COMPLEX WITH PF-03814735, N-{2-[(1S,4R)-6-{[4-(CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1,2,3,4-TETRAHYDRO-1,4-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE	x-ray	2.4	A	q9y6e0	443		36..320
4qmw	pdb	MST3 IN COMPLEX WITH PP-121, 1-CYCLOPENTYL-3-(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE	x-ray	1.6	A	q9y6e0	443		36..320
4qmx	pdb	MST3 in complex with SARACATINIB	x-ray	1.882	A	q9y6e0	443		36..320
4qmy	pdb	MST3 IN COMPLEX WITH STAUROSPORINE	x-ray	1.883	A	q9y6e0	443		36..320
4qmz	pdb	MST3 IN COMPLEX WITH SUNITINIB	x-ray	1.88	A	q9y6e0	443		36..320
4qna	pdb	MST3 IN COMPLEX WITH 2-(4,6-Diamino-1,3,5-triazin-2-yl)phenol	x-ray	1.849	A	q9y6e0	443		36..320
4qny	pdb	Crystal structure of MapK from Leishmania donovani, LDBPK_331470	x-ray	2.257	A;B	a0a3q8itz9;a0a3q8itz9	408;408	;	15..315;15..315
4qo9	pdb	MST3 IN COMPLEX WITH Danusertib	x-ray	2.2	A;B	q9y6e0;q9y6e0	443;443	;	36..320;36..320
4qox	pdb	Crystal Structure of CDPK4 from Plasmodium Falciparum, PF3D7_0717500	x-ray	2.748	A	q8ibs5	528		52..346
4qp1	pdb	Crystal structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine	x-ray	2.7	A;B	p28482;p28482	360;360	;	19..322;19..322
4qp2	pdb	Crystal Structure of ERKs in complex with 5-chlorobenzo[d]oxazol-2-amine	x-ray	2.23	A;B	p28482;p28482	360;360	;	19..322;19..322
4qp3	pdb	Crystal Structure of ERK2 in complex with (S)-2-((9H-purin-6-yl)amino)-3-phenylpropan-1-ol	x-ray	2.599	A;B	p28482;p28482	360;360	;	19..322;19..322
4qp4	pdb	Crystal Structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine	x-ray	2.2	A;B	p28482;p28482	360;360	;	19..322;19..322
4qp6	pdb	Crystal Structure of ERK2 in complex with 5H-pyrrolo[2,3-b]pyrazine	x-ray	3.1	A;B	p28482;p28482	360;360	;	19..322;19..322
4qp7	pdb	Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-5H-pyrrolo[2,3-b]pyrazine	x-ray	2.249	A;B	p28482;p28482	360;360	;	19..322;19..322
4qp8	pdb	Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-7-(pyridin-3-yl)-5H-pyrrolo[2,3-b]pyrazine	x-ray	2.446	A;B	p28482;p28482	360;360	;	19..322;19..322
4qp9	pdb	Crystal Structure of ERK2 in complex with 7-(1-propyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[2,3-b]pyrazine	x-ray	2.001	A	p28482	360		19..322
4qpa	pdb	Crystal Structure of ERK2 in complex with 7-(1-benzyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[2,3-b]pyrazine	x-ray	2.85	A;B	p28482;p28482	360;360	;	19..322;19..322
4qpm	pdb	Structure of Bub1 kinase domain	x-ray	2.202	A;B	o43683;o43683	1085;1085	;	789..1061;789..1061
4qps	pdb	Crystal structure of Jak3 complexed to N-[3-(6-Phenylamino-pyrazin-2-yl)-3H-benzoimidazol-5-yl]-acrylamide	x-ray	1.8	A;C	p52333;p52333	1124;1124	;	508..788,820..1097;508..788,820..1097
4qq5	pdb	Crystal Structure of FGF Receptor (FGFR) 4 Kinase Harboring the V550L Gate-Keeper Mutation in Complex With FIIN-2, an Irreversible Tyrosine Kinase Inhibitor Capable of Overcoming FGFR Kinase Gate-Keeper Mutations	x-ray	2.203	A	p22455	802		458..743
4qqc	pdb	Crystal Structure of FGF Receptor (FGFR) 4 Kinase Domain in Complex with FIIN-2, an Irreversible Tyrosine Kinase Inhibitor Capable of Overcoming FGFR Kinase Gate-Keeper Mutations	x-ray	2.4	A	p22455	802		458..743
4qqj	pdb	Crystal Structure of FGF Receptor (FGFR) 4 Kinase Domain Harboring the V550L Gate-Keeper Mutation	x-ray	1.682	A	p22455	802		458..743
4qqt	pdb	Crystal Structure of FGF Receptor (FGFR) 4 Tyrosine Kinase Domain	x-ray	1.501	A	p22455	802		458..743
4qrc	pdb	Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 4 in Complex with Ponatinib	x-ray	1.901	A	p22455	802		458..743
4qt1	pdb	JAK3 kinase domain in complex with 1-[(3S)-1-isobutylsulfonyl-3-piperidyl]-3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)urea	x-ray	2.4	A	p52333	1124		508..788,820..1097
4qta	pdb	Structure of human ERK2 in complex with SCH772984 revealing a novel inhibitor-induced binding pocket	x-ray	1.45	A	p28482	360		19..322
4qtb	pdb	Structure of human ERK1 in complex with SCH772984 revealing a novel inhibitor-induced binding pocket	x-ray	1.4	A;B	p27361;p27361	379;379	;	36..339;36..339
4qtc	pdb	Structure of human haspin (GSG2) in complex with SCH772984 revealing the first type-I binding mode	x-ray	1.4	A	q8tf76	798		474..698
4qtd	pdb	Structure of human JNK1 in complex with SCH772984 and the AMPPNP-hydrolysed triphosphate revealing the second type-I binding mode	x-ray	1.5	A	p45983	427		12..357
4qte	pdb	Structure of ERK2 in complex with VTX-11e, 4-{2-[(2-CHLORO-4-FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3-CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE	x-ray	1.5	A	p28482	360		19..322
4qye	pdb	CHK1 kinase domain in complex with diarylpyrazine compound 1	x-ray	2.05	A	o14757	476		6..317
4qyf	pdb	CHK1 kinase domain in complex with aminopyrazine compound 13	x-ray	2.15	A	o14757	476		6..317
4qyg	pdb	CHK1 kinase domain in complex with diazacarbazole compound 14	x-ray	1.75	A;B	o14757;o14757	476;476	;	6..317;6..317
4qyh	pdb	CHK1 kinase domain in complex with diazacarbazole GNE-783	x-ray	1.9	A;B	o14757;o14757	476;476	;	6..317;6..317
4qyy	pdb	Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Kinase State	x-ray	1.65	A	p63086	358		17..320
4r1v	pdb	Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors	x-ray	1.2	A	p08581	1390		1079..1341
4r1y	pdb	Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitor	x-ray	2	A	p08581	1390		1079..1341
4r3c	pdb	Crystal structure of p38 alpha MAP kinase in complex with a novel isoform selective drug candidate	x-ray	2.06	A	q16539	360		9..349
4r3p	pdb	Crystal structures of EGFR in complex with Mig6	x-ray	2.905	A	p00533	1210		708..1003
4r3r	pdb	Crystal structures of EGFR in complex with Mig6	x-ray	3.25	A	p00533	1210		708..1003
4r5s	pdb	Crystal structure of EGFR 696-1022 L858R in complex with FIIN-3	x-ray	3.001	A	p00533	1210		708..1003
4r5y	pdb	The complex structure of Braf V600E kinase domain with a novel Braf inhibitor	x-ray	3.5	A;B	p15056;p15056	766;766	;	449..717;449..717
4r6v	pdb	Crystal Structure of FGF Receptor (FGFR) 4 Kinase Harboring the V550L Gate-Keeper Mutation in Complex with FIIN-3, an Irreversible Tyrosine Kinase Inhibitor Capable of Overcoming FGFR kinase Gate-Keeper Mutations	x-ray	2.353	A	p22455	802		458..743
4r77	pdb	Crystal structure of choline kinase LicA from Streptococcus pneumoniae	x-ray	1.94	A;B	q8dpi4;q8dpi4	289;289	;	2..280;2..280
4r78	pdb	Crystal structure of LicA in complex with AMP	x-ray	1.45	A	q8dpi4	289		2..280
4r7b	pdb	Crystal structure of pneumococcal LicA in complex with choline	x-ray	2.01	A;B	q8dpi4;q8dpi4	289;289	;	2..280;2..280
4r7h	pdb	Crystal structure of FMS KINASE domain with a small molecular inhibitor, PLX3397	x-ray	2.8001	A	p07333	972		551..909
4r7i	pdb	Crystal structure of FMS kinase domain with a small molecular inhibitor, GLEEVEC	x-ray	2.75	A	p07333	972		551..909
4r8q	pdb	Structure and substrate recruitment of the human spindle checkpoint kinase bub1	x-ray	2.31	A	o43683	1085		789..1061
4ra4	pdb	Crystal Structure of Human Protein Kinase C Alpha in Complex with Compound 28 ((R)-6-((3S,4S)-1,3-Dimethyl-piperidin-4-yl)-7-(2-fluoro-phenyl)-4-methyl-2,10-dihydro-9-oxa-1,2,4a-triaza-phenanthren-3-one)	x-ray	2.63	A	p17252	672		335..631
4ra5	pdb	Human Protein Kinase C THETA IN COMPLEX WITH LIGAND COMPOUND 11a (6-[(1,3-Dimethyl-azetidin-3-yl)-methyl-amino]-4(R)-methyl-7-phenyl-2,10-dihydro-9-oxa-1,2,4a-triaza-phenanthren-3-one)	x-ray	2.61	A;B	q04759;q04759	706;706	;	377..683;377..683
4rbl	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives	x-ray	2.55	A	p11309	313		36..296
4rc2	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives	x-ray	2.096	A	p11309	313		36..296
4rc3	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives	x-ray	2.338	A	p11309	313		36..296
4rc4	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives	x-ray	2.651	A	p11309	313		36..296
4red	pdb	Crystal structure of human AMPK alpha1 KD-AID with K43A mutation	x-ray	2.95	A;B	q13131;q13131	559;559	;	24..308;24..308
4rer	pdb	Crystal structure of the phosphorylated human alpha1 beta2 gamma1 holo-AMPK complex bound to AMP and cyclodextrin	x-ray	4.047	A	q13131	559		24..308
4rew	pdb	Crystal structure of the non-phosphorylated human alpha1 beta2 gamma1 holo-AMPK complex	x-ray	4.58	A	q13131	559		24..308
4rfm	pdb	ITK kinase domain in complex with compound 1 N-{1-[(1,1-dioxo-1-thian-2-yl)(phenyl)methyl]-1H- pyrazol-4-yl}-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carboxamide	x-ray	2.1	A	q08881	620		352..613
4rfy	pdb	Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-3,4-dihydroisoquinolin-1-one	x-ray	1.7	A	q06187	659		382..648
4rfz	pdb	Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]isoquinolin-1-one	x-ray	1.17	A	q06187	659		382..648
4rg0	pdb	Crystal structure of BTK kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]-2-methyl-propanenitrile	x-ray	2.5	A	q06187	659		382..648
4rgj	pdb	Apo crystal structure of CDPK4 from Plasmodium falciparum, PF3D7_0717500	x-ray	2.303	A	q8ibs5	528		52..346
4rio	pdb	Crystal structure of JAK3 kinase domain in complex with a pyrrolopyridazine carboxamide inhibitor	x-ray	2.69	A	p52333	1124		508..788,820..1097
4riw	pdb	Crystal structure of an EGFR/HER3 kinase domain heterodimer	x-ray	3.1	A;B;C;D	p21860;p00533;p21860;p00533	1342;1210;1342;1210	;;;	706..977;708..1003;706..977;708..1003
4rix	pdb	Crystal structure of an EGFR/HER3 kinase domain heterodimer containing the cancer-associated HER3-Q790R mutation	x-ray	3.1	A;B;C;D	p21860;p00533;p21860;p00533	1342;1210;1342;1210	;;;	706..977;708..1003;706..977;708..1003
4riy	pdb	Crystal structure of an EGFR/HER3 kinase domain heterodimer containing the cancer-associated HER3-E909G mutation	x-ray	2.981	A;B;C;D	p21860;p00533;p21860;p00533	1342;1210;1342;1210	;;;	706..977;708..1003;706..977;708..1003
4rj3	pdb	CDK2 with EGFR inhibitor compound 8	x-ray	1.63	A	p24941	298		1..292
4rj4	pdb	EGFR kinase (T790M/L858R) with inhibitor compound 6	x-ray	2.78	A	p00533	1210		708..1003
4rj5	pdb	EGFR kinase (T790M/L858R) with inhibitor compound 5	x-ray	3.1	A	p00533	1210		708..1003
4rj6	pdb	EGFR kinase (T790M/L858R) with inhibitor compound 4	x-ray	2.7	A	p00533	1210		708..1003
4rj7	pdb	EGFR kinase (T790M/L858R) with inhibitor compound 1	x-ray	2.55	A	p00533	1210		708..1003
4rj8	pdb	EGFR kinase (T790M/L858R) with inhibitor compound 8	x-ray	2.5	A	p00533	1210		708..1003
4rlk	pdb	Crystal structure of Z. mays CK2alpha in complex with the ATP-competitive inhibitor 4-[(E)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoate	x-ray	1.24	A	p28523	332		11..323
4rll	pdb	Crystal structure of human CK2alpha in complex with the ATP-competitive inhibitor 4-[(E)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoate	x-ray	1.85	A	p68400	391		5..328
4rlo	pdb	Human p70s6k1 with ruthenium-based inhibitor EM5	x-ray	2.527	A;B	p23443;p23443	525;525	;	86..409;86..409
4rlp	pdb	Human p70s6k1 with ruthenium-based inhibitor FL772	x-ray	2.79	A	p23443	525		86..409
4rmz	pdb	Crystal Structure of IRAK-4	x-ray	2.2	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
4rpv	pdb	co-crystal structure of Pim1 with compound 3	x-ray	3.05	A	p11309	313		36..296
4rqk	pdb	Crystal structure of PDK1 in complex with ATP and the PIF-pocket ligand RS1	x-ray	1.55	A	o15530	556		79..400
4rqv	pdb	Crystal structure of PDK1 in complex with ATP and the PIF-pocket ligand RS2	x-ray	1.502	A	o15530	556		79..400
4rrv	pdb	Crystal structure of PDK1 in complex with ATP and PIFtide	x-ray	1.412	A	o15530	556		79..400
4rss	pdb	Crystal structure of tyrosine-protein kinase SYK with an inhibitor	x-ray	1.83	A	p43405	635		375..627
4rt7	pdb	Crystal Structure of FLT3 with a small molecule inhibitor	x-ray	3.1	A	p36888	993		576..941
4rvk	pdb	CHK1 kinase domain with diazacarbazole compound 8: N-[3-(6-cyano-9H-pyrrolo[2,3-b:5,4-c']dipyridin-3-yl)phenyl]acetamide	x-ray	1.85	A	o14757	476		6..317
4rvl	pdb	CHK1 kinase domain with diazacarbazole compound 7: 3-(2-hydroxyphenyl)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile	x-ray	1.85	A	o14757	476		6..317
4rvm	pdb	CHK1 kinase domain with diazacarbazole compound 19	x-ray	1.86	A	o14757	476		6..317
4rvt	pdb	MAP4K4 in complex with a pyridin-2(1H)-one derivative	x-ray	2.4	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4rwi	pdb	Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M), apo	x-ray	2.292	A;B	p11362;p11362	822;822	;	468..754;468..754
4rwj	pdb	Crystal Structure of FGFR1 (C488A, C584S) in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)	x-ray	2.489	A;B	p11362;p11362	822;822	;	468..754;468..754
4rwk	pdb	Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M) in complex with N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)	x-ray	2.982	A;B	p11362;p11362	822;822	;	468..754;468..754
4rwl	pdb	Crystal structure of FGFR1 (C488A, C584C) in complex with 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide (E3810)	x-ray	2.193	A;B	p11362;p11362	822;822	;	468..754;468..754
4rx5	pdb	Bruton's tyrosine kinase (BTK) with pyridazinone compound 23	x-ray	1.356	A	q06187	659		382..648
4rx7	pdb	SYK Catalytic Domain Complexed with a Potent Triazine Inhibitor	x-ray	1.8	A	p43405	635		375..627
4rx8	pdb	SYK Catalytic Domain Complexed with a Potent Triazine Inhibitor2	x-ray	1.59	A	p43405	635		375..627
4rx9	pdb	SYK Catalytic Domain Complexed with a Potent Pyrimidine Inhibitor	x-ray	1.75	A	p43405	635		375..627
4rz7	pdb	Crystal Structure of PVX_084705 with bound PCI32765	x-ray	2.351	A	a5k0n4	846		517..813
4rzv	pdb	Crystal structure of the BRAF (R509H) kinase domain monomer bound to Vemurafenib	x-ray	2.994	A;B	p15056;p15056	766;766	;	449..717;449..717
4rzw	pdb	Crystal structure of BRAF (R509H) kinase domain bound to AZ628	x-ray	3.493	A;B	p15056;p15056	766;766	;	449..717;449..717
4s2z	pdb	ERK2 Intrinsically active mutant R65S	x-ray	1.48	A	p63086	358		17..320
4s30	pdb	ERK2 intrinsically active mutant (I84A)	x-ray	2	A	p63086	358		17..320
4s31	pdb	Crystal structure of mitogen-activated protein kinase 1 wtERK2 at 1.45A	x-ray	1.45	A	p63086	358		17..320
4s32	pdb	Crystal structure of ERK2 AMP-PNP complex	x-ray	1.34	A	p63086	358		17..320
4s33	pdb	ERK2 R65S mutant complexed with AMP-PNP	x-ray	1.48	A	p63086	358		17..320
4s34	pdb	ERK2 (I84A) in complex with AMP-PNP	x-ray	2.5	A	p63086	358		17..320
4tks	pdb	Native-SAD phasing for human EGFR kinase domain.	x-ray	3.2017	A	p00533	1210		708..1003
4tl0	pdb	Crystal structure of death-associated protein kinase 1 with a crucial phosphomimicking mutation	x-ray	2.7	A	p53355	1430		6..291
4tn6	pdb	CK1d in complex with inhibitor	x-ray	2.41	A;B	p48730;p48730	415;415	;	5..290;5..290
4tnb	pdb	Crystal Structure of G Protein-Coupled Receptor Kinase 5 in Complex with Sangivamycin	x-ray	2.113	A	p34947	590		184..537
4tnd	pdb	Crystal Structure of G Protein-Coupled Receptor Kinase 5 in Complex with AMP-PNP	x-ray	1.802	A	p34947	590		184..537
4tpt	pdb	Crystal Structure of the Human LIMK2 Kinase Domain In Complex With a Non-ATP Competitive Inhibitor	x-ray	2.6	A;B	p53671;p53671	638;638	;	304..597;304..597
4trl	pdb	Structure of Ephrin type-A receptor 2	x-ray	2.452	A	p29317	976		605..909
4tt7	pdb	Crystal structure of human ALK with a covalent modification	x-ray	2.1	A	q9um73	1620		1089..1381
4tth	pdb	Crystal structure of a CDK6/Vcyclin complex with inhibitor bound	x-ray	2.9	B	q00534	326		9..303
4tuu	pdb	Isolated p110a subunit of PI3Ka provides a platform for structure-based drug design	x-ray	2.64	A	p42336	1068		699..1060
4tv3	pdb	Isolated p110a subunit of PI3Ka provides a platform for structure-based drug design	x-ray	2.85	A	p42336	1068		699..1060
4tw9	pdb	Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1delta and epsilon with nanomolar inhibitory activity on cancer cell proliferation	x-ray	2.4	A;B	p48730;p48730	415;415	;	5..290;5..290
4twc	pdb	2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4- carboxamide derivatives as potent inhibitors of CK1d/e	x-ray	1.7	A;B	p48730;p48730	415;415	;	5..290;5..290
4twn	pdb	Human EphA3 Kinase domain in complex with Birb796	x-ray	1.706	A	p29320	983		614..915
4two	pdb	Human EphA3 Kinase domain in complex with compound 164	x-ray	2.047	A	p29320	983		614..915
4twp	pdb	The crystal structure of human abl1 T315I gatekeeper mutant kinase domain in complex with axitinib	x-ray	2.4	A;B	p00519;p00519	1130;1130	;	231..498;231..498
4txc	pdb	Crystal Structure of DAPK1 kinase domain in complex with a small molecule inhibitor	x-ray	1.951	A	p53355	1430		6..291
4ty1	pdb	Crystal structure of human Pim-1 kinase in complex with an aminooxadiazole-indole inhibitor.	x-ray	2.7	A	p11309	313		36..296
4tye	pdb	Structural analysis of the human Fibroblast Growth Factor Receptor 4 Kinase	x-ray	2.8	A	p22455	802		458..743
4tyg	pdb	Structural analysis of the human Fibroblast Growth Factor Receptor 4 Kinase	x-ray	2.4	A	p22455	802		458..743
4tyh	pdb	Ternary complex of P38 and MK2 with a P38 inhibitor	x-ray	3	A;B	p49137;p47811	400;360	;	59..369;9..349
4tyi	pdb	Structural analysis of the human Fibroblast Growth Factor Receptor 4	x-ray	3.4	A	p22455	802		458..743
4tyj	pdb	Structural analysis of the human Fibroblast Growth Factor Receptor 4 Kinase	x-ray	2.45	A	p22455	802		458..743
4tzr	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1561	x-ray	2	A	q9bjf5	507		35..330
4u0i	pdb	Crystal structure of KIT in complex with ponatinib	x-ray	2	A	p10721	976		564..923
4u3y	pdb	Apo Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4)	x-ray	1.45	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4u3z	pdb	APO MAP4K4 T181E Phosphomimetic Mutant	x-ray	2.09	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4u40	pdb	Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) Bound to AMPPNP	x-ray	2.3	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4u41	pdb	MAP4K4 Bound to inhibitor compound 1	x-ray	2.2	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4u42	pdb	MAP4K4 T181E Mutant Bound to inhibitor compound 1	x-ray	2.504	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4u43	pdb	MAP4K4 in complex with inhibitor (compound 6)	x-ray	2.18	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4u44	pdb	MAP4K4 in complex with inhibitor (compound 16)	x-ray	2.43	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4u45	pdb	MAP4K4 in complex with inhibitor (compound 25)	x-ray	2.58	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4u5j	pdb	C-Src in complex with Ruxolitinib	x-ray	2.26	A;B	p00523;p00523	533;533	;	256..526;256..526
4u6r	pdb	Crystal structure of human IRE1 cytoplasmic domains in complex with a sulfonamide inhibitor.	x-ray	2.5	A	o75460	977		571..851
4u79	pdb	Crystal structure of human JNK3 in complex with a benzenesulfonamide inhibitor.	x-ray	2.23	A	p53779	464		52..396
4u7z	pdb	Mitogen-Activated Protein Kinase Kinase (MEK1) bound to G805	x-ray	2.805	A	q02750	393		63..365
4u80	pdb	MEK 1 kinase bound to G799	x-ray	2.8	A	q02750	393		63..365
4u81	pdb	MEK1 Kinase bound to small molecule inhibitor G659	x-ray	2.701	A	q02750	393		63..365
4u8z	pdb	Crystal structure of MST3 with a pyrrolopyrimidine inhibitor (PF-06447475)	x-ray	1.63	A	q9y6e0	443		36..320
4u94	pdb	Structure of mycobacterial maltokinase, the missing link in the essential GlgE-pathway	x-ray	1.473	A	a1th50	441		134..420
4u97	pdb	Crystal Structure of Asymmetric IRAK4 Dimer	x-ray	2.65	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
4u98	pdb	Structure of mycobacterial maltokinase, the missing link in the essential GlgE-pathway (AppCp complex)	x-ray	1.15	A	a1th50	441		134..420
4u9a	pdb	Sulphur Anomalous Crystal Structure of Asymmetric IRAK4 Dimer	x-ray	2.8	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
4uak	pdb	MRCK beta in complex with ADP	x-ray	1.73	A	q9y5s2	1711		56..396
4ual	pdb	MRCK beta in complex with BDP00005290	x-ray	1.71	A	q9y5s2	1711		56..396
4ub7	pdb	High-salt structure of protein kinase CK2 catalytic subunit with 4'-carboxy-6,8-bromo-flavonol (FLC26) showing an extreme distortion of the ATP-binding loop combined with a pi-halogen bond	x-ray	2.1	A	p68400	391		5..328
4uba	pdb	Low-salt structure of protein kinase CK2 catalytic subunit with 4'-carboxy-6,8-bromo-flavonol (FLC26)	x-ray	2.995	A;B	p68400;p68400	391;391	;	5..328;5..328
4ueu	pdb	Tyrosine kinase AS - a common ancestor of Src and Abl	x-ray	2.95	A				
4uj1	pdb	Protein Kinase A in complex with an Inhibitor	x-ray	1.768	A	p17612	351		30..339
4uj2	pdb	Protein Kinase A in complex with an Inhibitor	x-ray	2.019	A	p17612	351		30..339
4uj9	pdb	Protein Kinase A in complex with an Inhibitor	x-ray	1.87	A	p17612	351		30..339
4uja	pdb	Protein Kinase A in complex with an Inhibitor	x-ray	1.93	A	p17612	351		30..339
4ujb	pdb	Protein Kinase A in complex with an Inhibitor	x-ray	1.949	A	p17612	351		30..339
4ump	pdb	Structure of MELK in complex with inhibitors	x-ray	2.3	A;B;C;D	q14680;q14680;q14680;q14680	651;651;651;651	;;;	8..308;8..308;8..308;8..308
4umq	pdb	Structure of MELK in complex with inhibitors	x-ray	2.6	A	q14680	651		8..308
4umr	pdb	Structure of MELK in complex with inhibitors	x-ray	3	A	q14680	651		8..308
4umt	pdb	Structure of MELK in complex with inhibitors	x-ray	1.98	A	q14680	651		8..308
4umu	pdb	Structure of MELK in complex with inhibitors	x-ray	2.02	A	q14680	651		8..308
4un0	pdb	Crystal structure of the human CDK12-cyclinK complex	x-ray	3.15	C;D	q9nyv4;q9nyv4	1490;1490	;	721..1024;721..1024
4urk	pdb	PI3Kg in complex with AZD6482	x-ray	2.9	A	p48736	1102		728..1089
4usd	pdb	Human STK10 (LOK) with SB-633825	x-ray	3.05	A;B	o94804;o94804	968;968	;	31..302;31..302
4use	pdb	Human STK10 (LOK) with SB-633825	x-ray	2.65	A;B	o94804;o94804	968;968	;	31..302;31..302
4usf	pdb	Human SLK with SB-440719	x-ray	1.75	A;B	q9h2g2;q9h2g2	1235;1235	;	29..293;29..293
4uv0	pdb	Structure of a semisynthetic phosphorylated DAPK	x-ray	2.49	A	p53355	1430		6..291
4uw0	pdb	Low resolution structure of WbdD with C-terminal bundle ordered to residue 505	x-ray	3.87	A				
4uwb	pdb	Fibroblast growth factor receptor 1 kinase in complex with JK-P5	x-ray	2.31	A;B	p11362;p11362	822;822	;	468..754;468..754
4uwc	pdb	Fibroblast growth factor receptor 1 kinase in complex with JK-P3	x-ray	1.96	A;B	p11362;p11362	822;822	;	468..754;468..754
4uwf	pdb	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors	x-ray	2.99	A	q8neb9	887		538..883
4uwg	pdb	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors	x-ray	2.7	A	q8neb9	887		538..883
4uwh	pdb	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors	x-ray	1.93	A	q8neb9	887		538..883
4uwk	pdb	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors	x-ray	2.83	A	q8neb9	887		538..883
4uwl	pdb	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors	x-ray	2.8	A	q8neb9	887		538..883
4uwy	pdb	FGFR1 Apo structure	x-ray	2.305	A;B	p11362;p11362	822;822	;	468..754;468..754
4ux9	pdb	Crystal structure of JNK1 bound to a MKK7 docking motif	x-ray	2.34	A;B;C;D	p45983;p45983;p45983;p45983	427;427;427;427	;;;	12..357;12..357;12..357;12..357
4uxl	pdb	Structure of Human ROS1 Kinase Domain in Complex with PF-06463922	x-ray	2.4	A	p08922	2347		1935..2215
4uxq	pdb	FGFR4 in complex with Ponatinib	x-ray	1.85	A	p22455	802		458..743
4uy9	pdb	Structure of MLK1 kinase domain with leucine zipper 1	x-ray	2.81	A;B	p80192;p80192	1104;1104	;	120..403;120..403
4uya	pdb	Structure of MLK4 kinase domain with ATPgammaS	x-ray	2.8	A	q5tcx8	1036		102..398
4uyn	pdb	SAR156497 an exquisitely selective inhibitor of Aurora kinases	x-ray	1.9	A	o14965	403		120..386
4uzd	pdb	SAR156497 an exquisitely selective inhibitor of Aurora kinases	x-ray	3.2	A;B	o14965;o14965	403;403	;	120..386;120..386
4uzh	pdb	SAR156497 an exquisitely selective inhibitor of Aurora kinases	x-ray	2	A	o14965	403		120..386
4v01	pdb	FGFR1 in complex with ponatinib (co-crystallisation).	x-ray	2.33	A;B	p11362;p11362	822;822	;	468..754;468..754
4v04	pdb	FGFR1 in complex with ponatinib.	x-ray	2.12	A;B	;	;	;	;
4v05	pdb	FGFR1 in complex with AZD4547.	x-ray	2.57	A;B	;	;	;	;
4v0g	pdb	JAK3 in complex with a covalent EGFR inhibitor	x-ray	3	A;B	p52333;p52333	1124;1124	;	508..788,820..1097;508..788,820..1097
4v0i	pdb	Water Network Determines Selectivity for a Series of Pyrimidone Indoline Amide PI3KBeta Inhibitors over PI3K-Delta	x-ray	2.54	A;B	o35904;o35904	1043;1043	;	677..1032;677..1032
4w4v	pdb	JNK2/3 in complex with 3-(4-{[(2-chlorophenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-4-yl)benzamide	x-ray	2.01	A	p53779	464		52..396
4w4w	pdb	JNK2/3 in complex with N-(2-methylpyridin-4-yl)-3-{4-[(phenylcarbamoyl)amino]-1H-pyrazol-1-yl}benzamide	x-ray	1.9	A	p53779	464		52..396
4w4x	pdb	JNK2/3 in complex with 3-(4-{[(4-fluorophenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-4-yl)benzamide	x-ray	2.65	A	p53779	464		52..396
4w4y	pdb	JNK2/3 in complex with 3-(4-{[(4-methylphenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-4-yl)benzamide	x-ray	2.3	A	p53779	464		52..396
4w7p	pdb	Crystal Structure of ROCK 1 bound to YB-15-QD37	x-ray	2.8	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
4w8d	pdb	Crystal structure of MST3 with a pyrrolopyrimidine inhibitor (PF-06454589).	x-ray	1.77	A	q9y6e0	443		36..320
4w8e	pdb	Structure of MST3 with a pyrrolopyrimidine inhibitor (PF-06645342)	x-ray	1.79	A	q9y6e0	443		36..320
4w9w	pdb	Crystal Structure of BMP-2-inducible kinase in complex with small molecule AZD-7762	x-ray	1.72	A	q9nsy1	1161		52..313
4w9x	pdb	Crystal Structure of BMP-2-inducible kinase in complex with baricitinib	x-ray	2.14	A	q9nsy1	1161		52..313
4wa9	pdb	The crystal structure of human abl1 wild type kinase domain in complex with axitinib	x-ray	2.2	A;B	p00519;p00519	1130;1130	;	231..498;231..498
4wae	pdb	Phosphatidylinositol 4-kinase III beta crystallized with ATP	x-ray	3.318	A	q9ubf8	816		325..810
4waf	pdb	Crystal Structure of a novel tetrahydropyrazolo[1,5-a]pyrazine in an engineered PI3K alpha	x-ray	2.39	A	p42336	1068		699..1060
4wag	pdb	Phosphatidylinositol 4-kinase III beta crystallized with MI103 inhibitor	x-ray	3.407	A	q9ubf8	816		325..810
4wb5	pdb	Crystal structure of human cAMP-dependent protein kinase A (catalytic alpha subunit)	x-ray	1.641	A	p17612	351		30..339
4wb6	pdb	Crystal structure of a L205R mutant of human cAMP-dependent protein kinase A (catalytic alpha subunit)	x-ray	2.1	A;B	p17612;p17612	351;351	;	30..339;30..339
4wb7	pdb	Crystal structure of a chimeric fusion of human DnaJ (Hsp40) and cAMP-dependent protein kinase A (catalytic alpha subunit)	x-ray	1.9	A;B	p17612;p17612	351;351	;	30..339;30..339
4wb8	pdb	Crystal structure of human cAMP-dependent protein kinase A (catalytic alpha subunit), exon 1 deletion	x-ray	1.55	A	p17612	351		30..339
4wbb	pdb	Single Turnover Autophosphorylation Cycle of the PKA RIIb Holoenzyme	x-ray	2.8	B	p05132	351		28..339
4wbo	pdb	Bovine G Protein Coupled Receptor Kinase 1 in Complex with Amlexanox	x-ray	2.81	A;B;C;D	p28327;p28327;p28327;p28327	561;561;561;561	;;;	187..529;187..529;187..529;187..529
4wd5	pdb	Crystal structure of EGFR 696-1022 T790M in complex with QL-X138	x-ray	3.3	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
4wg3	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1610	x-ray	2.2	A	q9bjf5	507		35..330
4wg4	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1613	x-ray	2.3	A	q9bjf5	507		35..330
4wg5	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1647	x-ray	2.3	A	q9bjf5	507		35..330
4wh1	pdb	N-Acetylhexosamine 1-kinase (ligand free)	x-ray	2.05	A	e8mf12	359		4..341
4wh2	pdb	N-acetylhexosamine 1-kinase in complex with ADP	x-ray	1.847	A	e8mf12	359		4..341
4wh3	pdb	N-acetylhexosamine 1-kinase in complex with ATP	x-ray	1.8	A	e8mf12	359		4..341
4whz	pdb	Design and Synthesis of Highly Potent and Isoform Selective JNK3 Inhibitors: SAR Studies on Aminopyrazole Derivatives	x-ray	1.79	A	p53779	464		52..396
4wih	pdb	Crystal structure of cAMP-dependent Protein Kinase A from Cricetulus griseus	x-ray	1.139	A	p25321	351		29..339
4wkq	pdb	1.85 angstrom structure of EGFR kinase domain with gefitinib	x-ray	1.85	A	p00533	1210		708..1003
4wnk	pdb	Crystal Structure of Bovine G Protein Coupled-Receptor Kinase 5 in Complex with CCG215022	x-ray	2.42	A	p43249	590		184..538
4wnm	pdb	SYK catalytic domain in complex with a potent triazolopyridine inhibitor	x-ray	2.5	A	p43405	635		375..627
4wno	pdb	Structure of ULK1 bound to an inhibitor	x-ray	1.56	A	o75385	1050		16..325
4wnp	pdb	Structure of ULK1 bound to a potent inhibitor	x-ray	1.88	A;B;C;D	o75385;o75385;o75385;o75385	1050;1050;1050;1050	;;;	16..325;16..325;16..325;16..325
4wo5	pdb	Crystal structure of a BRAF kinase domain monomer	x-ray	2.83	A;B	p15056;p15056	766;766	;	449..717;449..717
4wot	pdb	ROCK2 IN COMPLEX WITH 1426382-07-1	x-ray	2.93	A;B;C;D	o75116;o75116;o75116;o75116	1388;1388;1388;1388	;;;	89..412;89..412;89..412;89..412
4wov	pdb	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0, 6]DODECA-1(9),2(6),4,7,11-PENTAEN-11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE	x-ray	1.8	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
4wrg	pdb	1.9 angstrom structure of EGFR kinase domain	x-ray	1.9	A	p00533	1210		708..1003
4wrs	pdb	Crystal structure of human Pim-1 kinase in complex with an azaspiro pyrazinyl-indazole inhibitor.	x-ray	2.2	A	p11309	313		36..296
4wsq	pdb	Crystal Structure of Adaptor Protein 2 Associated Kinase (AAK1) in complex with small molecule inhibitor	x-ray	1.95	A;B	q2m2i8;q2m2i8	961;961	;	46..309;46..309
4wsy	pdb	Crystal structure of human Pim-1 kinase in complex with a thiazolamine-indazole inhibitor.	x-ray	2.3	A	p11309	313		36..296
4wt6	pdb	Crystal structure of human Pim-1 kinase in complex with a thiadiazolamine-indole inhibitor.	x-ray	2.3	A	p11309	313		36..296
4wua	pdb	Crystal structure of human SRPK1 complexed to an inhibitor SRPIN340	x-ray	2	A	q96sb4	655		67..654
4wun	pdb	Structure of FGFR1 in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) at 1.65 angstrom	x-ray	1.65	A;B	p11362;p11362	822;822	;	468..754;468..754
4ww5	pdb	Crystal structure of binary complex Bud32-Cgi121 in complex with AMPP	x-ray	1.997	A	p53323	261		20..198
4ww7	pdb	Crystal structure of binary complex Bud32-Cgi121 in complex with AMP	x-ray	1.669	A	p53323	261		20..198
4ww9	pdb	Crystal structure of binary complex Bud32-Cgi121 in complex with ADP	x-ray	1.951	A	p53323	261		20..198
4wwa	pdb	Crystal structure of binary complex Bud32-Cgi121	x-ray	2.953	A	p53323	261		20..198
4wwn	pdb	Crystal structure of human PI3K-gamma in complex with (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine AMG319 inhibitor	x-ray	2.7	A	p48736	1102		728..1089
4wwo	pdb	Crystal structure of human PI3K-gamma in complex with phenylquinoline inhibitor N-{(1S)-1-[8-chloro-2-(3-fluorophenyl)quinolin-3-yl]ethyl}-9H-purin-6-amine	x-ray	2.3	A	p48736	1102		728..1089
4wwp	pdb	Crystal structure of human PI3K-gamma in complex with pyridinylquinoline inhibitor N-{(1S)-1-[8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl]ethyl}-9H-purin-6-amine	x-ray	2.4	A	p48736	1102		728..1089
4wzy	pdb	Structure of mycobacterial maltokinase, the missing link in the essential GlgE-pathway (ATP complex)	x-ray	1.71	A	a1th50	441		134..420
4x0m	pdb	Selection of fragments for kinase inhibitor design: decoration is key	x-ray	1.68	A	p36897	503		180..492
4x21	pdb	The MAP kinase JNK3 as target for halogen bonding	x-ray	1.95	A;B	p53779;p53779	464;464	;	52..396;52..396
4x2f	pdb	Selection of fragments for kinase inhibitor design: decoration is key	x-ray	1.49	A	p36897	503		180..492
4x2g	pdb	Selection of fragments for kinase inhibitor design: decoration is key	x-ray	1.51	A	p36897	503		180..492
4x2j	pdb	Selection of fragments for kinase inhibitor design: decoration is key	x-ray	1.69	A	p36897	503		180..492
4x2k	pdb	Selection of fragments for kinase inhibitor design: decoration is key	x-ray	1.69	A	p36897	503		180..492
4x2n	pdb	Selection of fragments for kinase inhibitor design: decoration is key	x-ray	1.8	A	p36897	503		180..492
4x3f	pdb	Crystal structure of the intracellular domain of the M. tuberculosis Ser/Thr kinase PknA	x-ray	2.9	A;B;C	p9wi83;p9wi83;p9wi83	431;431;431	;;	11..274;11..274;11..274
4x3j	pdb	Selection of fragments for kinase inhibitor design: decoration is key	x-ray	2.5	A	q02763	1124		819..1107
4x6q	pdb	An Isoform-specific Myristylation Switch Targets RIIb PKA Holoenzymes to Membranes	x-ray	2.52	C	p05132	351		28..339
4x6r	pdb	An Isoform-specific Myristylation Switch Targets RIIb PKA Holoenzymes to Membranes	x-ray	2.4	A	p05132	351		28..339
4x7h	pdb	Co-crystal Structure of PERK bound to N-{5-[(6,7-dimethoxyquinolin-4-yl)oxy]pyridin-2-yl}-1-methyl-3-oxo-2-phenyl-5-(pyridin-4-yl)-2,3-dihydro-1H-pyrazole-4-carboxamide inhibitor	x-ray	2	A	q9nzj5	1116		587..1090
4x7j	pdb	Co-crystal Structure of PERK with 2-amino-N-[4-methoxy-3-(trifluoromethyl)phenyl]-4-methyl-3-[2-(methylamino)quinazolin-6-yl]benzamide inhibitor	x-ray	2.3	A	q9nzj5	1116		587..1090
4x7k	pdb	Co-crystal Structure of PERK bound to 4-{2-amino-3-[5-fluoro-2-(methylamino)quinazolin-6-yl]-4-methylbenzoyl}-1-methyl-2,5-diphenyl-1,2-dihydro-3H-pyrazol-3-one inhibitor	x-ray	1.8	A	q9nzj5	1116		587..1090
4x7l	pdb	Co-crystal Structure of PERK bound to 4-{2-amino-4-methyl-3-[2-(methylamino)-1,3-benzothiazol-6-yl]benzoyl}-1-methyl-2,5-diphenyl-1,2-dihydro-3H-pyrazol-3-one inhibitor	x-ray	1.9	A	q9nzj5	1116		587..1090
4x7n	pdb	Co-crystal Structure of PERK bound to 4-[2-amino-4-methyl-3-(2-methylquinolin-6-yl)benzoyl]-1-methyl-2,5-diphenyl-1,2-dihydro-3H-pyrazol-3-one inhibitor	x-ray	2.35	A	q9nzj5	1116		587..1090
4x7o	pdb	Co-crystal Structure of PERK bound to 1-[5-(4-amino-2,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydro-1H-indol-1-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone inhibitor	x-ray	2.65	A	q9nzj5	1116		587..1090
4x7q	pdb	PIM2 kinase in complex with Compound 1s	x-ray	2.33	A;B	q9p1w9;q9p1w9	311;311	;	31..290;31..290
4xbr	pdb	In cellulo Crystal Structure of PAK4 in complex with Inka	x-ray	2.94	A	o96013	591		323..578
4xbu	pdb	In vitro Crystal Structure of PAK4 in complex with Inka peptide	x-ray	2.06	A	o96013	591		323..578
4xcu	pdb	Crystal Structure of FGFR4 with an Irreversible Inhibitor	x-ray	1.71	A	p22455	802		458..743
4xe0	pdb	Idelalisib bound to the p110 subunit of PI3K delta	x-ray	2.434	A	o35904	1043		677..1032
4xey	pdb	Crystal structure of an SH2-kinase domain construct of c-Abl tyrosine kinase	x-ray	2.891	A;B	p00519;p00519	1130;1130	;	231..498;231..498
4xg2	pdb	Crystal structure of ligand-free Syk	x-ray	2.21	A	p43405	635		375..627
4xg3	pdb	Crystal structure of an inhibitor-bound Syk	x-ray	2.3	A;B	p43405;p43405	635;635	;	375..627;375..627
4xg4	pdb	Crystal structure of an inhibitor-bound Syk	x-ray	2.3	A	p43405	635		375..627
4xg6	pdb	Crystal structure of an inhibitor-bound Syk	x-ray	2.4	A	p43405	635		375..627
4xg7	pdb	Crystal structure of an inhibitor-bound Syk	x-ray	1.76	A	p43405	635		375..627
4xg8	pdb	Crystal structure of an inhibitor-bound Syk	x-ray	2.4	A;C	p43405;p43405	635;635	;	375..627;375..627
4xg9	pdb	Crystal structure of an inhibitor-bound Syk	x-ray	2.91	A;B	p43405;p43405	635;635	;	375..627;375..627
4xh0	pdb	Structure of C. glabrata Hrr25 bound to ADP (SO4 condition)	x-ray	1.99	A	q6fs46	495		6..290
4xh6	pdb	Crystal structure of proto-oncogene kinase Pim1 bound to hispidulin	x-ray	2.04	A	p11309	313		36..296
4xhg	pdb	Structure of C. glabrata Hrr25 bound to ADP (formate condition)	x-ray	2.15	A	q6fs46	495		6..290
4xhh	pdb	Structure of C. glabrata Hrr25, Apo state	x-ray	2.908	A	q6fs46	495		6..290
4xhk	pdb	PIM1 kinase in complex with Compound 1s	x-ray	1.9	B	p11309	313		36..296
4xhl	pdb	Structure of S. cerevisiae Hrr25 1-394 (K38R mutant)	x-ray	3.01	A	p29295	494		6..290
4xi2	pdb	Crystal Structure of an auto-inhibited form of Bruton's Tryrosine Kinase	x-ray	2.6	A	p35991	659		383..648
4xj0	pdb	Crystal structure of ERK2 in complex with an inhibitor 14K	x-ray	2.58	A;B	p28482;p28482	360;360	;	19..322;19..322
4xli	pdb	Crystal structure of Abl2/Arg kinase in complex with dasatinib	x-ray	2.5	A;B	q4jim5;q4jim5	1182;1182	;	279..552;279..552
4xlv	pdb	Crystal structure of the activated insulin receptor tyrosine kinase dimer	x-ray	2.3	A	p06213	1382		996..1290
4xmo	pdb	Crystal structure of c-Met in complex with (R)-5-(8-fluoro-3-(1-fluoro-1-(3-methoxyquinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole	x-ray	1.75	A	p08581	1390		1079..1341
4xne	pdb	Crystal structure of ERK2 in complex with an inhibitor	x-ray	1.8	A	p63086	358		17..320
4xoy	pdb	Crystal structure of ERK2 in complex with an inhibitor	x-ray	2.1	A	p63086	358		17..320
4xoz	pdb	Crystal structure of ERK2 in complex with an inhibitor	x-ray	1.95	A	p63086	358		17..320
4xp0	pdb	Crystal structure of ERK2 in complex with an inhibitor	x-ray	1.46	A	p63086	358		17..320
4xp2	pdb	Crystal structure of ERK2 in complex with an inhibitor	x-ray	1.748	A	p63086	358		17..320
4xp3	pdb	Crystal structure of ERK2 in complex with an inhibitor	x-ray	1.782	A	p63086	358		17..320
4xr7	pdb	Structure of the Saccharomyces cerevisiae PAN2-PAN3 core complex	x-ray	3.796	B;C;E;F;H;I;K;L	p36102;p36102;p36102;p36102;p36102;p36102;p36102;p36102	679;679;679;679;679;679;679;679	;;;;;;;	309..551;309..551;309..551;309..551;309..551;309..551;309..551;309..551
4xrj	pdb	Crystal structure of ERK2 in complex with an inhibitor	x-ray	1.69	A	p63086	358		17..320
4xrl	pdb	Crystal structure at room temperature of Erk2 in complex with an inhibitor	x-ray	2.554	A	p63086	358		17..320
4xs2	pdb	Irak4-inhibitor co-structure	x-ray	2.73	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
4xuf	pdb	Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)	x-ray	3.2	A;B	p36888;p36888	993;993	;	576..941;576..941
4xv1	pdb	B-Raf Kinase V600E oncogenic mutant in complex with PLX7904	x-ray	2.47	A;B	p15056;p15056	766;766	;	449..717;449..717
4xv2	pdb	B-Raf Kinase V600E oncogenic mutant in complex with Dabrafenib	x-ray	2.5	A;B	p15056;p15056	766;766	;	449..717;449..717
4xv3	pdb	B-Raf Kinase V600E oncogenic mutant in complex with PLX7922	x-ray	2.8	A;B	p15056;p15056	766;766	;	449..717;449..717
4xv9	pdb	B-Raf Kinase domain in complex with PLX5568	x-ray	2	A	p15056	766		449..717
4xw4	pdb	X-ray structure of PKAc with AMPPNP, SP20, calcium ions	x-ray	1.82	A	p05132	351		28..339
4xw5	pdb	X-ray structure of PKAc with ATP, CP20, calcium ions	x-ray	1.95	A	p05132	351		28..339
4xw6	pdb	X-ray structure of PKAc with ADP, free phosphate ion, CP20, magnesium ions	x-ray	1.9	A	p05132	351		28..339
4xx5	pdb	Structure of PI3K gamma in complex with an inhibitor	x-ray	2.76	A	p48736	1102		728..1089
4xx9	pdb	Crystal structure of PDK1 in complex with ATP and the PIF-pocket ligand RF4	x-ray	1.4	A	o15530	556		79..400
4xyf	pdb	Crystal structure of c-Met in complex with (S)-5-(8-fluoro-3-(1-(3-(2-methoxyethoxy)quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole	x-ray	1.85	A	p08581	1390		1079..1341
4xz4	pdb	Structure of PI3K gamma in complex with an inhibitor	x-ray	2.6	A	p48736	1102		728..1089
4y0x	pdb	Crystal structure of the S/T protein kinase PknG from Mycobacterium tuberculosis in complex with ADP	x-ray	1.74	A	p9wi73	750		131..402
4y12	pdb	Crystal structure of the S/T protein kinase PknG from Mycobacterium tuberculosis in complex with AGS	x-ray	1.9	A	p9wi73	750		131..402
4y46	pdb	Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) inhibitors	x-ray	2.04	A	p53779	464		52..396
4y5h	pdb	Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) inhibitors	x-ray	2.055	A	p53779	464		52..396
4y5q	pdb	Activated Calcium-Dependent Protein Kinase 1 from Cryptosporidium parvum (CpCDPK1) in complex with AMP	x-ray	2	A	a3fq16	538		69..348
4y72	pdb	Human CDK1/CyclinB1/CKS2 With Inhibitor	x-ray	2.3	A	p06493	297		1..291
4y73	pdb	Crystal structure of IRAK4 kinase domain with inhibitor	x-ray	2.14	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
4y83	pdb	Crystal structure of COT kinase domain in complex with 5-(2-amino-5-(quinolin-3-yl)pyridin-3-yl)-1,3,4-oxadiazole-2(3H)-thione	x-ray	2.89	A;B;C	p41279;p41279;p41279	467;467;467	;;	141..399;141..399;141..399
4y85	pdb	Crystal structure of COT kinase domain in complex with 5-(5-(1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3,4-oxadiazol-2-amine	x-ray	2.33	A;B;C	p41279;p41279;p41279	467;467;467	;;	141..399;141..399;141..399
4y8d	pdb	Crystal structure of Cyclin-G associated kinase (GAK) complexed with selective 12i inhibitor	x-ray	2.1	A;B	;	;	;	;
4y93	pdb	Crystal structure of the PH-TH-kinase construct of Bruton's tyrosine kinase (Btk)	x-ray	1.695	A	q3zc95	659		382..648
4y95	pdb	Crystal structure of the kinase domain of Bruton's tyrosine kinase with mutations in the activation loop	x-ray	1.599	A;B;C;D	q3zc95;q3zc95;q3zc95;q3zc95	659;659;659;659	;;;	382..648;382..648;382..648;382..648
4ybj	pdb	Type II Dasatinib Analog Crystallized with c-Src Kinase	x-ray	2.61	A;B	p00523;p00523	533;533	;	256..526;256..526
4ybk	pdb	C-Helix-Out Dasatinib Analog Crystallized with c-Src Kinase	x-ray	2.5	A	p00523	533		256..526
4yc3	pdb	CDK1/CyclinB1/CKS2 Apo	x-ray	2.7	A	p06493	297		1..291
4yc6	pdb	CDK1/CKS1	x-ray	2.6	A;C;E;G	p06493;p06493;p06493;p06493	297;297;297;297	;;;	1..291;1..291;1..291;1..291
4yc8	pdb	C-Helix-Out Binding of Dasatinib Analog to c-Abl Kinase	x-ray	2.9	A;B	p00519;p00519	1130;1130	;	231..498;231..498
4yff	pdb	TNNI3K complexed with inhibitor 2	x-ray	3.07	A;B;C;D	q59h18;q59h18;q59h18;q59h18	835;835;835;835	;;;	454..727;454..727;454..727;454..727
4yfi	pdb	TNNI3K complexed with inhibitor 1	x-ray	2.7	A;B;C;D	q59h18;q59h18;q59h18;q59h18	835;835;835;835	;;;	454..727;454..727;454..727;454..727
4yga	pdb	CDPK1, from Toxoplasma gondii, bound to inhibitory VHH-1B7	x-ray	2.94	A;C;E;G	;;;	;;;	;;;	;;;
4yhf	pdb	Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitor	x-ray	2.2	A;B	q06187;q06187	659;659	;	382..648;382..648
4yhj	pdb	Structure and Function of the Hypertension Variant A486V of G Protein-coupled Receptor Kinase 4 (GRK4)	x-ray	2.6	A;B	p32298;p32298	578;578	;	185..520;185..520
4yht	pdb	bRaf complexed with an inhibitor	x-ray	3.05	A;B	p15056;p15056	766;766	;	449..717;449..717
4yjn	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1639	x-ray	2.6	A	q9bjf5	507		35..330
4yjo	pdb	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222	x-ray	1.6	A	p43405	635		375..627
4yjp	pdb	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223	x-ray	1.83	A	p43405	635		375..627
4yjq	pdb	SYK kinase domain in complex with inhibitor GTC000224	x-ray	1.34	A	p43405	635		375..627
4yjr	pdb	SYK kinase domain in complex with inhibitor GTC000225	x-ray	1.32	A	p43405	635		375..627
4yjs	pdb	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226	x-ray	2.22	A	p43405	635		375..627
4yjt	pdb	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233	x-ray	1.52	A	p43405	635		375..627
4yju	pdb	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249	x-ray	1.67	A	p43405	635		375..627
4yjv	pdb	THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250	x-ray	1.652	A	p43405	635		375..627
4ykn	pdb	Pi3K alpha lipid kinase with Active Site Inhibitor	x-ray	2.9	A	p27986	724		
4ylj	pdb	Crystal structure of DYRK1A in complex with 10-Iodo-substituted 11H-indolo[3,2-c]quinoline-6-carboxylic acid inhibitor 5j	x-ray	2.58	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
4ylk	pdb	Crystal structure of DYRK1A in complex with 10-Chloro-substituted 11H-indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5s	x-ray	1.4	A	q13627	763		147..489
4yll	pdb	Crystal structure of DYRK1AA in complex with 10-Bromo-substituted 11H-indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5t	x-ray	1.4	A	q13627	763		147..489
4ymj	pdb	(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors	x-ray	2	A;B	q16288;q16288	839;839	;	514..824;514..824
4yne	pdb	(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors	x-ray	2.0229	A	p04629	796		494..779
4yno	pdb	Crystal structure of MAPK13 at INACTIVE FORM	x-ray	1.7	A	o15264	365		19..314
4ynz	pdb	Structure of the N-terminal domain of SAD	x-ray	2	A;B	q69z98;q69z98	735;735	;	17..422;17..422
4yo4	pdb	Crystal Structure of DAPK1 catalytic domain in complex with the hinge binding fragment phthalazine	x-ray	1.6	A	p53355	1430		6..291
4yo6	pdb	Irak4-inhibitor co-structure	x-ray	2.32	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
4yom	pdb	Structure of SAD kinase	x-ray	2.49	B	q69z98	735		17..422
4yp8	pdb	Irak4-inhibitor co-structure	x-ray	2.641	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
4ypd	pdb	Crystal Structure of DAPK1 catalytic domain in complex with the hinge binding fragment 4-methylpyridazine	x-ray	1.4	A	p53355	1430		6..291
4yps	pdb	(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors	x-ray	2.1012	A	p04629	796		494..779
4yr8	pdb	Crystal structure of JNK in complex with a regulator protein	x-ray	2.4	A;C;E;F	p45983;p45983;p45983;p45983	427;427;427;427	;;;	12..357;12..357;12..357;12..357
4ysj	pdb	Calcium-Dependent Protein Kinase from Eimeria tenella in complex with ADP	x-ray	2.7	A;B	q3hnm4;q3hnm4	505;505	;	31..327;31..327
4ysm	pdb	Calcium-Dependent Protein Kinase from Eimeria tenella	x-ray	3.19	A;B	q3hnm4;q3hnm4	505;505	;	31..327;31..327
4ytc	pdb	Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Disease	x-ray	2.16	A	o60674	1132		522..814,842..1119
4ytf	pdb	Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases	x-ray	1.78	A	o60674	1132		522..814,842..1119
4yth	pdb	Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases	x-ray	2.04	A	o60674	1132		522..814,842..1119
4yti	pdb	Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Disease	x-ray	2.52	A	o60674	1132		522..814,842..1119
4yu2	pdb	Crystal structure of DYRK1A with harmine-derivatized AnnH-75 inhibitor	x-ray	2.9	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
4yuq	pdb	CDPK1 from Eimeria tenella in complex with inhibitor UW1354	x-ray	2.8	A;B	q3hnm4;q3hnm4	505;505	;	31..327;31..327
4yur	pdb	Crystal Structure of Plk4 Kinase Domain Bound to Centrinone	x-ray	2.65	A	o00444	970		9..266
4yvc	pdb	ROCK 1 bound to thiazole inhibitor	x-ray	3.2	A;B	q13464;q13464	1354;1354	;	73..413;73..413
4yve	pdb	ROCK 1 bound to methoxyphenyl thiazole inhibitor	x-ray	3.4	A;B	q13464;q13464	1354;1354	;	73..413;73..413
4yxr	pdb	CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH inhibitor.	x-ray	2	A	p00517	351		32..339
4yxs	pdb	CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24	x-ray	2.11	A	p00517	351		32..339
4yz9	pdb	Crystal Structure of human phosphorylated IRE1alpha in complex with a type III kinase inhibitor (GSK2850163A)	x-ray	2.463	A;B;C	o75460;o75460;o75460	977;977;977	;;	571..851;571..851;571..851
4yzb	pdb	CDPK1 from Eimeria tenella in complex with inhibitor UW1521	x-ray	2.9	A;B	q3hnm4;q3hnm4	505;505	;	31..327;31..327
4yzc	pdb	Crystal structure of pIRE1alpha in complex with staurosporine	x-ray	2.494	A;B	o75460;o75460	977;977	;	571..851;571..851
4yzd	pdb	Crystal Structure of human phosphorylated IRE1alpha in complex with ADP-Mg	x-ray	3.102	A;B;C	o75460;o75460;o75460	977;977;977	;;	571..851;571..851;571..851
4yzm	pdb	Humanized Roco4 bound to LRRK2-In1	x-ray	3	A;B	q6xhb2;q6xhb2	1726;1726	;	1019..1315;1019..1315
4yzn	pdb	Humanized Roco4 bound to Compound 19	x-ray	1.55	A	q6xhb2	1726		1019..1315
4z16	pdb	Crystal Structure of the Jak3 Kinase Domain Covalently Bound to N-(3-(((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)methyl)phenyl)acrylamide	x-ray	2.9	A;B;C;D	p52333;p52333;p52333;p52333	1124;1124;1124;1124	;;;	508..788,820..1097;508..788,820..1097;508..788,820..1097;508..788,820..1097
4z3v	pdb	Fragment-Based Discovery of a Small Molecule Reversible Inhibitor of Bruton's Tyrosine Kinase	x-ray	1.6	A	q06187	659		382..648
4z55	pdb	Anaplastic lymphoma kinase catalytic domain complexed with pyrazolopyrimidine derivative of LDK378	x-ray	1.55	A	q9um73	1620		1089..1381
4z7g	pdb	Crystal structure of human IRE1 cytoplasmic kinase-RNase region - apo	x-ray	2.6	A;B	o75460;o75460	977;977	;	571..851;571..851
4z7h	pdb	Crystal structure of human IRE1 cytoplasmic kinase-RNase region - complex with imidazopyridine compound 3	x-ray	2.9	A;B	o75460;o75460	977;977	;	571..851;571..851
4z83	pdb	PKAB3 in complex with pyrrolidine inhibitor 47a	x-ray	1.8	E	p00517	351		32..339
4z84	pdb	PKAB3 in complex with pyrrolidine inhibitor 34a	x-ray	1.554	A	p00517	351		32..339
4z9l	pdb	THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR	x-ray	2.1	A	p53779	464		52..396
4zau	pdb	AZD9291 complex with wild type EGFR	x-ray	2.8	A	p00533	1210		708..1003
4zeg	pdb	Crystal structure of TTK kinase domain in complex with a pyrazolopyrimidine inhibitor	x-ray	2.33	A	p33981	857		516..792
4zhx	pdb	Novel binding site for allosteric activation of AMPK	x-ray	2.99	A;C	p54646;p54646	552;552	;	13..269;13..269
4zim	pdb	CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1-CARBOXAMIDE INHIBITOR	x-ray	2.65	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
4zji	pdb	PAK1 in complex with 2-chloro-5-ethyl-8-fluoro-11-(4-methylpiperazin-1-yl)-dibenzodiazepine	x-ray	1.99	A;B;C;D	q13153;q13153;q13153;q13153	545;545;545;545	;;;	261..522;261..522;261..522;261..522
4zjj	pdb	PAK1 in complex with (S)-N-(tert-butyl)-3-((2-chloro-5-ethyl-8-fluoro-dibenzodiazepin-11-yl)amino)pyrrolidine-1-carboxamide	x-ray	2.2	A;B;C;D	q13153;q13153;q13153;q13153	545;545;545;545	;;;	261..522;261..522;261..522;261..522
4zjv	pdb	crystal structure of EGFR kinase domain in complex with Mitogen-inducible gene 6 protein	x-ray	2.7	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
4zk5	pdb	MAP4K4 in complex with inhibitor GNE-495	x-ray	2.89	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4zlo	pdb	Serine/threonine-protein kinase PAK1 complexed with a dibenzodiazepine: identification of an allosteric site on PAK1	x-ray	2.5	A;B	q13153;q13153	545;545	;	261..522;261..522
4zly	pdb	Crystal Structure of Bruton's Tyrosine Kinase bound to a Cinnoline Fragment	x-ray	1.65	A	q06187	659		382..648
4zlz	pdb	Crystal Structure of Bruton's Tyrosine Kinase in complex with a substituted Cinnoline	x-ray	2	A	q06187	659		382..648
4zme	pdb	Crystal Structure of the Alpha-kinase Domain of Myosin-II Heavy Chain Kinase A in Complex with Adenosine	x-ray	1.98	A;B	p42527;p42527	1146;1146	;	551..805;551..805
4zmf	pdb	Phosphorylated Aspartate in the Crystal Structure of the Alpha-kinase domain of Myosin-II Heavy Chain Kinase A	x-ray	2.39	A;B	p42527;p42527	1146;1146	;	551..805;551..805
4zog	pdb	VX-680/MK-0457 binds to human ABL1 also in inactive DFG conformations.	x-ray	2.3	A;B	p00519;p00519	1130;1130	;	231..498;231..498
4zop	pdb	Co-crystal Structure of Lipid Kinase PI3K alpha with a selective phosphatidylinositol-3 kinase alpha inhibitor	x-ray	2.62	A	p42336	1068		699..1060
4zp5	pdb	MAP4K4 in complex with inhibitor	x-ray	2.29	A;B	o95819;o95819	1239;1239	;	24..290;24..290
4zs0	pdb	Human Aurora A catalytic domain bound to SB-6-OH	x-ray	3	A	o14965	403		120..386
4zs4	pdb	Crystal Structure of the Inactive Alpha-kinase Domain of Myosin-II Heavy Chain Kinase A (D756A) Complexed with ATP	x-ray	2.4	A;B	p42527;p42527	1146;1146	;	551..805;551..805
4zsa	pdb	Crystal structure of FGFR1 kinase domain in complex with 7n	x-ray	2	A;B	p11362;p11362	822;822	;	468..754;468..754
4zse	pdb	Crystal structure of EGFR 696-1022 T790M/V948R, crystal form II	x-ray	1.97	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
4zsg	pdb	MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR	x-ray	1.79	A	q13164	816		48..356
4zsj	pdb	MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR	x-ray	2.48	A	q13164	816		48..356
4zsl	pdb	MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR	x-ray	2.25	A	q13164	816		48..356
4zth	pdb	Structure of human p38aMAPK-arylpyridazinylpyridine fragment complex used in inhibitor discovery	x-ray	2.15	A	q16539	360		9..349
4ztl	pdb	Irak4-inhibitor co-structure	x-ray	2.39	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
4ztm	pdb	Irak4-inhibitor co-structure	x-ray	2.66	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
4ztn	pdb	Irak4-inhibitor co-structure	x-ray	2.23	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
4ztq	pdb	Human Aurora A catalytic domain bound to FK932	x-ray	2.8	A	o14965	403		120..386
4ztr	pdb	Human Aurora A catalytic domain bound to FK1141	x-ray	2.85	A	o14965	403		120..386
4zts	pdb	Human Aurora A catalytic domain bound to FK1142	x-ray	2.9	A	o14965	403		120..386
4zxt	pdb	Complex of ERK2 with catechol	x-ray	2	A	p28482	360		19..322
4zy4	pdb	Crystal structure of P21 activated kinase 1 in complex with an inhibitor compound 4	x-ray	2.6	A;B	q13153;q13153	545;545	;	261..522;261..522
4zy5	pdb	Crystal Structure of p21-activated kinase 1 in complex with an inhibitor compound 17	x-ray	2.35	A;B	q13153;q13153	545;545	;	261..522;261..522
4zy6	pdb	Crystal structure of P21-activated kinase 1 in complex with an inhibitor compound 29	x-ray	2.15	A;B	q13153;q13153	545;545	;	261..522;261..522
4zzm	pdb	Human ERK2 in complex with an irreversible inhibitor	x-ray	1.89	A	p28482	360		19..322
4zzn	pdb	Human ERK2 in complex with an inhibitor	x-ray	1.33	A	p28482	360		19..322
4zzo	pdb	Human ERK2 in complex with an irreversible inhibitor	x-ray	1.63	A	p28482	360		19..322
5a14	pdb	Human CDK2 with type II inhibitor	x-ray	2	A	p24941	298		1..292
5a3x	pdb	DYRK1A in complex with hydroxy benzothiazole fragment	x-ray	2.26	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
5a46	pdb	FGFR1 in complex with dovitinib	x-ray	2.63	A;B	p11362;p11362	822;822	;	468..754;468..754
5a4c	pdb	FGFR1 ligand complex	x-ray	2.09	A;B	p11362;p11362	822;822	;	468..754;468..754
5a4e	pdb	DYRK1A in complex with methoxy benzothiazole fragment	x-ray	2.68	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
5a4l	pdb	DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT	x-ray	2.73	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
5a4q	pdb	DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT	x-ray	2.37	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
5a4t	pdb	DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT	x-ray	2.15	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
5a54	pdb	DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT	x-ray	2.63	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
5a6n	pdb	Crystal structure of human death associated protein kinase 3 (DAPK3) in complex with compound 2	x-ray	1.7	A;B	o43293;o43293	454;454	;	6..313;6..313
5a6o	pdb	Crystal structure of the apo form of the unphosphorylated human death associated protein kinase 3 (DAPK3)	x-ray	1.6	A;B	o43293;o43293	454;454	;	6..313;6..313
5a9u	pdb	Structure of C1156Y Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).	x-ray	1.6	A	q9um73	1620		1089..1381
5aa8	pdb	Structure of C1156Y,L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).	x-ray	1.86	A	q9um73	1620		1089..1381
5aa9	pdb	Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).	x-ray	1.93	A	q9um73	1620		1089..1381
5aaa	pdb	Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib	x-ray	1.73	A	q9um73	1620		1089..1381
5aab	pdb	Structure of C1156Y,L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib	x-ray	2.2	A	q9um73	1620		1089..1381
5aac	pdb	Structure of C1156Y Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib	x-ray	1.7	A	q9um73	1620		1089..1381
5aad	pdb	Aurora A kinase bound to an imidazopyridine inhibitor (7a)	x-ray	3.1	A	o14965	403		120..386
5aae	pdb	Aurora A kinase bound to an imidazopyridine inhibitor (14d)	x-ray	3.11	A	o14965	403		120..386
5aaf	pdb	Aurora A kinase bound to an imidazopyridine inhibitor (14a)	x-ray	2.78	A	o14965	403		120..386
5aag	pdb	Aurora A kinase bound to an imidazopyridine inhibitor (14b)	x-ray	2.85	A	o14965	403		120..386
5acb	pdb	Crystal Structure of the Human Cdk12-Cyclink Complex	x-ray	2.7	C;D	q9nyv4;q9nyv4	1490;1490	;	721..1024;721..1024
5ack	pdb	Human PDK1 Kinase Domain in Complex with Allosteric Compound 7 Bound to the PIF-Pocket	x-ray	1.24	A	o15530	556		79..400
5ae8	pdb	Crystal structure of mouse PI3 kinase delta in complex with GSK2269557	x-ray	2.42	A	o35904	1043		677..1032
5ae9	pdb	Crystal structure of mouse PI3 kinase delta in complex with GSK2292767	x-ray	2.44	A	o35904	1043		677..1032
5aep	pdb	Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders	x-ray	1.95	A	o60674	1132		522..814,842..1119
5afv	pdb	Pharmacophore-based virtual screening to discover new active compounds for human choline kinase alpha1.	x-ray	2.25	A;B	p35790;p35790	457;457	;	82..455;82..455
5aik	pdb	Human DYRK1A in complex with LDN-211898	x-ray	2.7	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
5air	pdb	Structural analysis of mouse GSK3beta fused with LRP6 peptide.	x-ray	2.53	A;B	o75581;q9wv60	1613;420	;	;55..377
5ajq	pdb	Human LOK (STK10) in complex with Bosutinib	x-ray	2.2	A;B	o94804;o94804	968;968	;	31..302;31..302
5am6	pdb	Native FGFR1 with an inhibitor	x-ray	1.96	A;B	p11362;p11362	822;822	;	468..754;468..754
5am7	pdb	FGFR1 mutant with an inhibitor	x-ray	1.957	A;B	p11362;p11362	822;822	;	468..754;468..754
5amn	pdb	The Discovery of 2-Substituted Phenol Quinazolines as Potent and Selective RET Kinase Inhibitors	x-ray	2.57	A	p07949	1114		699..1005
5and	pdb	Crystal structure of CDK2 in complex with 2-imidazol-1-yl-1H- benzimidazole processed with the CrystalDirect automated mounting and cryo-cooling technology	x-ray	2.3	A	p24941	298		1..292
5ane	pdb	Crystal structure of CDK2 in complex with 6-methoxy-7H-purine processed with the CrystalDirect automated mounting and cryo-cooling technology	x-ray	1.7	A	p24941	298		1..292
5ang	pdb	Crystal structure of CDK2 in complex with 7-hydroxy-4-(morpholinomethyl)chromen-2-one processed with the CrystalDirect automated mounting and cryo-cooling technology	x-ray	1.9	A	p24941	298		1..292
5ani	pdb	Crystal structure of CDK2 in complex with 6-chloro-7H-purine processed with the CrystalDirect automated mounting and cryo-cooling technology	x-ray	1.9	A	p24941	298		1..292
5anj	pdb	Crystal structure of CDK2 in complex with N-(9H-purin-6-yl)thiophene- 2-carboxamide processed with the CrystalDirect automated mounting and cryo-cooling technology	x-ray	1.6	A	p24941	298		1..292
5ank	pdb	Crystal structure of CDK2 in complex with 2,4,6-trioxo-1-phenyl- hexahydropyrimidine-5-carboxamide processed with the CrystalDirect automated mounting and cryo-cooling technology	x-ray	1.9	A	p24941	298		1..292
5anl	pdb	Crystal structure of VPS34 in complex with (2S)-8-((3R)-3- Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3, 4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one, processed with the CrystalDirect automated mounting and cryo-cooling technology	x-ray	2.7	A	q8neb9	887		538..883
5ano	pdb	Crystal structure of CDK2 processed with the CrystalDirect automated mounting and cryo-cooling technology	x-ray	1.7	A	p24941	298		1..292
5ap0	pdb	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.	x-ray	2.15	A	p33981	857		516..792
5ap1	pdb	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.	x-ray	2.05	A	p33981	857		516..792
5ap2	pdb	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.	x-ray	2.8	A	p33981	857		516..792
5ap3	pdb	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.	x-ray	2.7	A	p33981	857		516..792
5ap4	pdb	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.	x-ray	2.85	A	p33981	857		516..792
5ap5	pdb	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.	x-ray	2.8	A	p33981	857		516..792
5ap6	pdb	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.	x-ray	2.1	A	p33981	857		516..792
5ap7	pdb	Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.	x-ray	2.45	A	p33981	857		516..792
5ar2	pdb	RIP2 Kinase Catalytic Domain (1 - 310)	x-ray	2.44	A;B	o43353;o43353	540;540	;	11..297;11..297
5ar3	pdb	RIP2 Kinase Catalytic Domain (1 - 310) complex with AMP-PCP	x-ray	3.23	A;B	o43353;o43353	540;540	;	11..297;11..297
5ar4	pdb	RIP2 Kinase Catalytic Domain (1 - 310) complex with SB-203580	x-ray	2.7	A;B	o43353;o43353	540;540	;	11..297;11..297
5ar5	pdb	RIP2 Kinase Catalytic Domain (1 - 310) complex with Benzimidazole	x-ray	2.66	A;B	o43353;o43353	540;540	;	11..297;11..297
5ar7	pdb	RIP2 Kinase Catalytic Domain (1 - 310) complex with Biaryl Urea	x-ray	2.71	A;B	o43353;o43353	540;540	;	11..297;11..297
5ar8	pdb	RIP2 Kinase Catalytic Domain (1 - 310) complex with Biphenylsulfonamide	x-ray	2.79	A;B	o43353;o43353	540;540	;	11..297;11..297
5aut	pdb	Crystal structure of DAPK1 in complex with ANS.	x-ray	1.7	A	p53355	1430		6..291
5auu	pdb	Crystal structure of DAPK1 in complex with luteolin.	x-ray	1.7	A	p53355	1430		6..291
5auv	pdb	Crystal structure of DAPK1 in complex with apigenin.	x-ray	1.5	A	p53355	1430		6..291
5auw	pdb	Crystal structure of DAPK1 in complex with quercetin.	x-ray	1.5	A	p53355	1430		6..291
5aux	pdb	Crystal structure of DAPK1 in complex with kaempferol.	x-ray	1.5	A	p53355	1430		6..291
5auy	pdb	Crystal structure of DAPK1 in complex with morin.	x-ray	2	A	p53355	1430		6..291
5auz	pdb	Crystal structure of DAPK1 in complex with genistein.	x-ray	1.6	A	p53355	1430		6..291
5av0	pdb	Crystal structure of DAPK1 in complex with 7,3',4'-trihydroxyisoflavone.	x-ray	1.85	A	p53355	1430		6..291
5av1	pdb	Crystal structure of DAPK1 in the presence of bromide ions.	x-ray	1.5	A	p53355	1430		6..291
5av2	pdb	Crystal structure of DAPK1-kaempferol complex in the presence of bromide ions.	x-ray	1.502	A	p53355	1430		6..291
5av3	pdb	Crystal structure of DAPK1-kaempferol complex in the presence of iodide ions.	x-ray	1.9	A	p53355	1430		6..291
5av4	pdb	Crystal structure of DAPK1-genistein complex in the presence of bromide ions.	x-ray	1.4	A	p53355	1430		6..291
5awm	pdb	The Crystal Structure of JNK from Drosophila melanogaster Reveals an Evolutionarily Conserved Topology with that of Mammalian JNK Proteins.	x-ray	1.79	A	p92208	372		13..357
5ax3	pdb	Crystal structure of ERK2 complexed with allosteric and ATP-competitive inhibitors.	x-ray	2.984	A	p28482	360		19..322
5ax9	pdb	Crystal structure of the kinase domain of human TRAF2 and NCK-interacting protein kinase in complex with compund 9	x-ray	2.4	A;B;C	q9uke5;q9uke5;q9uke5	1360;1360;1360	;;	24..290;24..290;24..290
5b0x	pdb	Crystal structure of the CK2a/benzoic acid derivative complex	x-ray	2.3	A	p68400	391		5..328
5b2k	pdb	A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7	x-ray	2.75	A	o14733	419		113..384
5b2l	pdb	A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7	x-ray	2.1	A	o14733	419		113..384
5b2m	pdb	A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7	x-ray	3.06	A	o14733	419		113..384
5b7v	pdb	Human FGFR1 kinase in complex with CH5183284	x-ray	2.15	A;B	p11362;p11362	822;822	;	468..754;468..754
5bml	pdb	ROCK 1 bound to a pyridine thiazole inhibitor	x-ray	2.95	A;B	q13464;q13464	1354;1354	;	73..413;73..413
5bmm	pdb	Src in complex with DNA-templated macrocyclic inhibitor MC25b	x-ray	2.5	A;B	;	;	;	;
5bms	pdb	Crystal structure of P21-activated kinase 4 in complex with an inhibitor compound 29	x-ray	2.903	A	o96013	591		323..578
5bnj	pdb	CDK8/CYCC IN COMPLEX WITH 8-{3-Chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-pyridin- 4-yl}-2,8-diaza-spiro[4.5]decan-1-one	x-ray	2.64	A	p49336	464		25..341
5bpy	pdb	Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R)-3-(4-tert-bu tylbenzamido)piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine-3-carboxamide	x-ray	2.31	A;B	q06187;q06187	659;659	;	382..648;382..648
5bq0	pdb	Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R)-3-(4-tert-bu tylbenzamido)piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine-3-carboxamide	x-ray	1.57	A	q06187	659		382..648
5bue	pdb	ERK2 complexed with N-benzylpyridone tetrahydroazaindazole	x-ray	2.4	A	p28482	360		19..322
5bui	pdb	ERK2 complexed with 2-pyridiyl tetrahydroazaindazole	x-ray	2.12	A	p28482	360		19..322
5buj	pdb	ERK2 complexed with a N-H tetrahydroazaindazole	x-ray	1.85	A	p28482	360		19..322
5bvd	pdb	Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase	x-ray	1.9	A	p28482	360		19..322
5bve	pdb	Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase	x-ray	2	A	p28482	360		19..322
5bvf	pdb	Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase	x-ray	1.9	A	p28482	360		19..322
5bvk	pdb	Fragment-based discovery of potent and selective DDR1/2 inhibitors	x-ray	2.29	A	q08345	913		603..904
5bvn	pdb	Fragment-based discovery of potent and selective DDR1/2 inhibitors	x-ray	2.21	A	q08345	913		603..904
5bvo	pdb	Fragment-based discovery of potent and selective DDR1/2 inhibitors	x-ray	1.98	A	q08345	913		603..904
5bvw	pdb	Fragment-based discovery of potent and selective DDR1/2 inhibitors	x-ray	1.94	A	q08345	913		603..904
5bx0	pdb	An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery	x-ray	2.93	A	q02750	393		63..365
5bx6	pdb	PKA in complex with a halogenated phthalazinone fragment compound.	x-ray	1.89	A	p17612	351		30..339
5bx7	pdb	PKA in complex with a benzothiophene fragment compound.	x-ray	1.89	A	p17612	351		30..339
5byl	pdb	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPCP and Magnesium	x-ray	2.15	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
5byy	pdb	ERK5 IN COMPLEX WITH SMALL MOLECULE	x-ray	2.79	A	q13164	816		48..356
5byz	pdb	ERK5 in complex with small molecule	x-ray	1.65	A	q13164	816		48..356
5c01	pdb	Crystal Structure of kinase	x-ray	2.15	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
5c03	pdb	Crystal Structure of kinase	x-ray	1.9	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
5c1q	pdb	Serine/threonine-protein kinase pim-1	x-ray	3	B	p11309	313		36..296
5c26	pdb	Crystal structure of SYK in complex with compound 1	x-ray	1.95	A				
5c27	pdb	Crystal structure of SYK in complex with compound 2	x-ray	2.15	A				
5c46	pdb	Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta in complex with GTP gamma S loaded Rab11	x-ray	2.65	E	q9ubf8	816		325..810
5c4g	pdb	Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta with the inhibitor BQR695 in complex with GDP loaded Rab11	x-ray	3.2	E	q9ubf8	816		325..810
5c4k	pdb	"APH(2"")-IVa in complex with GET (G418) at room temperature"	x-ray	3.05	A;B	o68183;o68183	301;301	;	3..264;3..264
5c4l	pdb	"Conformational alternate of sisomicin in complex with APH(2"")-IVa"	x-ray	2.35	A;B	o68183;o68183	301;301	;	3..264;3..264
5c8k	pdb	"EGFR kinase domain mutant ""TMLR"" with compound 1"	x-ray	3	A	p00533	1210		708..1003
5c8m	pdb	"EGFR kinase domain mutant ""TMLR"" with compound 17"	x-ray	2.9	A	p00533	1210		708..1003
5c8n	pdb	"EGFR kinase domain mutant ""TMLR"" with compound 23"	x-ray	2.401	A	p00533	1210		708..1003
5c9c	pdb	CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND	x-ray	2.7	A;B	p15056;p15056	766;766	;	449..717;449..717
5cal	pdb	"EGFR kinase domain mutant ""TMLR"" with compound 24"	x-ray	2.7	A	p00533	1210		708..1003
5can	pdb	"EGFR kinase domain mutant ""TMLR"" with compound 27"	x-ray	2.8	A	p00533	1210		708..1003
5cao	pdb	"EGFR kinase domain mutant ""TMLR"" with compound 29"	x-ray	2.6	A	p00533	1210		708..1003
5cap	pdb	"EGFR kinase domain mutant ""TMLR"" with compound 30"	x-ray	2.4	A	p00533	1210		708..1003
5caq	pdb	"EGFR kinase domain mutant ""TMLR"" with compound 33"	x-ray	2.5	A	p00533	1210		708..1003
5cas	pdb	"EGFR kinase domain mutant ""TMLR"" with compound 41a"	x-ray	2.1	A	p00533	1210		708..1003
5cau	pdb	"EGFR kinase domain mutant ""TMLR"" with compound 41b"	x-ray	2.25	A	p00533	1210		708..1003
5cav	pdb	EGFR kinase domain with compound 41a	x-ray	2.73	A	p00533	1210		708..1003
5ce3	pdb	The Yersinia YopO - actin complex with MgADP	x-ray	2.93	B;D	q93kq6;q93kq6	729;729	;	151..407;151..407
5cei	pdb	Crystal structure of CDK8:Cyclin C complex with compound 22	x-ray	2.24	A	p49336	464		25..341
5cek	pdb	Pseudokinase domain of Human Tribbles Homolog 1	x-ray	2.8	A	q96ru8	372		105..341
5cem	pdb	Pseudokinase and C-terminal extension of Human Tribbles Homolog 1	x-ray	2.1	A	q96ru8	372		105..341
5cen	pdb	Crystal structure of DLK (kinase domain)	x-ray	1.7	A	q12852	859		104..364
5ceo	pdb	DLK in complex with inhibitor 2-((6-(3,3-difluoropyrrolidin-1-yl)-4-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-2-yl)amino)isonicotinonitrile	x-ray	2.28	A	q12852	859		104..364
5cep	pdb	DLK in complex with inhibitor N-(1-isopropyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl)-4-(trifluoromethyl)pyridin-2-amine	x-ray	1.99	A	q12852	859		104..364
5ceq	pdb	DLK in complex with inhibitor 2-((1-cyclopentyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)amino)isonicotinonitrile	x-ray	1.911	A	q12852	859		104..364
5cf4	pdb	CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE	x-ray	2.38	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
5cf5	pdb	CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-7-[(DIMETHYL-1,3-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.02,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE	x-ray	2.45	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
5cf6	pdb	CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-[(2S)-2,3-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-3,5,8,10-TETRAAZATRICYCLO [7.3.0.02,6]DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE	x-ray	2.5	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
5cf8	pdb	CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE	x-ray	1.8	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
5ci6	pdb	Crystal structure of Arabidopsis thaliana MPK6	x-ray	3	A;B	q39026;q39026	395;395	;	68..356;68..356
5ci7	pdb	Structure of ULK1 bound to a selective inhibitor	x-ray	1.74	A	o75385	1050		16..325
5ckw	pdb	Crystal structure of LegK4_AMPPNP Kinase	x-ray	2.49	A;B	q5wzw9;q5wzw9	961;961	;	84..281;84..281
5clp	pdb	Crystal Structure of CK2alpha with 3,4-dichlorophenethylamine bound	x-ray	1.684	A;B	p68400;p68400	391;391	;	5..328;5..328
5clr	pdb	Crystal structure of LegK4_APO Kinase	x-ray	3.706	A;B	q5wzw9;q5wzw9	961;961	;	84..281;84..281
5cnn	pdb	Crystal structure of the EGFR kinase domain mutant I682Q	x-ray	1.9	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
5cno	pdb	Crystal structure of the EGFR kinase domain mutant V924R	x-ray	1.55	A;B;X	p00533;p00533;p00533	1210;1210;1210	;;	708..1003;708..1003;708..1003
5cqu	pdb	Monoclinic Complex Structure of Protein Kinase CK2 Catalytic Subunit with a Benzotriazole-Based Inhibitor Generated by click-chemistry	x-ray	2.35	A	p68400	391		5..328
5cqw	pdb	Tetragonal Complex Structure of Protein Kinase CK2 Catalytic Subunit with a Benzotriazole-Based Inhibitor Generated by click-chemistry	x-ray	2.65	A;B	p68400;p68400	391;391	;	5..328;5..328
5cs6	pdb	Crystal Structure of CK2alpha with Compound 3 bound	x-ray	1.88	A;B	p68400;p68400	391;391	;	5..328;5..328
5csh	pdb	Crystal Structure of CK2alpha with Compound 4 bound	x-ray	1.59	A;B	p68400;p68400	391;391	;	5..328;5..328
5csp	pdb	Crystal Structure of CK2alpha with Compound 5 bound	x-ray	1.5	A	p68400	391		5..328
5csv	pdb	Crystal Structure of CK2alpha with Compound 6 bound	x-ray	1.375	A	p68400	391		5..328
5csw	pdb	B-RAF in complex with Dabrafenib	x-ray	2.66	A;B	p15056;p15056	766;766	;	449..717;449..717
5csx	pdb	CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370	x-ray	2.51	A	p15056	766		449..717
5ct0	pdb	Crystal structure of CK2alpha with 3-(3-chloro-4-(phenyl)benzylamino)propan-1-ol bound	x-ray	2.008	A;B	p68400;p68400	391;391	;	5..328;5..328
5ct7	pdb	BRAF in Complex with RAF265	x-ray	3.17	A;B	p15056;p15056	766;766	;	449..717;449..717
5ctp	pdb	Crystal structure of CK2alpha with N-(3-(3-chloro-4-(phenyl)benzylamino)propyl)acetamide bound	x-ray	2.033	A;B	p68400;p68400	391;391	;	5..328;5..328
5cu0	pdb	Crystal structure of CK2alpha with 2-hydroxy-5-methylbenzoic acid and N-(3-(3-chloro-4-(phenyl)benzylamino)propyl)acetamide bound	x-ray	2.18	A;B	p68400;p68400	391;391	;	5..328;5..328
5cu2	pdb	Crystal structure of CK2alpha with 2-hydroxy-5-methylbenzoic acid and (methyl 4-((3-(3-chloro-4-(phenyl)benzylamino)propyl)amino)-4-oxobutanoat bound	x-ray	1.705	A;B	p68400;p68400	391;391	;	5..328;5..328
5cu3	pdb	Crystal structure of CK2alpha bound to CAM4066	x-ray	1.787	A;B	p68400;p68400	391;391	;	5..328;5..328
5cu4	pdb	Crystal structure of CK2alpha bound to CAM4066	x-ray	1.56	A	p68400	391		5..328
5cu6	pdb	Crystal Structure of CK2alpha	x-ray	1.36	A	p68400	391		5..328
5cvf	pdb	Crystal Structure of CK2alpha with Compound 5 bound	x-ray	1.63	A	p68400	391		5..328
5cvg	pdb	Crystal Structure of CK2alpha with a novel closed conformation of the aD loop	x-ray	1.25	A	p68400	391		5..328
5cvh	pdb	Crystal Structure of CK2alpha	x-ray	1.848	A;B	p68400;p68400	391;391	;	5..328;5..328
5cwz	pdb	Crystal structure of the kinase domain of human TRAF2 and NCK-interacting protein kinase	x-ray	2.9	A;B;C	q9uke5;q9uke5;q9uke5	1360;1360;1360	;;	24..290;24..290;24..290
5cx9	pdb	Crystal structure of CK2alpha with (methyl 4-((3-(3-chloro-4-(phenyl)benzylamino)propyl)amino)-4-oxobutanoate bound	x-ray	1.732	A;B	p68400;p68400	391;391	;	5..328;5..328
5cxh	pdb	SYK catalytic domain complexed with a potent orally bioavailable thiazole inhibitor	x-ray	1.9	A	p43405	635		375..627
5cxz	pdb	SYK catalytic domain complexed with naphthyridine inhibitor	x-ray	1.7	A	p43405	635		375..627
5cy3	pdb	SYK catalytic domain complexed with a potent and orally bioavailable benzisothiazole inhibitor	x-ray	1.76	A	p43405	635		375..627
5cyi	pdb	CDK2/Cyclin A covalent complex with 6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-amine (NU6300)	x-ray	2	A;C	p24941;p24941	298;298	;	1..292;1..292
5cyz	pdb	Structure of S. cerevisiae Hrr25:Mam1 complex, form 1	x-ray	1.841	A	p29295	494		6..290
5czh	pdb	EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATE	x-ray	2.8	A				
5czi	pdb	EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE	x-ray	2.6	A	p00533	1210		708..1003
5czo	pdb	Structure of S. cerevisiae Hrr25:Mam1 complex, form 2	x-ray	2.894	A;B	p29295;p29295	494;494	;	6..290;6..290
5d10	pdb	Kinase domain of cSrc in complex with RL236	x-ray	2.7	A;B	p00523;p00523	533;533	;	256..526;256..526
5d11	pdb	Kinase domain of cSrc in complex with RL235	x-ray	2.3	A;B	p00523;p00523	533;533	;	256..526;256..526
5d12	pdb	Kinase domain of cSrc in complex with RL40	x-ray	3	A;B	p00523;p00523	533;533	;	256..526;256..526
5d1j	pdb	CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]-4-PIPERIDINECARBOXAMIDE (BMS-387032)	x-ray	1.8	A	p24941	298		1..292
5d41	pdb	EGFR kinase domain in complex with mutant selective allosteric inhibitor	x-ray	2.31	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
5d7a	pdb	Crystal structure of the kinase domain of TRAF2 and NCK-interacting protein kinase with NCB-0846	x-ray	2.9	A;B;C	q9uke5;q9uke5;q9uke5	1360;1360;1360	;;	24..290;24..290;24..290
5d7v	pdb	Crystal structure of PTK6 kinase domain	x-ray	2.33	A;B;C;D	q13882;q13882;q13882;q13882	451;451;451;451	;;;	173..439;173..439;173..439;173..439
5d9h	pdb	Crystal structure of SPAK (STK39) dimer in the basal activity state	x-ray	3.1	A;B	q9z1w9;q9z1w9	556;556	;	65..367;65..367
5d9k	pdb	Rsk2 N-terminal Kinase in Complex with BI-D1870	x-ray	2.55	A;B	p51812;p51812	740;740	;	66..390,402..717;66..390,402..717
5d9l	pdb	Rsk2 N-terminal Kinase in Complex with bis-phenol pyrazole	x-ray	2.15	A	p51812	740		66..390,402..717
5da3	pdb	Crystal structure of PTK6 Kinase domain with inhibitor	x-ray	1.7	A	q13882	451		173..439
5dbx	pdb	Crystal structure of murine SPAK(T243D) in complex with AMPPNP	x-ray	2.5	A;B	q9z1w9;q9z1w9	556;556	;	65..367;65..367
5de2	pdb	Structural mechanism of Nek7 activation by Nek9-induced dimerisation	x-ray	2.78	A;B	q8tdx7;q8tdx7	302;302	;	18..290;18..290
5dew	pdb	Crystal structure of PAK1 in complex with an inhibitor compound 5	x-ray	1.9	A;B	q13153;q13153	545;545	;	261..522;261..522
5dey	pdb	Crystal structure of PAK1 in complex with an inhibitor compound G-5555	x-ray	2.1	A;B	q13153;q13153	545;545	;	261..522;261..522
5dfp	pdb	Crystal structure of PAK1 in complex with an inhibitor compound FRAX1036	x-ray	2.2	A	q13153	545		261..522
5dfz	pdb	Structure of Vps34 complex II from S. cerevisiae.	x-ray	4.4	B;C	;	;	;	;
5dg5	pdb	CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP-4157	x-ray	2.6	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
5dgz	pdb	Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors	x-ray	2.502	A	p11309	313		36..296
5dh3	pdb	Crystal structure of MST2 in complex with XMU-MP-1	x-ray	2.468	A;B	q13188;q13188	491;491	;	24..287;24..287
5dhj	pdb	PIM1 in complex with Cpd4 (3-methyl-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine)	x-ray	2.457	A	p11309	313		36..296
5di1	pdb	MAP4K4 in complex with an inhibitor	x-ray	2.9	A;B	o95819;o95819	1239;1239	;	24..290;24..290
5dia	pdb	PIM1 in complex with Cpd36 ((1S,3S)-N1-(6-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)pyridin-2-yl)cyclohexane-1,3-diamine)	x-ray	1.964	A	p11309	313		36..296
5dls	pdb	Identification of Novel, in vivo Active Chk1 Inhibitors Utilizing Structure Guided Drug Design	x-ray	2.15	A	o14757	476		6..317
5dmz	pdb	Structure of human Bub1 kinase domain phosphorylated at Ser969	x-ray	2.4	A;B	o43683;o43683	1085;1085	;	789..1061;789..1061
5dn3	pdb	Aurora A in complex with ATP and AA35.	x-ray	2.05	A	o14965	403		120..386
5dnr	pdb	Aurora A Kinase in complex with ATP in space group P41212	x-ray	1.95	A	o14965	403		120..386
5dos	pdb	Aurora A Kinase in Complex with AA35 and ATP in Space Group P6122	x-ray	2.98	A	o14965	403		120..386
5dpv	pdb	Aurora A Kinase in Complex with AA35 and JNJ-7706621 in Space Group P6122	x-ray	2.285	A	o14965	403		120..386
5dr2	pdb	Aurora A Kinase in Complex with AA30 and ATP in Space Group P6122	x-ray	2.46	A	o14965	403		120..386
5dr6	pdb	Aurora A Kinase in Complex with AA30 and JNJ-7706621 in Space Group P6122	x-ray	2.534	A	o14965	403		120..386
5dr9	pdb	Aurora A Kinase in Complex with AA29 and JNJ-7706621 in Space Group P6122	x-ray	2.47	A	o14965	403		120..386
5drb	pdb	Crystal structure of WNK1 in complex with WNK463	x-ray	1.65	A	q9jih7	2126		226..480
5drd	pdb	Aurora A Kinase in Complex with ATP in Space Group P6122	x-ray	2.13	A	o14965	403		120..386
5dt0	pdb	Aurora A Kinase in Complex with JNJ-7706621 in Space Group P6122	x-ray	2.15	A	o14965	403		120..386
5dt3	pdb	Aurora A Kinase in Complex with ATP in Space Group P6122	x-ray	2.33	A	o14965	403		120..386
5dt4	pdb	Aurora A Kinase in Complex with AA35 and ATP in Space Group P6122	x-ray	2.86	A	o14965	403		120..386
5dvr	pdb	Crystal Structure of TgCDPK1 From Toxoplasma Gondii complexed with GW780159X	x-ray	2.4	A	q9bjf5	507		35..330
5dwr	pdb	Identification of N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1,2 and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies	x-ray	2	A	p11309	313		36..296
5dxh	pdb	p110alpha/p85alpha with compound 5	x-ray	3	A;D	p42336;p42336	1068;1068	;	699..1060;699..1060
5dxt	pdb	p110alpha with GDC-0326	x-ray	2.25	A	p42336	1068		699..1060
5dxu	pdb	p110delta/p85alpha with GDC-0326	x-ray	2.64	A	o00329	1044		678..1033
5dyj	pdb	Mysosin heavy chain kinase A catalytic domain mutant - D663A	x-ray	2.5	A;B	p42527;p42527	1146;1146	;	551..805;551..805
5dyk	pdb	Crystal structure of the cGMP-dependent protein kinase PKG from Plasmodium falciparum - Apo form	x-ray	2.45	A	q8i719	853		525..821
5dyl	pdb	Crystal structure of the cGMP-dependent protein kinase PKG from Plasmodium Vivax - Apo form	x-ray	2.4	A	a5k0n4	846		517..813
5dzc	pdb	Crystal structure of the cGMP-dependent protein kinase PKG from Plasmodium Vivax - AMPPNP bound	x-ray	2.3	A	a5k0n4	846		517..813
5e1e	pdb	Human JAK1 kinase in complex with compound 30 at 2.30 Angstroms resolution	x-ray	2.3	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
5e1s	pdb	The Crystal structure of INSR Tyrosine Kinase in complex with the Inhibitor BI 885578	x-ray	2.264	A	p06213	1382		996..1290
5e4h	pdb	Crystal Structure of Apoenzyme Alpha-kinase Domain of Myosin-II Heavy Chain Kinase A	x-ray	2.9	A;B;C;D;E;F;G;H	p42527;p42527;p42527;p42527;p42527;p42527;p42527;p42527	1146;1146;1146;1146;1146;1146;1146;1146	;;;;;;;	551..805;551..805;551..805;551..805;551..805;551..805;551..805;551..805
5e7r	pdb	Crystal structure of TL10-81 bound to TAK1-TAB1	x-ray	2.11	A	q15750	504		
5e8s	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)	x-ray	1.45	A	p36897	503		180..492
5e8t	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)	x-ray	1.7	A	p36897	503		180..492
5e8u	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F,S280T, Y282F,S287N,A350C,L352F)	x-ray	2.03	A	p36897	503		180..492
5e8v	pdb	TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A)	x-ray	1.69	A	p37173	567		244..537
5e8w	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE	x-ray	1.86	A	p36897	503		180..492
5e8x	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F,S280T, Y282F,S287N,A350C,L352F) IN COMPLEX WITH STAUROSPORINE	x-ray	1.45	A	p36897	503		180..492
5e8y	pdb	TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH STAUROSPORINE	x-ray	2.05	A	p37173	567		244..537
5e8z	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3-AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2-CARBOXAMIDE	x-ray	1.51	A	p36897	503		180..492
5e90	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F, S280T,Y282F,S287N,A350C,L352F) IN COMPLEX WITH 3-AMINO-6- [4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2-CARBOXAMIDE	x-ray	2.05	A	p36897	503		180..492
5e91	pdb	TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE	x-ray	2.42	A	p37173	567		244..537
5e92	pdb	TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH AMPPNP	x-ray	2.08	A	p37173	567		244..537
5e9e	pdb	Crystal Structure of the Alpha-kinase Domain of Myosin-II Heavy Chain Kinase A in Complex with AMP-PNP	x-ray	2.4	A;B	p42527;p42527	1146;1146	;	551..805;551..805
5eak	pdb	Optimization of Microtubule Affinity Regulating Kinase (MARK) Inhibitors with Improved Physical Properties	x-ray	2.8	A;B	q7kzi7;q7kzi7	788;788	;	50..305;50..305
5ebz	pdb	Crystal structure of human IKK1	x-ray	4.5	A;B;C;D;E;F;G;H;I;J;K;L	o15111;o15111;o15111;o15111;o15111;o15111;o15111;o15111;o15111;o15111;o15111;o15111	745;745;745;745;745;745;745;745;745;745;745;745	;;;;;;;;;;;	13..297;13..297;13..297;13..297;13..297;13..297;13..297;13..297;13..297;13..297;13..297;13..297
5edp	pdb	EGFR kinase (T790M/L858R) apo	x-ray	2.9	A	p00533	1210		708..1003
5edq	pdb	EGFR kinase (T790M/L858R) with inhibitor compound 15: ~{N}-(7-chloranyl-1~{H}-indazol-3-yl)-7,7-dimethyl-2-(1~{H}-pyrazol-4-yl)-5~{H}-furo[3,4-d]pyrimidin-4-amine	x-ray	2.8	A	p00533	1210		708..1003
5edr	pdb	EGFR kinase (T790M/L858R) with inhibitor compound 27: ~{N}-(1~{H}-indazol-3-yl)-7,7-dimethyl-2-(2-methylpyrazol-3-yl)-5~{H}-furo[3,4-d]pyrimidin-4-amine	x-ray	2.6	A	p00533	1210		708..1003
5eds	pdb	Crystal structure of human PI3K-gamma in complex with benzimidazole inhibitor 5	x-ray	2.8	A	p48736	1102		728..1089
5efq	pdb	Crystal structure of human Cdk13/Cyclin K in complex with ADP-aluminum fluoride	x-ray	2	A;C	q14004;q14004	1512;1512	;	699..1002;699..1002
5eg3	pdb	Crystal Structure of the Activated FGF Receptor 2 (FGFR2) Kinase Domain in complex with the cSH2 domain of Phospholipase C gamma (PLCgamma)	x-ray	2.606	A	p21802	821		471..757
5eh0	pdb	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach	x-ray	2.18	A	p33981	857		516..792
5ehl	pdb	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach	x-ray	2.66	A	p33981	857		516..792
5eho	pdb	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach	x-ray	2.18	A	p33981	857		516..792
5ehy	pdb	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach	x-ray	2.26	A	p33981	857		516..792
5ei2	pdb	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach	x-ray	2.67	A	p33981	857		516..792
5ei6	pdb	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach	x-ray	2.01	A	p33981	857		516..792
5ei8	pdb	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach	x-ray	2.17	A	p33981	857		516..792
5ek7	pdb	Structure of the autoinhibited Epha2 JMS-KD	x-ray	1.901	A;B	p29317;p29317	976;976	;	605..909;605..909
5ekn	pdb	Crystal structure of MAPK13 complex with inhibitor	x-ray	2.594	A	o15264	365		19..314
5eko	pdb	Crystal structure of MAPK13 complex with inhibitor	x-ray	2	A	o15264	365		19..314
5em5	pdb	"EGFR kinase domain mutant ""TMLR"" with pyridone compound 2: 4-[2-(4-chlorophenyl)ethylamino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide"	x-ray	2.65	A	p00533	1210		708..1003
5em6	pdb	"EGFR kinase domain mutant ""TMLR"" with pyridone compound 19: 4-[(2-azanylpyrimidin-4-yl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide"	x-ray	2.78	A	p00533	1210		708..1003
5em7	pdb	"EGFR kinase domain mutant ""TMLR"" with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide"	x-ray	2.81	A	p00533	1210		708..1003
5em8	pdb	EGFR kinase domain with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide	x-ray	2.8	A	p00533	1210		708..1003
5enn	pdb	The crystal structure of Human VPS34 in complex with a selective and potent inhibitor	x-ray	2.7	A;B	q8neb9;q8neb9	887;887	;	538..883;538..883
5eob	pdb	Crystal structure of CMET in complex with novel inhibitor	x-ray	1.75	A	p08581	1390		1079..1341
5eol	pdb	Crystal structure of human Pim-1 kinase in complex with a macrocyclic quinoxaline-pyrrolodihydropiperidinone inhibitor	x-ray	2.2	A	p11309	313		36..296
5eqe	pdb	Crystal structure of choline kinase alpha-1 bound by [4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]methanamine (compound 11)	x-ray	2.4	A;B	p35790;p35790	457;457	;	82..455;82..455
5eqp	pdb	Crystal structure of choline kinase alpha-1 bound by 6-[(4-methyl-1,4-diazepan-1-yl)methyl]quinoline (compound 37)	x-ray	2.35	A;B	p35790;p35790	457;457	;	82..455;82..455
5eqy	pdb	Crystal structure of choline kinase alpha-1 bound by 5-[(4-methyl-1,4-diazepan-1-yl)methyl]-2-[4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]benzenecarbonitrile (compound 65)	x-ray	2.5	A;B	p35790;p35790	457;457	;	82..455;82..455
5es1	pdb	CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR	x-ray	2.8	A	q96l34	752		56..311
5eta	pdb	Structure of MAPK14 with bound the KIM domain of the Toxoplasma protein GRA24	x-ray	2.8	A;B	q16539;q16539	360;360	;	9..349;9..349
5etc	pdb	Structure of inactive MAPK14 with ordered Activation Loop	x-ray	2.422	A	q16539	360		9..349
5etf	pdb	Structure of dead kinase MAPK14 with bound the KIM domain of MKK6	x-ray	2.4	A	q16539	360		9..349
5eti	pdb	Structure of dead kinase MAPK14	x-ray	2.8	A	q16539	360		9..349
5euq	pdb	Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta with a potent and selective inhibitor in complex with GDP loaded Rab11	x-ray	3.2	E	o02810	816		325..810
5ew3	pdb	Human Vascular Endothelial Growth Factor Receptor 2 (KDR) Kinase Domain in complex with AAL993	x-ray	2.5	A;B	p35968;p35968	1356;1356	;	815..1160;815..1160
5ew8	pdb	FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693	x-ray	1.63	A;B	p11362;p11362	822;822	;	468..754;468..754
5ew9	pdb	Crystal Structure of Aurora A Kinase Domain Bound to MK-5108	x-ray	2.181	A	o14965	403		120..386
5eyc	pdb	Crystal structure of c-Met in complex with naphthyridinone inhibitor 5	x-ray	1.8	A	p08581	1390		1079..1341
5eyd	pdb	Crystal structure of c-Met in complex with AMG 337	x-ray	1.85	A	p08581	1390		1079..1341
5eyk	pdb	CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325	x-ray	1.93	A;B	q6de08;q6de08	361;361	;	71..354;71..354
5eym	pdb	MEK1 IN COMPLEX WITH BI 847325	x-ray	2.7	A;B	q02750;q02750	393;393	;	63..365;63..365
5ezr	pdb	Crystal Structure of PVX_084705 bound to compound	x-ray	2.5	A	a5k0n4	846		517..813
5ezv	pdb	X-ray crystal structure of AMP-activated protein kinase alpha-2/alpha-1 RIM chimaera (alpha-2(1-347)/alpha-1(349-401)/alpha-2(397-end) beta-1 gamma-1) co-crystallized with C2 (5-(5-hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid)	x-ray	2.99	A;C	p54646;q13131	552;559	;	13..269;24..308
5f0a	pdb	CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND 1-tert-butyl-3-(3-chlorophenoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine INHIBITOR	x-ray	2.6	A	a5k0n4	846		517..813
5f1z	pdb	Structure of TYK2 with inhibitor 16: 3-azanyl-5-[(2~{S})-3-methylbutan-2-yl]-7-[1-methyl-5-(2-oxidanylpropan-2-yl)pyrazol-3-yl]-1~{H}-pyrazolo[4,3-c]pyridin-4-one	x-ray	2.65	A	p29597	1187		576..879,887..1166
5f20	pdb	Structure of TYK2 with inhibitor 4: 3-azanyl-5-(2-methylphenyl)-7-(1-methylpyrazol-3-yl)-1~{H}-pyrazolo[4,3-c]pyridin-4-one	x-ray	2.91	A	p29597	1187		576..879,887..1166
5f4n	pdb	Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)	x-ray	1.91	A	o14757	476		6..317
5f94	pdb	Crystal structure of GSK3b in complex with Compound 15: 2-[(cyclopropylcarbonyl)amino]-N-(4-methoxypyridin-3-yl)pyridine-4-carboxamide	x-ray	2.51	A;B	p49841;p49841	420;420	;	55..377;55..377
5f95	pdb	Crystal structure of GSK3b in complex with Compound 18: 2-[(cyclopropylcarbonyl)amino]-N-(4-phenylpyridin-3-yl)pyridine-4-carboxamide	x-ray	2.525	A;B	p49841;p49841	420;420	;	55..377;55..377
5f9e	pdb	Structure of Protein Kinase C theta with compound 10: 2,2-dimethyl-7-(2-oxidanylidene-3~{H}-imidazo[4,5-b]pyridin-1-yl)-1-(phenylmethyl)-3~{H}-quinazolin-4-one	x-ray	2	A;B	q04759;q04759	706;706	;	377..683;377..683
5fbl	pdb	PI4KB in complex with Rab11 and the MI356 Inhibitor	x-ray	3.372	A	q9ubf8	816		325..810
5fbn	pdb	BTK kinase domain with inhibitor 1	x-ray	1.8	C;D	q06187;q06187	659;659	;	382..648;382..648
5fbo	pdb	BTK-inhibitor co-structure	x-ray	1.894	A	q06187	659		382..648
5fbq	pdb	PI4KB in complex with Rab11 and the MI358 Inhibitor	x-ray	3.789	A	q9ubf8	816		325..810
5fbr	pdb	PI4KB in complex with Rab11 and the MI359 Inhibitor	x-ray	3.28	A	q9ubf8	816		325..810
5fbv	pdb	PI4KB in complex with Rab11 and the MI364 Inhibitor	x-ray	3.285	A	q9ubf8	816		325..810
5fbw	pdb	PI4KB in complex with Rab11 and the MI369 Inhibitor	x-ray	3.487	A	q9ubf8	816		325..810
5fd2	pdb	B-Raf wild-type kinase domain in complex with a purinylpyridinylamino-based inhibitor	x-ray	2.89	A;B	p15056;p15056	766;766	;	449..717;449..717
5fdp	pdb	Structure of DDR1 receptor tyrosine kinase in complex with D2099 inhibitor at 2.25 Angstroms resolution.	x-ray	2.25	A	q08345	913		603..904
5fdx	pdb	Structure of DDR1 receptor tyrosine kinase in complex with D2164 inhibitor at 2.65 Angstroms resolution.	x-ray	2.65	A;B	q08345;q08345	913;913	;	603..904;603..904
5fed	pdb	EGFR kinase domain in complex with a covalent aminobenzimidazole inhibitor.	x-ray	2.651	A	p00533	1210		708..1003
5fee	pdb	EGFR kinase domain T790M mutant in complex with a covalent aminobenzimidazole inhibitor.	x-ray	2.7	A	p00533	1210		708..1003
5feq	pdb	EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE	x-ray	3.4	A	p00533	1210		708..1003
5fet	pdb	Crystal Structure of PVX_084705 in presence of Compound 2	x-ray	3.07	A	a5k0n4	846		517..813
5fg8	pdb	Drosophila CaMKII-wt in complex with a fragment of the Eag potassium channel and Mg2+/ADP	x-ray	1.955	A	q00168	530		11..273
5fgk	pdb	CDK8-CYCC IN COMPLEX WITH 8-[3-(3-Amino-1H-indazol-6-yl)-5-chloro- pyridine-4-yl]-2,8-diaza-spiro[4.5]decan-1-one	x-ray	2.36	A	p49336	464		25..341
5fi4	pdb	Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model	x-ray	2.5	A	p42336	1068		699..1060
5flc	pdb	Architecture of human mTOR Complex 1 - 5.9 Angstrom reconstruction	em	5.9	B;F	;	;	;	;
5flf	pdb	DISEASE LINKED MUTATION IN FGFR	x-ray	2.58	A;B;C;D;E	p11362;p11362;p11362;p11362;p11362	822;822;822;822;822	;;;;	468..754;468..754;468..754;468..754;468..754
5fm2	pdb	Crystal structure of hyper-phosphorylated RET kinase domain with (proximal) juxtamembrane segment	x-ray	3.3	A	p07949	1114		699..1005
5fm3	pdb	Crystal structure of hyper-phosphorylated RET kinase domain with (proximal) juxtamembrane segment	x-ray	2.95	A	p07949	1114		699..1005
5fp5	pdb	Structure of cyclin-dependent kinase 2 with small-molecule ligand 4- fluorobenzoic acid (AT222) in an alternate binding site.	x-ray	2.16	A	p24941	298		1..292
5fp6	pdb	Structure of cyclin-dependent kinase 2 with small-molecule ligand 3-(4,7-dichloro-1H-indol-3-yl)prop-2-yn-1-ol (AT17833) in an alternate binding site.	x-ray	1.85	A	p24941	298		1..292
5fqd	pdb	Structural basis of Lenalidomide induced CK1a degradation by the crl4crbn ubiquitin ligase	x-ray	2.45	C;F	p48729;p48729	337;337	;	12..298;12..298
5fri	pdb	ALK5 in complex witha an N-(4-anilino-2-pyridyl)acetamide inhibitor.	x-ray	2	A	p36897	503		180..492
5ftg	pdb	Human choline kinase a1 in complex with compound 1-[[4-[2-[4-[[4-(dimethylamino)pyridin-1- yl]methyl]phenoxy]ethoxy]phenyl]methyl]-N,N- dimethyl-pyridin-4-amine (compound 10a)	x-ray	1.45	A	p35790	457		82..455
5fto	pdb	Crystal structure of the ALK kinase domain in complex with Entrectinib	x-ray	2.22	A	q9um73	1620		1089..1381
5ftq	pdb	Crystal structure of the ALK kinase domain in complex with Cmpd 17	x-ray	1.7	A	q9um73	1620		1089..1381
5fut	pdb	Human choline kinase a1 in complex with compound 4-(dimethylamino)-1-{4-[4-(4-{[4-(pyrrolidin- 1-yl)pyridinium-1-yl]methyl}phenyl)butyl]benzyl}pyridinium (compound BR25)	x-ray	1.6	A	p35790	457		82..455
5fvm	pdb	Cryo electron microscopy of a complex of Tor and Lst8	em	6.7	A;B	;	;	;	;
5fwk	pdb	Atomic cryoEM structure of Hsp90-Cdc37-Cdk4 complex	em	3.9	K	p11802	303		3..297
5fwl	pdb	Atomic cryoEM structure of Hsp90-Cdc37-Cdk4 complex	em	9	K	p11802	303		3..297
5fwm	pdb	Atomic cryoEM structure of Hsp90-Cdc37-Cdk4 complex	em	8	K	p11802	303		3..297
5fwp	pdb	Atomic cryoEM structure of Hsp90-Cdc37-Cdk4 complex	em	7.2	K	p11802	303		3..297
5fxq	pdb	IGFR-1R complex with a pyrimidine inhibitor.	x-ray	2.3	A	p08069	1367		970..1264
5fxr	pdb	IGFR-1R complex with a pyrimidine inhibitor.	x-ray	2.4	A	p08069	1367		970..1264
5fxs	pdb	IGFR-1R complex with a pyrimidine inhibitor.	x-ray	1.9	A	p08069	1367		970..1264
5g15	pdb	Structure Aurora A (122-403) bound to activating monobody Mb1 and AMPPCP	x-ray	2.06	A				
5g1x	pdb	Crystal structure of Aurora-A kinase in complex with N-Myc	x-ray	1.72	A	o14965	403		120..386
5g2n	pdb	X-ray structure of PI3Kinase Gamma in complex with Copanlisib	x-ray	2.68	A	p48736	1102		728..1089
5g55	pdb	3-Quinoline Carboxamides inhibitors of Pi3K	x-ray	2.45	A	p48736	1102		728..1089
5g6v	pdb	Crystal structure of the PCTAIRE1 kinase in complex with inhibitor	x-ray	2.2	A;B	q00536;q00536	496;496	;	159..448;159..448
5ghv	pdb	Crystal structure of an inhibitor-bound Syk	x-ray	2.8	A;B	p43405;p43405	635;635	;	375..627;375..627
5gjd	pdb	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 2	x-ray	2.79	A	o43318	606		14..292
5gjf	pdb	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 3	x-ray	2.89	A	q15750	504		
5gjg	pdb	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 4	x-ray	2.61	A	q15750	504		
5gmp	pdb	Crystal structure of EGFR 696-1022 T790M in complex with XTF-262	x-ray	2.797	A	p00533	1210		708..1003
5gnk	pdb	Crystal structure of EGFR 696-988 T790M in complex with LXX-6-34	x-ray	1.796	A	p00533	1210		708..1003
5grn	pdb	Crystal structure of PDGFRA in Complex with WQ-C-159	x-ray	1.77	A	p16234	1089		566..947
5gty	pdb	Crystal structure of EGFR 696-1022 T790M in complex with LXX-6-26	x-ray	3.14	A;B;C;D;E;F;G;H	p00533;p00533;p00533;p00533;p00533;p00533;p00533;p00533	1210;1210;1210;1210;1210;1210;1210;1210	;;;;;;;	708..1003;708..1003;708..1003;708..1003;708..1003;708..1003;708..1003;708..1003
5gtz	pdb	Crystal structure of EGFR 696-1022 T790M in complex with JTS-1-39	x-ray	2.999	A	p00533	1210		708..1003
5gz8	pdb	Crystal structure of catalytic domain of Protein O-mannosyl Kinase in ligand-free form	x-ray	2.5	A	q3tua9	349		67..329
5gz9	pdb	Crystal structure of catalytic domain of Protein O-mannosyl Kinase in complexes with AMP-PNP, Magnesium ions and glycopeptide	x-ray	2.4	A	q3tua9	349		67..329
5gza	pdb	protein O-mannose kinase	x-ray	2	A	q5u3w1	347		77..327
5h09	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-ethyl2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoate	x-ray	1.945	A	p08631	526		249..518
5h0b	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoic acid	x-ray	1.651	A	p08631	526		249..518
5h0e	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanamide	x-ray	2.1	A	p08631	526		249..518
5h0g	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-N,4-dimethylpentanamide	x-ray	1.8	A	p08631	526		249..518
5h0h	pdb	Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-N,N,4-trimethylpentanamide	x-ray	1.72	A	p08631	526		249..518
5h2u	pdb	Crystal structure of PTK6 Kinase Domain complexed with Dasatinib	x-ray	2.24	A;B;C;D	q13882;q13882;q13882;q13882	451;451;451;451	;;;	173..439;173..439;173..439;173..439
5h3q	pdb	Crystal Structure of TrkA kinase with ligand	x-ray	2.1	A	p04629	796		494..779
5h64	pdb	Cryo-EM structure of mTORC1	em	4.4	A;a	p42345;p42345	2549;2549	;	2095..2451;2095..2451
5h8b	pdb	Crystal structure of CK2 with compound 2	x-ray	2.55	A;B	p68400;p68400	391;391	;	5..328;5..328
5h8e	pdb	Crystal structure of CK2 with compound 7h	x-ray	2.15	A;B	p68400;p68400	391;391	;	5..328;5..328
5h8g	pdb	Crystal structure of CK2 with compound 7b	x-ray	2	A	p68400	391		5..328
5h9b	pdb	Drosophila CaMKII-wt in complex with a fragment of the Eag potassium channel and Mg2+/AMPPN	x-ray	2.25	A	q00168	530		11..273
5hbe	pdb	CDK8-CYCC IN COMPLEX WITH 8-[3-Chloro-5-(1-methyl-2,2-dioxo-2, 3-dihydro-1H-2l6-benzo[c]isothiazol-5-yl)-pyridin- 4-yl]-1-oxa-3,8-diaza-spiro[4.5]decan-2-one	x-ray	2.38	A	p49336	464		25..341
5hbh	pdb	CDK8-CYCC IN COMPLEX WITH 5-{5-Chloro-4-[1-(2-methoxy-ethyl)-1,8-diaza-spiro[4.5]dec-8-yl]-pyridin-3-yl}-1-methyl-1,3-dihydro-benzo[c]isothiazole 2,2-dioxide	x-ray	2.5	A	p49336	464		25..341
5hbj	pdb	CDK8-CYCC IN COMPLEX WITH 8-[2-Amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)-pyridin-4-yl]-2,8-diaza-spiro[4.5]decan-1-one	x-ray	3	A	p49336	464		25..341
5hcx	pdb	"EGFR kinase domain mutant ""TMLR"" with azabenzimidazole compound 7"	x-ray	2.6	A	p00533	1210		708..1003
5hcy	pdb	"EGFR kinase domain mutant ""TMLR"" with 3-carboxamide azaindole compound 13"	x-ray	2.46	A	p00533	1210		708..1003
5hcz	pdb	"EGFR kinase domain mutant ""TMLR"" with 3-azetidinyl azaindazole compound 21"	x-ray	2.62	A	p00533	1210		708..1003
5hd4	pdb	Dissecting Therapeutic Resistance to ERK Inhibition Rat Wild Type SCH772984 in complex with (3R)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)-N-[3-(pyridin-4-yl)-2H-indazol-5-yl]pyrrolidine-3-carboxamide	x-ray	1.45	A	p63086	358		17..320
5hd7	pdb	Dissecting Therapeutic Resistance to ERK Inhibition Rat Mutant SCH772984 in complex with (3R)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)-N-[3-(pyridin-4-yl)-2H-indazol-5-yl]pyrrolidine-3-carboxamide	x-ray	1.69	A	p63086	358		17..320
5he0	pdb	Bovine GRK2 in complex with Gbetagamma subunits and CCG215022	x-ray	2.56	A	p21146	689		187..532
5he1	pdb	Human GRK2 in complex with Gbetagamma subunits and CCG224062	x-ray	3.15	A	p25098	689		187..532
5he2	pdb	Bovine GRK2 in complex with Gbetagamma subunits and CCG224406	x-ray	2.79	A	p21146	689		187..532
5he3	pdb	Bovine GRK2 in complex with Gbetagamma subunits and CCG224411	x-ray	2.74	A	p21146	689		187..532
5hes	pdb	Human leucine zipper- and sterile alpha motif-containing kinase (ZAK, MLT, HCCS-4, MRK, AZK, MLTK) in complex with vemurafenib	x-ray	2.14	A;B	q9nyl2;q9nyl2	800;800	;	8..260;8..260
5hez	pdb	JAK2 kinase (JH1 domain) mutant P1057A in complex with TG101209	x-ray	2.66	A;B;C;D	o60674;o60674;o60674;o60674	1132;1132;1132;1132	;;;	522..814,842..1119;522..814,842..1119;522..814,842..1119;522..814,842..1119
5hg5	pdb	EGFR (L858R, T790M, V948R) in complex with N-{3-[(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamide	x-ray	1.52	A	p00533	1210		708..1003
5hg7	pdb	EGFR (L858R, T790M, V948R) in complex with 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988)	x-ray	1.85	A	p00533	1210		708..1003
5hg8	pdb	EGFR (L858R, T790M, V948R) in complex with N-[3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)phenyl]prop-2-enamide	x-ray	1.42	A	p00533	1210		708..1003
5hg9	pdb	EGFR (L858R, T790M, V948R) in complex with 1-[(3R,4R)-3-[({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-(trifluoromethyl)pyrrolidin-1-yl]prop-2-en-1-one	x-ray	2.15	A	p00533	1210		708..1003
5hgi	pdb	Crystal structure of apo human IRE1 alpha	x-ray	2.584	A	o75460	977		571..851
5hhw	pdb	Crystal structure of insulin receptor kinase domain in complex with cis-(R)-7-(3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-((tetrahydro-2H-pyran-2-yl)methoxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine.	x-ray	1.79	A	p06213	1382		996..1290
5hi2	pdb	BRAF Kinase domain b3aC loop deletion mutant in complex with sorafenib	x-ray	2.512	A	p15056	766		449..717
5hib	pdb	"EGFR kinase domain mutant ""TMLR"" with a pyrazolopyrimidine inhibitor"	x-ray	2.85	A	p00533	1210		708..1003
5hic	pdb	"EGFR kinase domain mutant ""TMLR"" with a imidazopyridinyl-aminopyrimidine inhibitor"	x-ray	2.6	A	p00533	1210		708..1003
5hid	pdb	BRAF Kinase domain b3aC loop deletion mutant in complex with AZ628	x-ray	2.5	A;B	p15056;p15056	766;766	;	449..717;449..717
5hie	pdb	BRAF Kinase domain b3aC loop deletion mutant in complex with dabrafenib	x-ray	3	A;B;C;D	p15056;p15056;p15056;p15056	766;766;766;766	;;;	449..717;449..717;449..717;449..717
5hkm	pdb	DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS	x-ray	2.1	A	o15530	556		79..400
5hln	pdb	X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021	x-ray	3.1	A;B	p49841;p49841	420;420	;	55..377;55..377
5hlp	pdb	X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937	x-ray	2.45	A;B	p49841;p49841	420;420	;	55..377;55..377
5hlw	pdb	Crystal structure of c-Met mutant Y1230H in complex with compound 14	x-ray	1.97	A	p08581	1390		1079..1341
5hnb	pdb	CDK8-CYCC IN COMPLEX WITH [6-Hydroxy-3-(3-methyl-benzyl)-1H-indazol-5-yl]-((S)-3-hydroxy-pyrrolidin-1-yl)-methanone	x-ray	2.35	A	p49336	464		25..341
5hng	pdb	DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS	x-ray	3.01	A	o15530	556		79..400
5hni	pdb	CRYSTAL STRUCTURE OF CMET WT with compound 3	x-ray	1.71	X;Y	p08581;p08581	1390;1390	;	1079..1341;1079..1341
5hnv	pdb	Crystal structure of PpkA	x-ray	1.41	A	a0a1s4nye5	302		19..297
5ho6	pdb	CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD.	x-ray	1.97	A	p08581	1390		1079..1341
5ho7	pdb	DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS	x-ray	3	A	o15530	556		79..400
5ho8	pdb	DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS	x-ray	2.7	A	o15530	556		79..400
5hoa	pdb	Crystal structure of c-Met L1195V in complex with SAR125844	x-ray	2.14	A	p08581	1390		1079..1341
5hor	pdb	Crystal structure of c-Met-M1250T in complex with SAR125844.	x-ray	2.2	A	p08581	1390		1079..1341
5hq0	pdb	Ternary complex of human proteins CDK1, Cyclin B and CKS2, bound to an inhibitor	x-ray	2.3	A	p06493	297		1..291
5htb	pdb	Crystal structure of haspin (GSG2) in complex with bisubstrate inhibitor ARC-3353	x-ray	1.7	A				
5htc	pdb	Crystal structure of haspin (GSG2) in complex with bisubstrate inhibitor ARC-3372	x-ray	1.5	A				
5hti	pdb	Crystal structure of c-Met kinase domain in complex with LXM108	x-ray	1.66	A	p08581	1390		1079..1341
5hu3	pdb	Drosophila CaMKII-D136N in complex with a phosphorylated fragment of the Eag potassium channel and Mg2+/ADP	x-ray	1.885	A	q00168	530		11..273
5hu9	pdb	Crystal structure of ABL1 in complex with CHMFL-074	x-ray	1.529	A	p00519	1130		231..498
5hvj	pdb	Crystal structure of LIMK1 D460N mutant in complex with AMP-PNP	x-ray	2.2	A;B	p53667;p53667	647;647	;	329..616;329..616
5hvk	pdb	Crystal structure of LIMK1 mutant D460N in complex with full-length cofilin-1	x-ray	3.5	A;C	p53667;p53667	647;647	;	329..616;329..616
5hvu	pdb	Rho-associated protein kinase 1 (ROCK 1) in complex with a pyridine thiazole piperidine inhibitor	x-ray	2.8	A;B	q13464;q13464	1354;1354	;	73..413;73..413
5hvy	pdb	CDK8/CYCC IN COMPLEX WITH COMPOUND 20	x-ray	2.39	A	p49336	464		25..341
5hx6	pdb	Crystal structure of RIP1 kinase with a benzo[b][1,4]oxazepin-4-one	x-ray	2.23	A;B	q13546;q13546	671;671	;	6..286;6..286
5hx8	pdb	Jak1 complex with 4-[(4-aminocyclohexyl)amino]-3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one	x-ray	2.2	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
5hze	pdb	Mek1 adopts DFG-out conformation when bound to an analog of E6201.	x-ray	2.4	A	q02750	393		63..365
5hzn	pdb	Structure of NVP-AEW541 in complex with IGF-1R kinase	x-ray	2.2	A;B;C;D;E;F;G;H	p08069;p08069;p08069;p08069;p08069;p08069;p08069;p08069	1367;1367;1367;1367;1367;1367;1367;1367	;;;;;;;	970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264
5i0b	pdb	Structure of PAK4	x-ray	3.09	A	o96013	591		323..578
5i35	pdb	Structure of the Human mitochondrial kinase COQ8A R611K with AMPPNP (Cerebellar Ataxia and Ubiquinone Deficiency Through Loss of Unorthodox Kinase Activity)	x-ray	2.3	A	q8ni60	647		315..522
5i3o	pdb	Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor	x-ray	2.4	A;B	q9nsy1;q9nsy1	1161;1161	;	52..313;52..313
5i3r	pdb	Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor	x-ray	2.4	A;B	q9nsy1;q9nsy1	1161;1161	;	52..313;52..313
5i4n	pdb	Crystal Structure of the E596A V617F Mutant JAK2 Pseudokinase Domain Bound to Mg-ATP	x-ray	1.54	A	o60674	1132		522..814,842..1119
5i4u	pdb	The crystal structure of PI3Kdelta with compound 34	x-ray	2.372	A	o35904	1043		677..1032
5i5z	pdb	CDK8-CYCC IN COMPLEX WITH 8-(1-Methyl-2,2-dioxo-2,3-dihydro-1H-2l6-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine-2-carboxylic acid methylamide	x-ray	2.6	A	p49336	464		25..341
5i6u	pdb	The crystal structure of PI3Kdelta with compound 32	x-ray	2.842	A	o35904	1043		677..1032
5i8a	pdb	TrkA with (6~{R})-3-methylsulfanyl-6-phenyl-1-(1~{H}-pyrazol-3-yl)-6,7-dihydro-5~{H}-thieno[3,4-c]pyridin-4-one	x-ray	2.33	A	p04629	796		494..779
5i9u	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase	x-ray	1.889	A	p29317	976		605..909
5i9v	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with AGS	x-ray	1.458	A	p29317	976		605..909
5i9w	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with ANP	x-ray	1.359	A	p29317	976		605..909
5i9x	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with bosutinib (SKI-606)	x-ray	1.427	A	p29317	976		605..909
5i9y	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with dasatinib	x-ray	1.228	A	p29317	976		605..909
5i9z	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with danusertib (PHA739358)	x-ray	1.698	A	p29317	976		605..909
5ia0	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with alisertib (MLN8237)	x-ray	1.948	A;B;C	p29317;p29317;p29317	976;976;976	;;	605..909;605..909;605..909
5ia1	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with MLN8054	x-ray	2.036	A	p29317	976		605..909
5ia2	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with compound 66	x-ray	1.619	A	p29317	976		605..909
5ia3	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with PD173955	x-ray	1.788	A	p29317	976		605..909
5ia4	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with foretinib (XL880)	x-ray	1.797	A	p29317	976		605..909
5ia5	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with golvatinib (E7050)	x-ray	1.776	A	p29317	976		605..909
5icp	pdb	CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-Chloro-phenyl)-pyrrolidin-1-yl]-(5-methyl-imidazo[5,1-b][1,3,4]thiadiazol-2-yl)-methanone	x-ray	2.18	A	p49336	464		25..341
5idn	pdb	CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-Chloro-phenyl)-pyrrolidin-1-yl]-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-methanone	x-ray	2.26	A	p49336	464		25..341
5idp	pdb	CDK8-CYCC IN COMPLEX WITH (3-Amino-1H-indazol-5-yl)-[(S)-2-(4-fluoro-phenyl)-piperidin-1-yl]-methanone	x-ray	2.65	A	p49336	464		25..341
5iev	pdb	Crystal structure of BAY 1000394 (Roniciclib) bound to CDK2	x-ray	2.03	A	p24941	298		1..292
5iex	pdb	Crystal structure of (R,S)-S-{4-[(5-Bromo-4-{[(2R,3R)-2-hydroxy-1-methylpropyl]oxy}- pyrimidin-2-yl)amino]phenyl}-S-cyclopropylsulfoximide bound to CDK2	x-ray	2.03	A	p24941	298		1..292
5iey	pdb	Crystal structure of a CDK inhibitor bound to CDK2	x-ray	1.66	A	p24941	298		1..292
5if1	pdb	Crystal structure apo CDK2/cyclin A	x-ray	2.61	A;C	p24941;p24941	298;298	;	1..292;1..292
5ig1	pdb	Crystal structure of S. rosetta CaMKII kinase domain	x-ray	2.9	A;B	f2upg5;f2upg5	479;479	;	20..286;20..286
5igh	pdb	Macrolide 2'-phosphotransferase type I	x-ray	1.55	A	q47396	301		38..262
5igi	pdb	Macrolide 2'-phosphotransferase type I - complex with guanosine and azithromycin	x-ray	1.2	A	q47396	301		38..262
5igj	pdb	Macrolide 2'-phosphotransferase type I - complex with guanosine and clarithromycin	x-ray	1.4	A	q47396	301		38..262
5igp	pdb	Macrolide 2'-phosphotransferase type I - complex with GDP and erythromycin	x-ray	1.6	A	q47396	301		38..262
5igr	pdb	Macrolide 2'-phosphotransferase type I - complex with GDP and oleandomycin	x-ray	1.6	A	q47396	301		38..262
5igs	pdb	Macrolide 2'-phosphotransferase type I - complex with guanosine and oleandomycin	x-ray	1.38	A	q47396	301		38..262
5igt	pdb	Macrolide 2'-phosphotransferase type I - complex with guanosine and erythromycin	x-ray	1.39	A	q47396	301		38..262
5igu	pdb	Macrolide 2'-phosphotransferase type II	x-ray	2.1	A	o32553	302		16..260
5igv	pdb	Macrolide 2'-phosphotransferase type II - complex with GDP and azithromycin	x-ray	1.55	A	o32553	302		16..260
5igw	pdb	Macrolide 2'-phosphotransferase type II - complex with GDP and clarithromycin	x-ray	2.096	A	o32553	302		16..260
5igy	pdb	Macrolide 2'-phosphotransferase type II - complex with GDP and erythromycin	x-ray	1.45	A	o32553	302		16..260
5igz	pdb	Macrolide 2'-phosphotransferase type II - complex with GDP and spiramycin	x-ray	1.6	A	o32553	302		16..260
5ih0	pdb	Macrolide 2'-phosphotransferase type II Y92M mutant - complex with GDP and erythromycin	x-ray	1.65	A	o32553	302		16..260
5ih1	pdb	Macrolide 2'-phosphotransferase type II - complex with GDP and phosphorylated josamycin	x-ray	1.31	A	o32553	302		16..260
5ih4	pdb	Human Casein Kinase 1 isoform delta apo (kinase domain)	x-ray	1.9	A	p48730	415		5..290
5ih5	pdb	Human Casein Kinase 1 isoform delta (kinase domain) in complex with Epiblastin A	x-ray	2.25	A	p48730	415		5..290
5ih6	pdb	Human Casein Kinase 1 isoform delta (kinase domain) in complex with Epiblastin A derivative	x-ray	2.3	A	p48730	415		5..290
5ih8	pdb	MELK in complex with NVS-MELK1	x-ray	1.85	A	q14680	651		8..308
5ih9	pdb	MELK in complex with NVS-MELK8A	x-ray	1.79	A	q14680	651		8..308
5iha	pdb	MELK in complex with NVS-MELK8F	x-ray	1.96	A	q14680	651		8..308
5ihc	pdb	MELK in complex with NVS-MELK12B	x-ray	2.14	A	q14680	651		8..308
5iis	pdb	Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl-amide scaffold	x-ray	2.1	A	p11309	313		36..296
5ikw	pdb	Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor	x-ray	2.41	A	q9nsy1	1161		52..313
5ime	pdb	Crystal structure of P21-activated kinase 1 (PAK1) in complex with compound 9	x-ray	2.217	A;B	q13153;q13153	545;545	;	261..522;261..522
5imx	pdb	Anaplastic lymphoma kinase (ALK) catalytic domain complexed with novel inhibitor 3-sulfonylpyrazol-4-amino pyrimidine	x-ray	2.12	A	q9um73	1620		1089..1381
5ipj	pdb	Crystal structure of human Pim-1 kinase in complex with a quinazolinone-pyrrolopyrrolone inhibitor.	x-ray	2.1	A	p11309	313		36..296
5iqa	pdb	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPNP and Magnesium	x-ray	2.15	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
5iqb	pdb	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPNP, Magnesium, and Kanamycin A	x-ray	2.3	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
5iqc	pdb	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPNP, Magnesium, and Gentamicin C1	x-ray	2.3	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
5iqd	pdb	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPNP, Magnesium, and Ribostamycin	x-ray	2.2	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
5iqe	pdb	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GMPPNP, Magnesium, and Neomycin B	x-ray	2.5	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
5iqf	pdb	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of APH(6')-Ie/APH(2'')-Ia) in complex with GDP and Magnesium	x-ray	2.35	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
5iqg	pdb	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) in complex with GDP, Magnesium, and Gentamicin C1	x-ray	2.5	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
5iqh	pdb	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) S214A mutant in complex with GMPPNP and Magnesium	x-ray	2.25	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
5iqi	pdb	Aminoglycoside Phosphotransferase (2'')-Ia (CTD of AAC(6')-Ie/APH(2'')-Ia) Y237F mutant in complex with GMPPNP and Magnesium	x-ray	2.15	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
5is5	pdb	Discovery and Pharmacological Characterization of Novel Quinazoline-based PI3K delta-selective Inhibitors	x-ray	2.85	A	o35904	1043		677..1032
5iso	pdb	STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR, A BENZIMIDAZOLE DERIVATIVE (991)	x-ray	2.63	A;C	p54646;p54646	552;552	;	13..269;13..269
5ita	pdb	Crystal Structure of BRAF Kinase Domain Bound to AZ-VEM	x-ray	1.95	A;B	p15056;p15056	766;766	;	449..717;449..717
5itd	pdb	Crystal structure of PI3K alpha with PI3K delta inhibitor	x-ray	3.02	A	p42336	1068		699..1060
5iu2	pdb	Discovery of imidazoquinolines as a novel class of potent, selective and in vivo efficacious COT kinase inhibitors	x-ray	2.7	A;B	p41279;p41279	467;467	;	141..399;141..399
5iug	pdb	Crystal Structure of Anaplastic Lymphoma Kinase (ALK) in complex with 5a	x-ray	1.93	A	q9um73	1620		1089..1381
5iuh	pdb	Crystal Structure of the Anaplastic Lymphoma Kinase (ALK) in complex with 5d	x-ray	2.1	A	q9um73	1620		1089..1381
5iui	pdb	Crystal Structure of Anaplastic Lyphoma Kinase (ALK) in complex with 4	x-ray	1.88	A	q9um73	1620		1089..1381
5iwu	pdb	Macrolide 2'-phosphotransferase type II complexed with erythromycin	x-ray	1.3	A	o32553	302		16..260
5izf	pdb	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1408	x-ray	2.1	A				
5izj	pdb	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1411	x-ray	1.85	A;B	;	;	;	;
5j0a	pdb	Crystal structure of PDZ-binding kinase	x-ray	2.74	A;B	q96kb5;q96kb5	322;322	;	33..319;33..319
5j1v	pdb	Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW29 (compound 13)	x-ray	2.52	A;B;C	p49759;p49759;p49759	484;484;484	;;	150..478;150..478;150..478
5j1w	pdb	Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW31 (compound 14)	x-ray	2.42	A;B;C	p49759;p49759;p49759	484;484;484	;;	150..478;150..478;150..478
5j5s	pdb	Src kinase in complex with a sulfonamide inhibitor	x-ray	2.153	A;B	p00523;p00523	533;533	;	256..526;256..526
5j5t	pdb	GLK co-crystal structure with aminopyrrolopyrimidine inhibitor	x-ray	2.85	A	q8ivh8	894		13..323
5j5x	pdb	Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1416	x-ray	2.6	A				
5j79	pdb	The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 Kinase, Compound 3 complex	x-ray	2.69	A;B	o43353;o43353	540;540	;	11..297;11..297
5j7b	pdb	The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 Kinase, GSK583 complex	x-ray	2.53	A;B	o43353;o43353	540;540	;	11..297;11..297
5j7s	pdb	Crystal structure of SM1-71 bound to TAK1-TAB1	x-ray	2.368	A	q15750	504		
5j87	pdb	Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a Highly Selective Irreversible BTK Kinase Inhibitor	x-ray	1.59	A;B;C;D	q06187;q06187;q06187;q06187	659;659;659;659	;;;	382..648;382..648;382..648;382..648
5j8i	pdb	Crystal structure of TL11-113 bound to TAK1-TAB1	x-ray	2.404	A	q15750	504		
5j95	pdb	MAP4K4 in complex with inhibitor	x-ray	2.5	A;B	o95819;o95819	1239;1239	;	24..290;24..290
5j9l	pdb	Crystal structure of CPT1691 bound to TAK1-TAB1	x-ray	2.7515	A	q15750	504		
5j9y	pdb	EGFR-T790M in complex with pyrazolopyrimidine inhibitor 1b	x-ray	2.8	A	p00533	1210		708..1003
5j9z	pdb	EGFR-T790M in complex with pyrazolopyrimidine inhibitor 1a	x-ray	2.5	A	p00533	1210		708..1003
5jeb	pdb	Crystal structure of EGFR tyrosine kinase domain with novel inhibitor of active state of HER2	x-ray	3.298	A	p00533	1210		708..1003
5jfs	pdb	Crystal structure of TrkA in complex with PF-00593174	x-ray	2.07	A	p04629	796		494..779
5jfv	pdb	Crystal structure of TrkA in complex with PF-05206283	x-ray	1.59	A	p04629	796		494..779
5jfw	pdb	Crystal structure of TrkA in complex with PF-05247452	x-ray	1.52	A	p04629	796		494..779
5jfx	pdb	Crystal structure of TrkA in complex with PF-06273340	x-ray	1.63	A	p04629	796		494..779
5jga	pdb	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 11c	x-ray	2	A	q15750	504		
5jgb	pdb	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 10	x-ray	2.8	A	o43318	606		14..292
5jgd	pdb	Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 12	x-ray	3.101	A	q15750	504		
5jh6	pdb	Crystal structure of TL10-92 bound to TAK1-TAB1	x-ray	2.365	A	q15750	504		
5jha	pdb	Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin2	x-ray	2.51	A	p48736	1102		728..1089
5jhb	pdb	Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin3	x-ray	2.48	A	p48736	1102		728..1089
5jk3	pdb	Crystal structure of TL11-128 bound to TAK1-TAB1	x-ray	2.371	A	o43318	606		14..292
5jkg	pdb	The crystal structure of FGFR4 kinase domain in complex with LY2874455	x-ray	2.352	A	p22455	802		458..743
5jms	pdb	Crystal structure of TgCDPK1 bound to CGP060476	x-ray	2.3	A	q9bjf5	507		35..330
5jn2	pdb	Crystal structure of TgCDPK1 bound to NVPACU106	x-ray	2.2	A	q9bjf5	507		35..330
5jq5	pdb	Crystal structure of CDK2 in complex with inhibitor ICEC0942	x-ray	1.94	A	p24941	298		1..292
5jq8	pdb	Crystal structure of CDK2 in complex with inhibitor ICEC0943	x-ray	1.94	A	p24941	298		1..292
5jr7	pdb	Crystal structure of an ACRDYS heterodimer [RIa(92-365):C] of PKA	x-ray	3.56	A;C	p05132;p05132	351;351	;	28..339;28..339
5jrq	pdb	BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-6-VEM	x-ray	2.287	A;B	p15056;p15056	766;766	;	449..717;449..717
5jrs	pdb	CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -3,4-DIHYDROQUINAZOLIN-3-YL)PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE	x-ray	1.97	A;B	q06187;q06187	659;659	;	382..648;382..648
5jsm	pdb	BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-3-VEM	x-ray	2.19	A;B;C;D	p15056;p15056;p15056;p15056	766;766;766;766	;;;	449..717;449..717;449..717;449..717
5jt2	pdb	BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-BISAMIDE	x-ray	2.702	A;B;C;D	p15056;p15056;p15056;p15056	766;766;766;766	;;;	449..717;449..717;449..717;449..717
5jy7	pdb	Complex of Mycobacterium smegmatis trehalose synthase with maltokinase	x-ray	3.6	I;J;K;L;M;N;O;P	a0r6d9;a0r6d9;a0r6d9;a0r6d9;a0r6d9;a0r6d9;a0r6d9;a0r6d9	441;441;441;441;441;441;441;441	;;;;;;;	134..440;134..440;134..440;134..440;134..440;134..440;134..440;134..440
5jzj	pdb	Crystal structure of DCLK1-KD in complex with AMPPN	x-ray	1.71	A;B	o15075;o15075	740;740	;	381..656;381..656
5jzn	pdb	Crystal structure of DCLK1-KD in complex with NVP-TAE684	x-ray	2.85	A;B	o15075;o15075	740;740	;	381..656;381..656
5k00	pdb	MELK in complex with NVS-MELK5	x-ray	1.77	A	q14680	651		8..308
5k0k	pdb	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC2434	x-ray	2.545	A;B	q12866;q12866	999;999	;	578..872;578..872
5k0x	pdb	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC2541	x-ray	2.231	A;B	q12866;q12866	999;999	;	578..872;578..872
5k3y	pdb	Crystal structure of AuroraB/INCENP in complex with BI 811283	x-ray	1.6	A;B	q6de08;q6de08	361;361	;	71..354;71..354
5k4i	pdb	Crystal Structure of ERK2 in complex with compound 22	x-ray	1.76	A	p28482	360		19..322
5k4j	pdb	Crystal Structure of CDK2 in complex with compound 22	x-ray	1.6	A	p24941	298		1..292
5k5n	pdb	Crystal structure of GSK-3beta complexed with PF-04802367, a highly selective brain-penetrant kinase inhibitor	x-ray	2.2	A;B	p49841;p49841	420;420	;	55..377;55..377
5k5x	pdb	Crystal structure of human PDGFRA	x-ray	2.168	A	p16234	1089		566..947
5k72	pdb	IRAK4 in complex with Compound 21	x-ray	2.22	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
5k75	pdb	IRAK4 in complex with Compound 1	x-ray	2.03	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
5k76	pdb	IRAK4 in complex with Compound 28	x-ray	2.74	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
5k7g	pdb	IRAK4 in complex with AZ3862	x-ray	2.23	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
5k7i	pdb	IRAK4 in complex with AZ3864	x-ray	2.31	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
5k9i	pdb	Crystal structure of c-SRC in complex with a covalent lysine probe	x-ray	2.5	A;B	p00523;p00523	533;533	;	256..526;256..526
5kae	pdb	Crystal structure of human PI3K-gamma in complex with quinoline-containing inhibitor 5g	x-ray	2.65	A	p48736	1102		728..1089
5kbq	pdb	Pak1 in complex with bis-anilino pyrimidine inhibitor	x-ray	2.58	A;B	q13153;q13153	545;545	;	261..522;261..522
5kbr	pdb	Pak1 in complex with 7-azaindole inhibitor	x-ray	2.36	A;B	q13153;q13153	545;545	;	261..522;261..522
5kc2	pdb	Negative stain structure of Vps15/Vps34 complex	em	28	B;C	p22219;p22543	1454;875	;	26..296;527..871
5kcv	pdb	Crystal structure of allosteric inhibitor, ARQ 092, in complex with autoinhibited form of AKT1	x-ray	2.7	A	p31749	480		145..459
5kcx	pdb	Pim-1 kinase in Complex with a Selective N-substituted 7-azaindole Inhibitor	x-ray	2.2	A	p11309	313		36..296
5ke0	pdb	Discovery of 1-1H-Pyrazolo 4,3-c pyridine-6-yl urea Inhibitors of Extracellular Signal Regulated Kinase ERK for the Treatment of Cancers	x-ray	1.68	A	p63086	358		17..320
5kgd	pdb	Crystal structure of PIM1 with inhibitor: 2-pyridin-3-yl-1~{H}-benzimidazole	x-ray	1.98	A	p11309	313		36..296
5kge	pdb	Crystal structure of PIM1 with inhibitor: 5-(3,4-dichlorophenyl)-1~{H}-pyrazol-3-amine	x-ray	2.23	A	p11309	313		36..296
5kgg	pdb	Crystal structure of PIM1 with inhibitor: 2-(5-chloranyl-1~{H}-indol-3-yl)ethanamine	x-ray	1.95	A	p11309	313		36..296
5kgi	pdb	Crystal structure of PIM1 with inhibitor 2-[3,4-bis(chloranyl)phenoxy]ethanamine	x-ray	2.13	A	p11309	313		36..296
5kgk	pdb	Crystal structure of PIM1 with inhibitor: 3-(4-methoxyphenyl)-1~{H}-pyrazol-5-amine	x-ray	2.66	A	p11309	313		36..296
5khu	pdb	Model of human Anaphase-promoting complex/Cyclosome (APC15 deletion mutant), in complex with the Mitotic checkpoint complex (APC/C-CDC20-MCC) based on cryo EM data at 4.8 Angstrom resolution	em	4.8	Q				
5khw	pdb	Crystal structure of JAK1 in complex with ADP	x-ray	2.47	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
5khx	pdb	Crystal structure of JAK1 in complex with PF-4950736	x-ray	2.4	A	p23458	1154		565..850,873..1146
5kkr	pdb	KSR2:MEK1 Complex Bound to the Small Molecule APS-2-79	x-ray	3.509	B;C	q6vab6;p29678	950;393	;	642..928;63..365
5kks	pdb	ROCK 1 bound to azaindole thiazole inhibitor	x-ray	3.3	A;B	q13464;q13464	1354;1354	;	73..413;73..413
5kkt	pdb	ROCK 1 bound to azaindole thiazole piperazine inhibitor	x-ray	2.8	A;B	q13464;q13464	1354;1354	;	73..413;73..413
5kmi	pdb	TrkA JM-kinase with 1-(9{H}-fluoren-9-yl)-3-(2-methyl-4-phenyl-pyrimidin-5-yl)urea	x-ray	1.87	A	p04629	796		494..779
5kmj	pdb	TrkA JM-kinase with {N}-(2-pyridylmethyl)-2-[2-(2-thienyl)indol-1-yl]acetamide	x-ray	2.04	A	p04629	796		494..779
5kmk	pdb	TrkA JM-kinase with 2-fluoro-{N}-[2-(4-fluorophenyl)-6-methyl-3-pyridyl]-4-(trifluoromethyl)benzamide	x-ray	2.24	A	p04629	796		494..779
5kml	pdb	TrkA JM-kinase with 1-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-3-[[2-(trifluoromethyl)phenyl]methyl]urea	x-ray	2.01	A	p04629	796		494..779
5kmm	pdb	TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-(1-naphthyl)urea	x-ray	2.12	A	p04629	796		494..779
5kmn	pdb	TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-[[2-(trifluoromethyl)phenyl]methyl]urea	x-ray	2.14	A	p04629	796		494..779
5kmo	pdb	TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-(2-pyridyl)urea	x-ray	2.67	A	p04629	796		494..779
5knj	pdb	Pseudokinase Domain of MLKL bound to Compound 1.	x-ray	2.88	A;B	q8nb16;q8nb16	471;471	;	213..466;213..466
5ko1	pdb	Pseudokinase Domain of MLKL bound to Compound 4.	x-ray	2.16	A	q8nb16	471		213..466
5kpk	pdb	Glycogen Synthase Kinase 3 beta Complexed with BRD0209	x-ray	2.4	A;B	p49841;p49841	420;420	;	55..377;55..377
5kpl	pdb	Glycogen Synthase Kinase 3 beta Complexed with BRD0705	x-ray	2.6	A;B	p49841;p49841	420;420	;	55..377;55..377
5kpm	pdb	Glycogen Synthase Kinase 3 beta Complexed with BRD3731	x-ray	2.69	A;B	p49841;p49841	420;420	;	55..377;55..377
5kq5	pdb	AMPK bound to allosteric activator	x-ray	3.41	A	p54645	559		24..308
5ku8	pdb	Crystal structure of CK2	x-ray	2.22	A;B	p68400;p68400	391;391	;	5..328;5..328
5kup	pdb	Bruton's tyrosine kinase (BTK) with pyridazinone compound 9	x-ray	1.389	A	q06187	659		382..648
5kvt	pdb	THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB	x-ray	2.45	A	p04629	796		494..779
5kwh	pdb	Crystal structure of CK2	x-ray	2.12	A;B	p68400;p68400	391;391	;	5..328;5..328
5kx7	pdb	Irak4-inhibitor co-structure	x-ray	2.8	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
5kx8	pdb	Irak4-inhibitor co-structure	x-ray	2.671	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
5kz0	pdb	Structure of Human Anaplastic Lymphoma Kinase in Complex With 2-[(1R)-1-{[2-amino-5-(1,3-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl]oxy}ethyl]-4-fluoro-N,N-dimethylbenzamide	x-ray	2.3	A	q9um73	1620		1089..1381
5kz7	pdb	Mark2 complex with 7-[(1S)-1-(4-fluorophenyl)ethyl]-5,5-dimethyl-2-(3-pyridylamino)pyrrolo[2,3-d]pyrimidin-6-one	x-ray	3.2	A;B	q7kzi7;q7kzi7	788;788	;	50..305;50..305
5kz8	pdb	Mark2 complex with 7-[(1S)-1-(4-fluorophenyl)ethyl]-5,5-dimethyl-2-(3-pyridylamino)pyrrolo[2,3-d]pyrimidin-6-one	x-ray	3.21	A;B	q7kzi7;q7kzi7	788;788	;	50..305;50..305
5kzi	pdb	Crystal structure of human Pim-1 kinase in complex with an imidazopyridazine inhibitor.	x-ray	2.1	A	p11309	313		36..296
5l1z	pdb	TAR complex with HIV-1 Tat-AFF4-P-TEFb	x-ray	5.9	A	p50750	372		12..321
5l2i	pdb	The X-ray co-crystal structure of human CDK6 and Palbociclib.	x-ray	2.75	A	q00534	326		9..303
5l2q	pdb	Serine/threonine-protein kinase 40 (STK40) kinase homology domain	x-ray	2.53	A;B;C;D	q8n2i9;q8n2i9;q8n2i9;q8n2i9	435;435;435;435	;;;	31..326;31..326;31..326;31..326
5l2s	pdb	The X-ray co-crystal structure of human CDK6 and Abemaciclib.	x-ray	2.27	A	q00534	326		9..303
5l2t	pdb	The X-ray co-crystal structure of human CDK6 and Ribociclib.	x-ray	2.37	A	q00534	326		9..303
5l2w	pdb	The X-ray co-crystal structure of human CDK2/CyclinE and Dinaciclib.	x-ray	2.8	A	p24941	298		1..292
5l3a	pdb	Fragment-based discovery of 6-arylindazole JAK inhibitors	x-ray	1.98	A	o60674	1132		522..814,842..1119
5l4q	pdb	Crystal Structure of Adaptor Protein 2 Associated Kinase 1 (AAK1) in Complex with LKB1 (AAK1 Dual Inhibitor)	x-ray	1.97	A;B	q2m2i8;q2m2i8	961;961	;	46..309;46..309
5l6o	pdb	EphB3 kinase domain covalently bound to an irreversible inhibitor (compound 3)	x-ray	1.88	A	p54753	998		626..925
5l6p	pdb	EphB3 kinase domain covalently bound to an irreversible inhibitor (compound 6)	x-ray	2.26	A	p54753	998		626..925
5l6w	pdb	Structure Of the LIMK1-ATPgammaS-CFL1 Complex	x-ray	2.53	L	p53667	647		329..616
5l72	pdb	PI3 kinase delta in complex with N-[6-(5-methanesulfonamido-6-methoxypyridin-3-yl)-1,3-dihydro-2-benzofuran-4-yl]-2-(morpholin-4-yl)acetamide	x-ray	3.06	A	o35904	1043		677..1032
5l8j	pdb	Aurora-A kinase domain in complex with vNAR-D01 S93R	x-ray	1.68	A	o14965	403		120..386
5l8k	pdb	Aurora-A kinase domain in complex with vNAR-D01 (crystal form 2)	x-ray	1.79	A	o14965	403		120..386
5l8l	pdb	Aurora-A kinase domain in complex with vNAR-D01 (crystal form 1)	x-ray	1.67	A	o14965	403		120..386
5lar	pdb	Crystal structure of p38 alpha MAPK14 in complex with VPC00628	x-ray	1.5	A	p47811	360		9..349
5lcj	pdb	In-Gel Activity-Based Protein Profiling of a Clickable Covalent Erk 1/2 Inhibitor	x-ray	1.78	A	p28482	360		19..322
5lck	pdb	A Clickable Covalent ERK 1/2 Inhibitor	x-ray	1.89	A	p28482	360		19..322
5lcp	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with Fasudil (M77)	x-ray	1.433	A	p25321	351		29..339
5lcq	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with long-chain Fasudil-derivative (Ligand 05)	x-ray	1.423	A	p25321	351		29..339
5lcr	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with open-chain Fasudil-derivative (Ligand 04)	x-ray	1.565	A	p25321	351		29..339
5lct	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a R-methyl-piperazine substituted Fasudil-derivative (Ligand 02)	x-ray	1.615	A	p25321	351		29..339
5lcu	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a S-methyl-piperazine substituted Fasudil-derivative (Ligand 01)	x-ray	1.579	A	p25321	351		29..339
5li1	pdb	Structure of a Par3-inhibitory peptide bound to PKCiota core kinase domain	x-ray	2	A	p41743	596		252..578
5li9	pdb	Structure of a nucleotide-bound form of PKCiota core kinase domain	x-ray	1.79	A	p41743	596		252..578
5lih	pdb	Structure of a peptide-substrate bound to PKCiota core kinase domain	x-ray	3.25	A;B	p41743;p41743	596;596	;	252..578;252..578
5ljj	pdb	Crystal structure of human Mps1 (TTK) in complex with Reversine	x-ray	3	A	p33981	857		516..792
5lma	pdb	HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR	x-ray	1.43	A	p43405	635		375..627
5lmb	pdb	HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR	x-ray	1.95	A;B	p43405;p43405	635;635	;	375..627;375..627
5lmk	pdb	Structure of phopsho-CDK2-cyclin A in complex with an ATP-competitive inhibitor	x-ray	2.4	A;C	p24941;p24941	298;298	;	1..292;1..292
5loh	pdb	Kinase domain of human Greatwall	x-ray	3.1	A;B	q96gx5;q96gx5	879;879	;	30..872;30..872
5lpb	pdb	Crystal structure of the BRI1 kinase domain (865-1160) in complex with ADP from Arabidopsis thaliana	x-ray	1.98	A	o22476	1196		865..1155
5lpv	pdb	Crystal structure of the BRI1 kinase domain (865-1160) in complex with AMPPNP and Mn from Arabidopsis thaliana	x-ray	2.7	A	o22476	1196		865..1155
5lpw	pdb	Crystal structure of the apo-BRI1 kinase domain (865-1160)	x-ray	2.431	A	o22476	1196		865..1155
5lpy	pdb	Crystal structure of the BRI1 kinase domain (865-1160) in complex with ATP from Arabidopsis thaliana	x-ray	2.3	A	o22476	1196		865..1155
5lpz	pdb	Crystal structure of the BRI1 kinase domain (865-1196) in complex with ADP from Arabidopsis thaliana	x-ray	2.48	A	o22476	1196		865..1155
5lqf	pdb	CDK1/CyclinB1/CKS2 in complex with NU6102	x-ray	2.06	A;D	p06493;p06493	297;297	;	1..291;1..291
5luq	pdb	Crystal Structure of Human DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs)	x-ray	4.3	A;B	;	;	;	;
5lvl	pdb	Human PDK1 Kinase Domain in Complex with Compound PS653 Bound to the ATP-Binding Site	x-ray	1.4	A	o15530	556		79..400
5lvm	pdb	Human PDK1 Kinase Domain in Complex with Adenine Bound to the ATP-Binding Site	x-ray	1.26	A	o15530	556		79..400
5lvn	pdb	Human PDK1 Kinase Domain in Complex with Adenosine Bound to the ATP-Binding Site	x-ray	1.379	A	o15530	556		79..400
5lvo	pdb	Human PDK1 Kinase Domain in Complex with Allosteric Compound PSE10 Bound to the PIF-Pocket	x-ray	1.09	A	o15530	556		79..400
5lvp	pdb	Human PDK1 Kinase Domain in Complex with an HM-Peptide Bound to the PIF-Pocket	x-ray	2.5	A;B;C;D	;;;	;;;	;;;	;;;
5lw1	pdb	Crystal structure of DARPin-DARPin rigid fusion, variant DD_232_11_D12 in complex JNK1a1 and JIP1 peptide	x-ray	3.2	B;E;H	;;	;;	;;	;;
5lwm	pdb	Crystal structure of JAK3 in complex with Compound 4 (FM381)	x-ray	1.55	A	p52333	1124		508..788,820..1097
5lwn	pdb	Crystal structure of JAK3 in complex with Compound 5 (FM409)	x-ray	1.6	A	p52333	1124		508..788,820..1097
5lxc	pdb	Crystal structure of DYRK2 in complex with EHT 5372 (Compound 1)	x-ray	2.15	A;B	q92630;q92630	601;601	;	212..543;212..543
5lxd	pdb	Crystal structure of DYRK2 in complex with EHT 1610 (compound 2)	x-ray	2.58	A;B	q92630;q92630	601;601	;	212..543;212..543
5lxm	pdb	Crystal structure of Aurora-A bound to a hydrocarbon-stapled proteomimetic of TPX2	x-ray	2.08	A	o14965	403		120..386
5m06	pdb	Crystal structure of Mycobacterium tuberculosis PknI kinase domain	x-ray	2	A;B	p9wi69;p9wi69	585;585	;	10..257;10..257
5m07	pdb	Crystal structure of Mycobacterium tuberculosis PknI kinase domain, C20A mutant	x-ray	2.5	A;B	p9wi69;p9wi69	585;585	;	10..257;10..257
5m08	pdb	Crystal structure of Mycobacterium tuberculosis PknI kinase domain, C20A_R136A double mutant	x-ray	3.03	A;B	p9wi69;p9wi69	585;585	;	10..257;10..257
5m09	pdb	Crystal structure of Mycobacterium tuberculosis PknI kinase domain, C20A_R136N double mutant	x-ray	2.98	A;B	p9wi69;p9wi69	585;585	;	10..257;10..257
5m0b	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a short-chained N-(2-aminoethyl)isoquinoline-5-sulfonamide) Fasudil-derivative (Ligand 03)	x-ray	1.506	A	p25321	351		29..339
5m0c	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with the Fasudil-fragment isoquinoline-5-sulfonamide	x-ray	1.734	A	p25321	351		29..339
5m0l	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with the methylated Fasudil-derived fragment N-methylisoquinoline-5-sulfonamide (Ligand 02)	x-ray	1.465	A	p25321	351		29..339
5m0u	pdb	Apostructure structure of cAMP-dependent Protein Kinase (PKA) from CHO cells with a peptidic inhibitor fragment	x-ray	1.667	A	p25321	351		29..339
5m44	pdb	Complex structure of human protein kinase CK2 catalytic subunit with a thieno[2,3-d]pyrimidin inhibitor crystallized under high-salt conditions	x-ray	2.71	A	p68400	391		5..328
5m4c	pdb	Complex structure of human protein kinase CK2 catalytic subunit with a thieno[2,3-d]pyrimidin inhibitor crystallized under low-salt conditions	x-ray	1.935	A	p68400	391		5..328
5m4f	pdb	Complex structure of human protein kinase CK2 catalytic subunit with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21) crystallized under low-salt conditions	x-ray	1.519	A	p68400	391		5..328
5m4i	pdb	Complex structure of human protein kinase CK2 catalytic subunit with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21) crystallized under high-salt conditions	x-ray	2.218	A	p68400	391		5..328
5m4u	pdb	ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA') WITH THE INHIBITOR 4'-CARBOXY-6,8-CHLORO- FLAVONOL (FLC21)	x-ray	2.195	A	p19784	350		13..330
5m51	pdb	Nek2 bound to arylaminopurine compound 8	x-ray	1.899	A	p51955	445		5..280
5m53	pdb	Nek2 bound to arylaminopurine inhibitor 11	x-ray	1.9	A	p51955	445		5..280
5m55	pdb	Nek2 bound to arylaminopurine 71	x-ray	2.4	A	p51955	445		5..280
5m56	pdb	Monoclinic complex structure of human protein kinase CK2 catalytic subunit (isoform CK2alpha') with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21)	x-ray	2.237	A;B	p19784;p19784	350;350	;	13..330;13..330
5m57	pdb	Nek2 bound to arylaminopurine 6	x-ray	2.3	A	p51955	445		5..280
5m5a	pdb	Crystal structure of MELK in complex with an inhibitor	x-ray	1.9	A	q14680	651		8..308
5m6u	pdb	HUMAN PI3KDELTA IN COMPLEX WITH LASW1579	x-ray	2.85	A	o00329	1044		678..1033
5m6v	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a double methylated Fasudil-derivative	x-ray	1.418	A	p25321	351		29..339
5m6y	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a methylisoquinoline Fasudil-derivative	x-ray	1.367	A	p25321	351		29..339
5m71	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with an (R)-methyl substitued Fasudil-derivative.	x-ray	1.488	A	p25321	351		29..339
5m75	pdb	Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a (S)-methyl substitued Fasudil-derivative	x-ray	1.538	A	p25321	351		29..339
5maf	pdb	Crystal structure of MELK in complex with an inhibitor	x-ray	2.8	A	q14680	651		8..308
5mag	pdb	Crystal structure of MELK in complex with an inhibitor	x-ray	2.35	A	q14680	651		8..308
5mah	pdb	Crystal structure of MELK in complex with an inhibitor	x-ray	2	A	q14680	651		8..308
5mai	pdb	Crystal structure of MELK in complex with an inhibitor	x-ray	2.15	A	q14680	651		8..308
5mhi	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule (5-chloro-2-methoxyphenyl)methanamine	x-ray	1.489	A	p25321	351		29..339
5mhq	pdb	CCT068127 in complex with CDK2	x-ray	1.3	A	p24941	298		1..292
5mja	pdb	Kinase domain of human EphB1 bound to a quinazoline-based inhibitor	x-ray	2.14	A;B	p54762;p54762	984;984	;	614..915;614..915
5mjb	pdb	Kinase domain of human EphB1, G703C mutant, covalently bound to a quinazoline-based inhibitor	x-ray	2.23	A;B	p54762;p54762	984;984	;	614..915;614..915
5ml5	pdb	Human p38alpha MAPK in complex with imidazolyl pyridine inhibitor 11b	x-ray	1.9	A	q16539	360		9..349
5mmf	pdb	Crystal Structure of CK2alpha with Compound 7 bound	x-ray	1.99	A;B	p68400;p68400	391;391	;	5..328;5..328
5mmr	pdb	Crystal Structure of CK2alpha with N-((2-chloro-[1,1'-biphenyl]-4-yl)methyl)butane-1,4-diamine bound	x-ray	2	A;B	p68400;p68400	391;391	;	5..328;5..328
5mo4	pdb	ABL1 kinase (T334I_D382N) in complex with asciminib and nilotinib	x-ray	2.17	A	p00519	1130		231..498
5mo5	pdb	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound	x-ray	2.04	A;B	p68400;p68400	391;391	;	5..328;5..328
5mo6	pdb	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound	x-ray	1.825	A;B	p68400;p68400	391;391	;	5..328;5..328
5mo7	pdb	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound	x-ray	2.15	A;B	p68400;p68400	391;391	;	5..328;5..328
5mo8	pdb	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound	x-ray	1.82	A;B	p68400;p68400	391;391	;	5..328;5..328
5mod	pdb	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound	x-ray	2.08	A;B	p68400;p68400	391;391	;	5..328;5..328
5moe	pdb	Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound	x-ray	1.89	A;B	p68400;p68400	391;391	;	5..328;5..328
5moh	pdb	Crystal structure of CK2alpha with ZT0583 bound.	x-ray	1.38	A	p68400	391		5..328
5mot	pdb	Crystal structure of CK2alpha with ZT0627 bound	x-ray	2.09	A	p68400	391		5..328
5mov	pdb	Crystal structure of Ck2alpha with ZT0633 bound	x-ray	2.2	A	p68400	391		5..328
5mow	pdb	Crystal Structure of CK2alpha with ZT0432 bound	x-ray	1.86	A;B	p68400;p68400	391;391	;	5..328;5..328
5mp8	pdb	Crystal Structure of CK2alpha with ZT0432 bound	x-ray	1.92	A;B	p68400;p68400	391;391	;	5..328;5..328
5mpj	pdb	1-(2-chloro-[1,1'-biphenyl]-4-yl)-N-methylethanamine	x-ray	2.14	A;B	p68400;p68400	391;391	;	5..328;5..328
5mqv	pdb	Crystal structure of human Casein Kinase I delta in complex with 4-(2,5-Dimethoxyphenyl)-N-(4-(5-(4-fluorphenyl)-2-(methylthio)-1H-imidazol-4-yl)-pyridin-2-yl)-1-methyl-1H-pyrrole-2-carboxamide	x-ray	2.154	A;B;C;D;E;F	p48730;p48730;p48730;p48730;p48730;p48730	415;415;415;415;415;415	;;;;;	5..290;5..290;5..290;5..290;5..290;5..290
5mrb	pdb	Crystal structure of human Mps1 (TTK) in complex with Cpd-5	x-ray	2.2	A	p33981	857		516..792
5mrd	pdb	Human PDK1-PKCiota Kinase Chimera in Complex with Allosteric Compound PS267 Bound to the PIF-Pocket	x-ray	1.41	A	o15530	556		79..400
5mtx	pdb	Dibenzooxepinone inhibitor 12b in complex with p38 MAPK	x-ray	1.8	A	q16539	360		9..349
5mty	pdb	Dibenzosuberone inhibitor 8e in complex with p38 MAPK	x-ray	2.31	A	q16539	360		9..349
5mxx	pdb	Crystal structure of human SR protein kinase 1 (SRPK1) in complex with compound 1	x-ray	1.75	A	q96sb4	655		67..654
5my8	pdb	Crystal structure of SRPK1 in complex with SPHINX31	x-ray	1.7	A	q96sb4	655		67..654
5myv	pdb	Crystal structure of SRPK2 in complex with compound 1	x-ray	2.9	A;B;C;D	p78362;p78362;p78362;p78362	688;688;688;688	;;;	68..687;68..687;68..687;68..687
5mz3	pdb	P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide]	x-ray	2.15	A	q16539	360		9..349
5mzl	pdb	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule N-quinolin-5-ylpyridine-3-carboxamide	x-ray	1.955	A				
5n1d	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule N-methyl-1-(5-pyridin-3-yloxyfuran-2-yl)methanamine	x-ray	1.609	A	p25321	351		29..339
5n1e	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule N-(1,3-benzodioxol-5-yl)-2-piperidin-1-ylacetamide	x-ray	1.529	A	p25321	351		29..339
5n1f	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule N-quinolin-5-ylpyridine-3-carboxamide	x-ray	1.12	A	p25321	351		29..339
5n1g	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-(2-Amino-1,3-thiazol-4-yl)-1-oxaspiro[4.5]decan-2-one	x-ray	1.14	A	p25321	351		29..339
5n1h	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule Methyl 4-(aminomethyl)benzoate	x-ray	1.18	A	p25321	351		29..339
5n1k	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-amino-1-(4-fluorophenyl)ethanol	x-ray	1.8	A	p25321	351		29..339
5n1l	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2,5-dimethyl-N-pyridin-4-ylfuran-3-carboxamide	x-ray	1.489	A	p25321	351		29..339
5n1m	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule (5-chloro-2-methoxyphenyl)methanamine	x-ray	1.436	A	p25321	351		29..339
5n1n	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-chloro-9-propan-2-ylpurine	x-ray	1.405	A	p25321	351		29..339
5n1o	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-chloro-4-(chloromethyl)-5-hydroxyphenyl)ethan-1-one	x-ray	1.8	A	p25321	351		29..339
5n1v	pdb	Crystal structure of the protein kinase CK2 catalytic subunit in complex with pyrazolo-pyrimidine macrocyclic ligand	x-ray	2.52	A;B	p68400;p68400	391;391	;	5..328;5..328
5n23	pdb	Protein kinase A mutants as surrogate model for Aurora B with AT9283 inhibitor	x-ray	2.088	A	p17612	351		30..339
5n32	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-chlorobenzyl carbamimidothioate	x-ray	1.833	A	p25321	351		29..339
5n33	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 3-amino-5-(trifluoromethyl)-1H-pyridin-2-one	x-ray	1.434	A	p25321	351		29..339
5n36	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 3H-isoindol-2-ium-1-amine	x-ray	1.58	A	p25321	351		29..339
5n37	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule N-(1,3-benzodioxol-5-ylmethyl)cyclopentanamine	x-ray	1.589	A	p25321	351		29..339
5n39	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyrrolidine	x-ray	1.45	A	p25321	351		29..339
5n3a	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-methyl-5-(1-methylimidazol-2-yl)-1,3-thiazol-2-amine	x-ray	1.404	A	p25321	351		29..339
5n3b	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-(pyridin-3-yl)ethanamine	x-ray	1.64	A	p25321	351		29..339
5n3c	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule Thiophene-3-Carboximidamide	x-ray	1.772	A	p25321	351		29..339
5n3d	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-(trifluoromethyl)benzenecarboximidamide	x-ray	1.77	A	p25321	351		29..339
5n3e	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 6-dimethylaminopyridine-3-carboxylic acid	x-ray	1.529	A	p25321	351		29..339
5n3f	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule N-[3-(aminomethyl)phenyl]acetamide	x-ray	1.68	A	p25321	351		29..339
5n3g	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule (R)-1,4-oxazepan-6-ol	x-ray	1.16	A	p25321	351		29..339
5n3h	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule pyridine-3-carboxamide	x-ray	1.36	A	p25321	351		29..339
5n3i	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule methyl (2S)-2-amino-3-phenylpropanoate	x-ray	1.14	A	p25321	351		29..339
5n3j	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-Nitrobenzoic acid	x-ray	1.12	A	p25321	351		29..339
5n3k	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule O-guanidino-L-homoserine	x-ray	1.33	A	p25321	351		29..339
5n3l	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol	x-ray	1.38	A	p25321	351		29..339
5n3m	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule D-arginine	x-ray	1.229	A	p25321	351		29..339
5n3n	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule [(2R)-2,4-dihydroxy-4-oxobutyl]-trimethylazanium	x-ray	1.224	A	p25321	351		29..339
5n3o	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 3-(1,3-oxazol-5-yl)aniline	x-ray	1.32	A	p25321	351		29..339
5n3p	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 1H-Indol-5-ol	x-ray	1.58	A	p25321	351		29..339
5n3q	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 3-Aminobenzamide	x-ray	1.31	A	p25321	351		29..339
5n3r	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 2-(carbamoylamino)-4-methylsulfanylbutanoic acid	x-ray	1.36	A	p25321	351		29..339
5n3s	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-Hydroxybenzamide	x-ray	1.14	A	p25321	351		29..339
5n3t	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 5-Chlorothiophene-2-sulfonamide	x-ray	1.209	A	p25321	351		29..339
5n4n	pdb	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 3,4-dimethyl-5-(1H-1,2,4-triazol-3-yl)thiophene-2-carbonitrile	x-ray	2.09	A				
5n4o	pdb	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule (E)-3-(p-tolyl)acrylic acid	x-ray	2.22	A				
5n4r	pdb	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 2-(azepan-1-yl)-1-(1H-indol-3-yl)propan-1-one	x-ray	2.13	A				
5n4u	pdb	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule 5-(2-amino-1,3-thiazol-4-yl)-1,3-dihydrobenzimidazol-2-one	x-ray	2.202	A				
5n4v	pdb	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule 2-cyclopropyl-4,5-dimethylthieno[5,4-d]pyrimidine-6-carboxylic acid	x-ray	1.85	A				
5n4x	pdb	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule 4,5-dibromothiophene-2-carbohydrazide	x-ray	2.2	A				
5n4y	pdb	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 2,5-dihydro-1H-isothiochromeno[3,4-d]pyrazol-3-one	x-ray	2.56	A				
5n4z	pdb	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule (E)-4-(4-hydroxyphenyl)but-3-en-2-one	x-ray	2.257	A				
5n50	pdb	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 2-(4-chlorophenyl)sulfanylacetohydrazide	x-ray	1.92	A				
5n51	pdb	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 3,4-Dibromothiophene-2-carboxylic acid	x-ray	2.118	A				
5n52	pdb	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule (E)-3-(2,3-dimethoxyphenyl)acrylic acid	x-ray	2.252	A				
5n5l	pdb	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and [2-oxo-2-(1H-pyrrol-2-yl)ethyl] 5-bromo-1H-indole-3-carboxylate	x-ray	1.97	A				
5n5m	pdb	Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and (R)-3-(2-((isoquinolin-5-ylmethyl)(methyl)carbamoyl)phenyl)pyrrolidin-1-ium	x-ray	2.21	A				
5n63	pdb	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9c	x-ray	2.4	A	q16539	360		9..349
5n64	pdb	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9g	x-ray	2.4	A	q16539	360		9..349
5n65	pdb	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9h	x-ray	2	A	q16539	360		9..349
5n66	pdb	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9j	x-ray	2.4	A	q16539	360		9..349
5n67	pdb	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9l	x-ray	1.9	A	q16539	360		9..349
5n68	pdb	Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9m	x-ray	1.85	A	q16539	360		9..349
5n7p	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 3-amino-5-(pyrrolidin-1-yl)-1H-pyrazole-4-carbonitrile	x-ray	1.501	A	p25321	351		29..339
5n7u	pdb	cAMP-dependent Protein Kinase A from Cricetulus griseus in complex with fragment like molecule 4-Bromo-3,5-dimethyl-1H-pyrazole	x-ray	1.371	A	p25321	351		29..339
5n7v	pdb	TTK kinase domain in complex with MPI-0479605	x-ray	2.52	A	p33981	857		516..792
5n84	pdb	TTK kinase domain in complex with Mps-BAY2b	x-ray	2.3	A	p33981	857		516..792
5n87	pdb	TTK kinase domain in complex with NTRC 0066-0	x-ray	2.29	A	p33981	857		516..792
5n93	pdb	TTK kinase domain in complex with TC-Mps1-12	x-ray	2.1	A	p33981	857		516..792
5n9k	pdb	Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive, tight-binding dibenzofuran inhibitor TF107 (5)	x-ray	1.643	A	p68400	391		5..328
5n9l	pdb	Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive dibenzofuran inhibitor TF (4b)	x-ray	1.79	A	p68400	391		5..328
5n9n	pdb	Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive, tight-binding dibenzofuran inhibitor TF85 (4a)	x-ray	1.841	A	p68400	391		5..328
5n9s	pdb	TTK kinase domain in complex with BAY 1161909	x-ray	2.3	A	p33981	857		516..792
5na0	pdb	TTK kinase domain in complex with a PEG-linked pyrimido-indolizine	x-ray	2.9	A	p33981	857		516..792
5nad	pdb	TTK kinase domain in complex with BAY 1217389	x-ray	2.8	A	p33981	857		516..792
5ncl	pdb	Crystal structure of the Cbk1-Mob2 kinase-coactivator complex with an SSD1 peptide	x-ray	3.15	A	p53894	756		334..713
5ncy	pdb	mPI3Kd IN COMPLEX WITH inh1	x-ray	1.9	A	o35904	1043		677..1032
5ncz	pdb	mPI3Kd IN COMPLEX WITH inh1	x-ray	1.94	A	o35904	1043		677..1032
5ndt	pdb	Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule (E)-3-(2-(thiophen-2-yl)vinyl)-3,4-dihydroquinoxalin-2(1H)-one	x-ray	1.985	A				
5nev	pdb	CDK2/Cyclin A in complex with compound 73	x-ray	2.97	A;C	p24941;p24941	298;298	;	1..292;1..292
5ng0	pdb	Structure of RIP2K(L294F) with bound AMPPCP	x-ray	2	A;B	o43353;o43353	540;540	;	11..297;11..297
5ng2	pdb	Structure of RIP2K(D146N) with bound Staurosporine	x-ray	2.8	A;B	o43353;o43353	540;540	;	11..297;11..297
5ng3	pdb	Structure of inactive kinase RIP2K(K47R)	x-ray	2.6	A;B;C;D	o43353;o43353;o43353;o43353	540;540;540;540	;;;	11..297;11..297;11..297;11..297
5ngb	pdb	X-Ray Diffraction Crystal Structure of the murine PI3K p110delta in complex with a pan inhibitor	x-ray	2.9	A	o35904	1043		677..1032
5ngu	pdb	Human Erk2 with an Erk1/2 inhibitor	x-ray	2.74	A	p28482	360		19..322
5nhf	pdb	Human Erk2 with an Erk1/2 inhibitor	x-ray	2.14	A	p28482	360		19..322
5nhh	pdb	Human Erk2 with an Erk1/2 inhibitor	x-ray	1.94	A	p28482	360		19..322
5nhj	pdb	Human Erk2 with an Erk1/2 inhibitor	x-ray	2.12	A	p28482	360		19..322
5nhl	pdb	Human Erk2 with an Erk1/2 inhibitor	x-ray	2.07	A	p28482	360		19..322
5nho	pdb	Human Erk2 with an Erk1/2 inhibitor	x-ray	2.24	A	p28482	360		19..322
5nhp	pdb	Human Erk2 with an Erk1/2 inhibitor	x-ray	1.99	A	p28482	360		19..322
5nhv	pdb	Human Erk2 with an Erk1/2 inhibitor	x-ray	2	A	p28482	360		19..322
5njz	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1g	x-ray	1.768	A	p29317	976		605..909
5nk0	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1j	x-ray	1.597	A	p29317	976		605..909
5nk1	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1k	x-ray	1.548	A	p29317	976		605..909
5nk2	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2b	x-ray	1.649	A	p29317	976		605..909
5nk3	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1l	x-ray	1.586	A	p29317	976		605..909
5nk4	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2c	x-ray	1.45	A	p29317	976		605..909
5nk5	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1m	x-ray	1.329	A	p29317	976		605..909
5nk6	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2d	x-ray	1.267	A	p29317	976		605..909
5nk7	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2a	x-ray	1.889	A	p29317	976		605..909
5nk8	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2f	x-ray	1.761	A	p29317	976		605..909
5nk9	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2e	x-ray	1.588	A	p29317	976		605..909
5nka	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2g	x-ray	1.377	A	p29317	976		605..909
5nkb	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 4a	x-ray	1.5	A	p29317	976		605..909
5nkc	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2h	x-ray	1.448	A	p29317	976		605..909
5nkd	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2i	x-ray	1.408	A	p29317	976		605..909
5nke	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3a	x-ray	1.39	A	p29317	976		605..909
5nkf	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3b	x-ray	1.099	A	p29317	976		605..909
5nkg	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3d	x-ray	1.1	A	p29317	976		605..909
5nkh	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3e	x-ray	1.29	A	p29317	976		605..909
5nki	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 4b	x-ray	1.675	A	p29317	976		605..909
5np0	pdb	Closed dimer of human ATM (Ataxia telangiectasia mutated)	em	5.7	A;B	q13315;q13315	3056;3056	;	2623..2974;2623..2974
5np1	pdb	Open protomer of human ATM (Ataxia telangiectasia mutated)	em	5.7	A	q13315	3056		2623..2974
5nqc	pdb	CK2alpha in complex with NMR154	x-ray	2	A	p68400	391		5..328
5ntj	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compound RKp032	x-ray	1.56	A	p25321	351		29..339
5ntt	pdb	Crystal structure of human Mps1 (TTK) C604Y mutant in complex with NMS-P715	x-ray	2.75	A	p33981	857		516..792
5nud	pdb	FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527	x-ray	2.5	A;B	p22455;p22455	802;802	;	458..743;458..743
5nw8	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp032 and Fasudil	x-ray	2.086	A	p25321	351		29..339
5nwz	pdb	FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527	x-ray	2.37	A;B	p22455;p22455	802;802	;	458..743;458..743
5nxc	pdb	LIM Domain Kinase 1 (LIMK1) In Complex With PF-00477736	x-ray	2.25	L	p53667	647		329..616
5nxd	pdb	LIM Domain Kinase 2 (LIMK2) In Complex With TH-300	x-ray	1.9	A;B	p53671;p53671	638;638	;	304..597;304..597
5nzz	pdb	Crystal structure of phosphorylated p38aMAPK in complex with TAB1	x-ray	2.6	E;F;G;H	p47811;p47811;p47811;p47811	360;360;360;360	;;;	9..349;9..349;9..349;9..349
5o0e	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and Fasudil	x-ray	1.5	A	p25321	351		29..339
5o0y	pdb	TLK2 kinase domain from human	x-ray	2.86	A	q86ue8	772		452..748
5o11	pdb	Crystal structure of PIM1 kinase in complex with small-molecule inhibitor	x-ray	2.4	A	p11309	313		36..296
5o12	pdb	Crystal structure of PIM1 kinase in complex with small-molecule inhibitor	x-ray	2.4	A	p11309	313		36..296
5o13	pdb	Crystal structure of PIM1 kinase in complex with small-molecule inhibitor	x-ray	2.44	A	p11309	313		36..296
5o1s	pdb	Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases	x-ray	1.9	A	p18654	740		66..390,402..717
5o1v	pdb	Crystal structure of WNK3 kinase domain in a monophosphorylated apo state (A-loop swapped)	x-ray	1.723	A;B	q9byp7;q9byp7	1800;1800	;	152..406;152..406
5o21	pdb	Crystal structure of WNK3 kinase domain in a monophosphorylated state with chloride bound in the active site	x-ray	2.06	A;B	q9byp7;q9byp7	1800;1800	;	152..406;152..406
5o23	pdb	Crystal structure of WNK3 kinase domain in a monophosphorylated apo state	x-ray	2.25	A;B	q9byp7;q9byp7	1800;1800	;	152..406;152..406
5o26	pdb	Crystal structure of WNK3 kinase domain in a diphosphorylated state and in complex with AMP-PNP/Mg2+	x-ray	2.379	A;B	q9byp7;q9byp7	1800;1800	;	152..406;152..406
5o2b	pdb	Crystal structure of WNK3 kinase domain in a diphosphorylated state and in a complex with the inhibitor PP-121	x-ray	2.038	A;B	q9byp7;q9byp7	1800;1800	;	152..406;152..406
5o2c	pdb	Crystal structure of WNK3 kinase and CCT1 didomain in a unphosphorylated state	x-ray	2.4	A	q9byp7	1800		152..406
5o49	pdb	Human FGF in complex with a covalent inhibitor	x-ray	1.91	A;B	p11362;p11362	822;822	;	468..754;468..754
5o4a	pdb	Human FGF in complex with a covalent inhibitor	x-ray	2.01	A;B	p11362;p11362	822;822	;	468..754;468..754
5o5m	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and RKp117	x-ray	1.583	A	p25321	351		29..339
5o7i	pdb	ERK5 in complex with a pyrrole inhibitor	x-ray	2.38	A	q13164	816		48..356
5o83	pdb	Discovery of CDZ173 (leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors	x-ray	2.9	A	o35904	1043		677..1032
5o8u	pdb	Covalent Inhibitor 4b bound to the Lipid Pocket of p38alpha Mutant S252C	x-ray	2	A	q16539	360		9..349
5o8v	pdb	Covalent Inhibitor 4a bound to the Lipid Pocket of p38alpha Mutant S251C	x-ray	2	A	q16539	360		9..349
5o90	pdb	Crystal structure of a P38alpha T185G mutant in complex with TAB1 peptide.	x-ray	2.49	A	p47811	360		9..349
5o91	pdb	Crystal structure of human Mps1 (TTK) C604W mutant in complex with Cpd-5	x-ray	3.2	A	p33981	857		516..792
5oat	pdb	PINK1 structure	x-ray	2.78	A;B;C;D;E;F	d6wmx4;d6wmx4;d6wmx4;d6wmx4;d6wmx4;d6wmx4	570;570;570;570;570;570	;;;;;	153..478;153..478;153..478;153..478;153..478;153..478
5obj	pdb	Aurora A kinase in complex with 2-(3-fluorophenyl)quinoline-4-carboxylic acid and ATP	x-ray	2.901	A	o14965	403		120..386
5obr	pdb	Aurora A kinase in complex with 2-(3-chloro-5-fluorophenyl)quinoline-4-carboxylic acid and JNJ-7706621	x-ray	2.62	A	o14965	403		120..386
5odt	pdb	Aurora-A in complex with TACC3	x-ray	2.021	A	o14965	403		120..386
5oej	pdb	Structure of Tra1 subunit within the chromatin modifying complex SAGA	em	5.7	B	c4qyv4	3825		3384..3755
5ojs	pdb	Cryo-EM structure of the SAGA and NuA4 coactivator subunit Tra1	em	3.7	T	p38811	3744		3307..3703
5ok3	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp241 and Fasudil	x-ray	1.588	A	p25321	351		29..339
5okt	pdb	Crystal structure of human Casein Kinase I delta in complex with IWP-2	x-ray	2.13	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
5ol3	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp013 and RKp117	x-ray	1.58	A	p25321	351		29..339
5omg	pdb	p38alpha in complex with pyrazolobenzothiazine inhibitor COXP4M12	x-ray	2	A	q16539	360		9..349
5omh	pdb	p38alpha in complex with pyrazolobenzothiazine inhibitor COXH11	x-ray	2.5	A	q16539	360		9..349
5omy	pdb	HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P	x-ray	1.95	A	p68400	391		5..328
5one	pdb	Crystal structure of Aurora-A in complex with FMF-03-145-1 (compound 2)	x-ray	2.6	A	o14965	403		120..386
5oni	pdb	LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P	x-ray	2	A;B	p68400;p68400	391;391	;	5..328;5..328
5oo0	pdb	Cdk2(WT) covalent adduct with D28 at C177	x-ray	1.6	A	p24941	298		1..292
5oo1	pdb	Cdk2(F80C, C177A) covalent adduct with C37 at F80C	x-ray	2	A	p24941	298		1..292
5oo3	pdb	Cdk2(F80C, C177A) with covalent ligand at F80C	x-ray	1.73	A	p24941	298		1..292
5ooi	pdb	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA') IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P	x-ray	1.998	A;B	p19784;p19784	350;350	;	13..330;13..330
5oop	pdb	Structure of CHK1 10-pt. mutant complex with AMP-PNP	x-ray	1.7	A	o14757	476		6..317
5oor	pdb	Structure of CHK1 10-pt. mutant complex with staurosporine	x-ray	1.9	A	o14757	476		6..317
5oot	pdb	Structure of CHK1 10-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor	x-ray	2.1	A	o14757	476		6..317
5op2	pdb	Structure of CHK1 10-pt. mutant complex with arylbenzamide LRRK2 inhibitor	x-ray	1.9	A	o14757	476		6..317
5op4	pdb	Structure of CHK1 10-pt. mutant complex with aminopyrimidine LRRK2 inhibitor	x-ray	2	A	o14757	476		6..317
5op5	pdb	Structure of CHK1 10-pt. mutant complex with pyrrolopyrimidine LRRK2 inhibitor	x-ray	1.9	A	o14757	476		6..317
5op7	pdb	Structure of CHK1 10-pt. mutant complex with pyrrolopyrimidine LRRK2 inhibitor	x-ray	1.8	A	o14757	476		6..317
5opb	pdb	Structure of CHK1 10-pt. mutant complex with indazole LRRK2 inhibitor	x-ray	1.55	A	o14757	476		6..317
5opr	pdb	Structure of CHK1 10-pt. mutant complex with aminopyridine LRRK2 inhibitor	x-ray	1.95	A	o14757	476		6..317
5ops	pdb	Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor	x-ray	2	A	o14757	476		6..317
5opu	pdb	Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor	x-ray	1.55	A	o14757	476		6..317
5opv	pdb	Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor	x-ray	1.9	A	o14757	476		6..317
5oq4	pdb	PQR309 - a Potent, Brain-Penetrant, Orally Bioavailable, pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology	x-ray	2.7	A	p48736	1102		728..1089
5oq5	pdb	Structure of CHK1 8-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor	x-ray	1.4	A	o14757	476		6..317
5oq6	pdb	Structure of CHK1 12-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor	x-ray	1.95	A	o14757	476		6..317
5oq7	pdb	Structure of CHK1 8-pt. mutant complex with arylbenzamide LRRK2 inhibitor	x-ray	2.1	A;B	o14757;o14757	476;476	;	6..317;6..317
5oq8	pdb	Structure of CHK1 12-pt. mutant complex with arylbenzamide LRRK2 inhibitor	x-ray	2	A	o14757	476		6..317
5oqu	pdb	The crystal structure of CK2alpha in complex with compound 5	x-ray	2.324	A;B	p68400;p68400	391;391	;	5..328;5..328
5orh	pdb	The crystal structure of CK2alpha in complex with compound 2	x-ray	1.75	A;B	p68400;p68400	391;391	;	5..328;5..328
5orj	pdb	The crystal structure of CK2alpha in complex with compound 3	x-ray	1.99	A;B	p68400;p68400	391;391	;	5..328;5..328
5ork	pdb	The crystal structure of CK2alpha in complex with compound 6	x-ray	2.143	A;B	p68400;p68400	391;391	;	5..328;5..328
5orl	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.69	A	o14965	403		120..386
5orn	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	2.19	A	o14965	403		120..386
5oro	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	2.12	A	o14965	403		120..386
5orp	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	2.19	A	o14965	403		120..386
5orr	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	2.09	A	o14965	403		120..386
5ors	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.98	A	o14965	403		120..386
5ort	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	2.56	A	o14965	403		120..386
5orv	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.88	A	o14965	403		120..386
5orw	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	2	A	o14965	403		120..386
5orx	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.88	A	o14965	403		120..386
5ory	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.99	A	o14965	403		120..386
5orz	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.92	A	o14965	403		120..386
5os0	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.74	A	o14965	403		120..386
5os1	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.9	A	o14965	403		120..386
5os2	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.92	A	o14965	403		120..386
5os3	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.81	A	o14965	403		120..386
5os4	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.88	A	o14965	403		120..386
5os5	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.74	A	o14965	403		120..386
5os6	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	2.2	A	o14965	403		120..386
5os7	pdb	The crystal structure of CK2alpha in complex with compound 4	x-ray	1.66	A;B	p68400;p68400	391;391	;	5..328;5..328
5os8	pdb	The crystal structure of CK2alpha in complex with compound 11	x-ray	1.55	A	p68400	391		5..328
5osd	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.99	A	o14965	403		120..386
5ose	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.9	A	o14965	403		120..386
5osf	pdb	Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment	x-ray	1.89	A	o14965	403		120..386
5osj	pdb	Cdk2(WT) with covalent adduct at C177	x-ray	1.83	A	p24941	298		1..292
5osl	pdb	The crystal structure of CK2alpha in complex with compound 7	x-ray	1.95	A	p68400	391		5..328
5osm	pdb	Cdk2(F80C, C177A) with covalent adduct at C80	x-ray	1.77	A	p24941	298		1..292
5osp	pdb	The crystal structure of CK2alpha in complex with an analogue of compound 1	x-ray	1.91	A	p68400	391		5..328
5osr	pdb	The crystal structure of CK2alpha in complex with an analogue of compound 1	x-ray	1.57	A	p68400	391		5..328
5osu	pdb	The crystal structure of CK2alpha in complex with analogues of compound 1	x-ray	1.63	A	p68400	391		5..328
5osz	pdb	The crystal structure of CK2alpha in complex with compound 23	x-ray	2	A	p68400	391		5..328
5ot3	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp191 and RKp117	x-ray	2.04	A	p25321	351		29..339
5ot5	pdb	The crystal structure of CK2alpha in complex with compound 24	x-ray	1.63	A;B	p68400;p68400	391;391	;	5..328;5..328
5ot6	pdb	The crystal structure of CK2alpha in complex with compound 19	x-ray	1.94	A;B	p68400;p68400	391;391	;	5..328;5..328
5otd	pdb	The crystal structure of CK2alpha in complex with compound 25	x-ray	1.57	A;B	p68400;p68400	391;391	;	5..328;5..328
5ote	pdb	MRCK beta in complex with BDP-00008900	x-ray	1.68	A	q9y5s2	1711		56..396
5otf	pdb	MRCK beta in complex with BDP-00009066	x-ray	2	A	q9y5s2	1711		56..396
5otg	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp013 and RKp190	x-ray	1.73	A	p25321	351		29..339
5oth	pdb	The crystal structure of CK2alpha in complex with compound 26	x-ray	1.69	A;B	p68400;p68400	391;391	;	5..328;5..328
5oti	pdb	The crystal structure of CK2alpha in complex with compound 27	x-ray	1.59	A	p68400	391		5..328
5otl	pdb	The crystal structure of CK2alpha in complex with compound 29	x-ray	1.57	A;B	p68400;p68400	391;391	;	5..328;5..328
5oto	pdb	The crystal structure of CK2alpha in complex with compound 30	x-ray	1.51	A;B	p68400;p68400	391;391	;	5..328;5..328
5otp	pdb	The crystal structure of CK2alpha in complex with an analogue of compound 22	x-ray	1.57	A;B	p68400;p68400	391;391	;	5..328;5..328
5otq	pdb	The crystal structure of CK2alpha in complex with compound 33	x-ray	1.38	A	p68400	391		5..328
5otr	pdb	The crystal structure of CK2alpha in complex with compound 14	x-ray	1.52	A	p68400	391		5..328
5ots	pdb	The crystal structure of CK2alpha in complex with an analogue of compound 22	x-ray	1.9	A	p68400	391		5..328
5oty	pdb	The crystal structure of CK2alpha in complex with CAM4712	x-ray	1.48	A	p68400	391		5..328
5otz	pdb	The crystal structure of CK2alpha in complex with compound 1	x-ray	1.46	A	p68400	391		5..328
5oua	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compound RKp017	x-ray	1.67	A	p25321	351		29..339
5ouc	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp191 and RKp190	x-ray	1.46	A	p25321	351		29..339
5oue	pdb	The crystal structure of CK2alpha in complex with compound 20	x-ray	2.01	A;B	p68400;p68400	391;391	;	5..328;5..328
5oul	pdb	The crystal structure of CK2alpha in complex with compound 9	x-ray	1.34	A	p68400	391		5..328
5oum	pdb	The crystal structure of CK2alpha in complex with compound 21	x-ray	2.05	A;B	p68400;p68400	391;391	;	5..328;5..328
5ous	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp193	x-ray	2.21	A	p25321	351		29..339
5ouu	pdb	The crystal structure of CK2alpha in complex with compound 22	x-ray	1.81	A;B	p68400;p68400	391;391	;	5..328;5..328
5owh	pdb	High salt structure of human protein kinase CK2alpha in complex with 3-aminopropyl-4,5,6,7-tetrabromobenzimidazol	x-ray	2.3	A	p68400	391		5..328
5owl	pdb	Low salt structure of human protein kinase CK2alpha in complex with 3-aminopropyl-4,5,6,7-tetrabromobenzimidazol	x-ray	2.23	A;B	p68400;p68400	391;391	;	5..328;5..328
5owq	pdb	Human STK10 bound to dovitinib	x-ray	2.7	A;B	o94804;o94804	968;968	;	31..302;31..302
5owr	pdb	Human STK10 bound to dasatinib	x-ray	2.3	A	o94804	968		31..302
5oxg	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with LDN-212854	x-ray	2.13	A;B;C;D	q04771;q04771;q04771;q04771	509;509;509;509	;;;	186..496;186..496;186..496;186..496
5oy4	pdb	GSK3beta complex with N-(6-(3,4-dihydroxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)acetamide	x-ray	3.2	A;B	p49841;p49841	420;420	;	55..377;55..377
5oy6	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with cyclical inhibitor OD36.	x-ray	2.56	A;B;C;D	q04771;q04771;q04771;q04771	509;509;509;509	;;;	186..496;186..496;186..496;186..496
5oyf	pdb	The crystal structure of CK2alpha in complex with compound 31	x-ray	1.54	A	p68400	391		5..328
5p9f	pdb	BTK IN COMPLEX WITH GDC-0834	x-ray	1.71	A	q06187	659		382..648
5p9g	pdb	Structure of BTK with RN486	x-ray	1.75	A	q06187	659		382..648
5p9h	pdb	BTK1 COCRYSTALLIZED WITH RN983	x-ray	1.95	A	q06187	659		382..648
5p9i	pdb	BTK1 SOAKED WITH IBRUTINIB-Rev	x-ray	1.11	A	q06187	659		382..648
5p9j	pdb	BTK1 COCRYSTALLIZED WITH IBRUTINIB	x-ray	1.08	A	q06187	659		382..648
5p9k	pdb	CRYSTAL STRUCTURE OF BTK with CNX 774	x-ray	1.28	A	q06187	659		382..648
5p9l	pdb	BTK1 IN COMPLEX WITH CC 292	x-ray	1.25	A	q06187	659		382..648
5p9m	pdb	BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059	x-ray	1.41	A	q06187	659		382..648
5qik	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(6-fluoropyridin-3-yl)-4-oxo-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl]pyridin-2-yl}acetamide	x-ray	1.58	A	p36897	503		180..492
5qil	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(6-METHOXYPYRIDIN-3-YL)-1H-PYRROLO[3,2-B]PYRIDIN-2-YL]PYRIDIN-2-YL}ACETAMIDE	x-ray	1.98	A	p36897	503		180..492
5qim	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(5-METHOXYPYRIDIN-2-YL)-1H-PYRROLO[3,2-B] PYRIDIN-2-YL]PYRIDIN-2-YL}ACETAMIDE	x-ray	1.75	A	p36897	503		180..492
5qin	pdb	TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN IN COMPLEX WITH N- {4-[3-(6-METHOXYPYRIDIN-3-YL)-1H-PYRROLO[3,2-B]PYRIDIN-2- YL]PYRIDIN-2-YL}ACETAMIDE	x-ray	1.57	A	p37173	567		244..537
5qtz	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 6-[1-(2,2-DIFLUOROETHYL)-4-(6-METHYLPYRIDIN-2-YL)-1H-IMIDAZOL-5-YL]IMIDAZO[1,2-A]PYRIDINE	x-ray	1.83	A	p36897	503		180..492
5qu0	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 6-[4-(3-CHLORO-4-FLUOROPHENYL)-1-(2-HYDROXYETHYL)-1H-IMIDAZOL-5-YL]IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE	x-ray	1.67	A	p36897	503		180..492
5r8u	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N05703b in complex with MAP kinase p38-alpha	x-ray	1.48	A	p47811	360		9..349
5r8v	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N09139b in complex with MAP kinase p38-alpha	x-ray	1.479	A	p47811	360		9..349
5r8w	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment K00283c in complex with MAP kinase p38-alpha	x-ray	1.5	A	p47811	360		9..349
5r8x	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11396a in complex with MAP kinase p38-alpha	x-ray	1.73	A	p47811	360		9..349
5r8y	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N08078b in complex with MAP kinase p38-alpha	x-ray	1.679	A	p47811	360		9..349
5r8z	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N01381c in complex with MAP kinase p38-alpha	x-ray	1.65	A	p47811	360		9..349
5r90	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11145a in complex with MAP kinase p38-alpha	x-ray	1.619	A	p47811	360		9..349
5r91	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL057 in complex with MAP kinase p38-alpha	x-ray	1.731	A	p47811	360		9..349
5r92	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL063 in complex with MAP kinase p38-alpha	x-ray	1.66	A	p47811	360		9..349
5r93	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL077 in complex with MAP kinase p38-alpha	x-ray	1.489	A	p47811	360		9..349
5r94	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL081 in complex with MAP kinase p38-alpha	x-ray	1.45	A	p47811	360		9..349
5r95	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL093 in complex with MAP kinase p38-alpha	x-ray	1.59	A	p47811	360		9..349
5r96	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL095 in complex with MAP kinase p38-alpha	x-ray	1.767	A	p47811	360		9..349
5r97	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13662a in complex with MAP kinase p38-alpha	x-ray	1.438	A	p47811	360		9..349
5r98	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14109a in complex with MAP kinase p38-alpha	x-ray	1.68	A	p47811	360		9..349
5r99	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13619a in complex with MAP kinase p38-alpha	x-ray	1.89	A	p47811	360		9..349
5r9a	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13838a in complex with MAP kinase p38-alpha	x-ray	1.53	A	p47811	360		9..349
5r9b	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13866a in complex with MAP kinase p38-alpha	x-ray	1.657	A	p47811	360		9..349
5r9c	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14074a in complex with MAP kinase p38-alpha	x-ray	1.74	A	p47811	360		9..349
5r9d	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment S00888c in complex with MAP kinase p38-alpha	x-ray	1.69	A	p47811	360		9..349
5r9e	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13693a in complex with MAP kinase p38-alpha	x-ray	1.775	A	p47811	360		9..349
5r9f	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13724a in complex with MAP kinase p38-alpha	x-ray	1.986	A	p47811	360		9..349
5r9g	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment PC587 in complex with MAP kinase p38-alpha	x-ray	1.73	A	p47811	360		9..349
5r9h	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment TCJ658 in complex with MAP kinase p38-alpha	x-ray	1.49	A	p47811	360		9..349
5r9i	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment TCJ795 in complex with MAP kinase p38-alpha	x-ray	1.813	A	p47811	360		9..349
5r9j	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14231a in complex with MAP kinase p38-alpha	x-ray	1.52	A	p47811	360		9..349
5r9k	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14246a in complex with MAP kinase p38-alpha	x-ray	1.498	A	p47811	360		9..349
5r9l	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14274a in complex with MAP kinase p38-alpha	x-ray	1.47	A	p47811	360		9..349
5r9m	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13418a in complex with MAP kinase p38-alpha	x-ray	1.809	A	p47811	360		9..349
5r9n	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13421a in complex with MAP kinase p38-alpha	x-ray	1.688	A	p47811	360		9..349
5r9o	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N06122b in complex with MAP kinase p38-alpha	x-ray	1.6	A	p47811	360		9..349
5r9p	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13430a in complex with MAP kinase p38-alpha	x-ray	1.72	A	p47811	360		9..349
5r9q	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N07422b in complex with MAP kinase p38-alpha	x-ray	1.645	A	p47811	360		9..349
5r9r	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13413a in complex with MAP kinase p38-alpha	x-ray	1.76	A	p47811	360		9..349
5r9s	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13470a in complex with MAP kinase p38-alpha	x-ray	1.7	A	p47811	360		9..349
5r9t	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13477a in complex with MAP kinase p38-alpha	x-ray	1.8	A	p47811	360		9..349
5r9u	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13475a in complex with MAP kinase p38-alpha	x-ray	1.67	A	p47811	360		9..349
5r9v	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13596a in complex with MAP kinase p38-alpha	x-ray	1.45	A	p47811	360		9..349
5r9w	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13598a in complex with MAP kinase p38-alpha	x-ray	1.89	A	p47811	360		9..349
5r9x	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13611a in complex with MAP kinase p38-alpha	x-ray	1.72	A	p47811	360		9..349
5r9y	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13619a in complex with MAP kinase p38-alpha	x-ray	1.57	A	p47811	360		9..349
5r9z	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13502a in complex with MAP kinase p38-alpha	x-ray	1.66	A	p47811	360		9..349
5ra0	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13421a in complex with MAP kinase p38-alpha	x-ray	1.91	A	p47811	360		9..349
5ra1	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N08141b in complex with MAP kinase p38-alpha	x-ray	1.61	A	p47811	360		9..349
5ra2	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N09036b in complex with MAP kinase p38-alpha	x-ray	1.57	A	p47811	360		9..349
5ra3	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N10836b in complex with MAP kinase p38-alpha	x-ray	1.57	A	p47811	360		9..349
5ra4	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11337a in complex with MAP kinase p38-alpha	x-ray	1.59	A	p47811	360		9..349
5ra5	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11302a in complex with MAP kinase p38-alpha	x-ray	1.54	A	p47811	360		9..349
5ra6	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11338a in complex with MAP kinase p38-alpha	x-ray	1.86	A	p47811	360		9..349
5ra7	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11351a in complex with MAP kinase p38-alpha	x-ray	1.92	A	p47811	360		9..349
5ra8	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N05711b in complex with MAP kinase p38-alpha	x-ray	1.78	A	p47811	360		9..349
5ra9	pdb	PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N08051b in complex with MAP kinase p38-alpha	x-ray	1.68	A	p47811	360		9..349
5s75	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010913a	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s76	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010916a	x-ray	1.31	A;B	q04771;q04771	509;509	;	186..496;186..496
5s77	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with XS035133b	x-ray	1.31	A;B	q04771;q04771	509;509	;	186..496;186..496
5s78	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010934a	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s79	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010910a	x-ray	1.5	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7a	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with PK012456b	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7b	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000329d	x-ray	1.32	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7c	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000274c	x-ray	1.31	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7d	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010923a	x-ray	1.31	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7e	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010930a	x-ray	1.32	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7f	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010935a	x-ray	1.31	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7g	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with XS035844b	x-ray	1.78	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7h	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010914a	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7i	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010928a	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7j	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000893d	x-ray	1.31	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7k	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010936a	x-ray	1.31	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7l	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010943a	x-ray	1.36	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7m	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000275d	x-ray	1.32	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7n	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010920a	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7o	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM007391c	x-ray	1.43	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7p	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010937a	x-ray	1.31	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7q	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010944a	x-ray	1.53	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7r	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010918a	x-ray	1.46	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7s	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010921a	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7t	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010926a	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7u	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010938a	x-ray	1.59	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7v	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010942a	x-ray	1.31	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7w	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with HM000007h	x-ray	1.33	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7x	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000376d	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7y	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010933a	x-ray	1.37	A;B	q04771;q04771	509;509	;	186..496;186..496
5s7z	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with NU074488b	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s80	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010946a	x-ray	1.67	A;B	q04771;q04771	509;509	;	186..496;186..496
5s81	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010947a	x-ray	1.43	A;B	q04771;q04771	509;509	;	186..496;186..496
5s82	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with XS035128c	x-ray	1.71	A;B	q04771;q04771	509;509	;	186..496;186..496
5s83	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010948a	x-ray	1.33	A;B	q04771;q04771	509;509	;	186..496;186..496
5s84	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010949a	x-ray	1.35	A;B	q04771;q04771	509;509	;	186..496;186..496
5s85	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000884c	x-ray	1.33	A;B	q04771;q04771	509;509	;	186..496;186..496
5s86	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010952a	x-ray	1.31	A;B	q04771;q04771	509;509	;	186..496;186..496
5s87	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010953a	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s88	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010954a	x-ray	1.31	A;B	q04771;q04771	509;509	;	186..496;186..496
5s89	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010957a	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s8a	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with NU074484b	x-ray	1.3	A;B	q04771;q04771	509;509	;	186..496;186..496
5s8b	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010960a	x-ray	1.64	A;B	q04771;q04771	509;509	;	186..496;186..496
5s9k	pdb	XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010955a	x-ray	1.35	A;B	q04771;q04771	509;509	;	186..496;186..496
5sau	pdb	DDR1, 3-[2-(6-aminopyridin-3-yl)ethynyl]-N-[3-(trifluoromethyl)phenyl]benzamide, 1.800A, P212121, Rfree=23.1%	x-ray	1.8	A	q08345	913		603..904
5sav	pdb	DDR1, N-[2-[3-(2-aminopyrimidin-5-yl)oxyphenyl]ethyl]-3-(trifluoromethoxy)benzamide, 1.760A, P212121, Rfree=23.5%	x-ray	1.76	A	q08345	913		603..904
5saw	pdb	DDR1, 2-[3-(2-pyridin-3-ylethynyl)phenyl]-N-[3-(trifluoromethyl)phenyl]acetamide, 1.601A, P212121, Rfree=22.6%	x-ray	1.601	A	q08345	913		603..904
5sax	pdb	DDR1, 2-[3-(2-pyridin-3-ylethynyl)phenyl]-N-[3-(trifluoromethyl)phenyl]acetamide, 1.902A, second P212121 form, Rfree=25.4%, second form	x-ray	1.902	A	q08345	913		603..904
5say	pdb	DDR1, N-[2-[3-(2-aminopyrimidin-5-yl)oxyphenyl]ethyl]-3-(trifluoromethoxy)benzamide, 2.190A, P1211, Rfree=27.7%	x-ray	2.19	A;B	q08345;q08345	913;913	;	603..904;603..904
5saz	pdb	DDR1, 3-chloro-N-[4-chloro-3-(1H-pyrrolo[2,3-b]pyridin-5-ylcarbamoyl)phenyl]-4-(2-hydroxyethylamino)benzamide, 1.802A, P212121, Rfree=22.2%	x-ray	1.8	A	q08345	913		603..904
5sb0	pdb	DDR1, N-[[2-(2-pyridin-3-yloxyethyl)cyclohexyl]methyl]-3-(trifluoromethoxy)benzamide, 1.970A, P212121, Rfree=25.6%	x-ray	1.97	A	q08345	913		603..904
5sb1	pdb	DDR1, 4-chloro-N-[(3S,4R)-4-phenylpyrrolidin-3-yl]-3-(1H-pyrrolo[2,3-b]pyridin-5-yloxymethyl)benzamide, 1.530A, P212121, Rfree=21.4%	x-ray	1.53	A	q08345	913		603..904
5sb2	pdb	DDR1, 3-chloro-N-[(1R,2S)-2-phenylcyclopropyl]-5-(1H-pyrrolo[2,3-b]pyridin-5-yloxymethyl)benzamide, 1.600A, P212121, Rfree=23.2%	x-ray	1.6	A	q08345	913		603..904
5sw8	pdb	Crystal structure of PI3Kalpha in complex with fragments 7 and 11	x-ray	3.3	A	p42336	1068		699..1060
5swg	pdb	Crystal Structure of PI3Kalpha in complex with fragments 5 and 21	x-ray	3.11	A	p42336	1068		699..1060
5swh	pdb	c-Src V281C kinase domain in complex with Rao-IV-151	x-ray	2.5	A;B	p00523;p00523	533;533	;	256..526;256..526
5swo	pdb	Crystal Structure of PI3Kalpha in complex with fragments 4 and 19	x-ray	3.5	A	p42336	1068		699..1060
5swp	pdb	Crystal Structure of PI3Kalpha in complex with fragments 6 and 24	x-ray	3.41	A	p42336	1068		699..1060
5swr	pdb	Crystal Structure of PI3Kalpha in complex with fragments 20 and 26	x-ray	3.31	A	p42336	1068		699..1060
5swt	pdb	Crystal Structure of PI3Kalpha in complex with fragments 17 and 27	x-ray	3.49	A	p42336	1068		699..1060
5sx8	pdb	Crystal Structure of PI3Kalpha in complex with fragments 12 and 15	x-ray	3.47	A	p42336	1068		699..1060
5sx9	pdb	Crystal Structure of PI3Kalpha in complex with fragment 14	x-ray	3.52	A	p42336	1068		699..1060
5sxa	pdb	Crystal Structure of PI3Kalpha in complex with fragment 10	x-ray	3.35	A	p42336	1068		699..1060
5sxb	pdb	Crystal Structure of PI3Kalpha in complex with fragment 23	x-ray	3.3	A	p42336	1068		699..1060
5sxc	pdb	Crystal Structure of PI3Kalpha in complex with fragment 8	x-ray	3.55	A	p42336	1068		699..1060
5sxd	pdb	Crystal Structure of PI3Kalpha in complex with fragment 22	x-ray	3.5	A	p42336	1068		699..1060
5sxe	pdb	Crystal Structure of PI3Kalpha in complex with fragments 19 and 28	x-ray	3.51	A	p42336	1068		699..1060
5sxf	pdb	Crystal Structure of PI3Kalpha in complex with fragment 9	x-ray	3.46	A	p42336	1068		699..1060
5sxi	pdb	Crystal Structure of PI3Kalpha in complex with fragment 13	x-ray	3.4	A	p42336	1068		699..1060
5sxj	pdb	Crystal Structure of PI3Kalpha in complex with fragment 29	x-ray	3.42	A	p42336	1068		699..1060
5sxk	pdb	Crystal Structure of PI3Kalpha in complex with fragment 18	x-ray	3.55	A	p42336	1068		699..1060
5sys	pdb	c-Src V281C bound to N-[3-({6-[(1E)-2-cyano-3-(methylamino)-3-oxoprop-1-en-1-yl]-7-(2-methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethynyl)-4-methylphenyl]-3-(trifluoromethyl)benzamide inhibitor	x-ray	2.8	A;B	p00523;p00523	533;533	;	256..526;256..526
5t0p	pdb	c-Src kinase domain in complex with Rao-IV-151	x-ray	2.5	A;B	p00523;p00523	533;533	;	256..526;256..526
5t18	pdb	Crystal structure of Bruton agammabulinemia tyrosine kinase complexed with BMS-986142 aka (2s)-6-fluoro-5-[3-(8-fluoro-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)-2-methylphenyl]-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1h-carbazole-8-carboxamide	x-ray	1.5	A	q06187	659		382..648
5t1h	pdb	Crystal structure of CK2	x-ray	2.11	A;B	p68400;p68400	391;391	;	5..328;5..328
5t1s	pdb	Irak4 kinase - compound 1 co-structure	x-ray	2.3	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
5t1t	pdb	Irak4 kinase - compound 1 co-structure	x-ray	2.34	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
5t23	pdb	PI3Kg IN COMPLEX WITH 5d	x-ray	2.78	A	p48736	1102		728..1089
5t27	pdb	mPI3Kd IN COMPLEX WITH 5d	x-ray	2.6	A	o35904	1043		677..1032
5t28	pdb	mPI3Kd IN COMPLEX WITH 5k	x-ray	2.8	A	o35904	1043		677..1032
5t2b	pdb	mPI3Kd IN COMPLEX WITH 5e	x-ray	2.3	A	o35904	1043		677..1032
5t2d	pdb	mPI3Kd IN COMPLEX WITH 7j	x-ray	2.9	A	o35904	1043		677..1032
5t2g	pdb	mPI3Kd IN COMPLEX WITH 7i	x-ray	2.55	A	o35904	1043		677..1032
5t2i	pdb	mPI3Kd IN COMPLEX WITH 7k	x-ray	2.3	A	o35904	1043		677..1032
5t2l	pdb	mPI3Kd IN COMPLEX WITH 7l	x-ray	2.55	A	o35904	1043		677..1032
5t2m	pdb	mPI3Kd IN COMPLEX WITH 7m	x-ray	2.8	A	o35904	1043		677..1032
5t31	pdb	Exploiting an Asp-Glu switch in Glycogen Synthase Kinase 3 to design paralog selective inhibitors for use in acute myeloid leukemia	x-ray	2.85	A;B	p49841;p49841	420;420	;	55..377;55..377
5t3q	pdb	Crystal structure of the c-Met kinase domain in complex with a pyrazolone inhibitor	x-ray	2	A	p08581	1390		1079..1341
5t5t	pdb	AMPK bound to allosteric activator	x-ray	3.46	A	p54645	559		24..308
5t68	pdb	Crystal structure of Syk catalytic domain in complex with a furo[3,2-d]pyrimidine	x-ray	2.93	A;B	p43405;p43405	635;635	;	375..627;375..627
5t6a	pdb	Crystal Structure of TgCDPK1 from toxoplasma gondii complexed with 5GA	x-ray	2.05	A	q9bjf5	507		35..330
5t6i	pdb	CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH 5GB	x-ray	2.05	A	q9bjf5	507		35..330
5t6k	pdb	Crystal Structure of TgCDPK1 From Toxoplasma Gondii complexed with GW780159X	x-ray	2.4	A	q9bjf5	507		35..330
5t7f	pdb	PI3Kdelta in complex with the inhibitor GS-643624	x-ray	2.6	A;B	o35904;o35904	1043;1043	;	677..1032;677..1032
5t8f	pdb	p110delta/p85alpha with taselisib (GDC-0032)	x-ray	2.91	A	o00329	1044		678..1033
5t8i	pdb	PI3Kdelta in complex with the inhibitor GS-9901	x-ray	2.6	A	o35904	1043		677..1032
5t8o	pdb	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to Imidazobenzoxepin Compound 3	x-ray	2.41	A;B	q9wul6;q9wul6	942;942	;	407..656;407..656
5t8p	pdb	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to benzoxepin compound 2	x-ray	2.32	A;B	q9wul6;q9wul6	942;942	;	407..656;407..656
5t8q	pdb	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to aryl pyrrole fragment 17	x-ray	2.63	A;B	q9wul6;q9wul6	942;942	;	407..656;407..656
5ta6	pdb	Crystal structure of PLK1 in complex with a novel 5,6-dihydroimidazolo[1,5-f]pteridine inhibitor.	x-ray	2.5	A	p53350	603		51..338
5ta8	pdb	Crystal structure of PLK1 in complex with a novel 5,6-dihydroimidazolo[1,5-f]pteridine inhibitor	x-ray	2.6	A	p53350	603		51..338
5tbe	pdb	Human p38alpha MAP Kinase in Complex with Dibenzosuberone Compound 2	x-ray	2.44	A	q16539	360		9..349
5tc0	pdb	Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate	x-ray	2.24	A;B	q12866;q12866	999;999	;	578..872;578..872
5tco	pdb	Human p38 MAP Kinase in Complex with Dibenzosuberone Compound 1	x-ray	2.1	A	q16539	360		9..349
5td2	pdb	Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate	x-ray	2.68	A;B	q12866;q12866	999;999	;	578..872;578..872
5te0	pdb	Crystal Structure of Adaptor Protein 2 Associated Kinase (AAK1) in complex with BIBF 1120	x-ray	1.9	A	q2m2i8	961		46..309
5teh	pdb	c-Src V281C kinase domain in complex with Rao-IV-156	x-ray	2.99	A;B	p00523;p00523	533;533	;	256..526;256..526
5tel	pdb	Pim-1 kinase in complex with a 7-azaindole	x-ray	2.214	A	p11309	313		36..296
5tex	pdb	Pim-1 kinase in complex with a 7-azaindole	x-ray	2.149	A	p11309	313		36..296
5tf9	pdb	Crystal structure of WNK1 in complex with Mn2+AMPPNP and WNK476	x-ray	2.5	A;B	q9h4a3;q9h4a3	2382;2382	;	226..769;226..769
5tiu	pdb	Crystal structure of SYK kinase domain with inhibitor	x-ray	1.49	A	p43405	635		375..627
5tkd	pdb	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(3,5-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO)IMIDAZO[1,2-B]PYRIDAZINE-3-CARBO XAMIDE	x-ray	1.92	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
5to8	pdb	Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency	x-ray	1.9849	A	q14289	1009		417..694
5tob	pdb	Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency	x-ray	2.117	A	q14289	1009		417..694
5toe	pdb	Pim-1 kinase in complex with a 7-azaindole	x-ray	2.301	A	p11309	313		36..296
5tos	pdb	Botrytis-induced kinase 1 (BIK1) from Arabidopsis thaliana	x-ray	2.35	A;B	o48814;o48814	395;395	;	51..359;51..359
5toz	pdb	JAK3 with covalent inhibitor PF-06651600	x-ray	1.98	A	p52333	1124		508..788,820..1097
5tq3	pdb	Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin	x-ray	2.69	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
5tq4	pdb	Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin	x-ray	2.3	A	o60674	1132		522..814,842..1119
5tq5	pdb	Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin	x-ray	2.3	A	o60674	1132		522..814,842..1119
5tq6	pdb	Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin	x-ray	2.06	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
5tq7	pdb	Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin	x-ray	2.1	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
5tq8	pdb	Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin	x-ray	1.59	A	o60674	1132		522..814,842..1119
5tqw	pdb	CryoEM reconstruction of human IKK1, open conformation 1	em	5.6	A;B	o15111;o15111	745;745	;	13..297;13..297
5tqx	pdb	CryoEM reconstruction of human IKK1, intermediate conformation 2	em	5.4	A;B	o15111;o15111	745;745	;	13..297;13..297
5tqy	pdb	CryoEM reconstruction of human IKK1, closed conformation 3	em	5.2	A;B	o15111;o15111	745;745	;	13..297;13..297
5tr6	pdb	Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)	x-ray	1.93	A	p43405	635		375..627
5ts8	pdb	Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE	x-ray	1.45	A	p28523	332		11..323
5tt7	pdb	Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)	x-ray	1.77	A	p43405	635		375..627
5tts	pdb	Jak3 with covalent inhibitor 4	x-ray	2.34	A	p52333	1124		508..788,820..1097
5ttu	pdb	Jak3 with covalent inhibitor 7	x-ray	1.72	A	p52333	1124		508..788,820..1097
5ttv	pdb	Jak3 with covalent inhibitor 6	x-ray	1.93	A	p52333	1124		508..788,820..1097
5tur	pdb	Pim-1 kinase in complex with a 7-azaindole	x-ray	2.948	A	p11309	313		36..296
5tvt	pdb	Structure of Maternal Embryonic Leucine Zipper Kinase	x-ray	2.28	A	q14680	651		8..308
5twl	pdb	Structure of Maternal Embryonic Leucine Zipper Kinase	x-ray	2.42	A	q14680	651		8..308
5twu	pdb	Structure of Maternal Embryonic Leucine Zipper Kinase	x-ray	2.603	A;B	q14680;q14680	651;651	;	8..308;8..308
5twy	pdb	Structure of Maternal Embryonic Leucine Zipper Kinase	x-ray	2.91	A;B	q14680;q14680	651;651	;	8..308;8..308
5twz	pdb	Structure of Maternal Embryonic Leucine Zipper Kinase	x-ray	2.631	A	q14680	651		8..308
5tx3	pdb	Structure of Maternal Embryonic Leucine Zipper Kinase	x-ray	2.9	A;B	q14680;q14680	651;651	;	8..308;8..308
5tx5	pdb	Rip1 Kinase ( flag 1-294, C34A, C127A, C233A, C240A) with GSK772	x-ray	2.56	A;B	q13546;q13546	671;671	;	6..286;6..286
5u6b	pdb	Structure of the Axl kinase domain in complex with a macrocyclic inhibitor	x-ray	2.84	A;B;C;D	p30530;p30530;p30530;p30530	894;894;894;894	;;;	528..817;528..817;528..817;528..817
5u6c	pdb	Crystal structure of the Mer kinase domain in complex with a macrocyclic inhibitor	x-ray	2.1	A;B	q12866;q12866	999;999	;	578..872;578..872
5u6i	pdb	Discovery of MLi-2, an Orally Available and Selective LRRK2 Inhibitor that Reduces Brain Kinase Activity	x-ray	1.69	A	p63086	358		17..320
5u6y	pdb	Pseudo-atomic model of the CaMKIIa holoenzyme.	em	20	A;B;C;D;E;F;G;H;I;J;K;L	p11275;p11275;p11275;p11275;p11275;p11275;p11275;p11275;p11275;p11275;p11275;p11275	478;478;478;478;478;478;478;478;478;478;478;478	;;;;;;;;;;;	9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272
5u7q	pdb	Identification of A New Class of Potent Cdc7 Inhibitors Designed by Putative Pharmacophore Model: Synthesis and Biological Evaluation of 2,3-Dihydrothieno[3,2-d]pyrimidin-4(1H)-ones	x-ray	3.15	A;B;C;D	o75116;o75116;o75116;o75116	1388;1388;1388;1388	;;;	89..412;89..412;89..412;89..412
5u7r	pdb	Identification of A New Class of Potent Cdc7 Inhibitors Designed by Putative Pharmacophore Model: Synthesis and Biological Evaluation of 2,3-Dihydrothieno[3,2-d]pyrimidin-4(1H)-ones	x-ray	3.33	A;B;C;D	o75116;o75116;o75116;o75116	1388;1388;1388;1388	;;;	89..412;89..412;89..412;89..412
5u8l	pdb	Crystal structure of EGFR kinase domain in complex with a sulfonyl fluoride probe XO44	x-ray	1.6	A	p00533	1210		708..1003
5u94	pdb	Crystal structure of the Mycobacterium tuberculosis PASTA kinase PknB in complex with the potential theraputic kinase inhibitor GSK690693.	x-ray	2.2	A	p9wi81	626		8..275
5u9d	pdb	Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-encoded chemical library	x-ray	1.33	A	q06187	659		382..648
5uab	pdb	MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody	x-ray	1.9	A	p08581	1390		1079..1341
5uad	pdb	MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody	x-ray	2.25	A	p08581	1390		1079..1341
5ubr	pdb	CRYSTAL STRUCTURE OF PI3K ALPHA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1-YL)PHENYL)PYRROLO[2,1-F][1,2,4] TRIAZIN-4-AMINE DERIVIATINE	x-ray	2.4	A	p42336	1068		699..1060
5ubt	pdb	CRYSTAL STRUCTURE OF PI3K DELTA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1-YL)PHENYL)PYRROLO[2,1-F][1,2,4] TRIAZIN-4-AMINE DERIVIATINE	x-ray	2.83	A	o00329	1044		678..1033
5ufu	pdb	Structure of AMPK bound to activator	x-ray	3.45	A	p54645	559		24..308
5ug8	pdb	Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibitor N-[(3R,4R)-4-fluoro-1-{6-[(1-methyl-1H-pyrazol-4-yl)amino]-9-(propan-2-yl)-9H-purin-2-yl}pyrrolidin-3-yl]propanamide	x-ray	1.46	A	p00533	1210		708..1003
5ug9	pdb	Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibitor N-[(3R,4R)-4-fluoro-1-{6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-(propan-2-yl)-9H-purin-2-yl}pyrrolidin-3-yl]propanamide	x-ray	1.33	A	p00533	1210		708..1003
5uga	pdb	Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with 4-(4-{[2-{[(3S)-1-acetylpyrrolidin-3-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl]amino}phenyl)-1-methylpiperazin-1-ium	x-ray	1.82	A	p00533	1210		708..1003
5ugb	pdb	Crystal structure of the EGFR kinase domain in complex with 4-(4-{[2-{[(3S)-1-acetylpyrrolidin-3-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl]amino}phenyl)-1-methylpiperazin-1-ium	x-ray	2.53	A	p00533	1210		708..1003
5ugc	pdb	Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibitor N-[(3R,4R)-4-fluoro-1-{6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-methyl-9H-purin-2-yl}pyrrolidin-3-yl]propanamide	x-ray	1.58	A	p00533	1210		708..1003
5ugl	pdb	Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation	x-ray	1.861	A;B	p21802;p21802	821;821	;	471..757;471..757
5ugx	pdb	Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 Harboring a E565A/D650V double Gain-of-Function Mutation	x-ray	2.349	A;B	p21802;p21802	821;821	;	471..757;471..757
5uhn	pdb	Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring a N549H/E565A Double Gain-of-Function Mutation	x-ray	2.909	A;B	p21802;p21802	821;821	;	471..757;471..757
5ui0	pdb	Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring an E565A/K659M Double Gain-of-Function Mutation	x-ray	2.05	A;B	p21802;p21802	821;821	;	471..757;471..757
5uiq	pdb	Crystal structure of IRAK4 in complex with compound 9	x-ray	2.64	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
5uir	pdb	Crystal structure of IRAK4 in complex with compound 11	x-ray	2.64	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
5uis	pdb	Crystal structure of IRAK4 in complex with compound 12	x-ray	2.5	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
5uit	pdb	Crystal structure of IRAK4 in complex with compound 14	x-ray	1.84	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
5uiu	pdb	Crystal structure of IRAK4 in complex with compound 30	x-ray	2.02	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
5uk8	pdb	The co-structure of (R)-4-(6-(1-(cyclopropylsulfonyl)cyclopropyl)-2-(1H-indol-4-yl)pyrimidin-4-yl)-3-methylmorpholine and a rationally designed PI3K-alpha mutant that mimics ATR	x-ray	2.5	A	p42336	1068		699..1060
5ukf	pdb	Crystal Structure of the Human Vaccinia-related Kinase 1 Bound to an Oxindole Inhibitor	x-ray	2.4	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
5ukj	pdb	The co-structure of N,N-dimethyl-4-[(6R)-6-methyl-5-(1H-pyrrolo[2,3- b]pyridin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazin-3-yl]benzenesulfonamide and a rationally designed PI3K-alpha mutant that mimics ATR	x-ray	2.8	A	p42336	1068		699..1060
5ukk	pdb	Human GRK2 in complex with human G-beta-gamma subunits and CCG211998 (14ak)	x-ray	2.6	A	p25098	689		187..532
5ukl	pdb	Human GRK2 in complex with Gbetagamma subunits and CCG222886 (14bd)	x-ray	2.15	A	p25098	689		187..532
5ukm	pdb	bovine GRK2 in complex with human Gbetagamma subunits and CCG258208 (14as)	x-ray	3.03	A	p21146	689		187..532
5ul1	pdb	The co-structure of 3-amino-6-(4-((1-(dimethylamino)propan-2-yl)sulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide and a rationally designed PI3K-alpha mutant that mimics ATR	x-ray	3	A	p42336	1068		699..1060
5umo	pdb	STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE	x-ray	2.26	A	p63086	358		17..320
5unp	pdb	Structure of CDC2-Like Kinase 2 (CLK2) in Complex with Compound T-025 [N2-methyl-N4-(pyrimidin-2-ylmethyl)-5-(quinolin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine]	x-ray	2.92	A;B	p49760;p49760	499;499	;	150..488;150..488
5uoj	pdb	THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION	x-ray	2.1	A	p47811	360		9..349
5uor	pdb	Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure	x-ray	2.75	A;B	q99683;q99683	1374;1374	;	685..939;685..939
5uox	pdb	Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure	x-ray	2.5	A;B	q99683;q99683	1374;1374	;	685..939;685..939
5up3	pdb	Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure	x-ray	2.95	A;B	q99683;q99683	1374;1374	;	685..939;685..939
5upk	pdb	CDC42 binds PAK4 via an extended GTPase-effector interface - 3 peptide: PAK4cat, PAK4-N45, CDC42	x-ray	2.4	B	o96013	591		323..578
5upl	pdb	CDC42 binds PAK4 via an extended GTPase-effector inteface - 2 peptide: PAK4FL, CDC42 - UNREFINED	x-ray	3.003	A	o96013	591		323..578
5uq0	pdb	FGFR1 kinase domain complex with fragment 2,2-dimethyl-2,3-dihydrobenzofuran-7-carboxamide	x-ray	2.3	A;B	p11362;p11362	822;822	;	468..754;468..754
5uq1	pdb	Crystal structure of human Cdk2-Spy1 complex	x-ray	3.201	A;C	p24941;p24941	298;298	;	1..292;1..292
5uq2	pdb	Crystal structure of human Cdk2-Spy1 complex	x-ray	2.7	A	p24941	298		1..292
5uq3	pdb	Crystal structure of human Cdk2-Spy1-P27 ternary complex	x-ray	3.6	A	p24941	298		1..292
5ur1	pdb	FGFR1 kinase domain complex with SN37333 in reversible binding mode	x-ray	2.2	A;B	p11362;p11362	822;822	;	468..754;468..754
5usq	pdb	ALK-5 kinase inhibitor complex	x-ray	2.55	A	p36897	503		180..492
5usy	pdb	JAK2 JH1 in complex with JNJ-7706621	x-ray	2	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
5usz	pdb	JAK2 JH2 in complex with JNJ-7706621	x-ray	2.103	A	o60674	1132		522..814,842..1119
5ut0	pdb	JAK2 JH2 in complex with AT9283	x-ray	2.102	A	o60674	1132		522..814,842..1119
5ut1	pdb	JAK2 JH2 in complex with BI-D1870	x-ray	1.95	A	o60674	1132		522..814,842..1119
5ut2	pdb	JAK2 JH2 in complex with PRT062607	x-ray	1.75	A	o60674	1132		522..814,842..1119
5ut3	pdb	JAK2 JH2 in complex with IKK-2 Inhibitor VI	x-ray	1.501	A	o60674	1132		522..814,842..1119
5ut4	pdb	JAK2 JH2 in complex with NVP-BSK805	x-ray	2	A	o60674	1132		522..814,842..1119
5ut5	pdb	JAK2 JH2 in complex with GLPG0634	x-ray	1.9	A	o60674	1132		522..814,842..1119
5ut6	pdb	JAK2 JH2 in complex with a diaminopyrimidine	x-ray	1.645	A	o60674	1132		522..814,842..1119
5uu1	pdb	Crystal Structure of Human Vaccinia-related kinase 2 (VRK-2) bound to BI-D1870	x-ray	2	A	q86y07	508		23..317
5uuu	pdb	Design, Synthesis, and Evaluation of the First Selective and Potent G-protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure	x-ray	2.7	A	p25098	689		187..532
5uv4	pdb	Crystal Structure of Maize SIRK1 (sucrose-induced receptor kinase 1) kinase domain bound to AMP-PNP	x-ray	2.3	A	k7viq3	1045		764..1040
5uvc	pdb	Design, Synthesis, and Evaluation of the First Selective and Potent G-protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure	x-ray	2.65	A	p25098	689		187..532
5uvf	pdb	Crystal Structure of the Human vaccinia-related kinase bound to BI-D1870	x-ray	2	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
5uwd	pdb	Crystal structure of EGFR kinase domain (L858R, T790M, V948R) in complex with the covalent inhibitor CO-1686	x-ray	3.06	A	p00533	1210		708..1003
5uxa	pdb	Crystal structure of macrolide 2'-phosphotransferase MphB from Escherichia coli	x-ray	1.95	A	o32553	302		16..260
5uxb	pdb	Crystal structure of macrolide 2'-phosphotransferase MphH from Brachybacterium faecium, apoenzyme	x-ray	2.794	A;B	c7mep1;c7mep1	298;298	;	30..259;30..259
5uxc	pdb	Crystal structure of macrolide 2'-phosphotransferase MphH from Brachybacterium faecium in complex with GDP	x-ray	1.72	A	c7mep1	298		30..259
5uxd	pdb	Crystal structure of macrolide 2'-phosphotransferase MphH from Brachybacterium faecium in complex with azithromycin	x-ray	1.7	A;B	c7mep1;c7mep1	298;298	;	30..259;30..259
5uy6	pdb	Crystal Structure of the Human CAMKK2B	x-ray	1.7	A	q96rr4	588		153..484
5uyj	pdb	Crystal Structure of the Human CAMKK2B	x-ray	1.6	A	q96rr4	588		153..484
5uzj	pdb	Crystal Structure of ROCK1 bound to an aminopyridine inhibitor	x-ray	3.3	A;B	q13464;q13464	1354;1354	;	73..413;73..413
5uzk	pdb	Crystal Structure of PKA bound to an pyrrolo pyridine inhibitor	x-ray	2.3	A	p17612	351		30..339
5v19	pdb	Structure-based drug design of novel ASK1 inhibitors using a fully integrated lead optimization strategy	x-ray	3.1	A;B	q99683;q99683	1374;1374	;	685..939;685..939
5v24	pdb	Structure-based drug design of novel ASK1 inhibitors using a fully integrated lead optimization strategy	x-ray	2.5	A;B	q99683;q99683	1374;1374	;	685..939;685..939
5v5n	pdb	Crystal structure of Takinib bound to TAK1	x-ray	2.006	A	o43318	606		14..292
5v5y	pdb	CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775	x-ray	1.9	A	p30291	646		279..580
5v60	pdb	Phospho-ERK2 bound to AMP-PCP	x-ray	2.18	A	p28482	360		19..322
5v61	pdb	Phospho-ERK2 bound to bivalent inhibitor SBP2	x-ray	2.2	A	p28482	360		19..322
5v62	pdb	Phospho-ERK2 bound to bivalent inhibitor SBP3	x-ray	1.9	A	p28482	360		19..322
5v80	pdb	PIM1 kinase in complex with Cpd1 (1-methyl-4-(3-(6-(piperazin-1-yl)pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)piperazin-2-one)	x-ray	2.252	A	p11309	313		36..296
5v82	pdb	PIM1 kinase in complex with Cpd17 (1-(6-(4,4-difluoropiperidin-3-yl)pyridin-2-yl)-6-(6-methylpyrazin-2-yl)-1H-pyrazolo[4,3-c]pyridine)	x-ray	1.888	A	p11309	313		36..296
5val	pdb	BRAF in Complex with N-(3-(tert-butyl)phenyl)-4-methyl-3-(6-morpholinopyrimidin-4-yl)benzamide	x-ray	2.26	A;B	p15056;p15056	766;766	;	449..717;449..717
5vam	pdb	BRAF in Complex with RAF709	x-ray	2.1	A;B	p15056;p15056	766;766	;	449..717;449..717
5vc3	pdb	CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB	x-ray	1.97	A	p30291	646		279..580
5vc4	pdb	Crystal structure of HUMAN WEE1 KINASE domain in complex with Bosutinib-isomer	x-ray	2.1	A	p30291	646		279..580
5vc5	pdb	Crystal structure of human WEE1 kinase domain in complex with PD-166285	x-ray	1.93	A	p30291	646		279..580
5vc6	pdb	crystal structure of human WEE1 kinase domain in complex with PHA-848125	x-ray	2	A	p30291	646		279..580
5vcv	pdb	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Dasatinib	x-ray	1.92	A	q99640	499		108..419
5vcw	pdb	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Pelitinib	x-ray	2.25	A;B	q99640;q99640	499;499	;	108..419;108..419
5vcx	pdb	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB	x-ray	2.7	A	q99640	499		108..419
5vcy	pdb	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB	x-ray	1.56	A	q99640	499		108..419
5vcz	pdb	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Bosutinib isomer	x-ray	1.5	A	q99640	499		108..419
5vd0	pdb	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775	x-ray	2.13	A	q99640	499		108..419
5vd1	pdb	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA-848125	x-ray	1.7	A	q99640	499		108..419
5vd2	pdb	crystal structure of human WEE1 kinase domain in complex with PF-03814735	x-ray	2.05	A	p30291	646		279..580
5vd3	pdb	CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (de-phosphorylated) IN COMPLEX WITH SARACATINIB	x-ray	1.8	A	q99640	499		108..419
5vd4	pdb	CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV-016, a MK1775 analougue	x-ray	2.02	A	p30291	646		279..580
5vd5	pdb	CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV-050, a MK1775 analougue	x-ray	2.05	A	p30291	646		279..580
5vd7	pdb	CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV-098, a MK1775 analogue	x-ray	2.08	A	p30291	646		279..580
5vd8	pdb	Crystal structure of human WEE1 kinase domain in complex with RAC-IV-099, a MK1775 analogue	x-ray	1.85	A	p30291	646		279..580
5vd9	pdb	Crystal structure of human WEE1 kinase domain in complex with RAC-IV-097, a MK1775 analogue	x-ray	1.87	A	p30291	646		279..580
5vda	pdb	Crystal structure of human WEE1 kinase domain in complex with RAC-IV-101, a MK1775 analogue	x-ray	2.1	A	p30291	646		279..580
5vdk	pdb	Crystal structure of human WEE2 kinase domain in complex with MK1775	x-ray	2.7	A	p0c1s8	567		206..508
5ve6	pdb	Crystal structure of Sugen kinase 223	x-ray	2.953	A	q86yv5	1406		1119..1323
5ved	pdb	PAK4 kinase domain in complex with Staurosporine	x-ray	2.301	A	o96013	591		323..578
5vee	pdb	PAK4 kinase domain in complex with FRAX486	x-ray	2.5	A	o96013	591		323..578
5vef	pdb	PAK4 kinase domain in complex with fasudil	x-ray	1.752	A	o96013	591		323..578
5vfi	pdb	Bruton's tyrosine kinase (BTK) with GDC-0853	x-ray	1.59	A	q06187	659		382..648
5vgo	pdb	Bruton's tyrosine kinase (BTK) with compound G-744	x-ray	1.621	A	q06187	659		382..648
5vhb	pdb	Crystal structure of Protein Kinase A in complex with the PKI peptide and Aminobenzothiazole based inhibitor	x-ray	1.61	A	p00517	351		32..339
5vi9	pdb	Crystal structure of Protein Kinase A in complex with the PKI peptide and Aminobenzothiazole based inhibitors	x-ray	1.95	A	p00517	351		32..339
5vib	pdb	Crystal structure of Protein Kinase A in complex with the PKI peptide and Aminobenzothiazole based inhibitors	x-ray	2.37	A	p00517	351		32..339
5vil	pdb	Crystal structure of ASK1 kinase domain with a potent inhibitor (analog 6)	x-ray	2.64	A;B;C;D	q99683;q99683;q99683;q99683	1374;1374;1374;1374	;;;	685..939;685..939;685..939;685..939
5vio	pdb	Crystal structure of ASK1 kinase domain with a potent inhibitor (analog 13)	x-ray	2.84	A;B;C;D	q99683;q99683;q99683;q99683	1374;1374;1374;1374	;;;	685..939;685..939;685..939;685..939
5vja	pdb	Crystal Structure of human zipper-interacting protein kinase (ZIPK, alias DAPK3) in complex with a pyrazolo[3,4-d]pyrimidinone ligand (HS38)	x-ray	2.46	A;B;C;D	o43293;o43293;o43293;o43293	454;454;454;454	;;;	6..313;6..313;6..313;6..313
5vlo	pdb	The structure of human CamKII with bound inhibitor	x-ray	2.05	A;B	q13557;q13557	499;499	;	10..273;10..273
5vlr	pdb	CRYSTAL STRUCTURE OF PI3K DELTA IN COMPLEX WITH A TRIFLUORO-ETHYL-PYRAZOL-PYROLOTRIAZINE INHIBITOR	x-ray	2.8	A	o00329	1044		678..1033
5vnd	pdb	Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to H3B-6527	x-ray	2.2	A;B	p11362;p11362	822;822	;	468..754;468..754
5vo1	pdb	DLK in complex with compound 10 (5-(1-isopropyl-5-(3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1H-pyrazol-3-yl)-3-(trifluoromethyl)pyridin-2-amine)	x-ray	2.45	A	q12852	859		104..364
5vo2	pdb	DLK in complex with inhibitor 5-(1-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)-3-(trifluoromethyl)pyridin-2-amine (compound 7)	x-ray	2.96	A	q12852	859		104..364
5vo6	pdb	CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR	x-ray	2.65	A	p52333	1124		508..788,820..1097
5vt1	pdb	Crystal Structure of the Human CAMKK2B bound to a thiadiazinone benzamide inhibitor	x-ray	1.9	A	q96rr4	588		153..484
5vua	pdb	Pim1 Kinase in complex with a benzofuranone inhibitor	x-ray	2.2	B	p11309	313		36..296
5vub	pdb	Pim1 Kinase in complex with a benzofuranone inhibitor	x-ray	2	B	p11309	313		36..296
5vuc	pdb	Pim1 Kinase in complex with a benzofuranone inhibitor	x-ray	2	B	p11309	313		36..296
5w1r	pdb	Cryo-EM structure of DNAPKcs	em	4.4	A	p78527	4128		3657..4049
5w4w	pdb	Identification and Profiling of a Selective and Brain Penetrant Radioligand for In Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) Inhibitors	x-ray	1.99	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
5w5j	pdb	Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases	x-ray	2.85	A;B	o43353;o43353	540;540	;	11..297;11..297
5w5o	pdb	Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases.	x-ray	2.89	A;B;C;D;E;F;G;H;I;J;K;L;M;N;O;P	o43353;o43353;o43353;o43353;o43353;o43353;o43353;o43353;o43353;o43353;o43353;o43353;o43353;o43353;o43353;o43353	540;540;540;540;540;540;540;540;540;540;540;540;540;540;540;540	;;;;;;;;;;;;;;;	11..297;11..297;11..297;11..297;11..297;11..297;11..297;11..297;11..297;11..297;11..297;11..297;11..297;11..297;11..297;11..297
5w5q	pdb	MAP4K4 in complex with inhibitor compound 12 (N3-methyl-10-(3-methyl-3-(5-methyloxazol-2-yl)but-1-yn-1-yl)-6,7-dihydro-5H-5,7-methanobenzo[c]imidazo[1,2-a]azepine-2,3-dicarboxamide)	x-ray	2.33	A;B	o95819;o95819	1239;1239	;	24..290;24..290
5w5v	pdb	TBK1 co-crystal structure with amlexanox	x-ray	3.645	A	q9uhd2	729		9..297
5w6o	pdb	Choline Kinase Alpha in Complex with TCD-717	x-ray	2.35	A;B	p35790;p35790	457;457	;	82..455;82..455
5w7t	pdb	STRUCTURE OF PHOSPHORYLATED WNK1	x-ray	2.01	A;B	q9jih7;q9jih7	2126;2126	;	226..480;226..480
5w80	pdb	Toxoplasma Gondii CDPK1 in complex with inhibitor GXJ-237	x-ray	2	A	q9bjf5	507		35..330
5w84	pdb	CRYSTAL STRUCTURE OF IRAK-4 WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)	x-ray	2.9	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
5w85	pdb	CRYSTAL STRUCTURE OF IRAK-4 WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)	x-ray	2.25	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
5w86	pdb	CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)	x-ray	2.61	A;B;C;D	p52333;p52333;p52333;p52333	1124;1124;1124;1124	;;;	508..788,820..1097;508..788,820..1097;508..788,820..1097;508..788,820..1097
5w8r	pdb	Toxoplasma Gondii CDPK1 in complex with inhibitor 3CIB-PPI	x-ray	2.2	A	q9bjf5	507		35..330
5w91	pdb	Toxoplasma Gondii CDPK1 in complex with inhibitor LZH118	x-ray	2.4	A	q9bjf5	507		35..330
5w9e	pdb	Toxoplasma Gondii CDPK1 in complex with inhibitor GXJ-186	x-ray	2.44	A	q9bjf5	507		35..330
5w9r	pdb	Toxoplasma Gondii CDPK1 in complex with inhibitor LJQ138	x-ray	2.7	A	q9bjf5	507		35..330
5wal	pdb	Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model	x-ray	2.45	A	p29597	1187		576..879,887..1166
5wax	pdb	Crystal Structure of Sugarcane SAPK10 (serine/threonine-protein kinase 10)	x-ray	2	A;B	a0a238lns4;a0a238lns4	362;362	;	21..306;21..306
5wbu	pdb	Crystal structure of mTOR(deltaN)-mLST8-PRAS40(alpha-helix & beta-strand) complex	x-ray	3.42	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
5wby	pdb	Crystal structure of mTOR(deltaN)-mLST8-PRAS40(beta-strand) complex	x-ray	3.1	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
5wdy	pdb	Crystal structure of WNK1 in complex with 1-cyclohexyl-N-({6-fluoro-1-[2-(3-methoxyphenyl)pyridin-4-yl]-1H-indol-3-yl}methyl)methanamine (compound 6)	x-ray	2.458	A;B	q9h4a3;q9h4a3	2382;2382	;	226..769;226..769
5we8	pdb	Crystal structure of WNK1 in complex with N-{(3R)-1-[(4-chlorophenyl)methyl]pyrrolidin-3-yl}-2-(3-methoxyphenyl)-N-methylquinoline-4-carboxamide (compound 8)	x-ray	2.006	A;B	q9h4a3;q9h4a3	2382;2382	;	226..769;226..769
5wev	pdb	Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model	x-ray	1.854	A	o60674	1132		522..814,842..1119
5wfj	pdb	THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR	x-ray	2.48	A	p52333	1124		508..788,820..1097
5wg3	pdb	Human GRK2 in complex with Gbetagamma subunits and CCG258748	x-ray	2.896	A	p25098	689		187..532
5wg4	pdb	Human GRK2 in complex with Gbetagamma subunits and CCG257284	x-ray	2.31	A	p25098	689		187..532
5wg5	pdb	Human GRK2 in complex with Gbetagamma subunits and CCG224061	x-ray	3.1	A	p25098	689		187..532
5wij	pdb	JAK2 Pseudokinase in complex with NU6140	x-ray	2.04	A	o60674	1132		522..814,842..1119
5wik	pdb	JAK2 Pseudokinase in complex with BI-D1870	x-ray	2.6	B	o60674	1132		522..814,842..1119
5wil	pdb	JAK2 Pseudokinase in complex with AZD7762	x-ray	2.2	A	o60674	1132		522..814,842..1119
5wim	pdb	JAK2 Pseudokinase in complex with AT9283	x-ray	2.55	A	o60674	1132		522..814,842..1119
5win	pdb	JAK2 Pseudokinase in complex with JNJ7706621	x-ray	2.38	A	o60674	1132		522..814,842..1119
5wjj	pdb	Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[1,2-b]pyridazine-based p38 MAP Kinase Inhibitors	x-ray	1.6	A	q16539	360		9..349
5wne	pdb	X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR	x-ray	2.6	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
5wnf	pdb	X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR	x-ray	2.45	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
5wng	pdb	X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR	x-ray	2.9	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
5wnh	pdb	X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR	x-ray	3.1	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
5wni	pdb	Crystal structure of murine receptor-interacting protein kinase 4 (Ripk4) D143N in complex with ATP	x-ray	2.65	A	q9erk0	786		18..292
5wnj	pdb	Crystal structure of murine receptor-interacting protein kinase 4 (Ripk4) D143N in complex with lestaurtinib	x-ray	2.55	A	q9erk0	786		18..292
5wnk	pdb	Crystal structure of murine receptor-interacting protein 4 (Ripk4) D143N bound to TG100-115	x-ray	3.11	A	q9erk0	786		18..292
5wnl	pdb	Crystal structure of murine receptor-interacting protein 4 (Ripk4) D143N bound to staurosporine	x-ray	2.5	A	q9erk0	786		18..292
5wnm	pdb	Crystal structure of murine receptor-interacting protein 4 (Ripk4) D143N bound to tozasertib (VX-680)	x-ray	2.6	A	q9erk0	786		18..292
5wno	pdb	Crystal structure of C. elegans LET-23 kinase domain complexed with AMP-PNP	x-ray	2.386	A	p24348	1323		887..1148
5wo4	pdb	JAK1 complexed with compound 28	x-ray	1.84	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
5wp1	pdb	Complex of ERK2 with 5,7-dihydroxychromone	x-ray	1.4	A	p28482	360		19..322
5wr7	pdb	Crystal structure of Trk-A complexed with a selective inhibitor CH7057288	x-ray	2.76	A	p04629	796		494..779
5wvd	pdb	Structure of Mnk1 in complex with DS12881479	x-ray	3	A;B	q9bub5;q9bub5	465;465	;	53..393;53..393
5x02	pdb	Crystal structure of the FLT3 kinase domain bound to the inhibitor FF-10101	x-ray	2.401	A	p36888	993		576..941
5x17	pdb	Crystal structure of murine CK1d in complex with ADP	x-ray	2	A;B	q9dc28;q9dc28	415;415	;	5..290;5..290
5x18	pdb	Crystal structure of Casein kinase I homolog 1	x-ray	1.8	A;B	p23291;p23291	538;538	;	68..352;68..352
5x1q	pdb	PpkA-294 with ATP and MnCl2	x-ray	1.602	A	a0a1s4nye5	302		19..297
5x1r	pdb	PpkA-294 apo form	x-ray	1.6	A	a0a1s4nye5	302		19..297
5x1s	pdb	PpkA-294 with Amppcp	x-ray	1.45	A	a0a1s4nye5	302		19..297
5x1t	pdb	PpkA-294	x-ray	1.55	A	a0a1s4nye5	302		19..297
5x26	pdb	Crystal structure of EGFR 696-1022 L858R in complex with SKLB(3)	x-ray	2.951	A	p00533	1210		708..1003
5x27	pdb	Crystal structure of EGFR 696-1022 L858R in complex with SKLB(5)	x-ray	2.952	A	p00533	1210		708..1003
5x28	pdb	Crystal structure of EGFR 696-1022 L858R in complex with SKLB(6)	x-ray	2.952	A	p00533	1210		708..1003
5x2a	pdb	Crystal structure of EGFR 696-1022 T790M/V948R in complex with SKLB(3)	x-ray	1.85	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
5x2c	pdb	Crystal structure of EGFR 696-1022 T790M/V948R in complex with SKLB(5)	x-ray	2.05	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
5x2f	pdb	Crystal structure of EGFR 696-1022 T790M/V948R in complex with SKLB(6)	x-ray	2.2	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
5x2k	pdb	Crystal structure of EGFR 696-1022 T790M in complex with WZ4003	x-ray	3.201	A	p00533	1210		708..1003
5x3f	pdb	Crystal structure of the YgjG-Protein A-Zpa963-PKA catalytic domain	x-ray	3.38	B	p05132	351		28..339
5x5o	pdb	Crystal structure of ZAK in complex with compound D2829	x-ray	1.868	A	q9nyl2	800		8..260
5x6o	pdb	Intact ATR/Mec1-ATRIP/Ddc2 complex	em	3.9	C	p38111	2368		2040..2367
5x8i	pdb	Crystal structure of human CLK1 in complex with compound 25	x-ray	1.902	A;B	p49759;p49759	484;484	;	150..478;150..478
5xd6	pdb	CARK1 phosphorylates ABA receptors	x-ray	1.898	A;B	q9lut0;q9lut0	364;364	;	42..345;42..345
5xdk	pdb	Crystal structure of EGFR 696-1022 T790M in complex with CO-1686	x-ray	2.346	A	p00533	1210		708..1003
5xdl	pdb	Crystal structure of EGFR 696-1022 L858R in complex with CO-1686	x-ray	2.7	A	p00533	1210		708..1003
5xff	pdb	Crystal structure of LY2874455 in complex of FGFR4 gatekeeper mutation (V550L)	x-ray	2.7	A	p22455	802		458..743
5xfj	pdb	Crystal structure of LY2874455 in complex of FGFR4 gatekeeper mutation (V550M)	x-ray	3.25	A	p22455	802		458..743
5xgh	pdb	Crystal structure of PI3K complex with an inhibitor	x-ray	2.97	A	p42336	1068		699..1060
5xgi	pdb	Crystal structure of PI3K complex with an inhibitor	x-ray	2.56	A	p42336	1068		699..1060
5xgj	pdb	Crystal structure of PI3K complex with an inhibitor	x-ray	2.97	A	p42336	1068		699..1060
5xgm	pdb	Crystal structure of EGFR 696-1022 T790M in complex with Go6976	x-ray	2.952	A	p00533	1210		708..1003
5xgn	pdb	Crystal structure of EGFR 696-1022 T790M/C797S in complex with Go6976	x-ray	3	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
5xka	pdb	Crystal structure of M.tuberculosis PknI kinase domain	x-ray	1.599	A;B	p9wi69;p9wi69	585;585	;	10..257;10..257
5xp5	pdb	C-Src in complex with ATP-Chf	x-ray	2.101	A;B	p00523;p00523	533;533	;	256..526;256..526
5xp7	pdb	C-Src in complex with ATP-CHCl	x-ray	2.012	A;B	p00523;p00523	533;533	;	256..526;256..526
5xqx	pdb	Human CDK8-CYCC in complex with compound 4: N-methyl-4-(4-pyridyl)-1H-pyrrole-2-carboxamide	x-ray	2.3	A	p49336	464		25..341
5xs2	pdb	CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-chloro-4-(4-pyridyl)-1H-pyrrole-2-carboxamide	x-ray	2.04	A	p49336	464		25..341
5xv7	pdb	SRPK1 in complex with Alectinib	x-ray	2.32	A	q96sb4	655		67..654
5xva	pdb	Crystal Structure of PAK4 in complex with inhibitor CZH216	x-ray	1.847	A	o96013	591		323..578
5xvf	pdb	Crystal Structure of PAK4 in complex with inhibitor CZH062	x-ray	2.655	A	o96013	591		323..578
5xvg	pdb	Crystal Structure of PAK4 in complex with inhibitor CZH226	x-ray	2.1	A	o96013	591		323..578
5xvu	pdb	Crystal structure of the protein kinase CK2 catalytic domain from Plasmodium falciparum bound to ATP	x-ray	3	A;B;C	q8iir9;q8iir9;q8iir9	335;335;335	;;	16..332;16..332;16..332
5xy1	pdb	Crystal structure of Lyn kinase domain in complex with N-(1H-indazol-6-yl)-8-(piperidin-4-yloxy)-6-propylquinazolin-2-amine	x-ray	2.7	A	p07948	512		234..500
5xyx	pdb	The structure of p38 alpha in complex with a triazol inhibitor	x-ray	2.61	A	q16539	360		9..349
5xyy	pdb	The structure of p38 alpha in complex with a triazol inhibitor	x-ray	1.7	A	q16539	360		9..349
5xyz	pdb	The structure of human BTK kinase domain in complex with a covalent inhibitor	x-ray	2.64	A;B	q06187;q06187	659;659	;	382..648;382..648
5xzv	pdb	Crystal structure of Rad53 1-466 in complex with AMP-PNP	x-ray	3.1	A;B	p22216;p22216	821;821	;	190..467;190..467
5xzw	pdb	Crystal structure of Rad53 1-466	x-ray	2.8	A;B	p22216;p22216	821;821	;	190..467;190..467
5y25	pdb	EGFR kinase domain mutant (T790M/L858R) with covalent ligand NS-062	x-ray	3.102	A	p00533	1210		708..1003
5y3r	pdb	Cryo-EM structure of Human DNA-PK Holoenzyme	em	6.6	C				
5y5t	pdb	Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor	x-ray	1.8	A	p43405	635		375..627
5y5u	pdb	Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor	x-ray	2.14	A;B	p43405;p43405	635;635	;	375..627;375..627
5y7z	pdb	Complex structure of cyclin G-associated kinase with gefitinib	x-ray	2.804	A;B	;	;	;	;
5y80	pdb	Complex structure of cyclin G-associated kinase with gefitinib	x-ray	2.5	A				
5y81	pdb	NuA4 TEEAA sub-complex	em	4.7	B				
5y86	pdb	Crystal structure of kinase	x-ray	1.9	A	o43781	588		199..531
5y8u	pdb	Crystal structure of the C276S mutant of MAP2K7	x-ray	2.92	A	o14733	419		113..384
5y90	pdb	MAP2K7 mutant -C218S	x-ray	1.3	A	o14733	419		113..384
5y9m	pdb	Crystal structure of CK2a2 form 3	x-ray	2.006	A;X	p19784;p19784	350;350	;	13..330;13..330
5y9t	pdb	Crystal Structure of EGFR T790M mutant in complex with naquotinib	x-ray	3.25	A	p00533	1210		708..1003
5ya5	pdb	CRYSTAL STRUCTURE OF c-MET IN COMPLEX WITH NOVEL INHIBITOR	x-ray	1.89	A	p08581	1390		1079..1341
5yf9	pdb	Crystal structure of CK2a2 form-2	x-ray	1.89	B;X	p19784;p19784	350;350	;	13..330;13..330
5yj9	pdb	Crystal structure of Tribolium castaneum PINK1 kinase domain in complex with AMP-PNP	x-ray	2.53	D	d6wmx4	570		153..478
5yjz	pdb	The native crystal structure of Rv3197 from Mycobacterium tuberculosis	x-ray	2.16	A	o53343	447		100..372
5yk0	pdb	The complex structure of Rv3197-ADP from Mycobacterium tuberculosis	x-ray	2.102	A	o53343	447		100..372
5yk1	pdb	The complex structure of Rv3197-AMPPNP from Mycobacterium tuberculosis	x-ray	2.103	A	o53343	447		100..372
5yk2	pdb	The complex structure of Rv3197-erythromycin from Mycobacterium tuberculosis	x-ray	2.807	A	o53343	447		100..372
5yks	pdb	Crystal structure of sucrose nonfermenting-related kinase (SNRK)	x-ray	2.9	A;B	q9nrh2;q9nrh2	765;765	;	12..292;12..292
5yt3	pdb	Structure of the Human Mitogen-Activated Protein Kinase Kinase 1 S218D and S222D mutant	x-ray	2.9	A;B;C;D	q02750;q02750;q02750;q02750	393;393;393;393	;;;	63..365;63..365;63..365;63..365
5yu9	pdb	Crystal structure of EGFR 696-1022 T790M in complex with Ibrutinib	x-ray	1.95	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
5yv8	pdb	Structure of CaMKK2 in complex with CKI-002	x-ray	1.927	A	q96rr4	588		153..484
5yv9	pdb	Structure of CaMKK2 in complex with CKI-009	x-ray	2.53	A	q96rr4	588		153..484
5yva	pdb	Structure of CaMKK2 in complex with CKI-010	x-ray	2.574	A	q96rr4	588		153..484
5yvb	pdb	Structure of CaMKK2 in complex with CKI-011	x-ray	2.02	A	q96rr4	588		153..484
5yvc	pdb	Structure of CaMKK2 in complex with CKI-012	x-ray	2.02	A	q96rr4	588		153..484
5ywm	pdb	Crystal structure of CK2a2 form-1	x-ray	1.939	X	p19784	350		13..330
5yz0	pdb	Cryo-EM Structure of human ATR-ATRIP complex	em	4.7	A;B	q13535;q13535	2644;2644	;	2221..2567;2221..2567
5z0s	pdb	Crystal structure of FGFR1 kinase domain in complex with a novel inhibitor	x-ray	2.45	A;B	p11362;p11362	822;822	;	468..754;468..754
5z1d	pdb	MAP2K7 C276S mutant-inhibitor	x-ray	2.28	A	o14733	419		113..384
5z1e	pdb	MAP2K7 C218S mutant-inhibitor	x-ray	2.3	A	o14733	419		113..384
5z33	pdb	Crystal structure of Mitogen-activated Protein Kinase Mps1 in Magnaporthe oryzae	x-ray	1.99	A	g4n374	415		15..320
5zan	pdb	Crystal Structure of Aurora-A in complex with a new Quinazoline inhibitor	x-ray	2.85	A	o14965	403		120..386
5zcs	pdb	4.9 Angstrom Cryo-EM structure of human mTOR complex 2	em	4.9	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
5zj6	pdb	Crystal structure of HCK kinase complexed with a pyrrolo-pyrimidine inhibitor 7-[trans-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	x-ray	1.696	A;B	p08631;p08631	526;526	;	249..518;249..518
5zjw	pdb	Crystal Structure of PAK4 in complex with inhibitor CZg353	x-ray	1.798	A	o96013	591		323..578
5zn1	pdb	X-ray structure of protein kinase ck2 alpha subunit in D2O	x-ray	1.05	A	p68400	391		5..328
5zn2	pdb	X-ray structure of protein kinase ck2 alpha subunit H148A mutant	x-ray	1.2	A	p68400	391		5..328
5zn3	pdb	X-ray structure of protein kinase ck2 alpha subunit H148S mutant	x-ray	1.5	A	p68400	391		5..328
5zn4	pdb	X-ray structure of protein kinase ck2 alpha subunit H148N mutant	x-ray	1.651	A	p68400	391		5..328
5zn5	pdb	X-ray structure of protein kinase ck2 alpha subunit H148A mutant	x-ray	1.7	A	p68400	391		5..328
5ztn	pdb	The crystal structure of human DYRK2 in complex with Curcumin	x-ray	2.496	A;B	q92630;q92630	601;601	;	212..543;212..543
5zto	pdb	Crystal structure of EGFR 696-1022 T790M/C797S in complex with D3003	x-ray	2.649	A	p00533	1210		708..1003
5zv2	pdb	FGFR-1 in complex with ligand lenvatinib	x-ray	2.86	A;B	p11362;p11362	822;822	;	468..754;468..754
5zwj	pdb	Crystal structure of EGFR 675-1022 T790M/C797S/V948R in complex with EAI045	x-ray	2.9	A	p00533	1210		708..1003
5zxb	pdb	Crystal structure of ACK1 with compound 10d	x-ray	2.198	A;B	q07912;q07912	1038;1038	;	120..398;120..398
5zz4	pdb	Crystal structure of bruton's tyrosine kinase in complex with inhibitor 2e	x-ray	2.9	A;B;C;D;E;F	q06187;q06187;q06187;q06187;q06187;q06187	659;659;659;659;659;659	;;;;;	382..648;382..648;382..648;382..648;382..648;382..648
6a1c	pdb	Crystal structure of the CK2a1-go289 complex	x-ray	1.68	A	p68400	391		5..328
6a1f	pdb	Crystal structure of human DYRK1A in complex with compound 14	x-ray	1.5	A	q13627	763		147..489
6a1g	pdb	Crystal structure of human DYRK1A in complex with compound 32	x-ray	2.15	A;B	q13627;q13627	763;763	;	147..489;147..489
6a32	pdb	Crystal structure of PDGFRA kinase domain mutant T674I	x-ray	1.87	A	p16234	1089		566..947
6aah	pdb	Crystal structure of JAK1 in complex with peficitinib	x-ray	1.83	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6aaj	pdb	Crystal structure of JAK2 in complex with peficitinib	x-ray	2.37	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6aak	pdb	Crystal structure of JAK3 in complex with peficitinib	x-ray	2.67	A;B;C;D	p52333;p52333;p52333;p52333	1124;1124;1124;1124	;;;	508..788,820..1097;508..788,820..1097;508..788,820..1097;508..788,820..1097
6aam	pdb	Crystal structure of TYK2 in complex with peficitinib	x-ray	1.98	A	p29597	1187		576..879,887..1166
6aar	pdb	Crystal structure of DAPK1 in complex with purpurin	x-ray	1.95	A	p53355	1430		6..291
6ac9	pdb	Crystal structure of human Vaccinia-related kinase 1 (VRK1) in complex with AMP-PNP	x-ray	2.07	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6acr	pdb	Crystal structure of human ALK2 kinase domain with R206H mutation in complex with RK-59638	x-ray	2.01	A;B	q04771;q04771	509;509	;	186..496;186..496
6ae3	pdb	Crystal structure of GSK3beta complexed with Morin	x-ray	2.14	A;B;C;D	q9wv60;q9wv60;q9wv60;q9wv60	420;420;420;420	;;;	55..377;55..377;55..377;55..377
6agx	pdb	The cocrystal structure of FGFR2 bound with compound 14 harboring 5H-pyrrolo[2,3-b]pyrazine scaffold	x-ray	2.95	A;B;C;D	p21802;p21802;p21802;p21802	821;821;821;821	;;;	471..757;471..757;471..757;471..757
6anl	pdb	Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[1,2-b]pyridazine-based p38 MAP Kinase Inhibitors	x-ray	2	A	q16539	360		9..349
6ao5	pdb	Crystal structure of human MST2 in complex with SAV1 SARAH domain	x-ray	2.955	A	q13188	491		24..287
6ate	pdb	SRC kinase bound to covalent inhibitor	x-ray	2.402	A	p12931	536		259..529
6ath	pdb	Cdk2/cyclin A/p27-KID-deltaC	x-ray	1.82	A	p24941	298		1..292
6aua	pdb	CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2625	x-ray	1.66	A	q06187	659		382..648
6aub	pdb	CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2815	x-ray	1.65	A	q06187	659		382..648
6aud	pdb	PI3K-gamma K802T in complex with Cpd 8 10-((1-(tert-butyl)piperidin-4-yl)sulfinyl)-2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine	x-ray	2.015	A	p48736	1102		728..1089
6ayd	pdb	Pim1 complexed with N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)cyclopropanecarboxamide	x-ray	3	A	p11309	313		36..296
6ayw	pdb	The structure of human CamKII with bound inhibitor	x-ray	2.05	A;B	q13557;q13557	499;499	;	10..273;10..273
6b16	pdb	P21-activated kinase 1 in complex with a 4-azaindole inhibitor	x-ray	2.285	A;B	q13153;q13153	545;545	;	261..522;261..522
6b1u	pdb	Structure of full-length human AMPK (a2b1g1) in complex with a small molecule activator SC4	x-ray	2.77	A;C	p54646;p54646	552;552	;	13..269;13..269
6b2e	pdb	Structure of full length human AMPK (a2b2g1) in complex with a small molecule activator SC4.	x-ray	3.8	A	p54646	552		13..269
6b2p	pdb	Dual Inhibition of the Essential Protein Kinases A and B in Mycobacterium tuberculosis	x-ray	3.01	A	p9wi81	626		8..275
6b2q	pdb	Dual Inhibition of the Essential Protein Kinases A and B in Mycobacterium tuberculosis	x-ray	2.88	A;B;C;D	p9wi83;p9wi83;p9wi83;p9wi83	431;431;431;431	;;;	11..274;11..274;11..274;11..274
6b3e	pdb	Crystal structure of human CDK12/CyclinK in complex with an inhibitor	x-ray	3.06	A;C	q9nyv4;q9nyv4	1490;1490	;	721..1024;721..1024
6b4w	pdb	TTK in Complex with Inhibitor	x-ray	2.9	A	p33981	857		516..792
6b5j	pdb	TNNI3K complexed with a 4,6-diaminopyrimidine	x-ray	2.97	A;B;C;D	q59h18;q59h18;q59h18;q59h18	835;835;835;835	;;;	454..727;454..727;454..727;454..727
6b8j	pdb	Co-structure of human glycogen synthase kinase beta with a selective (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine inhibitor	x-ray	2.595	A				
6b8u	pdb	Crystals Structure of B-Raf kinase domain in complex with an Imidazopyridinyl benzamide inhibitor	x-ray	2.68	A;B	p15056;p15056	766;766	;	449..717;449..717
6b8y	pdb	TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3-fluoropyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine	x-ray	1.65	A	p36897	503		180..492
6bab	pdb	The structure of human CamKII with bound inhibitor	x-ray	1.91	A;B;C;D	q6phz2;q6phz2;q6phz2;q6phz2	499;499;499;499	;;;	10..273;10..273;10..273;10..273
6bbu	pdb	Crystal Structure of JAK1 in complex with compound 25	x-ray	2.08	A	p23458	1154		565..850,873..1146
6bbv	pdb	Crystal Structure of JAK2 in complex with compound 25	x-ray	1.8	A	o60674	1132		522..814,842..1119
6bcu	pdb	Cryo-EM structure of the activated RHEB-mTORC1 refined to 3.4 angstrom	em	3.8	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
6bcx	pdb	mTORC1 structure refined to 3.0 angstroms	em	3.23	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
6bdl	pdb	Crystal structure of cGMP-dependent protein kinase Ialpha (PKG Ialpha) catalytic domain in apo state	x-ray	1.96	A;B	q13976;q13976	671;671	;	354..660;354..660
6bdn	pdb	Crystal structure of human TAO3 kinase binding ADP	x-ray	1.5	A	q9h2k8	898		26..278
6bfa	pdb	Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1553	x-ray	2.8	A	a0a0f7uua6	507		35..330
6bfn	pdb	Crystal structure of human IRAK1	x-ray	2.26	A;B	p51617;p51617	712;712	;	191..522;191..522
6bg2	pdb	Crystal structure of cGMP-dependent protein kinase Ialpha (PKG Ialpha) catalytic domain in AMP-PNP bound state	x-ray	1.83	A;B;C;D	q13976;q13976;q13976;q13976	671;671;671;671	;;;	354..660;354..660;354..660;354..660
6bhc	pdb	Crystal structure of pseduokinase PEAK1 (Sugen Kinase 269)	x-ray	2.3	A	q9h792	1746		1355..1664
6bik	pdb	BTK complex with compound 7	x-ray	1.901	A	q06187	659		382..648
6bke	pdb	BTK complex with compound 10	x-ray	1.95	A	q06187	659		382..648
6bkh	pdb	BTK complex with compound 11	x-ray	1.792	A	q06187	659		382..648
6bku	pdb	Crystal Structure of the Human CAMKK2B bound to GSK650394	x-ray	2	A	q96rr4	588		153..484
6bkw	pdb	BTK complex with compound 12	x-ray	1.499	A	q06187	659		382..648
6bl8	pdb	Predicting the Conformational Variability of Abl Tyrosine Kinase Using Molecular Dynamics Simulations and Markov State Models	x-ray	2.5	A;B	p00519;p00519	1130;1130	;	231..498;231..498
6ble	pdb	Crystal Structure of the Human CAMKK2B in complex with CP673451	x-ray	1.9	A	q96rr4	588		153..484
6bln	pdb	BTK complex with compound 13	x-ray	1.3	A	q06187	659		382..648
6bny	pdb	TBK1 in complex with tetrazole analog of amlexanox	x-ray	3.341	A	q9uhd2	729		9..297
6bod	pdb	TBK1 in complex with ethyl ester analog of amlexanox	x-ray	3.197	A	q9uhd2	729		9..297
6boe	pdb	TBK1 in complex with amide-coupled tetrazole analog of amlexanox	x-ray	3.598	A	q9uhd2	729		9..297
6bp0	pdb	Crystal Structure of the Human vaccinia-related kinase 1 bound to (R)-2-phenylaminopteridinone inhibitor	x-ray	1.9	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6bq1	pdb	Human PI4KIIIa lipid kinase complex	em	3.6	A;E	p42356;p42356	2102;2102	;	1728..2095;1728..2095
6bql	pdb	Crystal Structure of the Human CAMKK2B in complex with TAE-226	x-ray	2	A	q96rr4	588		153..484
6bqp	pdb	Crystal Structure of the Human CAMKK2B in complex with Crenolanib	x-ray	1.95	A	q96rr4	588		153..484
6bqq	pdb	Crystal Structure of the Human CAMKK2B in complex with BI2526	x-ray	1.8	A	q96rr4	588		153..484
6brc	pdb	Crystal Structure of the Human CAMKK2B in complex with AP26113-analog (ALK-IN-1)	x-ray	2.2	A;B	q96rr4;q96rr4	588;588	;	153..484;153..484
6brj	pdb	DDR1 bound to VX-680	x-ray	2.231	A	q08345	913		603..904
6bru	pdb	Crystal Structure of the Human vaccinia-related kinase bound to a (S)-2-phenylaminopteridinone inhibitor	x-ray	1.8	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6brw	pdb	JAK2 JH2 in complex with XMU-MP-1	x-ray	2.031	A	o60674	1132		522..814,842..1119
6bs0	pdb	JAK2 JH2 in complex with 63552444	x-ray	1.541	A	o60674	1132		522..814,842..1119
6bsd	pdb	DDR1 bound to Dasatinib	x-ray	2.606	A	q08345	913		603..904
6bsk	pdb	Human PIM1 kinase in complex with compound 12b	x-ray	2.573	A	p11309	313		36..296
6bss	pdb	JAK2 JH2 in complex with NU6102	x-ray	2.1	A	o60674	1132		522..814,842..1119
6btw	pdb	Crystal Structure of the Human vaccinia-related kinase bound to a phenyl-pteridinone inhibitor	x-ray	1.9	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6bu6	pdb	Crystal Structure of the Human vaccinia-related kinase bound to a bis-difluorophenol-aminopyridine inhibitor	x-ray	1.8	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6buu	pdb	Crystal structure of AKT1 (aa 144-480) with a bisubstrate	x-ray	2.4	A;B	p31749;p31749	480;480	;	145..459;145..459
6bwk	pdb	Crystal structure of the human MLKL pseudokinase domain T357E/S358E mutant	x-ray	2.79	A	q8nb16	471		213..466
6bx6	pdb	AMP-Activated protein kinase (AMPK) inhibition by SBI-0206965: alpha 2 kinase domain bound to SBI-0206965	x-ray	2.9	A	p54646	552		13..269
6bxi	pdb	X-ray crystal structure of NDR1 kinase domain	x-ray	2.2	A;B	q15208;q15208	465;465	;	73..429;73..429
6byr	pdb	Structures of the PKA RI alpha holoenzyme with the FLHCC driver J-PKAc alpha or native PKAc alpha	x-ray	3.661	A;C	p25685;p17612	340;351	;	;30..339
6bys	pdb	Structures of the PKA RI alpha holoenzyme with the FLHCC driver J-PKAc alpha or native PRKAc alpha	x-ray	4.75	A;C;E;G	p17612;p17612;p17612;p17612	351;351;351;351	;;;	30..339;30..339;30..339;30..339
6c0t	pdb	Crystal structure of cGMP-dependent protein kinase Ialpha (PKG Ialpha) catalytic domain bound with N46	x-ray	1.98	A	q13976	671		354..660
6c0u	pdb	Crystal structure of cAMP-dependent protein kinase Calpha subunit bound with N46	x-ray	2.65	A	p17612	351		30..339
6c18	pdb	FGFR1 kinase complex with inhibitor SN37115	x-ray	2.3	A;B	p11362;p11362	822;822	;	468..754;468..754
6c19	pdb	FGFR1 kinase complex with inhibitor SN36985	x-ray	2.12	A;B	p11362;p11362	822;822	;	468..754;468..754
6c1b	pdb	FGFR1 kinase complex with inhibitor SN37118	x-ray	2	A;B	p11362;p11362	822;822	;	468..754;468..754
6c1c	pdb	FGFR1 kinase complex with inhibitor SN37116	x-ray	2.15	A;B	p11362;p11362	822;822	;	468..754;468..754
6c1o	pdb	FGFR1 kinase domain complexed with FIIN-1	x-ray	2.29	A;B	p11362;p11362	822;822	;	468..754;468..754
6c1s	pdb	Phosphoinositide 3-Kinase gamma bound to an pyrrolopyridinone Inhibitor	x-ray	2.31	A	p48736	1102		728..1089
6c2r	pdb	Aurora A ligand complex	x-ray	1.96	A	o14965	403		120..386
6c2t	pdb	Aurora A ligand complex	x-ray	1.73	A	o14965	403		120..386
6c2y	pdb	Human GRK2 in complex with Gbetagamma subunits and CCG257142	x-ray	2.74	A	p25098	689		187..532
6c3e	pdb	CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR	x-ray	2.6	A;B	q13546;q13546	671;671	;	6..286;6..286
6c4d	pdb	Structure based design of RIP1 kinase inhibitors	x-ray	2.52	A;B;C;D	q13546;q13546;q13546;q13546	671;671;671;671	;;;	6..286;6..286;6..286;6..286
6c5u	pdb	Aminoglycoside Phosphotransferase (2'')-Ia in complex with GMPPNP, Magnesium, and Ribostamycin, Alternate form	x-ray	2.41	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
6c7y	pdb	Crystal structure of inhibitory protein SOCS1 in complex with JAK1 kinase domain	x-ray	2.499	A	p23458	1154		565..850,873..1146
6c83	pdb	Structure of Aurora A (122-403) bound to inhibitory Monobody Mb2 and AMPPCP	x-ray	2.55	A;B	;	;	;	;
6c9d	pdb	Crystal structure of KA1-autoinhibited MARK1 kinase	x-ray	2.499	A;B	q9p0l2;q9p0l2	795;795	;	57..312;57..312
6c9f	pdb	AMP-activated protein kinase bound to pharmacological activator R734	x-ray	2.924	A	q13131	559		24..308
6c9g	pdb	AMP-activated protein kinase bound to pharmacological activator R739	x-ray	2.7	A	q13131	559		24..308
6c9h	pdb	non-phosphorylated AMP-activated protein kinase bound to pharmacological activator R734	x-ray	2.65	A	q13131	559		24..308
6c9j	pdb	AMP-activated protein kinase bound to pharmacological activator R734	x-ray	3.05	A	q13131	559		24..308
6cad	pdb	Crystal structure of RAF kinase domain bound to the inhibitor 2a	x-ray	2.55	A;B	p15056;p15056	766;766	;	449..717;449..717
6cav	pdb	Aminoglycoside Phosphotransferase (2'')-Ia in complex with GMPPNP, Magnesium, and Dibekacin	x-ray	2.6	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
6ccf	pdb	Crystal Structure of the Human CAMKK1A in complex with Hesperadin	x-ray	2.1	A;B	q8n5s9;q8n5s9	505;505	;	116..450;116..450
6ccy	pdb	Crystal structure of Akt1 in complex with a selective inhibitor	x-ray	2.18	A	p31749	480		145..459
6cd6	pdb	Crystal Structure of the Human CAMKK1A in complex with GSK650394	x-ray	2.2	A;B;C;D	q8n5s9;q8n5s9;q8n5s9;q8n5s9	505;505;505;505	;;;	116..450;116..450;116..450;116..450
6cd7	pdb	"Crystal structure of APH(2"")-IVa in complex with plazomicin"	x-ray	1.53	A;B	o68183;o68183	301;301	;	3..264;3..264
6cdt	pdb	Structure of Human Anaplastic Lymphoma Kinase Domain	x-ray	1.8	A	q9um73	1620		1089..1381
6cey	pdb	Aminoglycoside Phosphotransferase (2'')-Ia in complex with GMPPNP, Magnesium, and Lividomycin moieties	x-ray	2.4	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
6cfm	pdb	Crystal Structure of the Human vaccinia-related kinase bound to a propynyl-pteridinone inhibitor	x-ray	2.45	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6cgd	pdb	Aminoglycoside Phosphotransferase (2'')-Ia in complex with GMPPNP, Magnesium, and Amikacin	x-ray	2.2	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
6cgg	pdb	Aminoglycoside Phosphotransferase (2'')-Ia in complex with GMPPNP, Magnesium, and Arbekacin	x-ray	2.4	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
6ch4	pdb	Aminoglycoside Phosphotransferase (2'')-Ia S376N mutant in complex with GMPPNP and Magnesium	x-ray	2.3	A;B;C;D	p0a0c1;p0a0c1;p0a0c1;p0a0c1	479;479;479;479	;;;	192..432;192..432;192..432;192..432
6cj5	pdb	Crystal Structure of Mnk2-D228G in Complex With Inhibitor	x-ray	2.8	A	q9hbh9	465		87..395
6cje	pdb	Crystal Structure of Mnk2-D228G in complex with Inhibitor	x-ray	3.36	A	q9hbh9	465		87..395
6cjh	pdb	Co-crystal structure of MNK2 in complex with an inhibitor	x-ray	3.6	A	q9hbh9	465		87..395
6cjw	pdb	Crystal Structure of Mnk2-D228G in Complex With Inhibitor	x-ray	3.38	A	q9hbh9	465		87..395
6cjy	pdb	Crystal Structure of Mnk2-D228G in complex with Inhibitor	x-ray	3.05	A	q9hbh9	465		87..395
6ck3	pdb	Co-crytsal Structure of MNK2 in Complex With an Inhibitor	x-ray	2.9	A	q9hbh9	465		87..395
6ck6	pdb	Crystal Structure of Mnk2-D228G in complex with Inhibitor	x-ray	3.32	A	q9hbh9	465		87..395
6cki	pdb	Co-crystal structure of MNK2 in Complex With Inhibitor	x-ray	2.95	A	q9hbh9	465		87..395
6ckx	pdb	Structure of CDK12/CycK in complex with a small molecule inhibitor N-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)acetamide	x-ray	2.8	A;C	q9nyv4;q9nyv4	1490;1490	;	721..1024;721..1024
6cmj	pdb	Human CAMKK2 with GSK650393	x-ray	2.4	A;B	q96rr4;q96rr4	588;588	;	153..484;153..484
6cmm	pdb	Crystal Structure of the Human vaccinia-related kinase bound to a N,N-dipropynyl-dihydropteridine inhibitor	x-ray	2.1	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6cn9	pdb	Crystal structure of the Kinase domain of WNK1	x-ray	1.8	A;B	q9jih7;q9jih7	2126;2126	;	226..480;226..480
6cnh	pdb	Human PRPF4B in complex with Rebastinib	x-ray	2	A	q13523	1007		674..1005
6cnx	pdb	Crystal Structure of the Human vaccinia-related kinase 1 (VRK1) bound to an N-propynyl-N-isopentyl-dihydropteridin inhibitor	x-ray	2	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6cpe	pdb	Structure of apo, dephosphorylated Aurora A (122-403) in an active conformation	x-ray	2.45	A	o14965	403		120..386
6cpf	pdb	Structure of dephosphorylated Aurora A (122-403) bound to AMPPCP in an active conformation	x-ray	2.3	A	o14965	403		120..386
6cpg	pdb	Structure of dephosphorylated Aurora A (122-403) in complex with inhibiting monobody and AT9283 in an inactive conformation	x-ray	2.8	A;D	;	;	;	;
6cpw	pdb	Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology	x-ray	1.85	A	p63086	358		17..320
6cpy	pdb	Structure of apo GRMZM2G135359 pseudokinase	x-ray	1.7	A;B	c0p4k9;c0p4k9	514;514	;	209..483;209..483
6cq0	pdb	TBK1 in Complex with Dimethyl Amino Analog of Amlexanox	x-ray	3.19	A	q9uhd2	729		9..297
6cq4	pdb	TBK1 in Complex with Cyclohexyl Analog of Amlexanox	x-ray	3.2	A	q9uhd2	729		9..297
6cq5	pdb	TBK1 in Complex with Sulfone Analog of Amlexanox	x-ray	3.354	A	q9uhd2	729		9..297
6cqd	pdb	Crystal structure of HPK1 in complex with ATP analogue (AMPPNP)	x-ray	2.12	A;B	q92918;q92918	833;833	;	14..444;14..444
6cqe	pdb	Crystal structure of HPK1 kinase domain S171A mutant	x-ray	1.886	A;B	q92918;q92918	833;833	;	14..444;14..444
6cqf	pdb	Crystal structure of HPK1 in complex an inhibitor G1858	x-ray	2.246	A	q92918	833		14..444
6cqh	pdb	Crystal Structure of the Human vaccinia-related kinase bound to a N-propynyl-N-ethyl-dihydropteridine inhibitor	x-ray	2.15	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6csw	pdb	Crystal Structure of the Human vaccinia-related kinase bound to a N-methyl-N-propyl-dihydropteridine inhibitor	x-ray	2.25	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6cth	pdb	Crystal Structure of Pathogenesis-related Protein 1G (PR-1G) Kinase Domain from Cacao	x-ray	1.7	A	a0a061fld4	582		253..549
6ctz	pdb	"Structure of the GDP and kanamycin complex of APH(2"")-IIia"	x-ray	1.34	A	p96762	306		13..254
6cyt	pdb	HIV-1 TAR loop in complex with Tat:AFF4:P-TEFb	x-ray	3.5	A	p50750	372		12..321
6cz2	pdb	Structure of the PTK6 kinase domain	x-ray	2.5	A	q13882	451		173..439
6cz3	pdb	Structure of the PTK6 kinase domain bound to a type I inhibitor (3-fluoro-4-{[6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)(morpholin-4-yl)methanone	x-ray	1.8	A	q13882	451		173..439
6cz4	pdb	Structure of the PTK6 kinase domain bound to a type II inhibitor 2-{[(3R,4S)-3-fluoro-1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl]oxy}-5-(1-methyl-1H-imidazol-4-yl)pyridine-3-carboxamide	x-ray	1.5	A	q13882	451		173..439
6d1y	pdb	Crystal structure of Tyrosine-protein kinase receptor in complex with 2,4-dichloro-N-(3-methyl-1-phenyl-1H-pyrazol-5-yl)benzamide Inhibitor	x-ray	1.93	A	p04629	796		494..779
6d1z	pdb	Crystal structure of Tyrosine-protein kinase receptor in complex with 5-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4(3H)-one Inhibitor	x-ray	1.87	A	p04629	796		494..779
6d20	pdb	Crystal structure of Tyrosine-protein kinase receptor in complex with 5-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4(3H)-one and 5-{[2,4-dichloro-5-(pyridin-2-yl)benzene-1-carbonyl]amino}-N-(2-hydroxy-2-methylpropyl)-1-phenyl-1H-pyrazole-3-carboxamide Inhibitors	x-ray	1.94	A	p04629	796		494..779
6d22	pdb	Crystal structure of Tyrosine-protein kinase receptor	x-ray	2.46	A	p04629	796		494..779
6d2i	pdb	JAK2 Pseudokinase V617F in complex with AT9283	x-ray	3.192	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6d3k	pdb	Crystal structure of unphosphorylated human PKR kinase domain in complex with ADP	x-ray	2.6	A;B;C	p19525;p19525;p19525	551;551;551	;;	259..536;259..536;259..536
6d3l	pdb	Crystal structure of unphosphorylated human PKR	x-ray	3.1	A	p19525	551		259..536
6d5y	pdb	Crystal structure of ERK2 G169D mutant	x-ray	2.86	A	p28482	360		19..322
6d8e	pdb	Discovery of a Highly Potent and Broadly Effective EGFR and HER2 Exon 20 Insertion Mutant Inhibitor	x-ray	2.537	A	p00533	1210		708..1003
6da4	pdb	JAK3 with Cyanamide CP10	x-ray	2.9	A	p52333	1124		508..788,820..1097
6db3	pdb	JAK3 with Cyanamide CP23	x-ray	1.97	A	p52333	1124		508..788,820..1097
6db4	pdb	JAK3 with Cyanamide CP34	x-ray	1.662	A	p52333	1124		508..788,820..1097
6dbk	pdb	Tyk2 with compound 8	x-ray	2	A	p29597	1187		576..879,887..1166
6dbm	pdb	Tyk2 with compound 23	x-ray	2.368	A	p29597	1187		576..879,887..1166
6dbn	pdb	Jak1 with compound 23	x-ray	2.48	A	p23458	1154		565..850,873..1146
6dc0	pdb	Tribbles (TRIB1) pseudokinase fused to CCAAT-enhancer binding protein (C/EBPalpha) degron	x-ray	2.8	A;B	p49715;p49715	358;358	;	;
6dcg	pdb	Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology	x-ray	1.45	A	p63086	358		17..320
6dd4	pdb	Crystal Structure of the Human vaccinia-related kinase bound to a N,N-dipropyl-dihydropteridine inhibitor	x-ray	2.1	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6dfl	pdb	WaaP in complex with acyl carrier protein	x-ray	2.396	A	q9huf7	268		35..217
6dgt	pdb	Selective PI3K beta inhibitor bound to PI3K delta	x-ray	2.601	A	o35904	1043		677..1032
6di0	pdb	CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND	x-ray	1.3	A	q06187	659		382..648
6di1	pdb	CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT FRAGMENT LIGAND	x-ray	1.1	A	q06187	659		382..648
6di3	pdb	CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND	x-ray	2	A	q06187	659		382..648
6di5	pdb	CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR	x-ray	1.42	A	q06187	659		382..648
6di9	pdb	CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR	x-ray	1.25	A	q06187	659		382..648
6dkb	pdb	Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 10b.	x-ray	2.68	A	p04629	796		494..779
6dkg	pdb	Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 13b.	x-ray	2.53	A	p04629	796		494..779
6dki	pdb	Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 19.	x-ray	2.11	A	p04629	796		494..779
6dkw	pdb	Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 3.	x-ray	2.91	A;B	p04629;p04629	796;796	;	494..779;494..779
6dmg	pdb	A multiconformer ligand model of EK6 bound to ERK2	x-ray	2.2	A	p28482	360		19..322
6drw	pdb	JAK2 JH1 in complex with JNJ-7706621 (Crystal Form 2)	x-ray	2.303	A	o60674	1132		522..814,842..1119
6dtl	pdb	Mitogen-activated protein kinase 6	x-ray	2.753	A;B	q39026;q39026	395;395	;	68..356;68..356
6dud	pdb	JAK3 with cyanamide CP12	x-ray	1.66	A	p52333	1124		508..788,820..1097
6duk	pdb	EGFR with an allosteric inhibitor	x-ray	2.2	A;B;C;D;E;F	p00533;p00533;p00533;p00533;p00533;p00533	1210;1210;1210;1210;1210;1210	;;;;;	708..1003;708..1003;708..1003;708..1003;708..1003;708..1003
6e0r	pdb	hALK in complex with compound 7 N-((1S)-1-(5-fluoropyridin-2-yl)ethyl)-1-(5-methyl-1H-pyrazol-3-yl)-3-(oxetan-3-ylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-6-amine	x-ray	2.303	A	q9um73	1620		1089..1381
6e2m	pdb	ASK1 kinase domain complex with inhibitor	x-ray	2.253	A;B	q99683;q99683	1374;1374	;	685..939;685..939
6e2n	pdb	ASK1 kinase domain complex with inhibitor	x-ray	2.098	A;B	q99683;q99683	1374;1374	;	685..939;685..939
6e2o	pdb	ASK1 kinase domain complex with inhibitor	x-ray	2.389	A;B	q99683;q99683	1374;1374	;	685..939;685..939
6e4f	pdb	Crystal structure of ARQ 531 in complex with the kinase domain of BTK	x-ray	1.15	A	q06187	659		382..648
6e4t	pdb	Structure of AMPK bound to activator	x-ray	3.4	A	p54645	559		24..308
6e4u	pdb	Structure of AMPK bound to activator	x-ray	3.27	A	p54645	559		24..308
6e4w	pdb	Structure of AMPK bound to activator	x-ray	3.35	A	p54645	559		24..308
6e6e	pdb	DGY-06-116, a novel and selective covalent inhibitor of SRC kinase	x-ray	2.15	A;B;C;D;E;F;G;H	p12931;p12931;p12931;p12931;p12931;p12931;p12931;p12931	536;536;536;536;536;536;536;536	;;;;;;;	259..529;259..529;259..529;259..529;259..529;259..529;259..529;259..529
6e99	pdb	Crystal structure of Protein Kinase A in complex with the PKI peptide and an amino-pyridinylbenzamide based inhibitor.	x-ray	1.88	A	p00517	351		32..339
6e9l	pdb	Crystal structure of Protein Kinase A in complex with the PKI peptide and a pyridinylbenzamide based inhibitor	x-ray	2.8	A	p00517	351		32..339
6e9w	pdb	Crystal structure of Rock1 with a pyridinylbenzamide based inhibitor	x-ray	2.96	A;B	q13464;q13464	1354;1354	;	73..413;73..413
6eas	pdb	Co-crystal of pseudokinase DRIK1 (drought responsive inactive kinase 1) bound to ENMD-2076	x-ray	2	A	c0p4k9	514		209..483
6ebw	pdb	hALK in complex with compound 9 (6-(((1S)-1-(5-Fluoropyridin-2-yl)ethyl)amino)-1-(3-methyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)(morpholin-4-yl)methanone	x-ray	2.455	A	q9um73	1620		1089..1381
6ed6	pdb	Crystal structure of Rock2 with a pyridinylbenzamide based inhibitor	x-ray	2.86	A;B	o75116;o75116	1388;1388	;	89..412;89..412
6edl	pdb	hALK in complex with compound 1 (S)-N-(1-(2,4-difluorophenyl)ethyl)-3-(3-methyl-1H-pyrazol-5-yl)imidazo[1,2-b]pyridazin-6-amine	x-ray	2.799	A	q9um73	1620		1089..1381
6ef6	pdb	Structure of the microcompartment-associated aminopropanol kinase	x-ray	1.35	A	a0qp47	334		9..304
6eg9	pdb	IRAK4 in complex with Ponatinib	x-ray	2.414	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6ega	pdb	IRAK4 in complex with a type II inhibitor	x-ray	2.512	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6egd	pdb	Crystal structure of the unphosphorylated IRAK4 kinase domain Bound to a type I inhibitor	x-ray	2.1	A;D	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6ege	pdb	Crystal structure of the unphosphorylated IRAK4 kinase domain Bound to a type I inhibitor	x-ray	1.401	A;D	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6egf	pdb	Crystal structure of the inactive unphosphorylated IRAK4 kinase domain bound to AMP-PNP	x-ray	2.61	B	q9nwz3	460		156..454
6egw	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp017 and RKp117	x-ray	1.74	A	p25321	351		29..339
6eh0	pdb	Apo crystal structure of the Protein-Kinase A catalytic subunit from Criteculus	x-ray	1.49	A	p25321	351		29..339
6eh2	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp032 and AMP	x-ray	1.76	A	p25321	351		29..339
6eh3	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and RKp190	x-ray	1.95	A	p25321	351		29..339
6ehk	pdb	The crystal structure of CK2alpha in complex with CAM4712 and compound 37	x-ray	1.4	A	p68400	391		5..328
6ehu	pdb	The crystal structure of CK2alpha in complex with compound 32	x-ray	1.95	A;B	p68400;p68400	391;391	;	5..328;5..328
6eif	pdb	DYRK1A in complex with XMD7-117	x-ray	2.22	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6eii	pdb	The crystal structure of CK2alpha in complex with compound 18	x-ray	1.935	A;B	p68400;p68400	391;391	;	5..328;5..328
6eij	pdb	DYRK1A in complex with HG-8-60-1	x-ray	2.42	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6eil	pdb	DYRK1A in complex with XMD8-49	x-ray	2.465	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6eim	pdb	Human STK10 bound to GW683134A	x-ray	1.43	A;B	o94804;o94804	968;968	;	31..302;31..302
6eip	pdb	DYRK1A in complex with XMD8-62e	x-ray	2.56	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6eiq	pdb	DYRK1A in complex with XMD14-124	x-ray	2.3	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6eir	pdb	DYRK1A in complex with XMD15-27-2	x-ray	2.4	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6eis	pdb	DYRK1A in complex with JWC-055	x-ray	2.36	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6eiv	pdb	DYRK1A in complex with JWD-065	x-ray	2.68	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6eix	pdb	Crystal structure of the kinase domain of the Q207E mutant of ACVR1 (ALK2) in complex with a 2-aminopyridine inhibitor K02288	x-ray	2.3	A	q04771	509		186..496
6ej4	pdb	DYRK1A in complex with XMD7-112	x-ray	2.88	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6ekd	pdb	Crystal structure of JNK3 in complex with a pyridinylimidazole inhibitor	x-ray	2.1	A	p53779	464		52..396
6elr	pdb	Human jak1 kinase domain in complex with compound 7	x-ray	1.8	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6em2	pdb	Crystal structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with Fasudil	x-ray	1.3	A	p25321	351		29..339
6em6	pdb	Crystal structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp032 and ADP	x-ray	1.64	A	p25321	351		29..339
6em7	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and ADP	x-ray	1.238	A	p25321	351		29..339
6ema	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and ATP	x-ray	1.88	A	p25321	351		29..339
6emh	pdb	Crystal structure of JNK3 in complex with a pyridinylimidazole inhibitor	x-ray	1.76	A;B;C;D	p53779;p53779;p53779;p53779	464;464;464;464	;;;	52..396;52..396;52..396;52..396
6emk	pdb	Cryo-EM Structure of Saccharomyces cerevisiae Target of Rapamycin Complex 2	em	7.9	A;C	;	;	;	;
6eml	pdb	Cryo-EM structure of a late pre-40S ribosomal subunit from Saccharomyces cerevisiae	em	3.6	r	p40160	425		95..281
6ep9	pdb	Crystal structure of BTK kinase domain complexed with N-[2-methyl-3-[4-methyl-6-[4-(4-methylpiperazine-1-carbonyl)anilino]-5-oxo-pyrazin-2-yl]phenyl]-4-(1-piperidyl)benzamide	x-ray	2.01	A	q06187	659		382..648
6eq9	pdb	Crystal structure of JNK3 in complex with AMP-PCP	x-ray	1.83	A;B	p53779;p53779	464;464	;	52..396;52..396
6eqi	pdb	Structure of PINK1 bound to ubiquitin	x-ray	3.1	C				
6ert	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp193 and RKp117	x-ray	1.8	A	p25321	351		29..339
6eru	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compound RKp120	x-ray	2.15	A	p25321	351		29..339
6erv	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp013	x-ray	2.06	A	p25321	351		29..339
6erw	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp013 and Fasudil	x-ray	1.89	A	p25321	351		29..339
6es0	pdb	Crystal structure of the kinase domain of human RIPK2 in complex with the activation loop targeting inhibitor CS-R35	x-ray	2.38	A;B	o43353;o43353	540;540	;	11..297;11..297
6esa	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Criteculus Griseus in complex with compounds RKp120 and AMP	x-ray	1.307	A	p25321	351		29..339
6ewx	pdb	Structure of Pragmin pseudo-kinase reveals a dimerization mechanism to regulate protein tyrosine phosphorylation and nuclear transcription	x-ray	2.771	A;B	d3zmk9;d3zmk9	1368;1368	;	1089..1285;1089..1285
6eyz	pdb	PI3 kinase delta in complex with 4-Fluorophenyl 5-(4-(5-((4-isopropylpiperazin-1-yl)methyl)oxazol-2-yl)-1H-indazol-6-yl)-2-methoxynicotinate	x-ray	2.2	A	o35904	1043		677..1032
6ez6	pdb	PI3 kinase delta in complex with Methyl 5-(4-(5-((4-isopropylpiperazin-1-yl)methyl)oxazol-2-yl)-1H-indazol-6-yl)-2-methoxynicotinate	x-ray	2.04	A	o35904	1043		677..1032
6f14	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with isoquinoline and PKI (5-24)	x-ray	1.867	A	p25321	351		29..339
6f1w	pdb	Crystal structure of human Casein Kinase I delta in complex with compound 31a	x-ray	1.864	A;B	p48730;p48730	415;415	;	5..290;5..290
6f26	pdb	Crystal structure of human Casein Kinase I delta in complex with compound 31b	x-ray	1.83	A;B	p48730;p48730	415;415	;	5..290;5..290
6f3d	pdb	IRAK4 IN COMPLEX WITH inhibitor	x-ray	2.38	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6f3e	pdb	IRAK4 IN COMPLEX WITH inhibitor	x-ray	2.67	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6f3f	pdb	Autoinhibited Src kinase bound to ADP	x-ray	2.41796	A	p05480	535		258..528
6f3g	pdb	IRAK4 IN COMPLEX WITH inhibitor	x-ray	2.37	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6f3i	pdb	IRAK4 IN COMPLEX WITH inhibitor	x-ray	2.14	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6f5e	pdb	Crystal structure of DARPin-DARPin rigid fusion, variant DD_D12_10_47 in complex JNK1a1 and JIP1 peptide	x-ray	2.7	B				
6f7b	pdb	Crystal structure of the human Bub1 kinase domain in complex with BAY 1816032	x-ray	2	A	o43683	1085		789..1061
6fad	pdb	SR protein kinase 1 (SRPK1) in complex with the RGG-box of HSV1 ICP27	x-ray	2.801	A;B;C;D	q96sb4;q96sb4;q96sb4;q96sb4	655;655;655;655	;;;	67..654;67..654;67..654;67..654
6fai	pdb	Structure of a eukaryotic cytoplasmic pre-40S ribosomal subunit	em	3.4	l	p40160	425		95..281
6fc8	pdb	CHK1 KINASE IN COMPLEX WITH COMPOUND 13	x-ray	1.61	A	o14757	476		6..317
6fcf	pdb	CHK1 KINASE IN COMPLEX WITH COMPOUND 44	x-ray	1.85	A	o14757	476		6..317
6fck	pdb	CHK1 KINASE IN COMPLEX WITH COMPOUND 13	x-ray	1.9	A	o14757	476		6..317
6fd3	pdb	Thiophosphorylated PAK3 kinase domain	x-ray	1.52	A	o75914	559		274..536
6fdm	pdb	Human Rio2 kinase structure	x-ray	2.1	A;B;C;D	q9bvs4;q9bvs4;q9bvs4;q9bvs4	552;552;552;552	;;;	97..272;97..272;97..272;97..272
6fdn	pdb	Rio2 structure	x-ray	2.9	A;B	q9bvs4;q9bvs4	552;552	;	97..272;97..272
6fdo	pdb	Rio2 structure	x-ray	2.6	A;B	q9bvs4;q9bvs4	552;552	;	97..272;97..272
6fdy	pdb	Unc-51-Like Kinase 3 (ULK3) In Complex With Bosutinib	x-ray	1.7	U	q6phr2	472		11..271
6fdz	pdb	Unc-51-Like Kinase 3 (ULK3) In Complex With Momelotinib	x-ray	2.55	U	q6phr2	472		11..271
6fek	pdb	Oncogenic point mutation of RET receptor tyrosine kinase	x-ray	2.3	A	p07949	1114		699..1005
6fer	pdb	Crystal Structure of human DDR2 kinase in complex with 2-[4,5-difluoro-2-oxo-1'-(1H-pyrazolo[3,4-b]pyridine-5-carbonyl)spiro[indole-3,4'-piperidine]-1-yl]-N-(2,2,2-trifluoroethyl)acetamide	x-ray	2.87	A;B;C;D;E;F;G;H;I;J;K;L	q16832;q16832;q16832;q16832;q16832;q16832;q16832;q16832;q16832;q16832;q16832;q16832	855;855;855;855;855;855;855;855;855;855;855;855	;;;;;;;;;;;	551..846;551..846;551..846;551..846;551..846;551..846;551..846;551..846;551..846;551..846;551..846;551..846
6few	pdb	DDR1, 2-[8-(1H-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-N-methylacetamide, 1.440A, P1211, Rfree=24.1%	x-ray	1.44	A	q08345	913		603..904
6fex	pdb	DDR1, 2-[4-bromo-2-oxo-1'-(1H-pyrazolo[4,3-b]pyridine-5-carbonyl)spiro[indole-3,4'-piperidine]-1-yl]-N-(2,2,2-trifluoroethyl)acetamide, 1.291A, P212121, Rfree=17.4%	x-ray	1.291	A	q08345	913		603..904
6fh5	pdb	PI3Kg IN COMPLEX WITH Compound 7	x-ray	2.84	A	p48736	1102		728..1089
6fha	pdb	Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289A and S308A mutations	x-ray	2.3	A	p53355	1430		6..291
6fhb	pdb	Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289A and S308E mutations	x-ray	1.75	A	p53355	1430		6..291
6fi3	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.52	A	p63086	358		17..320
6fi6	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.65	A	p63086	358		17..320
6fil	pdb	DDR1, 2-[8-(1H-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-N-methylacetamide, 1.730A, P212121, Rfree=24.5%	x-ray	1.73	A	q08345	913		603..904
6fin	pdb	DDR1, 3-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-8-(1H-indazole-5-carbonyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one, 1.670A, P1211, Rfree=22.8%	x-ray	1.67	A	q08345	913		603..904
6fio	pdb	DDR1, 2-[1'-(1H-indazole-5-carbonyl)-4-methyl-2-oxospiro[indole-3,4'-piperidine]-1-yl]-N-(2,2,2-trifluoroethyl)acetamide, 1.990A, P6522, Rfree=27.7%	x-ray	1.99	A	q08345	913		603..904
6fiq	pdb	DDR1, 1-(1H-indazole-5-carbonyl)-5'-methoxy-1'-[2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl]spiro[piperidine-4,3'-pyrrolo[3,2-b]pyridine]-2'-one, 1.790A, P212121, Rfree=23.8%	x-ray	1.79	A	q08345	913		603..904
6fj0	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.659	A	p63086	358		17..320
6fjb	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.85	A	p63086	358		17..320
6fjz	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.864	A	p63086	358		17..320
6fle	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.48	A	p63086	358		17..320
6flv	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.91	A	p63086	358		17..320
6fma	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.667	A	p63086	358		17..320
6fn5	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.932	A	p63086	358		17..320
6fnf	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with NVP-BHG712	x-ray	1.556	A	p29317	976		605..909
6fng	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with an isomer of NVP-BHG712	x-ray	1.038	A	p29317	976		605..909
6fnh	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with a pyrazolo[3,4-d]pyrimidine fragment of NVP-BHG712	x-ray	1.379	A;B;C	p29317;p29317;p29317	976;976;976	;;	605..909;605..909;605..909
6fni	pdb	Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with NVP-BHG712	x-ray	1.468	A	p54760	987		609..886
6fnj	pdb	Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with an isomer of NVP-BHG712	x-ray	1.239	A;B	p54760;p54760	987;987	;	609..886;609..886
6fnk	pdb	Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with a pyrazolo[3,4-d]pyrimidine fragment of NVP-BHG712	x-ray	1.049	A	p54760	987		609..886
6fnl	pdb	Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase	x-ray	1.269	A	p54760	987		609..886
6fnm	pdb	Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with Dasatinib	x-ray	1.157	A	p54760	987		609..886
6fq7	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.6	A	p63086	358		17..320
6fr1	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.561	A	p63086	358		17..320
6frp	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.53	A	p63086	358		17..320
6frx	pdb	PKA variant as Aurora B mimic in complex with a dianilinopyrimidine inhibitor	x-ray	1.88	A	p17612	351		30..339
6ft7	pdb	Crystal structure of CLK3 in complex with compound 8a	x-ray	2.02	A;B	p49761;p49761	490;490	;	145..479;145..479
6ft8	pdb	Crystal structure of CLK1 in complex with inhibitor 8g	x-ray	1.45	A	p49759	484		150..478
6ft9	pdb	Crystal structure of CLK1 in complex with inhibitor 16	x-ray	1.87	A;B;C	p49759;p49759;p49759	484;484;484	;;	150..478;150..478;150..478
6ftn	pdb	mPI3Kd IN COMPLEX WITH AZ2	x-ray	2	A	o35904	1043		677..1032
6fu5	pdb	Structure of the kinase domain of human RIPK2 in complex with the inhibitor CSLP18	x-ray	3.26	A;B	o43353;o43353	540;540	;	11..297;11..297
6fuc	pdb	Structure of aminoglycoside phosphotransferase APH(3'')-Id from Streptomyces rimosus ATCC10970	x-ray	1.17	A				
6fux	pdb	Structure of aminoglycoside phosphotransferase APH(3'')-Id from Streptomyces rimosus ATCC10970 in complex with ADP and streptomycin	x-ray	1.65	A				
6fvf	pdb	The Structure of CK2alpha with CCh503 bound	x-ray	1.47	A	p68400	391		5..328
6fvg	pdb	The Structure of CK2alpha with CCh507 bound	x-ray	1.6	A	p68400	391		5..328
6fxv	pdb	Crystal structure of ERK2 in complex with an adenosine derivative	x-ray	1.53	A	p63086	358		17..320
6fyi	pdb	X-ray Structure of CLK2-KD(130-496)/TG003 at 2.6A	x-ray	2.6	A	p49760	499		150..488
6fyk	pdb	X-Ray structure of CLK2-KD(136-496)/Indazole1 at 2.39A	x-ray	2.39	A;B;C	p49760;p49760;p49760	499;499;499	;;	150..488;150..488;150..488
6fyl	pdb	X-ray structure of CLK2-KD(136-496)/CX-4945 at 1.95A	x-ray	1.95	A	p49760	499		150..488
6fyo	pdb	X-RAY STRUCTURE OF CLK1-KD(148-484)/Cpd-2 AT 2.32A	x-ray	2.32	A	p49759	484		150..478
6fyp	pdb	X-RAY STRUCTURE OF CLK3-KD(GP-[275-632], NON-PHOS.)/CX-4945 AT 2.29A	x-ray	2.29	A	p49761	490		145..479
6fyr	pdb	X-RAY STRUCTURE OF CLK3-KD(GP-[275-632], NON-PHOS.)/Cpd-2 AT 1.42A	x-ray	1.42	A	p49761	490		145..479
6fyv	pdb	X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A	x-ray	2.46	A	q9haz1	481		148..476
6g18	pdb	Cryo-EM structure of a late human pre-40S ribosomal subunit - State C	em	3.6	v	q9bvs4	552		97..272
6g33	pdb	Crystal structure of CLK1 in complex with 5-iodotubercidin	x-ray	2.05	A;B;C	p49759;p49759;p49759	484;484;484	;;	150..478;150..478;150..478
6g34	pdb	Crystal structure of haspin in complex with 5-iodotubercidin	x-ray	1.76	A	q8tf76	798		474..698
6g35	pdb	Crystal structure of haspin in complex with 5-bromotubercidin	x-ray	1.55	A	q8tf76	798		474..698
6g36	pdb	Crystal structure of haspin in complex with 5-chlorotubercidin	x-ray	1.46	A	q8tf76	798		474..698
6g37	pdb	Crystal structure of haspin in complex with 5-fluorotubercidin	x-ray	1.48	A	q8tf76	798		474..698
6g38	pdb	Crystal structure of haspin in complex with tubercidin	x-ray	1.47	A	q8tf76	798		474..698
6g39	pdb	Crystal structure of haspin F605Y mutant in complex with 5-iodotubercidin	x-ray	1.45	A	q8tf76	798		474..698
6g3a	pdb	Crystal structure of haspin F605T mutant in complex with 5-iodotubercidin	x-ray	1.43	A	q8tf76	798		474..698
6g3c	pdb	Crystal Structure of JAK2-V617F pseudokinase domain in complex with Compound 2	x-ray	1.6	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6g4j	pdb	Structure of the protein kinase YabT from Bacillus subtilis in complex with an alphaREP crystallization helper	x-ray	1.599	A				
6g4y	pdb	Crystal structure of murine NF-kappaB inducing kinase (NIK) in complex with compound 1a	x-ray	2.65	A;B	q9wul6;q9wul6	942;942	;	407..656;407..656
6g4z	pdb	Crystal structure of murine NF-kappaB inducing kinase (NIK) in complex with compound 2f	x-ray	2.84	A;B	q9wul6;q9wul6	942;942	;	407..656;407..656
6g51	pdb	Cryo-EM structure of a late human pre-40S ribosomal subunit - State D	em	4.1	v	q9bvs4	552		97..272
6g54	pdb	Crystal structure of ERK2 covalently bound to SM1-71	x-ray	2.05	A	p28482	360		19..322
6g5i	pdb	Cryo-EM structure of a late human pre-40S ribosomal subunit - State R	em	3.5	z	q9brs2	568		181..368
6g6w	pdb	HUMAN PI3KDELTA IN COMPLEX WITH LIGAND LASW1976	x-ray	2.72	A	o00329	1044		678..1033
6g76	pdb	Phosphorylated RSK4 N-terminal Kinase Domain in complex with AMP-PNP	x-ray	3	A;B	q9uk32;q9uk32	745;745	;	72..392,421..704;72..392,421..704
6g77	pdb	RSK4 N-terminal Kinase Domain in complex with AMP-PNP	x-ray	2.499	A;B	q9uk32;q9uk32	745;745	;	72..392,421..704;72..392,421..704
6g78	pdb	RSK4 N-terminal Kinase Domain S232E in complex with AMP-PNP	x-ray	2.5	A;B	q9uk32;q9uk32	745;745	;	72..392,421..704;72..392,421..704
6g8x	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.76	A	p28482	360		19..322
6g91	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.8	A	p28482	360		19..322
6g92	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.99	A	p28482	360		19..322
6g93	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.67	A	p28482	360		19..322
6g97	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.9	A	p28482	360		19..322
6g9a	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.91	A	p28482	360		19..322
6g9d	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.8	A	p28482	360		19..322
6g9h	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.73	A	p28482	360		19..322
6g9j	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.98	A	p28482	360		19..322
6g9k	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.94	A	p28482	360		19..322
6g9m	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.86	A	p28482	360		19..322
6g9n	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.76	A	p28482	360		19..322
6gcr	pdb	Focal Adhesion Kinase catalytic domain in complex with irreversible inhibitor	x-ray	2.3	A	q00944	1053		409..698
6gcw	pdb	Focal Adhesion Kinase catalytic domain in complex with irreversible inhibitor	x-ray	2	A;B	q00944;q00944	1053;1053	;	409..698;409..698
6gcx	pdb	Focal Adhesion Kinase catalytic domain in complex with irreversible inhibitor	x-ray	1.553	A	q00944	1053		409..698
6gdm	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.91	A	p28482	360		19..322
6gdq	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.86	A	p28482	360		19..322
6ge0	pdb	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.82	A	p28482	360		19..322
6ges	pdb	Crystal structure of ERK1 covalently bound to SM1-71	x-ray	2.07	A;B	p27361;p27361	379;379	;	36..339;36..339
6ggh	pdb	Human jak1 kinase domain in complex with inhibitor	x-ray	1.7	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6gi6	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with a Quinazolinone based ALK2 inhibitor with a 5-methyl core.	x-ray	1.98	A	q04771	509		186..496
6gih	pdb	Crystal Structure of CK2alpha with CAM187 bound	x-ray	1.96	A	p68400	391		5..328
6gin	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with an Quinazolinone based ALK2 inhibitor with a 4-morpholinophenyl solvent accessible group.	x-ray	2.2	A;B	q04771;q04771	509;509	;	186..496;186..496
6gip	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with a Quinazolinone based ALK2 inhibitor with a 2, 5-dimethyl core.	x-ray	2.17	A	q04771	509		186..496
6gjb	pdb	Erk2 signalling protein	x-ray	1.82	A	p28482	360		19..322
6gjd	pdb	Erk2 signalling protein	x-ray	1.58	A	p28482	360		19..322
6gjo	pdb	Crystal Structure of Glycogen Synthase Kinase-3 beta in Complex with BI-91BS	x-ray	2.91	A;B	p49841;p49841	420;420	;	55..377;55..377
6gl3	pdb	Crystal structure of human Phosphatidylinositol 4-kinase III beta (PI4KIIIbeta) in complex with ligand 44	x-ray	2.77	A;B	q9ubf8;q9ubf8	816;816	;	325..810;325..810
6gl9	pdb	Crystal structure of JAK3 in complex with Compound 10 (FM475)	x-ray	1.7	A;B	p52333;p52333	1124;1124	;	508..788,820..1097;508..788,820..1097
6gla	pdb	Crystal structure of JAK3 in complex with Compound 11 (FM481)	x-ray	1.92	A;B	p52333;p52333	1124;1124	;	508..788,820..1097;508..788,820..1097
6glb	pdb	Crystal structure of JAK3 in complex with Compound 20 (FM484)	x-ray	2	A;B	p52333;p52333	1124;1124	;	508..788,820..1097;508..788,820..1097
6gmd	pdb	The crystal structure of CK2alpha in complex with compound 3	x-ray	1.66	A;B	p68400;p68400	391;391	;	5..328;5..328
6gn1	pdb	Crystal Structure of Glycogen synthase kinase-3 beta (GSK3B) in Complex with PIK-75	x-ray	2.6	A;B	p49841;p49841	420;420	;	55..377;55..377
6gq7	pdb	PI3Kg IN COMPLEX WITH INH	x-ray	2.84	A	p48736	1102		728..1089
6gqj	pdb	Crystal structure of human c-KIT kinase domain in complex with AZD3229-analogue (compound 18)	x-ray	2.33	A;B	p10721;p10721	976;976	;	564..923;564..923
6gqk	pdb	Crystal structure of human c-KIT kinase domain in complex with AZD3229-analogue (compound 23)	x-ray	2.31	A;B	p10721;p10721	976;976	;	564..923;564..923
6gql	pdb	Crystal structure of human c-KIT kinase domain in complex with AZD3229-analogue (compound 35)	x-ray	2.01	A;B	p10721;p10721	976;976	;	564..923;564..923
6gqm	pdb	Crystal structure of human c-KIT kinase domain in complex with a small molecule inhibitor, AZD3229	x-ray	2	A;B	p10721;p10721	976;976	;	564..923;564..923
6gqo	pdb	Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 18)	x-ray	1.87	A	p35968	1356		815..1160
6gqp	pdb	Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 23)	x-ray	2.09	A	p35968	1356		815..1160
6gqq	pdb	Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 35)	x-ray	1.52	A	p35968	1356		815..1160
6gr8	pdb	Human AURKC INCENP complex bound to BRD-7880	x-ray	1.75	A	q9uqb9	309		28..302
6gr9	pdb	Human AURKC INCENP complex bound to VX-680	x-ray	2.25	A	q9uqb9	309		28..302
6gra	pdb	Human AURKA bound to BRD-7880	x-ray	2.6	A	o14965	403		120..386
6gro	pdb	Human CSNK1G3 bound to SB-223133	x-ray	1.45	A	q9y6m4	447		39..325
6gtt	pdb	Human STK10 bound to BIRB-796	x-ray	2.25	A	o94804	968		31..302
6gu2	pdb	CDK1/CyclinB/Cks2 in complex with Flavopiridol	x-ray	2	A	p06493	297		1..291
6gu3	pdb	CDK1/CyclinB/Cks2 in complex with AZD5438	x-ray	2.65	A	p06493	297		1..291
6gu4	pdb	CDK1/CyclinB/Cks2 in complex with CGP74514A	x-ray	2.73	A	p06493	297		1..291
6gu6	pdb	CDK1/Cks2 in complex with Dinaciclib	x-ray	2.33	A	p06493	297		1..291
6gu7	pdb	CDK1/Cks2 in complex with AZD5438	x-ray	2.75	A;C;E;G	p06493;p06493;p06493;p06493	297;297;297;297	;;;	1..291;1..291;1..291;1..291
6gub	pdb	CDK2/CyclinA in complex with Flavopiridol	x-ray	2.52	A;C	p24941;p24941	298;298	;	1..292;1..292
6guc	pdb	CDK2/CyclinA in complex with SU9516	x-ray	2	A;C	p24941;p24941	298;298	;	1..292;1..292
6gue	pdb	CDK2/CyclinA in complex with AZD5438	x-ray	1.99	A;C	p24941;p24941	298;298	;	1..292;1..292
6guf	pdb	CDK2/CyclinA in complex with CGP74514A	x-ray	2.65	A;C	p24941;p24941	298;298	;	1..292;1..292
6guh	pdb	CDK2 in complex with AZD5438	x-ray	1.5	A	p24941	298		1..292
6guk	pdb	CDK2 in complex with CGP74514A	x-ray	1.3	A	p24941	298		1..292
6gva	pdb	CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR4455	x-ray	2.15	A	p24941	298		1..292
6gvf	pdb	Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine	x-ray	2.5	A	p42336	1068		699..1060
6gvg	pdb	Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine	x-ray	3	A	p42336	1068		699..1060
6gvh	pdb	Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-4-chloro-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine	x-ray	2.74	A	p42336	1068		699..1060
6gvi	pdb	Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine	x-ray	2.9	A	p42336	1068		699..1060
6gvj	pdb	Human Mps1 kinase domain with ordered activation loop	x-ray	2.41	A	p33981	857		516..792
6gvx	pdb	Crystal structure of Maternal Embryonic Leucine Zipper Kinase (MELK) in complex with dorsomorphin (Compound C)	x-ray	2.24	A;B	q14680;q14680	651;651	;	8..308;8..308
6gwr	pdb	Structure of the kinase domain of human DDR1 in complex with a potent and selective inhibitor of DDR1 and DDR2	x-ray	2.07	A;B	q08345;q08345	913;913	;	603..904;603..904
6gy0	pdb	mPI3Kd IN COMPLEX WITH AZ3	x-ray	2.55	A	o35904	1043		677..1032
6gzd	pdb	Crystal structure of Human CSNK1A1 with A86	x-ray	2.28	A	p48729	337		12..298
6gzh	pdb	Crystal Structure of Human CDK9/cyclinT1 with A86	x-ray	3.17	A	p50750	372		12..321
6gzm	pdb	Crystal Structure of Human CKIdelta with A86	x-ray	1.59	A;B	p48730;p48730	415;415	;	5..290;5..290
6h0u	pdb	Glycogen synthase kinase-3 beta (GSK3) complex with a covalent [1,2,4]triazolo[1,5-a][1,3,5]triazine inhibitor	x-ray	2.3	A;B	p49841;p49841	420;420	;	55..377;55..377
6h3k	pdb	Introduction of a methyl group curbs metabolism of pyrido[3,4-d]pyrimidine MPS1 inhibitors and enables the discovery of the Phase 1 clinical candidate BOS172722.	x-ray	2.48	A	p33981	857		516..792
6hbn	pdb	HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA/CSKN2A1 GENE PRODUCT) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR THN27	x-ray	1.59	A;B	p68400;p68400	391;391	;	5..328;5..328
6hd4	pdb	ABL1 IN COMPLEX WITH COMPOUND 7 AND IMATINIB (STI-571)	x-ray	2.03	A;B	p00520;p00520	1123;1123	;	231..498;231..498
6hd6	pdb	ABL1 IN COMPLEX WITH COMPOUND6 AND IMATINIB (STI-571)	x-ray	2.3	A;B	p00520;p00520	1123;1123	;	231..498;231..498
6hdp	pdb	Human DYRK2 bound to Scorzodihydrostilbene A	x-ray	2.3	A	q92630	601		212..543
6hdr	pdb	Human DYRK2 bound to Curcumin	x-ray	2.2	A	q92630	601		212..543
6hes	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative AT050	x-ray	1.128	A	p29317	976		605..909
6het	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative AT055	x-ray	1.208	A	p29317	976		605..909
6heu	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative AT058	x-ray	1.719	A	p29317	976		605..909
6hev	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative AT061	x-ray	1.28	A	p29317	976		605..909
6hew	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative AT069	x-ray	1.268	A	p29317	976		605..909
6hex	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATMM006	x-ray	1.413	A	p29317	976		605..909
6hey	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATNK002	x-ray	1.367	A	p29317	976		605..909
6hh1	pdb	Structure of c-Kit with allosteric inhibitor 3G8	x-ray	2.25	A	p10721	976		564..923
6hhf	pdb	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor Borussertib	x-ray	2.9	A	p31749	480		145..459
6hhg	pdb	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 27	x-ray	2.3	A	p31749	480		145..459
6hhh	pdb	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 31	x-ray	2.7	A	p31749	480		145..459
6hhi	pdb	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 30b	x-ray	2.7	A	p31749	480		145..459
6hhj	pdb	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 24b	x-ray	2.3	A	p31749	480		145..459
6hho	pdb	Crystal structure of RIP1 kinase in complex with GSK547	x-ray	3.49	A;B	q13546;q13546	671;671	;	6..286;6..286
6hi1	pdb	PI3 Kinase Delta in complex with 3[6(morpholin4yl)pyridin2yl]phenol	x-ray	2.07	A	o35904	1043		677..1032
6hi2	pdb	PI3 Kinase Delta in complex with 3{6[(1S,6R)3oxabicyclo[4.1.0]heptan6yl]pyridin2yl}phenol	x-ray	1.9	A	o35904	1043		677..1032
6hi9	pdb	PI3 Kinase Delta in complex with 3[6(oxan4yl)pyridin2yl]phenol	x-ray	2.08	A	o35904	1043		677..1032
6hjj	pdb	Crystal structure of Aurora-A L210C catalytic domain in complex with ASDO6 ligand	x-ray	2.13	A	o14965	403		120..386
6hjk	pdb	Crystal Structure of Aurora-A L210C catalytic domain in complex with ASDO2	x-ray	2.4	A	o14965	403		120..386
6hk3	pdb	Crystal structure of GSK-3B in complex with pyrazine inhibitor C44	x-ray	2.35	A;B	;	;	;	;
6hk4	pdb	Crystal structure of GSK-3B in complex with pyrazine inhibitor C22	x-ray	2.5	A;B	;	;	;	;
6hk6	pdb	Human RIOK2 bound to inhibitor	x-ray	2.35	A;B;C;D;E;F;G;H;I;J	q9bvs4;q9bvs4;q9bvs4;q9bvs4;q9bvs4;q9bvs4;q9bvs4;q9bvs4;q9bvs4;q9bvs4	552;552;552;552;552;552;552;552;552;552	;;;;;;;;;	97..272;97..272;97..272;97..272;97..272;97..272;97..272;97..272;97..272;97..272
6hk7	pdb	Crystal structure of GSK-3B in complex with pyrazine inhibitor C50	x-ray	3.2	A	p49841	420		55..377
6hkm	pdb	Crystal structure of Compound 1 with ERK5	x-ray	2.47	A	q13164	816		48..356
6hkn	pdb	Crystal structure of Compound 35 with ERK5	x-ray	2.33	A	q13164	816		48..356
6hm6	pdb	CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A 2-(PYRIDINYLOXYMETHYL)PYRIDINE INHIBITOR	x-ray	2.1	A	p43405	635		375..627
6hm7	pdb	CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A 2-(PHENOXYMETHYL)PYRIDINE INHIBITOR	x-ray	1.64	A	p43405	635		375..627
6hmb	pdb	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 Gene product) IN COMPLEX WITH the inhibitor CX-4945 (Silmitasertib)	x-ray	1.04	A	p19784	350		13..330
6hmc	pdb	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 gene product) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR THN27	x-ray	1.03	A	p19784	350		13..330
6hmd	pdb	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 gene product) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR AR18	x-ray	1	A	p19784	350		13..330
6hme	pdb	LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA; CSNK2A1 gene product) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR THN27	x-ray	1.85	A;B	p68400;p68400	391;391	;	5..328;5..328
6hmp	pdb	Crystal structure of human Casein Kinase I delta in complex with a photoswitchable 2-Azoimidazole-based Inhibitor (compound 3)	x-ray	2.039	A;B	p48730;p48730	415;415	;	5..290;5..290
6hmq	pdb	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE BENZOTRIAZOLE-TYPE INHIBITOR MB002	x-ray	0.97	A	p19784	350		13..330
6hmr	pdb	Crystal structure of human Casein Kinase I delta in complex with a photoswitchable 2-Azothiazole-based inhibitor (compound 2)	x-ray	1.782	A;B	p48730;p48730	415;415	;	5..290;5..290
6hmx	pdb	RIP2 Kinase Catalytic Domain complex with N(4,5dimethyl1Hpyrazol3yl)7methoxy6(2methylpropane2sulfonyl)quinolin4amine	x-ray	2.53	A;B	o43353;o43353	540;540	;	11..297;11..297
6hnw	pdb	Human protein kinase CK2 alpha in complex with coumestrol	x-ray	2	A	p68400	391		5..328
6hny	pdb	Human protein kinase CK2 alpha in complex with boldine	x-ray	1.65	A	p68400	391		5..328
6hop	pdb	Human protein kinase CK2 alpha in complex with curcumin degradation products	x-ray	1.55	A	p68400	391		5..328
6hoq	pdb	Human protein kinase CK2 alpha in complex with ferulic acid	x-ray	1.55	A	p68400	391		5..328
6hor	pdb	Human protein kinase CK2 alpha in complex with feruloylmethane	x-ray	1.8	A	p68400	391		5..328
6hot	pdb	Human protein kinase CK2 alpha in complex with ferulic aldehyde	x-ray	1.5	A	p68400	391		5..328
6hou	pdb	Human protein kinase CK2 alpha in complex with vanillin	x-ray	1.8	A	p68400	391		5..328
6hp9	pdb	Structure of the kinase domain of human DDR1 in complex with a 2-Amino-2,3-Dihydro-1H-Indene-5-Carboxamide-based inhibitor	x-ray	1.96	A;B	q08345;q08345	913;913	;	603..904;603..904
6hrp	pdb	CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-3,4-dihydroisoquinolin-1-one	x-ray	1.12	A	q06187	659		382..648
6hrt	pdb	CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-yl)-9-hydroxy-6-methyl-4-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-azatricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,11,13-pentaen-5-one	x-ray	1.36	A	q06187	659		382..648
6hv0	pdb	IRE1 kinase/RNase in complex with imidazo[1,2-b]pyridazin-8-amine compound 33	x-ray	2.73	A	o75460	977		571..851
6hvd	pdb	Human SLK bound to a maleimide inhibitor	x-ray	1.63	A	q9h2g2	1235		29..293
6hve	pdb	Kinase domain of cSrc in complex with compound 9	x-ray	1.9	A;B	p00523;p00523	533;533	;	256..526;256..526
6hvf	pdb	Kinase domain of cSrc in complex with compound 29B	x-ray	2.1	A;B	p00523;p00523	533;533	;	256..526;256..526
6hwj	pdb	Glucosamine kinase (crystal form A)	x-ray	1.979	A;B	a0a1h7tqr5;a0a1h7tqr5	438;438	;	109..420;109..420
6hwk	pdb	Glucosamine kinase (crystal form B)	x-ray	2.688	A;B;C;D	a0a1h7tqr5;a0a1h7tqr5;a0a1h7tqr5;a0a1h7tqr5	438;438;438;438	;;;	109..420;109..420;109..420;109..420
6hwl	pdb	Glucosamine kinase in complex with glucosamine, ADP and inorganic phosphate	x-ray	2.148	A;B	a0a1h7tqr5;a0a1h7tqr5	438;438	;	109..420;109..420
6hwt	pdb	Crystal structure of p38alpha in complex with a reduced photoswitchable 2-Azothiazol-based Inhibitor (compound 31)	x-ray	1.7	A	q16539	360		9..349
6hwu	pdb	Crystal structure of p38alpha in complex with a photoswitchable 2-Azothiazol-based Inhibitor (compound 2)	x-ray	2.3	A	q16539	360		9..349
6hwv	pdb	Crystal structure of p38alpha in complex with a photoswitchable 2-Azoimidazol-based Inhibitor (compound 3)	x-ray	1.7	A	q16539	360		9..349
6hx1	pdb	IRE1 ALPHA IN COMPLEX WITH imidazo[1,2-b]pyridazin-8-amine compound 2	x-ray	2.14	A	o75460	977		571..851
6hxf	pdb	Human STK10 bound to a maleimide inhibitor	x-ray	2.09	A;B;C;D	o94804;o94804;o94804;o94804	968;968;968;968	;;;	31..302;31..302;31..302;31..302
6hzu	pdb	HUMAN JAK1 IN COMPLEX WITH LASW1393	x-ray	2.2	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6hzv	pdb	HUMAN JAK3 IN COMPLEX WITH LASW959 PROTEIN IN COMPLEX WITH LIGAND	x-ray	2.46	A;B;C;D	p52333;p52333;p52333;p52333	1124;1124;1124;1124	;;;	508..788,820..1097;508..788,820..1097;508..788,820..1097;508..788,820..1097
6i1s	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with FKBP12 and the inhibitor E6201	x-ray	1.52	A	q04771	509		186..496
6i2a	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Cricetulus Griseus in complex with compounds RKp153 and Fasudil	x-ray	1.75	A	p25321	351		29..339
6i2b	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Cricetulus Griseus in complex with compounds RKp153 and RKp117	x-ray	1.97	A	p25321	351		29..339
6i2c	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Cricetulus Griseus in complex with compounds RKp182 and Fasudil	x-ray	1.82	A	p25321	351		29..339
6i2d	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Cricetulus Griseus in complex with compounds RKp182 and RKp117	x-ray	1.91	A	p25321	351		29..339
6i2h	pdb	Crystal Structure of the Protein-Kinase A catalytic subunit from Cricetulus Griseus in complex with compounds RKp182 and RKp190	x-ray	1.68	A	p25321	351		29..339
6i2p	pdb	Crystal structure of the Mycobacterium tuberculosis PknB kinase domain (L33E mutant) in complex with its substrate GarA	x-ray	2.37	A;B	;	;	;	;
6i2u	pdb	Aurora-A kinase domain in complex with Coenzyme A	x-ray	2.5	A	o14965	403		120..386
6i2y	pdb	Human STK10 bound to Foretinib	x-ray	2.56	A;B	o94804;o94804	968;968	;	31..302;31..302
6i3u	pdb	Optimization of potent and selective ATM inhibitors suitable for a proof-of-concept study in Huntington's disease models	x-ray	2.09	A	q8neb9	887		538..883
6i5h	pdb	Crystal structure of CLK1 in complex with furanopyrimidin VN412	x-ray	1.49	A	p49759	484		150..478
6i5i	pdb	Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound 12h	x-ray	1.6	A	p49759	484		150..478
6i5k	pdb	Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound VN345 (derivative of compound 12h)	x-ray	2.3	A;B;C	p49759;p49759;p49759	484;484;484	;;	150..478;150..478;150..478
6i5l	pdb	Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound VN316 (derivative of compound 12h)	x-ray	2.55	A;B;C	p49759;p49759;p49759	484;484;484	;;	150..478;150..478;150..478
6i82	pdb	Crystal structure of partially phosphorylated RET V804M tyrosine kinase domain complexed with PDD00018412	x-ray	2.05	A;B	p07949;p07949	1114;1114	;	699..1005;699..1005
6i83	pdb	Crystal structure of phosphorylated RET V804M tyrosine kinase domain complexed with PDD00018366	x-ray	1.88	A	p07949	1114		699..1005
6i8z	pdb	Crystal structure of PTK2 in complex with BI-4464.	x-ray	1.99	A	q05397	1052		409..693
6i99	pdb	Bone Marrow Tyrosine Kinase in Chromosome X in complex with a newly designed covalent inhibitor JS24	x-ray	2.001	A;B	p51813;p51813	675;675	;	396..664;396..664
6ib0	pdb	The structure of MKK7 in complex with the covalent 4-amino-pyrazolopyrimidine 3a	x-ray	2.6	A	o14733	419		113..384
6ib2	pdb	The structure of MKK7 in complex with the covalent 4-amino-pyrazolopyrimidine 4a	x-ray	2.1	A	o14733	419		113..384
6ig8	pdb	Crystal structure of CSF-1R kinase domain with a small molecular inhibitor, JTE-952	x-ray	1.8	A	p07333	972		551..909
6ig9	pdb	Tra1 subunit from Saccharomyces cerevisiae SAGA complex	em	4.6	T	p38811	3744		3307..3703
6il3	pdb	Crystal structure of the FLT3 kinase bound to a small molecule inhibitor	x-ray	2.5	A	p36888	993		576..941
6ilz	pdb	Crystal structure of PKCiota in complex with inhibitor	x-ray	3.261	A;C;E;G	p41743;p41743;p41743;p41743	596;596;596;596	;;;	252..578;252..578;252..578;252..578
6in0	pdb	Crystal structure of EphA3 in complex with 18-Crown-6	x-ray	1.501	A	p29320	983		614..915
6in4	pdb	Crystal structure of apo DAPK1 in the presence of 18-crown-6	x-ray	1.8	A	p53355	1430		6..291
6inl	pdb	Crystal structure of CDK2 IN complex with Inhibitor CVT-313	x-ray	1.75	A	p24941	298		1..292
6iqn	pdb	Crystal structure of TrkA kinase with ligand	x-ray	2.54	A;B	p04629;p04629	796;796	;	494..779;494..779
6ise	pdb	Crystal structure of AMPPNP bound CK2 alpha from C. neoformans	x-ray	2.8	A;B	q5kf69;q5kf69	336;336	;	9..327;9..327
6isj	pdb	Crystal structure of CX-4945 bound CK2 alpha from C. neoformans	x-ray	2.3	A				
6itj	pdb	Crystal structure of FGFR1 kinase domain in complex with compound 3	x-ray	1.994	A;B	p11362;p11362	822;822	;	468..754;468..754
6itt	pdb	Crystal structure of unactivated c-KIT in complex with compound	x-ray	2.103	A;B	p10721;p10721	976;976	;	564..923;564..923
6itv	pdb	Crystal structure of activated c-KIT in complex with compound	x-ray	1.881	A	p10721	976		564..923
6iuo	pdb	Crystal structure of FGFR4 kinase domain in complex with a covalent inhibitor	x-ray	2.3	A	p22455	802		458..743
6iup	pdb	Crystal structure of FGFR4 kinase domain in complex with compound 5	x-ray	2	A	p22455	802		458..743
6iy9	pdb	"Crystal structure of aminoglycoside 7""-phoshotransferase-Ia (APH(7"")-Ia/HYG) from Streptomyces hygroscopicus complexed with hygromycin B"	x-ray	2.4	A;B	p09979;p09979	332;332	;	42..294;42..294
6j5l	pdb	Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 10e	x-ray	2.3	A	p04629	796		494..779
6j5t	pdb	Reconstitution and structure of a plant NLR resistosome conferring immunity	em	3.4	A;B;D;E;H;I;J;K;M;N	o49839;q9svy5;o49839;q9svy5;q9svy5;o49839;o49839;q9svy5;o49839;q9svy5	426;351;426;351;351;426;426;351;426;351	;;;;;;;;;	65..370;42..340;65..370;42..340;42..340;65..370;65..370;42..340;65..370;42..340
6j5u	pdb	Ligand-triggered allosteric ADP release primes a plant NLR complex	em	3.9	B;C	q9svy5;o49839	351;426	;	42..340;65..370
6j5v	pdb	Ligand-triggered allosteric ADP release primes a plant NLR complex	em	4.25	B;C	q9svy5;o49839	351;426	;	42..340;65..370
6j5w	pdb	Ligand-triggered allosteric ADP release primes a plant NLR complex	em	3.7	B	q9svy5	351		42..340
6j6i	pdb	Reconstitution and structure of a plant NLR resistosome conferring immunity	em	3.7	A;B	o49839;q9svy5	426;351	;	65..370;42..340
6j6m	pdb	Co-crystal structure of BTK kinase domain with Zanubrutinib	x-ray	1.25	A	q06187	659		382..648
6jgm	pdb	Crystal structure of CDK2 IN complex with Inhibitor NU-6140	x-ray	2.3	A	p24941	298		1..292
6jk8	pdb	Cryo-EM structure of the full-length human IGF-1R in complex with insulin	em	5	A;B	p08069;p08069	1367;1367	;	970..1264;970..1264
6jkk	pdb	Crystal structure of BubR1 kinase domain	x-ray	1.85	A	a1z6i7	1460		1172..1439
6jkm	pdb	Crystal structure of BubR1 kinase domain	x-ray	1.95	A	a1z6i7	1460		1172..1439
6jlr	pdb	Crystal structure of wild type MNK2 in complex with inhibitor	x-ray	2.901	A	q9hbh9	465		87..395
6jmf	pdb	Crystal structure of human tyrosine-protein kinase Fes/Fps in complex with compound 4	x-ray	2	A	p07332	822		549..818
6joi	pdb	Crystal structure of PDGFRA T674I in complex with crenolanib by co-crystallization	x-ray	3.1	A	p16234	1089		566..947
6joj	pdb	Crystal structure of PDGFRA T674I in complex with crenolanib by soaking	x-ray	2.6	A	p16234	1089		566..947
6jok	pdb	Crystal structure of PDGFRA in complex with sunitinib by soaking	x-ray	3.8	A	p16234	1089		566..947
6jol	pdb	Crystal structure of PDGFRA in complex with imatinib by co-crystallization	x-ray	1.9	A	p16234	1089		566..947
6jpe	pdb	Crystal structure of FGFR4 kinase domain with irreversible inhibitor 1	x-ray	1.601	A	p22455	802		458..743
6jpj	pdb	Crystal structure of FGF401 in complex of FGFR4	x-ray	2.638	A	p22455	802		458..743
6jqr	pdb	Crystal structure of FLT3 in complex with gilteritinib	x-ray	2.2	A	p36888	993		576..941
6jrj	pdb	The structure of co-crystals of 8r-B-EGFR T790M/C797S complex	x-ray	2.943	A	p00533	1210		708..1003
6jrk	pdb	The structure of co-crystals of 8r-B-EGFR WT complex	x-ray	2.796	A	p00533	1210		708..1003
6jrx	pdb	EGFR T790M/C797S in complex with compound 6i	x-ray	2.201	A	p00533	1210		708..1003
6jut	pdb	Crystal structure of ZAK in complex with compound 6k	x-ray	2.1	A	q9nyl2	800		8..260
6juu	pdb	Crystal structure of ZAK in complex with compound 6r	x-ray	1.903	A	q9nyl2	800		8..260
6jux	pdb	Crystal structure of human ALK2 kinase domain with R206H mutation in complex with RK-71807	x-ray	1.75	A	q04771	509		186..496
6jwa	pdb	Crystal structure of CK2a1 with 5-iodotubercidin	x-ray	1.781	A	p68400	391		5..328
6jwl	pdb	Crystal structure of EGFR 696-1022 L858R in complex with AZD9291	x-ray	2.551	A	p00533	1210		708..1003
6jx0	pdb	Crystal structure of EGFR 696-1022 T790M in complex with AZD9291 prepared by co-crystallization	x-ray	2.53	A	p00533	1210		708..1003
6jx4	pdb	Crystal structure of EGFR 696-1022 T790M in complex with AZD9291 prepared by soaking	x-ray	2.531	A	p00533	1210		708..1003
6jxa	pdb	Tel1 kinase compact monomer	em	4.3	A	p38110	2787		2362..2710
6jxc	pdb	Tel1 kinase butterfly symmetric dimer	em	4.1	A	p38110	2787		2362..2710
6jxt	pdb	Crystal structure of EGFR 696-1022 WT in complex with AZD9291 prepared by cocrystallization	x-ray	2.307	A	p00533	1210		708..1003
6jz0	pdb	Crystal structure of EGFR kinase domain in complex with compound 78	x-ray	2.86	A	p00533	1210		708..1003
6k0j	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor	x-ray	2.352	A	q92630	601		212..543
6k3l	pdb	Crystal structure of CX-4945 bound Cka1 from C. neoformans	x-ray	2.09	B	j9vnh4	338		9..327
6k74	pdb	Crystal structure of AMPPNP bound Ck1a alpha from C. neoformans	x-ray	2.28	A				
6k77	pdb	Crystal structure of AMPPNP bound Ck1a alpha from C. neoformans	x-ray	2.4	A				
6k9k	pdb	Monomeric human ATM (Ataxia telangiectasia mutated) kinase	em	7.82	A	q13315	3056		2623..2974
6k9l	pdb	4.27 Angstrom resolution cryo-EM structure of human dimeric ATM kinase	em	4.27	A;B	q13315;q13315	3056;3056	;	2623..2974;2623..2974
6ka4	pdb	Cryo-EM structure of the AtMLKL3 tetramer	em	3.4	A;B;C;D	q9lmn2;q9lmn2;q9lmn2;q9lmn2	1025;1025;1025;1025	;;;	551..839;551..839;551..839;551..839
6khd	pdb	Crystal structure of CLK1 in complex with CX-4945	x-ray	2.7	A;B;C	p49759;p49759;p49759	484;484;484	;;	150..478;150..478;150..478
6khe	pdb	Crystal structure of CLK2 in complex with CX-4945	x-ray	2.8	A	p49760	499		150..488
6khf	pdb	Crystal structure of CLK3 in complex with CX-4945	x-ray	2.598	A	p49761	490		145..479
6kla	pdb	Crystal structure of human c-KIT kinase domain in complex with compound 15a	x-ray	2.109	A	p10721	976		564..923
6kmh	pdb	The crystal structure of CASK/Mint1 complex	x-ray	2.4	A;B	o14936;o14936	926;926	;	7..292;7..292
6ko6	pdb	Crystal structure of AMPPNP bound Cka1 from C. neoformans	x-ray	2.4	B	j9vnh4	338		9..327
6kyq	pdb	Crystal structure of DCLK1 Autoinhibited Kinase Domain	x-ray	2.141	A;B	o15075;o15075	740;740	;	381..656;381..656
6kyr	pdb	Crystal structure of DCLK1 mutant (P675L) Autoinhibited Kinase Domain	x-ray	2.206	A;B	o15075;o15075	740;740	;	381..656;381..656
6kzc	pdb	crystal structure of TRKc in complex with 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methyl-N-(3-((4- methylpiperazin-1-yl)methyl)-5- (trifluoromethyl)phenyl)benzamide	x-ray	2	A	q16288	839		514..824
6kzd	pdb	Crystal structure of TRKc in complex with 3-((6-(4-aminophenyl)imidazo[1,2-a]pyrazin-3-yl)ethynyl)- N-(3-isopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-2- methylbenzamide	x-ray	1.708	A	q16288	839		514..824
6kzi	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with thioridazine derivatives	x-ray	2.8	A	p11309	313		36..296
6l11	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives	x-ray	2.05	A	p11309	313		36..296
6l12	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives	x-ray	1.87	A	p11309	313		36..296
6l13	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives	x-ray	2.24	A	p11309	313		36..296
6l14	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives	x-ray	1.95	A	p11309	313		36..296
6l15	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives	x-ray	2.6	A	p11309	313		36..296
6l16	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives	x-ray	2.1	A	p11309	313		36..296
6l17	pdb	Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives	x-ray	1.75	A	p11309	313		36..296
6l1z	pdb	Crystal structure of CK2a1 with hematein	x-ray	1.90821	A	p68400	391		5..328
6l20	pdb	Crystal structure of CK2a2 with hematein	x-ray	3.08735	A;D;G;J	p19784;p19784;p19784;p19784	350;350;350;350	;;;	13..330;13..330;13..330;13..330
6l21	pdb	Crystal structure of CK2a1 H160A with hematein	x-ray	2.05452	A	p68400	391		5..328
6l22	pdb	Crystal structure of CK2a1 H115Y with hematein	x-ray	2.12318	A	p68400	391		5..328
6l23	pdb	Crystal structure of CK2a1 V116I with hematein	x-ray	1.97449	A	p68400	391		5..328
6l24	pdb	Crystal structure of CK2a1 H115Y/V116I with hematein	x-ray	2.40009	A	p68400	391		5..328
6l53	pdb	Structure of SMG1	em	3.63	A	q96q15	3661		2070..2430
6l54	pdb	Structure of SMG189	em	3.43	A	q96q15	3661		2070..2430
6l8l	pdb	C-Src in complex with ibrutinib	x-ray	2.888	A;B;C;D	p00523;p00523;p00523;p00523	533;533;533;533	;;;	256..526;256..526;256..526;256..526
6lba	pdb	Cryo-EM structure of the AtMLKL2 tetramer	em	4.1	A;B;C;D	q9fgg5;q9fgg5;q9fgg5;q9fgg5	711;711;711;711	;;;	266..518;266..518;266..518;266..518
6lk5	pdb	MLKL mutant - T357ES358D	x-ray	2.5	A	q8nb16	471		213..466
6lk6	pdb	MLKL mutant - T357AS358A	x-ray	2.41	A	q8nb16	471		213..466
6ln1	pdb	A natural inhibitor of DYRK1A for treatment of diabetes mellitus	x-ray	2.699	A;B	q13627;q13627	763;763	;	147..489;147..489
6lnm	pdb	Crystal structure of CASK-CaMK in complex with Mint1-CID	x-ray	2.4	A;C;E	q62915;q62915;q62915	909;909;909	;;	7..292;7..292;7..292
6lub	pdb	Crystal Structure of EGFR(L858R/T790M/C797S) in complex with CH7233163	x-ray	2.315	A	p00533	1210		708..1003
6lud	pdb	Crystal Structure of EGFR(L858R/T790M/C797S) in complex with Osimertinib	x-ray	2.05	A	p00533	1210		708..1003
6lvk	pdb	Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative	x-ray	2.29	A;B	p21802;p21802	821;821	;	471..757;471..757
6lvl	pdb	Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative	x-ray	2.98	A;B	p21802;p21802	821;821	;	471..757;471..757
6lvm	pdb	Crystal structure of FGFR3 in complex with pyrimidine derivative	x-ray	2.53	A	p22607	806		463..748
6lxy	pdb	IRAK4 in complex with inhibitor	x-ray	2.19	A;B;D;E	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
6m0u	pdb	Structure of AhSYMRK kinase domain mutant - K625E	x-ray	2.29	A	e6yc17	926		577..869
6m11	pdb	Crystal structure of Rnase L in complex with Sunitinib	x-ray	2.46	a;b	a5h025;a5h025	743;743	;	368..584;368..584
6m12	pdb	Crystal Structure of Rnase L in complex with SU11652	x-ray	2.4	a;b	a5h025;a5h025	743;743	;	368..584;368..584
6m13	pdb	Crystal structure of Rnase L in complex with Toceranib	x-ray	2.56	a;b	a5h025;a5h025	743;743	;	368..584;368..584
6m7z	pdb	A divergent kinase lacking the glycine-rich loop regulates membrane ultrastructure of the Toxoplasma parasitophorous vacuole	x-ray	2.5	A;B;C;D;E;F	a0a7j6kd88;a0a7j6kd88;a0a7j6kd88;a0a7j6kd88;a0a7j6kd88;a0a7j6kd88	377;377;377;377;377;377	;;;;;	199..364;199..364;199..364;199..364;199..364;199..364
6m95	pdb	Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridine-2-one based p38 MAP Kinase Inhibitors by scaffold hopping: compound 1	x-ray	1.8	A	q16539	360		9..349
6m9h	pdb	JAK2 JH2 in complex with diaminopyrimidine JAK040	x-ray	1.79	A	o60674	1132		522..814,842..1119
6m9l	pdb	Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridine-2-one based p38 MAP Kinase Inhibitors by scaffold hopping - compound 10	x-ray	2.45	A	q16539	360		9..349
6mcp	pdb	L. pneumophila effector kinase LegK7 (AMP-PNP bound) in complex with human MOB1A	x-ray	2.5	A;C	q5zu83;q5zu83	930;930	;	283..466;283..466
6mcq	pdb	L. pneumophila effector kinase LegK7 in complex with human MOB1A	x-ray	2.57	A;C	q5zu83;q5zu83	930;930	;	283..466;283..466
6mep	pdb	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC3437	x-ray	2.893	A;B	q12866;q12866	999;999	;	578..872;578..872
6mib	pdb	Crystal structure of the ILK ATP-binding deficient mutant (L207W)/alpha-parvin core complex	x-ray	1.8	A	q13418	452		177..444
6mm5	pdb	Catalytic subunit of cAMP-dependent protein kinase A in complex with RyR2 peptide (2799-2810)	x-ray	1.95	E	p05132	351		28..339
6mm6	pdb	Catalytic subunit of cAMP-dependent protein kinase A in complex with RyR2 phosphorylation domain (2699-2904)	x-ray	2.39	C;E	p05132;p05132	351;351	;	28..339;28..339
6mm7	pdb	Catalytic subunit of cAMP-dependent protein kinase A in complex with RyR2 K2879A, S2813D phosphomimetic (2699-2904) crystal form 1	x-ray	1.85	A;D	p05132;p05132	351;351	;	28..339;28..339
6mm8	pdb	Catalytic subunit of cAMP-dependent protein kinase A in complex with RyR2 K2879A, S2813D phosphomimetic (2699-2904) crystal form 2	x-ray	1.85	C	p05132	351		28..339
6mnh	pdb	ULK1 Unc-51 like autophagy activating kinase in complex with inhibitor BTC	x-ray	1.73	A	o75385	1050		16..325
6mny	pdb	Crystal structure of mouse BTK kinase domain in complex with compound 9a	x-ray	2.8	A;B	p35991;p35991	659;659	;	383..648;383..648
6mob	pdb	Crystal structure of KIT1 in complex with DP2976 via co-crystallization	x-ray	1.8	A	p10721	976		564..923
6mom	pdb	Crystal structure of human Interleukin-1 receptor associated Kinase 4 (IRAK 4, CID 100300) in complex with compound NCC00371481 (BSI 107591)	x-ray	2.1	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
6mt0	pdb	Crystal structure of human Pim-1 kinase in complex with a quinazolinone-pyrrolodihydropyrrolone inhibitor	x-ray	2.2	A	p11309	313		36..296
6mul	pdb	Murine PI3K delta kinsae domain - cpd 1	x-ray	3.09	A;B	o35904;o35904	1043;1043	;	677..1032;677..1032
6mum	pdb	Murine PI3K delta kinsae domain - cpd 3	x-ray	3.06	A;B	o35904;o35904	1043;1043	;	677..1032;677..1032
6mwe	pdb	CRYSTAL STRUCTURE OF TIE2 IN COMPLEX WITH DECIPERA COMPOUND DP1919	x-ray	2.05	A;B	q02763;q02763	1124;1124	;	819..1107;819..1107
6mx8	pdb	Crystal structure of anaplastic lymphoma kinase (ALK) bound by Brigatinib	x-ray	1.96	A	q9um73	1620		1089..1381
6myn	pdb	Crystal structure of murine NF-kappaB inducing kinase (NIK) bound to inhibitor R7	x-ray	2.744	A;B	q9wul6;q9wul6	942;942	;	407..656;407..656
6mzq	pdb	TAS-120 in reversible binding mode with FGFR1	x-ray	2	A;B	p11362;p11362	822;822	;	468..754;468..754
6mzw	pdb	TAS-120 covalent complex with FGFR1	x-ray	2.2	A;B	p11362;p11362	822;822	;	468..754;468..754
6n0p	pdb	BRAF in complex with N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (LXH254)	x-ray	2.37	A;B	p15056;p15056	766;766	;	449..717;449..717
6n0q	pdb	BRAF in complex with N-(4-methyl-3-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)phenyl)-3-(trifluoromethyl)benzamide.	x-ray	2.04	A;B	p15056;p15056	766;766	;	449..717;449..717
6n33	pdb	Crystal structure of fms kinase domain with a small molecular inhibitor, PLX5622	x-ray	2.25	A	p07333	972		551..909
6n3l	pdb	Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents	x-ray	2.61	A;B	q9p2k8;q9p2k8	1649;1649	;	336..550,589..1021;336..550,589..1021
6n3n	pdb	Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents	x-ray	3.01	A	q9p2k8	1649		336..550,589..1021
6n3o	pdb	Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents	x-ray	2.4	A	q9p2k8	1649		336..550,589..1021
6n6o	pdb	Crystal structure of the human TTK in complex with an inhibitor	x-ray	2.6	A	p33981	857		516..792
6n77	pdb	Structure of the human JAK1 kinase domain with compound 15	x-ray	1.64	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6n78	pdb	Structure of the human JAK1 kinase domain with compound 21	x-ray	1.83	A	p23458	1154		565..850,873..1146
6n79	pdb	Structure of the human JAK1 kinase domain with compound 20	x-ray	2.27	A	p23458	1154		565..850,873..1146
6n7a	pdb	Structure of the human JAK1 kinase domain with compound 39	x-ray	1.33	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6n7b	pdb	Structure of the human JAK1 kinase domain with compound 38	x-ray	1.81	A	p23458	1154		565..850,873..1146
6n7c	pdb	Structure of the human JAK1 kinase domain with compound 56	x-ray	1.69	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6n7d	pdb	Structure of the human JAK1 kinase domain with compound 54	x-ray	1.78	A	p23458	1154		565..850,873..1146
6n8g	pdb	IRAK4 bound to benzoxazole compound	x-ray	2	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
6n9p	pdb	Discovery of affinity-based probes for Btk occupancy assay	x-ray	2.23	A	q06187	659		382..648
6nbs	pdb	WT ERK2 with compound 2507-8	x-ray	1.9	A	p28482	360		19..322
6ncg	pdb	Crystal Structure of Human Vaccinia-related kinase 2 (VRK-2) bound to pyridin-benzenesulfonamide inhibitor	x-ray	2.45	A;B	q86y07;q86y07	508;508	;	23..317;23..317
6nct	pdb	Structure of p110alpha/niSH2 - vector data collection	x-ray	3.35	A	p42336	1068		699..1060
6ne7	pdb	Structure of G810A mutant of RET protein tyrosine kinase domain.	x-ray	1.99	A	p07949	1114		699..1005
6nec	pdb	STRUCTURE OF RET PROTEIN TYROSINE KINASE DOMAIN IN COMPLEX WITH NINTEDANIB	x-ray	1.87	A;C	p07949;p07949	1114;1114	;	699..1005;699..1005
6nfh	pdb	BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydroxypropoxy]phenyl}amino)-5,8-dihydropteridine-6,7-dione	x-ray	1.4	A	q06187	659		382..648
6nfi	pdb	BTK in complex with inhibitor N-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyrazol-6-yl)methanesulfonamide	x-ray	2.41	A	q06187	659		382..648
6nfy	pdb	Crystal structure of nonphosphorylated, HPK1 kinase domain in complex with sunitinib in the inactive state.	x-ray	2.17	A;B	q92918;q92918	833;833	;	14..444;14..444
6nfz	pdb	Crystal structure of diphosphorylated HPK1 kinase domain in complex with sunitinib in the active state.	x-ray	2.966	A;B	q92918;q92918	833;833	;	14..444;14..444
6ng0	pdb	Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with sunitinib in the inactive state.	x-ray	2.05	A;B	q92918;q92918	833;833	;	14..444;14..444
6nja	pdb	Structure of WT RET protein tyrosine kinase domain at 1.92A resolution.	x-ray	1.92	A	p07949	1114		699..1005
6no7	pdb	Crystal Structure of the full-length wild-type PKA RIa Holoenzyme	x-ray	3.55	A;C;E;G	p17612;p17612;p17612;p17612	351;351;351;351	;;;	30..339;30..339;30..339;30..339
6no8	pdb	PIM1 in complex with Cpd9 ((R)-5-amino-N-(3-(4-aminoazepan-1-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide)	x-ray	2.377	A	p11309	313		36..296
6no9	pdb	PIM1 in complex with Cpd16 (5-amino-N-(5-((4R,5R)-4-amino-5-fluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide)	x-ray	1.712	A	p11309	313		36..296
6npe	pdb	C-abl Kinase domain with the activator(cmpd6), 2-cyano-N-(4-(3,4-dichlorophenyl)thiazol-2-yl)acetamide	x-ray	2.15	A;B	p00519;p00519	1130;1130	;	231..498;231..498
6npn	pdb	Crystal Structure of the Human vaccinia-related kinase bound to a N,N-dipropynyl-dihydropteridine-3-hydroxyindazole inhibitor	x-ray	2.2	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6npt	pdb	TRK-A IN COMPLEX WITH LIGAND 1	x-ray	2.19	A	p04629	796		494..779
6npu	pdb	C-abl Kinase domain with the activator(cmpd29), N-(1-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)acetamide	x-ray	2.33	A;B	p00519;p00519	1130;1130	;	231..498;231..498
6npv	pdb	C-abl Kinase domain with the activator(cmpd51), N-(1-(3,4-dichlorophenyl)-4-(2-hydroxyethyl)-4,5-dihydro-1H-pyrazol-3-yl)isonicotinamide	x-ray	1.86	A;B	p00519;p00519	1130;1130	;	231..498;231..498
6npy	pdb	Cryo-EM structure of NLRP3 bound to NEK7	em	3.8	B	q8tdx7	302		18..290
6npz	pdb	Crystal structure of Akt1 (aa 123-480) kinase with a bisubstrate	x-ray	2.12	A;B	;	;	;	;
6nsl	pdb	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound-6c AKA 6-((1-(4-CYANOPHENY L)-2-OXO-1,2-DIHYDRO-3-PYRIDINYL)AMINO)-N-CYCLOPROPYL-8-(M ETHYLAMINO)IMIDAZO[1,2-B]PYRIDAZINE-3-CARBOXAMIDE	x-ray	2.15	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
6nsp	pdb	TRK-A IN COMPLEX WITH LIGAND 9	x-ray	2.31	A	p04629	796		494..779
6nsq	pdb	Crystal structure of BRAF kinase domain bound to the inhibitor 2l	x-ray	3.05	A;B	p15056;p15056	766;766	;	449..717;449..717
6nss	pdb	TRK-A IN COMPLEX WITH LIGAND 6	x-ray	1.97	A	p04629	796		494..779
6nt9	pdb	Cryo-EM structure of the complex between human TBK1 and chicken STING	em	3.3	A;B	q9uhd2;q9uhd2	729;729	;	9..297;9..297
6nvg	pdb	FGFR4 complex with N-(3,5-dichloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)phenyl)acrylamide	x-ray	1.99	A	p22455	802		458..743
6nvh	pdb	FGFR4 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide	x-ray	1.9	A	p22455	802		458..743
6nvi	pdb	FGFR4 complex with N-(3-chloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-5-fluorophenyl)acrylamide	x-ray	2.117	A	p22455	802		458..743
6nvj	pdb	FGFR4 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-fluorophenyl)acrylamide	x-ray	2.3	A	p22455	802		458..743
6nvk	pdb	FGFR4 complex with BLU-554, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide	x-ray	2.3	A	p22455	802		458..743
6nvl	pdb	FGFR1 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide	x-ray	2.7	A;B;C;D	p11362;p11362;p11362;p11362	822;822;822;822	;;;	468..754;468..754;468..754;468..754
6nw2	pdb	Structure of human RIPK1 kinase domain in complex with compound 11	x-ray	2	A;B	q13546;q13546	671;671	;	6..286;6..286
6ny4	pdb	Crystal structure of JAK3 kinase domain in complex with a pyrrolopyridazine carboxamide inhibitor	x-ray	2.33	A	p52333	1124		508..788,820..1097
6nyb	pdb	Structure of a MAPK pathway complex	em	4.1	A;B	p15056;q02750	766;393	;	449..717;63..365
6nyh	pdb	Structure of human RIPK1 kinase domain in complex with GNE684	x-ray	2.1	A;B	q13546;q13546	671;671	;	6..286;6..286
6nze	pdb	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_5 AKA 4-[(2-CARBAMOYLPHEN YL)AMINO]-6-[(5-FLUOROPYRIDIN-2-YL)AMINO]-N-METHYLPYRIDINE -3-CARBOXAMIDE	x-ray	1.96	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
6nzf	pdb	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_5 AKA 4-[(2-CARBAMOYLPHEN YL)AMINO]-6-[(5-FLUOROPYRIDIN-2-YL)AMINO]-N-METHYLPYRIDINE -3-CARBOXAMIDE	x-ray	2.39	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
6nzh	pdb	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_40 AKA 6-cyclopropaneamido-4-[(2-methanesulfonylphenyl)amino]-N-methylpyridine-3-carboxamide	x-ray	2.73	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
6nzm	pdb	Brutons tyrosine kinase in complex with compound 50.	x-ray	1.72	A;D	q06187;q06187	659;659	;	382..648;382..648
6nzp	pdb	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH COMPOUND-11 AKA 6-CYCLOPROPANEAMIDO-4-{[2-METHOXY-3-(1-METHYL-1H-1,2,4-TRI AZOL-3-YL)PHENYL]AMINO}-N-(?H?)METHYLPYRIDAZINE-3-CARBOXAMIDE	x-ray	2.35	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
6nzq	pdb	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_29 AKA 6-[(5-FLUORO-4-METH YLPYRIDIN-2-YL)AMINO]-4-({2-METHOXY-3-[(PYRIDIN-2-YLMETHYL )CARBAMOYL]PHENYL}AMINO)-N-METHYLPYRIDINE-3-CARBOXAMIDE	x-ray	2.11	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
6nzr	pdb	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_12 AKA 4-[(2-methanesulfonylphenyl)amino]-N-(H3)methyl-6-[(pyridin-2- yl)amino]pyridazine-3-carboxamide	x-ray	2.56	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
6o5z	pdb	Crystal Structure of the human MLKL pseudokinase domain bound to compound 2	x-ray	2.285	A;B	q8nb16;q8nb16	471;471	;	213..466;213..466
6o6q	pdb	Crystal structure of Cka1p, a casein kinase 2 alpha ortholog from Candida albicans	x-ray	2.7	A;B	a0a1d8pua2;a0a1d8pua2	335;335	;	10..331;10..331
6o8b	pdb	Crystal structure of STING CTD in complex with TBK1	x-ray	3.4	A;B	q9uhd2;q9uhd2	729;729	;	9..297;9..297
6o8c	pdb	Crystal structure of STING CTT in complex with TBK1	x-ray	3.17	A;B	q9wun2;q9wun2	729;729	;	9..297;9..297
6o8i	pdb	BTK In Complex With Inhibitor	x-ray	1.42	A	q06187	659		382..648
6o8u	pdb	Crystal structure of IRAK4 in complex with compound 23	x-ray	1.8	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
6o94	pdb	Structure of the IRAK4 kinase domain with compound 17	x-ray	1.98	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
6o95	pdb	Structure of the IRAK4 kinase domain with compound 41	x-ray	1.77	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
6o9d	pdb	Structure of the IRAK4 kinase domain with compound 5	x-ray	2.51	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
6o9l	pdb	Human holo-PIC in the closed state	em	7.2	8	p50613	346		8..299
6oac	pdb	PQR530 [(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine] bound to the PI3Ka catalytic subunit p110alpha	x-ray	3.15	A	p42336	1068		699..1060
6oav	pdb	JAK2 JH2 in complex with JAK146	x-ray	1.939	A	o60674	1132		522..814,842..1119
6obb	pdb	JAK2 JH2 in complex with JAK170	x-ray	1.904	A	o60674	1132		522..814,842..1119
6obf	pdb	JAK2 JH2 in complex with JAK179	x-ray	1.71	A	o60674	1132		522..814,842..1119
6obl	pdb	JAK2 JH2 in complex with JAK168	x-ray	2.061	A	o60674	1132		522..814,842..1119
6occ	pdb	JAK2 JH2 in complex with JAK190	x-ray	2.03	A	o60674	1132		522..814,842..1119
6oco	pdb	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 6	x-ray	2.58	A	o00329	1044		678..1033
6ocq	pdb	Crystal structure of RIP1 kinase in complex with a pyrrolidine	x-ray	2.793	A;B	q13546;q13546	671;671	;	6..286;6..286
6ocu	pdb	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 29	x-ray	2.77	A	o00329	1044		678..1033
6ohd	pdb	P38 in complex with T-3220137	x-ray	2.5	A	q16539	360		9..349
6oid	pdb	Redox Regulation of FN3K from Arabidopsis thaliana	x-ray	2.365	A;B	q9lew8;q9lew8	326;326	;	32..317;32..317
6oko	pdb	Crystal structure of mRIPK3 complexed with N-(3-fluoro-4-{1H-pyrrolo[2,3-b]pyridin-4-yloxy}phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide	x-ray	2.1	A;B	q9qzl0;q9qzl0	486;486	;	17..285;17..285
6ol2	pdb	Crystallography of novel WNK1 and WNK3 inhibitors discovered from high-throughput-screening	x-ray	2.1	A	q9jih7	2126		226..480
6omu	pdb	Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinib	x-ray	1.41	A	q06187	659		382..648
6op9	pdb	HER3 pseudokinase domain bound to bosutinib	x-ray	2.501	A	p21860	1342		706..977
6opg	pdb	phosphorylated ERK2 with AMP-PNP	x-ray	2.9	A	p28482	360		19..322
6oph	pdb	phosphorylated ERK2 with GDC-0994	x-ray	2.4	A	p28482	360		19..322
6opi	pdb	phosphorylated ERK2 with SCH-CPD336	x-ray	3	A	p28482	360		19..322
6opk	pdb	Phosphorylated ERK2 with Vertex-11e	x-ray	2.54	A	p63086	358		17..320
6oqi	pdb	CDK2 in complex with Cpd14 (5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine)	x-ray	2	A	p24941	298		1..292
6oql	pdb	CDK6 in complex with Cpd13 (R)-5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine	x-ray	2.707	A	q00534	326		9..303
6oqo	pdb	CDK6 in complex with Cpd24 N-(5-(6-ethyl-2,6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)pyrimidin-2-amine	x-ray	1.977	A	q00534	326		9..303
6ot6	pdb	Rat ERK2 D319N	x-ray	1.65	A	p63086	358		17..320
6ots	pdb	Rat ERK2 E320K	x-ray	2.1	A	p63086	358		17..320
6ova	pdb	Crystal Structure of TYK2 with novel pyrrolidinone inhibitor	x-ray	2.5	A	p29597	1187		576..879,887..1166
6oyt	pdb	ASK1 kinase domain in complex with GS-4997	x-ray	2.824	A;B;C;D	q99683;q99683;q99683;q99683	1374;1374;1374;1374	;;;	685..939;685..939;685..939;685..939
6oyw	pdb	ASK1 kinase domain in complex with Compound 11	x-ray	2.603	A;B;C;D	q99683;q99683;q99683;q99683	1374;1374;1374;1374	;;;	685..939;685..939;685..939;685..939
6p1d	pdb	Crystal structure of EGFR with mutant-selective dihydrodibenzodiazepinone allosteric inhibitor	x-ray	2.4	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
6p1l	pdb	Crystal structure of EGFR in complex with EAI045	x-ray	2.8	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
6p3d	pdb	The co-crystal structure of BRAF(V600E) with ponatinib	x-ray	2.11	A	p15056	766		449..717
6p3w	pdb	Crystal structure of the Cyclin A-CDK2-ORC1 complex	x-ray	2.54	A;C	p24941;p24941	298;298	;	1..292;1..292
6p5m	pdb	Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Anti-Tumor Agent	x-ray	2.65	A;B;C;D	o75116;o75116;o75116;o75116	1388;1388;1388;1388	;;;	89..412;89..412;89..412;89..412
6p5p	pdb	Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Anti-Tumor Agent	x-ray	3.3	A;B;C;D	o75116;o75116;o75116;o75116	1388;1388;1388;1388	;;;	89..412;89..412;89..412;89..412
6p5s	pdb	HIPK2 kinase domain bound to CX-4945	x-ray	2.194	A	q9h2x6	1198		190..537
6p68	pdb	Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 22.	x-ray	2.9	A;B;C	p11362;p11362;p11362	822;822;822	;;	468..754;468..754;468..754
6p69	pdb	Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 11.	x-ray	2.2	A;B	p11362;p11362	822;822	;	468..754;468..754
6p7g	pdb	The co-crystal structure of BRAF(V600E) with PHI1	x-ray	2.65	A;B;C;D	p15056;p15056;p15056;p15056	766;766;766;766	;;;	449..717;449..717;449..717;449..717
6p8e	pdb	Crystal structure of CDK4 in complex with CyclinD1 and P27	x-ray	2.3	B	p11802	303		3..297
6p8f	pdb	Crystal structure of CDK4 in complex with CyclinD1 and P27	x-ray	2.89	B	p11802	303		3..297
6p8g	pdb	Crystal structure of CDK4 in complex with CyclinD1 and P27	x-ray	2.8	B	p11802	303		3..297
6p8h	pdb	Crystal structure of CDK4 in complex with CyclinD1 and P21	x-ray	3.19	B	p11802	303		3..297
6p8q	pdb	EGFR in complex with a dihydrodibenzodiazepinone allosteric inhibitor.	x-ray	1.9	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
6paw	pdb	Crystal structure of DAPK2 S308A Calcium/Calmodulin complex	x-ray	2.953	A;B;E;F	q9uik4;q9uik4;q9uik4;q9uik4	370;370;370;370	;;;	13..302;13..302;13..302;13..302
6pcw	pdb	Human PIM1 bound to benzothiophene inhibitor 213	x-ray	2.2	A				
6pdi	pdb	Human PIM1 bound to benzothiophene inhibitor 224	x-ray	1.85	A				
6pdj	pdb	Tyrosine-protein kinase LCK bound to Compound 11	x-ray	1.81	A	p06239	509		231..500
6pdn	pdb	Human PIM1 bound to benzothiophene inhibitor 292	x-ray	2.4	A				
6pdo	pdb	Human PIM1 bound to benzothiophene inhibitor 354	x-ray	2.4	A				
6pdp	pdb	Human PIM1 bound to benzothiophene inhibitor 379	x-ray	2.5	A				
6pjj	pdb	Human PRPF4B bound to benzothiophene inhibitor 224	x-ray	2.4	A;B;C;D	q13523;q13523;q13523;q13523	1007;1007;1007;1007	;;;	674..1005;674..1005;674..1005;674..1005
6pjx	pdb	Crystal Structure of G Protein-Coupled Receptor Kinase 5 (GRK5) in Complex with Calmodulin (CaM)	x-ray	1.96	A	p34947	590		184..537
6pk6	pdb	Human PRPF4B bound to benzothiophene inhibitor 329	x-ray	2.1	A	q13523	1007		674..1005
6pl1	pdb	TRK-A IN COMPLEX WITH LIGAND 1B	x-ray	2.03	A	p04629	796		494..779
6pl2	pdb	TRK-A IN COMPLEX WITH LIGAND 1a	x-ray	2.59	A	p04629	796		494..779
6pl3	pdb	TRK-A IN COMPLEX WITH LIGAND 2a	x-ray	3	A	p04629	796		494..779
6pl4	pdb	TRK-A IN COMPLEX WITH LIGAND 1	x-ray	2.06	A	p04629	796		494..779
6pma	pdb	TRK-A IN COMPLEX WITH LIGAND	x-ray	2.53	A	p04629	796		494..779
6pmb	pdb	TRK-A IN COMPLEX WITH LIGAND 1a	x-ray	2.81	A	p04629	796		494..779
6pmc	pdb	TRK-A IN COMPLEX WITH LIGAND 1a	x-ray	2.19	A	p04629	796		494..779
6pme	pdb	TRK-A IN COMPLEX WITH LIGAND	x-ray	3	A;B;C	p04629;p04629;p04629	796;796;796	;;	494..779;494..779;494..779
6pnx	pdb	Crystal Structure of an Asymmetric Dimer of FGF Receptor 3 Kinases Trapped in A-loop Tyrosine Transphosphorylation Reaction	x-ray	2.199	A;B	p22607;p22607	806;806	;	463..748;463..748
6pp9	pdb	Crystal structure of BRAF:MEK1 complex	x-ray	2.59	A;B	p15056;q02750	766;393	;	449..717;63..365
6pxn	pdb	Human Casein Kinase 1 delta Tau mutant (R178C)	x-ray	1.551	A;B	p48730;p48730	415;415	;	5..290;5..290
6pxo	pdb	Human Casein Kinase 1 delta (anion-free crystallization conditions)	x-ray	2	A;B	p48730;p48730	415;415	;	5..290;5..290
6pxp	pdb	Human Casein Kinase 1 delta Site 2 mutant (K171E)	x-ray	2.35	A;B	p48730;p48730	415;415	;	5..290;5..290
6pxv	pdb	Cryo-EM structure of full-length insulin receptor bound to 4 insulin. 3D refinement was focused on the extracellular region.	em	3.2	A;C	p06213;p06213	1382;1382	;	996..1290;996..1290
6pxw	pdb	Cryo-EM structure of full-length insulin receptor bound to 4 insulin. 3D refinement was focused on the top part of the receptor complex.	em	3.1	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
6pyh	pdb	Cryo-EM structure of full-length IGF1R-IGF1 complex. Only the extracellular region of the complex is resolved.	em	4.3	A;D	q60751;q60751	1373;1373	;	971..1265;971..1265
6pyr	pdb	Human PI3Kdelta in complex with Compound 2-10 ((3S)-3-benzyl-3-methyl-5-[5-(2-methylpyrimidin-5-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-1,3-dihydro-2H-indol-2-one)	x-ray	2.21	A	o00329	1044		678..1033
6pys	pdb	Human PI3Kalpha in complex with Compound 2-10 ((3S)-3-benzyl-3-methyl-5-[5-(2-methylpyrimidin-5-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-1,3-dihydro-2H-indol-2-one)	x-ray	2.19	A	p42336	1068		699..1060
6pyu	pdb	Human PI3Kdelta in complex with Compound 4-2 ((3S)-1'-(cyclopropanecarbonyl)-5-(quinoxalin-6-yl)spiro[indole-3,2'-pyrrolidin]-2(1H)-one)	x-ray	2.54	A	o00329	1044		678..1033
6q0j	pdb	Structure of a MAPK pathway complex	em	4.9	A;B;C;D	p15056;p15056;q02750;q02750	766;766;393;393	;;;	449..717;449..717;63..365;63..365
6q0k	pdb	Structure of a MAPK pathway complex	em	6.8	A;B	p15056;p15056	766;766	;	449..717;449..717
6q0t	pdb	Structure of a MAPK pathway complex	em	5.7	A;B;C	p15056;p15056;q02750	766;766;393	;;	449..717;449..717;63..365
6q2a	pdb	Trypanosoma brucei CLK1 kinase domain in complex with a covalent aminobenzimidazole inhibitor AB1	x-ray	2.6	A;B;C;D;E;F;G;H;I;J;K;L;M;N;O;P	q382u0;q382u0;q382u0;q382u0;q382u0;q382u0;q382u0;q382u0;q382u0;q382u0;q382u0;q382u0;q382u0;q382u0;q382u0;q382u0	465;465;465;465;465;465;465;465;465;465;465;465;465;465;465;465	;;;;;;;;;;;;;;;	121..455;121..455;121..455;121..455;121..455;121..455;121..455;121..455;121..455;121..455;121..455;121..455;121..455;121..455;121..455;121..455
6q38	pdb	The Crystal structure of CK2a bound to P1-C4	x-ray	1.74	A				
6q3b	pdb	CDK2 in complex with FragLite2	x-ray	1.11	A	p24941	298		1..292
6q3c	pdb	CDK2 in complex with FragLite1	x-ray	1.29	A	p24941	298		1..292
6q3f	pdb	CDK2 in complex with FragLite2	x-ray	1.18	A	p24941	298		1..292
6q48	pdb	CDK2 in complex with FragLite7	x-ray	1.03	A	p24941	298		1..292
6q49	pdb	CDK2 in complex with FragLite6	x-ray	1	A	p24941	298		1..292
6q4a	pdb	CDK2 in complex with FragLite14	x-ray	1.13	A	p24941	298		1..292
6q4b	pdb	CDK2 in complex with FragLite13	x-ray	1.12	A	p24941	298		1..292
6q4c	pdb	CDK2 in complex with FragLite16	x-ray	1.73	A	p24941	298		1..292
6q4d	pdb	CDK2 in complex with FragLite31	x-ray	1.07	A	p24941	298		1..292
6q4e	pdb	CDK2 in complex with FragLite33	x-ray	1.06	A	p24941	298		1..292
6q4f	pdb	CDK2 in complex with FragLite32	x-ray	1.21	A	p24941	298		1..292
6q4g	pdb	CDK2 in complex with FragLite37	x-ray	0.98	A	p24941	298		1..292
6q4h	pdb	CDK2 in complex with FragLite36	x-ray	1	A	p24941	298		1..292
6q4i	pdb	CDK2 in complex with FragLite35	x-ray	1.11	A	p24941	298		1..292
6q4j	pdb	CDK2 in complex with FragLite34	x-ray	1.05	A	p24941	298		1..292
6q4k	pdb	CDK2 in complex with FragLite38	x-ray	1.06	A	p24941	298		1..292
6q4q	pdb	The Crystal structure of CK2a bound to P2-C4	x-ray	1.45	A;B	;	;	;	;
6q6y	pdb	PI3K delta in complex with N(2chloro5phenylpyridin3yl)benzenesulfonamide	x-ray	2.03	A	o35904	1043		677..1032
6q73	pdb	PI3K delta in complex with N[2chloro5(3,6dihydro2Hpyran4yl)pyridin3yl]methanesulfonamide	x-ray	2.21	A	o35904	1043		677..1032
6q74	pdb	PI3K delta in complex with 1benzylN[5(3,6dihydro2Hpyran4yl)2methoxypyridin3yl]2methyl1Himidazole4sulfonamide	x-ray	2.48	A	o35904	1043		677..1032
6q7b	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL09	x-ray	1.009	A	p29317	976		605..909
6q7c	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL11	x-ray	1.049	A	p29317	976		605..909
6q7d	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL13	x-ray	0.978	A	p29317	976		605..909
6q7e	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL14	x-ray	1.059	A	p29317	976		605..909
6q7f	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL18	x-ray	1.204	A	p29317	976		605..909
6q7g	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATHA01	x-ray	1.047	A	p29317	976		605..909
6q7k	pdb	ERK2 mini-fragment binding	x-ray	1.84	A	p28482	360		19..322
6q7s	pdb	ERK2 mini-fragment binding	x-ray	1.73	A	p28482	360		19..322
6q7t	pdb	ERK2 mini-fragment binding	x-ray	1.6	A	p28482	360		19..322
6q8k	pdb	CLK1 with bound pyridoquinazoline	x-ray	2.29	A	p49759	484		150..478
6q8p	pdb	Structure of CLK1 with bound N-methyl-10-nitropyrido[3,4-g]quinazolin-2-amine	x-ray	3	A;B;C	p49759;p49759;p49759	484;484;484	;;	150..478;150..478;150..478
6qa1	pdb	ERK2 mini-fragment binding	x-ray	1.58	A	p28482	360		19..322
6qa3	pdb	ERK2 mini-fragment binding	x-ray	1.57	A	p28482	360		19..322
6qa4	pdb	ERK2 mini-fragment binding	x-ray	1.6	A	p28482	360		19..322
6qag	pdb	ERK2 mini-fragment binding	x-ray	2.07	A	p28482	360		19..322
6qah	pdb	ERK2 mini-fragment binding	x-ray	1.58	A	p28482	360		19..322
6qal	pdb	ERK2 mini-fragment binding	x-ray	1.57	A	p28482	360		19..322
6qaq	pdb	ERK2 mini-fragment binding	x-ray	1.58	A	p28482	360		19..322
6qas	pdb	Crystal structure of ULK1 in complexed with PF-03814735	x-ray	1.75	A;B	o75385;o75385	1050;1050	;	16..325;16..325
6qat	pdb	Crystal structure of ULK2 in complexed with hesperadin	x-ray	2.77	A;B;C;D	q8iyt8;q8iyt8;q8iyt8;q8iyt8	1036;1036;1036;1036	;;;	8..344;8..344;8..344;8..344
6qau	pdb	Crystal structure of ULK2 in complexed with MRT67307	x-ray	2.48	A;B;C	q8iyt8;q8iyt8;q8iyt8	1036;1036;1036	;;	8..344;8..344;8..344
6qav	pdb	Crystal structure of ULK2 in complexed with MRT68921	x-ray	2.05	A;B;C;D	q8iyt8;q8iyt8;q8iyt8;q8iyt8	1036;1036;1036;1036	;;;	8..344;8..344;8..344;8..344
6qaw	pdb	ERK2 mini-fragment binding	x-ray	1.84	A	p28482	360		19..322
6qdz	pdb	P38 alpha complex with AR117045	x-ray	1.73	A	q16539	360		9..349
6qe1	pdb	P38 alpha complex with AR117046	x-ray	1.85	A	q16539	360		9..349
6qf4	pdb	X-Ray structure of human Serine/Threonine Kinase 17B (STK17B) aka DRAK2 in complex with ADP obtained by on-chip soaking	x-ray	2.495	A	o94768	372		28..321
6qfl	pdb	Structure of the mitogen activated kinase kinase 7 active conformation	x-ray	2.2	A	o14733	419		113..384
6qfr	pdb	Structure of the mitogen activated kinase kinase 7 dfg-out conformation	x-ray	2.3	A	o14733	419		113..384
6qft	pdb	Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidin 1b	x-ray	2.7	A	o14733	419		113..384
6qg4	pdb	Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine inhibitor 1h	x-ray	2.3	A	o14733	419		113..384
6qg7	pdb	Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine 1k	x-ray	2.1	A	o14733	419		113..384
6qho	pdb	Dual specificity mitogen-activated protein kinase kinase 7 in complex with pyrazolopyrimidine 1a	x-ray	2.7	A	o14733	419		113..384
6qhr	pdb	Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine 1m	x-ray	2.52	A	o14733	419		113..384
6qj7	pdb	Difluorophenyl diacylhydrazides: Potent inhibitors of Serum- and Glucocorticoid-inducible Kinase 1 (SGK1)	x-ray	1.69	A	p17612	351		30..339
6qmo	pdb	Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289E and S308A mutations	x-ray	1.87	A	p53355	1430		6..291
6qn4	pdb	Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289E and S308E mutations	x-ray	2.5	A	p53355	1430		6..291
6qp5	pdb	Apo Human Calcium/Calmodulin-dependent kinase type 1D	x-ray	1.9	A	q8iu85	385		16..307
6qs5	pdb	Crystal Structure of maize CK2 in complex with tyrphostin AG99	x-ray	1.961	A	p28523	332		11..323
6qtg	pdb	Crystal structure of human CDK8/CYCC in complex with BI-1347	x-ray	2.7	A	p49336	464		25..341
6qtj	pdb	Crystal structure of human CDK8/CYCC in complex with BI 919811	x-ray	2.48	A	p49336	464		25..341
6qty	pdb	Non-phosphorylated human CLK1 in complex with an indole inhibitor to 1.65 Ang	x-ray	1.65	A	p49759	484		150..478
6qu2	pdb	Crystal structure of DYRK1A complexed with FC162 inhibitor	x-ray	2.9	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6qx9	pdb	Structure of a human fully-assembled precatalytic spliceosome (pre-B complex).	em	3.28	K	q13523	1007		674..1005
6qxk	pdb	Human PIM1 bound to OX0999	x-ray	2.1	B				
6qy7	pdb	Human CSNK2A1 bound to ERB-041	x-ray	2.1	A;B	p68400;p68400	391;391	;	5..328;5..328
6qy8	pdb	Human CSNK2A2 bound to ERB-041	x-ray	1.7	A;B;C;D	p19784;p19784;p19784;p19784	350;350;350;350	;;;	13..330;13..330;13..330;13..330
6qy9	pdb	Human CSNK2A2 bound to a Pyrrolo[2,3-d]pyrimidinyl inhibitor	x-ray	1.5	A	p19784	350		13..330
6qyx	pdb	p38(alpha) MAP kinase with the activation loop of ERK2	x-ray	1.66	A	d2ciu1	146		1..146
6r3d	pdb	Crystal structure of di-phosphorylated human CLK1 in complex with 4-(6,7-dichloro-1H-indol-3-yl)pyrimidin-2-amine	x-ray	1.85	A	p49759	484		150..478
6r3s	pdb	CRYSTAL STRUCTURE OF CDK8-CycC IN COMPLEX WITH COMPOUND 1	x-ray	2.19	A	p49336	464		25..341
6r49	pdb	Aurora-A in complex with shape-diverse fragment 39	x-ray	2.209	A	o14965	403		120..386
6r4a	pdb	Aurora-A in complex with shape-diverse fragment 55	x-ray	1.937	A	o14965	403		120..386
6r4b	pdb	Aurora-A in complex with shape-diverse fragment 56	x-ray	2.15	A	o14965	403		120..386
6r4c	pdb	Aurora-A in complex with shape-diverse fragment 57	x-ray	2.04	A	o14965	403		120..386
6r4d	pdb	Aurora-A in complex with shape-diverse fragment 58	x-ray	2.009	A	o14965	403		120..386
6r5f	pdb	Crystal structure of RIP1 kinase in complex with DHP77	x-ray	3.25	A;B;C;D	q13546;q13546;q13546;q13546	671;671;671;671	;;;	6..286;6..286;6..286;6..286
6r5k	pdb	Cryo-EM structure of a poly(A) RNP bound to the Pan2-Pan3 deadenylase	em	4.8	N;O	p36102;p36102	679;679	;	309..551;309..551
6r6e	pdb	Crystal structure of di-phosphorylated human CLK1 in complex with 5-(6,7-dichloro-1-methyl-1H-indol-3-yl)pyrimidin-4-amine	x-ray	2.25	A	p49759	484		150..478
6r6x	pdb	Crystal structure of di-phosphorylated human CLK1 in complex with 5-(1-methyl-1H-indol-3-yl)pyrimidin-4-amine	x-ray	2.05	A	p49759	484		150..478
6r8j	pdb	Crystal structure of di-phosphorylated human CLK1 in complex with 4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine	x-ray	1.75	A	p49759	484		150..478
6ra5	pdb	Human tnik in complex with compound 9	x-ray	2.9	A;B	q9uke5;q9uke5	1360;1360	;	24..290;24..290
6ra7	pdb	Human tnik in complex with compound 9	x-ray	1.2	A	q9uke5	1360		24..290
6raa	pdb	CLK1 Kinase domain with bound imidazopyridin inhibitor TP003	x-ray	2.1	A	p49759	484		150..478
6rb1	pdb	Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 1	x-ray	1.5	A	p68400	391		5..328
6rbd	pdb	State 1 of yeast Tsr1-TAP Rps20-Deltaloop pre-40S particles	em	3.47	l	p40160	425		95..281
6rcb	pdb	Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 14	x-ray	2.05	A	p68400	391		5..328
6rcg	pdb	Crystal structure of Casein kinase 1 delta (CK1 delta) complexed with SR3029 inhibitor	x-ray	1.4	A	p48730	415		5..290
6rch	pdb	Crystal structure of Casein kinase I isoform delta (CK1 delta) complexed with SR4133 inhibitor	x-ray	1.45	A;B	p48730;p48730	415;415	;	5..290;5..290
6rcm	pdb	Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 3	x-ray	1.7	A	p68400	391		5..328
6rct	pdb	Crystal structure of CLK3 in complex with T3-CLK	x-ray	2.32	A;B	p49761;p49761	490;490	;	145..479;145..479
6rfe	pdb	Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 4	x-ray	1.54	A	p68400	391		5..328
6rff	pdb	Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 7	x-ray	1.8	A	p68400	391		5..328
6rfi	pdb	IRAK4 IN COMPLEX WITH inhibitor	x-ray	2.31	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6rfj	pdb	IRAK4 IN COMPLEX WITH inhibitor	x-ray	2.61	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6rfo	pdb	ERK2 MAP kinase with the activation loop of p38alpha	x-ray	1.7	A	p63086	358		17..320
6rfp	pdb	ERK2 MAP kinase with mutations at Helix-G	x-ray	1.74	A	p63086	358		17..320
6rij	pdb	CDK2/cyclin A2 in complex with open-ring 5-nitrosopyrimidine inhibitor LC436	x-ray	2.2	A;C	p24941;p24941	298;298	;	1..292;1..292
6rln	pdb	Crystal structure of RIP1 kinase in complex with GSK3145095	x-ray	2.87	A;B	q13546;q13546	671;671	;	6..286;6..286
6rn8	pdb	RIP2 Kinase Catalytic Domain complex with 2(4[(1,3benzothiazol5yl)amino]6(2methylpropane2sulfonyl)quinazolin7yl)oxy)ethyl phosphate	x-ray	2.69	A;B	o43353;o43353	540;540	;	11..297;11..297
6rna	pdb	RIP2 Kinase Catalytic Domain complex with 2({4[(1,3benzothiazol5yl)amino]6(2methylpropane2sulfonyl)quinazolin7yl}oxy)ethan1ol	x-ray	2.62	A;B	o43353;o43353	540;540	;	11..297;11..297
6rq4	pdb	Inhibitor of ERK2	x-ray	1.96	A	p28482	360		19..322
6rsb	pdb	Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class	x-ray	1.8	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6rsc	pdb	Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class	x-ray	1.85	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6rsd	pdb	Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class	x-ray	1.76	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6rse	pdb	Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class	x-ray	1.8	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6rsh	pdb	Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class	x-ray	1.71	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6rsr	pdb	TBK1 in complex with compound 2	x-ray	3.15	A	q9uhd2	729		9..297
6rst	pdb	TBK1 in complex with inhibitor compound 24	x-ray	3.29	A	q9uhd2	729		9..297
6rsu	pdb	TBK1 in complex with Inhibitor compound 35	x-ray	2.75	A	q9uhd2	729		9..297
6ru6	pdb	Crystal structure of Casein Kinase I delta (CK1d) in complex with monophosphorylated p63 PAD1P peptide	x-ray	2.05	A;B	p48730;p48730	415;415	;	5..290;5..290
6ru7	pdb	Crystal structure of Casein Kinase I delta (CK1d) in complex with double phosphorylated p63 PAD2P peptide	x-ray	2.08	A;B	p48730;p48730	415;415	;	5..290;5..290
6ru8	pdb	Crystal structure of Casein Kinase I delta (CK1d) in complex with triple phosphorylated p63 PAD3P peptide	x-ray	1.92	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
6ruu	pdb	Pseudokinase domain of human IRAK3	x-ray	2.95	A;B;C	q9y616;q9y616;q9y616	596;596;596	;;	151..452;151..452;151..452
6s11	pdb	Crystal Structure of DYRK1A with small molecule inhibitor	x-ray	2.445	A;B	q13627;q13627	763;763	;	147..489;147..489
6s14	pdb	Crystal Structure of DYRK1A with small molecule inhibitor	x-ray	1.05	A	q13627	763		147..489
6s17	pdb	Crystal Structure of DYRK1A with small molecule inhibitor	x-ray	1.1	A	q13627	763		147..489
6s1b	pdb	Crystal Structure of DYRK1A with small molecule inhibitor	x-ray	1.3	A	q13627	763		147..489
6s1f	pdb	Structure of the kinase domain of human RIPK2 in complex with the inhibitor CSLP3	x-ray	3.11	A;B;C;D	o43353;o43353;o43353;o43353	540;540;540;540	;;;	11..297;11..297;11..297;11..297
6s1h	pdb	Crystal Structure of DYRK1A with small molecule inhibitor	x-ray	1.05	A	q13627	763		147..489
6s1i	pdb	Crystal Structure of DYRK1A with small molecule inhibitor	x-ray	2.38	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6s1j	pdb	Crystal Structure of DYRK1A with small molecule inhibitor	x-ray	1.408	A	q13627	763		147..489
6s73	pdb	Crystal structure of Nek7 SRS mutant bound to compound 51	x-ray	3.5	A;B;C;D	q8tdx7;q8tdx7;q8tdx7;q8tdx7	302;302;302;302	;;;	18..290;18..290;18..290;18..290
6s75	pdb	Crystal structure of Nek7 bound to compound 51	x-ray	3.3	A;B;C;D	q8tdx7;q8tdx7;q8tdx7;q8tdx7	302;302;302;302	;;;	18..290;18..290;18..290;18..290
6s76	pdb	Crystal structure of human Nek7	x-ray	3.38	A;B;C;D	q8tdx7;q8tdx7;q8tdx7;q8tdx7	302;302;302;302	;;;	18..290;18..290;18..290;18..290
6s89	pdb	Crystal Structure of EGFR-T790M/C797S in Complex with Covalent Pyrrolopyrimidine 19g	x-ray	2.701	A	p00533	1210		708..1003
6s8a	pdb	Crystal Structure of EGFR-T790M/C797S in Complex with Covalent Pyrrolopyrimidine 19h	x-ray	2.6	A	p00533	1210		708..1003
6s8f	pdb	Structure of nucleotide-bound Tel1/ATM	em	4	F;H	p38110;p38110	2787;2787	;	2362..2710;2362..2710
6s90	pdb	BTK in complex with an inhibitor	x-ray	1.82	A;B	q06187;q06187	659;659	;	382..648;382..648
6s9b	pdb	EGFR-KINASE IN COMPLEX WITH COMPOUND 1	x-ray	3.25	A	p00533	1210		708..1003
6s9c	pdb	EGFR-KINASE IN COMPLEX WITH COMPOUND 5	x-ray	2.73	A	p00533	1210		708..1003
6s9d	pdb	EGFR-KINASE IN COMPLEX WITH COMPOUND 6	x-ray	2.67	A	p00533	1210		708..1003
6s9w	pdb	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 16a	x-ray	2.3	A	p31749	480		145..459
6s9x	pdb	Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 15c	x-ray	2.6	A	p31749	480		145..459
6sb0	pdb	cryo-EM structure of mTORC1 bound to PRAS40-fused active RagA/C GTPases	em	5.5	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
6sb2	pdb	cryo-EM structure of mTORC1 bound to active RagA/C GTPases	em	6.2	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
6sd9	pdb	Crystal structure of wild-type cMET bound by foretinib	x-ray	2.35	A	p08581	1390		1079..1341
6sdc	pdb	Crystal structure of D1228V cMET bound by foretinib	x-ray	1.67	A	p08581	1390		1079..1341
6sdd	pdb	Crystal structure of D1228V cMET bound by BMS-777607	x-ray	1.93	A	p08581	1390		1079..1341
6sde	pdb	Crystal structure of wild-type cMET bound by savolitinib	x-ray	2.49	A	p08581	1390		1079..1341
6seq	pdb	Lemur tyrosine kinase 3 (LMTK3)	x-ray	2.1	A	q96q04	1460		128..426
6sfi	pdb	Crystal structure of p38 alpha in complex with compound 75 (MCP33)	x-ray	1.6	A	q16539	360		9..349
6sfj	pdb	Crystal structure of p38 alpha in complex with compound 77 (MCP41)	x-ray	1.95	A	q16539	360		9..349
6sfk	pdb	Crystal structure of p38 alpha in complex with compound 81 (MCP42)	x-ray	1.8	A	q16539	360		9..349
6sfo	pdb	MAPK14 with bound inhibitor SR-318	x-ray	1.75	A	q16539	360		9..349
6sg4	pdb	Structure of CDK2/cyclin A M246Q, S247EN	x-ray	2.43	A;C	p24941;p24941	298;298	;	1..292;1..292
6sgd	pdb	Nek2 kinase covalently bound to 2-arylamino-6-ethynylpurine inhibitor 24	x-ray	2	A	p51955	445		5..280
6sgh	pdb	Nek2 kinase covalently bound to 2-arylamino-6-ethynylpurine inhibitor 66	x-ray	3	A	p51955	445		5..280
6sgi	pdb	Nek2 kinase bound to inhibitor 96	x-ray	2.3	A	p51955	445		5..280
6sgk	pdb	Nek2 kinase bound to inhibitor 102	x-ray	2	A	p51955	445		5..280
6sk9	pdb	Nek2 bound to purine compound 51	x-ray	2	A	p51955	445		5..280
6sky	pdb	FAT and kinase domain of CtTel1	em	2.8	A;B	g0s4s9;g0s4s9	2925;2925	;	2551..2847;2551..2847
6skz	pdb	Structure of the closed conformation of CtTel1	em	3.4	A	g0s4s9	2925		2551..2847
6sl0	pdb	Complete CtTel1 dimer with C2 symmetry	em	3.7	A;B	g0s4s9;g0s4s9	2925;2925	;	2551..2847;2551..2847
6sl1	pdb	Structure of the open conformation of CtTel1	em	3.6	A	g0s4s9	2925		2551..2847
6slg	pdb	HUMAN ERK2 WITH ERK1/2 INHIBITOR, AZD0364.	x-ray	1.33	A				
6sm8	pdb	Human jak1 kinase domain in complex with inhibitor	x-ray	1.85	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6smb	pdb	Human jak1 kinase domain in complex with inhibitor	x-ray	2.04	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6snn	pdb	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with benzoic acid	x-ray	1.817	A	p25321	351		29..339
6snx	pdb	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with benzamide	x-ray	1.4	A	p25321	351		29..339
6so1	pdb	Fragment N13569a in complex with MAP kinase p38-alpha	x-ray	1.66	A	p47811	360		9..349
6so2	pdb	Fragment N13460a in complex with MAP kinase p38-alpha	x-ray	1.6	A	p47811	360		9..349
6so4	pdb	Fragment RZ132 in complex with MAP kinase p38-alpha	x-ray	1.51	A	p47811	360		9..349
6sod	pdb	Fragment N14056a in complex with MAP kinase p38-alpha	x-ray	1.87	A	p47811	360		9..349
6soi	pdb	Fragment N13788a in complex with MAP kinase p38-alpha	x-ray	1.55	A	p47811	360		9..349
6sot	pdb	Fragment N11290a in complex with MAP kinase p38-alpha	x-ray	1.54	A	p47811	360		9..349
6sou	pdb	Fragment N13565a in complex with MAP kinase p38-alpha	x-ray	1.5	A	p47811	360		9..349
6sov	pdb	Fragments KCL_615 and KCL_802 in complex with MAP kinase p38-alpha	x-ray	1.31	A	p47811	360		9..349
6sox	pdb	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 4-carbamoylbenzoic acid	x-ray	1.38	A	p25321	351		29..339
6sp9	pdb	Fragment KCL802 in complex with MAP kinase p38-alpha	x-ray	1.22	A	p47811	360		9..349
6spl	pdb	Fragment KCL615 in complex with MAP kinase p38-alpha	x-ray	1.38	A	p47811	360		9..349
6spm	pdb	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 4-(trifluoromethyl)benzoic acid	x-ray	1.37	A	p25321	351		29..339
6sps	pdb	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 4-(trifluoromethyl)benzamide	x-ray	1.65	A	p25321	351		29..339
6spu	pdb	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 3-aminobenzoic acid	x-ray	1.39	A	p25321	351		29..339
6spw	pdb	Structure of protein kinase CK2 catalytic subunit with the CK2beta-competitive bisubstrate inhibitor ARC3140	x-ray	1.599	A				
6spx	pdb	Structure of protein kinase CK2 catalytic subunit in complex with the CK2beta-competitive bisubstrate inhibitor ARC1502	x-ray	1.994	A				
6spy	pdb	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 6-(morpholin-4-yl)pyridine-3-carboxamide	x-ray	1.6	A	p25321	351		29..339
6sq1	pdb	Crystal structure of cAMP-dependent Protein Kinase A (CHO PKA) in complex with Aminofasudil	x-ray	1.49	A	p25321	351		29..339
6srh	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2117	x-ray	1.25	A;B	q04771;q04771	509;509	;	186..496;186..496
6ssb	pdb	syk in complex with compound 30	x-ray	2.08	A	p43405	635		375..627
6sui	pdb	AMICOUMACIN KINASE AMIN	x-ray	1.6	A	a8far5	335		13..305
6sul	pdb	Amicoumacin kinase AmiN in complex with AMP-PNP, Mg2+ and Ami	x-ray	1.35	A;B;C;D	a8far5;a8far5;a8far5;a8far5	335;335;335;335	;;;	13..305;13..305;13..305;13..305
6sum	pdb	Amicoumacin kinase hAmiN in complex with AMP-PNP, MG2+ and Ami	x-ray	1.35	A;B	;	;	;	;
6sun	pdb	Amicoumacin kinase hAmiN in complex with AMP-PNP, Ca2+ and Ami	x-ray	1.35	A				
6sv5	pdb	Amicoumacin kinase AmiN in complex with ATP	x-ray	2	A	a8far5	335		13..305
6syt	pdb	Structure of the SMG1-SMG8-SMG9 complex	em	3.45	A	q96q15	3661		2070..2430
6sze	pdb	RIP2 Kinase Catalytic Domain complex with 5-Amino-1-Phenylpyrazole-4-Carboxamide.	x-ray	2.94	A;B	o43353;o43353	540;540	;	11..297;11..297
6szj	pdb	RIP2 Kinase Catalytic Domain complex with 5amino1tertbutyl3(3methoxyphenyl)1H pyrazole4carboxamide.	x-ray	2.53	A;B	o43353;o43353	540;540	;	11..297;11..297
6szm	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2009	x-ray	1.42	A;B	q04771;q04771	509;509	;	186..496;186..496
6t28	pdb	Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) bound to compound 19 (CS640)	x-ray	1.55	AAA	q8iu85	385		16..307
6t29	pdb	Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) bound to compound 18 (CS587)	x-ray	1.484	AAA	q8iu85	385		16..307
6t2w	pdb	Crystal structure of the CSF1R kinase domain with a dihydropurinone inhibitor (compound 4)	x-ray	1.7	A	p07333	972		551..909
6t3b	pdb	Crystal structure of PI3Kgamma with a dihydropurinone inhibitor (compound 4)	x-ray	3.01	A	p48736	1102		728..1089
6t3c	pdb	Crystal structure of PI3Kgamma in complex with DNA-PK inhibitor AZD7648	x-ray	2.62	A	p48736	1102		728..1089
6t41	pdb	CDK8/Cyclin C in complex with N-(4-chlorobenzyl)isoquinolin-4-amine	x-ray	2.45	A	p49336	464		25..341
6t6a	pdb	Crystal structure of DYRK1A complexed with KuFal319 (compound 11)	x-ray	2.8	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6t6d	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2149	x-ray	2.56	A;B;C;D	q04771;q04771;q04771;q04771	509;509;509;509	;;;	186..496;186..496;186..496;186..496
6t6f	pdb	Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) bound to compound 8 (CS275)	x-ray	1.97	A;B	q8iu85;q8iu85	385;385	;	16..307;16..307
6t8n	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K3007	x-ray	1.77	A;B	q04771;q04771	509;509	;	186..496;186..496
6t8x	pdb	Crystal structure of MAPKAPK2 (MK2) complexed with PF-3644022 and 5-(4-bromophenyl)-N-[4-(1-piperazinyl)phenyl]-N-(2-pyridinylmethyl)-2-furancarboxamide	x-ray	2.81	A;B;C;D;E;F	p49137;p49137;p49137;p49137;p49137;p49137	400;400;400;400;400;400	;;;;;	59..369;59..369;59..369;59..369;59..369;59..369
6t9i	pdb	cryo-EM structure of transcription coactivator SAGA	em	3.9	T				
6t9j	pdb	SAGA Tra1 module	em	3.4	T	p38811	3744		3307..3703
6tb4	pdb	Structure of SAGA bound to TBP	em	3.8	L				
6tbm	pdb	Structure of SAGA bound to TBP, including Spt8 and DUB	em	20	L				
6tca	pdb	Phosphorylated p38 and MAPKAPK2 complex with inhibitor	x-ray	3.7	A;B;C;D;E;F;G;H	p49137;q16539;p49137;q16539;p49137;q16539;p49137;q16539	400;360;400;360;400;360;400;360	;;;;;;;	59..369;9..349;59..369;9..349;59..369;9..349;59..369;9..349
6tcu	pdb	Glycogen synthase kinase-3 beta (GSK3b) in complex with ligand 1	x-ray	2.14	A	p49841	420		55..377
6td3	pdb	Structure of DDB1 bound to CR8-engaged CDK12-cyclinK	x-ray	3.46	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
6te2	pdb	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the 2-aminothiazole-type inhibitor 17	x-ray	0.922	A	p19784	350		13..330
6tei	pdb	Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the 2-aminothiazole-type inhibitor 17	x-ray	1.756	A;B	p68400;p68400	391;391	;	5..328;5..328
6tew	pdb	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the 2-aminothiazole-type inhibitor 27	x-ray	1.082	A	p19784	350		13..330
6tfp	pdb	BTK in complex with LOU064, a potent and highly selective covalent inhibitor	x-ray	2	A;B;C;D;E	q06187;q06187;q06187;q06187;q06187	659;659;659;659;659	;;;;	382..648;382..648;382..648;382..648;382..648
6tfu	pdb	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 14d	x-ray	2	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
6tfv	pdb	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18b	x-ray	1.5	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
6tfw	pdb	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18d	x-ray	2	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
6tfy	pdb	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18c	x-ray	1.7	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
6tfz	pdb	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 19	x-ray	1.8	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
6tg0	pdb	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21a	x-ray	1.5	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
6tg1	pdb	Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21b	x-ray	1.6	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
6tgu	pdb	Crystal structure of human protein kinase CK2alpha'(CSNK2A2 gene product) in complex with the 2-aminothiazole-type inhibitor Cl-OH-3	x-ray	0.833	A	p19784	350		13..330
6thw	pdb	IRAK4 in complex with inhibitor	x-ray	2.44	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6thx	pdb	IRAK4 in complex with inhibitor	x-ray	1.99	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6thz	pdb	IRAK4 IN COMPLEX WITH inhibitor	x-ray	2.38	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6ti8	pdb	IRAK4 IN COMPLEX WITH inhibitor	x-ray	2.32	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
6tia	pdb	IRAK4 IN COMPLEX WITH inhibitor	x-ray	2.52	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
6tlj	pdb	Cryo-EM structure of the Anaphase-promoting complex/Cyclosome, in complex with the Mitotic checkpoint complex (APC/C-MCC) at 3.8 angstrom resolution	em	3.8	S	o60566	1050		791..984
6tll	pdb	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (tBBT)	x-ray	1.88	A	p68400	391		5..328
6tlo	pdb	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,5,6-TRIBROMOBENZOTRIAZOLE	x-ray	1.69	A	p68400	391		5..328
6tlp	pdb	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE	x-ray	1.93	A	p68400	391		5..328
6tlr	pdb	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,7-DIBROMOBENZOTRIAZOLE	x-ray	1.64	A	p68400	391		5..328
6tls	pdb	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,6-DIBROMOBENZOTRIAZOLE	x-ray	1.46	A	p68400	391		5..328
6tlu	pdb	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,5-DIBROMOBENZOTRIAZOLE	x-ray	1.81	AAA	p68400	391		5..328
6tlv	pdb	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5-BROMOBENZOTRIAZOLE	x-ray	1.67	A	p68400	391		5..328
6tlw	pdb	HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4-BROMOBENZOTRIAZOLE	x-ray	1.73	A	p68400	391		5..328
6tm5	pdb	Cryo-EM structure of the Anaphase-promoting complex/Cyclosome, in complex with the Nek2A substrate at 3.9 angstrom resolution	em	3.9	Q;S	;	;	;	;
6tn8	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound BI-9564	x-ray	1.63	A	q04771	509		186..496
6tn9	pdb	X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 16	x-ray	2.6	A	p33981	857		516..792
6tnb	pdb	X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 41	x-ray	2.65	A	p33981	857		516..792
6tnc	pdb	X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 46	x-ray	2.3	A	p33981	857		516..792
6tnd	pdb	X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 79	x-ray	2.58	A	p33981	857		516..792
6tnr	pdb	PI3K delta in complex with N[5(7{2[4(2hydroxypropan2yl)piperidin1 yl]ethoxy}1,3dihydro2benzofuran5yl)2 methoxypyridin3yl]methanesulfonamide	x-ray	1.9	A	o35904	1043		677..1032
6tns	pdb	PI3K delta in complex with 2methoxyN[2methoxy5(7{[(2R)4(oxetan3 yl)morpholin2yl]methoxy}1,3dihydro2 benzofuran5yl)pyridin3yl]ethane1 sulfonamide	x-ray	2.4	A	o35904	1043		677..1032
6tpa	pdb	CDK8/CyclinC in complex with drug ETP-50775	x-ray	2.8	A	p49336	464		25..341
6tpd	pdb	Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity	x-ray	1.99	A	o60674	1132		522..814,842..1119
6tpe	pdb	Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity	x-ray	2.87	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6tpf	pdb	Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity	x-ray	2.31	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
6tsz	pdb	The ULK4 Pseudokinase Domain Bound To ATPgammaS	x-ray	1.9	U	q96c45	1275		2..282
6tu9	pdb	The ROR1 Pseudokinase Domain Bound To Ponatinib	x-ray	1.94	A;B	q01973;q01973	937;937	;	467..757;467..757
6tua	pdb	The RYK Pseudokinase Domain	x-ray	2.38	A	p34925	607		312..596
6tw2	pdb	Re-refined crystal structure of di-phosphorylated human CLK1 in complex with a novel substituted indole inhibitor	x-ray	1.8	E	p49759	484		150..478
6ty3	pdb	FAK structure from single particle analysis of 2D crystals	em	6.32	A;B	q00944;q00944	1053;1053	;	409..698;409..698
6ty4	pdb	FAK structure with AMP-PNP from single particle analysis of 2D crystals	em	5.96	A;B	q00944;q00944	1053;1053	;	409..698;409..698
6u0k	pdb	TTBK2 kinase domain in complex with Compound 1	x-ray	1.744	A;B	q6iq55;q6iq55	1244;1244	;	17..298;17..298
6u2g	pdb	BRAF-MEK complex with AMP-PCP bound to BRAF	x-ray	2.886	A;B	q02750;p15056	393;766	;	63..365;449..717
6u2h	pdb	BRAF dimer bound to 14-3-3	x-ray	2.5	C;D	p15056;p15056	766;766	;	449..717;449..717
6u5l	pdb	Structure of human ULK4 in complex with an inhibitor	x-ray	1.75	A	q96c45	1275		2..282
6u69	pdb	Crystal structure of Yck2 from Candida albicans, apoenzyme	x-ray	2.61	A	a0a1d8pkb4	495		43..327
6u6a	pdb	Crystal structure of Yck2 from Candida albicans in complex with kinase inhibitor GW461484A	x-ray	2.45	A	a0a1d8pkb4	495		43..327
6u7c	pdb	Human GRK2 in complex with Gbetagamma subunits and CCG258747	x-ray	2.44	A	p25098	689		187..532
6uan	pdb	B-Raf:14-3-3 complex	em	3.9	B;C	p15056;p15056	766;766	;	449..717;449..717
6ubw	pdb	MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody	x-ray	2	A	p08581	1390		1079..1341
6uip	pdb	DYRK1A Kinase Domain in Complex with a 6-azaindole Derivative, GNF2133.	x-ray	3.7	A;B;C	q13627;q13627;q13627	763;763;763	;;	147..489;147..489;147..489
6ul8	pdb	RIP2 kinase catalytic domain complex with (5S,6S,8R)-2-(benzo[d]thiazol-5-yl)-6-hydroxy-4,5,6,7,8,9-hexahydro-5,8-methanopyrazolo[1,5-a][1,3]diazocine-3-carboxamide	x-ray	2.68	A;B	o43353;o43353	540;540	;	11..297;11..297
6umw	pdb	Crystal structure of hEphB1 bound with chlortetracycline	x-ray	1.982	A	p54762	984		614..915
6una	pdb	Crystal structure of inactive p38gamma	x-ray	2.554	A;B	p53778;p53778	367;367	;	18..351;18..351
6urc	pdb	Crystal structure of IRE1a in complex with compound 18	x-ray	2.2	A;B	o75460;o75460	977;977	;	571..851;571..851
6uuo	pdb	Crystal structure of BRAF kinase domain bound to the PROTAC P4B	x-ray	3.288	A;B	p15056;p15056	766;766	;	449..717;449..717
6uwy	pdb	DYRK1A bound to a harmine derivative	x-ray	2.95	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6uya	pdb	Crystal structure of Compound 19 bound to IRAK4	x-ray	1.74	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
6v2u	pdb	Crystal structure of the insect cell-expressed WT-BRAF kinase in complex with Dabrafenib	x-ray	3.78	A;B	p15056;p15056	766;766	;	449..717;449..717
6v2w	pdb	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP	x-ray	3.12	A;B	p15056;q02750	766;393	;	449..717;63..365
6v34	pdb	Crystal structure of BRAF V600E oncogenic mutant in complex with TAK-580	x-ray	3.15	A;B	p15056;p15056	766;766	;	449..717;449..717
6v5n	pdb	EGFR(T790M/V948R) in complex with LN2084	x-ray	2.4	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
6v5p	pdb	EGFR(T790M/V948R) in complex with LN2725	x-ray	2.3	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
6v66	pdb	EGFR(T790M/V948R) in complex with LN2899	x-ray	1.79	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
6v6a	pdb	Inhibitory scaffolding of the ancient MAPK, ERK7	x-ray	2.1	A;C	q2qdg8;q2qdg8	683;683	;	7..315;7..315
6v6k	pdb	EGFR(T790M/V948R) in complex with LN2057	x-ray	2.2	A;B;C;D;E;F;G;H	p00533;p00533;p00533;p00533;p00533;p00533;p00533;p00533	1210;1210;1210;1210;1210;1210;1210;1210	;;;;;;;	708..1003;708..1003;708..1003;708..1003;708..1003;708..1003;708..1003;708..1003
6v6l	pdb	Co-structure of human glycogen synthase kinase beta with 1-(6-((2-((6-amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one	x-ray	2.19	A	p49841	420		55..377
6v6o	pdb	EGFR(T790M/V948R) in complex with LN2380	x-ray	2.1	A;B;C;D;E;F;G;H	p00533;p00533;p00533;p00533;p00533;p00533;p00533;p00533	1210;1210;1210;1210;1210;1210;1210;1210	;;;;;;;	708..1003;708..1003;708..1003;708..1003;708..1003;708..1003;708..1003;708..1003
6v6q	pdb	Crystal Structure of Monophosphorylated FGF Receptor 2 isoform IIIb with PTR657	x-ray	2.46	A;B;C;D	p21802;p21802;p21802;p21802	821;821;821;821	;;;	471..757;471..757;471..757;471..757
6v9c	pdb	Crystal structure of FGFR4 kinase domain in complex with covalent inhibitor	x-ray	1.9	A	p22455	802		458..743
6vbz	pdb	Crystal structure of the rat MLKL pseudokinase domain	x-ray	2.192	A;B	d3zkp6;d3zkp6	462;462	;	198..448;198..448
6vc0	pdb	Crystal structure of the horse MLKL pseudokinase domain	x-ray	2.746	A;B;C	f6s337;f6s337;f6s337	543;543;543	;;	275..533;275..533;275..533
6vg3	pdb	Structure of unliganded, inactive PTK7 kinase domain	x-ray	1.95	A;B;C	q13308;q13308;q13308	1070;1070;1070	;;	778..1059;778..1059;778..1059
6vgl	pdb	JAK2 JH1 in complex with ruxolitinib	x-ray	1.9	A;B;C;D	o60674;o60674;o60674;o60674	1132;1132;1132;1132	;;;	522..814,842..1119;522..814,842..1119;522..814,842..1119;522..814,842..1119
6vh4	pdb	Wild type EGFR in complex with LN2380	x-ray	2.8	A	p00533	1210		708..1003
6vhg	pdb	Crystal structure of phosphorylated RET tyrosine kinase domain complexed with a pyrazolo[1,5-a]pyrimidine inhibitor	x-ray	2.303	A	p07949	1114		699..1005
6vhn	pdb	Wild type EGFR in complex with LN2057	x-ray	2.4	A	p00533	1210		708..1003
6vhp	pdb	Wild type EGFR in complex with LN2899	x-ray	3.6	A	p00533	1210		708..1003
6vn8	pdb	JAK2 JH1 in complex with baricitinib	x-ray	1.9	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6vnb	pdb	JAK2 JH1 in complex with BL2-084	x-ray	2.19	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6vnc	pdb	JAK2 JH1 in complex with BL2-096	x-ray	2.3	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6vne	pdb	JAK2 JH1 in complex with Fedratinib	x-ray	2.32	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6vnf	pdb	JAK2 JH1 in complex with MA9-086	x-ray	2.06	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6vng	pdb	JAK2 JH1 in complex with PN2-118	x-ray	2.5	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6vnh	pdb	JAK2 JH1 in complex with PN2-123	x-ray	2.4	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6vni	pdb	JAK2 JH1 in complex with PN3-115	x-ray	2.1	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6vnj	pdb	JAK2 JH1 in complex with PN4-014	x-ray	1.9	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6vnk	pdb	JAK2 JH1 in complex with PN4-073	x-ray	2	A;B;C;D	o60674;o60674;o60674;o60674	1132;1132;1132;1132	;;;	522..814,842..1119;522..814,842..1119;522..814,842..1119;522..814,842..1119
6vnl	pdb	JAK2 JH1 in complex with SG3-179	x-ray	2.4	A;B;C;D	o60674;o60674;o60674;o60674	1132;1132;1132;1132	;;;	522..814,842..1119;522..814,842..1119;522..814,842..1119;522..814,842..1119
6vnm	pdb	JAK2 JH1 in complex with SY5-103	x-ray	2.2	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6vno	pdb	Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Repeat Kinase 2 (LRRK2)	em	3.5	A	q5s007	2527		1884..2132
6vns	pdb	Crystal structure of TYK2 kinase with compound 13	x-ray	2.09	A	p29597	1187		576..879,887..1166
6vnv	pdb	Crystal structure of TYK2 kinase with compound 14	x-ray	2.15	A	p29597	1187		576..879,887..1166
6vnx	pdb	Crystal structure of TYK2 kinase with compound 19	x-ray	2.18	A	p29597	1187		576..879,887..1166
6vny	pdb	Crystal structure of TYK2 kinase with compound 10	x-ray	2.3	A	p29597	1187		576..879,887..1166
6vov	pdb	Crystal structure of Syk in complex with GS-9876	x-ray	1.95	A;B	p43405;p43405	635;635	;	375..627;375..627
6vp6	pdb	Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Repeat Kinase 2 (LRRK2)	em	3.47	A;B;C	q5s007;q5s007;q5s007	2527;2527;2527	;;	1884..2132;1884..2132;1884..2132
6vp7	pdb	Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Repeat Kinase 2 (LRRK2)	em	3.5	A	q5s007	2527		1884..2132
6vp8	pdb	Cryo-EM structure of the C-terminal half of the Parkinson's Disease-linked protein Leucine Rich Repeat Kinase 2 (LRRK2)	em	3.5	A;B	q5s007;q5s007	2527;2527	;	1884..2132;1884..2132
6vpg	pdb	TPX2 residues 7-20 fused to Aurora A residues 116-389 in complex with AMP-PNP	x-ray	2.64	A	o14965	403		120..386
6vph	pdb	TPX2 residues 7-20 fused to Aurora A residues 116-389 modified with cacodylate and in complex with AMP-PNP	x-ray	2.14	A	o14965	403		120..386
6vpi	pdb	TPX2 residues 7-20 fused to Aurora A residues 116-389 C247V + D256N + C319V triple mutant disulfide homodimer in complex with AMP-PNP	x-ray	2	A	q9ulw0	747		
6vpj	pdb	TPX2 residues 7-20 fused to Aurora A residues 116-389 C247V + C319V double mutant dephosphorylated, and in complex with AMP-PNP	x-ray	2.1	A	q9ulw0	747		
6vpl	pdb	TPX2 residues 7-20 fused to Aurora A residues 116-389 with C290 disulfide bonded to compound 7-80, and in complex with AMP-PNP	x-ray	1.86	A;B	q9ulw0;q9ulw0	747;747	;	;
6vpm	pdb	TPX2 residues 7-20 fused to Aurora A residues 116-389 with C290 disulfide bonded to compound 8-34, and in complex with AMP-PNP	x-ray	1.58	A;B	o14965;o14965	403;403	;	120..386;120..386
6vql	pdb	CRYSTAL STRUCTURE OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4-WT) COMPLEX WITH A NICOTINAMIDE INHIBITOR	x-ray	2.069	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
6vqm	pdb	Crystal Structure Analysis of human ACK1	x-ray	2.87	A;B	q07912;q07912	1038;1038	;	120..398;120..398
6vre	pdb	Structure of ASK1 bound to BIO-1772961	x-ray	2.29	A;B	q99683;q99683	1374;1374	;	685..939;685..939
6vrf	pdb	ADP bound TTBK2 kinase domain	x-ray	1.5	A;B	q6iq55;q6iq55	1244;1244	;	17..298;17..298
6vru	pdb	PIM-inhibitor complex 1	x-ray	2.07	A	p11309	313		36..296
6vrv	pdb	Discovery of SARxxxx92, a pan-PIM kinase inhibitor, efficacious in a KG1 tumor model	x-ray	1.74	A	p11309	313		36..296
6vs3	pdb	JAK2 JH1 in complex with BL2-057	x-ray	2	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6vsn	pdb	JAK2 JH1 in complex with BL2-110	x-ray	2.5	A;B;C;D	o60674;o60674;o60674;o60674	1132;1132;1132;1132	;;;	522..814,842..1119;522..814,842..1119;522..814,842..1119;522..814,842..1119
6vvc	pdb	Legionella pneumophila Lpg2603 kinase	x-ray	2.1	A	q5zsb6	434		
6vvd	pdb	Legionella pneumophila Lpg2603 kinase bound to IP6	x-ray	2.65	A;B;C	q5zsb6;q5zsb6;q5zsb6	434;434;434	;;	;;
6vve	pdb	Legionella pneumophila Lpg2603 kinase bound to IP6, Mn2+, and ADP	x-ray	1.85	A	q5zsb6	434		
6vvg	pdb	Structure of the Cydia pomonella Granulovirus kinase, PK-1	x-ray	2.01	A;B	a0a097p1p8;a0a097p1p8	279;279	;	13..277;13..277
6vxq	pdb	Bruton's tyrosine kinase in complex with compound 5	x-ray	1.4	A	q06187	659		382..648
6vxr	pdb	Structure of Maternal embryonic leucine zipper kinase bound to LDSM276	x-ray	2.1	A	q14680	651		8..308
6vxu	pdb	Structure of Human Vaccinia-related Kinase 1 (VRK1) bound to ACH471	x-ray	2	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6vzh	pdb	Structure of Human Vaccinia-related Kinase 1 (VRK1) Bound to LDSM311	x-ray	2.55	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
6vzk	pdb	Crystal structure of human CaMKII-alpha (CAMK2A)kinase domain	x-ray	2.55	A	q9uqm7	478		9..272
6w06	pdb	Bruton's tyrosine kinase in complex with compound 6	x-ray	1.55	A	q06187	659		382..648
6w07	pdb	Bruton's tyrosine kinase in complex with compound 1	x-ray	1.51	A	q06187	659		382..648
6w39	pdb	Structure of unphosphorylated IRE1 in complex with G-1749	x-ray	1.736	A;B	o75460;o75460	977;977	;	571..851;571..851
6w3a	pdb	Structure of unphosphorylated IRE1 in complex with G-7658	x-ray	2.606	A;B	o75460;o75460	977;977	;	571..851;571..851
6w3b	pdb	Structure of apo unphosphorylated IRE1	x-ray	2.57	A	o75460	977		571..851
6w3c	pdb	Structure of phosphorylated apo IRE1	x-ray	2.3	A;B;C;D	o75460;o75460;o75460;o75460	977;977;977;977	;;;	571..851;571..851;571..851;571..851
6w3e	pdb	Structure of phosphorylated IRE1 in complex with G-0701	x-ray	2.737	A;B	o75460;o75460	977;977	;	571..851;571..851
6w3k	pdb	Structure of unphosphorylated human IRE1 bound to G-9807	x-ray	2.08	A	o75460	977		571..851
6w4o	pdb	CaMKII alpha-30 Cryo-EM reconstruction	em	4.8	A;B;C;D;E;F;G;I;J;K;L;M;O	q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7	478;478;478;478;478;478;478;478;478;478;478;478;478	;;;;;;;;;;;;	9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272
6w4p	pdb	CaMKII alpha-30 Cryo-EM reconstruction - Class B	em	6.6	A;B;C;D;E;F;G;H;I;J;K;L;M	q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7;q9uqm7	478;478;478;478;478;478;478;478;478;478;478;478;478	;;;;;;;;;;;;	9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272;9..272
6w7o	pdb	Ternary complex structure - BTK cIAP compound 17	x-ray	2.17	A;B	q06187;q06187	659;659	;	382..648;382..648
6w8i	pdb	Ternary complex structure - BTK cIAP compound 15	x-ray	3.8	A;B;C	q06187;q06187;q06187	659;659;659	;;	382..648;382..648;382..648
6w8l	pdb	Crystal structure of JAK1 kinase with compound 10	x-ray	2.11	A	p23458	1154		565..850,873..1146
6w9e	pdb	Crystal Structure of Human CDK9/cyclinT1 in complex with MC180295	x-ray	3.1	A	p50750	372		12..321
6wa2	pdb	Crystal structure of EGFR(T790M/V948R) in complex with LN3753	x-ray	2.4	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
6wak	pdb	A crystal structure of EGFR(T790M/V948R) in complex with LN3754	x-ray	2.4	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
6whp	pdb	Structure of Choline kinase from Cryptococcus neoformans var. grubii serotype A	x-ray	2.25	A	j9vwy8	519		102..515
6wiw	pdb	c-Src Bound to ATP-Competitive Inhibitor I14	x-ray	2.3	A;B	p00523;p00523	533;533	;	256..526;256..526
6wjf	pdb	PKA RIIbeta holoenzyme with DnaJB1-PKAc fusion in fibrolamellar hepatoceullar carcinoma	em	7.5	A;B	p17612;p25685	351;340	;	30..339;
6wjg	pdb	PKA RIIbeta holoenzyme with DnaJB1-PKAc fusion in fibrolamellar hepatoceullar carcinoma	em	6.2	A;B	p17612;p25685	351;340	;	30..339;
6wlx	pdb	PAK4 kinase domain in complex with beta-catenin Ser675 substrate peptide	x-ray	2.2	A	o96013	591		323..578
6wly	pdb	PAK4 kinase domain in complex with LIMK1 Thr508 substrate peptide	x-ray	1.9	A	o96013	591		323..578
6wpp	pdb	HUMAN NIK IN COMPLEX WITH LIGAND COMPOUND X	x-ray	2.55	A;B	q99558;q99558	947;947	;	405..654;405..654
6wqx	pdb	Human PRPK-TPRKB complex	x-ray	2.53	C;D	q96s44;q96s44	253;253	;	36..225;36..225
6wtn	pdb	Human JAK2 JH1 domain in complex with Ruxolitinib	x-ray	1.83	A	o60674	1132		522..814,842..1119
6wto	pdb	Human JAK2 JH1 domain in complex with Baricitinib	x-ray	1.74	A	o60674	1132		522..814,842..1119
6wtp	pdb	Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 3	x-ray	2.5	A	o60674	1132		522..814,842..1119
6wtq	pdb	Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 4	x-ray	1.79968	A	o60674	1132		522..814,842..1119
6wxj	pdb	CSF1R signaling is a regulator of pathogenesis in progressive MS	x-ray	2.62	A	p07333	972		551..909
6wxn	pdb	EGFR(T790M/V948R) in complex with LN3844	x-ray	1.76	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
6x3n	pdb	Co-structure of BTK kinase domain with L-005085737 inhibitor	x-ray	1.95	A	q06187	659		382..648
6x3o	pdb	Co-structure of BTK kinase domain with L-005191930 inhibitor	x-ray	1.9	A;B	q06187;q06187	659;659	;	382..648;382..648
6x3p	pdb	Co-structure of BTK kinase domain with L-005298385 inhibitor	x-ray	1.34	A	q06187	659		382..648
6x5g	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and LRRC7 inhibitory domain	x-ray	1.85	A	q9uqm7	478		9..272
6x5q	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluA1	x-ray	2.14	A	q9uqm7	478		9..272
6x8e	pdb	Crystal structure of JAK2 with Compound 11	x-ray	1.75	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
6x8f	pdb	Crystal structure of TYK2 with Compound 11	x-ray	2.15	A;C	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
6x8g	pdb	Crystal structure of TYK2 with Compound 22	x-ray	2.21	A	p29597	1187		576..879,887..1166
6xag	pdb	Apo BRAF dimer bound to 14-3-3	x-ray	3.3	C;D	p15056;p15056	766;766	;	449..717;449..717
6xbz	pdb	Structure of the human CDK-activating kinase	em	2.8	J	p50613	346		8..299
6xd3	pdb	Structure of the human CAK in complex with THZ1	em	3.3	J	p50613	346		8..299
6xdb	pdb	Crystal structure of IRE1a in complex with G-6904	x-ray	2.45	A	o75460	977		571..851
6xdd	pdb	Crystal structure of IRE1 in complex with G-3053	x-ray	2.4	A;B	o75460;o75460	977;977	;	571..851;571..851
6xdf	pdb	Crystal structure of IRE1a in complex with G-4100	x-ray	2.54	A;B	o75460;o75460	977;977	;	571..851;571..851
6xe4	pdb	BTK Fluorocyclopropyl amide inhibitor, Compound 25	x-ray	1.6	A	q06187	659		382..648
6xfp	pdb	Crystal Structure of BRAF kinase domain bound to Belvarafenib	x-ray	2	A	p15056	766		449..717
6xi8	pdb	Yeast TFIIK (Kin28/Ccl1/Tfb3) Complex	em	3.64	A	p06242	306		6..297
6xih	pdb	Structure-guided optimization of a novel class of ASK1 inhibitors with increased sp3 character and an exquisite selectivity profile	x-ray	2.65	A;B	q99683;q99683	1374;1374	;	685..939;685..939
6xjk	pdb	JAK2 JH2 in complex with JAK067	x-ray	2.02351	A	o60674	1132		522..814,842..1119
6xka	pdb	TPX2 residues 7-20 fused to Aurora A residues 116-389 dephosphorylated, and CoAlated on C290	x-ray	2.65	A	o14965	403		120..386
6xl4	pdb	EGFR(T790M/V948R) in complex with AZD9291 and DDC4002	x-ray	2.06	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
6xlo	pdb	Crystal structure of bRaf in complex with inhibitor	x-ray	2.493	A;B	p15056;p15056	766;766	;	449..717;449..717
6xr4	pdb	Integrative in situ structure of Parkinsons disease-linked human LRRK2	em	14	A;B	q5s007;q5s007	2527;2527	;	1884..2132;1884..2132
6xr6	pdb	Abl 1b isoform active state	nmr		A	p00519	1130		231..498
6xr7	pdb	Abl isoform 1b inactive1 state	nmr		A	p00519	1130		231..498
6xrg	pdb	Abl 1b isoform inactive2 state	nmr		A	p00519	1130		231..498
6xrl	pdb	Crystal structure of human PI3K-gamma in complex with inhibitor IPI-549	x-ray	2.99	A	p48736	1102		728..1089
6xrm	pdb	Crystal structure of human PI3K-gamma in complex with Compound 4	x-ray	2.88	A	p48736	1102		728..1089
6xrn	pdb	Crystal structure of human PI3K-gamma in complex with Compound 17	x-ray	2.96	A	p48736	1102		728..1089
6xv9	pdb	Crystal structure of the kinase domain of human c-KIT in complex with a type-II inhibitor	x-ray	3.38	A;B	p10721;p10721	976;976	;	564..923;564..923
6xva	pdb	Crystal structure of the kinase domain of human c-KIT in complex with a type-II inhibitor bearing an acrylamide	x-ray	2.3	A;B	p10721;p10721	976;976	;	564..923;564..923
6xvb	pdb	Crystal structure of the kinase domain of human c-KIT with a cyclic imidate inhibitor covalently bound to Cys788	x-ray	2.15	A;B	p10721;p10721	976;976	;	564..923;564..923
6xvj	pdb	Crystal structure of the KDR (VEGFR2) kinase domain in complex with a type-II inhibitor	x-ray	1.78	A	p35968	1356		815..1160
6xvk	pdb	Crystal structure of the KDR (VEGFR2) kinase domain in complex with a type-II inhibitor bearing an acrylamide	x-ray	1.99	A	p35968	1356		815..1160
6xx6	pdb	Arabidopsis thaliana Casein Kinase 2 (CK2) alpha-1 crystal form I	x-ray	1.8492	A	q08467	409		81..399
6xx7	pdb	Arabidopsis thaliana Casein Kinase 2 (CK2) alpha-1 crystal in complex with ANP	x-ray	2.4	A	q08467	409		81..399
6xx8	pdb	Arabidopsis thaliana Casein Kinase 2 (CK2) alpha-1 crystal form II	x-ray	1.8	A;B	q08467;q08467	409;409	;	81..399;81..399
6xx9	pdb	Arabidopsis thaliana Casein Kinase 2 (CK2) alpha-1 crystal form III	x-ray	1.84	A	q08467	409		81..399
6y05	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with adenine and PKI (5-24)	x-ray	1.7	A	p25321	351		29..339
6y0a	pdb	CRYSTAL STRUCTURE OF CDK8-CycC IN COMPLEX WITH BI00690300	x-ray	2.19	A	p49336	464		25..341
6y0b	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with quinazolin-4-amine and PKI (5-24)	x-ray	1.71	A	p25321	351		29..339
6y23	pdb	DDR1 kinase autoinhibited by its juxtamembrane region	x-ray	2.58	A;B;C	q08345;q08345;q08345	913;913;913	;;	603..904;603..904;603..904
6y2o	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with 1,7-Naphthyridin-8-amine and PKI (5-24)	x-ray	2.01	A	p25321	351		29..339
6y2u	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with aminofasudil and PKI (5-24)	x-ray	1.93	A	p25321	351		29..339
6y4t	pdb	Crystal structure of p38 in complex with SR63.	x-ray	1.98	A	p47811	360		9..349
6y4u	pdb	Crystal structure of p38 in complex with SR65	x-ray	1.86	A	p47811	360		9..349
6y4v	pdb	Crystal structure of p38 in complex with SR68	x-ray	1.75	A	p47811	360		9..349
6y4w	pdb	Crystal structure of p38 in complex with SR69	x-ray	1.86	A	p47811	360		9..349
6y4x	pdb	Crystal structure of p38 in complex with SR72	x-ray	1.6	A	p47811	360		9..349
6y6f	pdb	Crystal structure of STK17B (DRAK2) in complex with PKIS43	x-ray	1.98	A	o94768	372		28..321
6y6h	pdb	Crystal structure of STK17b (DRAK2) in complex with UNC-AP-194 probe	x-ray	1.95	A	o94768	372		28..321
6y6v	pdb	p38a bound with MCP-81	x-ray	2.1	A	p47811	360		9..349
6y7c	pdb	Early cytoplasmic yeast pre-40S particle (purified with Tsr1 as bait)	em	3.8	l	p40160	425		95..281
6y7w	pdb	Fragment KCL_1337 in complex with MAP kinase p38-alpha	x-ray	1.39	A	p47811	360		9..349
6y7x	pdb	Fragment KCL_771 in complex with MAP kinase p38-alpha	x-ray	1.45	A	p47811	360		9..349
6y7y	pdb	Fragments KCL_771 and KCL_802 in complex with MAP kinase p38-alpha	x-ray	1.51	A	p47811	360		9..349
6y7z	pdb	Fragment KCL_914 in complex with MAP kinase p38-alpha	x-ray	1.35	A	p47811	360		9..349
6y80	pdb	Fragment KCL_916 in complex with MAP kinase p38-alpha	x-ray	1.24	A	p47811	360		9..349
6y81	pdb	Fragment KCL_1088 in complex with MAP kinase p38-alpha	x-ray	1.54	A	p47811	360		9..349
6y82	pdb	Fragment KCL_804 in complex with MAP kinase p38-alpha	x-ray	1.44	A	p47811	360		9..349
6y85	pdb	Fragment KCL_1410 in complex with MAP kinase p38-alpha	x-ray	1.58	A	p47811	360		9..349
6y89	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with Methyl 5-isoquinolinecarboxylate and PKI (5-24)	x-ray	1.56	A	p25321	351		29..339
6y8c	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with ATP and PKI (5-24)	x-ray	1.76	A	p25321	351		29..339
6y8h	pdb	Novel p38-alpha crystal lattice with highly exposed p38/TAB1 non-canonical PPI surface.	x-ray	1.37	A	p47811	360		9..349
6y9r	pdb	Crystal structure of GSK-3b in complex with the 1H-indazole-3-carboxamide inhibitor 2	x-ray	2.08	A	p49841	420		55..377
6y9s	pdb	Crystal structure of GSK-3b in complex with the imidazo[1,5-a]pyridine-3-carboxamide inhibitor 16	x-ray	2.03	A;B	p49841;p49841	420;420	;	55..377;55..377
6ya6	pdb	Minimal construct of Cdc7-Dbf4 bound to XL413	x-ray	1.44	A	o00311	574		46..572
6ya7	pdb	Cdc7-Dbf4 bound to an Mcm2-S40 derived bivalent substrate	x-ray	1.67	A	o00311	574		46..572
6ya8	pdb	Cdc7-Dbf4 bound to ADP-BeF3	x-ray	1.79	A	o00311	574		46..572
6yat	pdb	Crystal structure of STK4 (MST1) in complex with compound 6	x-ray	2.58	A;B	q13043;q13043	487;487	;	27..285;27..285
6ycu	pdb	Fragment KCL_K777 in complex with MAP kinase p38-alpha	x-ray	1.35	A	p47811	360		9..349
6ycw	pdb	Fragment KCL_K767 in complex with MAP kinase p38-alpha	x-ray	1.34	A	p47811	360		9..349
6yf8	pdb	DYRK1A with PST001	x-ray	3.198	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
6yfz	pdb	Crystal structure of MKK7 (MAP2K7), apo form	x-ray	1.9	A	o14733	419		113..384
6yg0	pdb	Crystal structure of S287D,T291D MKK7 (MAP2K7), apo form	x-ray	2	A	o14733	419		113..384
6yg1	pdb	Crystal structure of MKK7 (MAP2K7) in an active state, allosterically triggered by the N-terminal helix	x-ray	2.22	A;B;C	o14733;o14733;o14733	419;419;419	;;	113..384;113..384;113..384
6yg2	pdb	Crystal structure of MKK7 (MAP2K7) in complex with ibrutnib, with covalent and allosteric binding modes	x-ray	2	A	o14733	419		113..384
6yg3	pdb	Crystal structure of MKK7 (MAP2K7) covalently bound with CPT1-70-1	x-ray	2.05	A	o14733	419		113..384
6yg4	pdb	Crystal structure of MKK7 (MAP2K7) in complex with K00007	x-ray	2.3	A	o14733	419		113..384
6yg5	pdb	Crystal structure of MKK7 (MAP2K7) in complex with ASC69	x-ray	2.4	A	o14733	419		113..384
6yg6	pdb	Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor TL10-105	x-ray	2.15	A;B	o14733;o14733	419;419	;	113..384;113..384
6yg7	pdb	Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor SB1-G-23	x-ray	2.2	A;B	o14733;o14733	419;419	;	113..384;113..384
6ygn	pdb	Titin kinase and its flanking domains	x-ray	2.4	A;B	q8wz42;q8wz42	34350;34350	;	32174..32462;32174..32462
6yi8	pdb	HUMAN FGFR4 KINASE DOMAIN (447-753) IN COMPLEX WITH ROBLITINIB	x-ray	2.13	A;B	p22455;p22455	802;802	;	458..743;458..743
6yid	pdb	Crystal structure of ULK2 in complex with SBI-0206965	x-ray	2.7	A;B;C;D	q8iyt8;q8iyt8;q8iyt8;q8iyt8	1036;1036;1036;1036	;;;	8..344;8..344;8..344;8..344
6yjc	pdb	Crystal structure of p38alpha in complex with SR154	x-ray	1.74101	A	p47811	360		9..349
6yk7	pdb	Crystal structure of p38 in complex with SR43	x-ray	1.9	A	p47811	360		9..349
6ykd	pdb	Human Pim-1 kinase in complex with an inhibitor identified by virtual screening	x-ray	1.86	A	p11309	313		36..296
6ykg	pdb	Structure-based exploration of selectivity for ATM inhibitors in Huntingtons disease	x-ray	3.12	AAA	q8neb9	887		538..883
6yky	pdb	Biochemical, Cellular and Structural Characterization of Novel ERK3 Inhibitors	x-ray	2.52	A;B;C;D	q16659;q16659;q16659;q16659	721;721;721;721	;;;	12..323;12..323;12..323;12..323
6yl1	pdb	Cdk2(F80C) with Covalent Adduct TK37 at F80C	x-ray	1.66	A	p24941	298		1..292
6yl6	pdb	Cdk2(F80C)	x-ray	1.7	A	p24941	298		1..292
6ylc	pdb	Biochemical, Cellular and Structural Characterization of Novel ERK3 Inhibitors	x-ray	2.43	A;B;C;D	q16659;q16659;q16659;q16659	721;721;721;721	;;;	12..323;12..323;12..323;12..323
6ylk	pdb	Cdk2(F80C) with Covalent Adduct TK22 at F80C	x-ray	1.65	A	p24941	298		1..292
6yll	pdb	Biochemical, Cellular and Structural Characterization of Novel ERK3 Inhibitors	x-ray	2.89	A;B	q16659;q16659	721;721	;	12..323;12..323
6yna	pdb	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with Fasudil (M77, soaked)	x-ray	1.47	A	p25321	351		29..339
6ynb	pdb	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with short-chain Fasudil-derivative N-(2-aminoethyl)isoquinoline-5-sulfonamide (soaked)	x-ray	1.72	A	p25321	351		29..339
6ync	pdb	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with the methylated Fasudil-derived fragment N-methylisoquinoline-5-sulfonamide (soaked)	x-ray	1.4	A	p25321	351		29..339
6ynr	pdb	Crystal structure of the cAMP-dependent protein kinase A in complex with 1,7-Naphthyridin-8-amine (soaked) and PKI (5-24)	x-ray	1.9	A	p25321	351		29..339
6ynt	pdb	Crystal structure of the cAMP-dependent protein kinase A in complex with aminofasudil and PKI (5-24)	x-ray	1.52	A	p25321	351		29..339
6yoj	pdb	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one	x-ray	1.361	A	q05397	1052		409..693
6yot	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with N,N-dimethylisoquinoline-5-sulfonamide and PKI (5-24)	x-ray	1.96	A	p25321	351		29..339
6you	pdb	Crystal structure of the cAMP-dependent protein kinase A in complex with Pyrido[3,2-d]pyrimidin-4-amine (soaked)	x-ray	1.73	A	p25321	351		29..339
6ypg	pdb	Crystal Structure of CK2alpha with Compound 2 bound to second crystal form	x-ray	1.51	A	p68400	391		5..328
6yph	pdb	Crystal Structure of CK2alpha with Compound 2 bound	x-ray	1.67	A;B	p68400;p68400	391;391	;	5..328;5..328
6ypj	pdb	Crystal Structure of CK2alpha with Compound 1 bound	x-ray	1.64	A	p68400	391		5..328
6ypk	pdb	Crystal Structure of CK2alpha with GTP bound	x-ray	1.79	A	p68400	391		5..328
6ypn	pdb	Crystal Structure of CK2alpha with 2 molecules of ADP bound	x-ray	1.58	B	p68400	391		5..328
6ypp	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with PKI (5-24). Soaking of aminofasudil and displacing it with the fragment isoquinoline.	x-ray	1.75	A	p25321	351		29..339
6yps	pdb	Crystal structure of the cAMP-dependent protein kinase A in complex with 4-hydroxybenzamidine	x-ray	1.35	A	p25321	351		29..339
6yq1	pdb	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-(3-{[2-(2-oxo-1,2,3,4-tetrahydro-quinolin-6-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide	x-ray	1.784	A;B;C;D	q05397;q05397;q05397;q05397	1052;1052;1052;1052	;;;	409..693;409..693;409..693;409..693
6yqi	pdb	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with long-chain Fasudil-derivative N-[2-(propylamino)ethyl]isoquinoline-5-sulfonamide (soaked)	x-ray	1.42	A	p25321	351		29..339
6yqj	pdb	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with open-chain Fasudil-derivative 2-[isoquinolin-5-ylsulfonyl(propyl)amino]ethylazanium (soaked)	x-ray	1.58	A	p25321	351		29..339
6yqk	pdb	Crystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a methylisoquinoline Fasudil-derivative (soaked)	x-ray	1.67	A	p25321	351		29..339
6yr9	pdb	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide	x-ray	1.925	A;B;C;D	q05397;q05397;q05397;q05397	1052;1052;1052;1052	;;;	409..693;409..693;409..693;409..693
6yt6	pdb	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide	x-ray	1.537	A;B	q05397;q05397	1052;1052	;	409..693;409..693
6yta	pdb	CLK1 bound with imidazopyridazine (Cpd 1)	x-ray	2.3	A	p49759	484		150..478
6ytd	pdb	CLK1 V324A mutant bound with benzothiazole Tg003 (Cpd 2)	x-ray	2	A	p49759	484		150..478
6yte	pdb	CLK1 bound with benzothiazole Tg003 (Cpd 2)	x-ray	2.3	C	p49759	484		150..478
6ytg	pdb	CLK1 bound with beta-carboline KH-CARB13 (Cpd 3)	x-ray	1.95	A	p49759	484		150..478
6yti	pdb	CLK1 bound with ETH1610 (Cpd 17)	x-ray	2.4	A	p49759	484		150..478
6ytw	pdb	CLK3 bound with benzothiazole Tg003 (Cpd 2)	x-ray	2	A;B	p49761;p49761	490;490	;	145..479;145..479
6yty	pdb	CLK3 A319V mutant bound with benzothiazole Tg003 (Cpd 2)	x-ray	1.76	A	p49761	490		145..479
6yu1	pdb	CLK3 bound with beta-carboline KH-CARB13 (Cpd 3)	x-ray	1.9	a;c	p49761;p49761	490;490	;	145..479;145..479
6yul	pdb	CK2 alpha bound to Macrocycle	x-ray	2.4	AAA;GGG	p68400;p68400	391;391	;	5..328;5..328
6yum	pdb	CK2 alpha bound to unclosed Macrocycle	x-ray	2.75	AAA;GGG	p68400;p68400	391;391	;	5..328;5..328
6yvs	pdb	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 5-{4-[(Pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one	x-ray	1.81	A;B;C;D	q05397;q05397;q05397;q05397	1052;1052;1052;1052	;;;	409..693;409..693;409..693;409..693
6yvy	pdb	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide	x-ray	1.918	A;B;C;D	q05397;q05397;q05397;q05397	1052;1052;1052;1052	;;;	409..693;409..693;409..693;409..693
6yxs	pdb	Crystal structure of the apo form of choline kinase from Plasmodium falciparum	x-ray	2	A	q8im71	440		64..429
6yxt	pdb	Crystal structure of the ADP-bound form of choline kinase from Plasmodium falciparum	x-ray	2.2	A	q8im71	440		64..429
6yxv	pdb	FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-{3-[(2-phenylamino-5-trifluoromethyl-pyrimidin-4-ylamino)-methyl]-pyridin-2-yl}-methanesulfonamide	x-ray	2.298	A;B;C;D	q05397;q05397;q05397;q05397	1052;1052;1052;1052	;;;	409..693;409..693;409..693;409..693
6yz4	pdb	Crystal structure of MKK7 (MAP2K7) with ibrutinib bound at allosteric site	x-ray	1.7	A	o14733	419		113..384
6yzh	pdb	Crystal structure of P8C9 bound to CK2alpha	x-ray	1.19	A				
6z08	pdb	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with 4-Nitrophenol	x-ray	1.49	A	p25321	351		29..339
6z19	pdb	Crystal structure of P8C9 bound to CK2alpha	x-ray	1.47	B				
6z1c	pdb	Crystal structure of Arabidopsis thaliana CK2-alpha-1 in complex with TTP-22	x-ray	1.75	A	q08467	409		81..399
6z1q	pdb	MAP3K14 (NIK) in complex with DesF-3R/4076	x-ray	2.42	AAA;BBB	q99558;q99558	947;947	;	405..654;405..654
6z1t	pdb	MAP3K14 (NIK) in complex with 4S/3694	x-ray	2.31	AAA;BBB	q99558;q99558	947;947	;	405..654;405..654
6z2v	pdb	CLK3 A319V mutant bound with beta-carboline KH-CARB13 (Cpd 3)	x-ray	2.6	A	p49761	490		145..479
6z2w	pdb	Mec1-Ddc2 (F2244L mutant) in complex with Mg AMP-PNP	em	2.82	E;F	p38111;p38111	2368;2368	;	2040..2367;2040..2367
6z2x	pdb	Mec1-Ddc2 (F2244L mutant) in complex with Mg AMP-PNP (State II)	em	3.2	E;F	p38111;p38111	2368;2368	;	2040..2367;2040..2367
6z36	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2118	x-ray	1.37	A;B	q04771;q04771	509;509	;	186..496;186..496
6z3a	pdb	Mec1-Ddc2 (wild-type) in complex with AMP-PNP	em	3.8	E;F	p38111;p38111	2368;2368	;	2040..2367;2040..2367
6z3r	pdb	Structure of SMG1-8-9 kinase complex bound to UPF1-LSQ	em	2.97	A	q96q15	3661		2070..2430
6z3u	pdb	Structure of the CAK complex form Chaetomium thermophilum	x-ray	2.6	B;E	g0sfc6;g0sfc6	437;437	;	89..388;89..388
6z44	pdb	Crystal structure of the cAMP-dependent protein kinase A in complex with phenol	x-ray	1.38	A	p25321	351		29..339
6z45	pdb	CDK9-Cyclin-T1 complex bound by compound 24	x-ray	3.37	A	p50750	372		12..321
6z4b	pdb	Crystal Structure of EGFR-T790M/V948R in Complex with Osimertinib and EAI045	x-ray	2.5	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
6z4d	pdb	Crystal Structure of EGFR-T790M/V948R in Complex with Mavelertinib and EAI001	x-ray	2	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
6z4x	pdb	Structure of the CAK complex form Chaetomium thermophilum bound to ATP-gamma-S	x-ray	2.98	B;E	g0sfc6;g0sfc6	437;437	;	89..388;89..388
6z4y	pdb	Crystal structure of Aurora A (STK6) in complex with macrocycle ODS2003208	x-ray	2.25	A	o14965	403		120..386
6z4z	pdb	Crystal structure of CLK1 in complex with macrocycle ODS2004070	x-ray	2.07	A;B;C	p49759;p49759;p49759	484;484;484	;;	150..478;150..478;150..478
6z50	pdb	Crystal structure of CLK1 in complex with macrocycle ODS2003208	x-ray	1.6	A	p49759	484		150..478
6z51	pdb	Crystal structure of CLK3 in complex with macrocycle ODS2002941	x-ray	1.92	A	p49761	490		145..479
6z52	pdb	Crystal structure of CLK3 in complex with macrocycle ODS2003136	x-ray	2.12	A;B	p49761;p49761	490;490	;	145..479;145..479
6z53	pdb	Crystal structure of CLK3 in complex with macrocycle ODS2003128	x-ray	1.65	A	p49761	490		145..479
6z54	pdb	Crystal structure of CLK3 in complex with macrocycle ODS2003178	x-ray	1.73	A	p49761	490		145..479
6z55	pdb	Crystal structure of CLK3 in complex with macrocycle ODS2004070	x-ray	1.7	A;B	p49761;p49761	490;490	;	145..479;145..479
6z56	pdb	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003208	x-ray	1.9	A	q8tf76	798		474..698
6z57	pdb	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004078	x-ray	1.5	A	q8tf76	798		474..698
6z58	pdb	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003791	x-ray	1.8	A	q8tf76	798		474..698
6z59	pdb	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003816	x-ray	2	A	q8tf76	798		474..698
6z5a	pdb	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2002941	x-ray	1.55	A	q8tf76	798		474..698
6z5b	pdb	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003128	x-ray	1.9	A	q8tf76	798		474..698
6z5c	pdb	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004070	x-ray	1.75	A	q8tf76	798		474..698
6z5d	pdb	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004082	x-ray	1.75	A	q8tf76	798		474..698
6z5e	pdb	Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004093	x-ray	1.5	A	q8tf76	798		474..698
6z83	pdb	CK2 alpha bound to chemical probe SGC-CK2-1	x-ray	2.171	AAA;BBB	p68400;p68400	391;391	;	5..328;5..328
6z84	pdb	CK2 alpha bound to chemical probe SGC-CK2-1 derivative	x-ray	2.5	AAA;BBB	p68400;p68400	391;391	;	5..328;5..328
6zaa	pdb	PI3K Delta in complex with methoxy(methylsulfamoyl)pyridinylN(methylpiperidinyl)dihydrobenzoxazinecarboxamide	x-ray	2.52	A	o35904	1043		677..1032
6zac	pdb	PI3K Delta in complex with [(dimethylamino)methyldihydrobenzoxazin2methoxypyridinyl]methanesulfonamide	x-ray	2.15	A	o35904	1043		677..1032
6zad	pdb	PI3K Delta in complex with methoxymethyloxathiatetraazatetracyclodocosahexaenedione	x-ray	2.24	A	o35904	1043		677..1032
6zc0	pdb	SYK Kinase domain in complex with azabenzimidazole inhibitor 2b	x-ray	1.97	A	p43405	635		375..627
6zcp	pdb	SYK Kinase domain in complex with azabenzimidazole inhibitor 2b	x-ray	2.2	A	p43405	635		375..627
6zcq	pdb	SYK Kinase domain in complex with diamine inhibitor 5	x-ray	2.32	A	p43405	635		375..627
6zcr	pdb	SYK Kinase domain in complex with azabenzimidazole inhibitor 7	x-ray	1.73	A	p43405	635		375..627
6zcs	pdb	SYK Kinase domain in complex with azabenzimidazole inhibitor 3	x-ray	1.47	A	p43405	635		375..627
6zcu	pdb	syk in complex with 57262_SYKB-AZ13344324-2	x-ray	1.73	A	p43405	635		375..627
6zcx	pdb	SYK Kinase domain in complex with azabenzimidazole inhibitor 18	x-ray	1.66	A	p43405	635		375..627
6zcy	pdb	SYK Kinase domain in complex with diamine inhibitor 16	x-ray	1.81	A	p43405	635		375..627
6zfp	pdb	Cryo-EM structure of DNA-PKcs (State 2)	em	3.24	A	p78527	4128		3657..4049
6zgc	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound Saracatinib (AZD0530)	x-ray	2.67	A;B;C;D	q04771;q04771;q04771;q04771	509;509;509;509	;;;	186..496;186..496;186..496;186..496
6zh2	pdb	Cryo-EM structure of DNA-PKcs (State 1)	em	3.92	A	p78527	4128		3657..4049
6zh4	pdb	Cryo-EM structure of DNA-PKcs (State 3)	em	3.62	A	p78527	4128		3657..4049
6zh6	pdb	Cryo-EM structure of DNA-PKcs:Ku80ct194	em	3.93	A	p78527	4128		3657..4049
6zh8	pdb	Cryo-EM structure of DNA-PKcs:DNA	em	4.14	A	p78527	4128		3657..4049
6zha	pdb	Cryo-EM structure of DNA-PK monomer	em	3.91	A	p78527	4128		3657..4049
6zhe	pdb	Cryo-EM structure of DNA-PK dimer	em	7.24	A;F	p78527;p78527	4128;4128	;	3657..4049;3657..4049
6ziw	pdb	The IRAK3 Pseudokinase Domain Bound To ATPgammaS	x-ray	2.18	I	q9y616	596		151..452
6zjf	pdb	Crystal structure of STK17B (DRAK2) in complex with AP-229	x-ray	1.75	A	o94768	372		28..321
6zln	pdb	CLK1 bound with GW807982X (Cpd 8)	x-ray	1.7	A	p49759	484		150..478
6zn0	pdb	Crystal structure of cAMP-dependent protein kinase A (CHO PKA) in complex with isonicotinamidine	x-ray	1.59	A	p25321	351		29..339
6zqs	pdb	Crystal structure of double-phosphorylated p38alpha with ATF2(83-102)	x-ray	1.95	A	q16539	360		9..349
6zr5	pdb	Crystal structure of JNK1 in complex with ATF2(19-58)	x-ray	2.699	A;B	p45983;p45983	427;427	;	12..357;12..357
6zv6	pdb	Human RIO1(kd)-StHA late pre-40S particle, structural state B (post 18S rRNA cleavage)	em	2.9	h	q9brs2	568		181..368
6zwm	pdb	cryo-EM structure of human mTOR complex 2, overall refinement	em	3.2	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
6zwo	pdb	cryo-EM structure of human mTOR complex 2, focused on one half	em	3	B	p42345	2549		2095..2451
6zwp	pdb	p38a bound with SR348	x-ray	1.9	A	q16539	360		9..349
6zwr	pdb	p38a bound with SR92	x-ray	1.9	A	p47811	360		9..349
6zxd	pdb	Cryo-EM structure of a late human pre-40S ribosomal subunit - State F1	em	3.2	z	q9brs2	568		181..368
6zxe	pdb	Cryo-EM structure of a late human pre-40S ribosomal subunit - State F2	em	3	z	q9brs2	568		181..368
6zxf	pdb	Cryo-EM structure of a late human pre-40S ribosomal subunit - State G	em	3.7	z	q9brs2	568		181..368
6zxg	pdb	Cryo-EM structure of a late human pre-40S ribosomal subunit - State H1	em	2.6	z	q9brs2	568		181..368
6zxh	pdb	Cryo-EM structure of a late human pre-40S ribosomal subunit - State H2	em	2.7	z	q9brs2	568		181..368
7a04	pdb	Structure of human CKa1 in complex with compound b	x-ray	2.15	A;B	p35790;p35790	457;457	;	82..455;82..455
7a06	pdb	Structure of human CKa1 in complex with compound o	x-ray	1.8	A	p35790	457		82..455
7a1b	pdb	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 5,6-dibromo-1H-triazolo[4,5-b]pyridine	x-ray	1.287	A	p19784	350		13..330
7a1z	pdb	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 6-bromo-5-chloro-1H-triazolo[4,5-b]pyridine	x-ray	1.024	A	p19784	350		13..330
7a21	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2158	x-ray	2.14	A;B	q04771;q04771	509;509	;	186..496;186..496
7a22	pdb	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 5,6,7-tribromo-1H-triazolo[4,5-b]pyridine	x-ray	1.01	A	p19784	350		13..330
7a2a	pdb	Crystal Structure of EGFR-T790M/V948R in Complex with Spebrutinib and EAI001	x-ray	1.9	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
7a2h	pdb	Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 5,6,7-tribromo-1H-imidazo[4,5-b]pyridine	x-ray	1.01	A	p19784	350		13..330
7a49	pdb	Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the ATP-competitive inhibitor 6-bromo-5-chloro-1H-triazolo[4,5-b]pyridine	x-ray	2.03	A;B	p68400;p68400	391;391	;	5..328;5..328
7a4b	pdb	Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the ATP-competitive inhibitor 5,6-dibromo-1H-triazolo[4,5-b]pyridine	x-ray	2.06	A;B	p68400;p68400	391;391	;	5..328;5..328
7a4c	pdb	Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the ATP-competitive inhibitor 5,6,7-tribromo-1H-triazolo[4,5-b]pyridine	x-ray	2.502	A;B	p68400;p68400	391;391	;	5..328;5..328
7a4o	pdb	Structure of DYRK1A in complex with AMPNP	x-ray	1.9	A;B	q13627;q13627	763;763	;	147..489;147..489
7a4q	pdb	The Crystal structure of RO4613269 bound to CK2alpha	x-ray	1.42	A	p68400	391		5..328
7a4r	pdb	Structure of DYRK1A in complex with compound 1	x-ray	1.8	A;B	q13627;q13627	763;763	;	147..489;147..489
7a4s	pdb	Structure of DYRK1A in complex with compound 2	x-ray	3.1	A	q13627	763		147..489
7a4w	pdb	Structure of DYRK1A in complex with compound 3	x-ray	2.7	A;B	q13627;q13627	763;763	;	147..489;147..489
7a4z	pdb	Structure of DYRK1A in complex with compound 4	x-ray	1.9	A	q13627	763		147..489
7a51	pdb	Structure of DYRK1A in complex with compound 5	x-ray	1.9	A	q13627	763		147..489
7a52	pdb	Structure of DYRK1A in complex with compound 6	x-ray	2.1	A;B	q13627;q13627	763;763	;	147..489;147..489
7a53	pdb	Structure of DYRK1A in complex with compound 7	x-ray	2.2	A;B	q13627;q13627	763;763	;	147..489;147..489
7a55	pdb	Structure of DYRK1A in complex with compound 8	x-ray	2.2	A;B	q13627;q13627	763;763	;	147..489;147..489
7a5b	pdb	Structure of DYRK1A in complex with complex 10	x-ray	2.6	A;B	q13627;q13627	763;763	;	147..489;147..489
7a5d	pdb	Structure of DYRK1A in complex with compound 16	x-ray	1.8	A	q13627	763		147..489
7a5l	pdb	tructure of DYRK1A in complex with compound 24	x-ray	2.1	A	q13627	763		147..489
7a5n	pdb	Structure of DYRK1A in complex with compound 34	x-ray	2.3	A;B	q13627;q13627	763;763	;	147..489;147..489
7a6i	pdb	Crystal Structure of EGFR-T790M/V948R in Complex with LDC8201	x-ray	2.4	A	p00533	1210		708..1003
7a6j	pdb	Crystal Structure of EGFR-T790M/V948R in Complex with Poziotinib	x-ray	2	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
7a6k	pdb	Crystal Structure of EGFR-T790M/V948R in Complex with TAK-788	x-ray	2	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7aax	pdb	Crystal structure of MerTK kinase domain in complex with LDC1267	x-ray	1.762	A	q12866	999		578..872
7aay	pdb	Crystal structure of MerTK kinase domain in complex with Merestinib	x-ray	1.87	A	q12866	999		578..872
7aaz	pdb	Crystal structure of MerTK in complex with a type 1.5 aminopyridine inhibitor	x-ray	1.855	A	q12866	999		578..872
7ab0	pdb	Apo crystal structure of the MerTK kinase domain	x-ray	1.74	A	q12866	999		578..872
7ab1	pdb	Crystal structure of MerTK kinase domain in complex with Gilteritinib	x-ray	1.93	A	q12866	999		578..872
7ab2	pdb	Crystal structure of MerTK kinase domain in complex with UNC2025	x-ray	1.78	A	q12866	999		578..872
7ack	pdb	CDK2/cyclin A2 in complex with an imidazo[1,2-c]pyrimidin-5-one inhibitor	x-ray	1.8	A;C	p24941;p24941	298;298	;	1..292;1..292
7aei	pdb	Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series	x-ray	2.65	A	p00533	1210		708..1003
7aem	pdb	Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series	x-ray	2.65	A	p00533	1210		708..1003
7ah3	pdb	Kinase domain of cSrc in complex with a pyrazolopyrimidine	x-ray	1.95	A;B	p00523;p00523	533;533	;	256..526;256..526
7aj2	pdb	Structure of DYRK1A in complex with compound 3	x-ray	2.1	A	q13627	763		147..489
7aj4	pdb	Structure of DYRK1A in complex with compound 5	x-ray	2	A	q13627	763		147..489
7aj5	pdb	Structure of DYRK1A in complex with compound 10	x-ray	2	A	q13627	763		147..489
7aj7	pdb	Structure of DYRK1A in complex with compound 16	x-ray	2.9	A	q13627	763		147..489
7aj8	pdb	Structure of DYRK1A in complex with compound 25	x-ray	2	A	q13627	763		147..489
7aja	pdb	Structure of DYRK1A in complex with compound 28	x-ray	2.2	A	q13627	763		147..489
7ajm	pdb	Structure of DYRK1A in complex with compound 32	x-ray	2.4	A;B	q13627;q13627	763;763	;	147..489;147..489
7ajs	pdb	Structure of DYRK1A in complex with compound 33	x-ray	2.15	A;B	q13627;q13627	763;763	;	147..489;147..489
7ajv	pdb	Structure of DYRK1A in complex with compound 38	x-ray	2.1	A;B	q13627;q13627	763;763	;	147..489;147..489
7ajw	pdb	Structure of DYRK1A in complex with compound 46	x-ray	2.8	A	q13627	763		147..489
7ajy	pdb	Structure of DYRK1A in complex with compound 51	x-ray	2.2	A;B	q13627;q13627	763;763	;	147..489;147..489
7ak2	pdb	Structure of DYRK1A in complex with compound 53	x-ray	2.1	A;B	q13627;q13627	763;763	;	147..489;147..489
7ak3	pdb	CLK1 bound with CAF052	x-ray	2.5	A	p49759	484		150..478
7aka	pdb	Structure of DYRK1A in complex with compound 54	x-ray	1.9	A;B	q13627;q13627	763;763	;	147..489;147..489
7akb	pdb	Structure of DYRK1A in complex with compound 56	x-ray	2.8	A;B	q13627;q13627	763;763	;	147..489;147..489
7ake	pdb	Structure of DYRK1A in complex with compound 58	x-ray	2.3	A;B	q13627;q13627	763;763	;	147..489;147..489
7akf	pdb	Structure of DYRK2 in complex with compound 50	x-ray	2.6	A	q92630	601		212..543
7akg	pdb	Crystal structure of STK17B with bound dovitinib	x-ray	2.08	A	o94768	372		28..321
7akh	pdb	Structure of DYRK2 in complex with compound 58	x-ray	2.85	A	q92630	601		212..543
7akl	pdb	Structure of DYRK1A in complex with compound 50	x-ray	2	A	q13627	763		147..489
7akm	pdb	Crystal structure of CHK1 kinase domain in complex with ATPyS	x-ray	1.93	A;B	o14757;o14757	476;476	;	6..317;6..317
7ako	pdb	Crystal structure of CHK1 kinase domain in complex with a CLASPIN phosphopeptide	x-ray	1.8	A;B	o14757;o14757	476;476	;	6..317;6..317
7apf	pdb	Crystal structure of JAK3 in complex with FM601 (compound 10a)	x-ray	1.95	A;B	p52333;p52333	1124;1124	;	508..788,820..1097;508..788,820..1097
7apg	pdb	Crystal structure of JAK3 in complex with FM587 (compound 9a)	x-ray	2.4	A;B;C;D	p52333;p52333;p52333;p52333	1124;1124;1124;1124	;;;	508..788,820..1097;508..788,820..1097;508..788,820..1097;508..788,820..1097
7apj	pdb	Structure of autoinhibited Akt1 reveals mechanism of PIP3-mediated activation	x-ray	2.05	A				
7aqb	pdb	Crystal structure of human mitogen activated protein kinase 6 (MAPK6)	x-ray	2.25	A;B	q16659;q16659	721;721	;	12..323;12..323
7at5	pdb	Structure of protein kinase ck2 catalytic subunit (csnk2a1 gene product) in complex with the bivalent inhibitor KN2	x-ray	1.77	A;B	p68400;p68400	391;391	;	5..328;5..328
7at9	pdb	Structure of protein kinase ck2 catalytic subunit (csnk2a2 gene product) in complex with the ATP-competitive inhibitor MB002 and the alphaD-pocket ligand 3,4-dichlorophenethylamine	x-ray	1.05	A	p19784	350		13..330
7ats	pdb	The LIMK1 Kinase Domain Bound To LIJTF500127	x-ray	2.8	A	p53667	647		329..616
7atu	pdb	The LIMK1 Kinase Domain Bound To LIJTF500025	x-ray	2.8	A;B;C;D	p53667;p53667;p53667;p53667	647;647;647;647	;;;	329..616;329..616;329..616;329..616
7atv	pdb	Structure of protein kinase ck2 catalytic subunit (csnk2a2 gene product) in complex with the bivalent inhibitor KN2	x-ray	0.98	A	p19784	350		13..330
7auv	pdb	The structure of ERK2 in complex with dual inhibitor ASTX029	x-ray	1.76	A	p28482	360		19..322
7avq	pdb	Crystal structure of haspin in complex with disubstituted imidazo[1,2- b]pyridazine inhibitor (compound 12)	x-ray	1.65	A	q8tf76	798		474..698
7avx	pdb	MerTK kinase domain in complex with NPS-1034	x-ray	2.44	A;B	q12866;q12866	999;999	;	578..872;578..872
7avy	pdb	MerTK kinase domain in complex with quinazoline-based inhbitor	x-ray	2.31	A	q12866	999		578..872
7avz	pdb	MerTK kinase domain in complex with a bisaminopyrimidine inhibitor	x-ray	2.04	A	q12866	999		578..872
7aw0	pdb	MerTK kinase domain in complex with purine inhibitor	x-ray	1.893	A	q12866	999		578..872
7aw1	pdb	MerTK kinase domain in complex with a type 2 inhibitor	x-ray	1.98	A	q12866	999		578..872
7aw2	pdb	MerTK kinase domain with type 1.5 inhibitor from a DNA-encoded library	x-ray	2.1	A	q12866	999		578..872
7aw3	pdb	MerTK kinase domain with type 1 inhibitor from a DNA-encoded library	x-ray	1.99	A	q12866	999		578..872
7aw4	pdb	MerTK kinase domain with type 3 inhibitor from a DNA-encoded library	x-ray	1.98	A;B	q12866;q12866	999;999	;	578..872;578..872
7ax4	pdb	Human TYK2 pseudokinase domain (575-869) in complex with 5-(4-Fluoro-phenyl)-2-ureido-thiophene-3-carboxylic acid amide.	x-ray	2.12	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
7axt	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with isoquinoline-5-carboxylic acid and PKI (5-24)	x-ray	1.86	A	p25321	351		29..339
7axv	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with 5-isoquinolinesulfonic acid and PKI (5-24)	x-ray	1.79	A	p25321	351		29..339
7axw	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with 1-aminoisoquinoline and PKI (5-24)	x-ray	1.69	A	p25321	351		29..339
7ay9	pdb	Crystal structure of CK2 bound by compound 7	x-ray	2.25	A;B	p68400;p68400	391;391	;	5..328;5..328
7aya	pdb	Crystal structure of CK2 bound by compound 9	x-ray	2.45	A;B	p68400;p68400	391;391	;	5..328;5..328
7ayh	pdb	Crystal structure of Aurora A in complex with 7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-one derivative (compound 2c)	x-ray	2.8	A	o14965	403		120..386
7ayi	pdb	Crystal structure of Aurora A in complex with 7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-one derivative (compound 2a)	x-ray	2.86	A	o14965	403		120..386
7aym	pdb	Structure of DDR2 Kinase domain in complex with IBZ3	x-ray	2.12	A	q08345	913		603..904
7b30	pdb	MST3 in complex with compound G-5555	x-ray	2.1	A	q9y6e0	443		36..320
7b31	pdb	MST3 in complex with compound MRIA9	x-ray	1.8	A	q9y6e0	443		36..320
7b32	pdb	MST3 in complex with MRIA7	x-ray	1.75	A	q9y6e0	443		36..320
7b33	pdb	MST3 in complex with MRIA11	x-ray	1.9	A	q9y6e0	443		36..320
7b34	pdb	MST3 in complex with compound MRIA12	x-ray	2.1	A	q9y6e0	443		36..320
7b35	pdb	MST3 in complex with compound MRIA13	x-ray	2.40005	A;B	q9y6e0;q9y6e0	443;443	;	36..320;36..320
7b36	pdb	MST4 in complex with compound G-5555	x-ray	2.10681	A;C	q9p289;q9p289	416;416	;	24..320;24..320
7b3m	pdb	MEK1 in complex with compound 6	x-ray	2.3	A;B	q02750;q02750	393;393	;	63..365;63..365
7b3q	pdb	Crystal structure of c-MET bound by compound 1	x-ray	1.75	A	p08581	1390		1079..1341
7b3t	pdb	Crystal structure of c-MET bound by compound 2	x-ray	2.23	A	p08581	1390		1079..1341
7b3v	pdb	Crystal structure of c-MET bound by compound 3	x-ray	1.93	A	p08581	1390		1079..1341
7b3w	pdb	Crystal structure of c-MET bound by compound 4	x-ray	2.02	A	p08581	1390		1079..1341
7b3z	pdb	Crystal structure of c-MET bound by compound 5	x-ray	1.8	A	p08581	1390		1079..1341
7b40	pdb	Crystal structure of c-MET bound by compound 6	x-ray	1.76	A	p08581	1390		1079..1341
7b41	pdb	Crystal structure of c-MET bound by compound 7	x-ray	1.97	A	p08581	1390		1079..1341
7b42	pdb	Crystal structure of c-MET bound by compound 8	x-ray	1.8	A	p08581	1390		1079..1341
7b43	pdb	Crystal structure of c-MET bound by compound 9	x-ray	1.87	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
7b44	pdb	Crystal structure of c-MET bound by compound S1	x-ray	1.76	A	p08581	1390		1079..1341
7b55	pdb	Crystal structure of CaMKII-actinin complex bound to MES	x-ray	1.6	B	p11798	478		9..272
7b56	pdb	Crystal structure of CaMKII-actinin complex bound to AMPPNP	x-ray	1.45	B	p11798	478		9..272
7b57	pdb	Crystal structure of CaMKII-actinin complex bound to ADP	x-ray	1.95	B	p11798	478		9..272
7b5l	pdb	Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: NEDD8-CUL1-RBX1-SKP1-SKP2-CKSHS1-Cyclin A-CDK2-p27-UBE2L3~Ub~ARIH1. Transition State 1	em	3.8	L	p24941	298		1..292
7b5o	pdb	Cryo-EM structure of the human CAK bound to ICEC0942 at 2.5 Angstroms resolution	em	2.5	J	p50613	346		8..299
7b5q	pdb	Cryo-EM structure of the human CAK bound to ICEC0942 (PHENIX-OPLS3e)	em	2.5	J	p50613	346		8..299
7b5r	pdb	Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: CUL1-RBX1-SKP1-SKP2-CKSHS1-Cyclin A-CDK2-p27	em	3.8	L	p24941	298		1..292
7b6f	pdb	GSK3-beta in complex with compound (S)-5c	x-ray	2.05	A	p49841	420		55..377
7b7r	pdb	MEK1 in complex with compound 4	x-ray	1.7	A;B	q02750;q02750	393;393	;	63..365;63..365
7b7s	pdb	CDK2/cyclin A2 in complex with 3H-pyrazolo[4,3-f]quinoline-based derivative HSD1368	x-ray	2.54	A;C	p24941;p24941	298;298	;	1..292;1..292
7b85	pdb	Crystal Structure of EGFR-WT in Complex with TAK-788	x-ray	2.5	A	p00533	1210		708..1003
7b8h	pdb	Monoclinic structure of human protein kinase CK2 catalytic subunit in complex with a heparin oligo saccharide	x-ray	1.34	A	p68400	391		5..328
7b8i	pdb	Tetragonal structure of human protein kinase CK2 catalytic subunit in complex with a heparin oligo saccharide	x-ray	2.55	A;B	p68400;p68400	391;391	;	5..328;5..328
7b8w	pdb	Structure of LIMK1 Kinase domain with allosteric inhibitor TH-470	x-ray	2.8	A;B;C;D	p53667;p53667;p53667;p53667	647;647;647;647	;;;	329..616;329..616;329..616;329..616
7b94	pdb	MEK1 in complex with compound 6	x-ray	2	A;B	q02750;q02750	393;393	;	63..365;63..365
7b9l	pdb	MEK1 in complex with compound 23	x-ray	1.7	A;B	q02750;q02750	393;393	;	63..365;63..365
7baq	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with a chiral ligand (S- and E-configuration) and PKI (5-24)	x-ray	1.54	A	p25321	351		29..339
7bar	pdb	Crystal structure of the cAMP-dependent protein kinase A with a chiral ligand (S- and E-configuration, soaked)	x-ray	1.37	A	p25321	351		29..339
7bb0	pdb	Crystal structure of the cAMP-dependent protein kinase A cocrystallized with NAT22-366511 and PKI (5-24)	x-ray	1.75	A	p25321	351		29..339
7bcm	pdb	The DDR1 Kinase Domain Bound To SR302	x-ray	2.3	A;B	q08345;q08345	913;913	;	603..904;603..904
7bdo	pdb	MAPK14 bound with SR302	x-ray	2.7	A	p47811	360		9..349
7bdq	pdb	MAPK14 bound with SR300	x-ray	2.75	A	p47811	360		9..349
7be4	pdb	Crystal structure of MAP kinase p38 alpha in complex with inhibitor SR159	x-ray	2.1	A	p47811	360		9..349
7be5	pdb	Crystal structure of MAP kinase p38 alpha in complex with inhibitor SR276	x-ray	1.80005	A	p47811	360		9..349
7be6	pdb	Structure of DDR1 receptor tyrosine kinase in complex with inhibitor SR159	x-ray	1.87082	A	q08345	913		603..904
7bi2	pdb	PI3KC2aDeltaN and DeltaC-C2	x-ray	3.25	A	q61194	1686		1042..1391
7bi4	pdb	PI3KC2a core apo	x-ray	2.42	A	q61194	1686		1042..1391
7bi6	pdb	PI3KC2a core in complex with ATP	x-ray	2.75	A	q61194	1686		1042..1391
7bi9	pdb	PI3KC2a core in complex with PIK90	x-ray	2.65	A	q61194	1686		1042..1391
7bjd	pdb	Crystal structure of CHK1-10pt-mutant complex with compound 3	x-ray	2	A	o14757	476		6..317
7bje	pdb	Crystal structure of CHK1-10pt-mutant complex with adenine	x-ray	1.8	A	o14757	476		6..317
7bjh	pdb	Crystal structure of CHK1-10pt-mutant complex with compound 8	x-ray	1.8	A	o14757	476		6..317
7bjj	pdb	Crystal structure of CHK1-10pt-mutant complex with compound 9	x-ray	1.8	A	o14757	476		6..317
7bjm	pdb	Crystal structure of CHK1-10pt-mutant complex with compound 10	x-ray	2.3	A	o14757	476		6..317
7bjo	pdb	Crystal structure of CHK1-10pt-mutant complex with compound 13	x-ray	2.3	A	o14757	476		6..317
7bjr	pdb	Crystal structure of CHK1-10pt-mutant complex with compound 18	x-ray	1.9	A	o14757	476		6..317
7bjx	pdb	Crystal structure of CHK1-10pt-mutant complex with compound 26	x-ray	2.4	A;B	o14757;o14757	476;476	;	6..317;6..317
7bk1	pdb	Crystal structure of CHK1-10pt-mutant complex with compound 32	x-ray	2	A	o14757	476		6..317
7bk2	pdb	Crystal structure of CHK1-10pt-mutant complex with compound 44	x-ray	2	A	o14757	476		6..317
7bk3	pdb	Crystal structure of CHK1-10pt-mutant complex with compound 45	x-ray	2	A	o14757	476		6..317
7bkn	pdb	Crystal structure of CHK1 complex with adenine	x-ray	2.74	A	o14757	476		6..317
7bko	pdb	Crystal structure of CHK1 complex with compound 9	x-ray	2.3	A	o14757	476		6..317
7bl1	pdb	human complex II-BATS bound to membrane-attached Rab5a-GTP	em	9.8	BBB;CCC	;	;	;	;
7bmk	pdb	ATP-Competitive Partial Antagonists-'PAIR's-Rheostatically Modulate IRE1alpha's Kinase Helix-alphaC to Segregate its RNase-Mediated Biological Outputs	x-ray	1.85	A;B	o75460;o75460	977;977	;	571..851;571..851
7btt	pdb	A X-ray cocrystal structure of XMU-MP-5 bound to the ALK kinase domain	x-ray	1.86	A	q9um73	1620		1089..1381
7bu4	pdb	Crystal structure of CK2a1 complexed with KY49	x-ray	1.70227	A	p68400	391		5..328
7bw7	pdb	Cryo-EM Structure for the Ectodomain of the Full-length Human Insulin Receptor in Complex with 1 Insulin.	em	4.1	A;C	p06213;p06213	1382;1382	;	996..1290;996..1290
7bw8	pdb	Cryo-EM Structure for the Insulin Binding Region in the Ectodomain of the Full-length Human Insulin Receptor in Complex with 1 Insulin	em	3.8	A;C	p06213;p06213	1382;1382	;	996..1290;996..1290
7bwa	pdb	Cryo-EM Structure for the Ectodomain of the Full-length Human Insulin Receptor in Complex with 2 Insulin	em	4.9	A;C	p06213;p06213	1382;1382	;	996..1290;996..1290
7byk	pdb	Crystal structure of the Legionella pneumophila LegK7 effector kinase	x-ray	2.65	A;B	q5zu83;q5zu83	930;930	;	283..466;283..466
7c2v	pdb	Crystal Structure of IRAK4 kinase in complex with the inhibitor CA-4948	x-ray	2.44	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
7c2w	pdb	Crystal Structure of IRAK4 kinase in complex with a small molecule inhibitor	x-ray	3.2	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
7c3g	pdb	Crystal structure of human ALK2 kinase domain with R206H mutation in complex with a bicyclic pyrazole inhibitor RK-73134	x-ray	1.802	A;B	q04771;q04771	509;509	;	186..496;186..496
7c3n	pdb	Crystal structure of JAK3 in complex with Delgocitinib	x-ray	1.98	A	p52333	1124		508..788,820..1097
7cbx	pdb	Crystal structure of MAP2K7 complexed with a covalent inhibitor 12	x-ray	2.061	A	o14733	419		113..384
7cc2	pdb	Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL Inhibitors	x-ray	2.723	A;B	p00519;p00519	1130;1130	;	231..498;231..498
7ccu	pdb	Crystal structure of death-associated protein kinase 1 in complex with resveratrol	x-ray	1.649	A	p53355	1430		6..291
7ccv	pdb	Crystal structure of death-associated protein kinase 1 in complex with piceatannol	x-ray	1.753	A	p53355	1430		6..291
7ccw	pdb	Crystal structure of death-associated protein kinase 1 in complex with resveratrol and MES	x-ray	1.4	A	p53355	1430		6..291
7chm	pdb	Crystal structure of TTK kinase domain in complex with compound 8	x-ray	2.65	A	p33981	857		516..792
7chn	pdb	Crystal structure of TTK kinase domain in complex with compound 9	x-ray	2.4	A	p33981	857		516..792
7cht	pdb	Crystal structure of TTK kinase domain in complex with compound 30	x-ray	2.4	A	p33981	857		516..792
7cil	pdb	Crystal structure of TTK kinase domain in complex with compound 7	x-ray	2.3	A	p33981	857		516..792
7cja	pdb	Crystal structure of TTK kinase domain in complex with compound 28	x-ray	2.49	A	p33981	857		516..792
7clh	pdb	Crystal structure of TTK kinase domain in complex with compound 19	x-ray	2.9	A	p33981	857		516..792
7cmb	pdb	Crystal Structure of PAK4 in complex with inhibitor 41	x-ray	2.592	A	o96013	591		323..578
7cml	pdb	The Crystal Structure of human JNK2 from Biortus.	x-ray	2.15	A;B	p45984;p45984	424;424	;	13..356;13..356
7cp3	pdb	Crystal Structure of PAK4 in complex with inhibitor 47	x-ray	2.9	A	o96013	591		323..578
7cp4	pdb	Crystal Structure of PAK4 in complex with inhibitor 55	x-ray	2.5	A	o96013	591		323..578
7cqe	pdb	Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with AZD-7762	x-ray	2.69	A;C	q12866;q12866	999;999	;	578..872;578..872
7ctv	pdb	Crystal structure of Arabidopsis thaliana SOBIR1 kinase domain D489A mutant in complex with AMP-PNP and magnesium	x-ray	2.88561	A;B	q9skb2;q9skb2	641;641	;	345..636;345..636
7ctx	pdb	Crystal structure of Arabidopsis thaliana SOBIR1 kinase domain(residues 388-401 deleted) in complex with AMP-PNP and magnesium	x-ray	2.907	A;B	q9skb2;q9skb2	641;641	;	345..636;345..636
7cy2	pdb	The open conformation of MSMEG_1954 from Mycobacterium smegmatis	x-ray	2.75	A	a0qtt2	439		95..309
7cyr	pdb	The closed conformation of MSMEG_1954 from Mycobacterium smegmatis	x-ray	2.05	A	a0qtt2	439		95..309
7cz2	pdb	The complex structure of MSMEG_1954-ADP from Mycobacterium smegmatis	x-ray	1.8	A	a0qtt2	439		95..309
7d57	pdb	C-Src in complex with FIIN-2	x-ray	2.104	A;B	p00523;p00523	533;533	;	256..526;256..526
7d5o	pdb	C-Src in complex with TAS-120	x-ray	2.69	A;B	p00523;p00523	533;533	;	256..526;256..526
7dd1	pdb	Crystal structure of SRPK1 in complex with a peptide inhibitor	x-ray	2.05	A				
7dg4	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor 6	x-ray	2.58	A	q92630	601		212..543
7dh3	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor 5	x-ray	2.33	A	q92630	601		212..543
7dh9	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor 7	x-ray	2.194	A	q92630	601		212..543
7dhc	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor 10	x-ray	2.592	A	q92630	601		212..543
7dhh	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor 19	x-ray	2.486	A	q92630	601		212..543
7dhk	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor 13	x-ray	2.341	A	q92630	601		212..543
7dhl	pdb	Crystal structure of FGFR3 in complex with pyrimidine derivative	x-ray	2.57	A	p22607	806		463..748
7dhn	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor 20	x-ray	2.38	A	q92630	601		212..543
7dho	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor 14	x-ray	3.29	A	q92630	601		212..543
7dhv	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor 8	x-ray	2.679	A	q92630	601		212..543
7djo	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor 17	x-ray	2.499	A	q92630	601		212..543
7dl6	pdb	The co-crystal structure of DYRK2 with a small molecule inhibitor 18	x-ray	2.648	A	q92630	601		212..543
7dsy	pdb	Crystal Structure of RNase L in complex with KM05073	x-ray	2.651	a;b	a5h025;a5h025	743;743	;	368..584;368..584
7dt2	pdb	Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL Inhibitors	x-ray	2.3	A;B	p00519;p00519	1130;1130	;	231..498;231..498
7dts	pdb	Crystal structure of RNase L in complex with AC40357	x-ray	2.63	a;b	a5h025;a5h025	743;743	;	368..584;368..584
7dtz	pdb	FGFR4 complex with a covalent inhibitor	x-ray	2.01	A	p22455	802		458..743
7du8	pdb	Crystal structure of human Proto-oncogene tyrosine-protein kinase receptor Ret in complex with Selpercatinib	x-ray	2.75	A;B	p07949;p07949	1114;1114	;	699..1005;699..1005
7du9	pdb	Crystal structure of human Proto-oncogene tyrosine-protein kinase receptor Ret in complex with Pralsetinib	x-ray	2.31	A;B	p07949;p07949	1114;1114	;	699..1005;699..1005
7dua	pdb	Crystal structure of human Proto-oncogene tyrosine-protein kinase receptor Ret in complex with 4-amino-7-(1-methylcyclopropyl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[2,3-d]pyrimidine-5-carboxamide	x-ray	1.64	A;B	p07949;p07949	1114;1114	;	699..1005;699..1005
7dxl	pdb	Fragment-based Lead Discovery of Indazole-based Compounds as AXL Kinase Inhibitors	x-ray	3.146	A;B	q12866;q12866	999;999	;	578..872;578..872
7e0z	pdb	Crystal structure of PKAc-PLN complex	x-ray	2.162	A	p05132	351		28..339
7e11	pdb	Crystal structure of PKAc-PLN R9C complex	x-ray	3.43	A	p05132	351		28..339
7e12	pdb	Crystal structure of PKAc-A11E complex	x-ray	2.796	A	p05132	351		28..339
7e34	pdb	Crystal structure of SUN1-Speedy A-CDK2	x-ray	3.19	A	p24941	298		1..292
7e73	pdb	Crystal structure of human ERK2 mutant (Y36H)	x-ray	2.28	A	p28482	360		19..322
7e75	pdb	Crystal structure of human ERK2 mutant (G37C)	x-ray	2.481	A	p28482	360		19..322
7egb	pdb	TFIID-based holo PIC on SCP promoter	em	3.3	8				
7egc	pdb	p53-bound TFIID-based holo PIC on HDM2 promoter	em	3.9	8				
7ejv	pdb	The co-crystal structure of DYRK2 with YK-2-69	x-ray	2.5	A;B	q92630;q92630	601;601	;	212..543;212..543
7elw	pdb	Crystal structure of RNase L in complex with Myricetin	x-ray	3.55	a;b	a5h025;a5h025	743;743	;	368..584;368..584
7ena	pdb	TFIID-based PIC-Mediator holo-complex in pre-assembled state (pre-hPIC-MED)	em	4.07	8				
7enc	pdb	TFIID-based PIC-Mediator holo-complex in fully-assembled state (hPIC-MED)	em	4.13	8				
7er2	pdb	Crystal structure of EGFR 696-1022 T790M/C797S in complex with LS_2_40	x-ray	2.662	A	p00533	1210		708..1003
7f0a	pdb	Crystal structure of capreomycin phosphotransferase	x-ray	1.95	A	q53826	281		23..252
7f0b	pdb	Crystal structure of capreomycin phosphotransferase in complex with ATP	x-ray	2.14	A	q53826	281		23..252
7f0c	pdb	Crystal structure of capreomycin phosphotransferase in complex with CMN IIA	x-ray	2.07	A				
7f0f	pdb	Crystal structure of capreomycin phosphotransferase in complex with CMN IIB	x-ray	2.1	A				
7f2x	pdb	Crystal structure of MEK1 C121S mutant	x-ray	2.007	A	q02750	393		63..365
7f3g	pdb	Crystal structure of DCLK1 kinase domain in complex with ruxolitinib	x-ray	2.1	A;B	o15075;o15075	740;740	;	381..656;381..656
7f3m	pdb	Crystal structure of FGFR4 kinase domain with PRN1371	x-ray	2.289	A	p22455	802		458..743
7f7w	pdb	JAK2-JH2	x-ray	1.83	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
7fcz	pdb	Crystal Structure of human RIPK1 kinase domain in complex with a novel inhibitor	x-ray	2.21	A;B	q13546;q13546	671;671	;	6..286;6..286
7fd0	pdb	Crystal Structure of human RIPK1 kinase domain in complex with a novel inhibitor	x-ray	2	A;B	q13546;q13546	671;671	;	6..286;6..286
7feh	pdb	Crystal structure of human DDR1 in complex with CH5541127	x-ray	1.61	A	q08345	913		603..904
7fhs	pdb	Crystal structure of DYRK1A in complex with RD0392	x-ray	2.42	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
7fht	pdb	Crystal structure of DYRK1A in complex with RD0448	x-ray	2.68	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
7fic	pdb	Reversible lysine-targeted probes reveal residence time-based kinase selectivity in vivo	x-ray	2.32	A	o14965	403		120..386
7jis	pdb	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 2F	x-ray	2.42	A	o00329	1044		678..1033
7jnt	pdb	CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE 2 (ROCK2) IN COMPLEX WITH A POTENT AND SELECTIVE DUAL ROCK INHIBITOR	x-ray	2.214	A;B;C;D;E;F;G;H	o75116;o75116;o75116;o75116;o75116;o75116;o75116;o75116	1388;1388;1388;1388;1388;1388;1388;1388	;;;;;;;	89..412;89..412;89..412;89..412;89..412;89..412;89..412;89..412
7jou	pdb	CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK1) IN COMPLEX WITH A PHENYLPYRAZOLE AMIDE INHIBITOR	x-ray	3.318	A	q13464	1354		73..413
7jov	pdb	CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE 2 (ROCK2) IN COMPLEX WITH A PHENYLPYRAZOLE AMIDE INHIBITOR	x-ray	2.586	A;B;C;D;E;F;G;H	o75116;o75116;o75116;o75116;o75116;o75116;o75116;o75116	1388;1388;1388;1388;1388;1388;1388;1388	;;;;;;;	89..412;89..412;89..412;89..412;89..412;89..412;89..412;89..412
7ju5	pdb	Structure of RET protein tyrosine kinase in complex with pralsetinib	x-ray	1.9	A;B	p07949;p07949	1114;1114	;	699..1005;699..1005
7ju6	pdb	Structure of RET protein tyrosine kinase in complex with selpercatinib	x-ray	2.06	A;B	p07949;p07949	1114;1114	;	699..1005;699..1005
7juq	pdb	Crystal Structure of KSR2:MEK1 in complex with ADP	x-ray	3.22	B;C	q6vab6;p29678	950;393	;	642..928;63..365
7jur	pdb	Crystal Structure of KSR2:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Trametinib	x-ray	2.82	B;C	q6vab6;p29678	950;393	;	642..928;63..365
7jus	pdb	Crystal Structure of KSR2:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Cobimetinib	x-ray	2.99	B;C	q6vab6;p29678	950;393	;	642..928;63..365
7jut	pdb	Crystal Structure of KSR2:MEK1 in complex with ANP-PNP, and allosteric MEK inhibitor Selumetinib	x-ray	3.09	B;C	q6vab6;p29678	950;393	;	642..928;63..365
7juu	pdb	Crystal Structure of KSR2:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor PD0325901	x-ray	3.19	B;C	q6vab6;p29678	950;393	;	642..928;63..365
7juv	pdb	Crystal Structure of KSR2:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor APS-9-95-1	x-ray	3.36	B;C	q6vab6;p29678	950;393	;	642..928;63..365
7juw	pdb	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP	x-ray	2.88	B;C	q8ivt5;p29678	923;393	;	597..879;63..365
7jux	pdb	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Trametinib	x-ray	3.34	A;C	q8ivt5;p29678	923;393	;	597..879;63..365
7juy	pdb	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Cobimetinib	x-ray	3.096	B;C	q8ivt5;p29678	923;393	;	597..879;63..365
7juz	pdb	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Selumetinib	x-ray	3.21	A;C	q8ivt5;p29678	923;393	;	597..879;63..365
7jv0	pdb	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor PD0325901	x-ray	3.63	A;C	q8ivt5;p29678	923;393	;	597..879;63..365
7jv1	pdb	Crystal Structure of KSR1:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor APS-9-95-1	x-ray	3.62	C;D	p29678;q8ivt5	393;923	;	63..365;597..879
7jv7	pdb	Crystal Structure of the yeast RNA Pol II CTD kinase CTDK-1 complex	x-ray	1.85055	A	q03957	528		176..475
7jw7	pdb	Structure of monobody 27 human MLKL pseudokinase domain complex	x-ray	2.63	A				
7jwe	pdb	Gedatolisib bound to the PI3Kg catalytic subunit p110 gamma	x-ray	2.55	A	p48736	1102		728..1089
7jwz	pdb	IPI-549 bound to the PI3Kg catalytic subunit p110 gamma	x-ray	2.65	A	p48736	1102		728..1089
7jx0	pdb	NVS-PI3-4 bound to the PI3Kg catalytic subunit p110 gamma	x-ray	3.15	A	p48736	1102		728..1089
7jxh	pdb	HER2 in complex with JBJ-08-178-01	x-ray	3.27	A;B;C;D;E;F;G;H	p04626;p04626;p04626;p04626;p04626;p04626;p04626;p04626	1255;1255;1255;1255;1255;1255;1255;1255	;;;;;;;	716..992;716..992;716..992;716..992;716..992;716..992;716..992;716..992
7jxi	pdb	EGFR kinase (T790M/V948R) in complex with PF-06747775	x-ray	3	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7jxk	pdb	EGFR kinase (T790M/V948R) in complex with PF-06747775 and JBJ-04-125-02	x-ray	3.1	A;B;C;D;E;F	p00533;p00533;p00533;p00533;p00533;p00533	1210;1210;1210;1210;1210;1210	;;;;;	708..1003;708..1003;708..1003;708..1003;708..1003;708..1003
7jxl	pdb	EGFR kinase (T790M/V948R) in complex with AZ5104	x-ray	2.4	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7jxm	pdb	EGFR kinase (T790M/V948R) in complex with osimertinib and EAI045	x-ray	2.192	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7jxp	pdb	EGFR kinase (T790M/V948R) in complex with osimertinib and JBJ-04-125-02	x-ray	2.16	A;B;C;D;E;F	p00533;p00533;p00533;p00533;p00533;p00533	1210;1210;1210;1210;1210;1210	;;;;;	708..1003;708..1003;708..1003;708..1003;708..1003;708..1003
7jxq	pdb	EGFR kinase (T790M/V948R) in complex with allosteric inhibitor JBJ-09-063	x-ray	1.83	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7jxu	pdb	Structure of monobody 32 human MLKL pseudokinase domain complex	x-ray	2.44	A;B	;	;	;	;
7jxw	pdb	EGFR kinase (T790M/V948R) in complex with osimertinib and JBJ-09-063	x-ray	2.5	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7jxx	pdb	Structure of TTBK1 kinase domain in complex with Compound 3	x-ray	1.56	A	q5tcy1	1321		30..311
7jxy	pdb	Structure of TTBK1 kinase domain in complex with Compound 18	x-ray	2.15	A;B	q5tcy1;q5tcy1	1321;1321	;	30..311;30..311
7jy4	pdb	hALK in complex with ((1S,2S)-1-(2,4-difluorophenyl)-2-(2-(3-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenoxy)cyclopropyl)methanamine	x-ray	2.42	A	q9um73	1620		1089..1381
7jyo	pdb	JAK2 JH2 in complex with JAK064	x-ray	2.16127	A	o60674	1132		522..814,842..1119
7jyq	pdb	JAK2 JH2 in complex with JAK020	x-ray	1.85942	A	o60674	1132		522..814,842..1119
7jyr	pdb	hALK in complex with 1-[(1R,2R)-1-(2,4-difluorophenyl)-2-[2-(5-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)phenoxy]cyclopropyl]methanamine	x-ray	2.32	A	q9um73	1620		1089..1381
7jys	pdb	hALK in complex with 3-(3-chlorophenyl)-5-methyl-1H-pyrazole	x-ray	2.22	A	q9um73	1620		1089..1381
7jyt	pdb	hALK in complex with 3-(3-methyl-1H-pyrazol-5-yl)pyridine	x-ray	2	A	q9um73	1620		1089..1381
7k0v	pdb	Crystal structure of bRaf in complex with inhibitor GNE-0749	x-ray	1.93	A;B;C;D	p15056;p15056;p15056;p15056	766;766;766;766	;;;	449..717;449..717;449..717;449..717
7k0y	pdb	Cryo-EM structure of activated-form DNA-PK (complex VI)	em	3.7	A	p78527	4128		3657..4049
7k10	pdb	CryoEM structure of activated-form FATKIN domain of DNA-PK	em	3.3	A	p78527	4128		3657..4049
7k11	pdb	CryoEM structure of inactivated-form FATKIN domain of DNA-PK	em	3.21	A	p78527	4128		3657..4049
7k17	pdb	Re-refined crystal structure of DNA-dependent protein kinase catalytic subunit complexed with Ku80 C-terminal helix	x-ray	4.3	A;B	;	;	;	;
7k19	pdb	CryoEM structure of DNA-PK catalytic subunit complexed with DNA (Complex I)	em	4.3	A	p78527	4128		3657..4049
7k1b	pdb	CryoEM structure of DNA-PK catalytic subunit complexed with DNA (Complex II)	em	4.3	A	p78527	4128		3657..4049
7k1h	pdb	EGFR L858R/V948R in complex with osimertinib and allosteric inhibitor JBJ-09-063	x-ray	2.602	A;B;C;D;E;F	p00533;p00533;p00533;p00533;p00533;p00533	1210;1210;1210;1210;1210;1210	;;;;;	708..1003;708..1003;708..1003;708..1003;708..1003;708..1003
7k1i	pdb	EGFR kinase (L858R/V948R) in complex with allosteric inhibitor JBJ-09-063	x-ray	3.202	A	p00533	1210		708..1003
7k1j	pdb	CryoEM structure of inactivated-form DNA-PK (Complex III)	em	3.9	A	p78527	4128		3657..4049
7k1k	pdb	CryoEM structure of inactivated-form DNA-PK (Complex IV)	em	4.1	A	p78527	4128		3657..4049
7k1n	pdb	CryoEM structure of inactivated-form DNA-PK (Complex V)	em	3.9	A	p78527	4128		3657..4049
7k6m	pdb	Crystal structure of PI3Kalpha selective Inhibitor PF-06843195	x-ray	2.413	A	p42336	1068		699..1060
7k6n	pdb	Crystal structure of PI3Kalpha selective Inhibitor 11-1575	x-ray	2.77	A	p42336	1068		699..1060
7k6o	pdb	Crystal structure of PI3Kalpha inhibitor 10-5429	x-ray	2.738	A	p42336	1068		699..1060
7k71	pdb	Crystal structure of PI3Kalpha inhibitor 4-0686	x-ray	2.9	A	p42336	1068		699..1060
7k7l	pdb	Structure of a hit for G Protein Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure	x-ray	2.539	A	p25098	689		187..532
7k7o	pdb	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH COMPOUND-12 AKA:6-[(cyclopropanecarbonyl)amino]-4-{[2-methoxy-3-(pyrimidin-2-yl)phenyl]amino}-N-methylpyridazine-3-carboxamide	x-ray	2.82	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
7k7q	pdb	CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH COMPOUND-12 AKA:6-[(cyclopropanecarbonyl)amino]-4-({3-[6-(dimethylcarbamoyl)pyridazin-3-yl]-2-methoxyphenyl}amino)-N-methylpyridazine-3-carboxamide	x-ray	2.27	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
7k7z	pdb	Structure of a hit for G Protein Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure	x-ray	2.60609	A	p25098	689		187..532
7kac	pdb	Crystal structure of HPK1 (MAP4K1) kinase in complex with 5-{[4-{[(1S)-2-HYDROXY-1-PHENYLETHYL]AMINO}-5-(1,3,4-OXADIAZOL-2-YL)PYRIMIDIN-2-YL]AMINO}-3,3-DIMETHYL-2-BENZOFURAN-1(3H)-ONE	x-ray	1.85	A;B	q92918;q92918	833;833	;	14..444;14..444
7khg	pdb	Crystal structure of KIT kinase domain with a small molecule inhibitor, PLX3397	x-ray	2.15	A	p10721	976		564..923
7kia	pdb	Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 19	x-ray	2.22	A;B	p21802;p21802	821;821	;	471..757;471..757
7kie	pdb	Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 3	x-ray	2.47	A;B	p21802;p21802	821;821	;	471..757;471..757
7kja	pdb	Crystal structure of the EphA2 intracellular KD-SAM domains	x-ray	1.75	A;B	p29317;p29317	976;976	;	605..909;605..909
7kjb	pdb	Crystal structure of the EphA2 S897E/S901E mutant intracellular KD-SAM domains	x-ray	2.8	A	p29317	976		605..909
7kjc	pdb	Crystal structure of the EphA2 S901E mutant intracellular KD-SAM domains	x-ray	2.3	A;B	p29317;p29317	976;976	;	605..909;605..909
7kjs	pdb	Crystal structure of CDK2/cyclin E in complex with PF-06873600	x-ray	2.187	A	p24941	298		1..292
7kke	pdb	Phosphoinositide 3-Kinase gamma bound to a thiazole inhibitor	x-ray	2.81	A	p48736	1102		728..1089
7kl0	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)	x-ray	2.4	A;B	q9uqm7;q9uqm7	478;478	;	9..272;9..272
7kl1	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)	x-ray	2.4	A;B	q9uqm7;q9uqm7	478;478	;	9..272;9..272
7kl2	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)	x-ray	2.56	A	q9uqm7	478		9..272
7kp6	pdb	Structure of Ack1 kinase in complex with a selective inhibitor	x-ray	1.79	A;B	q07912;q07912	1038;1038	;	120..398;120..398
7kpl	pdb	Crystal structure of hEphB1 in apo form	x-ray	2.705	A	p54762	984		614..915
7kpm	pdb	Crystal structure of hEphB1 bound with ADP	x-ray	1.608	A	p54762	984		614..915
7kpv	pdb	Structure of kinase and Central lobes of yeast CKM	em	3.8	A	p39073	555		66..485
7kpx	pdb	Structure of the yeast CKM	em	4.4	A	p39073	555		66..485
7ksi	pdb	Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors	x-ray	1.726	A	p53779	464		52..396
7ksj	pdb	Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors	x-ray	2.06	A	p53779	464		52..396
7ksk	pdb	Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors	x-ray	1.84	A	p53779	464		52..396
7ktr	pdb	Cryo-EM structure of the human SAGA coactivator complex (TRRAP, core)	em	2.93	A	q9y4a5	3859		3433..3826
7kts	pdb	Negative stain EM structure of the human SAGA coactivator complex (TRRAP, core, splicing module)	em	19.09	A	f2z2u4	3848		3422..3815
7kue	pdb	CryoEM structure of Yeast TFIIK (Kin28/Ccl1/Tfb3) Complex	em	3.5	A	p06242	306		6..297
7kx6	pdb	Crystal structure of DCLK1-KD in complex with XMD8-85	x-ray	2.5	A;B	o15075;o15075	740;740	;	381..656;381..656
7kx8	pdb	Crystal structure of DCLK1-Cter in complex with FMF-03-055-1	x-ray	3.1	A;B	o15075;o15075	740;740	;	381..656;381..656
7kxl	pdb	BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTERED	x-ray	1.84	A	q06187	659		382..648
7kxm	pdb	BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTERED	x-ray	1.33	A	q06187	659		382..648
7kxn	pdb	BTK1 SOAKED WITH COMPOUND 26	x-ray	1.34	A	q06187	659		382..648
7kxo	pdb	BTK1 SOAKED WITH COMPOUND 24	x-ray	1.94	A	q06187	659		382..648
7kxp	pdb	BTK1 SOAKED WITH COMPOUND 25	x-ray	1.83	A	q06187	659		382..648
7kxq	pdb	BTK1 SOAKED WITH COMPOUND 30	x-ray	1.38	A	q06187	659		382..648
7kxw	pdb	Crystal structure of DCLK1-KD in complex with DCLK1-IN-1	x-ray	3.002	A;B	o15075;o15075	740;740	;	381..656;381..656
7kxz	pdb	Active conformation of EGFR kinase in complex with BI-4020	x-ray	2.4	A	p00533	1210		708..1003
7ky0	pdb	Inactive conformation of EGFR (T790M/V948R) kinase in complex with BI-4020	x-ray	3.1	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7l1x	pdb	Structure of human CK2 alpha kinase (catalytic subunit) with the inhibitor 108600.	x-ray	1.8	A	p68400	391		5..328
7l24	pdb	HPK1 IN COMPLEX WITH COMPOUND 11	x-ray	2.68	A;B;C;D	q92918;q92918;q92918;q92918	833;833;833;833	;;;	14..444;14..444;14..444;14..444
7l25	pdb	HPK1 IN COMPLEX WITH COMPOUND 18	x-ray	1.85	A;B	q92918;q92918	833;833	;	14..444;14..444
7l26	pdb	HPK1 IN COMPLEX WITH COMPOUND 38	x-ray	2.3	A;B;C;D	q92918;q92918;q92918;q92918	833;833;833;833	;;;	14..444;14..444;14..444;14..444
7l5o	pdb	Crystal structure of the noncovalently bonded complex of rilzabrutinib with BTK	x-ray	1.21	A	q06187	659		382..648
7l5p	pdb	Crystal structure of the covalently bonded complex of rilzabrutinib with BTK	x-ray	2.14	A;B	q06187;q06187	659;659	;	382..648;382..648
7lbm	pdb	Structure of the human Mediator-bound transcription pre-initiation complex	em	4.8	e	p50613	346		8..299
7lg8	pdb	EGFR (T79M/V948R) in complex with naquotinib and an allosteric inhibitor	x-ray	2.93	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7lgs	pdb	Structure of EGFR_D770_N771insNPG/V948R in complex with covalent inhibitor Osimertinib.	x-ray	3.1	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7lht	pdb	Structure of the LRRK2 dimer	em	3.5	A;B	q5s007;q5s007	2527;2527	;	1884..2132;1884..2132
7lhw	pdb	Structure of the LRRK2 monomer	em	3.7	A	q5s007	2527		1884..2132
7li3	pdb	Structure of the LRRK2 G2019S mutant	em	3.8	A	q5s007	2527		1884..2132
7li4	pdb	Structure of LRRK2 after symmetry expansion	em	3.1	A	q5s007	2527		1884..2132
7ll4	pdb	High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-114.	x-ray	1.31	A	o60674	1132		522..814,842..1119
7ll5	pdb	High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-150.	x-ray	1.5	A	o60674	1132		522..814,842..1119
7lm2	pdb	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 3C	x-ray	2.79	A	o00329	1044		678..1033
7lq1	pdb	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 28	x-ray	2.96	A	o00329	1044		678..1033
7lqd	pdb	Structure of Human MPS1 (TTK) covalently bound to RMS-07 inhibitor	x-ray	1.95	A	p33981	857		516..792
7lt3	pdb	NHEJ Long-range synaptic complex	em	4.6	C;L	;	;	;	;
7ltx	pdb	EGFR (T790M/V948R) in complex with quinazolinone allosteric inhibitor	x-ray	2.3	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7lty	pdb	Bruton's tyrosine kinase in complex with compound 23	x-ray	1.69	A	q06187	659		382..648
7ltz	pdb	Bruton's tyrosine kinase in complex with compound 51	x-ray	1.53	A	q06187	659		382..648
7lv3	pdb	Crystal structure of human protein kinase G (PKG) R-C complex in inhibited state	x-ray	2.41	A;B	q13976;q13976	671;671	;	354..660;354..660
7m0k	pdb	HPK1 IN COMPLEX WITH COMPOUND 1	x-ray	2.01	A;B;C;D	q92918;q92918;q92918;q92918	833;833;833;833	;;;	14..444;14..444;14..444;14..444
7m0l	pdb	HPK1 IN COMPLEX WITH COMPOUND 1	x-ray	2.43	A;B;C;D	q92918;q92918;q92918;q92918	833;833;833;833	;;;	14..444;14..444;14..444;14..444
7m0m	pdb	HPK1 IN COMPLEX WITH COMPOUND 1	x-ray	1.93	A;B	q92918;q92918	833;833	;	14..444;14..444
7m0t	pdb	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Selumetinib	x-ray	3.19	A;B	p15056;q02750	766;393	;	449..717;63..365
7m0u	pdb	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Binimetinib	x-ray	3.09	A;B	p15056;q02750	766;393	;	449..717;63..365
7m0v	pdb	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Cobimetinib	x-ray	3.16	A;B	p15056;q02750	766;393	;	449..717;63..365
7m0w	pdb	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Pimasertib	x-ray	3.09	A;B	p15056;q02750	766;393	;	449..717;63..365
7m0x	pdb	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and PD0325901	x-ray	2.47	A;B	p15056;q02750	766;393	;	449..717;63..365
7m0y	pdb	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Trametinib	x-ray	3.45	A;B	p15056;q02750	766;393	;	449..717;63..365
7m0z	pdb	Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and CH5126766	x-ray	3.12	A;B	p15056;q02750	766;393	;	449..717;63..365
7m2f	pdb	CDK2 with compound 14 inhibitor with carboxylate	x-ray	1.632	A	p24941	298		1..292
7m5z	pdb	Crystal Structure of the MerTK Kinase Domain in Complex with Inhibitor MIPS15692	x-ray	3.06	A;B	q12866;q12866	999;999	;	578..872;578..872
7mck	pdb	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 18	x-ray	1.65	A	o14757	476		6..317
7mez	pdb	Structure of the phosphoinositide 3-kinase p110 gamma (PIK3CG) p101 (PIK3R5) complex	em	2.89	A	p48736	1102		728..1089
7mf0	pdb	Co-crystal structure of PERK with inhibitor (R)-2-amino-N-cyclopropyl-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)nicotinamide	x-ray	2.809	AAA	q9nzj5	1116		587..1090
7mfc	pdb	Crystal structure of CSF1R in complex with vimseltinib	x-ray	2.8	A	p07333	972		551..909
7mfd	pdb	Autoinhibited BRAF:(14-3-3)2:MEK complex with the BRAF RBD resolved	em	3.66	A;B	p15056;q02750	766;393	;	449..717;63..365
7mfe	pdb	Autoinhibited BRAF:(14-3-3)2 complex with the BRAF RBD resolved	em	4.07	A	p15056	766		449..717
7mff	pdb	Dimeric (BRAF)2:(14-3-3)2 complex bound to SB590885 Inhibitor	em	3.89	A;B	p15056;p15056	766;766	;	449..717;449..717
7mgj	pdb	TNNI3K complexed with N-methyl-4-(4-(3-(3-(trifluoromethyl) phenyl) ureido) phenoxy)picolinamide	x-ray	2.95	A;B;C;D	q59h18;q59h18;q59h18;q59h18	835;835;835;835	;;;	454..727;454..727;454..727;454..727
7mgk	pdb	TNNI3K complexed with 1-(3,5-dichloro-4-((6-(methylamino)pyrimidin-4-yl)oxy)phenyl)-3-(3-(trifluoromethyl)phenyl)urea	x-ray	3.1	A;B;C;D	q59h18;q59h18;q59h18;q59h18	835;835;835;835	;;;	454..727;454..727;454..727;454..727
7mkx	pdb	Crystal Structure Analysis of human CDK2 and CCNA2 complex	x-ray	3.08	A;C	p24941;p24941	298;298	;	1..292;1..292
7mlk	pdb	Crystal structure of human PI3Ka (p110a subunit) with MMV085400 bound to the active site determined at 2.9 angstroms resolution	x-ray	2.91	A	p42336	1068		699..1060
7mn5	pdb	Structure of the HER2/HER3/NRG1b Heterodimer Extracellular Domain	em	2.93	B;A	p04626;p21860	1255;1342	;	716..992;706..977
7mn6	pdb	Structure of the HER2 S310F/HER3/NRG1b Heterodimer Extracellular Domain	em	3.09	B;A	p04626;p21860	1255;1342	;	716..992;706..977
7mn8	pdb	Structure of the HER2/HER3/NRG1b Heterodimer Extracellular Domain bound to Trastuzumab Fab	em	3.45	A;B	;	;	;	;
7mo7	pdb	Cryo-EM structure of 2:2 c-MET/HGF holo-complex	em	4.8	B;E	p08581;p08581	1390;1390	;	1079..1341;1079..1341
7mo8	pdb	Cryo-EM structure of 1:1 c-MET I/HGF I complex after focused 3D refinement of holo-complex	em	4.5	B	p08581	1390		1079..1341
7mo9	pdb	Cryo-EM map of the c-MET II/HGF I/HGF II (K4 and SPH) sub-complex	em	4	E	p08581	1390		1079..1341
7moa	pdb	Cryo-EM structure of the c-MET II/HGF I complex bound with HGF II in a rigid conformation	em	4.9	E	p08581	1390		1079..1341
7mob	pdb	Cryo-EM structure of 2:2 c-MET/NK1 complex	em	5	C;D	p08581;p08581	1390;1390	;	1079..1341;1079..1341
7mon	pdb	Structure of human RIPK3-MLKL complex	x-ray	2.23	A;B	q8nb16;q9y572	471;518	;	213..466;16..294
7mp8	pdb	Crystal structure of the cytosolic domain of Tribolium castaneum PINK1 in the non-phosphorylated state	x-ray	3	A	d6wmx4	570		153..478
7mp9	pdb	Crystal structure of the cytosolic domain of Tribolium castaneum PINK1 phosphorylated at Ser205 in complex with ADP analog	x-ray	2.8	A	d6wmx4	570		153..478
7mt9	pdb	Rhodopsin kinase (GRK1) in complex with rhodopsin	em	7	G	p28327	561		187..529
7mu6	pdb	Ask1 bound to compound 28	x-ray	2.165	A;B	q99683;q99683	1374;1374	;	685..939;685..939
7mu7	pdb	Ask1 bound to compound 3	x-ray	2.298	A;B	q99683;q99683	1374;1374	;	685..939;685..939
7mx3	pdb	Crystal structure of human RIPK3 complexed with GSK'843	x-ray	3.23	A;B;C;D	q9y572;q9y572;q9y572;q9y572	518;518;518;518	;;;	16..294;16..294;16..294;16..294
7mxb	pdb	Crystal structure of the S/T protein kinase PknG from Corynebacterium glutamicum in complex with AMP-PNP	x-ray	2.2	A;B	q8nm29;q8nm29	751;751	;	93..360;93..360
7mxj	pdb	Crystal structure of the S/T protein kinase PknG from Corynebacterium glutamicum (residues 130-433) in complex with AMP-PNP, isoform 1	x-ray	1.92	A	q8nm29	751		93..360
7mxk	pdb	Crystal structure of the S/T protein kinase PknG from Corynebacterium glutamicum (residues 130-433) in complex with AMP-PNP, isoform 2	x-ray	1.99	A	q8nm29	751		93..360
7myj	pdb	Structure of full length human AMPK (a2b1g1) in complex with a small molecule activator MSG011	x-ray	2.95	A;C	p54646;p54646	552;552	;	13..269;13..269
7myn	pdb	Cryo-EM Structure of p110alpha in complex with p85alpha	em	2.79	A	p42336	1068		699..1060
7myo	pdb	Cryo-EM structure of p110alpha in complex with p85alpha inhibited by BYL-719	em	2.92	A	p42336	1068		699..1060
7n3u	pdb	Crystal structure of human WEE1 kinase domain in complex with ZN-c3	x-ray	2.65	A	p30291	646		279..580
7n4q	pdb	Bruton's tyrosine kinase in complex with compound 45	x-ray	1.5	A	q06187	659		382..648
7n4r	pdb	Bruton's tyrosine kinase in complex with compound 21	x-ray	1.62	A	q06187	659		382..648
7n4s	pdb	Bruton's tyrosine kinase in complex with compound 65	x-ray	2.05	A	q06187	659		382..648
7n5o	pdb	Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor	x-ray	1.25	A	q06187	659		382..648
7n5r	pdb	Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor	x-ray	1.55	A	q06187	659		382..648
7n5x	pdb	Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor	x-ray	1.6	A	q06187	659		382..648
7n5y	pdb	Fragment-Based Drug Design of a Novel, Covalent Bruton's Tyrosine Kinase Inhibitor	x-ray	1.85	A	q06187	659		382..648
7n8t	pdb	Crystal Structure of AMP-bound Human JNK2	x-ray	1.69	A	p45984	424		13..356
7n91	pdb	P70 S6K1 IN COMPLEX WITH MSC2317067A-1	x-ray	3	A;B	p23443;p23443	525;525	;	86..409;86..409
7n93	pdb	P70 S6K1 IN COMPLEX WITH MSC2363318A-1	x-ray	2.74	A;B	p23443;p23443	525;525	;	86..409;86..409
7n9g	pdb	Crystal structure of the Abl 1b Kinase domain in complex with Dasatinib and Imatinib	x-ray	2.2	A;B;C	p00519;p00519;p00519	1130;1130;1130	;;	231..498;231..498;231..498
7naa	pdb	Crystal structure of Mycobacterium tuberculosis H37Rv PknF kinase domain	x-ray	2.75	A;B;C;D	p9wi75;p9wi75;p9wi75;p9wi75	476;476;476;476	;;;	11..367;11..367;11..367;11..367
7nb1	pdb	Crystal structure of human choline alpha in complex with an inhibitor	x-ray	2.3	AAA;BBB	p35790;p35790	457;457	;	82..455;82..455
7nb2	pdb	Crystal structure of human choline alpha in complex with an inhibitor	x-ray	2.4	AAA;BBB	p35790;p35790	457;457	;	82..455;82..455
7nb3	pdb	Crystal structure of human choline alpha in complex with an inhibitor	x-ray	2	AAA;BBB	p35790;p35790	457;457	;	82..455;82..455
7ncf	pdb	Crystal structure of HIPK2 in complex with MU135 (compound 21e)	x-ray	2.72	A	q9h2x6	1198		190..537
7nfc	pdb	Cryo-EM structure of NHEJ super-complex (dimer)	em	4.14	A;F	p78527;p78527	4128;4128	;	3657..4049;3657..4049
7nfe	pdb	Cryo-EM structure of NHEJ super-complex (monomer)	em	4.29	A	p78527	4128		3657..4049
7ng7	pdb	Src kinase bound to eCF506 trapped in inactive conformation	x-ray	1.5	A	p12931	536		259..529
7nh4	pdb	Co-Crystal Structure of Akt1 in Complex with Covalent-Allosteric Akt Inhibitor 3	x-ray	2.3	A	p31749	480		145..459
7nh5	pdb	Co-Crystal Structure of Akt1 in Complex with Covalent-Allosteric Akt Inhibitor 6	x-ray	1.9	A	p31749	480		145..459
7ni4	pdb	Human ATM kinase domain with bound M4076 inhibitor	em	3	A;B	q13315;q13315	3056;3056	;	2623..2974;2623..2974
7ni5	pdb	Human ATM kinase with bound inhibitor KU-55933	em	2.78	A;B	q13315;q13315	3056;3056	;	2623..2974;2623..2974
7ni6	pdb	Human ATM kinase with bound ATPyS	em	2.8	A;B	q13315;q13315	3056;3056	;	2623..2974;2623..2974
7nj0	pdb	CryoEM structure of the human Separase-Cdk1-cyclin B1-Cks1 complex	em	3.6	B	p06493	297		1..291
7nns	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound Momelotinib	x-ray	2.14	B	q04771	509		186..496
7nqq	pdb	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.943	A	p28482	360		19..322
7nqw	pdb	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.775	A	p28482	360		19..322
7nr3	pdb	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.897	A	p28482	360		19..322
7nr5	pdb	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.766	A	p28482	360		19..322
7nr8	pdb	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.627	A	p28482	360		19..322
7nr9	pdb	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2	x-ray	1.906	A	p28482	360		19..322
7nrb	pdb	Re-refinement of MK3-inhibitor complex	x-ray	1.9	A	q16644	382		36..343
7nry	pdb	Re-refinement of MAPKAP kinase-2/inhibitor complex 3fyj	x-ray	3.8	X	p49137	400		59..369
7nth	pdb	Structure of TAK1 in complex with compound 54	x-ray	1.97	A	q15750	504		
7nti	pdb	Structure of TAK1 in complex with compound 22	x-ray	1.98	A	o43318	606		14..292
7nur	pdb	Structure of the Toxoplasma gondii kinase Ron13, kinase-dead mutant	em	3.125	A	s7vrx1	1375		331..774
7nvr	pdb	Human Mediator with RNA Polymerase II Pre-initiation complex	em	4.5	8				
7nwk	pdb	Crystal structure of CDK9-Cyclin T1 bound by compound 6	x-ray	2.81	A	p50750	372		12..321
7nxj	pdb	Crystal structure of human Cdk13/Cyclin K in complex with the inhibitor THZ531	x-ray	2.36	A;C	q14004;q14004	1512;1512	;	699..1002;699..1002
7nxk	pdb	Crystal structure of human Cdk12/Cyclin K in complex with the inhibitor BSJ-01-175	x-ray	3	A;C	q9nyv4;q9nyv4	1490;1490	;	721..1024;721..1024
7nzn	pdb	Structure of RET kinase domain bound to inhibitor JB-48	x-ray	2.39	A	p07949	1114		699..1005
7nzy	pdb	Crystal structure of human Casein Kinase I delta in complex with CGS-15943	x-ray	1.85	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
7o2v	pdb	AURORA KINASE A IN COMPLEX WITH THE AUR-A/PDK1 INHIBITOR VI8	x-ray	3.1	A	o14965	403		120..386
7o7i	pdb	Crystal structure of the human HIPK3 kinase domain	x-ray	2.5	A	q9h422	1215		189..533
7o7j	pdb	Crystal structure of the human HIPK3 kinase domain bound to abemaciclib	x-ray	2.81	A	q9h422	1215		189..533
7o7k	pdb	Crystal structure of the human DYRK1A kinase domain bound to abemaciclib	x-ray	1.82	A;B	q13627;q13627	763;763	;	147..489;147..489
7o9y	pdb	Crystal structure of di-phosphorylated human CLK1 in complex with 4-(1H-indol-3-yl)pyrimidin-2-amine	x-ray	1.66	A	p49759	484		150..478
7oa0	pdb	Crystal structure of di-phosphorylated human CLK1 in complex with 5-(6,7-dichloro-1H-indol-3-yl)pyrimidin-4-amine	x-ray	1.81	AAA	p49759	484		150..478
7oai	pdb	Crystal structure of pseudokinase CASK in complex with PFE-PKIS12	x-ray	2.3	A;B;C;D	o14936;o14936;o14936;o14936	926;926;926;926	;;;	7..292;7..292;7..292;7..292
7oaj	pdb	Crystal structure of pseudokinase CASK in complex with compound 7	x-ray	1.93	A;B;C;D	o14936;o14936;o14936;o14936	926;926;926;926	;;;	7..292;7..292;7..292;7..292
7oak	pdb	Crystal structure of pseudokinase CASK in complex with compound 26	x-ray	2.23	A;B;C;D	o14936;o14936;o14936;o14936	926;926;926;926	;;;	7..292;7..292;7..292;7..292
7oal	pdb	Crystal structure of pseudokinase CASK in complex with compound 25	x-ray	2.17	A;B;C;D	o14936;o14936;o14936;o14936	926;926;926;926	;;;	7..292;7..292;7..292;7..292
7oam	pdb	Kinase domain of MERTK in complex with compound 8	x-ray	2.65	A;B	q12866;q12866	999;999	;	578..872;578..872
7ols	pdb	MerTK kinase domain with type 1.5 inhibitor containing a di-methyl pyrazole group	x-ray	1.89	A	q12866	999		578..872
7olv	pdb	MerTK kinase domain with type 1.5 inhibitor containing a di-methyl, cyano pyrazole group	x-ray	2.13	A	q12866	999		578..872
7olx	pdb	MerTK kinase domain with type 1.5 inhibitor containing a tri-methyl pyrazole group	x-ray	1.98	A	q12866	999		578..872
7oov	pdb	Crystal structure of PIM1 in complex with ARC-1411	x-ray	1.96	A				
7oow	pdb	Crystal structure of PIM1 in complex with ARC-1415	x-ray	1.95	A				
7oox	pdb	Crystal structure of PIM1 in complex with ARC-3126	x-ray	1.97	A				
7opg	pdb	Crystal structure of CLK1 in complex with compound 2 (CC513)	x-ray	1.93	A;B;C	p49759;p49759;p49759	484;484;484	;;	150..478;150..478;150..478
7opm	pdb	Phosphorylated ERK2 in complex with ORF45	x-ray	2.45	A				
7opo	pdb	RSK2 N-terminal kinase domain in complex with ORF45	x-ray	2.75	A;C;E;G;I;K	p51812;p51812;p51812;p51812;p51812;p51812	740;740;740;740;740;740	;;;;;	66..390,402..717;66..390,402..717;66..390,402..717;66..390,402..717;66..390,402..717;66..390,402..717
7ops	pdb	Crystal structure of haspin in complex with ZW282 (compound 2a)	x-ray	2.38	A	q8tf76	798		474..698
7ote	pdb	Src Kinase Domain in complex with ponatinib	x-ray	2.49	A;B	p12931;p12931	536;536	;	259..529;259..529
7otm	pdb	Cryo-EM structure of DNA-PKcs in complex with NU7441	em	3.33	A	p78527	4128		3657..4049
7otp	pdb	DNA-PKcs in complex with ATPgammaS-Mg	em	3.4	A	p78527	4128		3657..4049
7otv	pdb	DNA-PKcs in complex with wortmannin	em	3.24	A	p78527	4128		3657..4049
7otw	pdb	DNA-PKcs in complex with AZD7648	em	2.99	A	p78527	4128		3657..4049
7oty	pdb	DNA-PKcs in complex with M3814	em	2.96	A	p78527	4128		3657..4049
7ovi	pdb	Protein kinase MKK7 in complex with phenethyltriazole-substituted pyrazolopyrimidine	x-ray	1.95	A	o14733	419		113..384
7ovj	pdb	Protein kinase MKK7 in complex with difluoro-phenethyltriazole-substituted pyrazolopyrimidine	x-ray	2.35	A	o14733	419		113..384
7ovk	pdb	Protein kinase MKK7 in complex with 5-bromo-2-hydroxyphenyl-substituted pyrazolopyrimidine	x-ray	2.05	A	o14733	419		113..384
7ovl	pdb	Protein kinase MKK7 in complex with methoxycyclohexyl-substituted indazole	x-ray	2.9	A	o14733	419		113..384
7ovm	pdb	Protein kinase MKK7 in complex with cyclobutyl-substituted indazole	x-ray	2.9	A	o14733	419		113..384
7ovn	pdb	Protein kinase MKK7 in complex with tolyl-substituted indazole	x-ray	2.9	A	o14733	419		113..384
7owg	pdb	human DEPTOR in a complex with mutant human mTORC1 A1459P	em	4.7	B	p42345	2549		2095..2451
7oxb	pdb	Crystal structure of EGFR double mutant (T790M/L858R) in complex with compound 6.	x-ray	2.56	A	p00533	1210		708..1003
7oy5	pdb	Crystal structure of GSK3Beta in complex with ARN25068	x-ray	2.57	A;B	p49841;p49841	420;420	;	55..377;55..377
7oy6	pdb	Crystal structure of human DYRK1A in complex with ARN25068	x-ray	2.38	C	q13627	763		147..489
7ozb	pdb	FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 38.	x-ray	1.71	AAA;BBB	p11362;p11362	822;822	;	468..754;468..754
7ozd	pdb	FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 34.	x-ray	1.82	AAA;BBB	p11362;p11362	822;822	;	468..754;468..754
7ozf	pdb	FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 19.	x-ray	1.82	AAA;BBB	p11362;p11362	822;822	;	468..754;468..754
7ozy	pdb	FGFR2 kinase domain (residues 461-763) in complex with 38.	x-ray	2.28	AAA;BBB	p21802;p21802	821;821	;	471..757;471..757
7p1l	pdb	The MARK3 Kinase Domain Bound To AA-CS-1-008	x-ray	1.95	A;B	p27448;p27448	753;753	;	53..308;53..308
7p3v	pdb	B-Raf V600E structure bound to a new inhibitor	x-ray	2.37	A;B	p15056;p15056	766;766	;	449..717;449..717
7p5z	pdb	Structure of a DNA-loaded MCM double hexamer engaged with the Dbf4-dependent kinase	em	3.3	1	p06243	507		13..475
7p6n	pdb	ROCK2 IN COMPLEX WITH COMPOUND 12	x-ray	3	A;B;C;D;E;F;G;H	o75116;o75116;o75116;o75116;o75116;o75116;o75116;o75116	1388;1388;1388;1388;1388;1388;1388;1388	;;;;;;;	89..412;89..412;89..412;89..412;89..412;89..412;89..412;89..412
7p7f	pdb	Crystal structure of phosphorylated pT220 Casein Kinase I delta (CK1d), conformation 1	x-ray	1.96	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
7p7g	pdb	Crystal structure of phosphorylated pT220 Casein Kinase I delta (CK1d), conformation 2 and 3	x-ray	1.7	A;B	p48730;p48730	415;415	;	5..290;5..290
7p7h	pdb	Crystal structure of Casein Kinase I delta (CK1d) with alphaG-in conformation	x-ray	2.4	A;B	p48730;p48730	415;415	;	5..290;5..290
7pcd	pdb	HER2 IN COMPLEX WITH A COVALENT INHIBITOR	x-ray	1.77	A	p04626	1255		716..992
7pe7	pdb	cryo-EM structure of DEPTOR bound to human mTOR complex 2, overall refinement	em	3.41	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
7pe8	pdb	cryo-EM structure of DEPTOR bound to human mTOR complex 2, focussed on one protomer	em	3.2	A	p42345	2549		2095..2451
7pe9	pdb	cryo-EM structure of DEPTOR bound to human mTOR complex 2, DEPt-bound subset local refinement	em	3.7	A	p42345	2549		2095..2451
7pea	pdb	cryo-EM structure of DEPTOR bound to human mTOR complex 1, overall refinement	em	4.07	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
7peb	pdb	cryo-EM structure of DEPTOR bound to human mTOR complex 1, focussed on one protomer	em	3.67	A	p42345	2549		2095..2451
7pec	pdb	cryo-EM structure of DEPTOR bound to human mTOR complex 1, DEPt-bound subset local refinement	em	4.24	A	p42345	2549		2095..2451
7pg0	pdb	Low resolution Cryo-EM structure of full-length insulin receptor bound to 3 insulin with visible ddm micelle, conf 1	em	7.6	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
7pg2	pdb	Low resolution Cryo-EM structure of full-length insulin receptor bound to 3 insulin, conf 1	em	6.7	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
7pg3	pdb	Low resolution Cryo-EM structure of the full-length insulin receptor bound to 3 insulin, conf 2	em	7.3	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
7pg4	pdb	Low resolution Cryo-EM structure of the full-length insulin receptor bound to 2 insulin, conf 3	em	9.1	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
7pg5	pdb	Crystal Structure of PI3Kalpha	x-ray	2.20029	A	p42336	1068		699..1060
7pg6	pdb	Crystal Structure of PI3Kalpha in complex with the inhibitor NVP-BYL719	x-ray	2.49944	A	p42336	1068		699..1060
7pi4	pdb	FAK Protac GSK215 in complex with FAK and pVHL:ElonginC:ElonginB	x-ray	2.24	DDD	q05397	1052		409..693
7pid	pdb	Protein kinase A catalytic subunit in complex with PKI5-24 and EN060	x-ray	1.496	A	p25321	351		29..339
7pie	pdb	Protein kinase A catalytic subunit in complex with PKI5-24 and EN068	x-ray	1.427	A	p25321	351		29..339
7pif	pdb	Protein kinase A catalytic subunit in complex with PKI5-24 and EN086	x-ray	1.395	A	p25321	351		29..339
7pig	pdb	Protein kinase A catalytic subunit in complex with PKI5-24 and EN088	x-ray	1.553	A	p25321	351		29..339
7pih	pdb	Protein kinase A catalytic subunit in complex with PKI5-24 and EN093	x-ray	1.374	A	p25321	351		29..339
7pns	pdb	Protein kinase A catalytic subunit in complex with PKI5-24 and EN081	x-ray	1.855	A	p25321	351		29..339
7pop	pdb	PI3 kinase delta in complex with 5-[3,6-dihydro-2H-pyran-4-yl]-2-methoxy-N-[2-methylpyridin-4-yl]pyridine-3-sulfonamide	x-ray	2.491	A	o35904	1043		677..1032
7por	pdb	PI3 kinase delta in complex with N-[2-(2-fluoro-4-{[4-(propan-2-yl)piperazin-1-yl]methyl}phenyl)pyridin-4-yl]-2-methoxy-5-(morpholin-4-yl)pyridine-3-sulfonamide	x-ray	2.26	A	o35904	1043		677..1032
7pos	pdb	PI3 kinase delta in complex with 5-(3,6-dihydro-2H-pyran-4-yl)-2-methoxy-N-(5-{3-[4-(propan-2-yl)piperazin-1-yl]prop-1-yn-1-yl}pyridin-3-yl)pyridine-3-sulfonamide	x-ray	2.493	A	o35904	1043		677..1032
7pot	pdb	PI3 kinase delta in complex with N-[5-(3,6-dihydro-2H-pyran-4-yl)-2-methoxypyridin-3-yl]benzenesulfonamide	x-ray	2.391	A	o35904	1043		677..1032
7pqh	pdb	Cryo-EM structure of Saccharomyces cerevisiae TOROID (TORC1 Organized in Inhibited Domains).	em	3.87	E;F;H;K	p32600;p32600;p32600;p32600	2474;2474;2474;2474	;;;	2034..2470;2034..2470;2034..2470;2034..2470
7pqs	pdb	SRPK1 in complex with MSC2711186	x-ray	2.2	A;B	q96sb4;q96sb4	655;655	;	67..654;67..654
7pqv	pdb	MEK1 IN COMPLEX WITH COMPOUND 7	x-ray	2.13	A	q02750	393		63..365
7psu	pdb	Structure of protein kinase CK2alpha mutant K198R associated with the Okur-Chung Neurodevelopmental Syndrome	x-ray	1.77	A;B	p68400;p68400	391;391	;	5..328;5..328
7pt6	pdb	Structure of MCM2-7 DH complexed with Cdc7-Dbf4 in the presence of ATPgS, state III	em	3.2	8;H	;	;	;	;
7pt7	pdb	Structure of MCM2-7 DH complexed with Cdc7-Dbf4 in the presence of ADP:BeF3, state I	em	3.8	8				
7pue	pdb	Human serum and glucocorticoid-regulated kinase 1 in complex with pyrazolopyridine inhibitor 3a	x-ray	2.506	A	o00141	431		74..401
7pus	pdb	ERK5 in complex with Pyrrole Carboxamide scaffold	x-ray	2.59	AAA	q13164	816		48..356
7pvu	pdb	Crystal structure of p38alpha C162S in complex with CAS2094511-69-8, P 1 21 1	x-ray	2.154	A;B	p47811;p47811	360;360	;	9..349;9..349
7pw4	pdb	Human SMG1-8-9 kinase complex bound to a SMG1 inhibitor	em	3.27	A	q96q15	3661		2070..2430
7pw5	pdb	Human SMG1-8-9 kinase complex with AlphaFold predicted SMG8 C-terminus, bound to a SMG1 inhibitor	em	3.4	A	q96q15	3661		2070..2430
7pw6	pdb	Human SMG1-8-9 kinase complex bound to a SMG1 inhibitor - SMG1 body	em	3.05	A	q96q15	3661		2070..2430
7pw7	pdb	Human SMG1-9 kinase complex bound to a SMG1 inhibitor	em	3.59	A	q96q15	3661		2070..2430
7pw8	pdb	Human SMG1-8-9 kinase complex bound to AMPPNP	em	2.82	A	q96q15	3661		2070..2430
7pw9	pdb	Human SMG1-9 kinase complex bound to AMPPNP	em	3.12	A	q96q15	3661		2070..2430
7pwd	pdb	Structure of an inhibited GRK2-G-beta and G-gamma complex	x-ray	2.6	A	p25098	689		187..532
7q4a	pdb	Toxoplasma gondii PRP4K kinase domain (L715F) bound to altiratinib	x-ray	2.31	A;B	s7ut92;s7ut92	928;928	;	565..901;565..901
7q52	pdb	Crystal structure of S/T protein kinase PknG from Mycobacterium tuberculosis in complex with inhibitor L2W	x-ray	2.35	AAA	p9wi73	750		131..402
7q6h	pdb	HUMAN JAK3 KINASE DOMAIN WITH 1-(4-((2-((1-methyl-1H-pyrazol-4-yl)amino)quinazolin-8-yl)amino)piperidin-1-yl)ethan-1-one	x-ray	1.749	AAA	p52333	1124		508..788,820..1097
7q7c	pdb	Room temperature structure of the human Serine/Threonine Kinase 17B (STK17B/DRAK2) in complex with ADP at atmospheric pressure	x-ray	2.85	A	o94768	372		28..321
7q7d	pdb	Room temperature structure of the human Serine/Threonine Kinase 17B (STK17B/DRAK2) in complex with ATP/ADP at 111 MPa helium gas pressure in a sapphire capillary	x-ray	2.6	A	o94768	372		28..321
7q7e	pdb	Room temperature structure of the human Serine/Threonine Kinase 17B (STK17B/DRAK2) in complex with ATP/ADP at atmospheric pressure in a sapphire capillary after high helium gas pressure release	x-ray	2.85	A	o94768	372		28..321
7q7i	pdb	JAK2 in complex with 4-{8-methoxy-2-[(1-methyl-1H-pyrazol-4-yl)amino]quinazolin-6-yl}phenol	x-ray	1.78	A	o60674	1132		522..814,842..1119
7q7k	pdb	JAK2 in complex with 4-(2-amino-8-methoxyquinazolin-6-yl)phenol	x-ray	1.61	A	o60674	1132		522..814,842..1119
7q7l	pdb	JAK2 in complex with 4-(2-amino-8-{[(2S)-1-hydroxypropan-2-yl]amino}quinazolin-6-yl)-5-ethyl-2-fluorophenol	x-ray	1.97	A	o60674	1132		522..814,842..1119
7q7w	pdb	JAK2 in complex with 4-(2-{[5-(dimethylamino)pentyl]amino}-8-{[(2S)-1-hydroxypropan-2-yl]amino}quinazolin-6-yl)-5-ethyl-2-fluorophenol	x-ray	1.85	A	o60674	1132		522..814,842..1119
7q8v	pdb	Crystal structure of TTBK1 in complex with VNG2.73 (compound 42)	x-ray	2.13	A	q5tcy1	1321		30..311
7q8w	pdb	Crystal structure of TTBK1 in complex with VNG1.35 (compound 23)	x-ray	2.02	A	q5tcy1	1321		30..311
7q8y	pdb	Crystal structure of TTBK2 in complex with VNG2.73 (compound 42)	x-ray	1.6	A;B	q6iq55;q6iq55	1244;1244	;	17..298;17..298
7q8z	pdb	Crystal structure of TTBK2 in complex with VNG1.33 (compound 27)	x-ray	1.57	A;B	q6iq55;q6iq55	1244;1244	;	17..298;17..298
7q90	pdb	Crystal structure of TTBK2 in complex with VNG1.63 (compound 32)	x-ray	1.6	A;B	q6iq55;q6iq55	1244;1244	;	17..298;17..298
7qb2	pdb	Pim1 in complex with (E)-4-((6-amino-1-methyl-2-oxoindolin-3-ylidene)methyl)benzoic acid and Pimtide	x-ray	2.53	A				
7qfm	pdb	Pim1 in complex with (E)-4-((2-oxoindolin-3-ylidene)methyl)benzoic acid and Pimtide	x-ray	1.95	A				
7qg1	pdb	IRAK4 in complex with inhibitor	x-ray	2.07	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
7qg2	pdb	IRAK4 in complex with inhibitor	x-ray	3.031	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
7qg3	pdb	IRAK4 in complex with inhibitor	x-ray	2.11	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
7qg5	pdb	IRAK4 in complex with inhibitor	x-ray	2.3	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
7qgb	pdb	H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE AT PH 6.5	x-ray	2.58	A	p68400	391		5..328
7qgc	pdb	H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE AT PH 5.5	x-ray	2.55	A	p68400	391		5..328
7qgd	pdb	H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE AT PH 8.5	x-ray	2.3	A	p68400	391		5..328
7qge	pdb	H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6,7,8-TETRABROMOBENZOTRIAZOLE (TBBt) AT PH 8.5	x-ray	2.27	A	p68400	391		5..328
7qgp	pdb	STK10 (LOK) bound to Macrocycle CKJB51	x-ray	1.9	A	o94804	968		31..302
7qhg	pdb	LIM domain kinase 2 (LIMK2) in complex with TH-470	x-ray	1.45	A;B	p53671;p53671	638;638	;	304..597;304..597
7qhl	pdb	Crystal structure of Cyclin-dependent kinase 2/cyclin A in complex with 3,5,7-Substituted pyrazolo[4,3-d]pyrimidine inhibitor 24	x-ray	1.7	A;C	p24941;p24941	298;298	;	1..292;1..292
7qhw	pdb	TTBK1 kinase domain in complex with inhibitor 29	x-ray	2.8	AAA;CCC	q5tcy1;q5tcy1	1321;1321	;	30..311;30..311
7qq6	pdb	GCN2 (EIF2ALPHA KINASE 4, E2AK4) IN COMPLEX WITH COMPOUND 1 (dovitinib)	x-ray	2.8	A;B;C;D	q9p2k8;q9p2k8;q9p2k8;q9p2k8	1649;1649;1649;1649	;;;	336..550,589..1021;336..550,589..1021;336..550,589..1021;336..550,589..1021
7qr9	pdb	Crystal structure of CK1 delta in complex with PK-09-82	x-ray	2.3	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
7qra	pdb	Crystal structure of CK1 delta in complex with VN725	x-ray	2.4	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
7qrb	pdb	Crystal structure of CK1 delta in complex with PK-09-129	x-ray	2.6	A;B;C;D	p48730;p48730;p48730;p48730	415;415;415;415	;;;	5..290;5..290;5..290;5..290
7que	pdb	The STK17A (DRAK1) Kinase Domain Bound to CKJB68	x-ray	2.4	A;B	q9uee5;q9uee5	414;414	;	60..328;60..328
7quf	pdb	The STK17A (DRAK1) Kinase Domain Bound to CK156	x-ray	2.6	A;B	q9uee5;q9uee5	414;414	;	60..328;60..328
7qux	pdb	Crystal structure of P7C8 bound to CK2alpha	x-ray	1.48	A				
7qwk	pdb	GCN2 (EIF2ALPHA KINASE 4, E2AK4) IN COMPLEX WITH COMPOUND 2	x-ray	2.3	A;B;C;D;E;F;G;H	q9p2k8;q9p2k8;q9p2k8;q9p2k8;q9p2k8;q9p2k8;q9p2k8;q9p2k8	1649;1649;1649;1649;1649;1649;1649;1649	;;;;;;;	336..550,589..1021;336..550,589..1021;336..550,589..1021;336..550,589..1021;336..550,589..1021;336..550,589..1021;336..550,589..1021;336..550,589..1021
7r26	pdb	PI3K delta in complex with SD5	x-ray	2.3	A	o35904	1043		677..1032
7r2b	pdb	PI3Kdelta in complex with an inhibitor	x-ray	2.7	A	o35904	1043		677..1032
7r60	pdb	BTK in complex with 18A	x-ray	1.94	A	q06187	659		382..648
7r61	pdb	BTK in complex with 25A	x-ray	1.52	A	q06187	659		382..648
7r7k	pdb	Structure of Human Anaplastic Lymphoma Kinase Domain in complex with (4-[6-amino-5-[(1~{R})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]isoindolin-1-one)	x-ray	1.831	A	q9um73	1620		1089..1381
7r7r	pdb	Structure of Human Anaplastic Lymphoma Kinase Domain in complex with ((2~{R})-2-[5-[6-amino-5-[(1~{R})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]-4-methyl-thiazol-2-yl]propane-1,2-diol)	x-ray	1.935	A	q9um73	1620		1089..1381
7r9l	pdb	Crystal structure of HPK1 in complex with compound 2	x-ray	2.332	A	q92918	833		14..444
7r9n	pdb	Crystal structure of HPK1 in complex with GNE1858	x-ray	1.5	A;B	q92918;q92918	833;833	;	14..444;14..444
7r9p	pdb	Crystal structure of HPK1 in complex with compound 14	x-ray	2.27	A;B	q92918;q92918	833;833	;	14..444;14..444
7r9t	pdb	Crystal structure of HPK1 in complex with compound 17	x-ray	2	A;B	q92918;q92918	833;833	;	14..444;14..444
7r9v	pdb	Structure of PIK3CA with covalent inhibitor 19	x-ray	2.69	A	p42336	1068		699..1060
7r9y	pdb	Structure of PIK3CA with covalent inhibitor 22	x-ray	2.85	A	p42336	1068		699..1060
7ree	pdb	High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to YM2-059	x-ray	1.38	A	o60674	1132		522..814,842..1119
7rn6	pdb	High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to type-II inhibitor BBT594	x-ray	1.5	A	o60674	1132		522..814,842..1119
7rsj	pdb	Structure of the VPS34 kinase domain with compound 14	x-ray	1.881	A	q8neb9	887		538..883
7rsp	pdb	Structure of the VPS34 kinase domain with compound 14	x-ray	1.67	A;B	q8neb9;q8neb9	887;887	;	538..883;538..883
7rsv	pdb	Structure of the VPS34 kinase domain with compound 5	x-ray	1.78	A;B	q8neb9;q8neb9	887;887	;	538..883;538..883
7run	pdb	Crystal structure of phosphorylated RET tyrosine kinase domain complexed with a pyrrolo[2,3-d]pyrimidine inhibitor.	x-ray	3.51	A;B	p07949;p07949	1114;1114	;	699..1005;699..1005
7rwe	pdb	Crystal structure of CDK2 liganded with compound GPHR787	x-ray	1.59	A	p24941	298		1..292
7rwf	pdb	Crystal structure of CDK2 in complex with TW8672	x-ray	1.5	A	p24941	298		1..292
7rxo	pdb	Crystal structure of CDK2 liganded with compound WN333	x-ray	1.38	A	p24941	298		1..292
7s1n	pdb	N-Aromatic-Substituted Indazole Derivatives as Brain Penetrant and Orally Bioavailable JNK3 Inhibitors	x-ray	2.11	A	p53779	464		52..396
7s25	pdb	ROCK1 IN COMPLEX WITH LIGAND G4998	x-ray	2.337	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
7s26	pdb	ROCK1 IN COMPLEX WITH LIGAND G5018	x-ray	2.744	A;B;C;D	q13464;q13464;q13464;q13464	1354;1354;1354;1354	;;;	73..413;73..413;73..413;73..413
7s3l	pdb	Structure of Bacillus subtilis CcrZ (previously called YtmP)	x-ray	2.6	A	c0spc1	269		6..231
7s46	pdb	PAK4cat (D440N/S474E) in complex with Integrin beta5 760-770 peptide	x-ray	2.1	A	o96013	591		323..578
7s47	pdb	Integrin beta5(743-774)-linker-PAK4cat(D440N/S474E)	x-ray	2	A	o96013	591		323..578
7s48	pdb	PAK4cat in complex with Integrin beta5 760-770 peptide	x-ray	1.9	A	o96013	591		323..578
7s4t	pdb	Crystal structure of CDK2 liganded with compound EF2252	x-ray	1.91	A	p24941	298		1..292
7s6u	pdb	Leishmania infantum Glycogen Synthase Kinase 3 beta bound to AZD5438	x-ray	1.74	A	a4hxq3	355		16..318
7s6v	pdb	Leishmania infantum Glycogen Synthase Kinase 3 beta bound to CGP60474	x-ray	1.66	A	a4hxq3	355		16..318
7s7a	pdb	Crystal structure of CDK2 liganded with compound EF3019	x-ray	1.7	A	p24941	298		1..292
7s84	pdb	Crystal structure of CDK2 liganded with compound TW8972	x-ray	2	A	p24941	298		1..292
7s85	pdb	Crystal structure of CDK2 liganded with compound WN316	x-ray	1.98	A	p24941	298		1..292
7s9x	pdb	Crystal structure of CDK2 liganded with compound WN378	x-ray	1.69	A	p24941	298		1..292
7sa0	pdb	Crystal structure of CDK2 liganded with compound EF4195	x-ray	1.59	A	p24941	298		1..292
7sgl	pdb	DNA-PK complex of DNA end processing	em	3	A	p78527	4128		3657..4049
7shq	pdb	Structure of a functional construct of eukaryotic elongation factor 2 kinase in complex with calmodulin.	x-ray	2.34	A	o00418	725		78..329
7shv	pdb	Crystal structure of BRAF kinase domain bound to GDC0879	x-ray	2.88	A;B	p15056;p15056	766;766	;	449..717;449..717
7si1	pdb	Crystal structure of apo EGFR kinase domain	x-ray	1.6	A	p00533	1210		708..1003
7sic	pdb	Human ATM Dimer	em	2.51	A;B	q13315;q13315	3056;3056	;	2623..2974;2623..2974
7sid	pdb	Human ATM Dimer Bound to Nbs1	em	2.53	A;C	q13315;q13315	3056;3056	;	2623..2974;2623..2974
7siu	pdb	Crystal structure of HPK1 (MAP4K1) complex with inhibitor A-745	x-ray	1.786	A;B	q92918;q92918	833;833	;	14..444;14..444
7sj3	pdb	Structure of CDK4-Cyclin D3 bound to abemaciclib	x-ray	2.51	A	p11802	303		3..297
7sl1	pdb	Full-length insulin receptor bound with site 1 binding deficient mutant insulin (A-V3E)	em	3.4	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
7sl2	pdb	Full-length insulin receptor bound with site 2 binding deficient mutant insulin (A-L13R) -- asymmetric conformation	em	3.6	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
7sl3	pdb	Full-length insulin receptor bound with site 2 binding deficient mutant insulin (A-L13R) -- symmetric conformation	em	3.4	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
7sl4	pdb	Full-length insulin receptor bound with site 2 binding deficient mutant insulin (B-L17R) -- asymmetric conformation	em	5	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
7sl6	pdb	Full-length insulin receptor bound with site 2 binding deficient mutant insulin (B-L17R) -- symmetric conformation	em	3.7	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
7sl7	pdb	Full-length insulin receptor bound with both site 1 binding deficient mutant insulin (A-V3E) and site 2 binding deficient mutant insulin (A-L13R)	em	3.1	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
7sqm	pdb	Discovery and Preclinical Pharmacology of INE963, A Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cure in Uncomplicated Malaria	x-ray	1.78	A	q8tf76	798		474..698
7sth	pdb	Full-length insulin receptor bound with unsaturated insulin WT (2 insulin bound) symmetric conformation	em	3.5	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
7sti	pdb	Full-length insulin receptor bound with unsaturated insulin WT (1 insulin bound) asymmetric conformation	em	4.9	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
7stj	pdb	Full-length insulin receptor bound with unsaturated insulin WT (2 insulins bound) asymmetric conformation (Conformation 1)	em	4.4	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
7stk	pdb	Full-length insulin receptor bound with unsaturated insulin WT (2 insulins bound) asymmetric conformation (Conformation 2)	em	4	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
7su3	pdb	CryoEM structure of DNA-PK complex VII	em	3.3	A	p78527	4128		3657..4049
7sud	pdb	CryoEM structure of DNA-PK complex VIII	em	3.6	A	p78527	4128		3657..4049
7suf	pdb	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 06	x-ray	1.48	A	o14757	476		6..317
7sug	pdb	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 09	x-ray	1.48	A	o14757	476		6..317
7suh	pdb	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 15	x-ray	2.46	A	o14757	476		6..317
7sui	pdb	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 22	x-ray	2.119	A	o14757	476		6..317
7suj	pdb	Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 24	x-ray	2.299	A;B	o14757;o14757	476;476	;	6..317;6..317
7sxf	pdb	BIO-2895 (BRD0705) bound GSK3alpha-axin complex	x-ray	1.94	A	p49840	483		119..436
7sxg	pdb	BIO-8546 bound GSK3alpha-axin complex	x-ray	2.4	A	p49840	483		119..436
7sxh	pdb	BIO-8546 bound GSK3beta-axin complex	x-ray	2.09	A	p49841	420		55..377
7sxj	pdb	BIO-2895 (BRD0705) bound GSK3beta-axin complex	x-ray	1.85	A	p49841	420		55..377
7syd	pdb	"Cryo-EM structure of the extracellular module of the full-length EGFR bound to EGF ""tips-juxtaposed"" conformation"	em	3.1	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
7sye	pdb	"Cryo-EM structure of the extracellular module of the full-length EGFR bound to EGF. ""tips-separated"" conformation"	em	3.3	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
7sz0	pdb	"Cryo-EM structure of the extracellular module of the full-length EGFR L834R bound to EGF. ""tips-juxtaposed"" conformation"	em	3.3	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
7sz1	pdb	"Cryo-EM structure of the extracellular module of the full-length EGFR L834R bound to EGF. ""tips-separated"" conformation"	em	3.4	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
7sz5	pdb	"Cryo-EM structure of the extracellular module of the full-length EGFR bound to TGF-alpha ""tips-separated"" conformation"	em	3.6	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
7sz7	pdb	"Cryo-EM structure of the extracellular module of the full-length EGFR bound to TGF-alpha. ""tips-juxtaposed"" conformation"	em	3.4	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
7sza	pdb	Crystal Structure Analysis of human PRPK complex with a compound	x-ray	1.9	A;C	q96s44;q96s44	253;253	;	36..225;36..225
7szb	pdb	Crystal Structure Analysis of human PRPK complex with a compound	x-ray	2.02	A;C	q96s44;q96s44	253;253	;	36..225;36..225
7szc	pdb	Crystal Structure Analysis of human PRPK complex with a compound	x-ray	1.71	A;C	q96s44;q96s44	253;253	;	36..225;36..225
7szd	pdb	Crystal Structure Analysis of human PRPK complex with a compound	x-ray	2.05	A;C	q96s44;q96s44	253;253	;	36..225;36..225
7szr	pdb	NIK bound to inhibitor G02792917	x-ray	2.8	A;B	q9wul6;q9wul6	942;942	;	407..656;407..656
7szw	pdb	JAK2 JH2 in complex with JAK249	x-ray	1.90646	A	o60674	1132		522..814,842..1119
7t0p	pdb	JAK2 JH2 IN COMPLEX WITH JAK315	x-ray	2.04	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
7t1t	pdb	JAK2 JH2 IN COMPLEX WITH JAK292	x-ray	2.08	A	o60674	1132		522..814,842..1119
7t3x	pdb	Structure of unphosphorylated Pediculus humanus (Ph) PINK1 D334A mutant	x-ray	3.53	A	e0w1i1	575		151..477
7t4i	pdb	Crystal Structure of wild type EGFR in complex with TAK-788	x-ray	2.61	A	p00533	1210		708..1003
7t4j	pdb	Crystal Structure of EGFR_D770_N771insNPG/V948R in complex with TAK-788	x-ray	2.2	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
7t4k	pdb	Structure of dimeric phosphorylated Pediculus humanus (Ph) PINK1 with kinked alpha-C helix in chain B	em	3.25	A;B	e0w1i1;e0w1i1	575;575	;	151..477;151..477
7t4l	pdb	Structure of dimeric phosphorylated Pediculus humanus (Ph) PINK1 with extended alpha-C helix in chain B	em	3.28	A;B	e0w1i1;e0w1i1	575;575	;	151..477;151..477
7t4m	pdb	Structure of dodecameric unphosphorylated Pediculus humanus (Ph) PINK1 D357A mutant	em	2.48	A;B;C;D;E;F;G;H;I;J;K;L	e0w1i1;e0w1i1;e0w1i1;e0w1i1;e0w1i1;e0w1i1;e0w1i1;e0w1i1;e0w1i1;e0w1i1;e0w1i1;e0w1i1	575;575;575;575;575;575;575;575;575;575;575;575	;;;;;;;;;;;	151..477;151..477;151..477;151..477;151..477;151..477;151..477;151..477;151..477;151..477;151..477;151..477
7t4n	pdb	Structure of dimeric unphosphorylated Pediculus humanus (Ph) PINK1 D357A mutant	em	2.35	A;B	e0w1i1;e0w1i1	575;575	;	151..477;151..477
7t4t	pdb	Crystal Structure of cGMP-dependent Protein Kinase	x-ray	2.08	A;B	q13976;q13976	671;671	;	354..660;354..660
7t4u	pdb	Crystal Structure of cGMP-dependent Protein Kinase	x-ray	1.99	A;B	q13976;q13976	671;671	;	354..660;354..660
7t4v	pdb	Crystal Structure of cGMP-dependent Protein Kinase	x-ray	2.28	A;B	q13976;q13976	671;671	;	354..660;354..660
7t4w	pdb	Crystal Structure of cGMP-dependent Protein Kinase	x-ray	2.23	A;B	q13976;q13976	671;671	;	354..660;354..660
7t6f	pdb	Structure of active Janus Kinase (JAK) dimer complexed with cytokine receptor intracellular domain	em	3.6	A;B	p52332;p52332	1153;1153	;	565..851,871..1145;565..851,871..1145
7tan	pdb	Structure of VRK1 C-terminal tail bound to nucleosome core particle	em	3	K;L	q99986;q99986	396;396	;	31..340;31..340
7teu	pdb	Crystal structure of JAK2 JH1 with type II inhibitor YLIU-04-105-1	x-ray	1.45	A	o60674	1132		522..814,842..1119
7tnh	pdb	Crystal structure of CSF1R kinase domain in complex with DP-6233	x-ray	2.7	A	p07333	972		551..909
7tvd	pdb	Crystal structure of the kinase domain of EGFR exon-19 (del-747-749) mutant	x-ray	2.96	A	p00533	1210		708..1003
7tyj	pdb	Cryo-EM Structure of insulin receptor-related receptor (IRR) in apo-state captured at pH 7. The 3D refinement was focused on one of two halves with C1 symmetry applied	em	3.3	A;B	p14616;p14616	1297;1297	;	952..1244;952..1244
7tyk	pdb	Cryo-EM Structure of insulin receptor-related receptor (IRR) in apo-state captured at pH 7. The 3D refinement was applied with C2 symmetry	em	3.5	A;B	p14616;p14616	1297;1297	;	952..1244;952..1244
7tym	pdb	Cryo-EM Structure of insulin receptor-related receptor (IRR) in active-state captured at pH 9. The 3D refinement was applied with C2 symmetry	em	3.4	A;B	p14616;p14616	1297;1297	;	952..1244;952..1244
7tyr	pdb	Cryo-EM structure of the basal state of the Artemis:DNA-PKcs complex (see COMPND 13/14)	em	3.33	A	p78527	4128		3657..4049
7tz7	pdb	PI3K alpha in complex with an inhibitor	x-ray	2.41	A	p42336	1068		699..1060
7tzo	pdb	The apo structure of human mTORC2 complex	em	3.28	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
7u2z	pdb	Crystal structure of human GSK3B in complex with G12	x-ray	2.21	A;B	p49841;p49841	420;420	;	55..377;55..377
7u31	pdb	Crystal structure of human GSK3B in complex with G5	x-ray	2.38	A;B	p49841;p49841	420;420	;	55..377;55..377
7u33	pdb	Crystal structure of human GSK3B in complex with ARN9133	x-ray	2.6	A;B	p49841;p49841	420;420	;	55..377;55..377
7u36	pdb	Crystal structure of human GSK3B in complex with ARN1484	x-ray	2.75	A;B	p49841;p49841	420;420	;	55..377;55..377
7u98	pdb	EGFR(T790M/V948R) in complex with a macrocyclic inhibitor	x-ray	3.42	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7u99	pdb	EGFR kinase in complex with a macrocyclic inhibitor	x-ray	2.5	A	p00533	1210		708..1003
7u9a	pdb	EGFR in complex with a macrocyclic inhibitor	x-ray	2.6	A	p00533	1210		708..1003
7udp	pdb	Crystal structure of COQ8A-CA157 inhibitor complex in space group C2	x-ray	2.01	A	q8ni60	647		315..522
7udq	pdb	Crystal structure of COQ8A-CA157 inhibitor complex in space group P1	x-ray	1.9	A;B	q8ni60;q8ni60	647;647	;	315..522;315..522
7ug1	pdb	CDK2 liganded with para chloro ANS	x-ray	1.84	A	p24941	298		1..292
7ugb	pdb	Crystal structure of rat ERK2 complexed with docking peptide from ISG20	x-ray	1.9	A	p63086	358		17..320
7uiq	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and Tiam1	x-ray	3.11	A;B	q9uqm7;q9uqm7	478;478	;	9..272;9..272
7uir	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and Tiam1 in complex with ATP	x-ray	3.1	A;B	q9uqm7;q9uqm7	478;478	;	9..272;9..272
7uis	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)	x-ray	2.58	A	q9uqm7	478		9..272
7ujp	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B	x-ray	2.56	A;B	q9uqm7;q9uqm7	478;478	;	9..272;9..272
7ujq	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B	x-ray	2.25	A;B	q9uqm7;q9uqm7	478;478	;	9..272;9..272
7ujr	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B	x-ray	1.95	A	q9uqm7	478		9..272
7ujs	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B in complex with ADP	x-ray	2.75	A	q9uqm7	478		9..272
7ujt	pdb	Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D) in complex with ATP	x-ray	2.1	A	q9uqm7	478		9..272
7ujx	pdb	Structure of cAMP-dependent protein kinase using a MD-MX procedure, produced using 2.4 Angstrom data	x-ray	2.4	E	p05132	351		28..339
7ukv	pdb	Wild type EGFR in complex with Lazertinib (YH25448)	x-ray	2.4	A	p00533	1210		708..1003
7ukw	pdb	EGFR(T790M/V948R) in complex with Lazertinib (YH25448)	x-ray	2.6	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
7ukz	pdb	CDK11 in complex with small molecule inhibitor OTS964	x-ray	2.6	A;B;C;D;E;F	p21127;p21127;p21127;p21127;p21127;p21127	795;795;795;795;795;795	;;;;;	431..730;431..730;431..730;431..730;431..730;431..730
7umb	pdb	NanoBRET tracer Tram-bo bound to a KSR2-MEK1 complex	x-ray	3.231	B;C	q6vab6;q02750	950;393	;	642..928;63..365
7uos	pdb	Structure of WNK1 inhibitor complex	x-ray	2.9	A	q9jih7	2126		226..480
7up4	pdb	Crystal structure of C-terminal Domain of MSK1 in complex with covalently bound pyrrolopyrimidine compound 20 (co-crystal)	x-ray	3	A;B	o75582;o75582	802;802	;	46..397,429..703;46..397,429..703
7up5	pdb	Crystal structure of C-terminal Domain of MSK1 in complex with covalently bound pyrrolopyrimidine compound 23 (co-crystal)	x-ray	2.8	A;B	o75582;o75582	802;802	;	46..397,429..703;46..397,429..703
7up6	pdb	Crystal structure of C-terminal domain of MSK1 in complex with in covalently bound literature RSK2 inhibitor pyrrolopyrimidine cyanoacrylamide compound 25 (co-crystal)	x-ray	2.6	A	o75582	802		46..397,429..703
7up7	pdb	Crystal structure of C-terminal Domain of MSK1 in complex with covalently bound with literature RSK2 inhibitor indazole cyanoacrylamide compound 26 (soak)	x-ray	2.8	A;B	o75582;o75582	802;802	;	46..397,429..703;46..397,429..703
7up8	pdb	Crystal structure of C-terminal Domain of MSK1 in complex with covalently bound pyrrolopyrimidine compound 27 (co-crystal)	x-ray	2.9	A;B	o75582;o75582	802;802	;	46..397,429..703;46..397,429..703
7upm	pdb	Tribbles (TRIB2) pseudokinase bound to nanobody Nb4.103	x-ray	2.7	A				
7uxc	pdb	cryo-EM structure of the mTORC1-TFEB-Rag-Ragulator complex with symmetry expansion	em	3.2	A	p42345	2549		2095..2451
7uxh	pdb	cryo-EM structure of the mTORC1-TFEB-Rag-Ragulator complex	em	3.2	A;C	p42345;p42345	2549;2549	;	2095..2451;2095..2451
7uxi	pdb	Structure of CDK2 in complex with FP19711, a Helicon Polypeptide	x-ray	2.07	A				
7uxk	pdb	Structure of CDK2 in complex with FP24322, a Helicon Polypeptide	x-ray	2.63	A				
7uy0	pdb	Crystal structure of human Fgr tyrosine kinase in complex with A-419259	x-ray	2.55	A;B	p09769;p09769	529;529	;	253..521;253..521
7uy3	pdb	Crystal structure of human Fgr tyrosine kinase in complex with TL02-59	x-ray	2.99	A	p09769	529		253..521
7uyr	pdb	Crystal structure of TYK2 kinase domain in complex with compound 12	x-ray	2.15	A	p29597	1187		576..879,887..1166
7uys	pdb	Crystal structure of TYK2 kinase domain in complex with compound 16	x-ray	2.15	A	p29597	1187		576..879,887..1166
7uyt	pdb	Crystal structure of TYK2 kinase domain in complex with compound 25	x-ray	2.14	A	p29597	1187		576..879,887..1166
7uyu	pdb	Crystal structure of TYK2 kinase domain in complex with compound 30	x-ray	2.05	A	p29597	1187		576..879,887..1166
7uyv	pdb	Crystal structure of JAK3 kinase domain in complex with compound 25	x-ray	2.15	A;B;C;D	p52333;p52333;p52333;p52333	1124;1124;1124;1124	;;;	508..788,820..1097;508..788,820..1097;508..788,820..1097;508..788,820..1097
7uyw	pdb	Crystal structure of JAK2 kinase domain in complex with compound 30	x-ray	2.51	A	o60674	1132		522..814,842..1119
7v0g	pdb	Structure of cAMP-dependent protein kinase using a MD-MX procedure, produced using 1.63 Angstrom data	x-ray	1.63	E	p05132	351		28..339
7v29	pdb	Crystal structure of FGFR4 with a dual-warhead covalent inhhibitor	x-ray	1.983	A;B	p22455;p22455	802;802	;	458..743;458..743
7v3r	pdb	Crystal structure of CMET in complex with a novel inhibitor	x-ray	1.7	A	p08581	1390		1079..1341
7v3s	pdb	Crystal structure of CMET in complex with a novel inhibitor	x-ray	1.9	A	p08581	1390		1079..1341
7v3v	pdb	Cryo-EM structure of MCM double hexamer bound with DDK in State I	em	2.9	H	p06243	507		13..475
7vbt	pdb	Crystal structure of RIOK2 in complex with CQ211	x-ray	2.54001	A;B	q9bvs4;q9bvs4	552;552	;	97..272;97..272
7vdp	pdb	The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 1	x-ray	2.09	A;B	q00535;q00535	292;292	;	1..290;1..290
7vdq	pdb	The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 7	x-ray	2.91	A;B	q00535;q00535	292;292	;	1..290;1..290
7vdr	pdb	The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 13	x-ray	2.55	A;B	q00535;q00535	292;292	;	1..290;1..290
7vds	pdb	The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 24	x-ray	3.05	A;B	q00535;q00535	292;292	;	1..290;1..290
7vjl	pdb	The crystal structure of FGFR4 kinase domain in complex with N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-(2,2,2-trifluoroacetyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide	x-ray	2.90017	A;B	p22455;p22455	802;802	;	458..743;458..743
7vkm	pdb	Crystal structure of TrkA (G595R) kinase domain	x-ray	2.55	A	p04629	796		494..779
7vkn	pdb	Crystal structure of TrkA (G595R) kinase with repotrectinib	x-ray	2.7	A	p04629	796		494..779
7vko	pdb	Crystal structure of TrkA kinase with repotrectinib	x-ray	2.9	A	p04629	796		494..779
7vnx	pdb	Crystal structure of TkArkI	x-ray	1.801	A	q5jdq4	216		9..155
7vra	pdb	The crystal structure of EGFR T790M/C797S with the inhibitor HC5476	x-ray	2.41	A	p00533	1210		708..1003
7vre	pdb	The crystal structure of EGFR T790M/C797S with the inhibitor HCD2892	x-ray	2.507	A	p00533	1210		708..1003
7vsy	pdb	Pim1 with N82K mutation	x-ray	2.141	A	p11309	313		36..296
7vto	pdb	The crystal structure of PAK1 with the inhibitor GW8510	x-ray	2.59	A;B	q13153;q13153	545;545	;	261..522;261..522
7vvy	pdb	TRA module of NuA4	em	3.1	L	p38811	3744		3307..3703
7vvz	pdb	NuA4 bound to the nucleosome	em	8.8	L	p38811	3744		3307..3703
7w15	pdb	Crystal Structure of MPH-E in complex with GTP and Erythromycin	x-ray	1.77	A;B	a5y459;a5y459	294;294	;	31..242;31..242
7w19	pdb	Crystal Structure of Acinetobacter baumannii MPH-E	x-ray	1.9	A;B	a5y459;a5y459	294;294	;	31..242;31..242
7w1a	pdb	Crystal Structure of MPH-E in complex with GMP and Azithromycin	x-ray	2.17	A;B	a5y459;a5y459	294;294	;	31..242;31..242
7w5c	pdb	Crystal structure of Mitogen Activated Protein Kinase 4 (MPK4) from Arabidopsis thaliana	x-ray	2.201	A;Q	q39024;q94a06	376;354	;	46..336;60..334
7w5o	pdb	Crystal structure of ERK2 with an allosteric inhibitor	x-ray	2.35	A;B	p28482;p28482	360;360	;	19..322;19..322
7w7x	pdb	The crystal structure of human abl1 kinase domain in complex with ABL1-A11	x-ray	2.00001	A;B	p00519;p00519	1130;1130	;	231..498;231..498
7w7y	pdb	The crystal structure of human abl1 kinase domain in complex with ABL2-A5	x-ray	2.20003	A;B	p00519;p00519	1130;1130	;	231..498;231..498
7wcl	pdb	Crystal structure of FGFR1 kinase domain with Pemigatinib	x-ray	2.495	A;B	p11362;p11362	822;822	;	468..754;468..754
7wct	pdb	Crystal structure of FGFR4 kinase domain with 7v	x-ray	2.106	A	p22455	802		458..743
7wcw	pdb	Crystal structure of FGFR4(V550L) kinase domain with 7v	x-ray	2.317	A	p22455	802		458..743
7wcx	pdb	Crystal structure of FGFR4(V550M) kinase domain with 7v	x-ray	2.175	A	p22455	802		458..743
7wf5	pdb	c-Src in complex with ponatinib	x-ray	1.798	A;B	p00523;p00523	533;533	;	256..526;256..526
7wj6	pdb	Crystal Structure of the Kinase Domain of a Class III Lanthipeptide Synthetase CurKC	x-ray	2.55	A;B	d1abx1;d1abx1	866;866	;	224..426;224..426
7wj7	pdb	Crystal Structure of the Kinase Domain with Adenosine of a Class III Lanthipeptide Synthetase CurKC	x-ray	2.55	A;B	d1abx1;d1abx1	866;866	;	224..426;224..426
7wtt	pdb	Cryo-EM structure of a human pre-40S ribosomal subunit - State RRP12-A1 (with CK1)	em	3.1	a	p48729	337		12..298
7wu0	pdb	Cryo-EM structure of a human pre-40S ribosomal subunit - State RRP12-B3	em	3.3	v	q9bvs4	552		97..272
7wzr	pdb	Cryo-EM structure of Mec1-HU	em	4.7	C;F	p38111;p38111	2368;2368	;	2040..2367;2040..2367
7wzw	pdb	Cryo-EM structure of MEC1-DDC2-MMS	em	4	E;F	p38111;p38111	2368;2368	;	2040..2367;2040..2367
7x4h	pdb	Crystal structure of CK2a1 complexed with AG1112	x-ray	1.77	A	p68400	391		5..328
7x4u	pdb	Crystal structure of ERK2 with an allosteric inhibitor 2	x-ray	1.98	A	p28482	360		19..322
7xaf	pdb	The crystal structure of TrkA kinase in complex with 4^6,14-dimethyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-10-oxo-5-oxa-11,14-diaza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclo- tetradecaphan-2-yne-45-carboxamide	x-ray	3.00118	A	p04629	796		494..779
7xbi	pdb	The crystal structure of human TrkA kinase bound to the inhibitor	x-ray	2.16	A	p04629	796		494..779
7xbr	pdb	Crystal structure of phosphorylated AtMKK5	x-ray	3.2	A;B;C;D;E;F;G;H	q8rxg3;q8rxg3;q8rxg3;q8rxg3;q8rxg3;q8rxg3;q8rxg3;q8rxg3	348;348;348;348;348;348;348;348	;;;;;;;	68..344;68..344;68..344;68..344;68..344;68..344;68..344;68..344
7xc1	pdb	Crystal structure of ERK2 with an allosteric inhibitor 3	x-ray	2.09	A;B	p28482;p28482	360;360	;	19..322;19..322
7xdv	pdb	Crystal structure of a receptor like kinase from Arabidopsis	x-ray	1.97	A;B	q9scz4;q9scz4	895;895	;	511..809;511..809
7xdw	pdb	Crystal structure of a receptor like kinase from Arabidopsis	x-ray	1.926	A;B	q9scz4;q9scz4	895;895	;	511..809;511..809
7xdx	pdb	Crystal structure of a receptor like kinase from Arabidopsis	x-ray	2.23	A;B	q9scz4;q9scz4	895;895	;	511..809;511..809
7xdy	pdb	Crystal structure of a receptor like kinase from Arabidopsis	x-ray	2.28	A;B	q9scz4;q9scz4	895;895	;	511..809;511..809
7xhy	pdb	Crystal structure of MerTK Kinase domain with BMS794833	x-ray	2.16	A	q12866	999		578..872
7xlp	pdb	MEK1 bound to DS03090629	x-ray	2.1	A	q02750	393		63..365
7xmk	pdb	Crystal structure of human RIPK1 kinase domain in complex with compound SKLB923	x-ray	2.376	A;B	q13546;q13546	671;671	;	6..286;6..286
7xnc	pdb	MEK1 bound to DS94070624	x-ray	2.1	A	q02750	393		63..365
7xqk	pdb	The Crystal Structure of CDK3 and CyclinE1 Complex from Biortus.	x-ray	2.25	A	p08515	218		
7xsv	pdb	Crystal Structures of PIM1 in Complex with Macrocyclic Compound H3	x-ray	2.66	A	p11309	313		36..296
7xyh	pdb	Crystal structure of CK2a2 complexed with AG1112	x-ray	2.04	A;B	p19784;p19784	350;350	;	13..330;13..330
7xzq	pdb	Crystal structure of TNIK-thiopeptide TP1 complex	x-ray	2.09	A				
7xzr	pdb	Crystal structure of TNIK-AMPPNP-thiopeptide TP15 complex	x-ray	2.26	A;B	;	;	;	;
7y1g	pdb	Crystal structure of human PRKACA complexed with DS01080522	x-ray	2.3	A;B	p17612;p17612	351;351	;	30..339;30..339
7y4t	pdb	Crystal structure of cMET kinase domain bound by compound 9I	x-ray	2.16	A	p08581	1390		1079..1341
7y4u	pdb	Crystal structure of cMET kinase domain bound by compound 9Y	x-ray	2.26	A	p08581	1390		1079..1341
7yaw	pdb	Crystal structure of ZAK in complex with compound YH-180	x-ray	2.1	A;B;C;D	q9nyl2;q9nyl2;q9nyl2;q9nyl2	800;800;800;800	;;;	8..260;8..260;8..260;8..260
7yaz	pdb	Crystal structure of ZAK in complex with compound YH-186	x-ray	2.54	A	q9nyl2	800		8..260
7ybo	pdb	Crystal structure of FGFR4 kinase domain with 10z	x-ray	2.307	A	p22455	802		458..743
7ybp	pdb	Crystal structure of FGFR4(V550L) kinase domain with 10z	x-ray	2.243	A	p22455	802		458..743
7ybx	pdb	Crystal structure of FGFR4(V550M) kinase domain with 10z	x-ray	2.233	A	p22455	802		458..743
7yc1	pdb	Crystal structure of FGFR4 kinase domain with 10d	x-ray	2.535	A	p22455	802		458..743
7yc3	pdb	Crystal structure of FGFR4 kinase domain with 10t	x-ray	1.987	A	p22455	802		458..743
7yc9	pdb	Co-crystal structure of BTK kinase domain with inhibitor	x-ray	1.4	A	q06187	659		382..648
7ydx	pdb	Crystal structure of human RIPK1 kinase domain in complex with compound RI-962	x-ray	2.642	A;B	q13546;q13546	671;671	;	6..286;6..286
7yfn	pdb	Core module of the NuA4 complex in S. cerevisiae	em	3.8	T	p38811	3744		3307..3703
7yfp	pdb	The NuA4 histone acetyltransferase complex from S. cerevisiae	em	4	T	p38811	3744		3307..3703
7yl1	pdb	Crystal structure of JNK3 in complex with a fragment molecule	x-ray	2.48	A	p53779	464		52..396
7z1f	pdb	Crystal structure of GSK3b in complex with CX-4945	x-ray	3	A;B	p49841;p49841	420;420	;	55..377;55..377
7z1g	pdb	Crystal structure of nonphosphorylated (Tyr216) GSK3b in complex with CX-4945	x-ray	2.85	A	p49841	420		55..377
7z37	pdb	Structure of the RAF1-HSP90-CDC37 complex (RHC-II)	em	3.67	CP1	p04049	648		344..611
7z38	pdb	Structure of the RAF1-HSP90-CDC37 complex (RHC-I)	em	3.16	C	p04049	648		344..611
7z39	pdb	Structure of Belumosudil bound to CK2alpha	x-ray	1.6	A	p68400	391		5..328
7z4v	pdb	Structure of Serine-Threonine kinase STK25 in complex with compound	x-ray	1.644	A	o00506	426		20..329
7z5n	pdb	Crystal structure of DYRK1A in complex with CX-4945	x-ray	2.77	A;B;C;D;E;F;G;H	q13627;q13627;q13627;q13627;q13627;q13627;q13627;q13627	763;763;763;763;763;763;763;763	;;;;;;;	147..489;147..489;147..489;147..489;147..489;147..489;147..489;147..489
7z5w	pdb	ROS1 with AstraZeneca ligand 1	x-ray	2.254	A;B	p08922;p08922	2347;2347	;	1935..2215;1935..2215
7z5x	pdb	ROS1 with AstraZeneca ligand 2	x-ray	2.035	A;B	p08922;p08922	2347;2347	;	1935..2215;1935..2215
7z61	pdb	Crystal structure of PI3Kgamma with a dihydropurinone inhibitor (compound 18)	x-ray	2.738	A	p48736	1102		728..1089
7z6i	pdb	Crystal structure of p38alpha C162S in complex with SB20358 and CAS 2094667-81-7 (behind catalytic site; Y35 in), P 21 21 21	x-ray	2.25	AAA	p47811	360		9..349
7z6u	pdb	Pim1 in complex with (E)-4-((6-amino-2-oxoindolin-3-ylidene)methyl)benzoic acid and Pimtide	x-ray	2.28	A				
7z74	pdb	PI3KC2a core in complex with PITCOIN2	x-ray	2.5	A	q61194	1686		1042..1391
7z75	pdb	PI3KC2a core in complex with PITCOIN3	x-ray	2.59	A	q61194	1686		1042..1391
7z87	pdb	DNA-PK in the active state	em	2.91	A	p78527	4128		3657..4049
7z88	pdb	DNA-PK in the intermediate state	em	3.33	A	p78527	4128		3657..4049
7z9t	pdb	Crystal structure of p38alpha C162S in complex with ATPgS and CAS 2094667-81-7 (in catalytic site, Y35 out), P 1 21 1	x-ray	2.6	AAA;BBB	p47811;p47811	360;360	;	9..349;9..349
7zh8	pdb	DYRK1a in Complex with a Bromo-Triazolo-Pyridine	x-ray	2.3	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
7zhn	pdb	Crystal structure of TTBK1 in complex with AMG28	x-ray	1.85	A	q5tcy1	1321		30..311
7zho	pdb	Crystal structure of TTBK1 in complex with compound 3 (7-001)	x-ray	2.08	A	q5tcy1	1321		30..311
7zhp	pdb	Crystal structure of TTBK1 in complex with compound 9 (7-005)	x-ray	1.8	A	q5tcy1	1321		30..311
7zhq	pdb	Crystal structure of TTBK1 in complex with compound 10 (7-009)	x-ray	1.8	A	q5tcy1	1321		30..311
7zks	pdb	SRPK1 IN COMPLEX WITH INHIBITOR	x-ray	2.28	A	q96sb4	655		67..654
7zkx	pdb	SRPK2 IN COMPLEX WITH INHIBITOR	x-ray	2.06	A	p78362	688		68..687
7zpc	pdb	CDK2 in complex 9K-DOS	x-ray	1.4	A	p24941	298		1..292
7zr0	pdb	CryoEM structure of HSP90-CDC37-BRAF(V600E) complex.	em	3.4	K	p15056	766		449..717
7zr5	pdb	CryoEM structure of HSP90-CDC37-BRAF(V600E)-PP5(closed) complex	em	3.9	K	p15056	766		449..717
7zr6	pdb	CryoEM structure of HSP90-CDC37-BRAF(V600E)-PP5(open) complex	em	4.2	K	p15056	766		449..717
7ztl	pdb	Crystal structure of a covalently linked Aurora-A N-Myc complex	x-ray	1.9	A	o14965	403		120..386
7zun	pdb	Crystal structure of PIM1 in complex with a Pyrrolo-Pyrazinone compound	x-ray	2.5	A	p11309	313		36..296
7zvs	pdb	Crystal structure of the Schistosoma mansoni VKR2 kinase domain in an active-like state (ADP-bound)	x-ray	3.07	A;B;C	a0a3q0kq92;a0a3q0kq92;a0a3q0kq92	1641;1641;1641	;;	958..1258;958..1258;958..1258
7zvw	pdb	NuA4 Histone Acetyltransferase Complex	em	3.4	A	c4qyv4	3825		3384..3755
7zw8	pdb	Identification of M4205 a highly selective inhibitor of cKIT mutations for unresectable metastatic or recurrent GIST	x-ray	2.119	A	p10721	976		564..923
7zwe	pdb	The Crystal structure of GW8695 bound to CK2alpha	x-ray	1.47	A	p68400	391		5..328
7zwg	pdb	The Crystal structure of RO4493940 bound to CK2alpha	x-ray	1.31	A	p68400	391		5..328
7zy0	pdb	Crystal structure of compound 7 bound to CK2alpha	x-ray	1.44	A	p68400	391		5..328
7zy2	pdb	Crystal structure of compound 7 bound to CK2alpha	x-ray	1.51	A	p68400	391		5..328
7zy5	pdb	Crystal structure of compound 2 bound to CK2alpha	x-ray	1.82	A;B	p68400;p68400	391;391	;	5..328;5..328
7zy6	pdb	Identification of M4205 a highly selective inhibitor of cKIT mutations for unresectable metastatic or recurrent GIST	x-ray	3.09	A	p10721	976		564..923
7zy8	pdb	Crystal structure of compound 2 bound to CK2alpha	x-ray	1.85	A;B	p68400;p68400	391;391	;	5..328;5..328
7zyd	pdb	Structure of Compound 6 Bound to CK2alpha	x-ray	1.404	A	p68400	391		5..328
7zyk	pdb	Compound 9 Bound to CK2alpha	x-ray	1.31	A	p68400	391		5..328
7zym	pdb	Crystal Structure of EGFR-T790M/C797S in Complex with Brigatinib	x-ray	2.5	A	p00533	1210		708..1003
7zyn	pdb	Crystal Structure of EGFR-T790M/C797S in Complex with WZ4002	x-ray	2.3	A	p00533	1210		708..1003
7zyo	pdb	Compound 9 Bound to CK2alpha	x-ray	1.58	A	p68400	391		5..328
7zyp	pdb	Crystal Structure of EGFR-T790M/C797S in Complex with Reversible Aminopyrimidine 9	x-ray	2.8	A	p00533	1210		708..1003
7zyq	pdb	Crystal Structure of EGFR-T790M/V948R in Complex with Reversible Aminopyrimidine 13	x-ray	2.1	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
7zyr	pdb	Compound 20 Bound to CK2alpha	x-ray	1.85	A	p68400	391		5..328
8a27	pdb	EGFR kinase domain in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-1-oxo-4-(trifluoromethyl)isoindolin-2-yl]-N-thiazol-2-yl-acetamide	x-ray	1.07	A	p00533	1210		708..1003
8a2a	pdb	EGFR kinase domain in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-1-oxo-4-(trifluoromethyl)isoindolin-2-yl]-N-thiazol-2-yl-acetamide (form 2)	x-ray	1.43	A	p00533	1210		708..1003
8a2b	pdb	EGFR kinase domain (L858R/V948R) in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-1-oxo-4-(trifluoromethyl)isoindolin-2-yl]-N-thiazol-2-yl-acetamide	x-ray	1.69	A	p00533	1210		708..1003
8a2d	pdb	EGFR kinase domain (L858R/V948R) in complex with 2-[4-(difluoromethyl)-6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-7-methyl-indazol-2-yl]-2-spiro[6,7-dihydropyrrolo[1,2-c]imidazole-5,1'-cyclopropane]-1-yl-N-thiazol-2-yl-acetamide	x-ray	1.11	A	p00533	1210		708..1003
8a3t	pdb	S. cerevisiae APC/C-Cdh1 complex	em	3.5	S	p34244	1518		78..370
8a5j	pdb	Crystal structure of Human STE20-like kinase 1, MST1 in complex with compound XMU-MP-1	x-ray	2.123	A;B	q13043;q13043	487;487	;	27..285;27..285
8a66	pdb	Crystal structure of MST2 in complex with XMU-MP-1	x-ray	1.901	A;B	q13188;q13188	491;491	;	24..287;24..287
8a8m	pdb	Structure of the MAPK p38alpha in complex with its activating MAP2K MKK6	em	4	A;B	q16539;p52564	360;334	;	9..349;41..315
8a9i	pdb	PI3KC2a core in complex with PITCOIN1	x-ray	2.87	A	q61194	1686		1042..1391
8aau	pdb	LIM Domain Kinase 1 (LIMK1) bound to LIMKi3	x-ray	1.74	L	p53667	647		329..616
8acm	pdb	Crystal structure of WT p38alpha	x-ray	2.14	AAA	p47811	360		9..349
8aco	pdb	Crystal structure of WT p38alpha	x-ray	2.65	AAA	p47811	360		9..349
8ae7	pdb	The strucuture of Compound 15 bound to CK2alpha	x-ray	1.28	A	p68400	391		5..328
8aec	pdb	Structure of Compound 17 bound to CK2alpha	x-ray	1.09	A	p68400	391		5..328
8aek	pdb	Structure of Compound 14 bound to CK2alpha	x-ray	1.65	A	p68400	391		5..328
8aem	pdb	Structure of Compound 13 bound to CK2alpha	x-ray	1.6	A	p68400	391		5..328
8afr	pdb	Pim1 in complex with 4-((6-hydroxybenzofuran-3-yl)methyl)benzoic acid and Pimtide	x-ray	2.15	A				
8agy	pdb	The Corramycin phosphotransferase in complex with Corramycin	x-ray	1.5	A				
8ahd	pdb	The apo structure of the Corramycin phosphotransferase	x-ray	2.1	A;B	;	;	;	;
8ahg	pdb	PAC-FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery	x-ray	1.885	A	o96013	591		323..578
8ahh	pdb	PAC FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery	x-ray	2.037	A	o96013	591		323..578
8ahi	pdb	PAC-FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery	x-ray	2.69	A	o96013	591		323..578
8aj8	pdb	Structure of p110 gamma bound to the p84 regulatory subunit	x-ray	8.5	A;C;E;G	o02697;o02697;o02697;o02697	1102;1102;1102;1102	;;;	728..1089;728..1089;728..1089;728..1089
8ak2	pdb	Drosophila melanogaster UNC89 Protein Kinase Domain 1 (apo)	x-ray	1.75	A	a8dyp0	4218		3166..3466,3880..4192
8ak3	pdb	Drosophila melanogaster UNC89 Protein Kinase 1 in complex with ADP	x-ray	1.9	A	a8dyp0	4218		3166..3466,3880..4192
8am0	pdb	Crystal structure of human T1061E PI3Kalpha in complex with its regulatory subunit and the inhibitor GDC-0077 (Inavolisib)	x-ray	2.818	A	p42336	1068		699..1060
8an8	pdb	Crystal structure of wild-type c-MET bound by compound 7.	x-ray	2.394	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
8ans	pdb	Crystal structure of D1228V c-MET bound by compound 1.	x-ray	2.01	A	p08581	1390		1079..1341
8ao2	pdb	Specific covalent inhibitor (3) of ERK2	x-ray	1.796	A	p28482	360		19..322
8ao3	pdb	Specific covalent inhibitor of ERK2	x-ray	1.778	A	p28482	360		19..322
8ao4	pdb	Specific covalent inhibitor (5) of ERK2	x-ray	1.825	A	p28482	360		19..322
8ao5	pdb	Specific covalent inhibitor (6) of ERK2	x-ray	1.595	A	p28482	360		19..322
8ao6	pdb	electrophilic inhibitor (7) of ERK2	x-ray	1.811	A	p28482	360		19..322
8ao7	pdb	Specific covalent inhibitor (8) of ERK2	x-ray	1.61	A	p28482	360		19..322
8ao8	pdb	Specific covalent inhibitor(9) of ERK2	x-ray	1.697	A	p28482	360		19..322
8ao9	pdb	Specific covalent inhibitor(10) of ERK2	x-ray	1.624	A	p28482	360		19..322
8aoa	pdb	Covalent and non-covalent inhibitor of ERK2 (two sites)	x-ray	1.62	A	p28482	360		19..322
8aob	pdb	Specific covalent inhibitor(12) of ERK2	x-ray	1.623	A	p28482	360		19..322
8aoc	pdb	Specific covalent inhibitor of ERK2	x-ray	1.62	A	p28482	360		19..322
8aod	pdb	Specific covalent inhibitor(14) of ERK2	x-ray	1.62	A	p28482	360		19..322
8aoe	pdb	Specific covalent inhibitor(15) of ERK2	x-ray	1.687	A	p28482	360		19..322
8aof	pdb	Specific covalent inhibitor(16) of ERK2	x-ray	1.615	A	p28482	360		19..322
8aog	pdb	Non-specific covalent inhibitor(17) of ERK2	x-ray	1.603	A	p28482	360		19..322
8aoh	pdb	Specific covalent inhibitor(18) of ERK2	x-ray	1.6	A	p28482	360		19..322
8aoi	pdb	Specific covalent inhibitor(19) of ERK2	x-ray	1.602	A	p28482	360		19..322
8aoj	pdb	Specific covalent inhibitor of ERK2	x-ray	1.12	A	p28482	360		19..322
8arj	pdb	Anaplastic Lymphoma Kinase with a novel carboline inhibitor	x-ray	1.645	A	q9um73	1620		1089..1381
8atb	pdb	Discovery of IRAK4 Inhibitor 16	x-ray	2.35	AAA;BBB	q9nwz3;q9nwz3	460;460	;	156..454;156..454
8atl	pdb	Discovery of IRAK4 Inhibitor 23	x-ray	2.464	AAA;BBB	q9nwz3;q9nwz3	460;460	;	156..454;156..454
8atn	pdb	Discovery of IRAK4 Inhibitor 38	x-ray	2.171	AAA;BBB	q9nwz3;q9nwz3	460;460	;	156..454;156..454
8au3	pdb	c-MET Y1234E,Y1235E mutant in complex with Tepotinib	x-ray	2.26	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
8au5	pdb	c-MET F1200I mutant in complex with Tepotinib	x-ray	2.72	A	p08581	1390		1079..1341
8auz	pdb	Crystal structure of GSK3 beta (GSK3b) in complex with FL291.	x-ray	2.66	A;B	p49841;p49841	420;420	;	55..377;55..377
8av1	pdb	Crystal structure of GSK3 beta (GSK3b) in complex with CD7.	x-ray	2.15	A;B	p49841;p49841	420;420	;	55..377;55..377
8aw1	pdb	c-MET Y1235D mutant in complex with Tepotinib	x-ray	2.14	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
8aza	pdb	Structure of RIP2K dimer bound to the XIAP BIR2 domain	em	3.15	A;B	o43353;o43353	540;540	;	11..297;11..297
8b54	pdb	CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR6768	x-ray	2.6	A;C	p24941;p24941	298;298	;	1..292;1..292
8b8n	pdb	Crystal structure of JAK2 JH2-V617F in complex with Cdk2 inhibitor IV	x-ray	2	A	o60674	1132		522..814,842..1119
8b8u	pdb	Crystal structure of JAK2 JH2-V617F in complex with HTS-A3	x-ray	1.5	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
8b99	pdb	Crystal structure of JAK2 JH2-V617F in complex with JNJ-7706621	x-ray	1.6	A	o60674	1132		522..814,842..1119
8b9e	pdb	Crystal structure of JAK2 JH2-V617F in complex with Z902-A3	x-ray	1.5	A	o60674	1132		522..814,842..1119
8b9h	pdb	Crystal structure of JAK2 JH2 in complex with Z902-A3	x-ray	1.5	A	o60674	1132		522..814,842..1119
8ba2	pdb	Crystal structure of JAK2 JH2-V617F in complex with Z902-A1	x-ray	1.5	A	o60674	1132		522..814,842..1119
8ba3	pdb	Crystal structure of JAK2 JH2 in complex with Bemcentinib	x-ray	1.4	A	o60674	1132		522..814,842..1119
8ba4	pdb	Crystal structure of JAK2 JH2-V617F in complex with Bemcentinib	x-ray	2.1	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
8bab	pdb	Crystal structure of JAK2 JH2-V617F in complex with CB76	x-ray	1.55	A	o60674	1132		522..814,842..1119
8bak	pdb	Crystal structure of JAK2 JH2-V617F in complex with Reversine	x-ray	1.65	A	o60674	1132		522..814,842..1119
8bcy	pdb	HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 13	x-ray	2.43	A	o00329	1044		678..1033
8bem	pdb	STE20-like serine/threonine-protein kinase (SLK) in complex with Tivozanib	x-ray	2.6	A;B;D;G	q9h2g2;q9h2g2;q9h2g2;q9h2g2	1235;1235;1235;1235	;;;	29..293;29..293;29..293;29..293
8bfm	pdb	Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) in complex with FZ331	x-ray	1.7	A	q8iu85	385		16..307
8bfs	pdb	Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) in complex with FZ326	x-ray	1.95	A	q8iu85	385		16..307
8bfu	pdb	Crystal structure of the apo p110alpha catalytic subunit from homo sapiens	x-ray	2.41	A	p42336	1068		699..1060
8bgc	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with compound 2 (AA-CS-9-003)	x-ray	2.8	A;B	p68400;p68400	391;391	;	5..328;5..328
8bh3	pdb	DNA-PK Ku80 mediated dimer bound to PAXX	em	4.55	A;S	p78527;p78527	4128;4128	;	3657..4049;3657..4049
8bhv	pdb	DNA-PK XLF mediated dimer bound to PAXX	em	4.51	A;F	p78527;p78527	4128;4128	;	3657..4049;3657..4049
8bhy	pdb	DNA-PK Ku80 mediated dimer bound to PAXX and XLF	em	5.33	A;S	p78527;p78527	4128;4128	;	3657..4049;3657..4049
8bi2	pdb	Syk kinase domain in complex with macrocyclic inhibitor 20a	x-ray	1.508	A	p43405	635		375..627
8bi5	pdb	Crystal structure of human Choline Kinase A in complex with UNC0737	x-ray	2.5	A;B	p35790;p35790	457;457	;	82..455;82..455
8bi6	pdb	Crystal structure of human Choline Kinase A in complex with UNC0638	x-ray	2.4	A;B	p35790;p35790	457;457	;	82..455;82..455
8bik	pdb	Crystal structure of human AMPK heterotrimer in complex with allosteric activator C455	x-ray	2.5	A;D	p54646;p54646	552;552	;	13..269;13..269
8bin	pdb	Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with MR21	x-ray	1.5	A	p29317	976		605..909
8bio	pdb	Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with MRAL5	x-ray	1.6	A	p29317	976		605..909
8bjt	pdb	Structure of human PLK1 in complex with 2-Allyl-1-[6-(1-hydroxy-1-methyl-ethyl)-pyridin-2-yl]-6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,2-dihydro-pyrazolo[3,4-d]pyrimidin-3-one	x-ray	2.188	A	p53350	603		51..338
8bju	pdb	HUMAN WEE1 KINASE IN COMPLEX WITH INHIBITOR 1-[6-(1-Hydroxy-1-methyl-ethyl)-pyridin-2-yl]-2-(2-methoxy-phenyl)-6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,2-dihydro-pyrazolo[3,4-d]pyrimidin-3-one	x-ray	1.53	A	p30291	646		279..580
8bk0	pdb	Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with LDN-211904	x-ray	1.7	A	p29317	976		605..909
8bm2	pdb	Crystal structure of JAK2 JH1 in complex with gandotinib	x-ray	1.5	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
8bm8	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 11	x-ray	1.68	A	p29317	976		605..909
8boc	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 19	x-ray	1.9	A	p29317	976		605..909
8bod	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 20	x-ray	1.5	A	p29317	976		605..909
8bof	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 12	x-ray	1.82	A	p29317	976		605..909
8bog	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 7	x-ray	1.47	A	p29317	976		605..909
8boh	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 8	x-ray	1.42	A	p29317	976		605..909
8boi	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 9	x-ray	1.63	A	p29317	976		605..909
8bok	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 11	x-ray	2.02	A	p29317	976		605..909
8bom	pdb	Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 14	x-ray	1.12	A	p29317	976		605..909
8bot	pdb	Cryo-EM structure of NHEJ supercomplex(trimer)	em	7.76	A;F;S	p78527;p78527;p78527	4128;4128;4128	;;	3657..4049;3657..4049;3657..4049
8bpv	pdb	Crystal structure of JAK2 JH1 in complex with pacritinib	x-ray	1.7	A	o60674	1132		522..814,842..1119
8bpw	pdb	Crystal structure of JAK2 JH1 in complex with lestaurtinib	x-ray	1.8	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
8br5	pdb	Discovery of IRAK4 Inhibitor 41	x-ray	2.7	AAA;BBB;CCC;DDD	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
8br6	pdb	Discovery of IRAK4 Inhibitor 40	x-ray	2.167	AAA;BBB	q9nwz3;q9nwz3	460;460	;	156..454;156..454
8br7	pdb	Discovery of IRAK4 Inhibitors BAY1834845 and BAY1830839	x-ray	2.119	AAA;BBB	q9nwz3;q9nwz3	460;460	;	156..454;156..454
8bu1	pdb	Structure of DDB1 bound to DS17-engaged CDK12-cyclin K	x-ray	2.98	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bu2	pdb	Structure of DDB1 bound to DS18-engaged CDK12-cyclin K	x-ray	3.13	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bu3	pdb	Structure of DDB1 bound to DS19-engaged CDK12-cyclin K	x-ray	3.42	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bu4	pdb	Structure of DDB1 bound to DS22-engaged CDK12-cyclin K	x-ray	3.09	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bu5	pdb	Structure of DDB1 bound to SR-4835-engaged CDK12-cyclin K	x-ray	3.134	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bu6	pdb	Structure of DDB1 bound to DS55-engaged CDK12-cyclin K	x-ray	3.45	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bu7	pdb	Structure of DDB1 bound to 21195-engaged CDK12-cyclin K	x-ray	3.245	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bu9	pdb	Structure of DDB1 bound to roscovitine-engaged CDK12-cyclin K	x-ray	3.51	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bua	pdb	Structure of DDB1 bound to 919278-engaged CDK12-cyclin K	x-ray	3.193	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bub	pdb	Structure of DDB1 bound to dCeMM4-engaged CDK12-cyclin K	x-ray	3.42	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8buc	pdb	Structure of DDB1 bound to dCeMM3-engaged CDK12-cyclin K	x-ray	3.85	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bud	pdb	Structure of DDB1 bound to Z7-engaged CDK12-cyclin K	x-ray	3.2	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bue	pdb	Structure of DDB1 bound to Z11-engaged CDK12-cyclin K	x-ray	3.25	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8buf	pdb	Structure of DDB1 bound to Z12-engaged CDK12-cyclin K	x-ray	3.3	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bug	pdb	Structure of DDB1 bound to HQ461-engaged CDK12-cyclin K	x-ray	3.53	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8buh	pdb	Structure of DDB1 bound to WX3-engaged CDK12-cyclin K	x-ray	3.79	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bui	pdb	Structure of DDB1 bound to DRF-053-engaged CDK12-cyclin K	x-ray	3.5	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8buj	pdb	Structure of DDB1 bound to DS06-engaged CDK12-cyclin K	x-ray	3.62	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8buk	pdb	Structure of DDB1 bound to DS08-engaged CDK12-cyclin K	x-ray	3.41	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bul	pdb	Structure of DDB1 bound to DS11-engaged CDK12-cyclin K	x-ray	3.4	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bum	pdb	Structure of DDB1 bound to DS15-engaged CDK12-cyclin K	x-ray	3.36	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bun	pdb	Structure of DDB1 bound to DS16-engaged CDK12-cyclin K	x-ray	3.08	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8buo	pdb	Structure of DDB1 bound to DS24-engaged CDK12-cyclin K	x-ray	3.58	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bup	pdb	Structure of DDB1 bound to DS30-engaged CDK12-cyclin K	x-ray	3.41	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8buq	pdb	Structure of DDB1 bound to DS43-engaged CDK12-cyclin K	x-ray	3.2	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bur	pdb	Structure of DDB1 bound to DS50-engaged CDK12-cyclin K	x-ray	3.64	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bus	pdb	Structure of DDB1 bound to DS59-engaged CDK12-cyclin K	x-ray	3.26	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8but	pdb	Structure of DDB1 bound to DS61-engaged CDK12-cyclin K	x-ray	3.25	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
8bvw	pdb	RNA polymerase II pre-initiation complex with the distal +1 nucleosome (PIC-Nuc18W)	em	4	8				
8bw9	pdb	Cryo-EM structure of the RAF activating complex KSR-MEK-CNK-HYP	em	3.32	C;D	q24324;q24171	396;966	;	80..371;660..940
8bx6	pdb	Crystal structure of JAK2 JH1 in complex with cerdulatinib	x-ray	1.5	A	o60674	1132		522..814,842..1119
8bx9	pdb	Crystal structure of JAK2 JH1 in complex with ilginatinib	x-ray	1.4	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
8bxc	pdb	Crystal structure of JAK2 JH1 in complex with itacitinib	x-ray	1.9	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
8bxh	pdb	Crystal structure of JAK2 JH1 in complex with momelotinib	x-ray	1.3	A	o60674	1132		522..814,842..1119
8bya	pdb	Cryo-EM structure of SKP1-SKP2-CKS1-CDK2-CyclinA-p27KIP1 Complex	em	3.38	A	p24941	298		1..292
8byq	pdb	RNA polymerase II pre-initiation complex with the proximal +1 nucleosome (PIC-Nuc10W)	em	4.1	8	p50613	346		8..299
8bzi	pdb	Human MST3 (STK24) kinase in complex with inhibitor MR39	x-ray	1.72	A	q9y6e0	443		36..320
8bzj	pdb	Human MST3 (STK24) kinase in complex with inhibitor MRLW5	x-ray	2.52	A;B	q9y6e0;q9y6e0	443;443	;	36..320;36..320
8bzo	pdb	Cryo-EM structure of CDK2-CyclinA in complex with p27 from the SCFSKP2 E3 ligase Complex	em	3.5	A	p24941	298		1..292
8bzp	pdb	JNK3 (Mitogen-activated protein kinase 10) in Complex with Compound 23 bearing a C(sp3)F2Br moiety	x-ray	1.86	A;B	p53779;p53779	464;464	;	52..396;52..396
8c00	pdb	Enp1TAP-S21_A population of yeast small ribosomal subunit precursors depleted of rpS21/eS21	em	2.9	r	p40160	425		95..281
8c01	pdb	Enp1TAP_A population of yeast small ribosomal subunit precursors	em	2.7	r	p40160	425		95..281
8c08	pdb	Crystal structure of JAK2 JH2-K539L	x-ray	2.2	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
8c09	pdb	Crystal structure of JAK2 JH2-I559F	x-ray	1.9	A	o60674	1132		522..814,842..1119
8c0a	pdb	Crystal structure of JAK2 JH2-R683S	x-ray	1.7	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
8c12	pdb	Identification of an intermediate activation state of PAK5 reveals a novel mechanism of kinase inhibition.	x-ray	1.549	AAA				
8c14	pdb	Aurora A kinase in complex with TPX2-inhibitor 9	x-ray	1.93	A	o14965	403		120..386
8c15	pdb	Aurora A kinase in complex with TPX2-inhibitor 3	x-ray	2.41	A	o14965	403		120..386
8c1d	pdb	Aurora A kinase in complex with TPX2-inhibitor 9	x-ray	2.115	A	o14965	403		120..386
8c1e	pdb	Aurora A kinase in complex with TPX2-inhibitor 9	x-ray	2.798	A	o14965	403		120..386
8c1f	pdb	Aurora A kinase in complex with TPX2-inhibitor 6	x-ray	1.924	A	o14965	403		120..386
8c1g	pdb	Aurora A kinase in complex with TPX2-inhibitor 7	x-ray	1.96	A	o14965	403		120..386
8c1h	pdb	Aurora A kinase in complex with TPX2-inhibitor 8	x-ray	2.233	A	o14965	403		120..386
8c1i	pdb	Aurora A kinase in complex with TPX2-inhibitor 10	x-ray	2.81	A	o14965	403		120..386
8c1k	pdb	Aurora A kinase in complex with TPX2-inhibitor CAM2602	x-ray	2.43	A	o14965	403		120..386
8c1m	pdb	Aurora A kinase in complex with TPX2-inhibitor 2	x-ray	2.84	A	o14965	403		120..386
8c2z	pdb	Crystal structure of DYRK1B in complex with AZ191	x-ray	1.91	A	q9y463	629		99..439
8c3g	pdb	Crystal structure of DYRK1A in complex with AZ191	x-ray	2.08	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
8c3q	pdb	Crystal structure of DYRK1A in complex with rutin	x-ray	2.32	A;B	q13627;q13627	763;763	;	147..489;147..489
8c3r	pdb	Crystal structure of DYRK1A in complex with gossypin	x-ray	2.06	A;B	q13627;q13627	763;763	;	147..489;147..489
8c5q	pdb	CK2 kinase bound to inhibitor AB668	x-ray	2.5	A;B	p68400;p68400	391;391	;	5..328;5..328
8c6l	pdb	Human protein kinase CK2 alpha in complex with CK2-TN01	x-ray	1.8	A	p68400	391		5..328
8c6m	pdb	Human protein kinase CK2 alpha in complex with CK2-TN02	x-ray	1.8	A	p68400	391		5..328
8c6n	pdb	Human protein kinase CK2 alpha in complex with CK2-TN03	x-ray	2.05	A	p68400	391		5..328
8c7w	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2304	x-ray	2.26	A	q04771	509		186..496
8c7x	pdb	Crystal structure of BRAF in complex with a hybrid compound 6	x-ray	1.65	A;B	p15056;p15056	766;766	;	449..717;449..717
8c7y	pdb	Crystal structure of BRAF V600E in complex with a hybrid compound 6	x-ray	1.65	A;B	p15056;p15056	766;766	;	449..717;449..717
8c7z	pdb	Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2308	x-ray	2.23	A	q04771	509		186..496
8car	pdb	Discovery of the lanthipeptide Curvocidin and structural insights into its trifunctional synthetase CuvL	x-ray	2.68	A	d1a2f7	865		212..420
8cav	pdb	Discovery of the lanthipeptide Curvocidin and structural insights into its trifunctional synthetase CuvL	x-ray	2.87	A;B	d1a2f7;d1a2f7	865;865	;	212..420;212..420
8cbj	pdb	Cryo-EM structure of Otu2-bound cytoplasmic pre-40S ribosome biogenesis complex	em	3.8	l	p40160	425		95..281
8cdw	pdb	CRYSTAL STRUCTURE OF HUMAN HPK1 (MAP4K1) COMPLEX WITH 7-(1-methyl-1H-pyrazol-4-yl)-N-[4-(1-methylpiperidin-4-yl)phenyl]quinazolin-2-amine	x-ray	1.941	A;B	q92918;q92918	833;833	;	14..444;14..444
8cgc	pdb	Structure of CSF1R in complex with a pyrollopyrimidine (compound 23)	x-ray	1.925	A	p07333	972		551..909
8chf	pdb	cryo-EM Structure of Craf:14-3-3:Mek1	em	4.25	A;B;E;F	p04049;p04049;q02750;q02750	648;648;393;393	;;;	344..611;344..611;63..365;63..365
8cie	pdb	Crystal structure of the human CDKL5 kinase domain with compound YL-354	x-ray	2.2	A	o76039	960		8..301
8cij	pdb	CRYSTAL STRUCTURE OF HUMAN HPK1 (MAP4K1) COMPLEX WITH 2-[8-Amino-7-fluoro-6-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-isoquinolin-3-ylamino]-6-isopropyl-5,6-dihydro-4H-1,6,8a-triaza-azulen-7-one	x-ray	2.821	A	q92918	833		14..444
8cpd	pdb	Cryo-EM structure of CRaf dimer with 14:3:3	em	3.46	A;B	p04049;p04049	648;648	;	344..611;344..611
8cur	pdb	Crystal structure of Cdk2 in complex with Cyclin A inhibitor 6-[(E)-2-(4-chlorophenyl)ethenyl]-2-{[(2R)-3-(4-hydroxyphenyl)-1-methoxy-1-oxopropan-2-yl]carbamoyl}quinoline-4-carboxylic acid	x-ray	2.2	A	p24941	298		1..292
8d6c	pdb	Crystal Structure of Human Myt1 Kinase domain Bounded with compound 28	x-ray	2.2	A;B	q99640;q99640	499;499	;	108..419;108..419
8d6d	pdb	Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39	x-ray	2.35	A;B	q99640;q99640	499;499	;	108..419;108..419
8d6e	pdb	Crystal Structure of Human Myt1 Kinase domain Bounded with RP-6306	x-ray	2.15	A;B	q99640;q99640	499;499	;	108..419;108..419
8d6f	pdb	Crystal Structure of Human Myt1 Kinase domain Bounded with Eph receptor inhibitor / compound 41	x-ray	2.49	A;B	q99640;q99640	499;499	;	108..419;108..419
8d73	pdb	Crystal Structure of EGFR LRTM with compound 7	x-ray	2.17	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
8d76	pdb	Crystal Structure of EGFR LRTM with compound 24	x-ray	2.4	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
8d7m	pdb	Human Casein kinase 1 delta in complex with phosphorylated human PERIOD2 FASP peptide	x-ray	2.25	A;B	p48730;p48730	415;415	;	5..290;5..290
8d7n	pdb	Human Casein kinase 1 delta in complex with phosphorylated human PERIOD2 FASP peptide	x-ray	1.66	A;B	p48730;p48730	415;415	;	5..290;5..290
8d7o	pdb	Human Casein kinase 1 delta in complex with phosphorylated human PERIOD2 FASP peptide	x-ray	1.65	A;B	p48730;p48730	415;415	;	5..290;5..290
8d7p	pdb	Human Casein kinase 1 delta in complex with phosphorylated Drosophila PERIOD peptide	x-ray	2.25	A;B	p48730;p48730	415;415	;	5..290;5..290
8dcp	pdb	PI 3-kinase alpha with nanobody 3-126	em	2.41	A	p42336	1068		699..1060
8dcx	pdb	PI 3-kinase alpha with nanobody 3-159	em	2.8	A	p42336	1068		699..1060
8dd4	pdb	PI 3-kinase alpha with nanobody 3-142	em	3.1	A	p42336	1068		699..1060
8dd8	pdb	PI 3-kinase alpha with nanobody 3-142, crosslinked with DSG	em	3.4	A	p42336	1068		699..1060
8deg	pdb	Crystal structure of DLK in complex with inhibitor DN0011197	x-ray	2.79	A	q12852	859		104..364
8dfm	pdb	Ectodomain of full-length wild-type KIT-SCF dimers	em	3.45	A;B	p10721;p10721	976;976	;	564..923;564..923
8dfp	pdb	Ectodomain of full-length KIT(DupA502,Y503)-SCF dimers	em	3.17	A;B	p10721;p10721	976;976	;	564..923;564..923
8dfq	pdb	Ectodomain of full-length KIT(T417I,delta418-419)-SCF dimers	em	3.96	A;B	p10721;p10721	976;976	;	564..923;564..923
8dgs	pdb	Cryo-EM structure of a RAS/RAF complex (state 1)	em	4.3	A;B	p15056;q02750	766;393	;	449..717;63..365
8dgt	pdb	Cryo-EM structure of a RAS/RAF complex (state 2)	em	3.9	A;B	p15056;q02750	766;393	;	449..717;63..365
8djc	pdb	CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH (4S)-N-{4-[(2S)-2-methylmorpholin-4-yl] pyridin-3-yl}-2-phenylimidazo[1,2-b]pyridazine-8-carboxamide	x-ray	2.463	A;B	p49841;p49841	420;420	;	55..377;55..377
8djd	pdb	CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 3-[(CYCLOPROPYLMETHYL)AMINO] -N-(4-PHENYLPYRIDIN-3-YL)IMIDAZO[1,2-B]PYRIDAZINE-8-CARBOX AMIDE	x-ray	2.205	A;B	p49841;p49841	420;420	;	55..377;55..377
8dje	pdb	CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 3-[(CYCLOPROPYLMETHYL)AMINO] -N-(4-PHENYLPYRIDIN-3-YL)IMIDAZO[1,2-B]PYRIDAZINE-8-CARBOX AMIDE	x-ray	2.374	A;B	p49841;p49841	420;420	;	55..377;55..377
8dks	pdb	IRAK4 IN COMPLEX WITH COMPOUND #3	x-ray	2.45	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
8dp0	pdb	Structure of p110 gamma bound to the Ras inhibitory nanobody NB7	em	2.96	A				
8dqt	pdb	Human PDK1 kinase domain in complex with Valsartan	x-ray	1.31	A	o15530	556		79..400
8dso	pdb	Structure of cIAP1, BTK and BCCov	x-ray	2.334	B	q06187	659		382..648
8dsw	pdb	Crystal structure of EGFR kinase domain, Exon20 Insertion FQEA mutant	x-ray	2.39	A	p00533	1210		708..1003
8dtl	pdb	Cryo-EM structure of insulin receptor (IR) bound with S597 peptide	em	5.4	A;B	;	;	;	;
8dtm	pdb	Cryo-EM structure of insulin receptor (IR) bound with S597 component 2	em	3.5	A;B	;	;	;	;
8dwn	pdb	Crystal structure of bis-phosphorylated insulin receptor kinase domain	x-ray	2.15	A	p06213	1382		996..1290
8e04	pdb	Structure of monomeric LRRK1	em	3.8	A	q38sd2	2015		1234..1518
8e05	pdb	Structure of dimeric LRRK1	em	4.6	A;B	q38sd2;q38sd2	2015;2015	;	1234..1518;1234..1518
8e06	pdb	Symmetry expansion of dimeric LRRK1	em	4.3	A	q38sd2	2015		1234..1518
8e1x	pdb	FGFR2 kinase domain in complex with a Pyrazolo[1,5-a]pyrimidine analog (Compound 29)	x-ray	2.68	A;B	p21802;p21802	821;821	;	471..757;471..757
8e2m	pdb	Bruton's tyrosine kinase (BTK) with compound 13	x-ray	1.904	A	q06187	659		382..648
8e4t	pdb	Crystal structure of the kinase domain of RTKC8 from the choanoflagellate Monosiga brevicollis	x-ray	1.95	A	a9vbw0	1911		1412..1681
8e80	pdb	Structure of LRRK2-CHK1 10-pt. mutant complex with heteroaryl-1H-indazole LRRK2 inhibitor 14	x-ray	1.49	A	o14757	476		6..317
8e81	pdb	Structure of LRRK2-CHK1 10-pt. mutant complex with heteroaryl-1H-indazole LRRK2 inhibitor 25	x-ray	1.62	A	o14757	476		6..317
8edh	pdb	Identification of a class of WNK isoform-specific inhibitors through high-throughput screening	x-ray	3.111	A;C	q9byp7;q9byp7	1800;1800	;	152..406;152..406
8efj	pdb	A structural study of selectivity mechanisms for JNK3 and p38 alpha with indazole scaffold probing compounds	x-ray	2.31	A	p47811	360		9..349
8ej4	pdb	Cryo-EM structure of the active NLRP3 inflammasome disk	em	3.4	K;L;M;N;O;P;Q;R;S;T	q8tdx7;q8tdx7;q8tdx7;q8tdx7;q8tdx7;q8tdx7;q8tdx7;q8tdx7;q8tdx7;q8tdx7	302;302;302;302;302;302;302;302;302;302	;;;;;;;;;	18..290;18..290;18..290;18..290;18..290;18..290;18..290;18..290;18..290;18..290
8ejb	pdb	Bruton's tyrosine kinase in complex with 3-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-5-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazine-2-carboxamide	x-ray	1.58	A	q06187	659		382..648
8elc	pdb	Human JNK2 bound to covalent inhibitor YL2056	x-ray	2.072	A	p45984	424		13..356
8em8	pdb	Co-crystal structure of the cGMP-dependent protein kinase PKG from Plasmodium falciparum in complex with RY-1-165	x-ray	2.54	A				
8eme	pdb	EGFR(T790M/V948R) in complex with ZNL-0056	x-ray	3.32	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
8enj	pdb	Design, synthesis, biological evaluation, and X-ray crystallography of diarylpyrazole derivatives possessing terminal arylsulfonamide moieties as anti-proliferative agents targeting c-Jun N-terminal kinase (JNK)	x-ray	2.81	A	p53779	464		52..396
8eq5	pdb	Crystal structure of the N-terminal kinase domain of RSK2 in complex with SPRED2 (131-160)	x-ray	1.8	A	p51812	740		66..390,402..717
8eq9	pdb	Co-crystal structure of PERK with compound 11	x-ray	2.86	AAA	q9nzj5	1116		587..1090
8eqd	pdb	Co-crystal structure of PERK with compound 24	x-ray	2.92	AAA	q9nzj5	1116		587..1090
8eqe	pdb	Co-crystal structure of PERK with compound 26	x-ray	2.559	AAA	q9nzj5	1116		587..1090
8era	pdb	RMC-5552 in complex with mTORC1 and FKBP12	em	2.86	A	p42345	2549		2095..2451
8erd	pdb	Cyclin-free CDK2 in complex with Cpd17	x-ray	1.33	A	p24941	298		1..292
8ern	pdb	Cyclin-free CDK2 in complex with Cpd21	x-ray	1.64	A	p24941	298		1..292
8esc	pdb	Structure of the Yeast NuA4 Histone Acetyltransferase Complex	em	3.1	Z	p38811	3744		3307..3703
8ewy	pdb	Structure of Janus Kinase (JAK) dimer complexed with cytokine receptor intracellular domain	em	5.5	A;B	p52332;p52332	1153;1153	;	565..851,871..1145;565..851,871..1145
8ex0	pdb	Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with CDK2-IV	x-ray	1.85	A	o60674	1132		522..814,842..1119
8ex1	pdb	Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with Reversine	x-ray	1.5	A	o60674	1132		522..814,842..1119
8ex2	pdb	Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with HTSA3	x-ray	1.9	A	o60674	1132		522..814,842..1119
8exl	pdb	Crystal structure of PI3K-alpha in complex with taselisib	x-ray	1.989	A	p42336	1068		699..1060
8exo	pdb	Crystal structure of PI3K-alpha in complex with compound 19	x-ray	2.46	A	p42336	1068		699..1060
8exu	pdb	Crystal structure of PI3K-alpha in complex with compound 30	x-ray	2.68	A	p42336	1068		699..1060
8exv	pdb	Crystal structure of PI3K-alpha in complex with compound 32	x-ray	2.48	A	p42336	1068		699..1060
8eyr	pdb	Cryo-EM structure of two IGF1 bound full-length mouse IGF1R mutant (four glycine residues inserted in the alpha-CT; IGF1R-P674G4): symmetric conformation	em	4	A;B	q60751;q60751	1373;1373	;	971..1265;971..1265
8eyx	pdb	Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S; denoted as IR-3CS) Asymmetric conformation 1	em	4.5	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
8eyy	pdb	Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S, denoted as IR-3CS) Asymmetric conformation 2	em	4.9	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
8ez0	pdb	Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S; denoted as IR-3CS) Symmetric conformation	em	3.7	A;B	p15208;p15208	1372;1372	;	1000..1285;1000..1285
8ez9	pdb	Dimeric complex of DNA-PKcs	em	5.67	C;L	;	;	;	;
8eza	pdb	NHEJ Long-range complex with PAXX	em	4.39	C;L	;	;	;	;
8ezb	pdb	NHEJ Long-range complex with ATP	em	8.9	C;L	p78527;p78527	4128;4128	;	3657..4049;3657..4049
8f1h	pdb	EGFR kinase in complex with TAS6417 (CLN-081)	x-ray	2.8	A	p00533	1210		708..1003
8f1w	pdb	EGFR(T790M/V948R) kinase in complex with poziotinib	x-ray	3.2	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
8f1x	pdb	EGFR kinase in complex with mobocertinib (TAK-788)	x-ray	2.3	A	p00533	1210		708..1003
8f1y	pdb	EGFR kinase in complex with poziotinib	x-ray	2.75	A	p00533	1210		708..1003
8f1z	pdb	EGFR kinase in complex with Bayer #33	x-ray	2.4	A	p00533	1210		708..1003
8f7o	pdb	BRAF kinase in complex with TAK580 (tovorafenib)	x-ray	3.54	A;B	p15056;p15056	766;766	;	449..717;449..717
8f7p	pdb	BRAF kinase in complex with LXH254 (naporafenib)	x-ray	2.74	A;B	p15056;p15056	766;766	;	449..717;449..717
8fac	pdb	Structure of the leucine-rich repeat kinase 1 monomer	em	3.92	A	q38sd2	2015		1234..1518
8fd9	pdb	Structure of BTK kinase domain with the second-generation inhibitor acalabrutinib	x-ray	1.7	A	p35991	659		383..648
8fe2	pdb	Structure of J-PKAc chimera complexed with Aplithianine A	x-ray	2.34	A;B	p17612;p17612	351;351	;	30..339;30..339
8fe5	pdb	Structure of J-PKAc chimera complexed with Aplithianine B	x-ray	2.51	A;B	p25685;p17612	340;351	;	;30..339
8fe9	pdb	Crystal structure of Ack1 kinase K161Q mutant in complex with the selective inhibitor (R)-9b	x-ray	3.2	A	q07912	1038		120..398
8fec	pdb	Structure of J-PKAc chimera complexed with Aplithianine derivative	x-ray	2.7	A;B	p17612;p17612	351;351	;	30..339;30..339
8ff0	pdb	Structure of BTK kinase domain with the second-generation inhibitor tirabrutinib	x-ray	2.6	A	p35991	659		383..648
8ff8	pdb	CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 2-[(4-CYANOPHENYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIMIDINE-4-CARBOXAMIDE	x-ray	2.33	A;B	p49841;p49841	420;420	;	55..377;55..377
8fh4	pdb	Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with 3-[6-chloro-4-(9-methyl-1-oxa-4,9-diazaspiro[5.5]undec-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile	x-ray	1.827	A;B;C;D	q92918;q92918;q92918;q92918	833;833;833;833	;;;	14..444;14..444;14..444;14..444
8fjz	pdb	Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with 3-{4-[(3R,5S)-3-Amino-5-methylpiperidin-1-yl]-6-chloro-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile	x-ray	1.897	A;B;C;D;E;F	q92918;q92918;q92918;q92918;q92918;q92918	833;833;833;833;833;833	;;;;;	14..444;14..444;14..444;14..444;14..444;14..444
8fko	pdb	Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with 3-{4-[(2S,5R)-5-Amino-2-methylpiperidin-1-yl]-6-chloro-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile	x-ray	2.104	A;B;C;D;E;F	q92918;q92918;q92918;q92918;q92918;q92918	833;833;833;833;833;833	;;;;;	14..444;14..444;14..444;14..444;14..444;14..444
8flg	pdb	Bruton's tyrosine kinase in complex with an orthosteric inhibitor	x-ray	2.2	A	q06187	659		382..648
8flh	pdb	Bruton's tyrosine kinase in complex with an orthosteric inhibitor	x-ray	1.55	A	q06187	659		382..648
8fll	pdb	Crystal structure of BTK kinase domain in complex with pirtobrutinib	x-ray	1.498	A	q06187	659		382..648
8fln	pdb	Crystal structure of BTK C481S kinase domain in complex with pirtobrutinib	x-ray	1.334	A	q06187	659		382..648
8flv	pdb	Bruton's tyrosine kinase in complex with compound 34	x-ray	1.3	A	q06187	659		382..648
8fny	pdb	Nucleotide-bound structure of a functional construct of eukaryotic elongation factor 2 kinase.	x-ray	2.22	A;C	o00418;o00418	725;725	;	78..329;78..329
8fo2	pdb	Cryo-EM structure of Rab29-LRRK2 complex in the LRRK2 monomer state	em	4.13	E	q5s007	2527		1884..2132
8fo6	pdb	Nucleotide-free structure of a functional construct of eukaryotic elongation factor 2 kinase.	x-ray	2.553	A	o00418	725		78..329
8fo7	pdb	Cryo-EM structure of LRRK2 bound to type I inhibitor LRRK2-IN-1	em	3.52	C	q5s007	2527		1884..2132
8fo8	pdb	Cryo-EM structure of Rab29-LRRK2 complex in the LRRK2 dimer state	em	3.88	C;E	q5s007;q5s007	2527;2527	;	1884..2132;1884..2132
8fo9	pdb	Cryo-EM structure of Rab29-LRRK2 complex in the LRRK2 tetramer state	em	3.48	A;C;E;F	q5s007;q5s007;q5s007;q5s007	2527;2527;2527;2527	;;;	1884..2132;1884..2132;1884..2132;1884..2132
8fow	pdb	Ternary complex of CDK2 with small molecule ligands TW8672 and Dinaciclib	x-ray	1.6	A	p24941	298		1..292
8fp0	pdb	Ternary complex of CDK2 with small molecule ligands TW8672 and Roscovitine	x-ray	1.6	A	p24941	298		1..292
8fp1	pdb	PKCeta kinase domain in complex with compound 2	x-ray	1.85	A	p24723	683		352..677
8fp3	pdb	PKCeta kinase domain in complex with compound 11	x-ray	2.3	A	p24723	683		352..677
8fp5	pdb	CDK2 liganded with ATP and Mg2+	x-ray	1.7	A	p24941	298		1..292
8fv3	pdb	EGFR(T790M/V948R) in complex with compound 1 (LN4503)	x-ray	2.1	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
8fv4	pdb	EGFR(T790M/V948R) in complex with compound 2 (LN5993)	x-ray	2.2	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
8fx4	pdb	GC-C-Hsp90-Cdc37 regulatory complex	em	3.9	D	p25092	1073		506..774
8g63	pdb	Ralimetinib (LY2228820) in complex with wild type EGFR	x-ray	2.5	A	p00533	1210		708..1003
8g66	pdb	Structure with SJ3149	x-ray	3.45	C;F	p48729;p48729	337;337	;	12..298;12..298
8g6z	pdb	JAK2 crystal structure in complex with Compound 13	x-ray	2.45	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
8g8o	pdb	The crystal structure of JAK2 in complex with Compound 31	x-ray	2.2	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
8g8x	pdb	X-ray co-crystal structure of compound 27 in with complex JAK2	x-ray	1.97	A;B	o60674;o60674	1132;1132	;	522..814,842..1119;522..814,842..1119
8gae	pdb	Hsp90 provides platform for CRaf dephosphorylation by PP5	em	3.3	D	p04049	648		344..611
8gb4	pdb	EGFR(T790M/V948R) kinase in complex with benzimidazole allosteric inhibitor	x-ray	2.59	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
8gc7	pdb	Bruton's tyrosine kinase in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phenyl]amino}pyrazine-2-carboxamide	x-ray	1.9	A	q06187	659		382..648
8gc8	pdb	Bruton's tyrosine kinase L528W mutant in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phenyl]amino}pyrazine-2-carboxamide	x-ray	1.75	A	q06187	659		382..648
8gds	pdb	CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE 2 (ROCK2) IN COMPLEX WITH 4-(4-(2-(2,3-DIHYDRO-1H- INDOL-1-YL)-2-OXOETHYL)PHENYL)-1(2H)-PHTHALAZINONE	x-ray	2.71	A;B;C;D	o75116;o75116;o75116;o75116	1388;1388;1388;1388	;;;	89..412;89..412;89..412;89..412
8gft	pdb	Hsp90 provides platform for CRaf dephosphorylation by PP5	em	3.8	D	p04049	648		344..611
8gk5	pdb	EGFR(T790M/V948R) kinase in complex with osimertinib and benzimidazole allosteric inhibitor	x-ray	2.3	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
8gm4	pdb	Functional construct of the Eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor	x-ray	2.12	A	o00418	725		78..329
8gm5	pdb	Functional construct of the Eukaryotic elongation factor 2 kinase bound to Calmodulin, ADP and to the A-484954 inhibitor and showing two conformations for the 498-520 loop	x-ray	2.12	A	o00418	725		78..329
8gmb	pdb	Crystal structure of the full-length Bruton's tyrosine kinase (PH-TH domain not visible)	x-ray	3.4	A	p35991	659		383..648
8gmc	pdb	CRYSTAL STRUCTURE OF AP2 ASSOCIATED KINASE 1 COMPLEXED WITH 5-[(4-aminopiperidin-1-yl)methyl]-N-{3-[5-(propan-2-yl)-1,3,4-thiadiazol-2-yl]phenyl}pyrrolo[2,1-f][1,2,4]triazin-4-amine	x-ray	2.5	A;B	q2m2i8;q2m2i8	961;961	;	46..309;46..309
8gmd	pdb	CRYSTAL STRUCTURE OF AP2 ASSOCIATED KINASE 1 COMPLEXED WITH (5P)-3-({(8R)-5-[(4-aminopiperidin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-5-[2-(propan-2-yl)-2H-tetrazol-5-yl]phenol	x-ray	2.2	A;B	q2m2i8;q2m2i8	961;961	;	46..309;46..309
8gua	pdb	Cryo-EM structure of cancer-specific PI3Kalpha mutant E542K in complex with BYL-719	em	2.77	A	p42336	1068		699..1060
8gub	pdb	Cryo-EM structure of cancer-specific PI3Kalpha mutant H1047R in complex with BYL-719	em	2.73	A	p42336	1068		699..1060
8gud	pdb	Cryo-EM structure of cancer-specific PI3Kalpha mutant E545K in complex with BYL-719	em	2.62	A	p42336	1068		699..1060
8guw	pdb	Structure of Aurora Kinase A in complex with activator peptide	x-ray	2.7	A;B;C	o14965;o14965;o14965	403;403;403	;;	120..386;120..386;120..386
8gvj	pdb	Crystal structure of cMET kinase domain bound by D6808	x-ray	2.71	A	p08581	1390		1079..1341
8gw3	pdb	Crystal structure of human TAK1 kinase domain fused with TAB1	x-ray	2.05	A;B;C;D	o43318;q15750;q15750;q15750	606;504;504;504	;;;	14..292;;;
8gxq	pdb	PIC-Mediator in complex with +1 nucleosome (T40N) in MH-binding state	em	5.04	HI				
8gxs	pdb	PIC-Mediator in complex with +1 nucleosome (T40N) in H-binding state	em	4.16	HI				
8h4r	pdb	The Crystal Structure of CDK3 and CyclinE1 Complex with Dinaciclib from Biortus	x-ray	2.75	A	p08515	218		
8h59	pdb	A fungal MAP kinase in complex with an inhibitor	x-ray	2.15	A	g4n374	415		15..320
8h6e	pdb	Cryo-EM structure of human exon-defined spliceosome in the late pre-B state.	em	3.2	4Y	q13523	1007		674..1005
8h6j	pdb	Cryo-EM structure of human exon-defined spliceosome in the mature pre-B state.	em	3.25	4Y	q13523	1007		674..1005
8h6p	pdb	Complex structure of CDK2/Cyclin E1 and a potent, selective macrocyclic inhibitor	x-ray	2.44	A	p24941	298		1..292
8h6t	pdb	Complex structure of CDK2/Cyclin E1 and a potent, selective small molecule inhibitor	x-ray	3	A	p24941	298		1..292
8h75	pdb	FGFR2 in complex with YJ001	x-ray	3.75	A;B;C;D	p21802;p21802;p21802;p21802	821;821;821;821	;;;	471..757;471..757;471..757;471..757
8h7f	pdb	The crystal structure of human abl1 kinase domain in complex with abl1-B-EBA	x-ray	2.45013	A;B	p00519;p00519	1130;1130	;	231..498;231..498
8h7g	pdb	Cryo-EM structure of the human SAGA complex	em	3.7	C				
8h7h	pdb	The crystal structure of human abl1 kinase domain in complex with abl1-A-EBA	x-ray	2.2779	A;B	p00519;p00519	1130;1130	;	231..498;231..498
8h7x	pdb	Crystal structure of EGFR T790M/C797S mutant in complex with brigatinib	x-ray	3.404	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
8haq	pdb	The complex of Src with GW8510	x-ray	2.27	A;B	p12931;p12931	536;536	;	259..529;259..529
8hlt	pdb	The co-crystal structure of DYRK2 with YK-2-99B	x-ray	2.8	A;B	q92630;q92630	601;601	;	212..543;212..543
8hmt	pdb	The complex of ACK1 with the inhibitor 2-142	x-ray	3.17	A;B;C;D	q07912;q07912;q07912;q07912	1038;1038;1038;1038	;;;	120..398;120..398;120..398;120..398
8ho6	pdb	ScRIPK WT	x-ray	2.1	A				
8hoa	pdb	ScRIPK mutant K124R	x-ray	1.676	A	a0a811mc32	441		84..383
8hod	pdb	ScRIPK MUTANT-S253A, T254A	x-ray	1.95	A	a0a811ms43	435		76..375
8hv1	pdb	Crystal structure of EGFR_DMX in complex with covalently bound fragment 1	x-ray	2.4	A	p00533	1210		708..1003
8hv2	pdb	Crystal structure of EGFR_wt in complex with covalently bound fragment 4	x-ray	2.8	A	p00533	1210		708..1003
8hv3	pdb	Crystal structure of EGFR_DMX in complex with covalently bound fragment 4	x-ray	2.4	A	p00533	1210		708..1003
8hv4	pdb	Crystal structure of EGFR_TMX in complex with covalently bound fragment 4	x-ray	2.2	A	p00533	1210		708..1003
8hv5	pdb	Crystal structure of EGFR_DMX in complex with compound 7	x-ray	2.2	A	p00533	1210		708..1003
8hv6	pdb	Crystal structure of EGFR_TMX in complex with covalently bound fragment 8	x-ray	2.2	A	p00533	1210		708..1003
8hv7	pdb	Crystal structure of EGFR_TMX in complex with covalently bound fragment 9	x-ray	2.69	A	p00533	1210		708..1003
8hv8	pdb	Crystal structure of EGFR_TMX in complex with covalently bound fragment 10	x-ray	2.4	A	p00533	1210		708..1003
8hv9	pdb	Crystal structure of EGFR_TMX in complex with covalently bound fragment 12	x-ray	2.5	A	p00533	1210		708..1003
8hva	pdb	Crystal structure of EGFR_TMX in complex with covalently bound compound 14	x-ray	2.77	A	p00533	1210		708..1003
8hy7	pdb	"EGFR kinase domain mutant ""TMLR"" with compound 28f"	x-ray	2.91	A	p00533	1210		708..1003
8i0l	pdb	Structure of CDK9/cyclin T1 in complex with inhibitor	x-ray	3.6	A	p50750	372		12..321
8i0m	pdb	Structure of CDK6 in complex with inhibitor	x-ray	2.7772	A	q00534	326		9..303
8i2n	pdb	The RIPK1 kinase domain in complex with QY7-2B compound	x-ray	2.29	A;B	q13546;q13546	671;671	;	6..286;6..286
8i7s	pdb	The crystal structure of human abl1 kinase domain in complex with ABL1-B1	x-ray	1.94635	A;B	p00519;p00519	1130;1130	;	231..498;231..498
8i7t	pdb	The crystal structure of human abl1 kinase domain in complex with ABL1-B4	x-ray	2.80005	A;B	p00519;p00519	1130;1130	;	231..498;231..498
8i7z	pdb	The crystal structure of human abl1 kinase domain in complex with ABL1-B5	x-ray	2.25496	A;B	p00519;p00519	1130;1130	;	231..498;231..498
8i80	pdb	Crystal structure of Cph001-D189N	x-ray	2.3	A;B	d2b3f1;d2b3f1	286;286	;	24..243;24..243
8i82	pdb	Crystal structure of Cph001-D189N in complex with CMN IIA	x-ray	1.95	A;B	;	;	;	;
8i84	pdb	Crystal structure of Cph001-D189N in complex with CMN IIB	x-ray	2.2	A;B	;	;	;	;
8i85	pdb	Crystal structure of Cph001-D189N in complex with ATP	x-ray	2.17	A;B	d2b3f1;d2b3f1	286;286	;	24..243;24..243
8i86	pdb	Crystal structure of Cph001-D189N in complex with GTP	x-ray	2.23	A;B	d2b3f1;d2b3f1	286;286	;	24..243;24..243
8i89	pdb	Crystal structure of Cph001-D189N in complex with VIO	x-ray	2	A;B	;	;	;	;
8i8g	pdb	Crystal structure of Cph001-D189N in complex with CMN IIA and ATP	x-ray	3	A;B	;	;	;	;
8i8h	pdb	Crystal structure of Cph001-D189N in complex with VIO and ATP	x-ray	2.02	A;B	;	;	;	;
8ie5	pdb	Crystal structure of DAPK1 in complex with oxyresveratrol	x-ray	1.803	A	p53355	1430		6..291
8ie6	pdb	Crystal structure of DAPK1 in complex with pinostilbene	x-ray	1.701	A	p53355	1430		6..291
8ie7	pdb	Crystal structure of DAPK1 in complex with pterostilbene	x-ray	1.849	A	p53355	1430		6..291
8ie8	pdb	Crystal structure of DAPK1 in complex with isorhapontigenin	x-ray	1.75	A	p53355	1430		6..291
8ilr	pdb	Cryo-EM structure of PI3Kalpha in complex with compound 16	em	3.05	A	p42336	1068		699..1060
8ils	pdb	Cryo-EM structure of PI3Kalpha in complex with compound 17	em	3.1	A	p42336	1068		699..1060
8ilv	pdb	Cryo-EM structure of PI3Kalpha in complex with compound 18	em	3.19	A	p42336	1068		699..1060
8ixi	pdb	Crystal structure of macrolide phosphotransferase from Klebsiella pneumoniae	x-ray	2.28	A;B	d8l2f8;d8l2f8	294;294	;	31..242;31..242
8iyj	pdb	Cryo-EM structure of the 48-nm repeat doublet microtubule from mouse sperm	em	3.5	X6;X7;X8	q925k9;q925k9;q925k9	273;273;273	;;	11..268;11..268;11..268
8izc	pdb	Human CK1 Delta Kinase structure bound to Inhibitor	x-ray	1.45	A;B	p48730;p48730	415;415	;	5..290;5..290
8j5w	pdb	The crystal structure of TrkA(F589L) kinase in complex with N-(3-cyclopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4^6-methyl-14-oxo-5-oxa-13-aza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclotetradecaphan-2-yne-4^5-carboxamide	x-ray	2.28041	A	p04629	796		494..779
8j5x	pdb	The crystal structure of TrkA(G595R) kinase in complex with N-(3-cyclopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4^6-methyl-14-oxo-5-oxa-13-aza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclotetradecaphan-2-yne-4^5-carboxamide	x-ray	2.09192	A	p04629	796		494..779
8j61	pdb	The crystal structure of TrkA kinase in complex with 4^6-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-14-oxo-5-oxa-13-aza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclotetradecaphan-2-yne-4^5-carboxamide	x-ray	3.05065	A	p04629	796		494..779
8j63	pdb	The crystal structure of TrkA kinase in complex with 4^6-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-11-oxo-5-oxa-10,14-diaza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclotetradecaphan-2-yne-4^5-carboxamide	x-ray	3.0005	A	p04629	796		494..779
8jbi	pdb	SteC 202-375 mutant- C276S	x-ray	2.356	A;B;C;D	d0zib5;d0zib5;d0zib5;d0zib5	457;457;457;457	;;;	;;;
8jf3	pdb	C-Src in complex with compound 9	x-ray	2.84648	A;B	p12931;p12931	536;536	;	259..529;259..529
8jf4	pdb	The crystal structure of human AURKA kinase domain in complex with AURKA-compound 9	x-ray	2.89288	A	o14965	403		120..386
8jfk	pdb	PhK holoenzyme in inactive state, muscle isoform	em	2.9	C;G;K;O	q16816;q16816;q16816;q16816	387;387;387;387	;;;	12..325;12..325;12..325;12..325
8jfl	pdb	PhK holoenzyme in active state, muscle isoform	em	2.9	C;G;K;O	q16816;q16816;q16816;q16816	387;387;387;387	;;;	12..325;12..325;12..325;12..325
8jg8	pdb	The crystal structure of human aurka kinase domain in the complex with aurka-compound 25	x-ray	2.90002	A	o14965	403		120..386
8jmx	pdb	The crystal structure of human aurka kinase domain in complex with AURKA-A2	x-ray	2.9502	A	o14965	403		120..386
8jmz	pdb	FGFR1 kinase domain with sulfatinib	x-ray	1.988	A;B	p11362;p11362	822;822	;	468..754;468..754
8jn8	pdb	Crystal structure of c-Src in complex with covalent inhibitor DC-Srci-6668	x-ray	1.902	A	p12931	536		259..529
8jn9	pdb	Crystal structure of c-Src in complex with covalent inhibitor LW-Srci-8	x-ray	2.724	A	p12931	536		259..529
8jot	pdb	Crystal structure of CSF-1R kinase domain with sulfatinib	x-ray	1.69	A	p07333	972		551..909
8jpb	pdb	cryo-EM structure of NTSR1-GRK2-Galpha(q) complexes 1	em	3.07	G				
8jpc	pdb	cryo-EM structure of NTSR1-GRK2-Galpha(q) complexes 2	em	3.07	G				
8jpd	pdb	Focused refinement structure of GRK2 in NTSR1-GRK2-Galpha(q) complexes	em	2.81	G	p21146	689		187..532
8jup	pdb	Crystal structure of a receptor like kinase from rice	x-ray	1.98	A	q0ja29	1183		852..1176
8juv	pdb	Crystal structure of a receptor like kinase with ADP	x-ray	2.09	A	q0ja29	1183		852..1176
8k20	pdb	Cryo-EM structure of KEOPS complex from Arabidopsis thaliana	em	3.7	B	q94k14	226		14..174
8k5r	pdb	CDK9/cyclin T1 in complex with KB-0742	x-ray	3.751	A	p50750	372		12..321
8k78	pdb	Crystal structure of cMET kinase domain bound by TPX-0022	x-ray	2.67	A	p08581	1390		1079..1341
8k79	pdb	Crystal structure of c-SRC kinase domain bound by TPX-0022	x-ray	2.8	A;B	p00523;p00523	533;533	;	256..526;256..526
8kfq	pdb	The crystal structure of EGFR(T797M/L858R) with small molecule inhibitor B6	x-ray	3.22	A	p00533	1210		708..1003
8kh6	pdb	Crystal structure of FGFR4 kinase domain with 8r	x-ray	1.62	A	p22455	802		458..743
8kh7	pdb	Crystal structure of FGFR4 kinase domain with 8zc	x-ray	1.52	A	p22455	802		458..743
8kh8	pdb	Crystal structure of FGFR4(V550L) kinase domain with 8z	x-ray	1.49	A	p22455	802		458..743
8kh9	pdb	Crystal structure of FGFR4(V550M) kinase domain with 8z	x-ray	1.42	A	p22455	802		458..743
8of5	pdb	Crystal structure of Aurora A 122-403 C290A, N332A, Q335A, C393A bound to ADP	x-ray	1.97	A	o14965	403		120..386
8oku	pdb	Salt-Inducible Kinase 3 in complex with an inhibitor	x-ray	3.1	A;B	q9y2k2;q9y2k2	1321;1321	;	63..751;63..751
8omv	pdb	Crystal structure of the constitutively active S117E/S181E mutant of human IKK2	x-ray	4.16	A;B;C;D;E	o14920;o14920;o14920;o14920;o14920	756;756;756;756;756	;;;;	11..290;11..290;11..290;11..290;11..290
8or0	pdb	CAND1-CUL1-RBX1-SKP1-SKP2-CKS1-CDK2	em	3.1	H	p24941	298		1..292
8or4	pdb	Partially dissociated CAND1-CUL1-RBX1-SKP1-SKP2-CKS1-CDK2	em	3.8	H	p24941	298		1..292
8orm	pdb	Cryo-EM structure of CAK-THZ1	em	1.9	J	p50613	346		8..299
8otz	pdb	48-nm repeat of the native axonemal doublet microtubule from bovine sperm	em	3.6	1;2;x	;;	;;	;;	;;
8our	pdb	CRYSTAL STRUCTURE OF DLK IN COMPLEX WITH COMPOUND 16	x-ray	1.95	A	q12852	859		104..364
8ous	pdb	CRYSTAL STRUCTURE OF DLK IN COMPLEX WITH COMPOUND 19	x-ray	2.2	A	q12852	859		104..364
8out	pdb	CRYSTAL STRUCTURE OF DLK IN COMPLEX WITH COMPOUND 22	x-ray	1.935	A	q12852	859		104..364
8ouu	pdb	Crystal structure of D1228V c-MET bound by compound 29	x-ray	1.77	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
8ouv	pdb	Crystal structure of D1228V c-MET bound by compound 15	x-ray	1.783	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
8ov7	pdb	Crystal structure of D1228V c-MET bound by compound 10	x-ray	1.95	A	p08581	1390		1079..1341
8ovz	pdb	Crystal structure of D1228V c-MET bound by compound 16	x-ray	2.206	A;B	p08581;p08581	1390;1390	;	1079..1341;1079..1341
8ow2	pdb	Crystal structure of the p110alpha catalytic subunit from homo sapiens in complex with activator 1938	x-ray	2.57	A	p42336	1068		699..1060
8ow3	pdb	Crystal structure of wild-type c-MET bound by compound 2	x-ray	2.27	A	p08581	1390		1079..1341
8owg	pdb	Crystal structure of D1228V c-MET bound by compound 2	x-ray	2.631	A;B;C	p08581;p08581;p08581	1390;1390;1390	;;	1079..1341;1079..1341;1079..1341
8oxm	pdb	ATM(Q2971A) activated by oxidative stress in complex with Mg AMP-PNP and p53 peptide	em	3.3	A;B	q13315;q13315	3056;3056	;	2623..2974;2623..2974
8oxo	pdb	ATM(Q2971A) dimeric C-terminal region activated by oxidative stress in complex with Mg AMP-PNP and p53 peptide	em	3	A;B	q13315;q13315	3056;3056	;	2623..2974;2623..2974
8oxp	pdb	ATM(Q2971A) in complex with Mg AMP-PNP	em	2.6	A;B	q13315;q13315	3056;3056	;	2623..2974;2623..2974
8oxq	pdb	ATM(Q2971A) dimeric C-terminal region in complex with Mg AMP-PNP	em	2.5	A;B	q13315;q13315	3056;3056	;	2623..2974;2623..2974
8p04	pdb	Crystal structure of human CLK1 in complex with Leucettinib-92	x-ray	2.6	A	p49759	484		150..478
8p05	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with Leucettinib-92	x-ray	2.45	A;B	p68400;p68400	391;391	;	5..328;5..328
8p06	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((2-(4H-1,2,4-triazol-4-yl)pyridin-4-yl)amino)-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile	x-ray	2.4	A;B	p68400;p68400	391;391	;	5..328;5..328
8p07	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((3-(4H-1,2,4-triazol-4-yl)phenyl)amino)-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile	x-ray	2.4	A;B	p68400;p68400	391;391	;	5..328;5..328
8p08	pdb	Crystal structure of human CLK1 in complex with Leucettinib-21	x-ray	2.4	A	p49759	484		150..478
8p4z	pdb	Crystal structure of the human CDK7 kinase domain in complex with LDC4297	x-ray	2.75	A;B	p50613;p50613	346;346	;	8..299;8..299
8p5g	pdb	Kinase domain of wild type human ULK1 in complex with compound CCT241533	x-ray	2.019	A;B	o75385;o75385	1050;1050	;	16..325;16..325
8p5h	pdb	Kinase domain of mutant human ULK1 in complex with compound CCT241533	x-ray	1.941	A;B	o75385;o75385	1050;1050	;	16..325;16..325
8p5i	pdb	Kinase domain of mutant human ULK1 in complex with compound XMD-17-51	x-ray	1.829	A;B;C;D	o75385;o75385;o75385;o75385	1050;1050;1050;1050	;;;	16..325;16..325;16..325;16..325
8p5j	pdb	Kinase domain of mutant human ULK1 in complex with compound WZ4003	x-ray	2.164	A;B	o75385;o75385	1050;1050	;	16..325;16..325
8p5k	pdb	Kinase domain of mutant human ULK1 in complex with compound MRT68921	x-ray	2.209	A;B;C;D	o75385;o75385;o75385;o75385	1050;1050;1050;1050	;;;	16..325;16..325;16..325;16..325
8p5l	pdb	Kinase domain of mutant human ULK1 in complex with compound MRT67307	x-ray	1.836	A;B	o75385;o75385	1050;1050	;	16..325;16..325
8p6v	pdb	Cryo-EM structure of CAK in complex with inhibitor ICEC0942	em	1.9	J	p50613	346		8..299
8p6w	pdb	Cryo-EM structure of CAK in complex with inhibitor BS-181	em	1.9	J	p50613	346		8..299
8p6x	pdb	Cryo-EM structure of CAK in complex with inhibitor BS-194	em	1.9	J	p50613	346		8..299
8p6y	pdb	Cryo-EM structure of CAK in complex with nucleotide analogue ATPgS	em	1.9	J	p50613	346		8..299
8p6z	pdb	Cryo-EM structure of CAK in complex with inhibitor ICEC0510-R	em	2.1	J	p50613	346		8..299
8p70	pdb	Cryo-EM structure of CAK in complex with inhibitor ICEC0510-S	em	2	J	p50613	346		8..299
8p71	pdb	Cryo-EM structure of CAK in complex with inhibitor ICEC0574	em	2	J	p50613	346		8..299
8p72	pdb	Cryo-EM structure of CAK in complex with inhibitor ICEC0768	em	1.9	J	p50613	346		8..299
8p73	pdb	Cryo-EM structure of CAK in complex with inhibitor ICEC0829	em	2	J	p50613	346		8..299
8p74	pdb	Cryo-EM structure of CAK in complex with inhibitor ICEC0880 (ring-up conformation)	em	2.2	J	p50613	346		8..299
8p75	pdb	Cryo-EM structure of CAK in complex with inhibitor ICEC0880 (ring-down conformation)	em	2	J	p50613	346		8..299
8p76	pdb	Cryo-EM structure of CAK in complex with inhibitor ICEC0914	em	2	J	p50613	346		8..299
8p77	pdb	Cryo-EM structure of CAK in complex with inhibitor ICEC0943	em	1.8	J	p50613	346		8..299
8p78	pdb	Cryo-EM structure of CAK in complex with inhibitor dinaciclib	em	1.9	J	p50613	346		8..299
8p79	pdb	Cryo-EM structure of CAK with averaged inhibitor density	em	1.7	J	p50613	346		8..299
8p7j	pdb	Crystal structure of MAP2K6 with a covalent compound GCL96	x-ray	2.4	A;B	p52564;p52564	334;334	;	41..315;41..315
8p7l	pdb	Cryo-EM structure of CDK7 subunit of CAK in complex with inhibitor LDC4297	em	2.1	J	p50613	346		8..299
8p81	pdb	Crystal structure of human Cdk12/Cyclin K in complex with inhibitor SR-4835	x-ray	2.68	A	q9nyv4	1490		721..1024
8p9b	pdb	Crystal Structure of Mnk2-D228G in complex with Tinodasertib	x-ray	2.59	A	q9hbh9	465		87..395
8par	pdb	Crystal structure of human MAP4K1 with an inhibitor, BAY-405	x-ray	2	A	q92918	833		14..444
8pas	pdb	Crystal structure of MAP4K1 with a SMOL inhibitor	x-ray	2.7	A;B	q92918;q92918	833;833	;	14..444;14..444
8pau	pdb	Crystal structure of MAP4K1 with a SMOL inhibitor	x-ray	2.8	A;B	q92918;q92918	833;833	;	14..444;14..444
8pav	pdb	Crystal structure of MST1 with a MAP4K1 SMOL inhibitor	x-ray	1.9	A;B	q13043;q13043	487;487	;	27..285;27..285
8paw	pdb	Crystal structure of MST1 with a MAP4K1 SMOL inhibitor	x-ray	2.14	A;B	q13043;q13043	487;487	;	27..285;27..285
8peh	pdb	Crystal structure of Lotus japonicus SYMRK kinase domain D738N	x-ray	1.95	A;B;C	q8lkx1;q8lkx1;q8lkx1	923;923;923	;;	574..866;574..866;574..866
8plz	pdb	Cryo-EM structure of CAK in complex with inhibitor CT7030	em	1.9	J	p50613	346		8..299
8pm3	pdb	Crystal structure of MAP2K6 with a covalent compound GCL94	x-ray	2	A;B;C;D	p52564;p52564;p52564;p52564	334;334;334;334	;;;	41..315;41..315;41..315;41..315
8pnz	pdb	Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 16 bound to EGFR	x-ray	2.51	A	p00533	1210		708..1003
8po0	pdb	Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 12 bound to EGFRinsNPG	x-ray	2.523	A	p00533	1210		708..1003
8po1	pdb	Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 22 bound to EGFRinsNPG [V948R]	x-ray	2.11	A	p00533	1210		708..1003
8po2	pdb	Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 33 bound to EGFRinsNPG [V948R]	x-ray	2.28	A;B;D	p00533;p00533;p00533	1210;1210;1210	;;	708..1003;708..1003;708..1003
8po3	pdb	Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 18 bound to EGFR[V948R]	x-ray	2.13	A	p00533	1210		708..1003
8po4	pdb	Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 33 bound to EGFR[V948R]	x-ray	1.621	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
8pod	pdb	Crystal structure of the kinase domain of ACVR1 (ALK2) in complex with FKBP12 and MU1700	x-ray	2.59	A	q04771	509		186..496
8pq9	pdb	c-KIT kinase domain in complex with avapritinib	x-ray	1.7	A;C	p10721;p10721	976;976	;	564..923;564..923
8pqa	pdb	c-KIT kinase domain in complex with avapritinib derivative 4	x-ray	1.65	A;C	p10721;p10721	976;976	;	564..923;564..923
8pqb	pdb	c-KIT kinase domain in complex with avapritinib derivative 8	x-ray	1.87	A	p10721	976		564..923
8pqc	pdb	c-KIT kinase domain in complex with avapritinib derivative 9	x-ray	1.77	A;B	p10721;p10721	976;976	;	564..923;564..923
8pqd	pdb	c-KIT kinase domain in complex with avapritinib derivative 10	x-ray	1.5	A;B	p10721;p10721	976;976	;	564..923;564..923
8pqe	pdb	c-KIT kinase domain in complex with avapritinib derivative 11	x-ray	2	A;B	p10721;p10721	976;976	;	564..923;564..923
8pqf	pdb	c-KIT kinase domain in complex with avapritinib derivative 12	x-ray	1.9	A;C	p10721;p10721	976;976	;	564..923;564..923
8pqg	pdb	c-KIT T670I mutated kinase domain in complex with avapritinib	x-ray	2.4	A;C	p10721;p10721	976;976	;	564..923;564..923
8pqh	pdb	PDGFRA T674I mutant kinase domain in complex with avapritinib	x-ray	2.5	A	p16234	1089		566..947
8pqi	pdb	PDGFRA T674I mutant kinase domain in complex with avapritinib derivative 9	x-ray	2.6	A	p16234	1089		566..947
8pqj	pdb	PDGFRA wild-type kinase domain	x-ray	1.82	A	p16234	1089		566..947
8pqk	pdb	APO crystal structure of PDGFRA-T674I kinase domain	x-ray	2	A	p16234	1089		566..947
8pr7	pdb	Aurora-A in complex with CEP192 and an inhibitory monobody	x-ray	2.76	A;D	;	;	;	;
8ps7	pdb	Crystal structure of Medicago truncatula LYR4 kinase domain	x-ray	2.1	A;B	g7k7k0;g7k7k0	660;660	;	328..628;328..628
8psr	pdb	ERK2 covalently bound to SynthRevD-12-opt artificial peptide	x-ray	1.85	A				
8pst	pdb	ERK2 covelently bound to RU60 cyclohexenone based inhibitor	x-ray	1.9	A	p28482	360		19..322
8psw	pdb	ERK2 covalently bound to RU67 cyclohexenone based inhibitor	x-ray	2	A	p28482	360		19..322
8psy	pdb	ERK2 covelently bound to RU68 cyclohexenone based inhibitor	x-ray	2.55	A	p28482	360		19..322
8pt0	pdb	ERK2 covelently bound to RU75 cyclohexenone based inhibitor	x-ray	1.65	A	p28482	360		19..322
8pt1	pdb	ERK2 covelently bound to RU76 cyclohexenone based inhibitor	x-ray	1.8	A	p28482	360		19..322
8pt3	pdb	ERK2 covelently bound to RU77 cyclohexenone based inhibitor	x-ray	1.8	A	p28482	360		19..322
8pt5	pdb	ERK2 covelently bound to RU187 cyclohexenone based inhibitor	x-ray	1.95	A	p28482	360		19..322
8pt8	pdb	JNK1 covalently bound to RU135 cyclohexenone based inhibitor	x-ray	2.78	A;B;C	p45983;p45983;p45983	427;427;427	;;	12..357;12..357;12..357
8pt9	pdb	JNK1 covalently bound to BD838 cyclohexenone based inhibitor	x-ray	2.7	A;B;C	p45983;p45983;p45983	427;427;427	;;	12..357;12..357;12..357
8pta	pdb	JNK1 covalently bound to BD837 cyclohexenone based inhibitor	x-ray	2.41	A;B;C	p45983;p45983;p45983	427;427;427	;;	12..357;12..357;12..357
8pvo	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric compound FG5	x-ray	2.25	A;B	p68400;p68400	391;391	;	5..328;5..328
8pvp	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric compound FGJG18	x-ray	2.6	A;B	p68400;p68400	391;391	;	5..328;5..328
8pvu	pdb	Cryo-EM structure of DHS-ERK2 complex with 1:1 stoichiometry refined in C1 symmetry	em	3.5	E	p28482	360		19..322
8pyi	pdb	Human IGF1R with inhibitor 6	x-ray	3.06	AAA;BBB;CCC;DDD;EEE;FFF;GGG;HHH	p08069;p08069;p08069;p08069;p08069;p08069;p08069;p08069	1367;1367;1367;1367;1367;1367;1367;1367	;;;;;;;	970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264;970..1264
8pyj	pdb	Human IGF1R with inhibitor 8	x-ray	2.702	AAA	p08069	1367		970..1264
8pyk	pdb	Human IGF1R with inhibitor 47	x-ray	2.23	AAA	p08069	1367		970..1264
8pyl	pdb	Human IGF1R with inhibitor 53	x-ray	2.93	AAA	p08069	1367		970..1264
8pym	pdb	Human IGF1R with inhibitor 54	x-ray	2.652	AAA	p08069	1367		970..1264
8pyn	pdb	Human IGF1R with inhibitor 56	x-ray	1.71	AAA	p08069	1367		970..1264
8pyr	pdb	Crystal structure of the dual T-loop phosphorylated Cdk7/CycH/Mat1 complex	x-ray	2.15	A;E	;	;	;	;
8q1z	pdb	Crystal Structure of Human Vaccinia-related kinase 2 (VRK-2) bound to JA-296	x-ray	1.85	A	q86y07	508		23..317
8q61	pdb	Co-crystal structure of human AKT2 with compound 3	x-ray	2.32	A	p31751	481		147..460
8q6f	pdb	HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 4)	x-ray	1.506	A	q9ubf8	816		325..810
8q6g	pdb	HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 8)	x-ray	1.541	A	q9ubf8	816		325..810
8q6h	pdb	HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 11)	x-ray	1.94	A	q9ubf8	816		325..810
8q77	pdb	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE BISUBSTRATE INHIBITOR ARC-780	x-ray	1.255	A	p19784	350		13..330
8q9s	pdb	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE INHIBITOR SGC-CK2-1	x-ray	1.352	A	p19784	350		13..330
8qbu	pdb	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE INHIBITOR CX-4945 AND THE ALPHA-D-POCKET LIGAND 3,4-DICHLORO PHENETHYLAMINE (DPA)	x-ray	1.09	A	p19784	350		13..330
8qcd	pdb	STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE	x-ray	1.03	A	p19784	350		13..330
8qcg	pdb	STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (CK2ALPHA') IN COMPLEX WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMPPNP	x-ray	1.04	A;B	p19784;p19784	350;350	;	13..330;13..330
8qcw	pdb	The crystal structure of the truncated form of Lotus japonicus kinase 1	x-ray	2.9	A	q53vm1	467		137..447
8qel	pdb	PKR kinase domain- eIF2alpha in complex with compound	x-ray	2.451	B	p19525	551		259..536
8qf1	pdb	STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (CK2ALPHA') IN COMPLEX WITH THE NON-HYDROLYZABLE GTP ANALOGUE GMPPNP	x-ray	1.32	A;B	p19784;p19784	350;350	;	13..330;13..330
8qgy	pdb	Cryo-EM structure of C-terminally truncated Apoptosis signal-regulating kinase 1 (ASK1)	em	3.71	A;B	q99683;q99683	1374;1374	;	685..939;685..939
8qji	pdb	Crystal structure of GSK3b in complex with N-(4-(5-(1,2,4-oxadiazol-3-yl)thiophen-2-yl)pyridin-2-yl)cyclopropanecarboxamide inhibitor (TW362)	x-ray	3.02	A	p49841	420		55..377
8qlq	pdb	Human MST3 (STK24) kinase in complex with macrocyclic inhibitor JA310	x-ray	1.64	A	q9y6e0	443		36..320
8qlr	pdb	Human MST3 (STK24) kinase in complex with inhibitor MR24	x-ray	1.85	A;B	q9y6e0;q9y6e0	443;443	;	36..320;36..320
8qls	pdb	Human MST3 (STK24) kinase in complex with inhibitor MR26	x-ray	1.61	A	q9y6e0	443		36..320
8qlt	pdb	Human MST3 (STK24) kinase in complex with inhibitor MR30	x-ray	1.47	A	q9y6e0	443		36..320
8qqb	pdb	Crystal structure of protein kinase CK2 catalytic subunit in complex with a Dibromo Dihydro Dibenzofuranone derivative	x-ray	2.26	A;B	p68400;p68400	391;391	;	5..328;5..328
8qqg	pdb	Structure of BRAF in Complex With Exarafenib (KIN-2787).	x-ray	2.979	A;B;C	p15056;p15056;p15056	766;766;766	;;	449..717;449..717;449..717
8qqy	pdb	Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with JG165	x-ray	1.8	A	p29317	976		605..909
8qri	pdb	TRRAP and EP400 in the human Tip60 complex	em	3.5	C	q9y4a5	3859		3433..3826
8qwy	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 4-(6-((5-isopropoxy-2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acid	x-ray	2.6	A;B	p68400;p68400	391;391	;	5..328;5..328
8qwz	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 4-(6-(6-isopropoxy-1H-indol-1-yl)pyrazin-2-yl)benzoic acid	x-ray	2.6	A;B	p68400;p68400	391;391	;	5..328;5..328
8qxd	pdb	Cryo-EM structure of the cross-exon pre-B complex	em	9.6	K	q13523	1007		674..1005
8r08	pdb	Cryo-EM structure of the cross-exon pre-B+AMPPNP complex	em	6.1	K	q13523	1007		674..1005
8r0a	pdb	Cryo-EM structure of the cross-exon pre-B+5'ss complex	em	5.8	K	q13523	1007		674..1005
8r0h	pdb	Pim1 in complex with (E)-3-(2-(thiophen-2-yl)vinyl)-3,4-dihydroquinoxalin-2(1H)-one and Pimtide	x-ray	1.88	A				
8r0q	pdb	Pim1 in complex with 6-bromo-1H-benzo[d]imidazol-2-amine and Pimtide	x-ray	1.7	A				
8r0w	pdb	Pim1 in complex with 5-bromobenzo[d]oxazol-2-amine and Pimtide	x-ray	1.95	A				
8r0y	pdb	Pim1 in complex with 3-((3-hydroxyphenyl)amino)quinoxaline-2-carboxylic acid and Pimtide	x-ray	2.05	A				
8r10	pdb	Pim1 in complex with 4-(4-hydroxystyryl)benzoic acid and Pimtide	x-ray	2.2	A				
8r18	pdb	Pim1 in complex with (E)-4-(4-hydroxystyryl)benzoic acid and Pimtide	x-ray	1.89	A				
8r1k	pdb	Pim1 in complex with 6-bromobenzo[d]oxazol-2-amine and Pimtide	x-ray	1.95	A				
8r1n	pdb	Pim1 in complex with 4-(4-hydroxyphenethyl)benzoic acid and Pimtide	x-ray	2.21	A				
8r1p	pdb	Pim1 in complex with 6-bromobenzo[d]oxazol-2-amine and Pimtide	x-ray	2.45	A				
8r1t	pdb	Pim1 in complex with 4-(4-aminophenethyl)benzoic acid and Pimtide	x-ray	2	A				
8r1w	pdb	Pim1 in complex with 4-(5-(4-aminophenyl)-2H-1,2,3-triazol-4-yl)benzoic acid and Pimtide	x-ray	2.15	A				
8r25	pdb	Pim1 in complex with 4-(5-(4-aminophenyl)-1H-pyrazol-1-yl)benzoic acid and Pimtide	x-ray	2.1	A				
8r27	pdb	Pim1 in complex with (Z)-4-(1-cyano-2-(4-hydroxyphenyl)vinyl)benzoic acid and Pimtide	x-ray	1.95	A				
8r3x	pdb	Crystal structure of aPKC Iota kinase domain with LLGL2 peptide	x-ray	2.591	A;B	p41743;p41743	596;596	;	252..578;252..578
8r3y	pdb	Cryo EM structure of a stable LGL/aPKC Iota/Par-6 complex	em	3.68	I	p41743	596		252..578
8r4o	pdb	Salt inducible kinase 3 in complex with inhibitor	x-ray	2.725	A;C;E;G;I;K	;;;;;	;;;;;	;;;;;	;;;;;
8r4q	pdb	Salt inducible kinase 3 in complex with inhibitor	x-ray	2.838	A;C;E;G;I;K	;;;;;	;;;;;	;;;;;	;;;;;
8r4u	pdb	Structure of salt-inducible kinase 3 with inhibitors	x-ray	2.416	A;C;E;G	;;;	;;;	;;;	;;;
8r4v	pdb	Structure of Salt-inducible kinase 3 in complex with inhibitor	x-ray	1.9	A;B;C	q9y2k2;q9y2k2;q9y2k2	1321;1321;1321	;;	63..751;63..751;63..751
8r58	pdb	The RSK 2 N-terminal kinase domain in complex with BMF (1-19)	x-ray	2.31	A	p51812	740		66..390,402..717
8r5e	pdb	JNK1 covalently bound to RU77 cyclohexenone based inhibitor	x-ray	1.7	A	p45983	427		12..357
8r5f	pdb	ERK2 covalently bound to RU83 cyclohexenone based inhibitor	x-ray	1.65	A	p28482	360		19..322
8r7g	pdb	Crystal structure of the kinase domain of ACVR1 (ALK2) with M4K2234	x-ray	2.09	A;B;C;D	q04771;q04771;q04771;q04771	509;509;509;509	;;;	186..496;186..496;186..496;186..496
8r8e	pdb	DYRK1a in Complex with 2-Cyclopentyl-7-iodo-1H-indole-3-carbonitrile	x-ray	2.22	A;B;C;D	q13627;q13627;q13627;q13627	763;763;763;763	;;;	147..489;147..489;147..489;147..489
8r99	pdb	A soakable crystal form of human CDK7 in complex with AMP-PNP	x-ray	1.81	A	p50613	346		8..299
8r9a	pdb	A soakable crystal form of human CDK7 in complex with AMP-PNP	x-ray	1.71	A	p50613	346		8..299
8r9b	pdb	A soakable crystal form of human CDK7 in complex with AMP-PNP	x-ray	2.21	A;B;C;D	p50613;p50613;p50613;p50613	346;346;346;346	;;;	8..299;8..299;8..299;8..299
8r9o	pdb	A soakable crystal form of human CDK7 in complex with AMP-PNP	x-ray	2.22	A;B	p50613;p50613	346;346	;	8..299;8..299
8r9s	pdb	A soakable crystal form of human CDK7 in complex with AMP-PNP	x-ray	2.78	A;B	p50613;p50613	346;346	;	8..299;8..299
8r9u	pdb	A soakable crystal form of human CDK7 in complex with AMP-PNP	x-ray	1.937	A;B	p50613;p50613	346;346	;	8..299;8..299
8rch	pdb	CryoEM structure of mTORC1 with a paediatric kidney cancer-associated 1455-EWED-1458 duplication in mTOR, overall refinement	em	4	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
8rck	pdb	CryoEM structure of mTORC1 with a paediatric kidney cancer-associated 1455-EWED-1458 duplication in mTOR, Focused on one protomer copy.	em	3.4	B	p42345	2549		2095..2451
8rcn	pdb	CryoEM structure of mTORC1 with a paediatric kidney cancer-associated 1455-EWED-1458 duplication in mTOR, Focused region of mTOR and RAPTOR on one protomer copy.	em	3.1	B	p42345	2549		2095..2451
8rdk	pdb	Crystal structure of human Haspin (GSG2) kinase bound to MD420	x-ray	2	A	q8tf76	798		474..698
8roz	pdb	Cryo-EM structure of CDK2-cyclin A in complex with CDC25A	em	2.7	A	p24941	298		1..292
8rpc	pdb	Crystal structure of PfCLK3 with TCMDC-135051	x-ray	2.079	A	w7jm86	401		54..392
8rrq	pdb	Crystal structure of human SYK in complex with compound 24	x-ray	1.6	A	p43405	635		375..627
8rrz	pdb	Crystal structure of SYK kinase in complex with compound 1	x-ray	1.75	A	p43405	635		375..627
8ru8	pdb	A crystal form of a human CDK2-CDK7 chimera	x-ray	1.51	A	p24941	298		1..292
8rxr	pdb	Crystal structure of VPS34 in complex with inhibitor SB02024	x-ray	2.06	A;B	q8neb9;q8neb9	887;887	;	538..883;538..883
8s3r	pdb	HUMAN PI3KDELTA IN COMPLEX WITH PYRIDAZINONE INHIBITOR 7	x-ray	2.28	A	o00329	1044		678..1033
8s3x	pdb	LIM Domain Kinase 2 (LIMK2) bound to compound 52	x-ray	2.59	A;B;C;D	p53671;p53671;p53671;p53671	638;638;638;638	;;;	304..597;304..597;304..597;304..597
8s79	pdb	Lotus japonicus NFR5 intracellular domain in complex with Nanobody 200	x-ray	2.29	A;B	;	;	;	;
8s85	pdb	Crystal structure of JAK1 JH1 domain in complex with an inhibitor	x-ray	1.75	A;B	p23458;p23458	1154;1154	;	565..850,873..1146;565..850,873..1146
8s93	pdb	Crystal structure of the PH-TH/kinase complex of Bruton's tyrosine kinase	x-ray	2.1	A	p35991	659		383..648
8s98	pdb	Crystal structure of the TYK2 pseudokinase domain in complex with compound 8	x-ray	1.87	A;B;C	p29597;p29597;p29597	1187;1187;1187	;;	576..879,887..1166;576..879,887..1166;576..879,887..1166
8s99	pdb	Crystal structure of the TYK2 pseudokinase domain in complex with compound 11	x-ray	1.71	A;B;C	p29597;p29597;p29597	1187;1187;1187	;;	576..879,887..1166;576..879,887..1166;576..879,887..1166
8s9a	pdb	Crystal structure of the TYK2 pseudokinase domain in complex with TAK-279	x-ray	1.83	A;B;C	p29597;p29597;p29597	1187;1187;1187	;;	576..879,887..1166;576..879,887..1166;576..879,887..1166
8s9f	pdb	Crystal structure of the kinase domain of Bruton's Tyrosine Kinase bound to dasatinib	x-ray	2.6	A;B	p35991;p35991	659;659	;	383..648;383..648
8s9p	pdb	1:1:1 agrin/LRP4/MuSK complex	em	3.8	C	o15146	869		566..856
8sam	pdb	Crystal structure of class III lanthipeptide synthetase LP-GS-ThurKC in complex with ATP	x-ray	2.15	A;B	a0a6h0tj16;a0a6h0tj16	872;872	;	226..459;226..459
8sao	pdb	Crystal structure of class III lanthipeptide synthetase ThurKC in complex with ThurA1 leader peptide	x-ray	2.502	B;D	a0a6h0tj16;a0a6h0tj16	872;872	;	226..459;226..459
8sap	pdb	Crystal structure of class III lanthipeptide synthetase ThurKC	x-ray	2.52	A;B	a0a6h0tj16;a0a6h0tj16	872;872	;	226..459;226..459
8sbc	pdb	Co-structure of Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform and brain penetrant inhibitors	x-ray	2.3	A	p42336	1068		699..1060
8sbj	pdb	Co-structure Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform complexed with brain penetrant inhibitors	x-ray	3.1	A	p42336	1068		699..1060
8sc7	pdb	Structure of EGFR in complex with MTX-531	x-ray	1.984	A	p00533	1210		708..1003
8sc8	pdb	Structure of PI3KG in complex with MTX-531	x-ray	2.687	A	p48736	1102		728..1089
8sf8	pdb	Structure of bovine PKA bound to (R)-N-(4-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl)-2-amino-4-methylpentanamide	x-ray	1.7	A	p00517	351		32..339
8siv	pdb	Structure of Compound 2 bound to the CHK1 10-point mutant	x-ray	1.759	A	o14757	476		6..317
8siw	pdb	Structure of Compound 5 bound to the CHK1 10-point mutant	x-ray	1.877	A;B	o14757;o14757	476;476	;	6..317;6..317
8six	pdb	Structure of Compound 13 bound to the CHK1 10-point mutant	x-ray	1.55	A	o14757	476		6..317
8slz	pdb	Crystal structure of phosphorylated (T357/S358) human MLKL pseudokinase domain	x-ray	2.3	A	q8nb16	471		213..466
8smc	pdb	Cryo-EM structure of LRRK2 bound with type-I inhibitor DNL201	em	4.02	C	q5s007	2527		1884..2132
8so9	pdb	Phosphoinositide phosphate 3 kinase gamma	em	3.03	A	o02697	1102		728..1089
8soa	pdb	Phosphoinositide phosphate 3 kinase gamma bound with ATP	em	3.32	A	o02697	1102		728..1089
8sob	pdb	Phosphoinositide phosphate 3 kinase gamma bound with ADP	em	3.9	A	o02697	1102		728..1089
8soc	pdb	Phosphoinositide phosphate 3 kinase gamma bound with ADP and Gbetagamma	em	3.5	A	o02697	1102		728..1089
8sod	pdb	Phosphoinositide phosphate 3 kinase gamma bound with ADP and two Gbetagamma subunits in State 1	em	3.4	A	o02697	1102		728..1089
8soe	pdb	Phosphoinositide phosphate 3 kinase gamma bound with ADP and two Gbetagamma subunits in State 2	em	3.6	A	o02697	1102		728..1089
8sor	pdb	Structure of human PI3KC3-C1 complex	em	3.96	A;B	q99570;q8neb9	1358;887	;	22..311;538..883
8ssn	pdb	Abl kinase in complex with SKI and asciminib	x-ray	2.86	A;B	p00519;p00519	1130;1130	;	231..498;231..498
8sso	pdb	AurA bound to danusertib and inhibiting monobody Mb2	x-ray	1.97	A;D	;	;	;	;
8ssp	pdb	AurA bound to danusertib and activating monobody Mb1	x-ray	2.6	A				
8stg	pdb	Discovery and clinical validation of RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations	x-ray	3.79	A;B	p21802;p21802	821;821	;	471..757;471..757
8sv9	pdb	Crystal structure of ULK1 kinase domain with inhibitor MR-2088	x-ray	2.3	A;B	o75385;o75385	1050;1050	;	16..325;16..325
8swe	pdb	FGFR2 Kinase Domain Bound to Reversible Inhibitor Cmpd 3	x-ray	2.24	A;B	p21802;p21802	821;821	;	471..757;471..757
8sxn	pdb	Structure of NLRP3 and NEK7 complex	em	4.04	A;B	q8tdx7;q8tdx7	302;302	;	18..290;18..290
8t2h	pdb	DYRK1A complex with DYR530	x-ray	1.85	A;B	q13627;q13627	763;763	;	147..489;147..489
8t6k	pdb	Cryo-EM structure of tetradecameric CaMKII beta holoenzyme T287A T306A T307A	em	3	A;B;C;D;E;F;G;H;I;J;K;L;M;N	p08413;p08413;p42212;p42212;p08413;p42212;p42212;p08413;p08413;p42212;p42212;p42212;p42212;p42212	542;542;238;238;542;238;238;542;542;238;238;238;238;238	;;;;;;;;;;;;;	10..293;10..293;;;10..293;;;10..293;10..293;;;;;
8t6q	pdb	Cryo-EM structure of dodecameric CaMKII beta holoenzyme T287A T306A T307A	em	3.5	A;B;C;D;F;G;H;I;J;K;L;N	p08413;p08413;p08413;p08413;p08413;p42212;p08413;p42212;p42212;p42212;p08413;p08413	542;542;542;542;542;238;542;238;238;238;542;542	;;;;;;;;;;;	10..293;10..293;10..293;10..293;10..293;;10..293;;;;10..293;10..293
8t7t	pdb	CryoEM structure of the HisRS-like domain of human GCN2	em	3.2	A;B	q9p2k8;q9p2k8	1649;1649	;	336..550,589..1021;336..550,589..1021
8tb5	pdb	TYK2 JH2 bound to Compound7	x-ray	2.32	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
8tb6	pdb	TYK2 JH2 bound to Compound14	x-ray	1.96	A;B	p29597;p29597	1187;1187	;	576..879,887..1166;576..879,887..1166
8tdu	pdb	STX-478, a Mutant-Selective, Allosteric Inhibitor bound to PI3Kalpha	x-ray	3.11	A;C	p42336;p42336	1068;1068	;	699..1060;699..1060
8tgd	pdb	STX-478, a Mutant-Selective, Allosteric Inhibitor bound to H1047R PI3Kalpha	x-ray	2.928	A;C	p42336;p42336	1068;1068	;	699..1060;699..1060
8tjl	pdb	EGFR kinase in complex with pyrazolopyrimidine covalent inhibitor	x-ray	2.7	A	p00533	1210		708..1003
8to3	pdb	EGFR(T790M/V948R) in complex with LN5461	x-ray	2.49	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
8to4	pdb	EGFR(T790M/V948R) in complex with the allosteric inhibitor FRF-06-057	x-ray	2.99	A;B;C;D	p00533;p00533;p00533;p00533	1210;1210;1210;1210	;;;	708..1003;708..1003;708..1003;708..1003
8tq2	pdb	Structure of the kinase lobe of human CDK8 kinase module	em	3.8	A	p49336	464		25..341
8tqc	pdb	Structure of the human CDK8 kinase module	em	3.8	A	p49336	464		25..341
8tqw	pdb	Structure of human transcriptional Mediator complex	em	8.2	a				
8ts7	pdb	Human PI3K p85alpha/p110alpha	x-ray	2.71	A	p42336	1068		699..1060
8ts8	pdb	p85alpha/p110alpha heterodimer H1047R mutant	x-ray	2.72	A	p42336	1068		699..1060
8ts9	pdb	Human PI3K p85alpha/p110alpha H1047R bound to compound 1	x-ray	2.83	A	p42336	1068		699..1060
8tsa	pdb	Human PI3K p85alpha/p110alpha H1047R bound to compound 2	x-ray	2.51	A	p42336	1068		699..1060
8tsb	pdb	Human PI3K p85alpha/p110alpha bound to compound 2	x-ray	3.53	A	p42336	1068		699..1060
8tsc	pdb	Human PI3K p85alpha/p110alpha H1047R bound to compound 3	x-ray	3.62	A	p42336	1068		699..1060
8tsd	pdb	Human PI3K p85alpha/p110alpha bound to RLY-2608	x-ray	2.7	A	p42336	1068		699..1060
8tu3	pdb	Bruton's tyrosine kinase in complex with covalent inhibitor compound 10	x-ray	1.7	A	q06187	659		382..648
8tu4	pdb	Bruton's tyrosine kinase in complex with covalent inhibitor compound 25	x-ray	1.6	A	q06187	659		382..648
8tu5	pdb	Bruton's tyrosine kinase in complex with covalent inhibitor compound 27	x-ray	2.1	A	q06187	659		382..648
8tu6	pdb	CryoEM structure of PI3Kalpha	em	3.12	A	p42336	1068		699..1060
8tuc	pdb	Unphosphorylated CaMKK2 in complex with CC-8977	x-ray	1.5	A	q96rr4	588		153..484
8tvm	pdb	IRAK4 in complex with compound 24	x-ray	2.1	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
8tvn	pdb	IRAK4 in complex with compound 23	x-ray	1.95	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
8twy	pdb	Structure of p110 alpha bound to (S)-1-(4-((2-(4-(4-(2-amino-4-(difluoromethyl)pyrimidin-5-yl)-6-(3-methylmorpholino)-1,3,5- triazin-2-yl)piperazin-1-yl)-2-oxoethoxy)methyl)piperidin-1-yl)prop-2-en-1-one (compound 9)	x-ray	2.67	A	p42336	1068		699..1060
8tx0	pdb	IRAK4 in complex with compound	x-ray	2	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
8txy	pdb	X-ray crystal structure of JRD-SIK1/2i-3 bound to a MARK2-SIK2 chimera	x-ray	2.1	A;B	q7kzi7;q7kzi7	788;788	;	50..305;50..305
8txz	pdb	Structure of C-terminal LRRK2 bound to MLi-2	em	3.05	A	q5s007	2527		1884..2132
8tyq	pdb	Structure of the C-terminal half of LRRK2 bound to GZD-824 (G2019S mutant)	em	2.99	A				
8tzb	pdb	Structure of the C-terminal half of LRRK2 bound to GZD-824 (I2020T mutant)	em	3.1	A				
8tzc	pdb	Structure of C-terminal LRRK2 bound to MLi-2 (G2019S mutant)	em	2.7	A				
8tze	pdb	Structure of C-terminal half of LRRK2 bound to GZD-824	em	2.9	A	q5s007	2527		1884..2132
8tzf	pdb	Structure of full length LRRK2 bound to GZD-824 (I2020T mutant)	em	3.4	A				
8tzg	pdb	Structure of C-terminal LRRK2 bound to MLi-2 (I2020T mutant)	em	2.7	A	q5s007	2527		1884..2132
8tzh	pdb	Structure of full-length LRRK2 bound to MLi-2 (I2020T mutant)	em	3.9	A				
8u1b	pdb	C-terminal LRRK2 bound to E11 DARPin	em	3.7	A				
8u1f	pdb	FGFR2 Kinase Domain Bound to Irreversible Inhibitor Cmpd 10	x-ray	3.33	A;B	p21802;p21802	821;821	;	471..757;471..757
8u1l	pdb	Cryo-EM structure of the RAF1-HSP90-CDC37 complex in the closed state	em	3.7	C	p04049	648		344..611
8u2d	pdb	Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[3,4-b]indol-2-yl]-3-(3-methylphenyl)-1-oxopropan-2-yl]-1H-indazole-5-carboxamide	x-ray	1.95	A	q06187	659		382..648
8u2e	pdb	Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[3,4-b]indol-2-yl]-3-(3-methylphenyl)-1-oxopropan-2-yl]-1H-indazole-5-carboxamide	x-ray	1.9	A	q06187	659		382..648
8u2o	pdb	Crystal Structure of Cdk-related protein kinase 6 (PK6) from Plasmodium falciparum in complex with inhibitor TCMDC-123995	x-ray	2.15	A;B	q8idw1;q8idw1	305;305	;	5..296;5..296
8u37	pdb	Crystal structure of the catalytic domain of human PKC alpha (D463N, V568I, S657E) in complex with NVP-CJL037 at 2.48-A resolution	x-ray	2.48	A	p17252	672		335..631
8u4b	pdb	Cryo-EM structure of long form insulin receptor (IR-B) in the apo state	em	3.9	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
8u4c	pdb	Cryo-EM structure of long form insulin receptor (IR-B) with four IGF2 bound, symmetric conformation.	em	3.6	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
8u4e	pdb	Cryo-EM structure of long form insulin receptor (IR-B) with three IGF2 bound, asymmetric conformation.	em	4.2	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
8u7h	pdb	Cryo-EM structure of LRRK2 bound to type I inhibitor GNE-7915	em	3.8	C	q5s007	2527		1884..2132
8u7l	pdb	Cryo-EM structure of LRRK2 bound to type II inhibitor GZD824	em	3.6	A;B	q5s007;q5s007	2527;2527	;	1884..2132;1884..2132
8u8a	pdb	Cryo-EM structure of LRRK2 bound to type II inhibitor ponatinib	em	3.4	B;C	q5s007;q5s007	2527;2527	;	1884..2132;1884..2132
8u8b	pdb	Cryo-EM structure of LRRK2 bound to type II inhibitor rebastinib	em	3.7	A;B	q5s007;q5s007	2527;2527	;	1884..2132;1884..2132
8u8j	pdb	Co-crystal structure of phosphorylated ERK2 in complex with ERK1/2 inhibitor #16	x-ray	2.1	A	p28482	360		19..322
8u8k	pdb	Co-crystal structure of phosphorylated ERK2 in complex with ERK1/2 inhibitor #8	x-ray	2.1	A	p28482	360		19..322
8u8x	pdb	crystal structure of the receptor tyrosine kinase Human HER2 (ERBB2) YVMA mutant kinase domain in complex with inhibitor compound 27	x-ray	1.69	A	p04626	1255		716..992
8uak	pdb	Crystal structure of the catalytic domain of human PKC alpha (D463N, V568I, S657E) in complex with Darovasertib (NVP-LXS196) at 2.82-A resolution	x-ray	2.82	A	p17252	672		335..631
8uap	pdb	Crystal Structure of Human G Protein-Coupled Receptor Kinase 5 D311N in Complex with CCG273441	x-ray	2.5	A	p34947	590		184..537
8uaq	pdb	Crystal Structure of Human G Protein-Coupled Receptor Kinase 5 in Complex with GRL018-21	x-ray	2.8	A	p34947	590		184..537
8ucb	pdb	IRAK4 in complex with compound 8	x-ray	1.85	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
8ucc	pdb	IRAK4 in complex with compound 20	x-ray	1.8	A;B	q9nwz3;q9nwz3	460;460	;	156..454;156..454
8uct	pdb	Crystal structure of TcPINK1 in complex with PRT	x-ray	2.93	A	d6wmx4	570		153..478
8udc	pdb	Crystal structure of TcPINK1 in complex with CYC116	x-ray	3.1	A	d6wmx4	570		153..478
8udt	pdb	The X-RAY co-crystal structure of human FGFR3 and KIN-3248	x-ray	2.829	A;B;C	p22607;p22607;p22607	806;806;806	;;	463..748;463..748;463..748
8udu	pdb	The X-RAY co-crystal structure of human FGFR3 and Compound 17	x-ray	1.737	A;B	p22607;p22607	806;806	;	463..748;463..748
8udv	pdb	The X-RAY co-crystal structure of human FGFR3 V555M and Compound 17	x-ray	2.348	A;B;C	p22607;p22607;p22607	806;806;806	;;	463..748;463..748;463..748
8ue1	pdb	Crystal Structure of Human Fructosamine-3-kinase (FN3K)	x-ray	2.85	A	q9h479	309		21..307
8uoh	pdb	Crystal structure of human NUAK1-MARK3 kinase domain chimera bound with small molecule inhibitor #10	x-ray	2.15	A;B	p27448;p27448	753;753	;	53..308;53..308
8uoi	pdb	Crystal structure of human NUAK1-MARK3 kinase domain chimera bound with small molecule inhibitor #65	x-ray	1.8	A	p27448	753		53..308
8uoj	pdb	Crystal structure of human NUAK1-MARK3 kinase domain chimera bound with azepane (R)-#50 small molecule inhibitor	x-ray	1.6	A	p27448	753		53..308
8uok	pdb	Crystal structure of human NUAK1-MARK3 (7 mutations) kinase domain chimera bound with small molecule inhibitor #31	x-ray	1.85	A;B	p27448;p27448	753;753	;	53..308;53..308
8uol	pdb	Crystal structure of human NUAK1-MARK3 (6 mutations) kinase domain chimera bound with small molecule inhibitor #31	x-ray	1.9	A;B	p27448;p27448	753;753	;	53..308;53..308
8uso	pdb	Full-length human CaMKII delta holoenzyme	x-ray	2.3	A;B;C	d6r938;d6r938;d6r938	498;498;498	;;	10..273;10..273;10..273
8uv0	pdb	Discovery of (4-Pyrazolyl)-2-Aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2	x-ray	1.55	A	p24941	298		1..292
8uvl	pdb	Crystal structure of selective IRE1a inhibitor 29 at the enzyme active site	x-ray	2.43	A	o75460	977		571..851
8uvy	pdb	Structure of AKT1(E17K) with compound 3	x-ray	2.11	A				
8uw2	pdb	Structure of AKT1(E17K) with compound 3 (zinc-free)	x-ray	2.2	A				
8uw7	pdb	Structure of AKT1(WT) with compound 3	x-ray	1.972	A				
8uw9	pdb	Structure of AKT1(E17K) with compound 4	x-ray	1.9	A				
8uwn	pdb	Crystal structure of human CLK1 kinase in complex with compound 3	x-ray	1.8	A	p49759	484		150..478
8uwr	pdb	Crystal structure of human ACVR1 (ALK2) kinase in complex with compound 3	x-ray	2.04	A	q04771	509		186..496
8uyf	pdb	Structure of nucleotide-free Pediculus humanus (Ph) PINK1 dimer	em	2.75	A;B	e0w1i1;e0w1i1	575;575	;	151..477;151..477
8uyh	pdb	Structure of AMP-PNP-bound Pediculus humanus (Ph) PINK1 dimer	em	2.84	A;B	e0w1i1;e0w1i1	575;575	;	151..477;151..477
8uyi	pdb	Structure of ADP-bound and phosphorylated Pediculus humanus (Ph) PINK1 dimer	em	3.13	A;B	e0w1i1;e0w1i1	575;575	;	151..477;151..477
8v1o	pdb	Crystal structure of IRAK4 kinase domain with compound 4	x-ray	2.92	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
8v2f	pdb	Crystal structure of IRAK4 kinase domain with compound 9	x-ray	2.09	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
8v2l	pdb	Crystal structure of IRAK4 kinase domain with compound 8	x-ray	2.43	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
8v42	pdb	Structure of Human Vaccinia-related Kinase 1 (VRK1) Bound to ACH000400	x-ray	2.3	A;B;C;D	q99986;q99986;q99986;q99986	396;396;396;396	;;;	31..340;31..340;31..340;31..340
8v8h	pdb	PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 4).	x-ray	3.58	A;C	p42336;p42336	1068;1068	;	699..1060;699..1060
8v8i	pdb	PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket (compound 5).	x-ray	3.2	A;C	p42336;p42336	1068;1068	;	699..1060;699..1060
8v8j	pdb	PI3Ka H1047R co-crystal structure with inhibitors in two cryptic pockets (compounds 4 and 5).	x-ray	3.35	A;C	p42336;p42336	1068;1068	;	699..1060;699..1060
8v8u	pdb	PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 12).	x-ray	2.93	A;C	p42336;p42336	1068;1068	;	699..1060;699..1060
8v8v	pdb	PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 7).	x-ray	2.61	A;C	p42336;p42336	1068;1068	;	699..1060;699..1060
8vf6	pdb	Crystal structure of Serine/threonine-protein kinase 33 (STK33) Kinase Domain in complex with inhibitor CDD-2211	x-ray	2.7	A;B	q9byt3;q9byt3	514;514	;	104..412;104..412
8vh4	pdb	Cryo-EM structure of Rab12-LRRK2 complex in the LRRK2 monomer state	em	4.1	A	q5s007	2527		1884..2132
8vh5	pdb	Cryo-EM structure of Rab12-LRRK2 complex in the LRRK2 dimer state	em	4	A;C	q5s007;q5s007	2527;2527	;	1884..2132;1884..2132
8vjb	pdb	Cryo-EM structure of short form insulin receptor (IR-A) with four IGF2 bound, symmetric conformation.	em	3.6	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
8vjc	pdb	Cryo-EM structure of short form insulin receptor (IR-A) with three IGF2 bound, asymmetric conformation.	em	3.8	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
8vme	pdb	Crystal structure of the GSK-3/Axin complex bound to a phosphorylated beta-catenin T41A peptide	x-ray	2.3	A	q9wv60	420		55..377
8vmf	pdb	Crystal structure of a transition-state mimic of the GSK-3/Axin complex bound to a beta-catenin S45D peptide	x-ray	2.5	A	q9wv60	420		55..377
8vmg	pdb	Crystal structure of GSK-3 26-383 bound to Axin 383-435	x-ray	2.45	A;B	q9wv60;q9wv60	420;420	;	55..377;55..377
8vof	pdb	GI targeted CpPI4K inhibitor	x-ray	3	A	q9ubf8	816		325..810
8vq3	pdb	CDK2-CyclinE1 in complex with allosteric inhibitor I-198.	x-ray	1.84	A	p24941	298		1..292
8vq4	pdb	CDK2-CyclinE1 in complex with allosteric inhibitor I-125A.	x-ray	1.9	A	p24941	298		1..292
8vsu	pdb	Cryo-EM structure of LKB1-STRADalpha-MO25alpha heterocomplex	em	2.86	B;C	q7rtn6;q15831	431;433	;	57..401;41..336
8vxd	pdb	Structure of Casein kinase I isoform delta (CK1d) complexed with inhibitor 7	x-ray	2.47	A;B	p48730;p48730	415;415	;	5..290;5..290
8vxe	pdb	Structure of p38 alpha (Mitogen-activated protein kinase 14) complexed with inhibitor 6	x-ray	1.85	A	q16539	360		9..349
8vxf	pdb	Structure of Casein kinase I isoform delta (CK1d) complexed with inhibitor 15	x-ray	2.28	A;B	p48730;p48730	415;415	;	5..290;5..290
8w1l	pdb	Structure of CSF1R kinase domain in complex with Cpd 32	x-ray	2.26	A	p07333	972		551..909
8w3w	pdb	Crystal structure of IRAK4 in complex with compound 4	x-ray	1.976	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
8w3x	pdb	Crystal structure of IRAK4 in complex with compound 6	x-ray	1.765	A;B;C;D	q9nwz3;q9nwz3;q9nwz3;q9nwz3	460;460;460;460	;;;	156..454;156..454;156..454;156..454
8w5c	pdb	Crystal structure of FGFR4 kinase domain in complex with 8K	x-ray	2.3	A;B	p22455;p22455	802;802	;	458..743;458..743
8w7a	pdb	Cryo-EM structure of ClassIII Lanthipeptide modification enzyme PneKC in the presence of GTP.	em	3.77	A;B	a0a0h2zmf7;a0a0h2zmf7	869;869	;	217..382;217..382
8w7j	pdb	Cryo-EM structure of ClassIII Lanthipeptide modification enzyme PneKC with chain A bounded to substrate PneA and GTP.	em	3.98	A;B	;	;	;	;
8w7l	pdb	Cryo-EM structure of ClassIII Lanthipeptide modification enzyme PneKC mutant H522A.	em	3.75	A;B	;	;	;	;
8w9a	pdb	CryoEM structure of human PI3K-alpha (P85/P110-H1047R) with QR-7909 binding at an allosteric site	em	2.7	A	p42336	1068		699..1060
8w9b	pdb	CryoEM structure of human PI3K-alpha (P85/P110-H1047R) with QR-8557 binding at an allosteric site	em	3	A	p42336	1068		699..1060
8wd4	pdb	EGFR(L858R/T790/C797S) in complex with compound 5j	x-ray	2.55	A	p00533	1210		708..1003
8wdk	pdb	The complex structure of Cul2-VCB-Protac-Wee1	em	3.64	W	p30291	646		279..580
8wf4	pdb	The Crystal Structure of RSK1 from Biortus.	x-ray	2.65	A;B	q15418;q15418	735;735	;	60..381,400..719;60..381,400..719
8wgf	pdb	The Crystal Structure of JNK3 from Biortus.	x-ray	1.85	A	p53779	464		52..396
8wgo	pdb	Cryo-EM structure of ClassIII Lanthipeptide modification enzyme PneKC in the presence of PneA and GTPrS.	em	3.7	A;B	a0a0h2zmf7;a0a0h2zmf7	869;869	;	217..382;217..382
8wjy	pdb	PKMYT1_Cocrystal_Cpd 4	x-ray	1.88	A	q99640	499		108..419
8wm0	pdb	Crystal structure of TNIK-thiopeptide wTP3 complex	x-ray	2.8	A				
8wsw	pdb	The Crystal Structure of LIMK2a from Biortus	x-ray	2.5	A;B;C;D	p53671;p53671;p53671;p53671	638;638;638;638	;;;	304..597;304..597;304..597;304..597
8wtf	pdb	The Crystal Structure of IRAK4 from Biortus	x-ray	2	A	q9nwz3	460		156..454
8wyw	pdb	Crystal structure of spleen tyrosine kinase (SYK) in complex with SKI-O-592 (free form of SKI-O-703, cevidoplenib)	x-ray	1.9	A;B	p43405;p43405	635;635	;	375..627;375..627
8x06	pdb	Cryo-EM structure of the IR/IGF-I complex, conformation 1	em	3.24	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
8x23	pdb	The Crystal Structure of MAPK13 from Biortus.	x-ray	1.5	A	o15264	365		19..314
8x2a	pdb	The Crystal Structure of BMX from Biortus.	x-ray	1.3	A	p51813	675		396..664
8x2m	pdb	Cryo-EM structure of the IR/IGF-I complex, conformation 2	em	3.31	A;B	p06213;p06213	1382;1382	;	996..1290;996..1290
8x2o	pdb	RIPK2 in complex with K252	x-ray	2.26	A;B	o43353;o43353	540;540	;	11..297;11..297
8x3m	pdb	Crystal structure of p38alpha with an allosteric inhibitor 2	x-ray	1.85	A	q16539	360		9..349
8x5k	pdb	The Crystal Structure of SYK from Biortus.	x-ray	1.8	A	p43405	635		375..627
8x5l	pdb	The Crystal Structure of PRKACA from Biortus.	x-ray	2.75	A;B	p17612;p17612	351;351	;	30..339;30..339
8x5m	pdb	The Crystal Structure of JNK1 from Biortus.	x-ray	2	A	p45983	427		12..357
8x5z	pdb	The Crystal Structure of PAK1 kinase domain from Biortus.	x-ray	1.8	A	q13153	545		261..522
8x72	pdb	The Crystal Structure of PLK1 from Biortus.	x-ray	2.2	A	p53350	603		51..338
8x88	pdb	The Crystal Structure of TNIK from Biortus.	x-ray	2.7	A;B	q9uke5;q9uke5	1360;1360	;	24..290;24..290
8x8x	pdb	Crystal structure of ROCK2 with GNS-2591 inhibitor	x-ray	2.6	A;B	o75116;o75116	1388;1388	;	89..412;89..412
8x8y	pdb	Crystal structure of ROCK2 with GNS-2660 inhibitor	x-ray	3.2	A;B	o75116;o75116	1388;1388	;	89..412;89..412
8x8z	pdb	Crystal structure of ROCK2 with GNS-2664 inhibitor	x-ray	2.7	A;B	o75116;o75116	1388;1388	;	89..412;89..412
8x92	pdb	Crystal structure of ROCK2 with GNS-2666 inhibitor	x-ray	2.2	A;B	o75116;o75116	1388;1388	;	89..412;89..412
8xey	pdb	The Crystal Structure of C-terminal kinase domain of RSK2 from Biortus	x-ray	2.65	A	p51812	740		66..390,402..717
8xfl	pdb	The Crystal Structure of MARK4 from Biortus.	x-ray	3	A;B	q96l34;q96l34	752;752	;	56..311;56..311
8xfm	pdb	The Crystal Structure of MNK2 from Biortus.	x-ray	2.6	A	q9hbh9	465		87..395
8xfy	pdb	The Crystal Structure of RSK2 from Biortus.	x-ray	3.2	A;B;C;D;E;F;G;H;I;J	p51812;p51812;p51812;p51812;p51812;p51812;p51812;p51812;p51812;p51812	740;740;740;740;740;740;740;740;740;740	;;;;;;;;;	66..390,402..717;66..390,402..717;66..390,402..717;66..390,402..717;66..390,402..717;66..390,402..717;66..390,402..717;66..390,402..717;66..390,402..717;66..390,402..717
8xlo	pdb	FGFR1 kinase domain with a dual-warhead covalent inhibitor CXF-007	x-ray	2.36	A;B	p11362;p11362	822;822	;	468..754;468..754
8xlq	pdb	FGFR4 kinase domain with a dual-warhead covalent inhibitor CXF-007	x-ray	1.95	A	p22455	802		458..743
8xn6	pdb	The Crystal Structure of GSK3b from Biortus.	x-ray	2.4	A;B	p49841;p49841	420;420	;	55..377;55..377
8xn7	pdb	Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with compound 9f	x-ray	2.65	A;B	q92918;q92918	833;833	;	14..444;14..444
8xn8	pdb	The Crystal Structure of SRC from Biortus.	x-ray	1.95	A	p05480	535		258..528
8xov	pdb	The Crystal Structure of N-terminal kinase domain of human RSK-1 from Biortus.	x-ray	2.55	A	q15418	735		60..381,400..719
8xox	pdb	The Crystal Structure of FAK2 from Biortus.	x-ray	1.9	A	q14289	1009		417..694
8xpv	pdb	The Crystal Structure of EphA2 from Biortus.	x-ray	1.55	A	p29317	976		605..909
8xpz	pdb	The Crystal Structure of TTBK1 from Biortus.	x-ray	2.6	A	q5tcy1	1321		30..311
8xu4	pdb	The Crystal Structure of MAPK2 from Biortus.	x-ray	3.4	A;B;C;D;E;F;G;H;I;J;K;L	p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137;p49137	400;400;400;400;400;400;400;400;400;400;400;400	;;;;;;;;;;;	59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369;59..369
8xvg	pdb	Structure of human NuA4/TIP60 complex	em	9.4	L	q9y4a5	3859		3433..3826
8xvv	pdb	The TRRAP module of human NuA4/TIP60 complex	em	3.2	L	q9y4a5	3859		3433..3826
8xx1	pdb	The Crystal Structure of MAPKAP kinase 2 domain from Biortus	x-ray	2.55	A	p49137	400		59..369
8xy7	pdb	hPhK alpha-gamma subcomplex in active state	em	2.9	C	q16816	387		12..325
8xya	pdb	hPhK alpha-beta-gamma-delta subcomplex in inactive state	em	2.7	C	q16816	387		12..325
8xyb	pdb	hPhK gamma-delta subcomplex in inactive state	em	3.1	C	q16816	387		12..325
8xz7	pdb	FGFR1 kinase domain with a covalent inhibitor 10h	x-ray	1.75	A;B	p11362;p11362	822;822	;	468..754;468..754
8y22	pdb	FGFR1 kinase domain with a covalent inhibitor 9g	x-ray	2.792	A;B	p11362;p11362	822;822	;	468..754;468..754
8y6o	pdb	Cryo-EM Structure of the human minor pre-B complex (pre-precatalytic spliceosome) U11 and tri-snRNP part	em	3.38	Q	q13523	1007		674..1005
8ygw	pdb	The Crystal Structure of MAPK11 from Biortus	x-ray	3.301	A	q15759	364		10..348
8ygx	pdb	Structure of the PYK2 from Biortus.	x-ray	2	A	q14289	1009		417..694
8ygz	pdb	The Crystal Structure of TGF beta R2 kinase domain from Biortus.	x-ray	2.1	A	p37173	567		244..537
8yhf	pdb	The Crystal Structure of the Type I TGF beta receptor from Biortus.	x-ray	1.4	A	p36897	503		180..492
8yhk	pdb	The Crystal Structure of P21-Activated Kinases Pak4 from Biortus	x-ray	3.3	A	o96013	591		323..578
8yhl	pdb	The Crystal Structure of Tgf-Beta Type I Receptor (Alk5) from Biortus	x-ray	1.47	A	p36897	503		180..492
8yhw	pdb	The Crystal Structure of NF-kB-inducing Kinase (NIK) from Biortus	x-ray	2.9	A;B;C;D	q99558;q99558;q99558;q99558	947;947;947;947	;;;	405..654;405..654;405..654;405..654
8yki	pdb	FGFR-1 in complex with ligand tasurgratinib	x-ray	2.79	A;B	p11362;p11362	822;822	;	468..754;468..754
8yvv	pdb	The Crystal Structure of BTK from Biortus	x-ray	2.25	A;B	q06187;q06187	659;659	;	382..648;382..648
8zh5	pdb	The Crystal Structure of the ROCK1 from Biortus.	x-ray	3.7	A	q13464	1354		73..413
8zjv	pdb	Crystal Structure of the ERK2 complexed with 5-Iodotubercidin	x-ray	1.8	A	p28482	360		19..322
8zkd	pdb	The Crystal Structure of the RON from Biortus.	x-ray	2.05	A	q04912	1400		1085..1344
8ztx	pdb	Crystal Structure of Human Myt1 Kinase domain Bounded with compound 6b	x-ray	1.70033	A	q99640	499		108..419
8zu2	pdb	Crystal Structure of Human Myt1 Kinase domain Bounded with compound 8g	x-ray	1.79889	A	q99640	499		108..419
8zud	pdb	Crystal Structure of Human Myt1 Kinase domain Bounded with compound 8f	x-ray	1.5051	A	q99640	499		108..419
8zul	pdb	Crystal Structure of Human Myt1 Kinase domain Bounded with compound 8m	x-ray	1.80026	A	q99640	499		108..419
9av6	pdb	Crystal structure of CMGC family protein kinase from Trichomonas vaginalis (Apo)	x-ray	2	A	a2f9n1	320		21..316
9av7	pdb	Crystal structure of CMGC family protein kinase from Trichomonas vaginalis (AMP-PNP)	x-ray	2.1	A	a2f9n1	320		21..316
9axa	pdb	CryoEM structure of activated CRAF/MEK/14-3-3 complex with NST-628	em	4.36	A;C;B;D	p04049;p08515;q02750;q02750	648;218;393;393	;;;	344..611;;63..365;63..365
9axc	pdb	Activated CRAF/MEK heterotetramer from focused refinement of CRAF/MEK/14-3-3 complex	em	4.16	A;C;B;D	p04049;p08515;q02750;q02750	648;218;393;393	;;;	344..611;;63..365;63..365
9axh	pdb	Crystal structure of KSR1/MEK1 complex heterotetramer with NST-628	x-ray	2.81	A;B;C;D	q02750;q02750;q8ivt5;q8ivt5	393;393;923;923	;;;	63..365;63..365;597..879;597..879
9axm	pdb	Crystal structure of ARAF/MEK1 complex with NST-628 and a RAF dimer	x-ray	2.42	A;B;C;D	q02750;p10398;q02750;p10398	393;606;393;606	;;;	63..365;301..586;63..365;301..586
9axx	pdb	Crystal structure of BRAF/MEK1 complex with NST-628 and an active RAF dimer	x-ray	2.07	A;B;C;D	q02750;p15056;q02750;p15056	393;766;393;766	;;;	63..365;449..717;63..365;449..717
9axy	pdb	Crystal structure of BRAF/MEK complex with NST-628 and inactive RAF	x-ray	3.6	A;B	p15056;q02750	766;393	;	449..717;63..365
9ay7	pdb	Crystal structure of CRAF/MEK1 complex with NST-628 and inactive RAF	x-ray	2.41	A;B	p04049;q02750	648;393	;	344..611;63..365
9aya	pdb	Crystal structure of CRAF/MEK complex with NST-628 and active RAF dimer	x-ray	2.59	A;B;C;D	p04049;q02750;p04049;q02750	648;393;648;393	;;;	344..611;63..365;344..611;63..365
9b3s	pdb	Crystal structure of casein kinase 1 delta 1 with tethered phosphorylated tail	x-ray	2.4	A;B	p48730;p48730	415;415	;	5..290;5..290
9b9g	pdb	Structure of the PI4KA complex bound to Calcineurin	em	3.5	A;B	p42356;p42356	2102;2102	;	1728..2095;1728..2095
9bax	pdb	PI4KA complex bound to C-terminus of EFR3A	em	3.65	A;B	p42356;p42356	2102;2102	;	1728..2095;1728..2095
9bcl	pdb	Extracellular domain of apo GC-A, state 1	em	2.9	A;B	p16066;p16066	1061;1061	;	555..842;555..842
9bcn	pdb	Extracellular domain of apo GC-A, state 2	em	2.9	A;B	p16066;p16066	1061;1061	;	555..842;555..842
9bco	pdb	Intracellular domain of apo GC-A	em	4.4	A;B	p16066;p16066	1061;1061	;	555..842;555..842
9bcp	pdb	Kinase homology domain of apo GC-A	em	4.1	A;B	p16066;p16066	1061;1061	;	555..842;555..842
9bcq	pdb	Extracellular domain of GC-A bound to ANP	em	3.1	A;B	p16066;p16066	1061;1061	;	555..842;555..842
9bcs	pdb	Intracellular domain of GC-A bound to ANP	em	4.4	A;B	p16066;p16066	1061;1061	;	555..842;555..842
9bcv	pdb	Cyclase domain of GC-A bound to ANP	em	3.2	A;B	;	;	;	;
9bfb	pdb	Crystal structure of BRAF kinase domain with PF-07284890	x-ray	1.92	A	p15056	766		449..717
9bhi	pdb	Crystal structure of the MerTK kinase domain with SA4488	x-ray	2.07	A	q12866	999		578..872
9bhj	pdb	MerTK in complex with small molecule 6-{1-[([1,1'-biphenyl]-4-yl)carbamoyl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide	x-ray	2.294	A	q12866	999		578..872
9bhk	pdb	MerTK in complex with small molecule inhibitor 6-{1-[6-(3-hydroxy-3-methylbutoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide	x-ray	2.106	A	q12866	999		578..872
9bi8	pdb	Crystal structure of inhibitor GNE-6893 bound to HPK1	x-ray	2.25	A;B	q92918;q92918	833;833	;	14..444;14..444
9bik	pdb	Crystal structure of inhibitor 1 bound to HPK1	x-ray	2.25	A;B	q92918;q92918	833;833	;	14..444;14..444
9bj1	pdb	Crystal structure of inhibitor GNE-6893 bound to HPK1	x-ray	2.18	A;B	q92918;q92918	833;833	;	14..444;14..444
9bt8	pdb	Structure of Src in complex with beta-arrestin 1 revealing SH3 binding sites	em	3.34	C				
9byj	pdb	Crystal Structure of Hck in complex with the Src-family kinase inhibitor A-419259	x-ray	1.8	A	p08631	526		249..518
9c1r	pdb	Crystal structure of mutant cMET D1228N kinase domain in complex with inhibitor compound 13	x-ray	1.59	A	p08581	1390		1079..1341
9c1w	pdb	Structure of AKT2 with compound 3	x-ray	2	A	p31751	481		147..460
9c47	pdb	TRRAP module of the human TIP60 complex	em	3.4	C	q9y4a5	3859		3433..3826
9c82	pdb	Structure of human ULK1C:PI3KC3-C1 supercomplex	em	6.84	A;B	q99570;q8neb9	1358;887	;	22..311;538..883
9cd5	pdb	FGFR1 Kinase Domain Soak with Inhibitor TYRA-300	x-ray	2.939	A;B	p11362;p11362	822;822	;	468..754;468..754
9cd7	pdb	FGFR3 Kinase Domain with Inhibitor TYRA-300	x-ray	2.53	A;B;C	p22607;p22607;p22607	806;806;806	;;	463..748;463..748;463..748
9ce4	pdb	Structure of CHK1 10-pt. mutant complex with LRRK2 indazole inhibitor compound 6	x-ray	1.31	A	o14757	476		6..317
9cj1	pdb	Dual phosphorylated human p38 alpha bound to nilotinib	x-ray	1.8	A	q16539	360		9..349
9cj2	pdb	Dual phosphorylated human p38 alpha	x-ray	2.83	A;B	q16539;q16539	360;360	;	9..349;9..349
9cj3	pdb	Dual phosphorylated human p38 alpha bound to pexmetinib	x-ray	1.95	A	q16539	360		9..349
9cj4	pdb	Dual phosphorylated human p38 alpha bound to BIRB796	x-ray	1.8	A	q16539	360		9..349
9cj5	pdb	Unphosphorylated human p38 alpha bound to pexmetinib	x-ray	3.3	A	q16539	360		9..349
9cmz	pdb	Crystal Structure of Cdk-related protein kinase 6 (PK6) from Plasmodium falciparum in complex with inhibitor KG2-051	x-ray	2.45	A;B;C	q8idw1;q8idw1;q8idw1	305;305;305	;;	5..296;5..296;5..296
9d8e	pdb	Crystal structure of the ACVR1 (ALK2) Kinase Domain in complex with inhibitor CDD-2789	x-ray	1.72	A;B	q04771;q04771	509;509	;	186..496;186..496
9d8f	pdb	Crystal structure of the ACVR1 (ALK2) Kinase Domain in complex with inhibitor CDD-2281	x-ray	1.86	A;B	q04771;q04771	509;509	;	186..496;186..496
9d8s	pdb	Crystal Structure of calcium-dependent protein kinase 1 (CDPK1) from Cryptosporidium parvum (AMP/Mg bound)	x-ray	2.12	A	a3fq16	538		69..348
9d8z	pdb	Crystal structure of the ACVR1 (ALK2) Kinase Domain in complex with inhibitor CDD-2282	x-ray	1.85	A;B	q04771;q04771	509;509	;	186..496;186..496
9dk1	pdb	Lexapeptide dehydratase complex LxmKY apo	x-ray	2.4	A	a0aax3zkt3	401		25..341
9dk2	pdb	Lexapeptide dehydratase complex LxmKY, ATP bound	x-ray	2.5	A	a0aax3zkt3	401		25..341
9dk3	pdb	Lexapeptide dehydratase complex LxmKY, hydrolysed ATP bound	x-ray	2.3	A	a0aax3zkt3	401		25..341
9dub	pdb	Crystal Structure of Human DAPK1 Catalytic Subunit Complexed with Compound SRM-25-071	x-ray	1.5	A	p53355	1430		6..291
9due	pdb	Crystal Structure of Human DAPK1 Catalytic Subunit Complexed with Compound SRM-07-081a	x-ray	1.65	A	p53355	1430		6..291
9dw4	pdb	Dephosphorylated CFTR in 1:1 complex with PKA-C (site II)	em	9	K				
9dw5	pdb	Dephosphorylated CFTR in 1:1 complex with PKA-C (site I)	em	3.8	G	p00517	351		32..339
9dw7	pdb	Dephosphorylated CFTR in 1:2 complex with PKA-C	em	6	G;K	;	;	;	;
9dw8	pdb	Dephosphorylated (E1371Q)CFTR in complex with PKA-C	em	3.5	G	p00517	351		32..339
9dw9	pdb	Phosphorylated (E1371Q)CFTR in complex with PKA-C	em	2.8	G	p00517	351		32..339
9e4v	pdb	The structure of human vacuolar protein sorting 34 catalytic domain bound to MES	x-ray	2.36	B	q8neb9	887		538..883
9ep8	pdb	Crystal structure of ROCK2 in complex with a 8-(azaindolyl)-benzoazepinone inhibitor	x-ray	2.63	A;B;C;D	o75116;o75116;o75116;o75116	1388;1388;1388;1388	;;;	89..412;89..412;89..412;89..412
9epv	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGC333	x-ray	2.3	A;B	p68400;p68400	391;391	;	5..328;5..328
9epw	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGC3336	x-ray	2.3	B	p68400	391		5..328
9epx	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGC3331	x-ray	2.6	A;B	p68400;p68400	391;391	;	5..328;5..328
9epy	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGC3330	x-ray	2.65	A;B	p68400;p68400	391;391	;	5..328;5..328
9epz	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGC3337	x-ray	2.65	A;B	p68400;p68400	391;391	;	5..328;5..328
9eq0	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGJG12	x-ray	3.15	A;B	p68400;p68400	391;391	;	5..328;5..328
9eq1	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGJM24	x-ray	3	A;B	p68400;p68400	391;391	;	5..328;5..328
9esa	pdb	Aurora-C with SER mutation in complex with INCENP peptide	x-ray	2.8	AAA;BBB	q9uqb9;q9uqb9	309;309	;	28..302;28..302
9eto	pdb	PsiK from Psilocybe cubensis	x-ray	2.54	A;B	p0dpa8;p0dpa8	362;362	;	7..298;7..298
9ews	pdb	Optimisation of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations	x-ray	2.435	A	p00533	1210		708..1003
9ewt	pdb	Optimisation of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations	x-ray	3.019	A;B	p00533;p00533	1210;1210	;	708..1003;708..1003
9ez3	pdb	Crystal structure of human CLK3 bound to RN129	x-ray	2.7	A	p49761	490		145..479
9ezg	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((4-((2-aminoethyl)(ethyl)amino)-3-(4H-1,2,4-triazol-4-yl)phenyl)amino)-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile	x-ray	2.18	A;B	p68400;p68400	391;391	;	5..328;5..328
9f3v	pdb	RIP2K kinase domain dimer with bound compound 37 (N399), a speific NOD1 pathway inhibitor	x-ray	1.943	A;B	o43353;o43353	540;540	;	11..297;11..297
9f44	pdb	cryo-EM structure of LST2 TOS peptide bound to human mTOR complex 1	em	3.68	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
9f45	pdb	cryo-EM structure of human LST2 bound to human mTOR complex 1	em	3.74	A;B	p42345;p42345	2549;2549	;	2095..2451;2095..2451
9fet	pdb	Crystal Structure of Human Vaccinia-related kinase 2 (VRK-2) bound to JA-47	x-ray	2.4	A	q86y07	508		23..317
9flb	pdb	Crystal structure of haspin (GSG2) in complex with MU1464	x-ray	2.5	A	q8tf76	798		474..698
9flc	pdb	Crystal structure of haspin (GSG2) in complex with MU1668	x-ray	2.18	A	q8tf76	798		474..698
9flo	pdb	Crystal structure of human Haspin (GSG2) kinase bound to MU2181	x-ray	2.9	A	q8tf76	798		474..698
9flq	pdb	Crystal structure of human Haspin (GSG2) kinase bound to MU1959	x-ray	1.85	A	q8tf76	798		474..698
9flr	pdb	Crystal structure of human Haspin (GSG2) kinase bound to MU1963	x-ray	1.91	A	q8tf76	798		474..698
9flt	pdb	Crystal structure of human Haspin (GSG2) kinase bound to chemical probe MU1920	x-ray	2.4	A	q8tf76	798		474..698
9fmr	pdb	Structure of DDB1/Cdk12/Cyclin K with molecular glue SR-4835	x-ray	3.9	B;E;H	q9nyv4;q9nyv4;q9nyv4	1490;1490;1490	;;	721..1024;721..1024;721..1024
9fpd	pdb	Crystal structure of human TAK1/TAB1 fusion protein in complex with compound S1	x-ray	2.402	A	q15750	504		
9fr2	pdb	CDK2 in complex with WEIZ-WX-04-001	x-ray	1.6	A	p24941	298		1..292
9fyf	pdb	Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with TR06772818	x-ray	2.7	A;B	p68400;p68400	391;391	;	5..328;5..328
9gb9	pdb	Crystal structure of Lotus japonicus CERK6 kinase domain D460N	x-ray	1.85	A;B;C;D	d3ktz6;d3ktz6;d3ktz6;d3ktz6	622;622;622;622	;;;	305..594;305..594;305..594;305..594
9gbe	pdb	Structure of Human Anaplastic Lymphoma Kinase (ALK) harboring the G1202R/L1196M Compound Mutation in Complex with NVL-655	x-ray	1.58	A	q9um73	1620		1089..1381
9gfz	pdb	Crystal structure of Medicago Truncatula LYK3 kinase domain D459N	x-ray	2.5	A;B	q6ud73;q6ud73	620;620	;	304..592;304..592
9h46	pdb	EGFR wild type in complex with 25328	x-ray	3.163	A	p00533	1210		708..1003
9inv	pdb	Crystal structure of DAPK1 in complex with isoliquiritigenin	x-ray	1.61	A	p53355	1430		6..291
9inw	pdb	Crystal structure of DAPK1 in complex with compound 9	x-ray	1.52	A	p53355	1430		6..291
9inx	pdb	Crystal structure of DAPK1 in complex with compound 10	x-ray	1.72	A	p53355	1430		6..291
